confidence_score,doc_id,tissue_id,assay_type,assay_subcellular_fraction,src_assay_id,curated_by,chembl_id,src_id,assay_tissue,variant_id,assay_id,assay_test_type,relationship_type,bao_format,assay_cell_type,assay_tax_id,assay_category,assay_organism,description,assay_strain,tid,cell_id
8.0,11087.0,,B,,,Autocuration,CHEMBL615117,1.0,,,1.0,,H,BAO_0000019,,,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,12052.0,
0.0,684.0,,F,,,Autocuration,CHEMBL615118,1.0,,,2.0,,U,BAO_0000219,,,,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,22226.0,
0.0,15453.0,,B,,,Autocuration,CHEMBL615119,1.0,,,3.0,,U,BAO_0000019,,,,,,,22226.0,
4.0,17841.0,,B,,,Autocuration,CHEMBL615120,1.0,,,4.0,,H,BAO_0000249,,9913.0,,Bos taurus,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,104729.0,
1.0,17430.0,,F,,,Intermediate,CHEMBL615121,1.0,,,5.0,,N,BAO_0000219,143B,9606.0,,Homo sapiens,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,80001.0,163.0
1.0,17430.0,,F,,,Intermediate,CHEMBL615122,1.0,,,6.0,,N,BAO_0000219,143B,9606.0,,Homo sapiens,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,80001.0,163.0
1.0,13799.0,,F,,,Intermediate,CHEMBL615123,1.0,,,7.0,,N,BAO_0000219,143B,10090.0,,Mus musculus,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,80001.0,163.0
1.0,17774.0,,F,,,Expert,CHEMBL615124,1.0,,,8.0,,N,BAO_0000219,143B,9606.0,,Homo sapiens,In vitro cell cytotoxicity was determined against 143B cell line,,80001.0,163.0
1.0,3801.0,,F,,,Intermediate,CHEMBL615125,1.0,,,9.0,,N,BAO_0000219,143B,9606.0,,Homo sapiens,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,80001.0,163.0
1.0,17430.0,,F,,,Intermediate,CHEMBL615126,1.0,,,10.0,,N,BAO_0000219,143B,9606.0,,Homo sapiens,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,80001.0,163.0
1.0,17430.0,,F,,,Intermediate,CHEMBL615127,1.0,,,11.0,,N,BAO_0000219,143B,9606.0,,Homo sapiens,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,80001.0,163.0
1.0,17774.0,,F,,,Expert,CHEMBL615128,1.0,,,12.0,,N,BAO_0000219,143B,9606.0,,Homo sapiens,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,80001.0,163.0
1.0,11324.0,,F,,,Intermediate,CHEMBL857900,1.0,,,13.0,,N,BAO_0000218,,1280.0,,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,50185.0,
1.0,11324.0,,F,,,Intermediate,CHEMBL615129,1.0,,,14.0,,N,BAO_0000218,,1280.0,,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,50185.0,
1.0,11324.0,,F,,,Intermediate,CHEMBL615130,1.0,,,15.0,,N,BAO_0000218,,1280.0,,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,50185.0,
1.0,11324.0,,F,,,Intermediate,CHEMBL615131,1.0,,,16.0,,N,BAO_0000218,,1280.0,,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,50185.0,
9.0,11347.0,,A,,,Expert,CHEMBL884521,1.0,,,17.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,100122.0,
8.0,16474.0,,B,,,Autocuration,CHEMBL615132,1.0,,,18.0,,H,BAO_0000357,,,,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,12054.0,
8.0,10091.0,,B,,,Autocuration,CHEMBL615133,1.0,,,19.0,,H,BAO_0000019,,,,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,12054.0,
8.0,16474.0,,B,,,Autocuration,CHEMBL615134,1.0,,,20.0,,H,BAO_0000357,,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,12054.0,
8.0,16474.0,,B,,,Autocuration,CHEMBL615135,1.0,,,21.0,,H,BAO_0000357,,,,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,12054.0,
8.0,16474.0,,B,,,Autocuration,CHEMBL615136,1.0,,,22.0,,H,BAO_0000357,,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,12054.0,
8.0,16474.0,,B,,,Autocuration,CHEMBL615137,1.0,,,23.0,,H,BAO_0000357,,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,12054.0,
8.0,16474.0,,B,,,Autocuration,CHEMBL615138,1.0,,,24.0,,H,BAO_0000357,,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,12054.0,
0.0,14352.0,,B,,,Autocuration,CHEMBL836324,1.0,,,25.0,,U,BAO_0000219,,,,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,22226.0,
8.0,5646.0,,B,,,Autocuration,CHEMBL615139,1.0,,,26.0,,H,BAO_0000357,,9986.0,,Oryctolagus cuniculus,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,12054.0,
8.0,5646.0,,B,,,Autocuration,CHEMBL615140,1.0,,,27.0,,H,BAO_0000357,,9986.0,,Oryctolagus cuniculus,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,12054.0,
8.0,10997.0,,B,,,Autocuration,CHEMBL615141,1.0,,,28.0,,H,BAO_0000219,,,,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,12426.0,
8.0,6309.0,,B,,,Autocuration,CHEMBL615142,1.0,,,29.0,,H,BAO_0000357,,3847.0,,soya bean,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,12054.0,
8.0,167.0,,B,,,Autocuration,CHEMBL615143,1.0,,,30.0,,H,BAO_0000357,,3847.0,,Glycine max,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,12054.0,
8.0,167.0,,B,,,Autocuration,CHEMBL615144,1.0,,,31.0,,H,BAO_0000357,,3847.0,,Glycine max,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,12054.0,
8.0,11087.0,,B,,,Autocuration,CHEMBL872867,1.0,,,32.0,,H,BAO_0000357,,3847.0,,Glycine max,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,12054.0,
8.0,11087.0,,B,,,Autocuration,CHEMBL615145,1.0,,,33.0,,H,BAO_0000357,,3847.0,,Glycine max,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,12054.0,
8.0,13622.0,,B,,,Autocuration,CHEMBL615146,1.0,,,34.0,,H,BAO_0000357,,3847.0,,Glycine max,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,12054.0,
8.0,13622.0,,B,,,Autocuration,CHEMBL615147,1.0,,,35.0,,H,BAO_0000357,,3847.0,,Glycine max,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,12054.0,
0.0,11347.0,,A,,,Autocuration,CHEMBL615148,1.0,,,36.0,,U,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,22226.0,
0.0,5926.0,,B,,,Autocuration,CHEMBL615149,1.0,,,37.0,,U,BAO_0000019,,562.0,,Escherichia coli,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,22226.0,
0.0,4567.0,,B,,,Autocuration,CHEMBL615150,1.0,,,38.0,,U,BAO_0000019,,,,,Dissociation constant with dimeric 16S rRNA RNA construct B,,22226.0,
3.0,3782.0,,B,,,Intermediate,CHEMBL615151,1.0,,,39.0,,M,BAO_0000225,,,,,Dissociation constant towards 16S rRNA construct A,,22222.0,
3.0,3782.0,,B,,,Intermediate,CHEMBL615152,1.0,,,40.0,,M,BAO_0000225,,,,,Dissociation constant towards 16S rRNA construct B,,22222.0,
3.0,4466.0,,B,,,Expert,CHEMBL615153,1.0,,,41.0,,M,BAO_0000225,,562.0,,Escherichia coli,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,100263.0,
3.0,6592.0,,B,,,Expert,CHEMBL615154,1.0,,,42.0,,M,BAO_0000225,,562.0,,Escherichia coli,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,100263.0,
8.0,898.0,,B,,,Autocuration,CHEMBL615155,1.0,,,43.0,,H,BAO_0000019,,,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,13053.0,
8.0,898.0,,B,,,Autocuration,CHEMBL615156,1.0,,,44.0,,H,BAO_0000019,,,,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,13053.0,
8.0,13163.0,,B,,,Autocuration,CHEMBL615157,1.0,,,45.0,,H,BAO_0000019,,9606.0,,Homo sapiens,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,20001.0,
8.0,13163.0,,B,,,Autocuration,CHEMBL615158,1.0,,,46.0,,H,BAO_0000019,,9606.0,,Homo sapiens,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,20001.0,
9.0,10691.0,,B,,,Expert,CHEMBL615159,1.0,,,47.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,12971.0,
9.0,10691.0,,B,,,Expert,CHEMBL615172,1.0,,,48.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,12971.0,
9.0,10691.0,,B,,,Expert,CHEMBL615173,1.0,,,49.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,12971.0,
9.0,10691.0,,B,,,Expert,CHEMBL615174,1.0,,,50.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,12971.0,
8.0,898.0,,B,,,Autocuration,CHEMBL884518,1.0,,,51.0,,H,BAO_0000019,,,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,13053.0,
8.0,912.0,,B,,,Autocuration,CHEMBL615175,1.0,,,52.0,,H,BAO_0000357,,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,11512.0,
8.0,912.0,,B,,,Autocuration,CHEMBL615176,1.0,,,53.0,,H,BAO_0000357,,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,11512.0,
8.0,912.0,,B,,,Autocuration,CHEMBL615177,1.0,,,54.0,,H,BAO_0000357,,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,11512.0,
5.0,15103.0,,B,Membranes,,Autocuration,CHEMBL615178,1.0,,,55.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,104740.0,
1.0,5116.0,,F,,,Intermediate,CHEMBL615179,1.0,,,56.0,,N,BAO_0000219,1A9,9606.0,,Homo sapiens,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,80002.0,506.0
7.0,14578.0,,F,,,Autocuration,CHEMBL615180,1.0,,,57.0,,D,BAO_0000219,Oocytes,10116.0,,Rattus norvegicus,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,104835.0,
7.0,14578.0,,F,,,Autocuration,CHEMBL615181,1.0,,,58.0,,D,BAO_0000219,Oocytes,10116.0,,Rattus norvegicus,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,104821.0,
7.0,14578.0,,F,,,Autocuration,CHEMBL615182,1.0,,,59.0,,D,BAO_0000219,Oocytes,10116.0,,Rattus norvegicus,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,104848.0,
1.0,4787.0,,F,,,Expert,CHEMBL615183,1.0,,,60.0,,N,BAO_0000219,1A9,9606.0,,Homo sapiens,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,80002.0,506.0
1.0,4787.0,,F,,,Intermediate,CHEMBL615184,1.0,,,61.0,,N,BAO_0000219,1A9,9606.0,,Homo sapiens,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,80002.0,506.0
1.0,3547.0,,F,,,Intermediate,CHEMBL615185,1.0,,,62.0,,N,BAO_0000219,1A9,9606.0,,Homo sapiens,Cytotoxic activity against human ovarian cancer (1A9) cell line,,80002.0,506.0
1.0,3547.0,,F,,,Intermediate,CHEMBL615186,1.0,,,63.0,,N,BAO_0000219,1A9,9606.0,,Homo sapiens,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,80002.0,506.0
1.0,6726.0,,F,,,Intermediate,CHEMBL615187,1.0,,,64.0,,N,BAO_0000219,1A9,9606.0,,Homo sapiens,Effective dose of compound against replication of 1A9 cell line was evaluated,,80002.0,506.0
1.0,3455.0,,F,,,Expert,CHEMBL885343,1.0,,,65.0,,N,BAO_0000219,1A9,9606.0,,Homo sapiens,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,80002.0,506.0
1.0,5726.0,,F,,,Intermediate,CHEMBL615188,1.0,,,66.0,,N,BAO_0000219,1A9,9606.0,,Homo sapiens,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,80002.0,506.0
1.0,5726.0,,F,,,Intermediate,CHEMBL615189,1.0,,,67.0,,N,BAO_0000219,1A9,9606.0,,Homo sapiens,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,80002.0,506.0
1.0,5726.0,,F,,,Intermediate,CHEMBL615190,1.0,,,68.0,,N,BAO_0000219,1A9,9606.0,,Homo sapiens,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,80002.0,506.0
1.0,3395.0,,F,,,Intermediate,CHEMBL615191,1.0,,,69.0,,N,BAO_0000219,1A9,9606.0,,Homo sapiens,Inhibitory activity against Taxol resistant 1A9 cell lines,,80002.0,506.0
1.0,3415.0,,F,,,Expert,CHEMBL615192,1.0,,,70.0,,N,BAO_0000219,1A9,9606.0,,Homo sapiens,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,80002.0,506.0
1.0,3415.0,,F,,,Expert,CHEMBL827083,1.0,,,71.0,,N,BAO_0000219,1A9,9606.0,,Homo sapiens,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,80002.0,506.0
1.0,17099.0,,F,,,Expert,CHEMBL615193,1.0,,,72.0,,N,BAO_0000219,1A9,9606.0,,Homo sapiens,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,80002.0,506.0
1.0,17099.0,,F,,,Intermediate,CHEMBL615194,1.0,,,73.0,,N,BAO_0000219,1A9,9606.0,,Homo sapiens,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,80002.0,506.0
1.0,17099.0,,F,,,Intermediate,CHEMBL615195,1.0,,,74.0,,N,BAO_0000219,1A9,9606.0,,Homo sapiens,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,80002.0,506.0
1.0,17099.0,,F,,,Intermediate,CHEMBL615196,1.0,,,75.0,,N,BAO_0000219,1A9,9606.0,,Homo sapiens,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,80002.0,506.0
1.0,17721.0,,F,,,Intermediate,CHEMBL615197,1.0,,,76.0,,N,BAO_0000219,Jurkat,9606.0,,Homo sapiens,Inhibitory concentration against Jurkat cells,,81072.0,503.0
0.0,1229.0,,F,,,Intermediate,CHEMBL615198,1.0,,,77.0,,U,BAO_0000019,,,,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,22226.0,
9.0,11347.0,,A,,,Expert,CHEMBL615199,1.0,,,78.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,100121.0,
8.0,17117.0,,B,,,Expert,CHEMBL615200,1.0,,,79.0,,H,BAO_0000357,,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,11231.0,
8.0,17117.0,,B,,,Expert,CHEMBL615201,1.0,,,80.0,,H,BAO_0000357,,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,11231.0,
8.0,17117.0,,B,,,Expert,CHEMBL615202,1.0,,,81.0,,H,BAO_0000357,,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,11231.0,
8.0,11375.0,,B,Microsomes,,Autocuration,CHEMBL615203,1.0,,,82.0,,H,BAO_0000251,,5476.0,,Candida albicans,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,11231.0,
8.0,11375.0,,B,Microsomes,,Autocuration,CHEMBL615204,1.0,,,83.0,,H,BAO_0000251,,5476.0,,Candida albicans,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,11231.0,
8.0,11375.0,,B,Microsomes,,Autocuration,CHEMBL615205,1.0,,,84.0,,H,BAO_0000251,,4932.0,,Saccharomyces cerevisiae,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,11231.0,
8.0,11375.0,,B,Microsomes,,Autocuration,CHEMBL615206,1.0,,,85.0,,H,BAO_0000251,,4932.0,,Saccharomyces cerevisiae,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,11231.0,
8.0,11375.0,2107.0,B,Microsomes,,Autocuration,CHEMBL615207,1.0,Liver,,86.0,,H,BAO_0000251,,9823.0,,Sus scrofa,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,12083.0,
8.0,791.0,,B,,,Autocuration,CHEMBL827084,1.0,,,87.0,,H,BAO_0000019,,10116.0,,Rattus norvegicus,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,11231.0,
8.0,791.0,,B,,,Autocuration,CHEMBL615208,1.0,,,88.0,,H,BAO_0000019,,10116.0,,Rattus norvegicus,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,11231.0,
8.0,791.0,,B,,,Autocuration,CHEMBL615209,1.0,,,89.0,,H,BAO_0000019,,10116.0,,Rattus norvegicus,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,11231.0,
9.0,11375.0,2107.0,B,Microsomes,,Autocuration,CHEMBL615210,1.0,Liver,,90.0,,D,BAO_0000251,,10116.0,,Rattus norvegicus,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,12083.0,
9.0,11375.0,2107.0,B,Microsomes,,Autocuration,CHEMBL615211,1.0,Liver,,91.0,,D,BAO_0000251,,10116.0,,Rattus norvegicus,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,12083.0,
9.0,153.0,2107.0,B,Microsomes,,Autocuration,CHEMBL615212,1.0,Liver,,92.0,,D,BAO_0000251,,10116.0,,Rattus norvegicus,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,12083.0,
8.0,8269.0,,B,,,Expert,CHEMBL615213,1.0,,,93.0,,H,BAO_0000357,,,,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,11377.0,
8.0,8269.0,,B,,,Expert,CHEMBL615273,1.0,,,94.0,,H,BAO_0000357,,,,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,11377.0,
1.0,17653.0,,F,,,Expert,CHEMBL615274,1.0,,,95.0,,N,BAO_0000219,HepG2,9606.0,,Homo sapiens,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,81020.0,726.0
1.0,14277.0,,F,,,Intermediate,CHEMBL615275,1.0,,,96.0,,N,BAO_0000219,HepG2,9606.0,,Homo sapiens,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,81020.0,726.0
1.0,1717.0,,F,,,Intermediate,CHEMBL615276,1.0,,,97.0,,N,BAO_0000219,HepG2,9606.0,,Homo sapiens,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,81020.0,726.0
1.0,14091.0,,F,,,Intermediate,CHEMBL615277,1.0,,,98.0,,N,BAO_0000219,HepG2,9606.0,,Homo sapiens,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,81020.0,726.0
1.0,14091.0,,F,,,Intermediate,CHEMBL615326,1.0,,,99.0,,N,BAO_0000219,HepG2,9606.0,,Homo sapiens,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,81020.0,726.0
1.0,17653.0,,F,,,Expert,CHEMBL883130,1.0,,,100.0,,N,BAO_0000218,,10407.0,,Hepatitis B virus,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,50606.0,
1.0,13105.0,,F,,,Intermediate,CHEMBL884519,1.0,,,101.0,,N,BAO_0000219,HepG2,9606.0,,Homo sapiens,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,81020.0,726.0
1.0,1717.0,,F,,,Intermediate,CHEMBL615327,1.0,,,102.0,,N,BAO_0000219,HepG2,9606.0,,Homo sapiens,Concentration required to inhibit 50% of 2.2.15 cell line,,81020.0,726.0
1.0,13105.0,,A,,,Intermediate,CHEMBL615328,1.0,,,103.0,,N,BAO_0000219,HepG2,9606.0,,Homo sapiens,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,81020.0,726.0
1.0,13600.0,,F,,,Intermediate,CHEMBL615329,1.0,,,104.0,,N,BAO_0000218,2.2.15,9606.0,,Homo sapiens,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,50587.0,
1.0,13467.0,,F,,,Intermediate,CHEMBL615330,1.0,,,105.0,,N,BAO_0000218,2.2.15,9606.0,,Homo sapiens,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,50587.0,
1.0,17477.0,,F,,,Expert,CHEMBL615331,1.0,,,106.0,,N,BAO_0000218,2.2.15,10407.0,,Hepatitis B virus,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,50606.0,
1.0,1593.0,,F,,,Intermediate,CHEMBL615332,1.0,,,107.0,,N,BAO_0000218,2.2.15,9606.0,,Homo sapiens,In vitro anti-HBV activity in 2.2.15 cells,,50587.0,
1.0,1593.0,,F,,,Intermediate,CHEMBL615333,1.0,,,108.0,,N,BAO_0000218,2.2.15,9606.0,,Homo sapiens,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,50587.0,
1.0,15089.0,,F,,,Intermediate,CHEMBL615334,1.0,,,109.0,,N,BAO_0000218,2.2.15,9606.0,,Homo sapiens,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,50587.0,
1.0,15089.0,,F,,,Intermediate,CHEMBL615335,1.0,,,110.0,,N,BAO_0000218,2.2.15,9606.0,,Homo sapiens,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,50587.0,
1.0,1593.0,,F,,,Intermediate,CHEMBL615336,1.0,,,111.0,,N,BAO_0000218,2.2.15,9606.0,,Homo sapiens,Cytotoxicity in 2.2.15 cells,,50587.0,
1.0,1593.0,,F,,,Intermediate,CHEMBL615337,1.0,,,112.0,,N,BAO_0000218,2.2.15,9606.0,,Homo sapiens,Cytotoxicity in 2.2.15 cells; Not determined,,50587.0,
1.0,13600.0,,F,,,Intermediate,CHEMBL615338,1.0,,,113.0,,N,BAO_0000218,2.2.15,9606.0,,Homo sapiens,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,50587.0,
1.0,13467.0,,F,,,Intermediate,CHEMBL615339,1.0,,,114.0,,N,BAO_0000218,2.2.15,9606.0,,Homo sapiens,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,50587.0,
1.0,13467.0,,F,,,Intermediate,CHEMBL615340,1.0,,,115.0,,N,BAO_0000218,2.2.15,9606.0,,Homo sapiens,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,50587.0,
1.0,14764.0,,F,,,Intermediate,CHEMBL615341,1.0,,,116.0,,N,BAO_0000219,HepG2,9606.0,,Homo sapiens,Antiviral activity against HBV was determined in 2.215 cell line,,81020.0,726.0
0.0,6531.0,,B,Microsomes,,Autocuration,CHEMBL615342,1.0,,,117.0,,U,BAO_0000251,,9606.0,,Homo sapiens,Inhibition of 20-HETE synthesis in human renal microsomes,,22226.0,
0.0,17322.0,,B,,,Autocuration,CHEMBL615343,1.0,,,118.0,,U,BAO_0000019,,,,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,22226.0,
1.0,17072.0,,F,,,Intermediate,CHEMBL615344,1.0,,,119.0,,N,BAO_0000219,2008,9606.0,,Homo sapiens,Inhibitory concentration against 2008 (ovarian) cells,,80612.0,388.0
1.0,16936.0,,F,,,Intermediate,CHEMBL615345,1.0,,,120.0,,N,BAO_0000219,2008,9606.0,,Homo sapiens,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,80612.0,388.0
1.0,16936.0,,F,,,Intermediate,CHEMBL615346,1.0,,,121.0,,N,BAO_0000219,2008,9606.0,,Homo sapiens,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,80612.0,388.0
1.0,17146.0,,F,,,Intermediate,CHEMBL615347,1.0,,,122.0,,N,BAO_0000219,2008,9606.0,,Homo sapiens,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,80612.0,388.0
1.0,17146.0,,F,,,Intermediate,CHEMBL615348,1.0,,,123.0,,N,BAO_0000219,2008,9606.0,,Homo sapiens,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,80612.0,388.0
1.0,10797.0,,F,,,Intermediate,CHEMBL827085,1.0,,,124.0,,N,BAO_0000219,2008/R,9606.0,,Homo sapiens,In vitro inhibition of 2008/R ovarian cancer cell line,,80613.0,561.0
1.0,10797.0,,F,,,Intermediate,CHEMBL615349,1.0,,,125.0,,N,BAO_0000219,2008/R,9606.0,,Homo sapiens,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,80613.0,561.0
1.0,10797.0,,F,,,Intermediate,CHEMBL615350,1.0,,,126.0,,N,BAO_0000219,2008/S,9606.0,,Homo sapiens,In vitro inhibition of 2008/S ovarian cancer cell line,,80614.0,389.0
1.0,10797.0,,F,,,Intermediate,CHEMBL615351,1.0,,,127.0,,N,BAO_0000219,2008/S,9606.0,,Homo sapiens,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,80614.0,389.0
2.0,4823.0,,B,,,Expert,CHEMBL615352,1.0,,,128.0,,S,BAO_0000220,,9606.0,,Homo sapiens,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,100256.0,
2.0,12912.0,,B,,,Intermediate,CHEMBL615353,1.0,,,129.0,,S,BAO_0000220,,9606.0,,Homo sapiens,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,100256.0,
2.0,2957.0,,B,,,Expert,CHEMBL615354,1.0,,,130.0,,S,BAO_0000220,,,,,Inhibition of chymotrypsin-like activity of 20S proteasome,,100256.0,
2.0,2957.0,,B,,,Expert,CHEMBL615355,1.0,,,131.0,,S,BAO_0000220,,,,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,100256.0,
2.0,3260.0,,B,,,Intermediate,CHEMBL615356,1.0,,,132.0,,S,BAO_0000220,,,,,Inhibitory activity against 20S proteosome,,100256.0,
0.0,3451.0,,B,,,Autocuration,CHEMBL615357,1.0,,,133.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Compound was tested for inhibitory activity against tryptase,,22226.0,
1.0,13885.0,,F,,,Intermediate,CHEMBL615358,1.0,,,134.0,,N,BAO_0000219,HepG2,9606.0,,Homo sapiens,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,81020.0,726.0
1.0,13885.0,,F,,,Intermediate,CHEMBL827086,1.0,,,135.0,,N,BAO_0000219,HepG2,9606.0,,Homo sapiens,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,81020.0,726.0
0.0,3676.0,,B,,,Autocuration,CHEMBL615359,1.0,,,136.0,,U,BAO_0000019,,,,,Compound was tested for the inhibition of Alpha-glucosidase,,22226.0,
8.0,6043.0,,B,,,Autocuration,CHEMBL615360,1.0,,,137.0,,H,BAO_0000357,,,,,Inhibitory concentration against human neutrophil elastase (HNE),,235.0,
0.0,11140.0,948.0,F,,,Autocuration,CHEMBL615361,1.0,Heart,,138.0,,U,BAO_0000218,,10116.0,,Rattus norvegicus,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,22226.0,
8.0,10543.0,,F,,,Autocuration,CHEMBL615362,1.0,,,139.0,,H,BAO_0000019,,,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,19640.0,
8.0,10543.0,,F,,,Expert,CHEMBL615363,1.0,,,140.0,,H,BAO_0000019,,,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,19640.0,
8.0,10543.0,,B,,,Autocuration,CHEMBL615364,1.0,,,141.0,,H,BAO_0000357,,,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,19640.0,
8.0,10543.0,,F,,,Expert,CHEMBL615365,1.0,,,142.0,,H,BAO_0000019,,,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,19640.0,
1.0,11365.0,,F,,,Intermediate,CHEMBL615366,1.0,,,143.0,,N,BAO_0000219,P338,10090.0,,Mus musculus,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,80360.0,524.0
1.0,11365.0,,F,,,Intermediate,CHEMBL615367,1.0,,,144.0,,N,BAO_0000219,P338,10090.0,,Mus musculus,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,80360.0,524.0
1.0,11803.0,,F,,,Intermediate,CHEMBL615368,1.0,,,145.0,,N,BAO_0000219,PBL,9606.0,,Homo sapiens,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,80384.0,554.0
0.0,11803.0,,F,,,Autocuration,CHEMBL615369,1.0,,,146.0,,U,BAO_0000019,,9940.0,,Ovis aries,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,22226.0,
0.0,11803.0,,F,,,Autocuration,CHEMBL615370,1.0,,,147.0,,U,BAO_0000019,,9940.0,,Ovis aries,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,22226.0,
8.0,12278.0,,B,,,Autocuration,CHEMBL615673,1.0,,,148.0,,H,BAO_0000357,,,,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,191.0,
0.0,8249.0,,F,,,Autocuration,CHEMBL615674,1.0,,,149.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,22226.0,
0.0,8249.0,,F,,,Autocuration,CHEMBL615675,1.0,,,150.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,22226.0,
0.0,8249.0,,F,,,Autocuration,CHEMBL615676,1.0,,,151.0,,U,BAO_0000219,CCRF-CEM,9606.0,,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,22226.0,635.0
0.0,8249.0,,F,,,Autocuration,CHEMBL615677,1.0,,,152.0,,U,BAO_0000219,CCRF-CEM,9606.0,,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,22226.0,635.0
0.0,8249.0,,F,,,Autocuration,CHEMBL615678,1.0,,,153.0,,U,BAO_0000219,CCRF-CEM,9606.0,,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,22226.0,635.0
0.0,8249.0,,F,,,Autocuration,CHEMBL615679,1.0,,,154.0,,U,BAO_0000219,CCRF-CEM,9606.0,,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,22226.0,635.0
0.0,8249.0,,F,,,Autocuration,CHEMBL615680,1.0,,,155.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,22226.0,
0.0,8249.0,,F,,,Autocuration,CHEMBL615681,1.0,,,156.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,22226.0,
6.0,16992.0,,B,,,Autocuration,CHEMBL857972,1.0,,,157.0,,H,BAO_0000249,,,,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,104290.0,
1.0,10543.0,,F,,,Intermediate,CHEMBL857899,1.0,,,158.0,,N,BAO_0000218,,1314.0,,Streptococcus pyogenes,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,50264.0,
1.0,17833.0,,F,,,Intermediate,CHEMBL615371,1.0,,,159.0,,N,BAO_0000218,,10335.0,,Human herpesvirus 3,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,50527.0,
1.0,17290.0,,F,,,Expert,CHEMBL615372,1.0,,,160.0,,N,BAO_0000218,HEL,10335.0,,vericilla zoster virus,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,50527.0,468.0
1.0,17290.0,,F,,,Intermediate,CHEMBL615373,1.0,,,161.0,,N,BAO_0000218,,10335.0,,vericilla zoster virus,Antiviral activity against 07/1 strain of VZV; ND: No data,,50527.0,
1.0,17290.0,,F,,,Intermediate,CHEMBL615374,1.0,,,162.0,,N,BAO_0000218,,10335.0,,vericilla zoster virus,Antiviral activity against 07/1 strain of VZV; ND=No data,,50527.0,
1.0,10932.0,,F,,,Intermediate,CHEMBL615375,1.0,,,163.0,,N,BAO_0000218,,561.0,,escherichia cloac,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,50145.0,
0.0,9707.0,,B,,,Autocuration,CHEMBL615376,1.0,,,164.0,,U,BAO_0000019,,,,,Ratio of Ki at A2 to Ki at A1 receptors,,22226.0,
8.0,2346.0,,B,,,Expert,CHEMBL615377,1.0,,,165.0,,H,BAO_0000249,,5476.0,,Candida albicans,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,11143.0,
8.0,2205.0,,B,,,Expert,CHEMBL615378,1.0,,,166.0,,H,BAO_0000357,,284593.0,,Candida glabrata CBS 138,"Inhibition of 1,3-beta-glucan synthase",,18077.0,
1.0,11900.0,,F,,,Intermediate,CHEMBL615379,1.0,,,167.0,,N,BAO_0000219,1-87 tumor cell line,9606.0,,Homo sapiens,Inhibition of growth of 1-87 human tumor cell line,,80609.0,832.0
9.0,14864.0,,B,,,Expert,CHEMBL615380,1.0,,,168.0,,D,BAO_0000219,,10116.0,,Rattus norvegicus,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,12166.0,
9.0,16474.0,,B,,,Autocuration,CHEMBL615381,1.0,,,169.0,,D,BAO_0000357,,3847.0,,Glycine max,Inhibitory activity against soybean 1-lipoxygenase (SLO),,100171.0,
9.0,16474.0,,B,,,Autocuration,CHEMBL615382,1.0,,,170.0,,D,BAO_0000357,,3847.0,,Glycine max,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,100171.0,
9.0,16474.0,,B,,,Autocuration,CHEMBL615383,1.0,,,171.0,,D,BAO_0000357,,3847.0,,Glycine max,% inhibition against soybean 1-lipoxygenase (SLO),,100171.0,
9.0,16474.0,,B,,,Autocuration,CHEMBL615384,1.0,,,172.0,,D,BAO_0000357,,3847.0,,Glycine max,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,100171.0,
9.0,3094.0,,B,,,Autocuration,CHEMBL615385,1.0,,,173.0,,D,BAO_0000357,,3847.0,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,100171.0,
9.0,3094.0,,B,,,Autocuration,CHEMBL615386,1.0,,,174.0,,D,BAO_0000357,,3847.0,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,100171.0,
9.0,3094.0,,B,,,Autocuration,CHEMBL615387,1.0,,,175.0,,D,BAO_0000357,,3847.0,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,100171.0,
9.0,3094.0,,B,,,Autocuration,CHEMBL615388,1.0,,,176.0,,D,BAO_0000357,,3847.0,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,100171.0,
9.0,3094.0,,B,,,Autocuration,CHEMBL615214,1.0,,,177.0,,D,BAO_0000357,,3847.0,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,100171.0,
9.0,3094.0,,B,,,Autocuration,CHEMBL827087,1.0,,,178.0,,D,BAO_0000357,,3847.0,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,100171.0,
9.0,3094.0,,B,,,Autocuration,CHEMBL615215,1.0,,,179.0,,D,BAO_0000357,,3847.0,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,100171.0,
9.0,3094.0,,B,,,Autocuration,CHEMBL615216,1.0,,,180.0,,D,BAO_0000357,,3847.0,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,100171.0,
9.0,3094.0,,B,,,Autocuration,CHEMBL615217,1.0,,,181.0,,D,BAO_0000357,,3847.0,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,100171.0,
9.0,3094.0,,B,,,Autocuration,CHEMBL615218,1.0,,,182.0,,D,BAO_0000357,,3847.0,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,100171.0,
9.0,3094.0,,B,,,Autocuration,CHEMBL615219,1.0,,,183.0,,D,BAO_0000357,,3847.0,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,100171.0,
0.0,10413.0,,B,,,Autocuration,CHEMBL615220,1.0,,,184.0,,U,BAO_0000019,,10090.0,,Mus musculus,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,22226.0,
1.0,16929.0,,F,,,Intermediate,CHEMBL615221,1.0,,,185.0,,N,BAO_0000219,C3H 10T1/2,10090.0,,Mus musculus,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,80049.0,294.0
0.0,1229.0,,F,,,Intermediate,CHEMBL615222,1.0,,,186.0,,U,BAO_0000019,,,,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,22226.0,
8.0,16587.0,,B,,,Autocuration,CHEMBL615223,1.0,,,187.0,,H,BAO_0000357,,,,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,11489.0,
8.0,16587.0,,B,,,Autocuration,CHEMBL615224,1.0,,,188.0,,H,BAO_0000357,,,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,11862.0,
8.0,16587.0,,B,,,Autocuration,CHEMBL615225,1.0,,,189.0,,H,BAO_0000357,,,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,11862.0,
8.0,16587.0,,B,,,Autocuration,CHEMBL615226,1.0,,,190.0,,H,BAO_0000357,,,,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,11489.0,
8.0,16587.0,,B,,,Autocuration,CHEMBL615227,1.0,,,191.0,,H,BAO_0000357,,,,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,11862.0,
9.0,8058.0,,F,,,Expert,CHEMBL615228,1.0,,,192.0,,D,BAO_0000019,,9913.0,,Bos taurus,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,12347.0,
9.0,9065.0,,B,,,Expert,CHEMBL615229,1.0,,,193.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,100120.0,
9.0,8865.0,2369.0,B,,,Expert,CHEMBL615230,1.0,Adrenal gland,,194.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,100120.0,
9.0,9066.0,,B,,,Expert,CHEMBL615231,1.0,,,195.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibition of rat adrenal 11-beta-hydroxylase,,100120.0,
9.0,8394.0,,B,,,Expert,CHEMBL884520,1.0,,,196.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibition of rat adrenal 11-beta-hydroxylase,,100120.0,
9.0,8394.0,,B,,,Expert,CHEMBL615232,1.0,,,197.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,100120.0,
8.0,6431.0,,B,,,Autocuration,CHEMBL615233,1.0,,,198.0,,H,BAO_0000019,,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,10328.0,
8.0,6431.0,,B,,,Autocuration,CHEMBL827088,1.0,,,199.0,,H,BAO_0000357,,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,11490.0,
8.0,6431.0,,B,,,Autocuration,CHEMBL615234,1.0,,,200.0,,H,BAO_0000357,,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,11490.0,
8.0,9295.0,,F,,,Autocuration,CHEMBL615235,1.0,,,201.0,,H,BAO_0000019,,,,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,11134.0,
8.0,10193.0,,B,,,Autocuration,CHEMBL615236,1.0,,,202.0,,H,BAO_0000019,,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,12052.0,
8.0,13622.0,,B,,,Autocuration,CHEMBL615237,1.0,,,203.0,,H,BAO_0000019,,,,,Compound was tested in vitro for inhibition of 12-LO human platelet,,11134.0,
8.0,12079.0,,F,,,Autocuration,CHEMBL615238,1.0,,,204.0,,H,BAO_0000019,,,,,Inhibitory concentration against human platelet 12-lipoxygenase,,11134.0,
8.0,13622.0,,B,,,Autocuration,CHEMBL615239,1.0,,,205.0,,H,BAO_0000019,,,,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,11134.0,
9.0,12079.0,,F,,,Autocuration,CHEMBL615240,1.0,,,206.0,,D,BAO_0000019,,9606.0,,Homo sapiens,Inhibitory concentration against human platelet 12-lipoxygenase,,11134.0,
8.0,13500.0,,B,,,Expert,CHEMBL615241,1.0,,,207.0,,H,BAO_0000019,,,,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,11835.0,
8.0,13723.0,,B,,,Expert,CHEMBL615242,1.0,,,208.0,,H,BAO_0000357,,,,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,11601.0,
8.0,16474.0,,B,,,Autocuration,CHEMBL615243,1.0,,,209.0,,H,BAO_0000019,,,,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,11134.0,
8.0,1630.0,,B,,,Autocuration,CHEMBL615244,1.0,,,210.0,,H,BAO_0000019,,,,,Inhibitory activity against human platelet 12-lipoxygenase,,11134.0,
8.0,167.0,,B,,,Autocuration,CHEMBL615245,1.0,,,211.0,,H,BAO_0000019,,,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,11134.0,
8.0,16474.0,,B,,,Autocuration,CHEMBL615246,1.0,,,212.0,,H,BAO_0000019,,,,,% inhibition against human platelet 12-lipoxygenase (12-HLO),,11134.0,
8.0,167.0,,B,,,Autocuration,CHEMBL615247,1.0,,,213.0,,H,BAO_0000019,,,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,11134.0,
8.0,16474.0,,B,,,Autocuration,CHEMBL615248,1.0,,,214.0,,H,BAO_0000019,,,,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,11134.0,
8.0,10091.0,,B,,,Autocuration,CHEMBL615249,1.0,,,215.0,,H,BAO_0000357,,,,,Inhibitory activity towards porcine 12-lipoxygenase,,11601.0,
8.0,11966.0,,B,,,Autocuration,CHEMBL615250,1.0,,,216.0,,H,BAO_0000357,,,,,Tested for inhibition against porcine 12-LO,,11601.0,
8.0,951.0,,B,,,Autocuration,CHEMBL615251,1.0,,,217.0,,H,BAO_0000019,,,,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,12052.0,
8.0,10997.0,,B,,,Autocuration,CHEMBL615252,1.0,,,218.0,,H,BAO_0000019,,,,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,12052.0,
8.0,10193.0,,B,,,Expert,CHEMBL828340,1.0,,,219.0,,H,BAO_0000019,,,,,In vitro inhibition of rat platelet 12-lipoxygenase,,12052.0,
8.0,10193.0,,B,,,Autocuration,CHEMBL615253,1.0,,,220.0,,H,BAO_0000019,,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,12052.0,
8.0,10193.0,,B,,,Autocuration,CHEMBL615254,1.0,,,221.0,,H,BAO_0000019,,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,12052.0,
8.0,10193.0,,B,,,Autocuration,CHEMBL615255,1.0,,,222.0,,H,BAO_0000019,,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,12052.0,
8.0,10193.0,,B,,,Autocuration,CHEMBL615256,1.0,,,223.0,,H,BAO_0000019,,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,12052.0,
8.0,10193.0,,B,,,Autocuration,CHEMBL615257,1.0,,,224.0,,H,BAO_0000019,,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,12052.0,
8.0,11087.0,,B,,,Autocuration,CHEMBL615258,1.0,,,225.0,,H,BAO_0000019,,,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,12052.0,
1.0,15569.0,,F,,,Intermediate,CHEMBL615259,1.0,,,226.0,,N,BAO_0000219,41M,9606.0,,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,80007.0,621.0
1.0,12989.0,,F,,,Expert,CHEMBL615260,1.0,,,227.0,,N,BAO_0000219,41M,9606.0,,Homo sapiens,In vitro antitumor activity against 41M cell line.,,80007.0,621.0
1.0,16745.0,,F,,,Intermediate,CHEMBL615261,1.0,,,228.0,,N,BAO_0000219,41M,9606.0,,Homo sapiens,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,80007.0,621.0
1.0,15569.0,,F,,,Intermediate,CHEMBL615262,1.0,,,229.0,,N,BAO_0000219,41M,9606.0,,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,80007.0,621.0
1.0,12989.0,,F,,,Expert,CHEMBL615263,1.0,,,230.0,,N,BAO_0000219,41M,9606.0,,Homo sapiens,In vitro antitumor activity against 41McisR cell line.,,80007.0,621.0
1.0,12989.0,,F,,,Expert,CHEMBL838393,1.0,,,231.0,,N,BAO_0000219,41M,9606.0,,Homo sapiens,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,80007.0,621.0
1.0,16745.0,,F,,,Intermediate,CHEMBL615264,1.0,,,232.0,,N,BAO_0000219,41M,9606.0,,Homo sapiens,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,80007.0,621.0
9.0,6210.0,,B,,,Expert,CHEMBL615265,1.0,,,233.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,84.0,
9.0,6210.0,,B,,,Expert,CHEMBL615266,1.0,,,234.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,68.0,
8.0,6226.0,,B,,,Expert,CHEMBL615267,1.0,,,235.0,,H,BAO_0000357,,,,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,68.0,
8.0,17855.0,,B,,,Expert,CHEMBL615268,1.0,,,236.0,,H,BAO_0000357,,,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,10201.0,
8.0,17855.0,,B,,,Expert,CHEMBL615269,1.0,,,237.0,,H,BAO_0000357,,,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,10201.0,
8.0,17855.0,,B,,,Expert,CHEMBL615270,1.0,,,238.0,,H,BAO_0000357,,,,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,10201.0,
8.0,10413.0,,B,,,Autocuration,CHEMBL615271,1.0,,,239.0,,H,BAO_0000357,,,,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,12220.0,
8.0,10413.0,,B,,,Autocuration,CHEMBL615272,1.0,,,240.0,,H,BAO_0000357,,562.0,,Escherichia coli,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,11303.0,
8.0,10413.0,,B,,,Autocuration,CHEMBL615103,1.0,,,241.0,,H,BAO_0000357,,562.0,,Escherichia coli,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,11303.0,
8.0,10413.0,,B,,,Autocuration,CHEMBL615104,1.0,,,242.0,,H,BAO_0000357,,562.0,,Escherichia coli,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,11303.0,
8.0,10413.0,,B,,,Autocuration,CHEMBL615105,1.0,,,243.0,,H,BAO_0000357,,,,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,12220.0,
8.0,10413.0,,B,,,Autocuration,CHEMBL872866,1.0,,,244.0,,H,BAO_0000357,,,,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,12220.0,
8.0,7587.0,,B,,,Autocuration,CHEMBL615106,1.0,,,245.0,,H,BAO_0000357,,9823.0,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,11303.0,
8.0,7587.0,,B,,,Autocuration,CHEMBL615107,1.0,,,246.0,,H,BAO_0000019,,9823.0,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,11303.0,
8.0,7587.0,,B,,,Autocuration,CHEMBL615108,1.0,,,247.0,,H,BAO_0000357,,9823.0,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,11303.0,
8.0,7587.0,,B,,,Autocuration,CHEMBL615109,1.0,,,248.0,,H,BAO_0000357,,9823.0,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,11303.0,
8.0,7587.0,,B,,,Autocuration,CHEMBL615110,1.0,,,249.0,,H,BAO_0000357,,9823.0,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,11303.0,
8.0,7587.0,,B,,,Autocuration,CHEMBL840105,1.0,,,250.0,,H,BAO_0000019,,9823.0,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,11303.0,
8.0,7587.0,,B,,,Autocuration,CHEMBL615111,1.0,,,251.0,,H,BAO_0000019,,9823.0,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,11303.0,
8.0,7587.0,,B,,,Autocuration,CHEMBL615112,1.0,,,252.0,,H,BAO_0000019,,9823.0,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,11303.0,
8.0,7587.0,,B,,,Autocuration,CHEMBL615113,1.0,,,253.0,,H,BAO_0000019,,9823.0,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,11303.0,
8.0,7587.0,,B,,,Autocuration,CHEMBL615114,1.0,,,254.0,,H,BAO_0000019,,9823.0,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,11303.0,
8.0,7587.0,,B,,,Autocuration,CHEMBL615115,1.0,,,255.0,,H,BAO_0000357,,9823.0,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,11303.0,
8.0,7587.0,,B,,,Autocuration,CHEMBL615116,1.0,,,256.0,,H,BAO_0000019,,9823.0,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,11303.0,
8.0,7323.0,,B,,,Autocuration,CHEMBL615698,1.0,,,257.0,,H,BAO_0000357,,,,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,11303.0,
0.0,7587.0,,B,,,Autocuration,CHEMBL615699,1.0,,,258.0,,U,BAO_0000019,,9823.0,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,22226.0,
0.0,7587.0,,B,,,Autocuration,CHEMBL615700,1.0,,,259.0,,U,BAO_0000019,,9823.0,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,22226.0,
8.0,13750.0,,B,,,Expert,CHEMBL615701,1.0,,,260.0,,H,BAO_0000357,,4932.0,,Saccharomyces cerevisiae,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,100249.0,
0.0,7662.0,,B,,,Autocuration,CHEMBL615702,1.0,,,261.0,,U,BAO_0000019,,10116.0,,Rattus norvegicus,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,22226.0,
0.0,7662.0,,B,,,Autocuration,CHEMBL615703,1.0,,,262.0,,U,BAO_0000019,,10116.0,,Rattus norvegicus,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,22226.0,
0.0,7662.0,,B,,,Autocuration,CHEMBL615704,1.0,,,263.0,,U,BAO_0000019,,10116.0,,Rattus norvegicus,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,22226.0,
6.0,12211.0,,F,,,Autocuration,CHEMBL615705,1.0,,,264.0,,H,BAO_0000019,,,,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,104698.0,
6.0,12211.0,,F,,,Autocuration,CHEMBL615706,1.0,,,265.0,,H,BAO_0000019,,,,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,104698.0,
9.0,12211.0,2116.0,F,,,Intermediate,CHEMBL615707,1.0,Ileum,,266.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,20033.0,
8.0,12211.0,,F,,,Expert,CHEMBL615708,1.0,,,267.0,,H,BAO_0000019,,,,,Stimulatory activity of intragastric pressure was tested in the rat,,10623.0,
8.0,15453.0,,B,,,Autocuration,CHEMBL615709,1.0,,,268.0,,H,BAO_0000357,,,,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,121.0,
0.0,11884.0,,F,,,Autocuration,CHEMBL615710,1.0,,,269.0,,U,BAO_0000218,,10116.0,,Rattus norvegicus,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,22226.0,
8.0,7185.0,,F,,,Autocuration,CHEMBL615711,1.0,,,270.0,,H,BAO_0000019,,,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,12688.0,
9.0,6876.0,,B,,,Expert,CHEMBL615712,1.0,,,271.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,121.0,
9.0,6876.0,,B,,,Expert,CHEMBL836325,1.0,,,272.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,121.0,
8.0,11863.0,,F,,,Autocuration,CHEMBL615713,1.0,,,273.0,,H,BAO_0000019,,,,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,12198.0,
8.0,11863.0,,B,,,Autocuration,CHEMBL615714,1.0,,,274.0,,H,BAO_0000357,,,,,Inhibition constant of high-affinity 5-HT uptake,,12198.0,
8.0,11863.0,,F,,,Autocuration,CHEMBL615715,1.0,,,275.0,,H,BAO_0000019,,,,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,12198.0,
8.0,11863.0,,F,,,Autocuration,CHEMBL615716,1.0,,,276.0,,H,BAO_0000019,,,,,Maximum rate was determined for high affinity transport of 5-HT,,12198.0,
4.0,4639.0,,F,,,Autocuration,CHEMBL615717,1.0,,,277.0,,H,BAO_0000019,,,,,Compound was tested for agonistic activity against 5-HT uptake,,104714.0,
8.0,15796.0,,B,,,Expert,CHEMBL881818,1.0,,,278.0,,H,BAO_0000019,,,,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,10577.0,
8.0,15796.0,,B,,,Expert,CHEMBL884540,1.0,,,279.0,,H,BAO_0000357,,9913.0,,Bos taurus,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,105.0,
5.0,12801.0,,B,,,Autocuration,CHEMBL615718,1.0,,,280.0,,D,BAO_0000224,,10116.0,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,104744.0,
4.0,12801.0,,B,,,Autocuration,CHEMBL615719,1.0,,,281.0,,H,BAO_0000224,,,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,104744.0,
4.0,12120.0,,B,Membranes,,Autocuration,CHEMBL615720,1.0,,,282.0,,H,BAO_0000249,,,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,104744.0,
4.0,12120.0,,B,Membranes,,Autocuration,CHEMBL615721,1.0,,,283.0,,H,BAO_0000249,,,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,104744.0,
4.0,11963.0,,B,,,Autocuration,CHEMBL615722,1.0,,,284.0,,H,BAO_0000019,,,,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,104744.0,
8.0,11701.0,,F,,,Autocuration,CHEMBL615723,1.0,,,285.0,,H,BAO_0000019,,,,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,51.0,
8.0,9995.0,10000000.0,B,,,Autocuration,CHEMBL615724,1.0,Hippocampus,,286.0,,H,BAO_0000221,,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51.0,
8.0,9995.0,10000000.0,B,,,Autocuration,CHEMBL615725,1.0,Hippocampus,,287.0,,H,BAO_0000221,,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,51.0,
8.0,9995.0,10000000.0,B,,,Autocuration,CHEMBL615726,1.0,Hippocampus,,288.0,,H,BAO_0000221,,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51.0,
8.0,16394.0,,F,,,Autocuration,CHEMBL615727,1.0,,,289.0,In vivo,H,BAO_0000218,,,,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,10576.0,
9.0,11574.0,,F,,,Intermediate,CHEMBL615728,1.0,,,290.0,,D,BAO_0000019,,10141.0,,Cavia porcellus,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,105570.0,
8.0,15779.0,,B,,,Autocuration,CHEMBL857971,1.0,,,291.0,,H,BAO_0000219,CHO,,,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,279.0,449.0
8.0,15363.0,,B,,,Autocuration,CHEMBL615729,1.0,,,292.0,,H,BAO_0000357,,,,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,107.0,
9.0,15363.0,,F,,,Expert,CHEMBL615730,1.0,,,293.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Efficacy against 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,15329.0,,F,,,Expert,CHEMBL615731,1.0,,,294.0,,H,BAO_0000019,,,,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,12687.0,
8.0,15329.0,,F,,,Expert,CHEMBL615732,1.0,,,295.0,,H,BAO_0000019,,,,,Relative potency towards 5-HT2A receptor of rat tail artery,,12687.0,
8.0,15329.0,,F,,,Expert,CHEMBL615733,1.0,,,296.0,,H,BAO_0000019,,,,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,12687.0,
8.0,15329.0,,F,,,Expert,CHEMBL615734,1.0,,,297.0,,H,BAO_0000019,,,,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,12687.0,
8.0,15329.0,,F,,,Autocuration,CHEMBL615735,1.0,,,298.0,,H,BAO_0000019,,,,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,12687.0,
8.0,15329.0,,F,,,Expert,CHEMBL615736,1.0,,,299.0,,H,BAO_0000019,,,,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,12687.0,
9.0,273.0,2116.0,F,,,Intermediate,CHEMBL615737,1.0,Ileum,,300.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,20033.0,
9.0,273.0,2116.0,F,,,Intermediate,CHEMBL615738,1.0,Ileum,,301.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,20033.0,
9.0,273.0,2116.0,F,,,Intermediate,CHEMBL615739,1.0,Ileum,,302.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,20033.0,
8.0,12092.0,,B,,,Autocuration,CHEMBL615278,1.0,,,303.0,,H,BAO_0000357,,,,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,10623.0,
9.0,1317.0,,F,,,Expert,CHEMBL615279,1.0,,,304.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,10623.0,
8.0,12409.0,,B,,,Expert,CHEMBL615280,1.0,,,305.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 4 receptor,,168.0,
0.0,11126.0,,B,,,Autocuration,CHEMBL615281,1.0,,,306.0,,U,BAO_0000019,,9031.0,,Gallus gallus,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,22226.0,
0.0,11126.0,,F,,,Autocuration,CHEMBL615282,1.0,,,307.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,22226.0,
0.0,11126.0,,F,,,Autocuration,CHEMBL615283,1.0,,,308.0,,U,BAO_0000019,,9606.0,,Homo sapiens,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,22226.0,
1.0,11126.0,,B,,,Autocuration,CHEMBL615284,1.0,,,309.0,,N,BAO_0000219,HL-60,9606.0,,Homo sapiens,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,80156.0,649.0
0.0,11126.0,,B,,,Autocuration,CHEMBL615285,1.0,,,310.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,22226.0,
0.0,11126.0,,B,,,Autocuration,CHEMBL615286,1.0,,,311.0,,U,BAO_0000019,,9606.0,,Homo sapiens,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,22226.0,
7.0,17807.0,,B,,,Autocuration,CHEMBL615287,1.0,,,312.0,,D,BAO_0000219,Oocytes,9606.0,,Homo sapiens,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,104703.0,
2.0,16575.0,,F,,,Intermediate,CHEMBL615288,1.0,,,313.0,,S,BAO_0000220,,,,,Chymotryptic inhibitory activity against 26S proteasome,,100256.0,
2.0,15407.0,,B,,,Intermediate,CHEMBL615289,1.0,,,314.0,,S,BAO_0000220,,,,,Inhibitory activity against 26S proteasome degradation of IkB,,100256.0,
1.0,10797.0,,F,,,Intermediate,CHEMBL615290,1.0,,,315.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro inhibition of 2780/DOX ovarian cancer cell line,,81034.0,478.0
1.0,10797.0,,F,,,Intermediate,CHEMBL884522,1.0,,,316.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro inhibition of 2780/S ovarian cancer cell line,,81034.0,478.0
0.0,3469.0,,F,,,Autocuration,CHEMBL615291,1.0,,,317.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,22226.0,
3.0,16037.0,,B,,,Intermediate,CHEMBL615292,1.0,,,318.0,,M,BAO_0000225,,,,,Association constant for binding to AATT 28-mer AATT hairpin,,22222.0,
3.0,16037.0,,B,,,Intermediate,CHEMBL615293,1.0,,,319.0,,M,BAO_0000225,,,,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,22222.0,
3.0,16037.0,,B,,,Intermediate,CHEMBL615294,1.0,,,320.0,,M,BAO_0000225,,,,,Reaction Rate Parameter for 28-mer AATT hairpin,,22222.0,
3.0,16037.0,,B,,,Intermediate,CHEMBL615295,1.0,,,321.0,,M,BAO_0000225,,,,,Reaction Rate Parameter for 28-mer AATT hairpin,,22222.0,
0.0,16524.0,,F,,,Autocuration,CHEMBL825021,1.0,,,322.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,22226.0,
0.0,16524.0,,F,,,Autocuration,CHEMBL615296,1.0,,,323.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,22226.0,
0.0,16524.0,,F,,,Autocuration,CHEMBL615297,1.0,,,324.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,22226.0,
0.0,16758.0,,F,,,Autocuration,CHEMBL615298,1.0,,,325.0,,U,BAO_0000019,,10029.0,,Cricetulus griseus,Cytotoxicity against cell line 2SC/20 determined by MTT test,,22226.0,
0.0,16758.0,,F,,,Autocuration,CHEMBL615299,1.0,,,326.0,,U,BAO_0000019,,10029.0,,Cricetulus griseus,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,22226.0,
0.0,16758.0,,F,,,Autocuration,CHEMBL615300,1.0,,,327.0,,U,BAO_0000019,,10029.0,,Cricetulus griseus,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,22226.0,
8.0,14360.0,,B,,,Autocuration,CHEMBL615301,1.0,,,328.0,,H,BAO_0000357,,,,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,241.0,
9.0,14360.0,,B,,,Expert,CHEMBL615302,1.0,,,329.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,241.0,
0.0,9964.0,,B,,,Autocuration,CHEMBL615303,1.0,,,330.0,,U,BAO_0000019,,10116.0,,Rattus norvegicus,Selectivity ratio of ID50 in liver and heart,,22226.0,
8.0,9964.0,,B,,,Autocuration,CHEMBL615304,1.0,,,331.0,,H,BAO_0000019,,,,,"Selectivity, ratio of relative ID50 in liver and heart",,12132.0,
8.0,9964.0,,B,,,Autocuration,CHEMBL615305,1.0,,,332.0,,H,BAO_0000019,,,,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,12132.0,
8.0,9964.0,,B,,,Autocuration,CHEMBL615306,1.0,,,333.0,,H,BAO_0000218,,,,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,12132.0,
8.0,9964.0,,B,,,Autocuration,CHEMBL615307,1.0,,,334.0,,H,BAO_0000218,,,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,12132.0,
8.0,9964.0,,B,,,Autocuration,CHEMBL615308,1.0,,,335.0,In vivo,H,BAO_0000218,,,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,12132.0,
8.0,9964.0,,F,,,Autocuration,CHEMBL615309,1.0,,,336.0,In vivo,H,BAO_0000218,,,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,12132.0,
0.0,9964.0,,B,,,Autocuration,CHEMBL615310,1.0,,,337.0,,U,BAO_0000019,,,,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,22226.0,
8.0,9964.0,,B,,,Autocuration,CHEMBL615311,1.0,,,338.0,,H,BAO_0000019,,,,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,12132.0,
0.0,9964.0,,B,,,Autocuration,CHEMBL615312,1.0,,,339.0,,U,BAO_0000019,,9606.0,,Homo sapiens,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,22226.0,
8.0,9964.0,,B,,,Autocuration,CHEMBL615313,1.0,,,340.0,,H,BAO_0000019,,,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,12132.0,
8.0,9964.0,,F,,,Autocuration,CHEMBL615314,1.0,,,341.0,,H,BAO_0000019,,,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,12132.0,
8.0,9964.0,,B,,,Autocuration,CHEMBL615315,1.0,,,342.0,,H,BAO_0000019,,,,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,12132.0,
0.0,9964.0,,B,,,Autocuration,CHEMBL615316,1.0,,,343.0,,U,BAO_0000218,,10116.0,,Rattus norvegicus,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,22226.0,
8.0,9964.0,,B,,,Autocuration,CHEMBL615317,1.0,,,344.0,In vivo,H,BAO_0000218,,,,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,12132.0,
8.0,9964.0,,B,,,Autocuration,CHEMBL615318,1.0,,,345.0,,H,BAO_0000218,,,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,12132.0,
0.0,9964.0,,B,,,Autocuration,CHEMBL615319,1.0,,,346.0,,U,BAO_0000218,,10116.0,,Rattus norvegicus,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,22226.0,
8.0,9964.0,,B,,,Autocuration,CHEMBL615320,1.0,,,347.0,,H,BAO_0000019,,,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,12132.0,
8.0,9964.0,,F,,,Autocuration,CHEMBL615321,1.0,,,348.0,,H,BAO_0000019,,,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,12132.0,
0.0,3796.0,,B,,,Autocuration,CHEMBL615322,1.0,,,349.0,,U,BAO_0000019,,10116.0,,Rattus norvegicus,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,22226.0,
8.0,4251.0,,B,,,Autocuration,CHEMBL615323,1.0,,,350.0,,H,BAO_0000357,,562.0,,Escherichia coli,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,19690.0,
8.0,4251.0,,B,,,Autocuration,CHEMBL615407,1.0,,,351.0,,H,BAO_0000357,,562.0,,Escherichia coli,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,19690.0,
8.0,4251.0,,B,,,Autocuration,CHEMBL857267,1.0,,,352.0,,H,BAO_0000357,,562.0,,Escherichia coli,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,19690.0,
8.0,4251.0,,B,,,Autocuration,CHEMBL615408,1.0,,,353.0,,H,BAO_0000357,,562.0,,Escherichia coli,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,19690.0,
8.0,166.0,,B,,,Autocuration,CHEMBL615409,1.0,,,354.0,,H,BAO_0000357,,,,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,19690.0,
8.0,17861.0,,B,,,Autocuration,CHEMBL615410,1.0,,,355.0,,H,BAO_0000357,,,,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,19690.0,
8.0,166.0,,B,,,Autocuration,CHEMBL615411,1.0,,,356.0,,H,BAO_0000357,,,,,Inhibition constant against 3-dehydroquinate synthase,,19690.0,
8.0,166.0,,B,,,Autocuration,CHEMBL615412,1.0,,,357.0,,H,BAO_0000357,,,,,Association rate constant against 3-dehydroquinate synthase,,19690.0,
8.0,166.0,,B,,,Autocuration,CHEMBL615413,1.0,,,358.0,,H,BAO_0000357,,,,,Rate constant against 3-dehydroquinate synthase,,19690.0,
0.0,3548.0,,B,,,Autocuration,CHEMBL615414,1.0,,,359.0,,U,BAO_0000019,,,,,Inhibitory activity against fuc-TVII,,22226.0,
9.0,9877.0,2107.0,B,Microsomes,,Autocuration,CHEMBL615415,1.0,Liver,,360.0,,D,BAO_0000251,,10116.0,,Rattus norvegicus,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,12236.0,
9.0,9877.0,2107.0,B,Microsomes,,Autocuration,CHEMBL615416,1.0,Liver,,361.0,,D,BAO_0000251,,10116.0,,Rattus norvegicus,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,12236.0,
9.0,9877.0,2107.0,B,Microsomes,,Autocuration,CHEMBL615417,1.0,Liver,,362.0,,D,BAO_0000251,,10116.0,,Rattus norvegicus,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,12236.0,
9.0,9877.0,2107.0,B,Microsomes,,Autocuration,CHEMBL615418,1.0,Liver,,363.0,,D,BAO_0000251,,10116.0,,Rattus norvegicus,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,12236.0,
9.0,9877.0,2107.0,B,Microsomes,,Autocuration,CHEMBL615419,1.0,Liver,,364.0,,D,BAO_0000251,,10116.0,,Rattus norvegicus,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,12236.0,
9.0,9877.0,2107.0,B,Microsomes,,Autocuration,CHEMBL615420,1.0,Liver,,365.0,,D,BAO_0000251,,10116.0,,Rattus norvegicus,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,12236.0,
9.0,9877.0,2107.0,B,Microsomes,,Autocuration,CHEMBL615421,1.0,Liver,,366.0,,D,BAO_0000251,,10116.0,,Rattus norvegicus,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,12236.0,
9.0,9877.0,2107.0,B,Microsomes,,Autocuration,CHEMBL615422,1.0,Liver,,367.0,,D,BAO_0000251,,10116.0,,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,12236.0,
9.0,9877.0,2107.0,B,Microsomes,,Autocuration,CHEMBL615423,1.0,Liver,,368.0,,D,BAO_0000251,,10116.0,,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,12236.0,
9.0,9877.0,2107.0,B,Microsomes,,Autocuration,CHEMBL872868,1.0,Liver,,369.0,,D,BAO_0000251,,10116.0,,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,12236.0,
9.0,9877.0,2107.0,B,Microsomes,,Autocuration,CHEMBL615424,1.0,Liver,,370.0,,D,BAO_0000251,,10116.0,,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,12236.0,
4.0,3003.0,,B,,,Autocuration,CHEMBL825022,1.0,,,371.0,,H,BAO_0000224,,,,,Inhibitory activity against 3-phosphoglycerate kinase.,,104832.0,
4.0,3003.0,,B,,,Autocuration,CHEMBL615425,1.0,,,372.0,,H,BAO_0000224,,,,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,104832.0,
4.0,3003.0,,B,,,Autocuration,CHEMBL615426,1.0,,,373.0,,H,BAO_0000224,,,,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,104832.0,
9.0,17185.0,,B,,,Expert,CHEMBL615427,1.0,,,374.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,10612.0,
1.0,6072.0,,F,,,Intermediate,CHEMBL615428,1.0,,,375.0,,N,BAO_0000219,3677 melanoma cell line,9606.0,,Homo sapiens,Cytotoxicity on 3677 melanoma cells,,80616.0,844.0
1.0,6072.0,,F,,,Intermediate,CHEMBL615429,1.0,,,376.0,,N,BAO_0000219,3677 melanoma cell line,9606.0,,Homo sapiens,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,80616.0,844.0
1.0,5018.0,,F,,,Intermediate,CHEMBL615430,1.0,,,377.0,,N,BAO_0000219,MC-38,10090.0,,Mus musculus,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,80617.0,700.0
0.0,2852.0,,F,,,Intermediate,CHEMBL615431,1.0,,,378.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,22226.0,
0.0,8663.0,,F,,,Autocuration,CHEMBL615432,1.0,,,379.0,,U,BAO_0000218,B16,,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,22226.0,798.0
0.0,8663.0,,F,,,Autocuration,CHEMBL615433,1.0,,,380.0,,U,BAO_0000218,B16,,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,22226.0,798.0
9.0,3245.0,,F,,,Expert,CHEMBL615434,1.0,,,381.0,,D,BAO_0000019,,12131.0,,Human rhinovirus 14,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,12464.0,
1.0,3245.0,,F,,,Intermediate,CHEMBL615435,1.0,,,382.0,,N,BAO_0000218,,169066.0,,Human rhinovirus sp.,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,50085.0,
1.0,3877.0,,F,,,Intermediate,CHEMBL615436,1.0,,,383.0,,N,BAO_0000218,,169066.0,,human rhinovirus type 14,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,50679.0,
1.0,3877.0,,F,,,Intermediate,CHEMBL615437,1.0,,,384.0,,N,BAO_0000218,,169066.0,,human rhinovirus type 14,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,50679.0,
9.0,5861.0,,F,,,Expert,CHEMBL615438,1.0,,,385.0,,D,BAO_0000019,,12131.0,,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,12464.0,
9.0,5861.0,,F,,,Expert,CHEMBL615439,1.0,,,386.0,,D,BAO_0000019,,12131.0,,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,12464.0,
9.0,5861.0,,F,,,Expert,CHEMBL615440,1.0,,,387.0,,D,BAO_0000019,,12131.0,,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,12464.0,
9.0,5861.0,,F,,,Expert,CHEMBL615441,1.0,,,388.0,,D,BAO_0000019,,12131.0,,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,12464.0,
1.0,13748.0,,F,,,Intermediate,CHEMBL615641,1.0,,,389.0,,N,BAO_0000218,,12059.0,,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,50665.0,
1.0,13748.0,,F,,,Intermediate,CHEMBL872065,1.0,,,390.0,,N,BAO_0000218,,12059.0,,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,50665.0,
1.0,13748.0,,F,,,Intermediate,CHEMBL825023,1.0,,,391.0,,N,BAO_0000218,,12059.0,,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,50665.0,
1.0,13748.0,,F,,,Intermediate,CHEMBL615642,1.0,,,392.0,,N,BAO_0000218,,12059.0,,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,50665.0,
8.0,13748.0,,B,,,Expert,CHEMBL615643,1.0,,,393.0,,H,BAO_0000357,,147712.0,,Human rhinovirus B,Inhibition of human rhinovirus 3C protease,,12464.0,
0.0,17699.0,,B,,,Autocuration,CHEMBL615644,1.0,,,394.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,22226.0,
1.0,7145.0,,F,,,Intermediate,CHEMBL615645,1.0,,,395.0,,N,BAO_0000218,3EM 37,10090.0,,Mus musculus,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,80619.0,833.0
1.0,7145.0,,F,,,Intermediate,CHEMBL615646,1.0,,,396.0,,N,BAO_0000218,3EM 37,10090.0,,Mus musculus,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,80619.0,833.0
1.0,7145.0,,F,,,Intermediate,CHEMBL615647,1.0,,,397.0,,N,BAO_0000218,3EM 37,10090.0,,Mus musculus,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,80619.0,833.0
1.0,7145.0,,F,,,Intermediate,CHEMBL615648,1.0,,,398.0,,N,BAO_0000218,3EM 37,10090.0,,Mus musculus,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,80619.0,833.0
1.0,7145.0,,F,,,Intermediate,CHEMBL615649,1.0,,,399.0,,N,BAO_0000218,3EM 37,10090.0,,Mus musculus,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,80619.0,833.0
1.0,7145.0,,F,,,Intermediate,CHEMBL615650,1.0,,,400.0,,N,BAO_0000218,3EM 37,10090.0,,Mus musculus,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,80619.0,833.0
1.0,5325.0,,F,,,Intermediate,CHEMBL615651,1.0,,,401.0,,N,BAO_0000218,3LL cell line,10090.0,,Mus musculus,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,80620.0,847.0
1.0,5325.0,,F,,,Intermediate,CHEMBL615652,1.0,,,402.0,,N,BAO_0000218,3LL cell line,10090.0,,Mus musculus,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,80620.0,847.0
1.0,5325.0,,F,,,Expert,CHEMBL615653,1.0,,,403.0,,N,BAO_0000218,3LL cell line,10090.0,,Mus musculus,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615654,1.0,,,404.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615655,1.0,,,405.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL825024,1.0,,,406.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615656,1.0,,,407.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615657,1.0,,,408.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615658,1.0,,,409.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615659,1.0,,,410.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615660,1.0,,,411.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615661,1.0,,,412.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615662,1.0,,,413.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615663,1.0,,,414.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615664,1.0,,,415.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615665,1.0,,,416.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615666,1.0,,,417.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615667,1.0,,,418.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615668,1.0,,,419.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615669,1.0,,,420.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615670,1.0,,,421.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL836739,1.0,,,422.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615671,1.0,,,423.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615672,1.0,,,424.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615791,1.0,,,425.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615792,1.0,,,426.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615793,1.0,,,427.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615794,1.0,,,428.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,80620.0,847.0
1.0,16169.0,,F,,,Intermediate,CHEMBL615795,1.0,,,429.0,,N,BAO_0000219,3LL cell line,10090.0,,Mus musculus,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,80620.0,847.0
1.0,15547.0,,F,,,Intermediate,CHEMBL615590,1.0,,,430.0,,N,BAO_0000219,3LLD122,9606.0,,Homo sapiens,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,80621.0,971.0
0.0,8663.0,,F,,,Autocuration,CHEMBL615591,1.0,,,431.0,,U,BAO_0000218,,,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,22226.0,
0.0,8663.0,,F,,,Autocuration,CHEMBL615592,1.0,,,432.0,,U,BAO_0000218,,,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,22226.0,
0.0,8663.0,,F,,,Autocuration,CHEMBL615593,1.0,,,433.0,,U,BAO_0000218,,,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,22226.0,
0.0,8663.0,,F,,,Autocuration,CHEMBL615594,1.0,,,434.0,,U,BAO_0000218,,,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,22226.0,
1.0,4504.0,,F,,,Intermediate,CHEMBL615595,1.0,,,435.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,80951.0,723.0
1.0,4504.0,,F,,,Intermediate,CHEMBL615596,1.0,,,436.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,80951.0,723.0
8.0,12695.0,,F,,,Expert,CHEMBL615597,1.0,,,437.0,,H,BAO_0000219,NIH3T3,,,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,11169.0,723.0
1.0,12695.0,,F,,,Intermediate,CHEMBL615598,1.0,,,438.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,80951.0,723.0
1.0,12695.0,,F,,,Intermediate,CHEMBL615599,1.0,,,439.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,80951.0,723.0
1.0,17642.0,,F,,,Expert,CHEMBL615600,1.0,,,440.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Effective dose against murine 3T3 fibroblasts cells,,80951.0,723.0
1.0,17642.0,,F,,,Expert,CHEMBL615601,1.0,,,441.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,80951.0,723.0
1.0,12340.0,,F,,,Expert,CHEMBL615602,1.0,,,442.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Cytotoxic effect on 3T3 cells,,80951.0,723.0
1.0,12340.0,,F,,,Expert,CHEMBL615603,1.0,,,443.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Cytotoxic effect on 3T3 cells,,80951.0,723.0
1.0,12716.0,,F,,,Intermediate,CHEMBL615604,1.0,,,444.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,80951.0,723.0
1.0,6277.0,,F,,,Intermediate,CHEMBL615605,1.0,,,445.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,80951.0,723.0
1.0,6277.0,,F,,,Intermediate,CHEMBL615606,1.0,,,446.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,80951.0,723.0
1.0,6277.0,,F,,,Expert,CHEMBL884526,1.0,,,447.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,80951.0,723.0
1.0,6277.0,,F,,,Expert,CHEMBL615607,1.0,,,448.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,80951.0,723.0
1.0,6277.0,,F,,,Intermediate,CHEMBL615608,1.0,,,449.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,80951.0,723.0
1.0,6277.0,,F,,,Expert,CHEMBL615609,1.0,,,450.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,80951.0,723.0
1.0,6277.0,,F,,,Expert,CHEMBL615682,1.0,,,451.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,80951.0,723.0
1.0,6277.0,,F,,,Intermediate,CHEMBL615683,1.0,,,452.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,80951.0,723.0
1.0,17780.0,,F,,,Expert,CHEMBL615684,1.0,,,453.0,,N,BAO_0000218,NIH3T3,10090.0,,Mus musculus,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,80951.0,723.0
7.0,12751.0,,F,,,Autocuration,CHEMBL615685,1.0,,,454.0,,D,BAO_0000219,,10090.0,,Mus musculus,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,104860.0,
1.0,12380.0,,F,,,Expert,CHEMBL615686,1.0,,,455.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,80951.0,723.0
1.0,14892.0,,F,,,Intermediate,CHEMBL615687,1.0,,,456.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Inhibitory activity against 3T3 cell line,,80951.0,723.0
1.0,12695.0,,F,,,Intermediate,CHEMBL884523,1.0,,,457.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,80951.0,723.0
8.0,12695.0,,F,,,Expert,CHEMBL615688,1.0,,,458.0,,H,BAO_0000019,,,,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,11169.0,
1.0,12695.0,,F,,,Intermediate,CHEMBL615689,1.0,,,459.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,80951.0,723.0
1.0,12695.0,,F,,,Intermediate,CHEMBL615690,1.0,,,460.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,80951.0,723.0
8.0,12695.0,,F,,,Expert,CHEMBL615691,1.0,,,461.0,,H,BAO_0000019,,,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,11169.0,
8.0,12695.0,,F,,,Expert,CHEMBL615692,1.0,,,462.0,,H,BAO_0000019,,,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,11169.0,
1.0,6277.0,,F,,,Intermediate,CHEMBL615693,1.0,,,463.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,80951.0,723.0
1.0,6277.0,,F,,,Expert,CHEMBL615324,1.0,,,464.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,80951.0,723.0
9.0,4959.0,,F,,,Expert,CHEMBL615325,1.0,,,465.0,,D,BAO_0000219,NIH3T3,9606.0,,Homo sapiens,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,9.0,723.0
9.0,4959.0,,F,,,Expert,CHEMBL615490,1.0,,,466.0,,D,BAO_0000219,NIH3T3,9606.0,,Homo sapiens,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,9.0,723.0
9.0,4959.0,,F,,,Expert,CHEMBL615491,1.0,,,467.0,,D,BAO_0000219,NIH3T3,9606.0,,Homo sapiens,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,188.0,723.0
9.0,4959.0,,F,,,Expert,CHEMBL615492,1.0,,,468.0,,D,BAO_0000219,NIH3T3,9606.0,,Homo sapiens,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,188.0,723.0
1.0,12082.0,,F,,,Intermediate,CHEMBL615493,1.0,,,469.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,80951.0,723.0
1.0,12082.0,,F,,,Intermediate,CHEMBL615494,1.0,,,470.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,80951.0,723.0
1.0,12082.0,,F,,,Intermediate,CHEMBL615495,1.0,,,471.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,80951.0,723.0
1.0,12082.0,,F,,,Intermediate,CHEMBL615496,1.0,,,472.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,80951.0,723.0
1.0,2643.0,,F,,,Intermediate,CHEMBL615497,1.0,,,473.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,80951.0,723.0
1.0,11926.0,,F,,,Expert,CHEMBL615498,1.0,,,474.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,80951.0,723.0
1.0,15204.0,,A,,,Intermediate,CHEMBL615499,1.0,,,475.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,80951.0,723.0
1.0,15992.0,,F,,,Expert,CHEMBL835522,1.0,,,476.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,80951.0,723.0
1.0,16279.0,,F,,,Intermediate,CHEMBL615500,1.0,,,477.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,80951.0,723.0
1.0,16279.0,,F,,,Intermediate,CHEMBL615501,1.0,,,478.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,80951.0,723.0
1.0,16279.0,,F,,,Intermediate,CHEMBL615502,1.0,,,479.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,80951.0,723.0
1.0,16279.0,,F,,,Intermediate,CHEMBL615503,1.0,,,480.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,80951.0,723.0
1.0,16279.0,,F,,,Intermediate,CHEMBL615504,1.0,,,481.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,80951.0,723.0
1.0,16279.0,,F,,,Intermediate,CHEMBL615505,1.0,,,482.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,80951.0,723.0
1.0,12831.0,,F,,,Expert,CHEMBL615506,1.0,,,483.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Inhibition of swiss 3T3 mouse fibroblast proliferation,,80951.0,723.0
1.0,13497.0,,F,,,Intermediate,CHEMBL615507,1.0,,,484.0,,N,BAO_0000219,NIH3T3,10090.0,,Mus musculus,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,80951.0,723.0
1.0,13715.0,,F,,,Intermediate,CHEMBL615508,1.0,,,485.0,,N,BAO_0000218,3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,80006.0,620.0
1.0,13618.0,,F,,,Intermediate,CHEMBL615509,1.0,,,486.0,,N,BAO_0000219,3T3-L1,10090.0,,Mus musculus,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,80006.0,620.0
1.0,11902.0,,F,,,Intermediate,CHEMBL615510,1.0,,,487.0,,N,BAO_0000219,3T3-L1,10090.0,,Mus musculus,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,80006.0,620.0
1.0,11902.0,,F,,,Intermediate,CHEMBL615511,1.0,,,488.0,,N,BAO_0000219,3T3-L1,10090.0,,Mus musculus,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,80006.0,620.0
1.0,11902.0,,F,,,Intermediate,CHEMBL615512,1.0,,,489.0,,N,BAO_0000219,3T3-L1,10090.0,,Mus musculus,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,80006.0,620.0
1.0,14840.0,,F,,,Intermediate,CHEMBL615513,1.0,,,490.0,,N,BAO_0000218,3T3-L1,10090.0,,Mus musculus,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,80006.0,620.0
1.0,14840.0,,F,,,Intermediate,CHEMBL615514,1.0,,,491.0,,N,BAO_0000218,3T3-L1,10090.0,,Mus musculus,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,80006.0,620.0
1.0,13715.0,,F,,,Intermediate,CHEMBL615515,1.0,,,492.0,,N,BAO_0000219,3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,80006.0,620.0
1.0,13715.0,,F,,,Intermediate,CHEMBL615516,1.0,,,493.0,,N,BAO_0000219,3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,80006.0,620.0
1.0,13715.0,,F,,,Intermediate,CHEMBL615517,1.0,,,494.0,,N,BAO_0000219,3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,80006.0,620.0
1.0,13715.0,,F,,,Intermediate,CHEMBL615518,1.0,,,495.0,,N,BAO_0000219,3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,80006.0,620.0
1.0,13715.0,,F,,,Intermediate,CHEMBL615519,1.0,,,496.0,,N,BAO_0000219,3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,80006.0,620.0
1.0,13715.0,,F,,,Intermediate,CHEMBL615520,1.0,,,497.0,,N,BAO_0000218,3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,80006.0,620.0
1.0,13715.0,,F,,,Intermediate,CHEMBL615521,1.0,,,498.0,,N,BAO_0000218,3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,80006.0,620.0
1.0,13715.0,,F,,,Intermediate,CHEMBL615522,1.0,,,499.0,,N,BAO_0000218,3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,80006.0,620.0
1.0,13715.0,,F,,,Intermediate,CHEMBL615523,1.0,,,500.0,,N,BAO_0000218,3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,80006.0,620.0
1.0,13715.0,,F,,,Expert,CHEMBL615524,1.0,,,501.0,,N,BAO_0000218,3T3-L1,,,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,80006.0,620.0
1.0,13715.0,,F,,,Expert,CHEMBL615525,1.0,,,502.0,,N,BAO_0000218,3T3-L1,,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,80006.0,620.0
1.0,13715.0,,F,,,Intermediate,CHEMBL615526,1.0,,,503.0,,N,BAO_0000218,3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,80006.0,620.0
1.0,13715.0,,F,,,Intermediate,CHEMBL615527,1.0,,,504.0,,N,BAO_0000218,3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,80006.0,620.0
1.0,13715.0,,F,,,Intermediate,CHEMBL615528,1.0,,,505.0,,N,BAO_0000218,3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,80006.0,620.0
1.0,13715.0,,F,,,Expert,CHEMBL615529,1.0,,,506.0,,N,BAO_0000218,3T3-L1,,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,80006.0,620.0
1.0,13715.0,,F,,,Expert,CHEMBL615530,1.0,,,507.0,,N,BAO_0000218,3T3-L1,,,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,80006.0,620.0
1.0,13715.0,,F,,,Expert,CHEMBL615531,1.0,,,508.0,,N,BAO_0000218,3T3-L1,,,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,80006.0,620.0
1.0,13715.0,,F,,,Intermediate,CHEMBL615532,1.0,,,509.0,,N,BAO_0000219,3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,80006.0,620.0
1.0,13715.0,,F,,,Intermediate,CHEMBL615533,1.0,,,510.0,,N,BAO_0000219,3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,80006.0,620.0
1.0,13715.0,,F,,,Intermediate,CHEMBL615534,1.0,,,511.0,,N,BAO_0000219,3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,80006.0,620.0
1.0,13715.0,,F,,,Intermediate,CHEMBL615535,1.0,,,512.0,,N,BAO_0000218,3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,80006.0,620.0
1.0,13715.0,,F,,,Intermediate,CHEMBL615536,1.0,,,513.0,,N,BAO_0000218,3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,80006.0,620.0
1.0,13715.0,,F,,,Intermediate,CHEMBL615537,1.0,,,514.0,,N,BAO_0000218,3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,80006.0,620.0
1.0,13715.0,,F,,,Intermediate,CHEMBL615538,1.0,,,515.0,,N,BAO_0000218,3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,80006.0,620.0
1.0,13715.0,,F,,,Intermediate,CHEMBL836166,1.0,,,516.0,,N,BAO_0000218,3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,80006.0,620.0
8.0,6411.0,,F,,,Expert,CHEMBL615539,1.0,,,517.0,,H,BAO_0000219,3T3-L1,,,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,11214.0,620.0
1.0,6411.0,,F,,,Intermediate,CHEMBL615540,1.0,,,518.0,,N,BAO_0000219,3T3-L1,10090.0,,Mus musculus,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,80006.0,620.0
8.0,6411.0,,F,,,Expert,CHEMBL615541,1.0,,,519.0,,H,BAO_0000219,3T3-L1,,,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,11214.0,620.0
1.0,3966.0,,F,,,Expert,CHEMBL615542,1.0,,,520.0,,N,BAO_0000219,3T3-L1,10090.0,,Mus musculus,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,80006.0,620.0
1.0,3966.0,,F,,,Intermediate,CHEMBL615543,1.0,,,521.0,,N,BAO_0000219,3T3-L1,10090.0,,Mus musculus,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,80006.0,620.0
1.0,15556.0,,F,,,Expert,CHEMBL615544,1.0,,,522.0,,N,BAO_0000219,3T3-L1,10090.0,,Mus musculus,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,80006.0,620.0
1.0,5845.0,,F,,,Expert,CHEMBL615545,1.0,,,523.0,,N,BAO_0000219,3T3-L1,10090.0,,Mus musculus,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,80006.0,620.0
1.0,14422.0,,F,,,Expert,CHEMBL615546,1.0,,,524.0,,N,BAO_0000219,3T3-L1,10090.0,,Mus musculus,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,80006.0,620.0
1.0,5845.0,,F,,,Expert,CHEMBL615547,1.0,,,525.0,,N,BAO_0000219,3T3-L1,10090.0,,Mus musculus,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,80006.0,620.0
1.0,14508.0,,F,,,Expert,CHEMBL615548,1.0,,,526.0,,N,BAO_0000219,3T3-L1,10090.0,,Mus musculus,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,80006.0,620.0
1.0,14508.0,,F,,,Expert,CHEMBL615549,1.0,,,527.0,,N,BAO_0000219,3T3-L1,10090.0,,Mus musculus,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,80006.0,620.0
1.0,14508.0,,F,,,Expert,CHEMBL615550,1.0,,,528.0,,N,BAO_0000219,3T3-L1,10090.0,,Mus musculus,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,80006.0,620.0
1.0,6349.0,,F,,,Intermediate,CHEMBL615551,1.0,,,529.0,,N,BAO_0000219,3Y1 cell line,10116.0,,Rattus norvegicus,Inhibitory activity against rat fibroblast (3Y1) cell line,,80622.0,1118.0
1.0,15899.0,,F,,,Expert,CHEMBL615552,1.0,,,530.0,,N,BAO_0000219,3Y1 cell line,10116.0,,Rattus norvegicus,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,80622.0,1118.0
1.0,15899.0,,F,,,Expert,CHEMBL615553,1.0,,,531.0,,N,BAO_0000219,3Y1 cell line,10116.0,,Rattus norvegicus,Cytotoxicity in 3Y1 cells.,,80622.0,1118.0
1.0,15899.0,,F,,,Expert,CHEMBL615554,1.0,,,532.0,,N,BAO_0000219,3Y1 cell line,10116.0,,Rattus norvegicus,Cytostatic effect in 3Y1 cells.,,80622.0,1118.0
1.0,15899.0,,F,,,Intermediate,CHEMBL615555,1.0,,,533.0,,N,BAO_0000219,3Y1 cell line,10116.0,,Rattus norvegicus,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,80622.0,1118.0
1.0,17038.0,,F,,,Expert,CHEMBL615556,1.0,,,534.0,,N,BAO_0000219,3Y1 cell line,10116.0,,Rattus norvegicus,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,80622.0,1118.0
0.0,12421.0,,B,,,Autocuration,CHEMBL615557,1.0,,,535.0,,U,BAO_0000019,,,,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,22226.0,
0.0,12947.0,,B,,,Autocuration,CHEMBL615558,1.0,,,536.0,,U,BAO_0000019,,,,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,22226.0,
0.0,12947.0,,B,,,Autocuration,CHEMBL872066,1.0,,,537.0,,U,BAO_0000019,,,,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,22226.0,
9.0,4896.0,,B,,,Expert,CHEMBL615559,1.0,,,538.0,,D,BAO_0000019,,9823.0,,Sus scrofa,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,11607.0,
8.0,6148.0,,B,,,Autocuration,CHEMBL615560,1.0,,,539.0,,H,BAO_0000019,,,,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,11607.0,
8.0,16432.0,,B,,,Autocuration,CHEMBL615561,1.0,,,540.0,,H,BAO_0000019,,,,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,11607.0,
8.0,4978.0,,B,,,Expert,CHEMBL857062,1.0,,,541.0,,H,BAO_0000019,,,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,11607.0,
8.0,4978.0,,B,,,Expert,CHEMBL615562,1.0,,,542.0,,H,BAO_0000019,,,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,11607.0,
8.0,3723.0,,B,,,Autocuration,CHEMBL615563,1.0,,,543.0,,H,BAO_0000019,,,,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,11607.0,
8.0,3518.0,,B,,,Autocuration,CHEMBL615564,1.0,,,544.0,,H,BAO_0000357,,,,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,11607.0,
8.0,4164.0,,B,,,Autocuration,CHEMBL615565,1.0,,,545.0,,H,BAO_0000019,,,,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,11607.0,
8.0,3518.0,,B,,,Autocuration,CHEMBL615566,1.0,,,546.0,,H,BAO_0000019,,,,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,11607.0,
9.0,4164.0,,B,,,Expert,CHEMBL615567,1.0,,,547.0,,D,BAO_0000019,,9823.0,,Sus scrofa,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,11607.0,
8.0,3518.0,,B,,,Autocuration,CHEMBL615568,1.0,,,548.0,,H,BAO_0000019,,,,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,11607.0,
8.0,3518.0,,B,,,Autocuration,CHEMBL615569,1.0,,,549.0,,H,BAO_0000357,,,,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,11607.0,
8.0,4978.0,,B,,,Autocuration,CHEMBL615570,1.0,,,550.0,,H,BAO_0000019,,,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,11607.0,
8.0,4978.0,,B,,,Autocuration,CHEMBL615571,1.0,,,551.0,,H,BAO_0000019,,,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,11607.0,
4.0,6455.0,,B,,,Autocuration,CHEMBL615572,1.0,,,552.0,,H,BAO_0000224,,,,,Binding affinity against melatonin (MT1) receptor (pC1),,104733.0,
0.0,2222.0,,B,,,Autocuration,CHEMBL615573,1.0,,,553.0,,U,BAO_0000019,,,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,22226.0,
0.0,13020.0,,B,,,Autocuration,CHEMBL615574,1.0,,,554.0,,U,BAO_0000019,,,,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,22226.0,
0.0,13021.0,,B,,,Autocuration,CHEMBL615575,1.0,,,555.0,,U,BAO_0000019,,,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,22226.0,
8.0,14532.0,,B,,,Autocuration,CHEMBL615576,1.0,,,556.0,,H,BAO_0000357,,,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,10619.0,
8.0,14118.0,,B,,,Autocuration,CHEMBL615577,1.0,,,557.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,10619.0,
8.0,11884.0,10000000.0,B,,,Autocuration,CHEMBL615578,1.0,Hippocampus,,558.0,,H,BAO_0000221,,,,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,51.0,
8.0,13969.0,,B,,,Expert,CHEMBL615579,1.0,,,559.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,51.0,
8.0,13392.0,,B,,,Expert,CHEMBL615580,1.0,,,560.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 1A receptor,,51.0,
8.0,14430.0,,B,,,Expert,CHEMBL615581,1.0,,,561.0,,H,BAO_0000019,,,,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,51.0,
8.0,12248.0,10000000.0,B,,,Autocuration,CHEMBL615582,1.0,Hippocampus,,562.0,,H,BAO_0000221,,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,51.0,
8.0,12249.0,10000000.0,B,,,Autocuration,CHEMBL615583,1.0,Hippocampus,,563.0,,H,BAO_0000221,,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,51.0,
8.0,9995.0,10000000.0,B,,,Autocuration,CHEMBL615584,1.0,Hippocampus,,564.0,,H,BAO_0000221,,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,51.0,
8.0,9995.0,10000000.0,B,,,Autocuration,CHEMBL833691,1.0,Hippocampus,,565.0,,H,BAO_0000221,,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51.0,
8.0,9995.0,10000000.0,B,,,Autocuration,CHEMBL615585,1.0,Hippocampus,,566.0,,H,BAO_0000221,,,,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,51.0,
8.0,9995.0,10000000.0,B,,,Autocuration,CHEMBL615586,1.0,Hippocampus,,567.0,,H,BAO_0000221,,,,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,51.0,
8.0,9995.0,10000000.0,B,,,Autocuration,CHEMBL884524,1.0,Hippocampus,,568.0,,H,BAO_0000221,,,,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51.0,
8.0,12249.0,10000000.0,B,,,Autocuration,CHEMBL615587,1.0,Hippocampus,,569.0,,H,BAO_0000221,,,,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,51.0,
8.0,11799.0,10000000.0,B,,,Autocuration,CHEMBL615588,1.0,Hippocampus,,570.0,,H,BAO_0000221,,,,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,51.0,
9.0,14331.0,,B,Membranes,,Expert,CHEMBL615589,1.0,,,571.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,10576.0,
8.0,11884.0,10000000.0,B,,,Expert,CHEMBL615442,1.0,Hippocampus,,572.0,,H,BAO_0000221,,9913.0,,Bos taurus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,51.0,
8.0,14331.0,10000000.0,B,,,Autocuration,CHEMBL615443,1.0,Hippocampus,,573.0,,H,BAO_0000221,,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,51.0,
8.0,11701.0,10000000.0,B,,,Autocuration,CHEMBL615444,1.0,Hippocampus,,574.0,,H,BAO_0000221,,,,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,51.0,
8.0,11701.0,10000000.0,B,,,Expert,CHEMBL615445,1.0,Hippocampus,,575.0,,H,BAO_0000221,,,,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,51.0,
8.0,12248.0,10000000.0,B,,,Autocuration,CHEMBL615446,1.0,Hippocampus,,576.0,,H,BAO_0000221,,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,51.0,
8.0,12248.0,,B,,,Autocuration,CHEMBL615447,1.0,,,577.0,,H,BAO_0000219,CHO,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,51.0,449.0
8.0,12248.0,10000000.0,B,,,Expert,CHEMBL615448,1.0,Hippocampus,,578.0,,H,BAO_0000221,,,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,51.0,
8.0,12249.0,10000000.0,B,,,Expert,CHEMBL615449,1.0,Hippocampus,,579.0,,H,BAO_0000221,,,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,51.0,
8.0,12248.0,,B,,,Autocuration,CHEMBL615450,1.0,,,580.0,,H,BAO_0000219,CHO,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,51.0,449.0
8.0,11799.0,10000000.0,B,,,Expert,CHEMBL615451,1.0,Hippocampus,,581.0,,H,BAO_0000221,,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,51.0,
8.0,634.0,,B,,,Autocuration,CHEMBL615452,1.0,,,582.0,,H,BAO_0000357,,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,51.0,
8.0,9995.0,10000000.0,B,,,Autocuration,CHEMBL615453,1.0,Hippocampus,,583.0,,H,BAO_0000221,,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,51.0,
8.0,9995.0,10000000.0,B,,,Autocuration,CHEMBL615454,1.0,Hippocampus,,584.0,,H,BAO_0000221,,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51.0,
8.0,9995.0,10000000.0,B,,,Autocuration,CHEMBL615455,1.0,Hippocampus,,585.0,,H,BAO_0000221,,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,51.0,
8.0,9995.0,10000000.0,B,,,Autocuration,CHEMBL615456,1.0,Hippocampus,,586.0,,H,BAO_0000221,,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51.0,
8.0,9995.0,10000000.0,B,,,Autocuration,CHEMBL615457,1.0,Hippocampus,,587.0,,H,BAO_0000221,,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,51.0,
8.0,12210.0,10000000.0,B,,,Expert,CHEMBL615458,1.0,Hippocampus,,588.0,,H,BAO_0000218,,,,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,51.0,
8.0,13311.0,10000000.0,B,,,Expert,CHEMBL615459,1.0,Hippocampus,,589.0,,H,BAO_0000221,,,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51.0,
9.0,2331.0,,B,,,Expert,CHEMBL615460,1.0,,,590.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,51.0,449.0
8.0,1375.0,,F,,,Autocuration,CHEMBL615461,1.0,,,591.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,51.0,
8.0,1375.0,,F,,,Autocuration,CHEMBL615462,1.0,,,592.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,51.0,
8.0,11574.0,10000000.0,F,,,Autocuration,CHEMBL615463,1.0,Hippocampus,,593.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,51.0,
8.0,12867.0,2116.0,B,,,Autocuration,CHEMBL615464,1.0,Ileum,,594.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,51.0,
8.0,12867.0,2116.0,B,,,Autocuration,CHEMBL615465,1.0,Ileum,,595.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,51.0,
8.0,12867.0,2116.0,B,,,Autocuration,CHEMBL615466,1.0,Ileum,,596.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,51.0,
8.0,12867.0,2116.0,B,,,Autocuration,CHEMBL615467,1.0,Ileum,,597.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,51.0,
8.0,12867.0,2116.0,B,,,Autocuration,CHEMBL615468,1.0,Ileum,,598.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,51.0,
8.0,12867.0,2116.0,B,,,Autocuration,CHEMBL615469,1.0,Ileum,,599.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,51.0,
8.0,11574.0,,B,,,Autocuration,CHEMBL615470,1.0,,,600.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 1A receptor,,51.0,
8.0,13114.0,,B,,,Autocuration,CHEMBL615471,1.0,,,601.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,51.0,
8.0,13181.0,,B,,,Autocuration,CHEMBL615472,1.0,,,602.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,51.0,
8.0,10639.0,10000000.0,B,,,Autocuration,CHEMBL883242,1.0,Hippocampus,,603.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,106.0,
8.0,10639.0,10000000.0,F,,,Autocuration,CHEMBL615473,1.0,Hippocampus,,604.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,106.0,
8.0,11883.0,,B,,,Autocuration,CHEMBL615474,1.0,,,605.0,,H,BAO_0000218,CHO,10029.0,,Cricetulus griseus,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,11863.0,449.0
8.0,17785.0,,B,,,Autocuration,CHEMBL615475,1.0,,,606.0,,H,BAO_0000357,,,,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,51.0,
8.0,1558.0,,F,,,Autocuration,CHEMBL615476,1.0,,,607.0,,H,BAO_0000219,HeLa,,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,51.0,308.0
8.0,1558.0,,F,,,Autocuration,CHEMBL615477,1.0,,,608.0,,H,BAO_0000219,HeLa,,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,51.0,308.0
8.0,15740.0,,F,,,Autocuration,CHEMBL615478,1.0,,,609.0,,H,BAO_0000019,,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,51.0,
8.0,17624.0,,F,,,Autocuration,CHEMBL615160,1.0,,,610.0,,H,BAO_0000219,CHO,,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,51.0,449.0
8.0,17624.0,,F,,,Expert,CHEMBL615161,1.0,,,611.0,,H,BAO_0000219,CHO,,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,51.0,449.0
8.0,17624.0,,F,,,Autocuration,CHEMBL615162,1.0,,,612.0,,H,BAO_0000219,CHO,,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,51.0,449.0
8.0,17624.0,,F,,,Autocuration,CHEMBL615163,1.0,,,613.0,,H,BAO_0000219,CHO,,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,51.0,449.0
8.0,17624.0,,B,,,Expert,CHEMBL615164,1.0,,,614.0,,H,BAO_0000219,CHO,,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,51.0,449.0
8.0,17624.0,,B,,,Expert,CHEMBL615165,1.0,,,615.0,,H,BAO_0000219,CHO,,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,51.0,449.0
8.0,17624.0,,B,,,Autocuration,CHEMBL615166,1.0,,,616.0,,H,BAO_0000219,CHO,,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,51.0,449.0
8.0,14256.0,,F,,,Autocuration,CHEMBL615167,1.0,,,617.0,,H,BAO_0000219,,,,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,51.0,
9.0,3445.0,,B,,,Expert,CHEMBL615168,1.0,,,618.0,,D,BAO_0000219,HeLa,9606.0,,Homo sapiens,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,51.0,308.0
9.0,3445.0,,B,,,Expert,CHEMBL615169,1.0,,,619.0,,D,BAO_0000219,HeLa,9606.0,,Homo sapiens,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,51.0,308.0
9.0,17200.0,,B,,,Expert,CHEMBL615170,1.0,,,620.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,51.0,449.0
9.0,17200.0,,B,,,Expert,CHEMBL615171,1.0,,,621.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,51.0,449.0
8.0,15180.0,,F,,,Autocuration,CHEMBL615694,1.0,,,622.0,,H,BAO_0000019,,,,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,51.0,
8.0,15180.0,,F,,,Autocuration,CHEMBL615695,1.0,,,623.0,,H,BAO_0000019,,,,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,51.0,
8.0,16026.0,,F,,,Autocuration,CHEMBL615696,1.0,,,624.0,,H,BAO_0000019,,,,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,51.0,
8.0,2759.0,,F,,,Autocuration,CHEMBL615697,1.0,,,625.0,,H,BAO_0000219,CHO,,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,51.0,449.0
9.0,2759.0,,F,,,Expert,CHEMBL859410,1.0,,,626.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,51.0,449.0
8.0,2759.0,,F,,,Autocuration,CHEMBL615841,1.0,,,627.0,,H,BAO_0000219,CHO,,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,51.0,449.0
9.0,2759.0,,F,,,Expert,CHEMBL615842,1.0,,,628.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,51.0,449.0
8.0,2759.0,,F,,,Autocuration,CHEMBL835003,1.0,,,629.0,,H,BAO_0000219,CHO,,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,51.0,449.0
8.0,2759.0,,F,,,Autocuration,CHEMBL615843,1.0,,,630.0,,H,BAO_0000219,CHO,,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,51.0,449.0
9.0,2759.0,,F,,,Expert,CHEMBL615979,1.0,,,631.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,51.0,449.0
8.0,2759.0,,F,,,Autocuration,CHEMBL615980,1.0,,,632.0,,H,BAO_0000219,CHO,,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,51.0,449.0
9.0,2759.0,,F,,,Expert,CHEMBL615981,1.0,,,633.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,51.0,449.0
9.0,3445.0,,F,,,Expert,CHEMBL615982,1.0,,,634.0,,D,BAO_0000019,,9606.0,,Homo sapiens,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,51.0,
9.0,5272.0,,F,,,Expert,CHEMBL615983,1.0,,,635.0,,D,BAO_0000019,,9606.0,,Homo sapiens,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,51.0,
9.0,5272.0,,F,,,Expert,CHEMBL615984,1.0,,,636.0,,D,BAO_0000019,,9606.0,,Homo sapiens,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,51.0,
9.0,5272.0,,F,,,Expert,CHEMBL615985,1.0,,,637.0,,D,BAO_0000019,,9606.0,,Homo sapiens,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,51.0,
8.0,17624.0,,F,,,Autocuration,CHEMBL615986,1.0,,,638.0,,H,BAO_0000219,CHO,,,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,51.0,449.0
8.0,17624.0,,F,,,Autocuration,CHEMBL615987,1.0,,,639.0,,H,BAO_0000219,CHO,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,51.0,449.0
8.0,17624.0,,F,,,Autocuration,CHEMBL615988,1.0,,,640.0,,H,BAO_0000219,CHO,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,51.0,449.0
8.0,17624.0,,F,,,Expert,CHEMBL615989,1.0,,,641.0,,H,BAO_0000219,CHO,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,51.0,449.0
8.0,17624.0,,F,,,Autocuration,CHEMBL615990,1.0,,,642.0,,H,BAO_0000219,CHO,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,51.0,449.0
8.0,17624.0,,F,,,Autocuration,CHEMBL615991,1.0,,,643.0,,H,BAO_0000219,CHO,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,51.0,449.0
8.0,17624.0,,F,,,Autocuration,CHEMBL615992,1.0,,,644.0,,H,BAO_0000219,CHO,,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,51.0,449.0
8.0,17624.0,,F,,,Autocuration,CHEMBL615993,1.0,,,645.0,,H,BAO_0000219,CHO,,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,51.0,449.0
8.0,17624.0,,F,,,Expert,CHEMBL615994,1.0,,,646.0,,H,BAO_0000219,CHO,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,51.0,449.0
8.0,17624.0,,F,,,Autocuration,CHEMBL615995,1.0,,,647.0,,H,BAO_0000219,CHO,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,51.0,449.0
8.0,17624.0,,F,,,Autocuration,CHEMBL615996,1.0,,,648.0,,H,BAO_0000219,CHO,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,51.0,449.0
8.0,17624.0,,F,,,Autocuration,CHEMBL615997,1.0,,,649.0,,H,BAO_0000219,CHO,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,51.0,449.0
8.0,6563.0,,F,,,Autocuration,CHEMBL615998,1.0,,,650.0,,H,BAO_0000019,,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,51.0,
8.0,6563.0,,F,,,Autocuration,CHEMBL615999,1.0,,,651.0,,H,BAO_0000019,,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,51.0,
8.0,6563.0,,F,,,Autocuration,CHEMBL616000,1.0,,,652.0,,H,BAO_0000019,,,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,51.0,
8.0,17296.0,,F,,,Autocuration,CHEMBL616001,1.0,,,653.0,,H,BAO_0000219,HEK293,,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,51.0,722.0
9.0,6876.0,,F,,,Expert,CHEMBL616002,1.0,,,654.0,,D,BAO_0000019,,9606.0,,Homo sapiens,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,51.0,
8.0,6876.0,,F,,,Expert,CHEMBL616003,1.0,,,655.0,,H,BAO_0000019,,,,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,51.0,
9.0,5272.0,,F,,,Expert,CHEMBL616004,1.0,,,656.0,,D,BAO_0000019,,9606.0,,Homo sapiens,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,51.0,
9.0,5272.0,,F,,,Expert,CHEMBL616005,1.0,,,657.0,,D,BAO_0000019,,9606.0,,Homo sapiens,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,51.0,
8.0,5548.0,,F,,,Autocuration,CHEMBL616006,1.0,,,658.0,,H,BAO_0000019,,,,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,51.0,
8.0,5548.0,,F,,,Expert,CHEMBL616007,1.0,,,659.0,,H,BAO_0000019,,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,51.0,
8.0,5548.0,,F,,,Autocuration,CHEMBL616008,1.0,,,660.0,,H,BAO_0000019,,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,51.0,
8.0,5548.0,,F,,,Autocuration,CHEMBL616009,1.0,,,661.0,,H,BAO_0000019,,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,51.0,
8.0,5929.0,,F,,,Expert,CHEMBL616010,1.0,,,662.0,,H,BAO_0000019,,,,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,51.0,
9.0,5929.0,,F,,,Expert,CHEMBL616011,1.0,,,663.0,,D,BAO_0000019,,9606.0,,Homo sapiens,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,51.0,
9.0,5929.0,,F,,,Expert,CHEMBL615740,1.0,,,664.0,,D,BAO_0000019,,9606.0,,Homo sapiens,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,51.0,
8.0,16245.0,,F,,,Autocuration,CHEMBL615741,1.0,,,665.0,,H,BAO_0000019,,,,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,51.0,
8.0,5640.0,,F,,,Expert,CHEMBL615742,1.0,,,666.0,,H,BAO_0000019,,,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,51.0,
8.0,5640.0,,F,,,Autocuration,CHEMBL615743,1.0,,,667.0,,H,BAO_0000019,,,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,51.0,
8.0,14509.0,,F,,,Autocuration,CHEMBL615744,1.0,,,668.0,,H,BAO_0000219,CHO,,,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,51.0,449.0
8.0,14509.0,,F,,,Expert,CHEMBL615745,1.0,,,669.0,,H,BAO_0000219,CHO,,,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,51.0,449.0
8.0,15331.0,,B,,,Autocuration,CHEMBL615746,1.0,,,670.0,,H,BAO_0000357,,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,51.0,
8.0,15331.0,,B,,,Autocuration,CHEMBL615747,1.0,,,671.0,,H,BAO_0000357,,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,51.0,
8.0,6563.0,,F,,,Autocuration,CHEMBL615748,1.0,,,672.0,,H,BAO_0000019,,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,51.0,
8.0,6563.0,,F,,,Autocuration,CHEMBL615749,1.0,,,673.0,,H,BAO_0000019,,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,51.0,
8.0,6563.0,,F,,,Autocuration,CHEMBL615750,1.0,,,674.0,,H,BAO_0000019,,,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,51.0,
9.0,6563.0,,F,,,Expert,CHEMBL616259,1.0,,,675.0,,D,BAO_0000019,,9606.0,,Homo sapiens,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,51.0,
8.0,6563.0,,F,,,Autocuration,CHEMBL616260,1.0,,,676.0,,H,BAO_0000019,,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,51.0,
9.0,5272.0,,F,,,Expert,CHEMBL616261,1.0,,,677.0,,D,BAO_0000019,,9606.0,,Homo sapiens,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,51.0,
9.0,5272.0,,F,,,Expert,CHEMBL616262,1.0,,,678.0,,D,BAO_0000019,,9606.0,,Homo sapiens,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,51.0,
9.0,5272.0,,F,,,Expert,CHEMBL616263,1.0,,,679.0,,D,BAO_0000019,,9606.0,,Homo sapiens,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,51.0,
9.0,5272.0,,F,,,Expert,CHEMBL616264,1.0,,,680.0,,D,BAO_0000019,,9606.0,,Homo sapiens,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,51.0,
9.0,5272.0,,F,,,Expert,CHEMBL616265,1.0,,,681.0,,D,BAO_0000019,,9606.0,,Homo sapiens,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,51.0,
9.0,5272.0,,F,,,Expert,CHEMBL616266,1.0,,,682.0,,D,BAO_0000019,,9606.0,,Homo sapiens,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,51.0,
9.0,5272.0,,F,,,Expert,CHEMBL616267,1.0,,,683.0,,D,BAO_0000019,,9606.0,,Homo sapiens,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,51.0,
9.0,5272.0,,F,,,Expert,CHEMBL616268,1.0,,,684.0,,D,BAO_0000019,,9606.0,,Homo sapiens,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,51.0,
9.0,16146.0,,B,,,Expert,CHEMBL616269,1.0,,,685.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Inhibition of human 5-hydroxytryptamine 1A receptor,,51.0,
8.0,17624.0,,B,,,Autocuration,CHEMBL884528,1.0,,,686.0,,H,BAO_0000219,CHO,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,51.0,449.0
9.0,13706.0,,B,,,Expert,CHEMBL616270,1.0,,,687.0,,D,BAO_0000219,HEK293,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,105.0,722.0
8.0,15250.0,,B,,,Autocuration,CHEMBL616271,1.0,,,688.0,,H,BAO_0000219,CHO,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,51.0,449.0
8.0,17624.0,,F,,,Autocuration,CHEMBL616272,1.0,,,689.0,,H,BAO_0000219,CHO,,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,51.0,449.0
8.0,6861.0,,B,,,Expert,CHEMBL616273,1.0,,,690.0,,H,BAO_0000357,,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,51.0,
9.0,17200.0,,B,,,Expert,CHEMBL616274,1.0,,,691.0,,D,BAO_0000357,,9606.0,,Homo sapiens,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,51.0,
8.0,17624.0,,B,,,Autocuration,CHEMBL616275,1.0,,,692.0,,H,BAO_0000219,CHO,,,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,51.0,449.0
8.0,17624.0,,B,,,Autocuration,CHEMBL616276,1.0,,,693.0,,H,BAO_0000219,CHO,,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,51.0,449.0
0.0,12058.0,,F,,,Autocuration,CHEMBL616277,1.0,,,694.0,In vivo,U,BAO_0000218,,10116.0,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,22226.0,
0.0,12058.0,,F,,,Autocuration,CHEMBL616278,1.0,,,695.0,In vivo,U,BAO_0000218,,10116.0,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,22226.0,
0.0,12058.0,,F,,,Autocuration,CHEMBL616279,1.0,,,696.0,In vivo,U,BAO_0000218,,10116.0,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,22226.0,
0.0,12058.0,,F,,,Autocuration,CHEMBL616280,1.0,,,697.0,In vivo,U,BAO_0000218,,10116.0,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,22226.0,
0.0,12058.0,,F,,,Autocuration,CHEMBL616281,1.0,,,698.0,In vivo,U,BAO_0000218,,10116.0,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,22226.0,
0.0,12058.0,,F,,,Autocuration,CHEMBL616282,1.0,,,699.0,In vivo,U,BAO_0000218,,10116.0,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,22226.0,
0.0,12058.0,,F,,,Autocuration,CHEMBL616283,1.0,,,700.0,In vivo,U,BAO_0000218,,10116.0,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,22226.0,
0.0,12058.0,,F,,,Autocuration,CHEMBL616284,1.0,,,701.0,In vivo,U,BAO_0000218,,10116.0,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,22226.0,
0.0,12058.0,,F,,,Autocuration,CHEMBL616285,1.0,,,702.0,In vivo,U,BAO_0000218,,10116.0,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,22226.0,
0.0,12058.0,,F,,,Autocuration,CHEMBL616286,1.0,,,703.0,In vivo,U,BAO_0000218,,10116.0,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,22226.0,
0.0,12058.0,,F,,,Autocuration,CHEMBL616287,1.0,,,704.0,In vivo,U,BAO_0000218,,10116.0,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,22226.0,
0.0,12058.0,,F,,,Autocuration,CHEMBL616288,1.0,,,705.0,In vivo,U,BAO_0000218,,10116.0,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,22226.0,
0.0,12058.0,,F,,,Autocuration,CHEMBL616289,1.0,,,706.0,In vivo,U,BAO_0000218,,10116.0,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,22226.0,
0.0,12058.0,,F,,,Autocuration,CHEMBL615610,1.0,,,707.0,In vivo,U,BAO_0000218,,10116.0,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,22226.0,
0.0,12058.0,,F,,,Autocuration,CHEMBL615611,1.0,,,708.0,In vivo,U,BAO_0000218,,10116.0,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,22226.0,
0.0,12058.0,,F,,,Autocuration,CHEMBL615612,1.0,,,709.0,In vivo,U,BAO_0000218,,10116.0,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,22226.0,
0.0,12058.0,,F,,,Autocuration,CHEMBL615613,1.0,,,710.0,In vivo,U,BAO_0000218,,10116.0,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,22226.0,
0.0,12058.0,,F,,,Autocuration,CHEMBL615614,1.0,,,711.0,In vivo,U,BAO_0000218,,10116.0,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,22226.0,
0.0,12058.0,,F,,,Autocuration,CHEMBL615615,1.0,,,712.0,In vivo,U,BAO_0000218,,10116.0,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,22226.0,
4.0,11440.0,,B,,,Autocuration,CHEMBL615616,1.0,,,713.0,,H,BAO_0000019,,,,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,105093.0,
8.0,6238.0,1898.0,B,,,Autocuration,CHEMBL615617,1.0,Hypothalamus,,714.0,,H,BAO_0000249,,,,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,11923.0,
8.0,10046.0,,B,,,Autocuration,CHEMBL615618,1.0,,,715.0,,H,BAO_0000019,,,,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,10577.0,
8.0,10046.0,,B,,,Autocuration,CHEMBL615619,1.0,,,716.0,,H,BAO_0000019,,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,10577.0,
8.0,10046.0,,B,,,Expert,CHEMBL615620,1.0,,,717.0,,H,BAO_0000019,,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,10577.0,
8.0,167.0,,B,,,Autocuration,CHEMBL615621,1.0,,,718.0,,H,BAO_0000357,,,,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,55.0,
8.0,167.0,,B,,,Autocuration,CHEMBL615622,1.0,,,719.0,,H,BAO_0000357,,,,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,55.0,
8.0,11520.0,,F,,,Autocuration,CHEMBL615623,1.0,,,720.0,,H,BAO_0000019,,,,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,12166.0,
8.0,11520.0,,F,,,Autocuration,CHEMBL615624,1.0,,,721.0,,H,BAO_0000019,,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,12166.0,
8.0,11520.0,,F,,,Autocuration,CHEMBL615625,1.0,,,722.0,,H,BAO_0000019,,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,12166.0,
8.0,11520.0,,F,,,Autocuration,CHEMBL767045,1.0,,,723.0,,H,BAO_0000019,,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,12166.0,
8.0,135.0,,F,,,Autocuration,CHEMBL615626,1.0,,,724.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,55.0,
8.0,135.0,,F,,,Autocuration,CHEMBL615627,1.0,,,725.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,55.0,
8.0,11311.0,,B,,,Autocuration,CHEMBL615628,1.0,,,726.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,55.0,
8.0,10193.0,,B,,,Autocuration,CHEMBL615629,1.0,,,727.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,55.0,
9.0,12281.0,,B,,,Expert,CHEMBL615630,1.0,,,728.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Inhibitory concentration against 5-lipoxygenase from human whole blood,,55.0,
8.0,11311.0,,B,,,Autocuration,CHEMBL615631,1.0,,,729.0,,H,BAO_0000219,,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,55.0,
8.0,12576.0,,F,,,Autocuration,CHEMBL615632,1.0,,,730.0,,H,BAO_0000218,,,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,17087.0,
8.0,12281.0,,B,,,Autocuration,CHEMBL615633,1.0,,,731.0,,H,BAO_0000357,,,,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,17087.0,
8.0,12576.0,,F,,,Autocuration,CHEMBL615634,1.0,,,732.0,,H,BAO_0000218,,,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,17087.0,
8.0,11089.0,,B,,,Expert,CHEMBL615635,1.0,,,733.0,,H,BAO_0000019,,9823.0,,Sus scrofa,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,55.0,
8.0,11006.0,,B,,,Expert,CHEMBL615636,1.0,,,734.0,,H,BAO_0000357,,,,,In vitro inhibition of rat 5-Lipoxygenase,,12166.0,
9.0,11481.0,,B,,,Expert,CHEMBL615637,1.0,,,735.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibitory activity against 5-Lipoxygenase,,12166.0,
8.0,10864.0,,B,,,Expert,CHEMBL615638,1.0,,,736.0,,H,BAO_0000219,RBL-1,,,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,12166.0,702.0
8.0,3595.0,,B,,,Autocuration,CHEMBL615639,1.0,,,737.0,,H,BAO_0000219,RBL-1,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,12166.0,702.0
8.0,11311.0,,B,,,Autocuration,CHEMBL615640,1.0,,,738.0,,H,BAO_0000219,RBL-1,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,12166.0,702.0
8.0,11311.0,,B,,,Autocuration,CHEMBL615796,1.0,,,739.0,,H,BAO_0000019,,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,12166.0,
8.0,11311.0,,B,,,Autocuration,CHEMBL615845,1.0,,,740.0,,H,BAO_0000219,,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,12166.0,
8.0,11006.0,,B,,,Autocuration,CHEMBL615846,1.0,,,741.0,,H,BAO_0000357,,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,12166.0,
8.0,3595.0,,B,,,Autocuration,CHEMBL615847,1.0,,,742.0,,H,BAO_0000219,RBL-1,,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,12166.0,702.0
8.0,11311.0,,B,,,Autocuration,CHEMBL615848,1.0,,,743.0,,H,BAO_0000357,,,,,The compound was tested for inhibition of isolated 5-Lipoxygenase,,12166.0,
0.0,11481.0,,B,,,Autocuration,CHEMBL615849,1.0,,,744.0,,U,BAO_0000019,,10116.0,,Rattus norvegicus,Ratio of IC50 against 5-LO and COX,,22226.0,
8.0,11006.0,,B,,,Autocuration,CHEMBL615850,1.0,,,745.0,,H,BAO_0000357,,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,12166.0,
8.0,11006.0,,B,,,Autocuration,CHEMBL615851,1.0,,,746.0,,H,BAO_0000357,,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,12166.0,
8.0,11311.0,,B,,,Autocuration,CHEMBL615852,1.0,,,747.0,,H,BAO_0000219,,,,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,12166.0,
8.0,11006.0,,F,,,Autocuration,CHEMBL615853,1.0,,,748.0,,H,BAO_0000019,,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,12166.0,
8.0,4288.0,2367.0,B,,,Autocuration,CHEMBL884527,1.0,Prostate gland,,749.0,,H,BAO_0000357,,,,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,120.0,
0.0,7587.0,,B,,,Autocuration,CHEMBL872871,1.0,,,750.0,,U,BAO_0000019,,8932.0,,Columba livia,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,22226.0,
0.0,7587.0,,B,,,Autocuration,CHEMBL615854,1.0,,,751.0,,U,BAO_0000019,,8932.0,,Columba livia,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,22226.0,
0.0,7587.0,,B,,,Autocuration,CHEMBL767046,1.0,,,752.0,,U,BAO_0000019,,8932.0,,Columba livia,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,22226.0,
8.0,11249.0,,B,,,Autocuration,CHEMBL615855,1.0,,,753.0,,H,BAO_0000357,,,,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,10732.0,
9.0,8003.0,,F,,,Expert,CHEMBL615856,1.0,,,754.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,12198.0,
9.0,8003.0,,F,,,Expert,CHEMBL615857,1.0,,,755.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,12198.0,
9.0,8003.0,,F,,,Expert,CHEMBL615858,1.0,,,756.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,12198.0,
8.0,12416.0,10000000.0,B,,,Expert,CHEMBL615859,1.0,Hippocampus,,757.0,,H,BAO_0000221,,,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,10576.0,
8.0,16293.0,,B,,,Autocuration,CHEMBL615860,1.0,,,758.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,51.0,
0.0,13047.0,,B,,,Autocuration,CHEMBL615861,1.0,,,759.0,,U,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,22226.0,
0.0,13047.0,,B,,,Autocuration,CHEMBL615862,1.0,,,760.0,,U,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,22226.0,
0.0,13047.0,,B,,,Autocuration,CHEMBL615863,1.0,,,761.0,,U,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,22226.0,
0.0,13047.0,,B,,,Autocuration,CHEMBL615864,1.0,,,762.0,,U,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,22226.0,
4.0,10085.0,10000000.0,B,,,Autocuration,CHEMBL615865,1.0,Hippocampus,,763.0,,H,BAO_0000221,,,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,104744.0,
4.0,10085.0,10000000.0,B,,,Autocuration,CHEMBL615866,1.0,Hippocampus,,764.0,,H,BAO_0000221,,,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,104744.0,
4.0,10085.0,10000000.0,B,,,Autocuration,CHEMBL615867,1.0,Hippocampus,,765.0,,H,BAO_0000221,,,,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,104744.0,
4.0,9841.0,,B,Membranes,,Autocuration,CHEMBL615868,1.0,,,766.0,,H,BAO_0000249,,,,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,104744.0,
5.0,8822.0,,B,,,Autocuration,CHEMBL615869,1.0,,,767.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,104744.0,
5.0,9806.0,,B,,,Autocuration,CHEMBL615870,1.0,,,768.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,104744.0,
5.0,9806.0,,B,,,Autocuration,CHEMBL615871,1.0,,,769.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,104744.0,
4.0,8868.0,,B,,,Autocuration,CHEMBL615872,1.0,,,770.0,,H,BAO_0000224,,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,104744.0,
4.0,9036.0,10000000.0,B,,,Autocuration,CHEMBL833492,1.0,Hippocampus,,771.0,,H,BAO_0000221,,,,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,104744.0,
4.0,11374.0,10000000.0,B,,,Autocuration,CHEMBL615873,1.0,Hippocampus,,772.0,,H,BAO_0000221,,,,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,104744.0,
4.0,10881.0,,B,,,Autocuration,CHEMBL615479,1.0,,,773.0,,H,BAO_0000224,,,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,104744.0,
4.0,8822.0,,B,,,Autocuration,CHEMBL615480,1.0,,,774.0,,H,BAO_0000019,,,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,104744.0,
5.0,9806.0,,B,,,Autocuration,CHEMBL615481,1.0,,,775.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,104744.0,
4.0,15463.0,,B,,,Autocuration,CHEMBL872869,1.0,,,776.0,,H,BAO_0000019,,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,104744.0,
4.0,15463.0,,B,,,Autocuration,CHEMBL615482,1.0,,,777.0,,H,BAO_0000019,,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,104744.0,
4.0,14542.0,955.0,B,,,Autocuration,CHEMBL615483,1.0,Brain,,778.0,,H,BAO_0000221,,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,104744.0,
4.0,14542.0,955.0,B,,,Autocuration,CHEMBL615484,1.0,Brain,,779.0,,H,BAO_0000221,,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,104744.0,
4.0,8569.0,,B,,,Autocuration,CHEMBL615485,1.0,,,780.0,,H,BAO_0000019,,,,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,104744.0,
5.0,10062.0,,B,,,Autocuration,CHEMBL615486,1.0,,,781.0,,D,BAO_0000224,,10116.0,,Rattus norvegicus,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,104744.0,
4.0,4771.0,,B,,,Autocuration,CHEMBL615487,1.0,,,782.0,,H,BAO_0000224,,,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,104744.0,
4.0,10062.0,,B,,,Autocuration,CHEMBL615488,1.0,,,783.0,,H,BAO_0000224,,,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,104744.0,
4.0,10062.0,,B,,,Autocuration,CHEMBL615489,1.0,,,784.0,,H,BAO_0000224,,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,104744.0,
4.0,10062.0,,B,,,Autocuration,CHEMBL615389,1.0,,,785.0,,H,BAO_0000224,,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,104744.0,
4.0,15463.0,,B,,,Autocuration,CHEMBL615390,1.0,,,786.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,104744.0,
4.0,15463.0,,B,,,Autocuration,CHEMBL615391,1.0,,,787.0,,H,BAO_0000019,,,,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,104744.0,
4.0,9098.0,,B,,,Autocuration,CHEMBL615392,1.0,,,788.0,,H,BAO_0000224,,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,104744.0,
0.0,3070.0,,B,,,Autocuration,CHEMBL615393,1.0,,,789.0,,U,BAO_0000019,,10116.0,,Rattus norvegicus,Affinity for 5-hydroxytryptamine 1 receptor,,22226.0,
4.0,14542.0,955.0,B,,,Autocuration,CHEMBL615394,1.0,Brain,,790.0,,H,BAO_0000221,,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,104744.0,
4.0,14542.0,955.0,B,,,Autocuration,CHEMBL615395,1.0,Brain,,791.0,,H,BAO_0000221,,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,104744.0,
4.0,6398.0,,B,,,Autocuration,CHEMBL615396,1.0,,,792.0,,H,BAO_0000224,,,,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,104744.0,
4.0,1344.0,955.0,B,,,Autocuration,CHEMBL615397,1.0,Brain,,793.0,,H,BAO_0000221,,,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,104744.0,
4.0,11963.0,,B,,,Autocuration,CHEMBL615398,1.0,,,794.0,,H,BAO_0000019,,,,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,104744.0,
0.0,8908.0,,B,,,Autocuration,CHEMBL615399,1.0,,,795.0,,U,BAO_0000019,,10116.0,,Rattus norvegicus,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,22226.0,
4.0,9098.0,,B,,,Autocuration,CHEMBL615400,1.0,,,796.0,,H,BAO_0000019,,,,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,104744.0,
5.0,8841.0,,B,,,Autocuration,CHEMBL615401,1.0,,,797.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,104744.0,
0.0,8814.0,,B,,,Autocuration,CHEMBL615402,1.0,,,798.0,,U,BAO_0000019,,10116.0,,Rattus norvegicus,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,22226.0,
4.0,11752.0,,B,,,Autocuration,CHEMBL615403,1.0,,,799.0,,H,BAO_0000019,,,,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,104744.0,
4.0,11642.0,955.0,B,,,Autocuration,CHEMBL615404,1.0,Brain,,800.0,,H,BAO_0000221,,,,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,104744.0,
4.0,11642.0,,B,,,Autocuration,CHEMBL615781,1.0,,,801.0,,H,BAO_0000019,,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,104744.0,
4.0,9231.0,955.0,B,,,Autocuration,CHEMBL615782,1.0,Brain,,802.0,,H,BAO_0000220,,,,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,104744.0,
4.0,11351.0,955.0,B,,,Autocuration,CHEMBL615783,1.0,Brain,,803.0,,H,BAO_0000221,,,,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,104744.0,
0.0,4639.0,,B,,,Autocuration,CHEMBL873481,1.0,,,804.0,,U,BAO_0000019,,,,,Compound was tested for binding affinity against 5-HT1 receptor,,22226.0,
0.0,1205.0,,B,,,Autocuration,CHEMBL615784,1.0,,,805.0,,U,BAO_0000019,,,,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,22226.0,
8.0,10025.0,,B,,,Expert,CHEMBL615785,1.0,,,806.0,,H,BAO_0000357,,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,10576.0,
8.0,13241.0,,F,,,Autocuration,CHEMBL615786,1.0,,,807.0,,H,BAO_0000249,,,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,10576.0,
8.0,16245.0,,F,,,Autocuration,CHEMBL615787,1.0,,,808.0,In vivo,H,BAO_0000218,,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,10576.0,
8.0,16245.0,,F,,,Autocuration,CHEMBL615788,1.0,,,809.0,In vivo,H,BAO_0000218,,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,10576.0,
8.0,12438.0,,F,,,Autocuration,CHEMBL767044,1.0,,,810.0,,H,BAO_0000019,,,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,16245.0,,F,,,Autocuration,CHEMBL615789,1.0,,,811.0,In vivo,H,BAO_0000218,,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,10576.0,
8.0,16245.0,,F,,,Autocuration,CHEMBL615790,1.0,,,812.0,In vivo,H,BAO_0000218,,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,10576.0,
8.0,15740.0,,F,,,Autocuration,CHEMBL615813,1.0,,,813.0,,H,BAO_0000019,,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,10576.0,
8.0,15535.0,,F,,,Autocuration,CHEMBL615814,1.0,,,814.0,,H,BAO_0000219,,,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,10576.0,
8.0,15535.0,,F,,,Expert,CHEMBL615815,1.0,,,815.0,,H,BAO_0000219,,,,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,51.0,
8.0,15535.0,,F,,,Autocuration,CHEMBL615816,1.0,,,816.0,,H,BAO_0000219,,,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,10576.0,
8.0,9888.0,,B,,,Expert,CHEMBL615817,1.0,,,817.0,,H,BAO_0000249,,,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,10576.0,
8.0,10085.0,10000000.0,B,,,Autocuration,CHEMBL615818,1.0,Hippocampus,,818.0,,H,BAO_0000221,,,,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,10576.0,
8.0,10085.0,10000000.0,B,,,Autocuration,CHEMBL615819,1.0,Hippocampus,,819.0,,H,BAO_0000221,,,,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,10576.0,
8.0,17331.0,,B,Membranes,,Expert,CHEMBL615820,1.0,,,820.0,,H,BAO_0000249,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,10576.0,
9.0,10845.0,10000000.0,B,,,Expert,CHEMBL615821,1.0,Hippocampus,,821.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,10576.0,
9.0,10845.0,10000000.0,B,,,Expert,CHEMBL615822,1.0,Hippocampus,,822.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,10576.0,
8.0,10845.0,10000000.0,B,,,Expert,CHEMBL615823,1.0,Hippocampus,,823.0,,H,BAO_0000221,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,10576.0,
9.0,10845.0,10000000.0,B,,,Expert,CHEMBL615824,1.0,Hippocampus,,824.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,10576.0,
9.0,10845.0,10000000.0,B,,,Expert,CHEMBL615825,1.0,Hippocampus,,825.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,10576.0,
8.0,13730.0,,B,,,Expert,CHEMBL615826,1.0,,,826.0,,H,BAO_0000357,,,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,10576.0,
8.0,13508.0,,B,,,Expert,CHEMBL615827,1.0,,,827.0,,H,BAO_0000249,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,10576.0,
8.0,13508.0,10000000.0,B,,,Expert,CHEMBL615828,1.0,Hippocampus,,828.0,,H,BAO_0000249,,,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,10576.0,
8.0,12073.0,10000000.0,B,,,Expert,CHEMBL615829,1.0,Hippocampus,,829.0,,H,BAO_0000221,,,,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576.0,
8.0,4671.0,10000000.0,B,,,Autocuration,CHEMBL615830,1.0,Hippocampus,,830.0,,H,BAO_0000221,,,,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,10576.0,
8.0,13631.0,10000000.0,B,,,Expert,CHEMBL615831,1.0,Hippocampus,,831.0,,H,BAO_0000221,,,,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,10576.0,
8.0,12438.0,,B,,,Autocuration,CHEMBL615832,1.0,,,832.0,,H,BAO_0000357,,,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,10483.0,,B,,,Autocuration,CHEMBL615833,1.0,,,833.0,,H,BAO_0000019,,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,10576.0,
8.0,10483.0,10000000.0,B,,,Autocuration,CHEMBL615834,1.0,Hippocampus,,834.0,,H,BAO_0000221,,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,10576.0,
8.0,12352.0,,B,,,Intermediate,CHEMBL615835,1.0,,,835.0,,H,BAO_0000249,,,,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,10576.0,
8.0,14732.0,10000000.0,B,,,Autocuration,CHEMBL615836,1.0,Hippocampus,,836.0,,H,BAO_0000249,,,,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,10576.0,
9.0,11049.0,,B,,,Expert,CHEMBL615837,1.0,,,837.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,10576.0,
9.0,11049.0,,B,,,Expert,CHEMBL615838,1.0,,,838.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,10576.0,
8.0,13657.0,,B,,,Expert,CHEMBL615839,1.0,,,839.0,,H,BAO_0000249,,,,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,10576.0,
8.0,11473.0,,B,,,Autocuration,CHEMBL884525,1.0,,,840.0,,H,BAO_0000019,,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,10576.0,
8.0,2014.0,,B,,,Autocuration,CHEMBL615840,1.0,,,841.0,,H,BAO_0000249,,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,10576.0,
8.0,3086.0,10000000.0,B,,,Expert,CHEMBL615405,1.0,Hippocampus,,842.0,,H,BAO_0000221,,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576.0,
8.0,15854.0,,B,,,Expert,CHEMBL615406,1.0,,,843.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,10576.0,
8.0,10922.0,10000000.0,B,,,Expert,CHEMBL615900,1.0,Hippocampus,,844.0,,H,BAO_0000221,,,,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,10576.0,
8.0,13346.0,10000000.0,B,,,Expert,CHEMBL615901,1.0,Hippocampus,,845.0,,H,BAO_0000221,,,,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,10576.0,
8.0,15311.0,,B,,,Expert,CHEMBL615902,1.0,,,846.0,,H,BAO_0000357,,,,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,10576.0,
8.0,10922.0,10000000.0,B,,,Autocuration,CHEMBL615903,1.0,Hippocampus,,847.0,,H,BAO_0000221,,,,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,10576.0,
8.0,10025.0,,B,,,Autocuration,CHEMBL615904,1.0,,,848.0,,H,BAO_0000357,,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,10576.0,
8.0,10025.0,,B,,,Expert,CHEMBL615905,1.0,,,849.0,,H,BAO_0000357,,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,10576.0,
8.0,9742.0,,B,,,Autocuration,CHEMBL615906,1.0,,,850.0,,H,BAO_0000019,,,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,10576.0,
8.0,9742.0,,F,,,Autocuration,CHEMBL615907,1.0,,,851.0,,H,BAO_0000019,,,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,10576.0,
8.0,12304.0,,B,,,Expert,CHEMBL615908,1.0,,,852.0,,H,BAO_0000019,,,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,10576.0,
8.0,15789.0,10000000.0,B,,,Autocuration,CHEMBL615909,1.0,Hippocampus,,853.0,,H,BAO_0000221,,,,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,10576.0,
8.0,9912.0,,B,,,Autocuration,CHEMBL615910,1.0,,,854.0,,H,BAO_0000019,,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,10576.0,
8.0,9912.0,,B,,,Autocuration,CHEMBL615911,1.0,,,855.0,,H,BAO_0000019,,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,10576.0,
8.0,9912.0,,B,,,Autocuration,CHEMBL615912,1.0,,,856.0,,H,BAO_0000019,,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,10576.0,
8.0,16693.0,,B,,,Expert,CHEMBL615913,1.0,,,857.0,,H,BAO_0000019,,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,10576.0,
8.0,13276.0,,B,,,Expert,CHEMBL615914,1.0,,,858.0,,H,BAO_0000357,,,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,10576.0,
8.0,12678.0,10000000.0,B,,,Autocuration,CHEMBL615915,1.0,Hippocampus,,859.0,,H,BAO_0000221,,,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,10576.0,
8.0,11825.0,,B,,,Autocuration,CHEMBL615916,1.0,,,860.0,,H,BAO_0000357,,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,10576.0,
8.0,12443.0,,B,,,Expert,CHEMBL615917,1.0,,,861.0,,H,BAO_0000357,,,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,10576.0,
8.0,13830.0,,B,,,Expert,CHEMBL615918,1.0,,,862.0,,H,BAO_0000357,,,,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,14286.0,10000000.0,B,,,Expert,CHEMBL615919,1.0,Hippocampus,,863.0,,H,BAO_0000249,,,,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,10576.0,
9.0,14356.0,10000000.0,B,,,Expert,CHEMBL615920,1.0,Hippocampus,,864.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,10576.0,
8.0,15306.0,,B,,,Autocuration,CHEMBL615921,1.0,,,865.0,,H,BAO_0000357,,,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,15306.0,,B,,,Expert,CHEMBL615922,1.0,,,866.0,,H,BAO_0000357,,,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,10576.0,
9.0,16616.0,,F,,,Expert,CHEMBL881290,1.0,,,867.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,10576.0,
8.0,3651.0,10000000.0,B,,,Autocuration,CHEMBL615923,1.0,Hippocampus,,868.0,,H,BAO_0000221,,,,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,10576.0,
8.0,14331.0,10000000.0,F,,,Autocuration,CHEMBL615924,1.0,Hippocampus,,869.0,,H,BAO_0000221,,,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576.0,
8.0,14331.0,10000000.0,F,,,Autocuration,CHEMBL615925,1.0,Hippocampus,,870.0,,H,BAO_0000221,,,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576.0,
9.0,14178.0,,B,,,Expert,CHEMBL615926,1.0,,,871.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,10576.0,
9.0,10639.0,,B,,,Expert,CHEMBL615927,1.0,,,872.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,12306.0,10000000.0,B,,,Autocuration,CHEMBL615928,1.0,Hippocampus,,873.0,,H,BAO_0000221,,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,10576.0,
9.0,1348.0,,B,,,Expert,CHEMBL615929,1.0,,,874.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,10576.0,
8.0,13605.0,10000000.0,B,,,Autocuration,CHEMBL615930,1.0,Hippocampus,,875.0,,H,BAO_0000221,,,,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,10576.0,
8.0,17624.0,,B,,,Autocuration,CHEMBL615931,1.0,,,876.0,,H,BAO_0000219,CHO,,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,51.0,449.0
8.0,17624.0,,F,,,Autocuration,CHEMBL615932,1.0,,,877.0,,H,BAO_0000219,CHO,,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,51.0,449.0
8.0,17624.0,,F,,,Autocuration,CHEMBL615933,1.0,,,878.0,,H,BAO_0000219,CHO,,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,51.0,449.0
8.0,15267.0,,B,,,Autocuration,CHEMBL615934,1.0,,,879.0,,H,BAO_0000357,,,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,51.0,
8.0,16532.0,,B,,,Autocuration,CHEMBL615935,1.0,,,880.0,,H,BAO_0000357,,,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,51.0,
8.0,6563.0,,F,,,Autocuration,CHEMBL615936,1.0,,,881.0,,H,BAO_0000019,,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,51.0,
8.0,4751.0,,B,,,Autocuration,CHEMBL615937,1.0,,,882.0,,H,BAO_0000219,CHO,,,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,51.0,449.0
8.0,15463.0,,B,,,Autocuration,CHEMBL615938,1.0,,,883.0,,H,BAO_0000357,,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,51.0,
8.0,3805.0,,B,,,Autocuration,CHEMBL615797,1.0,,,884.0,,H,BAO_0000357,,,,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,51.0,
8.0,5640.0,,B,,,Autocuration,CHEMBL615798,1.0,,,885.0,,H,BAO_0000357,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51.0,
8.0,6563.0,,B,,,Autocuration,CHEMBL872870,1.0,,,886.0,,H,BAO_0000357,,,,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,51.0,
8.0,5548.0,,B,,,Autocuration,CHEMBL615799,1.0,,,887.0,,H,BAO_0000357,,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,51.0,
8.0,6347.0,,B,,,Autocuration,CHEMBL615800,1.0,,,888.0,,H,BAO_0000357,,,,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,51.0,
8.0,17296.0,,F,,,Autocuration,CHEMBL615801,1.0,,,889.0,,H,BAO_0000219,HEK293,,,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,51.0,722.0
8.0,13047.0,,B,,,Autocuration,CHEMBL615802,1.0,,,890.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,51.0,
8.0,15740.0,,B,,,Autocuration,CHEMBL615803,1.0,,,891.0,,H,BAO_0000357,,,,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,51.0,
8.0,5640.0,,F,,,Expert,CHEMBL835002,1.0,,,892.0,,H,BAO_0000019,,,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,51.0,
8.0,5640.0,,F,,,Autocuration,CHEMBL615804,1.0,,,893.0,,H,BAO_0000019,,,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,51.0,
8.0,17211.0,,B,,,Expert,CHEMBL615805,1.0,,,894.0,,H,BAO_0000219,HeLa,,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,51.0,308.0
8.0,4751.0,,B,,,Autocuration,CHEMBL615806,1.0,,,895.0,,H,BAO_0000219,CHO,,,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,51.0,449.0
9.0,6491.0,,B,,,Expert,CHEMBL615807,1.0,,,896.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,51.0,
8.0,4707.0,,B,,,Autocuration,CHEMBL615808,1.0,,,897.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,51.0,
9.0,13910.0,,B,,,Expert,CHEMBL615809,1.0,,,898.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity against 5-hydroxytryptamine 1A receptor,,51.0,
8.0,16190.0,,B,,,Autocuration,CHEMBL615810,1.0,,,899.0,,H,BAO_0000219,HeLa,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,51.0,308.0
8.0,16633.0,,B,,,Autocuration,CHEMBL615811,1.0,,,900.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51.0,
8.0,11898.0,,B,,,Autocuration,CHEMBL615812,1.0,,,901.0,,H,BAO_0000219,CHO,,,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,51.0,449.0
8.0,11898.0,,B,,,Autocuration,CHEMBL615751,1.0,,,902.0,,H,BAO_0000219,CHO,,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,51.0,449.0
8.0,14331.0,,B,,,Autocuration,CHEMBL615752,1.0,,,903.0,,H,BAO_0000357,,,,,Binding affinity against human 5-hydroxytryptamine 1A receptor,,51.0,
8.0,17624.0,,B,,,Expert,CHEMBL615753,1.0,,,904.0,,H,BAO_0000219,CHO,,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,51.0,449.0
8.0,17624.0,,B,,,Autocuration,CHEMBL615754,1.0,,,905.0,,H,BAO_0000219,CHO,,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,51.0,449.0
8.0,3307.0,,B,,,Autocuration,CHEMBL615755,1.0,,,906.0,,H,BAO_0000357,,,,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,51.0,
9.0,6563.0,,B,,,Expert,CHEMBL615756,1.0,,,907.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,51.0,449.0
8.0,14165.0,,B,,,Autocuration,CHEMBL615757,1.0,,,908.0,,H,BAO_0000019,,,,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,51.0,
8.0,5732.0,,B,,,Autocuration,CHEMBL615758,1.0,,,909.0,,H,BAO_0000357,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,51.0,
8.0,13366.0,,B,,,Expert,CHEMBL615759,1.0,,,910.0,,H,BAO_0000357,,,,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,51.0,
8.0,17626.0,,B,,,Autocuration,CHEMBL615760,1.0,,,911.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,51.0,
8.0,6588.0,,B,,,Expert,CHEMBL615761,1.0,,,912.0,,H,BAO_0000219,HeLa,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,51.0,308.0
8.0,16209.0,,B,,,Autocuration,CHEMBL872104,1.0,,,913.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,51.0,
8.0,15463.0,,B,,,Autocuration,CHEMBL615762,1.0,,,914.0,,H,BAO_0000357,,,,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,51.0,
8.0,15463.0,,B,,,Autocuration,CHEMBL615763,1.0,,,915.0,,H,BAO_0000357,,,,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,51.0,
8.0,14770.0,,B,,,Autocuration,CHEMBL615764,1.0,,,916.0,,H,BAO_0000357,,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,51.0,
8.0,16245.0,,B,,,Autocuration,CHEMBL615765,1.0,,,917.0,,H,BAO_0000219,Cell line,,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,51.0,1167.0
8.0,16245.0,,B,,,Autocuration,CHEMBL615766,1.0,,,918.0,,H,BAO_0000019,,,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,51.0,
8.0,5548.0,,B,,,Autocuration,CHEMBL615767,1.0,,,919.0,,H,BAO_0000357,,,,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,51.0,
8.0,5548.0,,B,,,Expert,CHEMBL615768,1.0,,,920.0,,H,BAO_0000357,,,,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51.0,
8.0,5548.0,,B,,,Autocuration,CHEMBL615769,1.0,,,921.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51.0,
8.0,6876.0,,B,,,Expert,CHEMBL615770,1.0,,,922.0,,H,BAO_0000357,,,,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,51.0,
8.0,2598.0,,B,,,Autocuration,CHEMBL615771,1.0,,,923.0,,H,BAO_0000357,,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51.0,
8.0,17785.0,,B,,,Expert,CHEMBL615772,1.0,,,924.0,,H,BAO_0000357,,,,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,51.0,
8.0,6013.0,,B,,,Autocuration,CHEMBL615773,1.0,,,925.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,51.0,
8.0,5929.0,,B,,,Expert,CHEMBL615774,1.0,,,926.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,51.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL615775,1.0,,,927.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51.0,
8.0,1558.0,,B,,,Autocuration,CHEMBL615776,1.0,,,928.0,,H,BAO_0000357,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,51.0,
8.0,16026.0,,B,,,Expert,CHEMBL615777,1.0,,,929.0,,H,BAO_0000357,,,,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51.0,
8.0,12469.0,,B,,,Autocuration,CHEMBL615778,1.0,,,930.0,,H,BAO_0000219,,,,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,51.0,
9.0,15874.0,,B,,,Expert,CHEMBL615779,1.0,,,931.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,51.0,
8.0,15874.0,,B,,,Autocuration,CHEMBL615780,1.0,,,932.0,,H,BAO_0000357,,,,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,51.0,
8.0,3935.0,,B,,,Autocuration,CHEMBL616298,1.0,,,933.0,,H,BAO_0000357,,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,51.0,
8.0,15818.0,,B,,,Autocuration,CHEMBL616299,1.0,,,934.0,,H,BAO_0000357,,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,51.0,
8.0,13706.0,,B,,,Autocuration,CHEMBL616300,1.0,,,935.0,,H,BAO_0000219,CHO-K1,,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,51.0,485.0
8.0,13729.0,,F,,,Expert,CHEMBL616301,1.0,,,936.0,,H,BAO_0000219,CHO-K1,,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,51.0,485.0
8.0,15413.0,,B,,,Autocuration,CHEMBL616302,1.0,,,937.0,,H,BAO_0000019,,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,51.0,
8.0,15413.0,,B,,,Autocuration,CHEMBL616117,1.0,,,938.0,,H,BAO_0000019,,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,51.0,
8.0,15413.0,,B,,,Autocuration,CHEMBL616118,1.0,,,939.0,,H,BAO_0000019,,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,51.0,
8.0,15413.0,,B,,,Autocuration,CHEMBL616119,1.0,,,940.0,,H,BAO_0000019,,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,51.0,
9.0,3445.0,,B,,,Expert,CHEMBL616120,1.0,,,941.0,,D,BAO_0000219,HeLa,9606.0,,Homo sapiens,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,51.0,308.0
8.0,15740.0,,B,,,Autocuration,CHEMBL616121,1.0,,,942.0,,H,BAO_0000357,,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,51.0,
8.0,15740.0,,B,,,Autocuration,CHEMBL616122,1.0,,,943.0,,H,BAO_0000357,,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,51.0,
8.0,17626.0,,B,,,Autocuration,CHEMBL616123,1.0,,,944.0,,H,BAO_0000357,,,,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,51.0,
9.0,4234.0,,B,,,Expert,CHEMBL616124,1.0,,,945.0,,D,BAO_0000357,,9606.0,,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,51.0,
8.0,5640.0,,B,,,Expert,CHEMBL616125,1.0,,,946.0,,H,BAO_0000357,,,,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,51.0,
8.0,5272.0,,B,,,Expert,CHEMBL616126,1.0,,,947.0,,H,BAO_0000357,,10116.0,,Rattus norvegicus,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,51.0,
8.0,4622.0,,B,,,Autocuration,CHEMBL616127,1.0,,,948.0,,H,BAO_0000219,CHO,,,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,51.0,449.0
8.0,17085.0,,B,,,Expert,CHEMBL616128,1.0,,,949.0,,H,BAO_0000019,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,51.0,
8.0,3025.0,,B,,,Autocuration,CHEMBL616129,1.0,,,950.0,,H,BAO_0000357,,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,51.0,
8.0,15315.0,,B,,,Expert,CHEMBL616130,1.0,,,951.0,,H,BAO_0000357,,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,51.0,
8.0,15267.0,,B,,,Autocuration,CHEMBL616131,1.0,,,952.0,,H,BAO_0000357,,,,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,51.0,
8.0,17158.0,,B,,,Autocuration,CHEMBL616132,1.0,,,953.0,,H,BAO_0000219,HeLa,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,51.0,308.0
9.0,14214.0,,B,,,Expert,CHEMBL616133,1.0,,,954.0,,D,BAO_0000219,HeLa,9606.0,,Homo sapiens,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,51.0,308.0
8.0,17133.0,,B,,,Autocuration,CHEMBL616134,1.0,,,955.0,,H,BAO_0000357,,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51.0,
8.0,16532.0,,B,,,Autocuration,CHEMBL616135,1.0,,,956.0,,H,BAO_0000357,,,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,51.0,
9.0,2391.0,,B,,,Expert,CHEMBL616136,1.0,,,957.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Affinity for 5-hydroxytryptamine 1A receptor subtype,,51.0,
8.0,14447.0,,B,,,Autocuration,CHEMBL616137,1.0,,,958.0,,H,BAO_0000019,,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,51.0,
8.0,14447.0,,B,,,Autocuration,CHEMBL872105,1.0,,,959.0,,H,BAO_0000019,,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,51.0,
8.0,15086.0,,B,,,Autocuration,CHEMBL616138,1.0,,,960.0,,H,BAO_0000357,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,51.0,
9.0,13051.0,,B,,,Expert,CHEMBL616139,1.0,,,961.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,51.0,
8.0,16026.0,,F,,,Autocuration,CHEMBL616140,1.0,,,962.0,,H,BAO_0000019,,,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,51.0,
8.0,17085.0,,B,,,Expert,CHEMBL616141,1.0,,,963.0,,H,BAO_0000019,,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,51.0,
8.0,17133.0,,B,,,Autocuration,CHEMBL616142,1.0,,,964.0,,H,BAO_0000357,,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51.0,
8.0,17133.0,,B,,,Autocuration,CHEMBL616143,1.0,,,965.0,,H,BAO_0000357,,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,51.0,
8.0,17211.0,,B,,,Autocuration,CHEMBL616144,1.0,,,966.0,,H,BAO_0000219,HeLa,,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,51.0,308.0
8.0,17211.0,,B,,,Autocuration,CHEMBL616145,1.0,,,967.0,,H,BAO_0000219,HeLa,,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,51.0,308.0
8.0,17211.0,,B,,,Autocuration,CHEMBL616012,1.0,,,968.0,,H,BAO_0000219,HeLa,,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,51.0,308.0
8.0,17211.0,,B,,,Autocuration,CHEMBL616013,1.0,,,969.0,,H,BAO_0000219,HeLa,,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,51.0,308.0
8.0,16394.0,,F,,,Autocuration,CHEMBL616014,1.0,,,970.0,,H,BAO_0000019,,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,51.0,
8.0,16394.0,,F,,,Autocuration,CHEMBL616015,1.0,,,971.0,,H,BAO_0000019,,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,51.0,
8.0,16394.0,,F,,,Autocuration,CHEMBL616016,1.0,,,972.0,,H,BAO_0000019,,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,51.0,
8.0,16394.0,,F,,,Autocuration,CHEMBL616017,1.0,,,973.0,In vivo,H,BAO_0000218,,,,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,51.0,
8.0,16394.0,,B,,,Autocuration,CHEMBL616018,1.0,,,974.0,,H,BAO_0000019,,,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,51.0,
8.0,15740.0,,F,,,Autocuration,CHEMBL616019,1.0,,,975.0,,H,BAO_0000019,,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,51.0,
8.0,15740.0,,F,,,Autocuration,CHEMBL616020,1.0,,,976.0,,H,BAO_0000019,,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,51.0,
8.0,15740.0,,B,,,Autocuration,CHEMBL858018,1.0,,,977.0,,H,BAO_0000357,,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,51.0,
8.0,17296.0,,F,,,Autocuration,CHEMBL616021,1.0,,,978.0,,H,BAO_0000219,HEK293,,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,51.0,722.0
8.0,5640.0,,F,,,Expert,CHEMBL616022,1.0,,,979.0,,H,BAO_0000019,,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,51.0,
8.0,5640.0,,F,,,Autocuration,CHEMBL616023,1.0,,,980.0,,H,BAO_0000019,,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,51.0,
8.0,5640.0,,F,,,Autocuration,CHEMBL616024,1.0,,,981.0,,H,BAO_0000019,,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,51.0,
8.0,5640.0,,F,,,Autocuration,CHEMBL616025,1.0,,,982.0,,H,BAO_0000019,,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,51.0,
8.0,2759.0,,F,,,Autocuration,CHEMBL616026,1.0,,,983.0,,H,BAO_0000219,CHO,,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,51.0,449.0
8.0,16394.0,,F,,,Autocuration,CHEMBL616027,1.0,,,984.0,,H,BAO_0000019,,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,51.0,
9.0,16394.0,,F,,,Expert,CHEMBL616028,1.0,,,985.0,,D,BAO_0000019,,9606.0,,Homo sapiens,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,51.0,
9.0,3445.0,,F,,,Expert,CHEMBL616029,1.0,,,986.0,,D,BAO_0000019,,9606.0,,Homo sapiens,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,51.0,
8.0,4316.0,,B,,,Expert,CHEMBL616030,1.0,,,987.0,,H,BAO_0000219,CHO,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,51.0,449.0
8.0,4316.0,,B,,,Expert,CHEMBL616031,1.0,,,988.0,,H,BAO_0000019,,,,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,51.0,
9.0,15180.0,,F,,,Expert,CHEMBL616032,1.0,,,989.0,,D,BAO_0000019,,9606.0,,Homo sapiens,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,51.0,
9.0,15180.0,,F,,,Expert,CHEMBL616033,1.0,,,990.0,,D,BAO_0000019,,9606.0,,Homo sapiens,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,51.0,
8.0,15042.0,,F,,,Autocuration,CHEMBL616034,1.0,,,991.0,,H,BAO_0000019,,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,51.0,
8.0,15042.0,,F,,,Autocuration,CHEMBL616035,1.0,,,992.0,,H,BAO_0000019,,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,51.0,
8.0,15042.0,,F,,,Autocuration,CHEMBL616036,1.0,,,993.0,,H,BAO_0000019,,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,51.0,
8.0,15042.0,,F,,,Autocuration,CHEMBL616037,1.0,,,994.0,,H,BAO_0000019,,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,51.0,
8.0,15042.0,,F,,,Autocuration,CHEMBL616038,1.0,,,995.0,,H,BAO_0000019,,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,51.0,
8.0,15042.0,,F,,,Autocuration,CHEMBL616039,1.0,,,996.0,,H,BAO_0000019,,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,51.0,
8.0,15042.0,,F,,,Autocuration,CHEMBL616040,1.0,,,997.0,,H,BAO_0000019,,,,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,51.0,
9.0,15180.0,,F,,,Expert,CHEMBL616041,1.0,,,998.0,,D,BAO_0000219,HeLa,9606.0,,Homo sapiens,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,51.0,308.0
9.0,15180.0,,F,,,Expert,CHEMBL616042,1.0,,,999.0,,D,BAO_0000219,HeLa,9606.0,,Homo sapiens,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,51.0,308.0
9.0,15180.0,,F,,,Expert,CHEMBL616043,1.0,,,1000.0,,D,BAO_0000219,HeLa,9606.0,,Homo sapiens,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,51.0,308.0
8.0,16245.0,,F,,,Autocuration,CHEMBL616044,1.0,,,1001.0,,H,BAO_0000019,,,,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,51.0,
8.0,16026.0,,F,,,Autocuration,CHEMBL616045,1.0,,,1002.0,,H,BAO_0000019,,,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,51.0,
8.0,17296.0,,F,,,Autocuration,CHEMBL616046,1.0,,,1003.0,,H,BAO_0000219,HEK293,,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,51.0,722.0
8.0,2759.0,,F,,,Autocuration,CHEMBL616047,1.0,,,1004.0,,H,BAO_0000219,CHO,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,51.0,449.0
8.0,2759.0,,F,,,Autocuration,CHEMBL616048,1.0,,,1005.0,,H,BAO_0000219,CHO,,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,51.0,449.0
9.0,2759.0,,F,,,Expert,CHEMBL616049,1.0,,,1006.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,51.0,449.0
8.0,2759.0,,F,,,Autocuration,CHEMBL616050,1.0,,,1007.0,,H,BAO_0000219,CHO,,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,51.0,449.0
8.0,15419.0,,F,,,Expert,CHEMBL616051,1.0,,,1008.0,,H,BAO_0000219,,,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,51.0,
8.0,15419.0,,F,,,Autocuration,CHEMBL616212,1.0,,,1009.0,,H,BAO_0000219,,,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,51.0,
8.0,16026.0,,F,,,Autocuration,CHEMBL616213,1.0,,,1010.0,,H,BAO_0000019,,,,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,51.0,
8.0,1414.0,,B,,,Expert,CHEMBL616214,1.0,,,1011.0,In vitro,H,BAO_0000219,,,,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,51.0,
8.0,1414.0,,B,,,Expert,CHEMBL616215,1.0,,,1012.0,In vitro,H,BAO_0000219,,,,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,51.0,
8.0,12861.0,,B,,,Autocuration,CHEMBL616216,1.0,,,1013.0,,H,BAO_0000357,,,,,Binding activity radioligand.,,51.0,
8.0,12861.0,,B,,,Autocuration,CHEMBL616217,1.0,,,1014.0,,H,BAO_0000019,,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,51.0,
8.0,5104.0,,B,,,Autocuration,CHEMBL616218,1.0,,,1015.0,,H,BAO_0000357,,,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,51.0,
8.0,5105.0,,B,,,Autocuration,CHEMBL616219,1.0,,,1016.0,,H,BAO_0000357,,,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,51.0,
8.0,16312.0,,B,,,Autocuration,CHEMBL616220,1.0,,,1017.0,,H,BAO_0000357,,,,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,51.0,
9.0,15180.0,,B,,,Expert,CHEMBL833493,1.0,,,1018.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,51.0,
8.0,5033.0,,B,,,Autocuration,CHEMBL616221,1.0,,,1019.0,,H,BAO_0000357,,,,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,51.0,
9.0,16909.0,,B,,,Expert,CHEMBL616222,1.0,,,1020.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,51.0,449.0
8.0,2590.0,,F,,,Autocuration,CHEMBL616223,1.0,,,1021.0,,H,BAO_0000019,,,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,51.0,
8.0,2590.0,,F,,,Autocuration,CHEMBL616224,1.0,,,1022.0,,H,BAO_0000019,,,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,51.0,
8.0,16394.0,,B,,,Expert,CHEMBL616225,1.0,,,1023.0,,H,BAO_0000019,,,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,51.0,
9.0,4540.0,,B,,,Expert,CHEMBL616226,1.0,,,1024.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,51.0,722.0
8.0,17296.0,,B,,,Autocuration,CHEMBL616227,1.0,,,1025.0,,H,BAO_0000219,HEK293,,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,51.0,722.0
8.0,17296.0,,B,,,Autocuration,CHEMBL616228,1.0,,,1026.0,,H,BAO_0000219,HEK293,,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,51.0,722.0
8.0,15779.0,,B,,,Autocuration,CHEMBL616229,1.0,,,1027.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,51.0,722.0
8.0,15779.0,,B,,,Autocuration,CHEMBL616230,1.0,,,1028.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,51.0,722.0
8.0,15779.0,,B,,,Autocuration,CHEMBL616231,1.0,,,1029.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,51.0,722.0
8.0,6166.0,,B,,,Autocuration,CHEMBL616232,1.0,,,1030.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,51.0,
8.0,15779.0,,B,,,Autocuration,CHEMBL616233,1.0,,,1031.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,51.0,722.0
8.0,4199.0,,B,,,Autocuration,CHEMBL857973,1.0,,,1032.0,,H,BAO_0000219,HEK293,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,51.0,722.0
8.0,15316.0,,B,,,Autocuration,CHEMBL616234,1.0,,,1033.0,,H,BAO_0000219,,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,51.0,
8.0,14875.0,,B,,,Autocuration,CHEMBL616235,1.0,,,1034.0,,H,BAO_0000357,,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,51.0,
8.0,14727.0,,B,,,Expert,CHEMBL616236,1.0,,,1035.0,,H,BAO_0000219,HeLa,,,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,51.0,308.0
8.0,14727.0,,B,,,Expert,CHEMBL616237,1.0,,,1036.0,,H,BAO_0000019,,,,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,51.0,
8.0,15146.0,,B,,,Autocuration,CHEMBL616238,1.0,,,1037.0,,H,BAO_0000219,HEK293,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,51.0,722.0
8.0,5213.0,,B,,,Autocuration,CHEMBL616239,1.0,,,1038.0,,H,BAO_0000219,HEK293,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,51.0,722.0
8.0,16429.0,,B,,,Autocuration,CHEMBL616240,1.0,,,1039.0,,H,BAO_0000219,,,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,51.0,
9.0,15042.0,,B,,,Expert,CHEMBL616241,1.0,,,1040.0,,D,BAO_0000219,HeLa,9606.0,,Homo sapiens,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,51.0,308.0
8.0,14818.0,,B,,,Autocuration,CHEMBL616242,1.0,,,1041.0,,H,BAO_0000219,HEK293,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,51.0,722.0
8.0,4829.0,,B,,,Autocuration,CHEMBL616243,1.0,,,1042.0,,H,BAO_0000219,HEK293,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,51.0,722.0
9.0,17200.0,,B,,,Expert,CHEMBL616244,1.0,,,1043.0,,D,BAO_0000357,,,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,51.0,
9.0,13051.0,,B,,,Autocuration,CHEMBL616245,1.0,,,1044.0,,D,BAO_0000357,,9606.0,,Homo sapiens,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,51.0,
8.0,5486.0,,B,,,Autocuration,CHEMBL616246,1.0,,,1045.0,,H,BAO_0000357,,,,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,106.0,
8.0,5254.0,,B,,,Autocuration,CHEMBL616247,1.0,,,1046.0,,H,BAO_0000357,,,,,Binding affinity against 5-HT1D receptor,,105.0,
8.0,5254.0,,B,,,Autocuration,CHEMBL616248,1.0,,,1047.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,105.0,
8.0,15331.0,,B,,,Autocuration,CHEMBL616249,1.0,,,1048.0,,H,BAO_0000357,,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,107.0,
8.0,13506.0,,B,,,Autocuration,CHEMBL616250,1.0,,,1049.0,,H,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,10576.0,
8.0,15267.0,,B,,,Autocuration,CHEMBL616251,1.0,,,1050.0,,H,BAO_0000357,,,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,51.0,
8.0,16616.0,,F,,,Autocuration,CHEMBL616252,1.0,,,1051.0,In vivo,H,BAO_0000218,,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,11863.0,
8.0,16616.0,,F,,,Autocuration,CHEMBL616253,1.0,,,1052.0,In vivo,H,BAO_0000218,,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,11863.0,
8.0,16616.0,,F,,,Autocuration,CHEMBL616254,1.0,,,1053.0,In vivo,H,BAO_0000218,,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,11863.0,
9.0,16616.0,,F,,,Expert,CHEMBL616255,1.0,,,1054.0,,D,BAO_0000218,,10090.0,,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,11863.0,
9.0,16616.0,,F,,,Expert,CHEMBL832872,1.0,,,1055.0,,D,BAO_0000218,,10090.0,,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,11863.0,
9.0,16616.0,,F,,,Expert,CHEMBL616256,1.0,,,1056.0,,D,BAO_0000218,,10090.0,,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,11863.0,
9.0,16616.0,,F,,,Expert,CHEMBL616257,1.0,,,1057.0,,D,BAO_0000218,,10090.0,,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,11863.0,
9.0,16616.0,,F,,,Expert,CHEMBL616258,1.0,,,1058.0,,D,BAO_0000218,,10090.0,,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,11863.0,
9.0,16616.0,,F,,,Expert,CHEMBL616384,1.0,,,1059.0,,D,BAO_0000218,,10090.0,,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,11863.0,
8.0,10297.0,10000000.0,B,,,Autocuration,CHEMBL616385,1.0,Hippocampus,,1060.0,,H,BAO_0000221,,,,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,11863.0,
8.0,13704.0,,B,,,Expert,CHEMBL616386,1.0,,,1061.0,,H,BAO_0000357,,,,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,11863.0,
9.0,10297.0,10000000.0,B,,,Expert,CHEMBL616387,1.0,Hippocampus,,1062.0,,D,BAO_0000221,,10090.0,,Mus musculus,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,11863.0,
8.0,10297.0,10000000.0,B,,,Autocuration,CHEMBL616388,1.0,Hippocampus,,1063.0,,H,BAO_0000221,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,11863.0,
9.0,10297.0,10000000.0,B,,,Expert,CHEMBL616389,1.0,Hippocampus,,1064.0,,D,BAO_0000221,,10090.0,,Mus musculus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,11863.0,
8.0,10297.0,10000000.0,B,,,Autocuration,CHEMBL616390,1.0,Hippocampus,,1065.0,,H,BAO_0000221,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,11863.0,
8.0,217.0,,B,,,Autocuration,CHEMBL616391,1.0,,,1066.0,,H,BAO_0000357,,,,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,11863.0,
9.0,10297.0,10000000.0,B,,,Expert,CHEMBL616392,1.0,Hippocampus,,1067.0,,D,BAO_0000221,,10090.0,,Mus musculus,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,11863.0,
8.0,4921.0,,B,,,Autocuration,CHEMBL616393,1.0,,,1068.0,,H,BAO_0000357,,9823.0,,Sus scrofa,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,51.0,
8.0,4921.0,,B,,,Autocuration,CHEMBL616394,1.0,,,1069.0,,H,BAO_0000357,,9823.0,,Sus scrofa,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,51.0,
8.0,4996.0,,B,,,Autocuration,CHEMBL616395,1.0,,,1070.0,,H,BAO_0000019,,9823.0,,Sus scrofa,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,51.0,
8.0,12918.0,,B,,,Autocuration,CHEMBL616396,1.0,,,1071.0,,H,BAO_0000357,,9823.0,,Sus scrofa,Compound was evaluated for the binding affinity at 5- HT1A receptor,,51.0,
8.0,5333.0,,B,,,Autocuration,CHEMBL872907,1.0,,,1072.0,,H,BAO_0000019,,9823.0,,Sus scrofa,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,51.0,
8.0,4437.0,,B,,,Autocuration,CHEMBL616397,1.0,,,1073.0,,H,BAO_0000019,,9823.0,,Sus scrofa,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,51.0,
8.0,1742.0,,B,,,Autocuration,CHEMBL616398,1.0,,,1074.0,,H,BAO_0000019,,9823.0,,Sus scrofa,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,51.0,
8.0,16688.0,,B,,,Expert,CHEMBL616399,1.0,,,1075.0,,H,BAO_0000357,,9823.0,,Sus scrofa,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,51.0,
8.0,12861.0,,B,,,Autocuration,CHEMBL857065,1.0,,,1076.0,,H,BAO_0000357,,9823.0,,Sus scrofa,Binding activity radioligand.,,51.0,
8.0,12861.0,,B,,,Expert,CHEMBL616400,1.0,,,1077.0,,H,BAO_0000019,,9823.0,,Sus scrofa,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,51.0,
8.0,12861.0,,B,,,Autocuration,CHEMBL616401,1.0,,,1078.0,,H,BAO_0000019,,9823.0,,Sus scrofa,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,51.0,
8.0,12490.0,,B,,,Expert,CHEMBL616402,1.0,,,1079.0,,H,BAO_0000019,,,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,10624.0,
8.0,11828.0,,B,,,Expert,CHEMBL616403,1.0,,,1080.0,,H,BAO_0000019,,9823.0,,Sus scrofa,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,51.0,
8.0,11866.0,10000000.0,B,,,Autocuration,CHEMBL616404,1.0,Hippocampus,,1081.0,,H,BAO_0000221,,9823.0,,Sus scrofa,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,51.0,
8.0,12827.0,,B,,,Autocuration,CHEMBL616405,1.0,,,1082.0,,H,BAO_0000249,,9823.0,,Sus scrofa,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,51.0,
8.0,12918.0,,B,,,Autocuration,CHEMBL616406,1.0,,,1083.0,,H,BAO_0000019,,9823.0,,Sus scrofa,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,51.0,
8.0,12919.0,,F,,,Expert,CHEMBL616407,1.0,,,1084.0,,H,BAO_0000019,,9823.0,,Sus scrofa,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,51.0,
8.0,13047.0,,B,,,Autocuration,CHEMBL616408,1.0,,,1085.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,51.0,
9.0,15796.0,,B,,,Expert,CHEMBL616409,1.0,,,1086.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,10576.0,
9.0,3651.0,10000000.0,B,,,Expert,CHEMBL616410,1.0,Hippocampus,,1087.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,10576.0,
8.0,188.0,,B,,,Autocuration,CHEMBL616411,1.0,,,1088.0,,H,BAO_0000357,,,,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,10576.0,
9.0,16616.0,,F,Membranes,,Expert,CHEMBL616412,1.0,,,1089.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,10576.0,
9.0,16616.0,10000000.0,F,Membranes,,Expert,CHEMBL616413,1.0,Hippocampus,,1090.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,10576.0,
8.0,12306.0,10000000.0,B,,,Autocuration,CHEMBL616414,1.0,Hippocampus,,1091.0,,H,BAO_0000221,,,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,10576.0,
9.0,17167.0,10000000.0,B,,,Expert,CHEMBL616415,1.0,Hippocampus,,1092.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,10576.0,
8.0,14776.0,,B,,,Autocuration,CHEMBL616416,1.0,,,1093.0,,H,BAO_0000019,,,,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,10576.0,
8.0,12158.0,,B,,,Expert,CHEMBL616417,1.0,,,1094.0,,H,BAO_0000357,,,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,10576.0,
8.0,13481.0,,B,,,Autocuration,CHEMBL616418,1.0,,,1095.0,,H,BAO_0000357,,,,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,10576.0,
8.0,13427.0,,B,,,Autocuration,CHEMBL616419,1.0,,,1096.0,In vitro,H,BAO_0000219,,,,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,10576.0,
8.0,10210.0,,B,,,Autocuration,CHEMBL616420,1.0,,,1097.0,,H,BAO_0000357,,,,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,10576.0,
8.0,10205.0,,B,Membranes,,Autocuration,CHEMBL616421,1.0,,,1098.0,,H,BAO_0000249,,,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,10576.0,
8.0,10205.0,,B,Membranes,,Autocuration,CHEMBL616422,1.0,,,1099.0,,H,BAO_0000249,,,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,10576.0,
8.0,10205.0,,B,Membranes,,Expert,CHEMBL616423,1.0,,,1100.0,,H,BAO_0000249,,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,10576.0,
9.0,12280.0,,B,,,Expert,CHEMBL616424,1.0,,,1101.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,10576.0,
8.0,17386.0,,B,,,Expert,CHEMBL616425,1.0,,,1102.0,,H,BAO_0000357,,,,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,13654.0,,B,,,Expert,CHEMBL616426,1.0,,,1103.0,,H,BAO_0000357,,,,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,10576.0,
8.0,14423.0,10000000.0,B,,,Autocuration,CHEMBL616427,1.0,Hippocampus,,1104.0,,H,BAO_0000221,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,10576.0,
8.0,15412.0,10000000.0,B,,,Autocuration,CHEMBL616428,1.0,Hippocampus,,1105.0,,H,BAO_0000221,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,10576.0,
8.0,12073.0,10000000.0,B,,,Autocuration,CHEMBL616290,1.0,Hippocampus,,1106.0,,H,BAO_0000221,,,,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576.0,
9.0,4101.0,,B,,,Expert,CHEMBL616052,1.0,,,1107.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,10062.0,,B,,,Autocuration,CHEMBL616053,1.0,,,1108.0,,H,BAO_0000357,,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,6238.0,,B,,,Autocuration,CHEMBL616054,1.0,,,1109.0,,H,BAO_0000249,,,,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,10576.0,
8.0,16273.0,,B,,,Autocuration,CHEMBL616055,1.0,,,1110.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,11139.0,,B,,,Autocuration,CHEMBL616056,1.0,,,1111.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,10576.0,
8.0,16796.0,,B,,,Expert,CHEMBL616057,1.0,,,1112.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,10576.0,
9.0,9548.0,955.0,B,,,Expert,CHEMBL616058,1.0,Brain,,1113.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,10576.0,
8.0,10381.0,955.0,B,,,Autocuration,CHEMBL616059,1.0,Brain,,1114.0,,H,BAO_0000221,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,10576.0,
8.0,13408.0,,B,,,Autocuration,CHEMBL616060,1.0,,,1115.0,,H,BAO_0000249,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,10576.0,
9.0,13825.0,10000000.0,B,,,Expert,CHEMBL616061,1.0,Hippocampus,,1116.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,10576.0,
8.0,11147.0,10000000.0,B,,,Expert,CHEMBL616062,1.0,Hippocampus,,1117.0,,H,BAO_0000221,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,10576.0,
8.0,10552.0,,B,,,Autocuration,CHEMBL616063,1.0,,,1118.0,,H,BAO_0000249,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,10576.0,
8.0,10552.0,2435.0,B,,,Autocuration,CHEMBL616064,1.0,Striatum,,1119.0,,H,BAO_0000249,,,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,10576.0,
9.0,17136.0,,B,Membranes,,Expert,CHEMBL616065,1.0,,,1120.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,10576.0,
9.0,5778.0,,B,Membranes,,Expert,CHEMBL616066,1.0,,,1121.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,10576.0,
8.0,13481.0,10000000.0,B,,,Autocuration,CHEMBL616067,1.0,Hippocampus,,1122.0,,H,BAO_0000221,,,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,10576.0,
8.0,13481.0,10000000.0,B,,,Autocuration,CHEMBL616068,1.0,Hippocampus,,1123.0,,H,BAO_0000221,,,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,10576.0,
8.0,13630.0,10000000.0,B,,,Intermediate,CHEMBL616069,1.0,Hippocampus,,1124.0,,H,BAO_0000221,,,,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,10576.0,
8.0,16245.0,,B,,,Expert,CHEMBL616070,1.0,,,1125.0,,H,BAO_0000249,,,,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,10576.0,
8.0,14509.0,10000000.0,B,,,Autocuration,CHEMBL616071,1.0,Hippocampus,,1126.0,,H,BAO_0000221,,,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,10576.0,
8.0,14509.0,10000000.0,B,,,Expert,CHEMBL616072,1.0,Hippocampus,,1127.0,,H,BAO_0000221,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,10576.0,
8.0,14509.0,10000000.0,B,,,Autocuration,CHEMBL616073,1.0,Hippocampus,,1128.0,,H,BAO_0000221,,,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,10576.0,
8.0,14509.0,10000000.0,B,,,Autocuration,CHEMBL616074,1.0,Hippocampus,,1129.0,,H,BAO_0000221,,,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,10576.0,
8.0,14256.0,,B,,,Expert,CHEMBL616075,1.0,,,1130.0,,H,BAO_0000019,,,,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,10576.0,
8.0,11139.0,,B,,,Autocuration,CHEMBL616076,1.0,,,1131.0,,H,BAO_0000357,,,,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,10576.0,
9.0,11047.0,,B,,,Expert,CHEMBL616077,1.0,,,1132.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,10576.0,
9.0,11047.0,,B,,,Expert,CHEMBL616078,1.0,,,1133.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,10576.0,
9.0,11047.0,,B,,,Expert,CHEMBL616079,1.0,,,1134.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,10576.0,
9.0,2395.0,,B,,,Expert,CHEMBL616080,1.0,,,1135.0,,D,BAO_0000219,CHO-K1,10116.0,,Rattus norvegicus,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,10576.0,485.0
8.0,9699.0,,B,,,Autocuration,CHEMBL616081,1.0,,,1136.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,10576.0,
9.0,12028.0,10000000.0,B,,,Expert,CHEMBL616082,1.0,Hippocampus,,1137.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,10576.0,
8.0,12028.0,10000000.0,B,,,Autocuration,CHEMBL616083,1.0,Hippocampus,,1138.0,,H,BAO_0000221,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,10576.0,
8.0,5815.0,,B,,,Autocuration,CHEMBL616084,1.0,,,1139.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,10576.0,
8.0,16616.0,,B,,,Expert,CHEMBL616085,1.0,,,1140.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,10576.0,
8.0,5815.0,,B,,,Autocuration,CHEMBL616086,1.0,,,1141.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,10576.0,
8.0,2761.0,10000000.0,B,,,Autocuration,CHEMBL616087,1.0,Hippocampus,,1142.0,,H,BAO_0000221,,,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,10576.0,
8.0,13133.0,,B,,,Expert,CHEMBL616088,1.0,,,1143.0,,H,BAO_0000357,,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,10576.0,
8.0,10444.0,,B,,,Autocuration,CHEMBL616089,1.0,,,1144.0,,H,BAO_0000019,,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,10576.0,
9.0,13278.0,,B,,,Expert,CHEMBL616090,1.0,,,1145.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,10576.0,
8.0,15874.0,,B,,,Autocuration,CHEMBL616091,1.0,,,1146.0,,H,BAO_0000357,,,,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,10576.0,
8.0,10552.0,2435.0,B,Membranes,,Autocuration,CHEMBL616092,1.0,Striatum,,1147.0,,H,BAO_0000249,,,,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,10576.0,
8.0,11130.0,,B,,,Autocuration,CHEMBL616093,1.0,,,1148.0,,H,BAO_0000357,,,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,10576.0,
8.0,11130.0,,B,,,Autocuration,CHEMBL616094,1.0,,,1149.0,In vivo,H,BAO_0000218,,,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,10576.0,
8.0,14542.0,955.0,B,,,Autocuration,CHEMBL616095,1.0,Brain,,1150.0,,H,BAO_0000221,,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,10576.0,
9.0,13670.0,,B,,,Expert,CHEMBL616096,1.0,,,1151.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,9888.0,,B,,,Expert,CHEMBL616097,1.0,,,1152.0,,H,BAO_0000249,,,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,10576.0,
9.0,3678.0,,B,Membranes,,Expert,CHEMBL616098,1.0,,,1153.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,10576.0,
8.0,11332.0,10000000.0,B,,,Autocuration,CHEMBL616099,1.0,Hippocampus,,1154.0,,H,BAO_0000221,,,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,10576.0,
8.0,11332.0,10000000.0,B,,,Autocuration,CHEMBL616100,1.0,Hippocampus,,1155.0,,H,BAO_0000221,,,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,10576.0,
8.0,1185.0,,B,,,Expert,CHEMBL616101,1.0,,,1156.0,,H,BAO_0000357,,,,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,2014.0,,B,,,Expert,CHEMBL616102,1.0,,,1157.0,,H,BAO_0000249,,,,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,10576.0,
8.0,1185.0,,B,,,Autocuration,CHEMBL616103,1.0,,,1158.0,,H,BAO_0000357,,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,14429.0,,B,,,Expert,CHEMBL616104,1.0,,,1159.0,,H,BAO_0000019,,,,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,10576.0,
8.0,16288.0,,B,,,Expert,CHEMBL616105,1.0,,,1160.0,,H,BAO_0000019,,,,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,10576.0,
9.0,5432.0,,B,,,Expert,CHEMBL616106,1.0,,,1161.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,14429.0,,B,,,Autocuration,CHEMBL616107,1.0,,,1162.0,,H,BAO_0000019,,,,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,10576.0,
8.0,13672.0,,B,,,Expert,CHEMBL616108,1.0,,,1163.0,,H,BAO_0000357,,,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,10576.0,
8.0,11296.0,10000000.0,B,,,Expert,CHEMBL616109,1.0,Hippocampus,,1164.0,,H,BAO_0000221,,,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,10576.0,
8.0,11296.0,,B,,,Autocuration,CHEMBL616110,1.0,,,1165.0,,H,BAO_0000357,,,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,10576.0,
8.0,14749.0,,B,,,Expert,CHEMBL616111,1.0,,,1166.0,,H,BAO_0000219,CHO,,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,10576.0,449.0
8.0,15086.0,,B,,,Expert,CHEMBL616112,1.0,,,1167.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,10576.0,
8.0,13462.0,10000000.0,B,,,Autocuration,CHEMBL616113,1.0,Hippocampus,,1168.0,,H,BAO_0000221,,,,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,10576.0,
8.0,15363.0,,B,,,Autocuration,CHEMBL616114,1.0,,,1169.0,,H,BAO_0000019,,,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,15363.0,,B,,,Autocuration,CHEMBL616115,1.0,,,1170.0,,H,BAO_0000019,,,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,10796.0,,B,,,Autocuration,CHEMBL616116,1.0,,,1171.0,,H,BAO_0000357,,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,12816.0,955.0,B,,,Expert,CHEMBL615844,1.0,Brain,,1172.0,,H,BAO_0000221,,,,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,10576.0,
8.0,13542.0,10000000.0,B,,,Expert,CHEMBL615939,1.0,Hippocampus,,1173.0,,H,BAO_0000221,,,,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,13308.0,,B,,,Expert,CHEMBL615940,1.0,,,1174.0,,H,BAO_0000019,,,,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,10576.0,
8.0,13541.0,10000000.0,B,,,Expert,CHEMBL615941,1.0,Hippocampus,,1175.0,,H,BAO_0000221,,,,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,10576.0,
8.0,10058.0,10000000.0,B,,,Autocuration,CHEMBL615942,1.0,Hippocampus,,1176.0,,H,BAO_0000221,,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,10576.0,
8.0,10058.0,10000000.0,B,,,Autocuration,CHEMBL615943,1.0,Hippocampus,,1177.0,,H,BAO_0000221,,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,10576.0,
8.0,10058.0,10000000.0,B,,,Autocuration,CHEMBL615944,1.0,Hippocampus,,1178.0,,H,BAO_0000221,,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,10576.0,
8.0,10058.0,10000000.0,B,,,Autocuration,CHEMBL615945,1.0,Hippocampus,,1179.0,,H,BAO_0000221,,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,10576.0,
8.0,10058.0,10000000.0,B,,,Autocuration,CHEMBL615946,1.0,Hippocampus,,1180.0,,H,BAO_0000221,,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,10576.0,
8.0,10058.0,10000000.0,B,,,Autocuration,CHEMBL615947,1.0,Hippocampus,,1181.0,,H,BAO_0000221,,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,10576.0,
8.0,10058.0,10000000.0,B,,,Autocuration,CHEMBL615948,1.0,Hippocampus,,1182.0,,H,BAO_0000221,,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,10576.0,
8.0,10058.0,10000000.0,B,,,Autocuration,CHEMBL615949,1.0,Hippocampus,,1183.0,,H,BAO_0000221,,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,10576.0,
8.0,10058.0,10000000.0,B,,,Autocuration,CHEMBL615950,1.0,Hippocampus,,1184.0,,H,BAO_0000221,,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,10576.0,
8.0,10058.0,10000000.0,B,,,Autocuration,CHEMBL615951,1.0,Hippocampus,,1185.0,,H,BAO_0000221,,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,10576.0,
8.0,10058.0,10000000.0,B,,,Autocuration,CHEMBL615952,1.0,Hippocampus,,1186.0,,H,BAO_0000221,,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,10576.0,
8.0,10058.0,10000000.0,B,,,Autocuration,CHEMBL615953,1.0,Hippocampus,,1187.0,,H,BAO_0000221,,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,10576.0,
8.0,10058.0,10000000.0,B,,,Autocuration,CHEMBL615954,1.0,Hippocampus,,1188.0,,H,BAO_0000221,,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,10576.0,
9.0,10058.0,10000000.0,B,,,Expert,CHEMBL615955,1.0,Hippocampus,,1189.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,10576.0,
8.0,10058.0,10000000.0,B,,,Autocuration,CHEMBL615956,1.0,Hippocampus,,1190.0,,H,BAO_0000221,,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,10576.0,
8.0,10058.0,10000000.0,B,,,Autocuration,CHEMBL615957,1.0,Hippocampus,,1191.0,,H,BAO_0000221,,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,10576.0,
8.0,12879.0,,B,,,Expert,CHEMBL615958,1.0,,,1192.0,,H,BAO_0000019,,,,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,10576.0,
8.0,11964.0,,B,,,Expert,CHEMBL615959,1.0,,,1193.0,,H,BAO_0000019,,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,10576.0,
8.0,11964.0,,B,,,Autocuration,CHEMBL615960,1.0,,,1194.0,,H,BAO_0000019,,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,10576.0,
8.0,11964.0,,B,,,Autocuration,CHEMBL615961,1.0,,,1195.0,,H,BAO_0000019,,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,10576.0,
8.0,9548.0,955.0,B,,,Expert,CHEMBL615962,1.0,Brain,,1196.0,,H,BAO_0000221,,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,10576.0,
8.0,9098.0,,B,,,Expert,CHEMBL615963,1.0,,,1197.0,,H,BAO_0000019,,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,10576.0,
8.0,9098.0,,B,,,Autocuration,CHEMBL615964,1.0,,,1198.0,,H,BAO_0000019,,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,10576.0,
8.0,9098.0,,B,,,Autocuration,CHEMBL615965,1.0,,,1199.0,,H,BAO_0000019,,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,10576.0,
8.0,13248.0,,B,,,Expert,CHEMBL615966,1.0,,,1200.0,,H,BAO_0000219,CHO,,,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,10576.0,449.0
8.0,3147.0,,B,,,Expert,CHEMBL615967,1.0,,,1201.0,,H,BAO_0000249,,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,10576.0,
8.0,13949.0,,B,,,Expert,CHEMBL615968,1.0,,,1202.0,,H,BAO_0000019,,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,10576.0,
8.0,11883.0,,B,,,Autocuration,CHEMBL615969,1.0,,,1203.0,,H,BAO_0000218,CHO,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,10576.0,449.0
8.0,11883.0,,B,,,Autocuration,CHEMBL615970,1.0,,,1204.0,,H,BAO_0000218,,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,10576.0,
9.0,11883.0,,B,,,Expert,CHEMBL615971,1.0,,,1205.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,10576.0,
8.0,15535.0,,B,Membranes,,Expert,CHEMBL615972,1.0,,,1206.0,,H,BAO_0000249,,,,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,10576.0,
8.0,15535.0,,B,,,Autocuration,CHEMBL615973,1.0,,,1207.0,,H,BAO_0000249,,,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,10576.0,
8.0,15535.0,,B,,,Autocuration,CHEMBL615974,1.0,,,1208.0,,H,BAO_0000249,,,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,10576.0,
9.0,16372.0,,B,,,Expert,CHEMBL615975,1.0,,,1209.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,51.0,449.0
8.0,14608.0,,B,,,Expert,CHEMBL615976,1.0,,,1210.0,,H,BAO_0000249,,,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,10576.0,
9.0,4795.0,10000000.0,B,,,Expert,CHEMBL872106,1.0,Hippocampus,,1211.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,10576.0,
8.0,13863.0,,B,,,Autocuration,CHEMBL615977,1.0,,,1212.0,,H,BAO_0000357,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,10576.0,
8.0,13863.0,,B,,,Autocuration,CHEMBL615978,1.0,,,1213.0,,H,BAO_0000357,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,10576.0,
8.0,13863.0,,B,,,Autocuration,CHEMBL616166,1.0,,,1214.0,,H,BAO_0000357,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,10576.0,
8.0,13863.0,,B,,,Autocuration,CHEMBL616167,1.0,,,1215.0,,H,BAO_0000357,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,10576.0,
8.0,13863.0,,B,,,Autocuration,CHEMBL616168,1.0,,,1216.0,,H,BAO_0000357,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,10576.0,
8.0,13863.0,,B,,,Autocuration,CHEMBL616169,1.0,,,1217.0,,H,BAO_0000357,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,10576.0,
8.0,13863.0,,B,,,Autocuration,CHEMBL616170,1.0,,,1218.0,,H,BAO_0000357,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,10576.0,
8.0,13863.0,,B,,,Autocuration,CHEMBL616171,1.0,,,1219.0,,H,BAO_0000357,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,10576.0,
8.0,13863.0,,B,,,Autocuration,CHEMBL616172,1.0,,,1220.0,,H,BAO_0000357,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,10576.0,
8.0,13863.0,,B,,,Autocuration,CHEMBL616173,1.0,,,1221.0,,H,BAO_0000357,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,10576.0,
8.0,13863.0,,B,,,Autocuration,CHEMBL616174,1.0,,,1222.0,,H,BAO_0000357,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,10576.0,
8.0,13863.0,,B,,,Autocuration,CHEMBL616175,1.0,,,1223.0,,H,BAO_0000357,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,10576.0,
8.0,13863.0,,B,,,Autocuration,CHEMBL616176,1.0,,,1224.0,,H,BAO_0000357,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,10576.0,
8.0,13863.0,,B,,,Autocuration,CHEMBL616177,1.0,,,1225.0,,H,BAO_0000357,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,10576.0,
8.0,13863.0,,B,,,Autocuration,CHEMBL616178,1.0,,,1226.0,,H,BAO_0000357,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,10576.0,
8.0,9742.0,,B,,,Autocuration,CHEMBL616179,1.0,,,1227.0,,H,BAO_0000019,,,,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,10576.0,
8.0,12073.0,,B,,,Autocuration,CHEMBL616180,1.0,,,1228.0,,H,BAO_0000357,,,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,4101.0,,B,,,Autocuration,CHEMBL616181,1.0,,,1229.0,,H,BAO_0000357,,,,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,10576.0,
8.0,15360.0,,B,,,Autocuration,CHEMBL616182,1.0,,,1230.0,,H,BAO_0000019,,,,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,10576.0,
8.0,11576.0,10000000.0,B,,,Autocuration,CHEMBL616183,1.0,Hippocampus,,1231.0,,H,BAO_0000221,,,,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,5834.0,,B,,,Expert,CHEMBL615874,1.0,,,1232.0,,H,BAO_0000019,,,,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,10576.0,
9.0,2395.0,,B,,,Expert,CHEMBL615875,1.0,,,1233.0,,D,BAO_0000219,CHO-K1,10116.0,,Rattus norvegicus,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,10576.0,485.0
8.0,1375.0,,B,,,Autocuration,CHEMBL615876,1.0,,,1234.0,,H,BAO_0000019,,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,10576.0,
8.0,1375.0,,B,,,Autocuration,CHEMBL615877,1.0,,,1235.0,,H,BAO_0000019,,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,10576.0,
8.0,3967.0,,B,,,Autocuration,CHEMBL615878,1.0,,,1236.0,,H,BAO_0000357,,,,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,10576.0,
8.0,12884.0,,B,,,Expert,CHEMBL615879,1.0,,,1237.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,10576.0,
8.0,2343.0,,B,,,Expert,CHEMBL615880,1.0,,,1238.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,10576.0,
8.0,11511.0,,B,,,Autocuration,CHEMBL615881,1.0,,,1239.0,,H,BAO_0000019,,,,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,10576.0,
9.0,11511.0,,B,,,Expert,CHEMBL615882,1.0,,,1240.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,10576.0,
8.0,16394.0,,F,,,Autocuration,CHEMBL615883,1.0,,,1241.0,In vivo,H,BAO_0000218,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,10576.0,
8.0,16394.0,,F,,,Autocuration,CHEMBL615884,1.0,,,1242.0,In vivo,H,BAO_0000218,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,10576.0,
8.0,16394.0,,F,,,Autocuration,CHEMBL615885,1.0,,,1243.0,In vivo,H,BAO_0000218,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,10576.0,
8.0,16394.0,,F,,,Autocuration,CHEMBL615886,1.0,,,1244.0,In vivo,H,BAO_0000218,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,10576.0,
8.0,16394.0,,F,,,Autocuration,CHEMBL615887,1.0,,,1245.0,In vivo,H,BAO_0000218,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,10576.0,
8.0,16394.0,,F,,,Autocuration,CHEMBL615888,1.0,,,1246.0,In vivo,H,BAO_0000218,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,10576.0,
8.0,16394.0,,F,,,Autocuration,CHEMBL615889,1.0,,,1247.0,In vivo,H,BAO_0000218,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,10576.0,
8.0,16394.0,,F,,,Autocuration,CHEMBL615890,1.0,,,1248.0,In vivo,H,BAO_0000218,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,10576.0,
8.0,16394.0,,F,,,Autocuration,CHEMBL615891,1.0,,,1249.0,In vivo,H,BAO_0000218,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,10576.0,
8.0,16394.0,,F,,,Autocuration,CHEMBL615892,1.0,,,1250.0,In vivo,H,BAO_0000218,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,10576.0,
8.0,16394.0,,F,,,Autocuration,CHEMBL615893,1.0,,,1251.0,In vivo,H,BAO_0000218,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,10576.0,
8.0,16394.0,,F,,,Autocuration,CHEMBL615894,1.0,,,1252.0,In vivo,H,BAO_0000218,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,10576.0,
8.0,16394.0,,F,,,Autocuration,CHEMBL615895,1.0,,,1253.0,In vivo,H,BAO_0000218,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,10576.0,
8.0,16394.0,,F,,,Autocuration,CHEMBL615896,1.0,,,1254.0,In vivo,H,BAO_0000218,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,10576.0,
8.0,16394.0,,F,,,Autocuration,CHEMBL615897,1.0,,,1255.0,In vivo,H,BAO_0000218,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,10576.0,
9.0,16616.0,,F,Membranes,,Expert,CHEMBL615898,1.0,,,1256.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,10576.0,
8.0,16796.0,,B,,,Autocuration,CHEMBL615899,1.0,,,1257.0,,H,BAO_0000019,,,,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,10576.0,
8.0,16796.0,,B,,,Autocuration,CHEMBL616291,1.0,,,1258.0,,H,BAO_0000019,,,,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,10576.0,
8.0,15629.0,,B,,,Autocuration,CHEMBL616292,1.0,,,1259.0,,H,BAO_0000357,,,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,10576.0,
8.0,13241.0,,F,,,Autocuration,CHEMBL616293,1.0,,,1260.0,,H,BAO_0000249,,,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,10576.0,
8.0,12073.0,10000000.0,B,,,Expert,CHEMBL616294,1.0,Hippocampus,,1261.0,,H,BAO_0000221,,,,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576.0,
8.0,14286.0,10000000.0,B,,,Autocuration,CHEMBL616295,1.0,Hippocampus,,1262.0,,H,BAO_0000249,,,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,10576.0,
8.0,14542.0,955.0,B,,,Autocuration,CHEMBL616296,1.0,Brain,,1263.0,,H,BAO_0000221,,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,10576.0,
8.0,13630.0,,F,,,Autocuration,CHEMBL616297,1.0,,,1264.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,10576.0,
8.0,13630.0,,F,,,Autocuration,CHEMBL616605,1.0,,,1265.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,10576.0,
8.0,13630.0,,F,,,Autocuration,CHEMBL616606,1.0,,,1266.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,10576.0,
8.0,13630.0,,F,,,Autocuration,CHEMBL616607,1.0,,,1267.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,10576.0,
8.0,13630.0,,F,,,Expert,CHEMBL616608,1.0,,,1268.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,10576.0,
8.0,13630.0,,F,,,Autocuration,CHEMBL616609,1.0,,,1269.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,10576.0,
9.0,13630.0,,F,,,Expert,CHEMBL616610,1.0,,,1270.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,10576.0,
8.0,13630.0,,F,,,Autocuration,CHEMBL616611,1.0,,,1271.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,10576.0,
8.0,13630.0,,F,,,Expert,CHEMBL616612,1.0,,,1272.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,10576.0,
8.0,13630.0,,F,,,Autocuration,CHEMBL616613,1.0,,,1273.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,10576.0,
8.0,13630.0,,F,,,Expert,CHEMBL616614,1.0,,,1274.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,10576.0,
8.0,13630.0,,F,,,Autocuration,CHEMBL616615,1.0,,,1275.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,10576.0,
8.0,13630.0,,F,,,Expert,CHEMBL616616,1.0,,,1276.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,10576.0,
8.0,13630.0,,F,,,Autocuration,CHEMBL616617,1.0,,,1277.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,10576.0,
8.0,13630.0,,F,,,Autocuration,CHEMBL616618,1.0,,,1278.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,10576.0,
8.0,13630.0,,F,,,Autocuration,CHEMBL616619,1.0,,,1279.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,10576.0,
8.0,13630.0,,F,,,Expert,CHEMBL616620,1.0,,,1280.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,10576.0,
8.0,13630.0,,F,,,Expert,CHEMBL616621,1.0,,,1281.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,10576.0,
8.0,13630.0,,F,,,Autocuration,CHEMBL616622,1.0,,,1282.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,10576.0,
8.0,13630.0,,F,,,Expert,CHEMBL616146,1.0,,,1283.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,10576.0,
8.0,13630.0,,F,,,Autocuration,CHEMBL832873,1.0,,,1284.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,10576.0,
8.0,13630.0,,F,,,Autocuration,CHEMBL616147,1.0,,,1285.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,10576.0,
8.0,13630.0,,F,,,Autocuration,CHEMBL872872,1.0,,,1286.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,10576.0,
8.0,13630.0,,F,,,Autocuration,CHEMBL616148,1.0,,,1287.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,10576.0,
8.0,9783.0,10000000.0,B,,,Autocuration,CHEMBL616149,1.0,Hippocampus,,1288.0,,H,BAO_0000221,,,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,10576.0,
8.0,9783.0,10000000.0,B,,,Expert,CHEMBL616150,1.0,Hippocampus,,1289.0,,H,BAO_0000221,,,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,10576.0,
9.0,14331.0,,B,Membranes,,Expert,CHEMBL616151,1.0,,,1290.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,10576.0,
8.0,15260.0,10000000.0,B,,,Expert,CHEMBL872873,1.0,Hippocampus,,1291.0,,H,BAO_0000221,,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,10576.0,
8.0,15260.0,10000000.0,B,,,Autocuration,CHEMBL616670,1.0,Hippocampus,,1292.0,,H,BAO_0000221,,,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,10576.0,
8.0,15260.0,10000000.0,B,,,Autocuration,CHEMBL616671,1.0,Hippocampus,,1293.0,,H,BAO_0000221,,,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,10576.0,
9.0,16616.0,,F,,,Expert,CHEMBL884861,1.0,,,1294.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,10576.0,
8.0,15629.0,,B,,,Autocuration,CHEMBL616672,1.0,,,1295.0,,H,BAO_0000357,,,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,10576.0,
8.0,15086.0,,B,,,Autocuration,CHEMBL616673,1.0,,,1296.0,,H,BAO_0000019,,,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,10576.0,
8.0,5717.0,,F,,,Expert,CHEMBL616674,1.0,,,1297.0,,H,BAO_0000019,,,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,10576.0,
8.0,12652.0,,B,,,Autocuration,CHEMBL616675,1.0,,,1298.0,,H,BAO_0000357,,,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,10576.0,
8.0,14608.0,10000000.0,B,,,Autocuration,CHEMBL616676,1.0,Hippocampus,,1299.0,,H,BAO_0000221,,,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,10576.0,
8.0,12306.0,10000000.0,B,,,Autocuration,CHEMBL616677,1.0,Hippocampus,,1300.0,,H,BAO_0000221,,,,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,10576.0,
8.0,12306.0,10000000.0,B,,,Autocuration,CHEMBL616678,1.0,Hippocampus,,1301.0,,H,BAO_0000221,,,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,10576.0,
9.0,15247.0,,B,,,Expert,CHEMBL616679,1.0,,,1302.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,17529.0,10000000.0,B,,,Expert,CHEMBL616680,1.0,Hippocampus,,1303.0,,H,BAO_0000221,,,,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,10576.0,
8.0,14826.0,10000000.0,B,,,Autocuration,CHEMBL616681,1.0,Hippocampus,,1304.0,,H,BAO_0000221,,,,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576.0,
8.0,14826.0,10000000.0,B,,,Autocuration,CHEMBL616682,1.0,Hippocampus,,1305.0,,H,BAO_0000221,,,,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576.0,
8.0,13241.0,10000000.0,B,,,Autocuration,CHEMBL616683,1.0,Hippocampus,,1306.0,,H,BAO_0000221,,,,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,14093.0,10000000.0,B,,,Autocuration,CHEMBL616684,1.0,Hippocampus,,1307.0,,H,BAO_0000221,,,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,14093.0,10000000.0,B,,,Autocuration,CHEMBL616685,1.0,Hippocampus,,1308.0,,H,BAO_0000221,,,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,10576.0,
8.0,14442.0,955.0,B,,,Autocuration,CHEMBL616686,1.0,Brain,,1309.0,,H,BAO_0000221,,,,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,10576.0,
8.0,9919.0,,B,,,Autocuration,CHEMBL616687,1.0,,,1310.0,,H,BAO_0000357,,,,,Affinity for 5-hydroxytryptamine 1A receptor site,,10576.0,
8.0,9919.0,,B,,,Autocuration,CHEMBL616688,1.0,,,1311.0,,H,BAO_0000357,,,,,Affinity for 5-hydroxytryptamine 1A receptor site,,10576.0,
8.0,11440.0,10000000.0,B,,,Autocuration,CHEMBL616689,1.0,Hippocampus,,1312.0,,H,BAO_0000221,,,,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,10576.0,
8.0,11257.0,,B,,,Autocuration,CHEMBL616690,1.0,,,1313.0,,H,BAO_0000357,,,,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,10576.0,
8.0,10330.0,,B,,,Expert,CHEMBL616691,1.0,,,1314.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,10576.0,
9.0,17331.0,10000000.0,B,,,Expert,CHEMBL616692,1.0,Hippocampus,,1315.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,10576.0,
8.0,16567.0,,B,,,Expert,CHEMBL616693,1.0,,,1316.0,,H,BAO_0000249,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,10576.0,
9.0,12058.0,,B,,,Expert,CHEMBL616694,1.0,,,1317.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,10576.0,
8.0,9699.0,10000000.0,B,,,Autocuration,CHEMBL616695,1.0,Hippocampus,,1318.0,,H,BAO_0000221,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,10576.0,
8.0,9547.0,,B,,,Autocuration,CHEMBL616696,1.0,,,1319.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,10576.0,
8.0,10330.0,,B,,,Autocuration,CHEMBL616697,1.0,,,1320.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,10576.0,
8.0,14331.0,,B,,,Autocuration,CHEMBL616698,1.0,,,1321.0,,H,BAO_0000357,,,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,10576.0,
9.0,14060.0,,B,,,Expert,CHEMBL616949,1.0,,,1322.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,14744.0,10000000.0,B,,,Autocuration,CHEMBL616950,1.0,Hippocampus,,1323.0,,H,BAO_0000221,,,,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,10576.0,
8.0,13506.0,,B,,,Autocuration,CHEMBL832875,1.0,,,1324.0,,H,BAO_0000357,,,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,10576.0,
8.0,10862.0,955.0,B,,,Expert,CHEMBL616951,1.0,Brain,,1325.0,,H,BAO_0000221,,,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,10576.0,
8.0,10862.0,955.0,B,,,Expert,CHEMBL616952,1.0,Brain,,1326.0,,H,BAO_0000221,,,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,10576.0,
8.0,10062.0,,B,,,Expert,CHEMBL616953,1.0,,,1327.0,,H,BAO_0000357,,,,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,10576.0,
8.0,12073.0,,B,,,Autocuration,CHEMBL616954,1.0,,,1328.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,10576.0,
8.0,14875.0,,B,,,Autocuration,CHEMBL616955,1.0,,,1329.0,,H,BAO_0000357,,,,,GTPgammaS radioligand binding assay,,106.0,
8.0,2391.0,,B,,,Autocuration,CHEMBL616956,1.0,,,1330.0,,H,BAO_0000357,,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,106.0,
8.0,2391.0,,F,,,Autocuration,CHEMBL616957,1.0,,,1331.0,,H,BAO_0000019,,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,106.0,
8.0,2391.0,,F,,,Autocuration,CHEMBL616958,1.0,,,1332.0,,H,BAO_0000019,,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,106.0,
8.0,2391.0,,B,,,Autocuration,CHEMBL616959,1.0,,,1333.0,,H,BAO_0000357,,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,106.0,
8.0,2391.0,,B,,,Autocuration,CHEMBL616960,1.0,,,1334.0,,H,BAO_0000357,,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,106.0,
8.0,2391.0,,F,,,Autocuration,CHEMBL616961,1.0,,,1335.0,,H,BAO_0000019,,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,106.0,
8.0,17211.0,,B,,,Expert,CHEMBL616962,1.0,,,1336.0,,H,BAO_0000219,HeLa,,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,106.0,308.0
8.0,17211.0,,B,,,Autocuration,CHEMBL616963,1.0,,,1337.0,,H,BAO_0000219,HeLa,,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,106.0,308.0
9.0,6491.0,,B,,,Expert,CHEMBL616524,1.0,,,1338.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,106.0,
8.0,16190.0,,B,,,Autocuration,CHEMBL616525,1.0,,,1339.0,,H,BAO_0000219,CHO,,,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,106.0,449.0
8.0,14165.0,,B,,,Autocuration,CHEMBL872908,1.0,,,1340.0,,H,BAO_0000019,,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,106.0,
8.0,14165.0,,B,,,Autocuration,CHEMBL616526,1.0,,,1341.0,,H,BAO_0000019,,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,106.0,
9.0,4234.0,,B,,,Expert,CHEMBL616527,1.0,,,1342.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,106.0,
8.0,6328.0,,B,,,Expert,CHEMBL616528,1.0,,,1343.0,,H,BAO_0000219,,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,106.0,
8.0,14770.0,,B,,,Autocuration,CHEMBL616529,1.0,,,1344.0,,H,BAO_0000357,,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,106.0,
8.0,2598.0,,B,,,Autocuration,CHEMBL616530,1.0,,,1345.0,,H,BAO_0000357,,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,106.0,
8.0,6897.0,,B,,,Expert,CHEMBL616531,1.0,,,1346.0,,H,BAO_0000357,,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,106.0,
8.0,6897.0,,B,,,Autocuration,CHEMBL616532,1.0,,,1347.0,,H,BAO_0000357,,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,106.0,
8.0,6013.0,,B,,,Autocuration,CHEMBL616533,1.0,,,1348.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,106.0,
8.0,5843.0,,B,,,Expert,CHEMBL616534,1.0,,,1349.0,,H,BAO_0000357,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,106.0,
8.0,14454.0,,B,,,Expert,CHEMBL616535,1.0,,,1350.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,106.0,
8.0,16209.0,,B,,,Autocuration,CHEMBL616536,1.0,,,1351.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,106.0,
8.0,3935.0,,B,,,Autocuration,CHEMBL616537,1.0,,,1352.0,,H,BAO_0000357,,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,106.0,
8.0,13729.0,,F,,,Expert,CHEMBL616538,1.0,,,1353.0,,H,BAO_0000219,CHO-K1,,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,106.0,485.0
8.0,14251.0,,F,,,Expert,CHEMBL616539,1.0,,,1354.0,,H,BAO_0000019,,,,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,106.0,
8.0,17085.0,,B,,,Expert,CHEMBL616540,1.0,,,1355.0,,H,BAO_0000019,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,106.0,
8.0,3025.0,,B,,,Autocuration,CHEMBL616429,1.0,,,1356.0,,H,BAO_0000357,,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,106.0,
8.0,15315.0,,B,,,Expert,CHEMBL616430,1.0,,,1357.0,,H,BAO_0000357,,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,106.0,
9.0,14214.0,,B,,,Expert,CHEMBL616431,1.0,,,1358.0,,D,BAO_0000219,,9606.0,,Homo sapiens,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,106.0,
9.0,3804.0,,B,,,Expert,CHEMBL616432,1.0,,,1359.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,106.0,
9.0,2391.0,,B,,,Expert,CHEMBL616433,1.0,,,1360.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Affinity for 5-hydroxytryptamine 1B receptor subtype,,106.0,
9.0,4175.0,,B,,,Expert,CHEMBL616434,1.0,,,1361.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1B receptor,,106.0,
8.0,17296.0,,B,,,Autocuration,CHEMBL616435,1.0,,,1362.0,,H,BAO_0000219,CHO,,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,106.0,449.0
8.0,17085.0,,B,,,Expert,CHEMBL616436,1.0,,,1363.0,,H,BAO_0000019,,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,106.0,
8.0,17211.0,,B,,,Autocuration,CHEMBL616437,1.0,,,1364.0,,H,BAO_0000219,HeLa,,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,106.0,308.0
8.0,17211.0,,B,,,Autocuration,CHEMBL616438,1.0,,,1365.0,,H,BAO_0000219,HeLa,,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,106.0,308.0
8.0,17211.0,,B,,,Autocuration,CHEMBL616439,1.0,,,1366.0,,H,BAO_0000219,HeLa,,,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,106.0,308.0
9.0,15926.0,,B,,,Expert,CHEMBL616440,1.0,,,1367.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,106.0,
8.0,16312.0,,B,,,Autocuration,CHEMBL616441,1.0,,,1368.0,,H,BAO_0000219,CHO-K1,,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,106.0,485.0
8.0,5843.0,,B,,,Expert,CHEMBL616442,1.0,,,1369.0,,H,BAO_0000357,,,,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,106.0,
8.0,5843.0,,B,,,Autocuration,CHEMBL616443,1.0,,,1370.0,,H,BAO_0000357,,,,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,106.0,
8.0,16312.0,,B,,,Expert,CHEMBL616444,1.0,,,1371.0,,H,BAO_0000219,CHO-K1,,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,106.0,485.0
9.0,15926.0,,B,,,Expert,CHEMBL616445,1.0,,,1372.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1B receptor,,106.0,
9.0,15926.0,,B,,,Expert,CHEMBL616446,1.0,,,1373.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1B receptor,,106.0,
9.0,4540.0,,B,,,Expert,CHEMBL616447,1.0,,,1374.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,106.0,449.0
8.0,6166.0,,B,,,Autocuration,CHEMBL616448,1.0,,,1375.0,,H,BAO_0000357,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,106.0,
8.0,17296.0,,B,,,Autocuration,CHEMBL616449,1.0,,,1376.0,,H,BAO_0000219,CHO,,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,106.0,449.0
8.0,17296.0,,B,,,Autocuration,CHEMBL616450,1.0,,,1377.0,,H,BAO_0000219,CHO,,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,106.0,449.0
8.0,17296.0,,B,,,Autocuration,CHEMBL857974,1.0,,,1378.0,,H,BAO_0000219,CHO,,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,106.0,449.0
8.0,15779.0,,B,,,Autocuration,CHEMBL616451,1.0,,,1379.0,,H,BAO_0000219,CHO,,,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,106.0,449.0
8.0,15779.0,,B,,,Autocuration,CHEMBL616452,1.0,,,1380.0,,H,BAO_0000219,CHO,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,106.0,449.0
8.0,15779.0,,B,,,Autocuration,CHEMBL616453,1.0,,,1381.0,,H,BAO_0000219,CHO,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,106.0,449.0
8.0,4199.0,,B,,,Autocuration,CHEMBL616454,1.0,,,1382.0,,H,BAO_0000219,CHO,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,106.0,449.0
9.0,14875.0,,B,,,Expert,CHEMBL616455,1.0,,,1383.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1B receptor,,106.0,
8.0,15146.0,,B,,,Autocuration,CHEMBL616456,1.0,,,1384.0,,H,BAO_0000219,CHO,,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,106.0,449.0
8.0,5213.0,,B,,,Autocuration,CHEMBL616457,1.0,,,1385.0,,H,BAO_0000357,,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,106.0,
8.0,14818.0,,B,,,Autocuration,CHEMBL616458,1.0,,,1386.0,,H,BAO_0000219,CHO,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,106.0,449.0
8.0,4829.0,,B,,,Autocuration,CHEMBL616459,1.0,,,1387.0,,H,BAO_0000219,CHO,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,106.0,449.0
8.0,14454.0,,F,,,Expert,CHEMBL616460,1.0,,,1388.0,,H,BAO_0000019,,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,106.0,
8.0,14454.0,,F,,,Expert,CHEMBL616461,1.0,,,1389.0,,H,BAO_0000019,,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,106.0,
8.0,14875.0,,F,,,Autocuration,CHEMBL616462,1.0,,,1390.0,,H,BAO_0000219,CHO,,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,106.0,449.0
8.0,14875.0,,F,,,Autocuration,CHEMBL616463,1.0,,,1391.0,,H,BAO_0000219,CHO,,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,106.0,449.0
8.0,15250.0,,F,,,Autocuration,CHEMBL616464,1.0,,,1392.0,,H,BAO_0000019,,,,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,105.0,
8.0,15250.0,,B,,,Autocuration,CHEMBL616465,1.0,,,1393.0,,H,BAO_0000219,CHO,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,105.0,449.0
8.0,15086.0,,B,,,Autocuration,CHEMBL832874,1.0,,,1394.0,,H,BAO_0000357,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,17105.0,
8.0,3025.0,,F,,,Autocuration,CHEMBL616184,1.0,,,1395.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,106.0,
8.0,14998.0,,B,,,Autocuration,CHEMBL616185,1.0,,,1396.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,106.0,
8.0,14998.0,,B,,,Intermediate,CHEMBL616186,1.0,,,1397.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,106.0,
8.0,14998.0,,B,,,Autocuration,CHEMBL616187,1.0,,,1398.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,106.0,
8.0,13969.0,,B,,,Expert,CHEMBL616188,1.0,,,1399.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,10577.0,
9.0,13392.0,,B,,,Intermediate,CHEMBL873475,1.0,,,1400.0,,D,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 1B receptor,,10577.0,
9.0,3651.0,2435.0,B,,,Expert,CHEMBL616189,1.0,Striatum,,1401.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,10577.0,
8.0,10025.0,,B,,,Expert,CHEMBL616190,1.0,,,1402.0,,H,BAO_0000357,,,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,10577.0,
8.0,13863.0,,B,,,Autocuration,CHEMBL616191,1.0,,,1403.0,,H,BAO_0000357,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,10576.0,
8.0,13863.0,,B,,,Autocuration,CHEMBL616192,1.0,,,1404.0,,H,BAO_0000357,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,10576.0,
8.0,13863.0,,B,,,Autocuration,CHEMBL616193,1.0,,,1405.0,,H,BAO_0000357,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,10576.0,
8.0,13863.0,,B,,,Autocuration,CHEMBL616194,1.0,,,1406.0,,H,BAO_0000357,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,10576.0,
8.0,13863.0,,B,,,Autocuration,CHEMBL616195,1.0,,,1407.0,,H,BAO_0000357,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,10576.0,
8.0,13863.0,,B,,,Autocuration,CHEMBL616196,1.0,,,1408.0,,H,BAO_0000357,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,10576.0,
8.0,4622.0,10000000.0,B,,,Autocuration,CHEMBL616197,1.0,Hippocampus,,1409.0,,H,BAO_0000249,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,10576.0,
8.0,14911.0,,B,,,Intermediate,CHEMBL616198,1.0,,,1410.0,,H,BAO_0000019,,,,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,10576.0,
8.0,12678.0,10000000.0,B,,,Autocuration,CHEMBL616199,1.0,Hippocampus,,1411.0,,H,BAO_0000221,,,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,10576.0,
8.0,12678.0,10000000.0,B,,,Expert,CHEMBL616200,1.0,Hippocampus,,1412.0,,H,BAO_0000221,,,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,10576.0,
8.0,14235.0,10000000.0,B,,,Expert,CHEMBL616201,1.0,Hippocampus,,1413.0,,H,BAO_0000221,,,,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,10576.0,
8.0,14949.0,10000000.0,B,,,Expert,CHEMBL616202,1.0,Hippocampus,,1414.0,,H,BAO_0000221,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,10576.0,
8.0,14949.0,10000000.0,B,,,Expert,CHEMBL616203,1.0,Hippocampus,,1415.0,,H,BAO_0000221,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,10576.0,
8.0,14949.0,10000000.0,B,,,Expert,CHEMBL616204,1.0,Hippocampus,,1416.0,,H,BAO_0000221,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,10576.0,
8.0,14949.0,10000000.0,B,,,Expert,CHEMBL616205,1.0,Hippocampus,,1417.0,,H,BAO_0000221,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,10576.0,
8.0,14949.0,10000000.0,B,,,Expert,CHEMBL616206,1.0,Hippocampus,,1418.0,,H,BAO_0000221,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,10576.0,
8.0,16118.0,,B,,,Expert,CHEMBL616207,1.0,,,1419.0,,H,BAO_0000249,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,10576.0,
8.0,3268.0,,B,,,Autocuration,CHEMBL616208,1.0,,,1420.0,,H,BAO_0000249,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,10576.0,
8.0,3268.0,,B,,,Autocuration,CHEMBL616209,1.0,,,1421.0,,H,BAO_0000249,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,10576.0,
8.0,16117.0,,B,,,Expert,CHEMBL616210,1.0,,,1422.0,,H,BAO_0000357,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,10576.0,
8.0,9783.0,10000000.0,B,,,Expert,CHEMBL616211,1.0,Hippocampus,,1423.0,,H,BAO_0000221,,,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,10576.0,
8.0,9783.0,10000000.0,B,,,Autocuration,CHEMBL616504,1.0,Hippocampus,,1424.0,,H,BAO_0000221,,,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,10576.0,
9.0,14356.0,10000000.0,B,,,Expert,CHEMBL616505,1.0,Hippocampus,,1425.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,15740.0,,F,,,Autocuration,CHEMBL616506,1.0,,,1426.0,,H,BAO_0000019,,,,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,12306.0,10000000.0,B,,,Autocuration,CHEMBL872107,1.0,Hippocampus,,1427.0,,H,BAO_0000221,,,,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,10576.0,
9.0,13348.0,10000000.0,B,,,Expert,CHEMBL616507,1.0,Hippocampus,,1428.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,10576.0,
8.0,10394.0,,B,,,Autocuration,CHEMBL616303,1.0,,,1429.0,,H,BAO_0000249,,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,10576.0,
8.0,15260.0,10000000.0,B,,,Autocuration,CHEMBL616304,1.0,Hippocampus,,1430.0,,H,BAO_0000221,,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,10576.0,
8.0,10046.0,10000000.0,B,,,Expert,CHEMBL616305,1.0,Hippocampus,,1431.0,,H,BAO_0000221,,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,10576.0,
8.0,15260.0,10000000.0,F,,,Intermediate,CHEMBL616306,1.0,Hippocampus,,1432.0,,H,BAO_0000221,,,,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,12851.0,,B,,,Autocuration,CHEMBL616307,1.0,,,1433.0,,H,BAO_0000357,,,,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,10576.0,
9.0,2148.0,10000000.0,B,,,Expert,CHEMBL881829,1.0,Hippocampus,,1434.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,10576.0,
8.0,13134.0,,B,,,Expert,CHEMBL616308,1.0,,,1435.0,,H,BAO_0000357,,,,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,10576.0,
8.0,12462.0,,B,,,Autocuration,CHEMBL616309,1.0,,,1436.0,,H,BAO_0000019,,,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,10576.0,
8.0,12462.0,,B,,,Expert,CHEMBL616310,1.0,,,1437.0,,H,BAO_0000019,,,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,10576.0,
8.0,12462.0,,B,,,Autocuration,CHEMBL616311,1.0,,,1438.0,,H,BAO_0000219,CHO,,,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,10576.0,449.0
8.0,11933.0,,B,,,Expert,CHEMBL616312,1.0,,,1439.0,,H,BAO_0000357,,,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,10576.0,
8.0,11933.0,,B,,,Autocuration,CHEMBL616313,1.0,,,1440.0,,H,BAO_0000357,,,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,10576.0,
9.0,403.0,10000000.0,B,,,Expert,CHEMBL616314,1.0,Hippocampus,,1441.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,15538.0,10000000.0,B,,,Autocuration,CHEMBL616315,1.0,Hippocampus,,1442.0,,H,BAO_0000221,,,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576.0,
8.0,15538.0,10000000.0,B,,,Autocuration,CHEMBL616567,1.0,Hippocampus,,1443.0,,H,BAO_0000221,,,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,10576.0,
8.0,15538.0,10000000.0,B,,,Autocuration,CHEMBL616568,1.0,Hippocampus,,1444.0,,H,BAO_0000221,,,,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,10576.0,
8.0,12464.0,,B,,,Intermediate,CHEMBL616569,1.0,,,1445.0,,H,BAO_0000019,,,,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,10576.0,
8.0,1455.0,,B,,,Expert,CHEMBL616570,1.0,,,1446.0,,H,BAO_0000357,,,,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,10576.0,
8.0,12652.0,,B,,,Autocuration,CHEMBL616571,1.0,,,1447.0,,H,BAO_0000357,,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,10576.0,
8.0,12639.0,10000000.0,B,,,Autocuration,CHEMBL616572,1.0,Hippocampus,,1448.0,,H,BAO_0000221,,,,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,10576.0,
8.0,13949.0,,B,,,Expert,CHEMBL616573,1.0,,,1449.0,,H,BAO_0000249,,,,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,10576.0,
9.0,12463.0,,B,,,Expert,CHEMBL616574,1.0,,,1450.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,10576.0,
8.0,14829.0,10000000.0,B,,,Expert,CHEMBL616575,1.0,Hippocampus,,1451.0,,H,BAO_0000221,,,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,10576.0,
8.0,14829.0,10000000.0,B,,,Autocuration,CHEMBL872108,1.0,Hippocampus,,1452.0,,H,BAO_0000221,,,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,10576.0,
8.0,12092.0,,B,,,Autocuration,CHEMBL616576,1.0,,,1453.0,,H,BAO_0000357,,,,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,10576.0,
8.0,403.0,,B,,,Autocuration,CHEMBL616577,1.0,,,1454.0,,H,BAO_0000249,,,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,10576.0,
8.0,403.0,,B,,,Autocuration,CHEMBL616578,1.0,,,1455.0,,H,BAO_0000249,,,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,10576.0,
8.0,3967.0,,B,,,Expert,CHEMBL616579,1.0,,,1456.0,,H,BAO_0000357,,,,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,10576.0,
9.0,12771.0,,B,,,Expert,CHEMBL616580,1.0,,,1457.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,10576.0,
8.0,15086.0,,B,,,Autocuration,CHEMBL616581,1.0,,,1458.0,,H,BAO_0000019,,,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,10576.0,
8.0,14909.0,10000000.0,B,,,Autocuration,CHEMBL616582,1.0,Hippocampus,,1459.0,,H,BAO_0000221,,,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576.0,
8.0,14949.0,10000000.0,B,,,Expert,CHEMBL616583,1.0,Hippocampus,,1460.0,,H,BAO_0000221,,,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576.0,
9.0,2309.0,10000000.0,B,,,Expert,CHEMBL616584,1.0,Hippocampus,,1461.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,10576.0,
8.0,4170.0,,B,,,Expert,CHEMBL616585,1.0,,,1462.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,10576.0,
9.0,11642.0,10000000.0,B,,,Expert,CHEMBL616586,1.0,Hippocampus,,1463.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,10576.0,
8.0,11642.0,10000000.0,B,,,Autocuration,CHEMBL616587,1.0,Hippocampus,,1464.0,,H,BAO_0000221,,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,10576.0,
8.0,12953.0,10000000.0,B,,,Autocuration,CHEMBL616588,1.0,Hippocampus,,1465.0,,H,BAO_0000221,,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,10576.0,
8.0,12953.0,10000000.0,B,,,Autocuration,CHEMBL616589,1.0,Hippocampus,,1466.0,,H,BAO_0000221,,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,10576.0,
8.0,12953.0,10000000.0,B,,,Expert,CHEMBL616590,1.0,Hippocampus,,1467.0,,H,BAO_0000221,,,,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,10576.0,
8.0,12903.0,,B,,,Expert,CHEMBL616591,1.0,,,1468.0,,H,BAO_0000219,CHO,,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,10576.0,449.0
8.0,12536.0,,B,,,Expert,CHEMBL616592,1.0,,,1469.0,,H,BAO_0000357,,,,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,10058.0,,B,,,Autocuration,CHEMBL616593,1.0,,,1470.0,,H,BAO_0000357,,,,,The inhibition activity of 5-HT1A at 1 uM,,10576.0,
8.0,12902.0,,B,,,Expert,CHEMBL616594,1.0,,,1471.0,,H,BAO_0000219,CHO-K1,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,10576.0,485.0
8.0,14057.0,,B,,,Expert,CHEMBL616595,1.0,,,1472.0,,H,BAO_0000249,,,,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,10576.0,
8.0,11296.0,,B,,,Autocuration,CHEMBL616596,1.0,,,1473.0,,H,BAO_0000357,,,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,10576.0,
8.0,11296.0,10000000.0,B,,,Autocuration,CHEMBL616597,1.0,Hippocampus,,1474.0,,H,BAO_0000221,,,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,10576.0,
8.0,11296.0,10000000.0,B,,,Expert,CHEMBL616598,1.0,Hippocampus,,1475.0,,H,BAO_0000221,,,,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,10576.0,
9.0,16616.0,,F,Membranes,,Expert,CHEMBL616599,1.0,,,1476.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,10576.0,
9.0,16616.0,10000000.0,F,Membranes,,Expert,CHEMBL616600,1.0,Hippocampus,,1477.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,10576.0,
8.0,16567.0,,B,,,Autocuration,CHEMBL616601,1.0,,,1478.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,10576.0,
8.0,16567.0,,B,,,Autocuration,CHEMBL616602,1.0,,,1479.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,10576.0,
8.0,16567.0,,B,,,Autocuration,CHEMBL616603,1.0,,,1480.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,10576.0,
8.0,16567.0,,B,,,Autocuration,CHEMBL616604,1.0,,,1481.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,10576.0,
8.0,17136.0,,B,,,Autocuration,CHEMBL616316,1.0,,,1482.0,,H,BAO_0000249,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,10576.0,
8.0,17136.0,,B,,,Autocuration,CHEMBL616317,1.0,,,1483.0,,H,BAO_0000249,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,10576.0,
9.0,16616.0,,B,,,Expert,CHEMBL616318,1.0,,,1484.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,10576.0,
8.0,17331.0,10000000.0,B,,,Autocuration,CHEMBL616319,1.0,Hippocampus,,1485.0,,H,BAO_0000221,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,10576.0,
8.0,17331.0,10000000.0,B,,,Autocuration,CHEMBL616320,1.0,Hippocampus,,1486.0,,H,BAO_0000221,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,10576.0,
9.0,17167.0,10000000.0,B,,,Expert,CHEMBL616321,1.0,Hippocampus,,1487.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,10576.0,
8.0,15740.0,,F,,,Autocuration,CHEMBL616322,1.0,,,1488.0,,H,BAO_0000019,,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,10576.0,
8.0,15740.0,,F,,,Autocuration,CHEMBL616323,1.0,,,1489.0,,H,BAO_0000019,,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,10576.0,
8.0,4671.0,,B,,,Autocuration,CHEMBL616324,1.0,,,1490.0,,H,BAO_0000357,,,,,Ratio of binding affinity to 5-HT 1A and D2 receptor,,10576.0,
8.0,10058.0,10000000.0,B,,,Autocuration,CHEMBL616325,1.0,Hippocampus,,1491.0,,H,BAO_0000221,,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,10576.0,
8.0,10058.0,10000000.0,B,,,Autocuration,CHEMBL616326,1.0,Hippocampus,,1492.0,,H,BAO_0000221,,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,10576.0,
8.0,10058.0,10000000.0,B,,,Autocuration,CHEMBL616327,1.0,Hippocampus,,1493.0,,H,BAO_0000221,,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,10576.0,
8.0,12073.0,,B,,,Autocuration,CHEMBL616328,1.0,,,1494.0,,H,BAO_0000357,,,,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,10576.0,
8.0,2759.0,,B,,,Autocuration,CHEMBL858110,1.0,,,1495.0,,H,BAO_0000249,,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,10576.0,
8.0,2759.0,,F,,,Autocuration,CHEMBL616329,1.0,,,1496.0,,H,BAO_0000249,,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,10576.0,
8.0,2759.0,,B,,,Autocuration,CHEMBL616330,1.0,,,1497.0,,H,BAO_0000249,,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,10576.0,
8.0,2759.0,,F,,,Autocuration,CHEMBL616331,1.0,,,1498.0,,H,BAO_0000249,,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,10576.0,
8.0,2759.0,,F,,,Autocuration,CHEMBL616332,1.0,,,1499.0,,H,BAO_0000249,,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,10576.0,
8.0,9737.0,955.0,B,,,Autocuration,CHEMBL857063,1.0,Brain,,1500.0,,H,BAO_0000249,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,10576.0,
8.0,9737.0,,B,,,Autocuration,CHEMBL616333,1.0,,,1501.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,10576.0,
8.0,5717.0,,F,,,Expert,CHEMBL616334,1.0,,,1502.0,,H,BAO_0000019,,,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,10576.0,
8.0,12253.0,10000000.0,B,,,Autocuration,CHEMBL616335,1.0,Hippocampus,,1503.0,,H,BAO_0000221,,,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,10576.0,
8.0,14025.0,,B,,,Autocuration,CHEMBL616336,1.0,,,1504.0,,H,BAO_0000019,,,,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,10576.0,
8.0,10425.0,,B,,,Expert,CHEMBL616337,1.0,,,1505.0,,H,BAO_0000249,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,10576.0,
8.0,14998.0,,B,,,Autocuration,CHEMBL616338,1.0,,,1506.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,10576.0,
8.0,13694.0,10000000.0,B,,,Autocuration,CHEMBL616339,1.0,Hippocampus,,1507.0,,H,BAO_0000221,,,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,10576.0,
8.0,13694.0,10000000.0,B,,,Autocuration,CHEMBL616340,1.0,Hippocampus,,1508.0,,H,BAO_0000221,,,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,10576.0,
8.0,4342.0,,B,,,Autocuration,CHEMBL616341,1.0,,,1509.0,,H,BAO_0000357,,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,10576.0,
9.0,12936.0,,B,,,Expert,CHEMBL616342,1.0,,,1510.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,10576.0,
9.0,13144.0,,B,,,Expert,CHEMBL616343,1.0,,,1511.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,10576.0,
8.0,13343.0,,B,,,Expert,CHEMBL616344,1.0,,,1512.0,,H,BAO_0000019,,,,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,10576.0,
8.0,12132.0,,B,,,Expert,CHEMBL616345,1.0,,,1513.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,10576.0,
8.0,15419.0,,B,,,Expert,CHEMBL616346,1.0,,,1514.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,10576.0,
8.0,1479.0,10000000.0,B,,,Autocuration,CHEMBL616347,1.0,Hippocampus,,1515.0,,H,BAO_0000221,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,10576.0,
8.0,14287.0,,B,,,Expert,CHEMBL616348,1.0,,,1516.0,,H,BAO_0000019,,,,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,10576.0,
8.0,13116.0,,B,,,Expert,CHEMBL616349,1.0,,,1517.0,,H,BAO_0000357,,,,,Binding affinity at 5-hydroxytryptamine 1A receptor,,10576.0,
9.0,2759.0,,B,Membranes,,Expert,CHEMBL616152,1.0,,,1518.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,10576.0,
8.0,2759.0,,B,,,Autocuration,CHEMBL616153,1.0,,,1519.0,,H,BAO_0000249,,,,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,10576.0,
8.0,14748.0,,B,,,Expert,CHEMBL616154,1.0,,,1520.0,,H,BAO_0000019,,,,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,10576.0,
8.0,12304.0,,B,,,Autocuration,CHEMBL616155,1.0,,,1521.0,,H,BAO_0000019,,,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,10576.0,
9.0,12409.0,10000000.0,B,,,Expert,CHEMBL616156,1.0,Hippocampus,,1522.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,10576.0,
9.0,12409.0,10000000.0,B,,,Expert,CHEMBL616157,1.0,Hippocampus,,1523.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,10576.0,
8.0,13267.0,10000000.0,B,,,Autocuration,CHEMBL616158,1.0,Hippocampus,,1524.0,,H,BAO_0000221,,,,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,10576.0,
8.0,15194.0,,B,,,Autocuration,CHEMBL616159,1.0,,,1525.0,,H,BAO_0000357,,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,10576.0,
8.0,14256.0,,B,,,Expert,CHEMBL616160,1.0,,,1526.0,,H,BAO_0000357,,,,,pKi value against rat 5-hydroxytryptamine 1A receptor.,,10576.0,
8.0,16567.0,,B,,,Autocuration,CHEMBL616161,1.0,,,1527.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,10576.0,
8.0,15740.0,,F,,,Autocuration,CHEMBL616162,1.0,,,1528.0,,H,BAO_0000019,,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,10576.0,
9.0,13278.0,,B,,,Expert,CHEMBL616163,1.0,,,1529.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,12687.0,
8.0,1970.0,,B,Membranes,,Expert,CHEMBL616164,1.0,,,1530.0,,H,BAO_0000249,,,,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,10626.0,
8.0,10034.0,955.0,B,,,Autocuration,CHEMBL616165,1.0,Brain,,1531.0,,H,BAO_0000221,,,,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,10576.0,
8.0,13348.0,,B,,,Autocuration,CHEMBL616355,1.0,,,1532.0,,H,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,51.0,
8.0,13630.0,,F,,,Autocuration,CHEMBL616356,1.0,,,1533.0,,H,BAO_0000019,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,10576.0,
8.0,10862.0,955.0,B,,,Autocuration,CHEMBL616357,1.0,Brain,,1534.0,,H,BAO_0000221,,,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,10576.0,
8.0,12058.0,,B,,,Autocuration,CHEMBL616358,1.0,,,1535.0,,H,BAO_0000019,,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,10576.0,
8.0,4639.0,,B,,,Autocuration,CHEMBL616359,1.0,,,1536.0,,H,BAO_0000357,,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,51.0,
8.0,15453.0,,B,,,Expert,CHEMBL616360,1.0,,,1537.0,,H,BAO_0000357,,,,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,51.0,
8.0,4820.0,,B,,,Expert,CHEMBL616361,1.0,,,1538.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,51.0,
8.0,1089.0,,B,,,Autocuration,CHEMBL616362,1.0,,,1539.0,,H,BAO_0000357,,,,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,51.0,
8.0,386.0,,B,Brain membranes,,Autocuration,CHEMBL616363,1.0,,,1540.0,,H,BAO_0000249,,,,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,51.0,
8.0,6011.0,,B,,,Autocuration,CHEMBL616364,1.0,,,1541.0,,H,BAO_0000357,,,,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,51.0,
8.0,5014.0,,B,,,Autocuration,CHEMBL616365,1.0,,,1542.0,,H,BAO_0000357,,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,51.0,
8.0,4402.0,,B,,,Expert,CHEMBL616366,1.0,,,1543.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,51.0,
8.0,17066.0,,B,,,Expert,CHEMBL872906,1.0,,,1544.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,51.0,
8.0,17515.0,,B,,,Autocuration,CHEMBL616367,1.0,,,1545.0,,H,BAO_0000357,,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,51.0,
8.0,2474.0,,B,,,Autocuration,CHEMBL616368,1.0,,,1546.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,51.0,
8.0,4775.0,,B,,,Autocuration,CHEMBL616369,1.0,,,1547.0,,H,BAO_0000357,,,,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,51.0,
9.0,14294.0,,B,,,Expert,CHEMBL616370,1.0,,,1548.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,51.0,
9.0,14294.0,,B,,,Expert,CHEMBL616371,1.0,,,1549.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,51.0,
8.0,12249.0,,B,,,Autocuration,CHEMBL616372,1.0,,,1550.0,,H,BAO_0000219,CHO,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,51.0,449.0
8.0,11376.0,,B,,,Expert,CHEMBL616373,1.0,,,1551.0,,H,BAO_0000219,,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,51.0,
8.0,2474.0,,B,,,Autocuration,CHEMBL616374,1.0,,,1552.0,In vivo,H,BAO_0000218,,,,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51.0,
8.0,13311.0,10000000.0,B,,,Autocuration,CHEMBL616375,1.0,Hippocampus,,1553.0,,H,BAO_0000221,,,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51.0,
8.0,4373.0,,B,,,Autocuration,CHEMBL616376,1.0,,,1554.0,,H,BAO_0000357,,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,51.0,
8.0,1633.0,,B,,,Expert,CHEMBL857064,1.0,,,1555.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,51.0,
8.0,11866.0,,B,,,Autocuration,CHEMBL616377,1.0,,,1556.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,51.0,
8.0,4373.0,,B,,,Autocuration,CHEMBL616378,1.0,,,1557.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,51.0,
8.0,4687.0,,B,,,Autocuration,CHEMBL616379,1.0,,,1558.0,,H,BAO_0000357,,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,51.0,
8.0,16946.0,,B,,,Autocuration,CHEMBL616380,1.0,,,1559.0,,H,BAO_0000357,,,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,11863.0,
8.0,13291.0,,B,,,Autocuration,CHEMBL616381,1.0,,,1560.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,11863.0,
8.0,14159.0,,B,,,Autocuration,CHEMBL616382,1.0,,,1561.0,,H,BAO_0000357,,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,11863.0,
8.0,10812.0,,B,,,Autocuration,CHEMBL616383,1.0,,,1562.0,,H,BAO_0000357,,,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,11863.0,
9.0,3032.0,,B,,,Expert,CHEMBL616350,1.0,,,1563.0,,D,BAO_0000219,CHO,10090.0,,Mus musculus,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,11863.0,449.0
8.0,16655.0,,B,,,Autocuration,CHEMBL616351,1.0,,,1564.0,,H,BAO_0000357,,,,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,11863.0,
8.0,14532.0,,B,,,Autocuration,CHEMBL616352,1.0,,,1565.0,,H,BAO_0000357,,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,11863.0,
8.0,13944.0,,B,,,Autocuration,CHEMBL616353,1.0,,,1566.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,11863.0,
8.0,13033.0,,B,,,Autocuration,CHEMBL616354,1.0,,,1567.0,,H,BAO_0000357,,,,,Binding affinity against serotonergic 5-HT1a receptor,,11863.0,
8.0,10321.0,,B,,,Autocuration,CHEMBL616508,1.0,,,1568.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,11863.0,
9.0,2968.0,,B,,,Expert,CHEMBL616559,1.0,,,1569.0,,D,BAO_0000357,,10090.0,,Mus musculus,Binding affinity for 5-hydroxytryptamine 1A receptor,,11863.0,
8.0,13964.0,,B,,,Autocuration,CHEMBL616560,1.0,,,1570.0,,H,BAO_0000357,,,,,Binding affinity at 5-hydroxytryptamine 1A receptor,,11863.0,
8.0,15527.0,,B,,,Autocuration,CHEMBL616561,1.0,,,1571.0,,H,BAO_0000357,,,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,11863.0,
8.0,12248.0,,B,,,Autocuration,CHEMBL616562,1.0,,,1572.0,,H,BAO_0000219,CHO,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,11863.0,449.0
8.0,12249.0,,B,,,Autocuration,CHEMBL616563,1.0,,,1573.0,,H,BAO_0000219,CHO,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,11863.0,449.0
8.0,15120.0,,B,,,Autocuration,CHEMBL616564,1.0,,,1574.0,,H,BAO_0000357,,,,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,11863.0,
8.0,13313.0,,B,,,Autocuration,CHEMBL616565,1.0,,,1575.0,,H,BAO_0000357,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,11863.0,
8.0,2613.0,,B,,,Autocuration,CHEMBL616566,1.0,,,1576.0,,H,BAO_0000218,,,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,11863.0,
8.0,16700.0,,B,,,Autocuration,CHEMBL616989,1.0,,,1577.0,,H,BAO_0000357,,,,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,11863.0,
8.0,2201.0,,B,,,Autocuration,CHEMBL857975,1.0,,,1578.0,,H,BAO_0000357,,,,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,11863.0,
9.0,1274.0,,B,,,Expert,CHEMBL616990,1.0,,,1579.0,,D,BAO_0000357,,10090.0,,Mus musculus,Binding affinity against 5-hydroxytryptamine 1A receptor,,11863.0,
8.0,1317.0,,B,,,Autocuration,CHEMBL616991,1.0,,,1580.0,,H,BAO_0000357,,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,11863.0,
8.0,12146.0,,B,,,Autocuration,CHEMBL616992,1.0,,,1581.0,,H,BAO_0000357,,,,,Tested against 5-hydroxytryptamine 1A receptor,,11863.0,
8.0,14059.0,,B,,,Autocuration,CHEMBL616993,1.0,,,1582.0,,H,BAO_0000357,,,,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,11863.0,
8.0,14025.0,,B,,,Expert,CHEMBL616994,1.0,,,1583.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,106.0,
8.0,14025.0,,B,,,Autocuration,CHEMBL616995,1.0,,,1584.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,106.0,
9.0,14447.0,,B,,,Intermediate,CHEMBL616996,1.0,,,1585.0,,D,BAO_0000219,HEK293,9593.0,,Gorilla gorilla,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,105571.0,722.0
8.0,3025.0,,F,,,Autocuration,CHEMBL616997,1.0,,,1586.0,In vivo,H,BAO_0000218,,10141.0,,Cavia porcellus,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,106.0,
8.0,3025.0,,F,,,Autocuration,CHEMBL616998,1.0,,,1587.0,In vivo,H,BAO_0000218,,10141.0,,Cavia porcellus,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,106.0,
8.0,15329.0,,F,,,Autocuration,CHEMBL616999,1.0,,,1588.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,106.0,
8.0,15329.0,,F,,,Autocuration,CHEMBL617000,1.0,,,1589.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,106.0,
8.0,15847.0,,F,,,Autocuration,CHEMBL617001,1.0,,,1590.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,106.0,
8.0,15847.0,,F,,,Autocuration,CHEMBL858111,1.0,,,1591.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,106.0,
8.0,14165.0,,F,,,Autocuration,CHEMBL617002,1.0,,,1592.0,,H,BAO_0000019,,,,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,106.0,
8.0,14214.0,,F,,,Autocuration,CHEMBL617003,1.0,,,1593.0,,H,BAO_0000019,,,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,106.0,
8.0,14214.0,,F,,,Autocuration,CHEMBL617004,1.0,,,1594.0,,H,BAO_0000019,,,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,106.0,
9.0,14214.0,,F,,,Expert,CHEMBL617005,1.0,,,1595.0,,D,BAO_0000019,,9606.0,,Homo sapiens,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,106.0,
9.0,13729.0,,F,,,Expert,CHEMBL616623,1.0,,,1596.0,,D,BAO_0000219,CHO-K1,9606.0,,Homo sapiens,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,106.0,485.0
8.0,3025.0,,F,,,Autocuration,CHEMBL616624,1.0,,,1597.0,,H,BAO_0000219,CHO,,,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,106.0,449.0
8.0,2391.0,,B,,,Autocuration,CHEMBL883243,1.0,,,1598.0,,H,BAO_0000357,,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,106.0,
8.0,2391.0,,F,,,Autocuration,CHEMBL616625,1.0,,,1599.0,,H,BAO_0000019,,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,106.0,
8.0,14956.0,,F,,,Expert,CHEMBL616626,1.0,,,1600.0,,H,BAO_0000219,CHO,,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,106.0,449.0
8.0,2598.0,,F,,,Autocuration,CHEMBL616627,1.0,,,1601.0,,H,BAO_0000219,CHO,,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,106.0,449.0
8.0,2598.0,,F,,,Autocuration,CHEMBL616628,1.0,,,1602.0,,H,BAO_0000219,CHO,,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,106.0,449.0
8.0,2598.0,,F,,,Autocuration,CHEMBL616629,1.0,,,1603.0,,H,BAO_0000219,CHO,,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,106.0,449.0
8.0,2598.0,,F,,,Autocuration,CHEMBL616630,1.0,,,1604.0,,H,BAO_0000219,CHO,,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,106.0,449.0
8.0,14956.0,,F,,,Expert,CHEMBL616631,1.0,,,1605.0,,H,BAO_0000019,,,,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,106.0,
8.0,14956.0,,F,,,Autocuration,CHEMBL616632,1.0,,,1606.0,,H,BAO_0000019,,,,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,106.0,
9.0,14214.0,,B,,,Expert,CHEMBL616633,1.0,,,1607.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,106.0,
8.0,3463.0,,B,,,Expert,CHEMBL616634,1.0,,,1608.0,,H,BAO_0000219,CHO,,,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,106.0,449.0
8.0,15331.0,,B,,,Autocuration,CHEMBL616635,1.0,,,1609.0,,H,BAO_0000357,,,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,106.0,
9.0,16146.0,,B,,,Expert,CHEMBL885358,1.0,,,1610.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity against 5-hydroxytryptamine 1B receptor,,106.0,
9.0,14159.0,,B,,,Expert,CHEMBL616636,1.0,,,1611.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,106.0,449.0
8.0,14158.0,,B,,,Expert,CHEMBL616637,1.0,,,1612.0,,H,BAO_0000219,CHO,,,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,106.0,449.0
8.0,14159.0,,B,,,Autocuration,CHEMBL616638,1.0,,,1613.0,,H,BAO_0000357,,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,106.0,
8.0,15250.0,,B,,,Expert,CHEMBL616639,1.0,,,1614.0,,H,BAO_0000219,CHO,,,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,106.0,449.0
8.0,15250.0,,B,,,Expert,CHEMBL616640,1.0,,,1615.0,,H,BAO_0000219,CHO,,,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,106.0,449.0
8.0,15331.0,,B,,,Expert,CHEMBL616641,1.0,,,1616.0,,H,BAO_0000219,CHO,,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,106.0,449.0
8.0,15332.0,,B,,,Expert,CHEMBL616642,1.0,,,1617.0,,H,BAO_0000219,CHO,,,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,106.0,449.0
8.0,14956.0,,B,,,Expert,CHEMBL616643,1.0,,,1618.0,,H,BAO_0000219,CHO,,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,106.0,449.0
8.0,3805.0,,B,,,Autocuration,CHEMBL616644,1.0,,,1619.0,,H,BAO_0000357,,,,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,106.0,
8.0,14875.0,,B,,,Autocuration,CHEMBL616645,1.0,,,1620.0,,H,BAO_0000357,,,,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,106.0,
8.0,14454.0,,F,,,Autocuration,CHEMBL616646,1.0,,,1621.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,105.0,
8.0,14454.0,,F,,,Expert,CHEMBL616647,1.0,,,1622.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,105.0,
8.0,16288.0,,B,,,Autocuration,CHEMBL616509,1.0,,,1623.0,,H,BAO_0000357,,,,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,105.0,
8.0,16288.0,,B,,,Autocuration,CHEMBL616510,1.0,,,1624.0,,H,BAO_0000357,,,,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,105.0,
8.0,16312.0,,B,,,Autocuration,CHEMBL616511,1.0,,,1625.0,,H,BAO_0000357,,,,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,105.0,
8.0,1348.0,,B,,,Expert,CHEMBL616512,1.0,,,1626.0,,H,BAO_0000357,,9913.0,,Bos taurus,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,105.0,
8.0,5834.0,,B,,,Autocuration,CHEMBL616513,1.0,,,1627.0,,H,BAO_0000357,,9913.0,,Bos taurus,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,105.0,
8.0,13366.0,2435.0,B,,,Autocuration,CHEMBL616514,1.0,Striatum,,1628.0,,H,BAO_0000019,,9913.0,,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,105.0,
8.0,1414.0,,B,,,Expert,CHEMBL616515,1.0,,,1629.0,,H,BAO_0000357,,9913.0,,Bos taurus,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,105.0,
8.0,14998.0,,B,,,Autocuration,CHEMBL616516,1.0,,,1630.0,,H,BAO_0000019,,9913.0,,Bos taurus,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,105.0,
8.0,11473.0,,B,,,Autocuration,CHEMBL616517,1.0,,,1631.0,,H,BAO_0000357,,9913.0,,Bos taurus,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,105.0,
8.0,11473.0,,B,,,Autocuration,CHEMBL616518,1.0,,,1632.0,,H,BAO_0000357,,9913.0,,Bos taurus,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,105.0,
8.0,10639.0,,B,,,Autocuration,CHEMBL616519,1.0,,,1633.0,,H,BAO_0000357,,9913.0,,Bos taurus,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,105.0,
8.0,10639.0,,B,,,Autocuration,CHEMBL616520,1.0,,,1634.0,,H,BAO_0000357,,9913.0,,Bos taurus,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,105.0,
8.0,1375.0,,B,,,Autocuration,CHEMBL616521,1.0,,,1635.0,,H,BAO_0000357,,9913.0,,Bos taurus,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,105.0,
8.0,1375.0,,B,,,Autocuration,CHEMBL616522,1.0,,,1636.0,,H,BAO_0000357,,9913.0,,Bos taurus,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,105.0,
8.0,16532.0,,B,,,Autocuration,CHEMBL884531,1.0,,,1637.0,,H,BAO_0000357,,9913.0,,Bos taurus,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,105.0,
8.0,11147.0,,B,,,Autocuration,CHEMBL616523,1.0,,,1638.0,,H,BAO_0000357,,9913.0,,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,105.0,
8.0,13366.0,2435.0,B,,,Autocuration,CHEMBL616731,1.0,Striatum,,1639.0,,H,BAO_0000019,,9913.0,,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,105.0,
8.0,10444.0,,B,,,Autocuration,CHEMBL616732,1.0,,,1640.0,,H,BAO_0000019,,9913.0,,Bos taurus,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,105.0,
8.0,16532.0,,B,,,Autocuration,CHEMBL616733,1.0,,,1641.0,,H,BAO_0000357,,9913.0,,Bos taurus,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,105.0,
8.0,16532.0,,B,,,Autocuration,CHEMBL616734,1.0,,,1642.0,,H,BAO_0000357,,9913.0,,Bos taurus,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,105.0,
8.0,12827.0,,B,,,Autocuration,CHEMBL616735,1.0,,,1643.0,,H,BAO_0000249,,9913.0,,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,105.0,
8.0,12827.0,,B,,,Autocuration,CHEMBL616736,1.0,,,1644.0,,H,BAO_0000249,,9913.0,,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,105.0,
8.0,12919.0,,F,,,Expert,CHEMBL616737,1.0,,,1645.0,,H,BAO_0000019,,9913.0,,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,105.0,
8.0,14025.0,,B,,,Autocuration,CHEMBL616738,1.0,,,1646.0,,H,BAO_0000019,,9913.0,,Bos taurus,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,105.0,
8.0,12919.0,,F,,,Expert,CHEMBL616739,1.0,,,1647.0,,H,BAO_0000019,,9913.0,,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,105.0,
8.0,12919.0,,F,,,Expert,CHEMBL616740,1.0,,,1648.0,,H,BAO_0000019,,9913.0,,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,105.0,
8.0,12919.0,,F,,,Expert,CHEMBL616741,1.0,,,1649.0,,H,BAO_0000019,,9913.0,,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,105.0,
8.0,14447.0,,B,,,Autocuration,CHEMBL616742,1.0,,,1650.0,,H,BAO_0000219,HEK293,9593.0,,Gorilla gorilla,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,105.0,722.0
9.0,1375.0,,B,,,Intermediate,CHEMBL616743,1.0,,,1651.0,,D,BAO_0000019,,10141.0,,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,105570.0,
9.0,1375.0,,B,,,Intermediate,CHEMBL616744,1.0,,,1652.0,,D,BAO_0000019,,10141.0,,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,105570.0,
9.0,12409.0,,F,,,Intermediate,CHEMBL616745,1.0,,,1653.0,,D,BAO_0000019,,10141.0,,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,105570.0,
9.0,12409.0,,F,,,Intermediate,CHEMBL616746,1.0,,,1654.0,,D,BAO_0000019,,10141.0,,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,105570.0,
9.0,12409.0,,F,,,Intermediate,CHEMBL616747,1.0,,,1655.0,,D,BAO_0000019,,10141.0,,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,105570.0,
9.0,12409.0,,F,,,Intermediate,CHEMBL616748,1.0,,,1656.0,,D,BAO_0000019,,10141.0,,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,105570.0,
9.0,12409.0,,F,,,Intermediate,CHEMBL616648,1.0,,,1657.0,,D,BAO_0000019,,10141.0,,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,105570.0,
9.0,11574.0,,B,,,Intermediate,CHEMBL616649,1.0,,,1658.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 1D receptor,,105570.0,
9.0,1558.0,,B,,,Intermediate,CHEMBL616650,1.0,,,1659.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,105570.0,
9.0,12409.0,,F,,,Intermediate,CHEMBL616651,1.0,,,1660.0,,D,BAO_0000218,,10141.0,,Cavia porcellus,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,105570.0,
9.0,12409.0,,F,,,Intermediate,CHEMBL616652,1.0,,,1661.0,,D,BAO_0000218,,10141.0,,Cavia porcellus,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,105570.0,
9.0,12409.0,,F,,,Intermediate,CHEMBL616653,1.0,,,1662.0,,D,BAO_0000218,,10141.0,,Cavia porcellus,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,105570.0,
9.0,12409.0,,F,,,Intermediate,CHEMBL616654,1.0,,,1663.0,,D,BAO_0000218,,10141.0,,Cavia porcellus,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,105570.0,
9.0,12253.0,,B,,,Intermediate,CHEMBL616655,1.0,,,1664.0,,D,BAO_0000019,,10141.0,,Cavia porcellus,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,105570.0,
9.0,12936.0,,B,,,Intermediate,CHEMBL616656,1.0,,,1665.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,105570.0,
8.0,13181.0,,B,,,Autocuration,CHEMBL616657,1.0,,,1666.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,105.0,
9.0,12409.0,2435.0,B,,,Intermediate,CHEMBL616658,1.0,Striatum,,1667.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,105570.0,
9.0,10639.0,,B,,,Intermediate,CHEMBL616659,1.0,,,1668.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,105570.0,
8.0,5254.0,,B,,,Autocuration,CHEMBL616660,1.0,,,1669.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,,51.0,
8.0,13051.0,,B,,,Autocuration,CHEMBL616661,1.0,,,1670.0,,H,BAO_0000357,,,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,106.0,
8.0,3463.0,,F,,,Expert,CHEMBL616662,1.0,,,1671.0,,H,BAO_0000019,,,,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,105.0,
8.0,15315.0,,F,,,Autocuration,CHEMBL616663,1.0,,,1672.0,,H,BAO_0000019,,,,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,105.0,
8.0,6011.0,,F,,,Autocuration,CHEMBL616664,1.0,,,1673.0,,H,BAO_0000019,,,,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,105.0,
9.0,14159.0,,F,,,Expert,CHEMBL881820,1.0,,,1674.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,105.0,449.0
8.0,14159.0,,F,,,Autocuration,CHEMBL616665,1.0,,,1675.0,,H,BAO_0000219,CHO,,,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,105.0,449.0
8.0,15250.0,,B,,,Expert,CHEMBL616666,1.0,,,1676.0,,H,BAO_0000219,CHO,,,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,105.0,449.0
8.0,15250.0,,B,,,Autocuration,CHEMBL616667,1.0,,,1677.0,,H,BAO_0000219,CHO,,,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,105.0,449.0
8.0,15331.0,,F,,,Expert,CHEMBL616668,1.0,,,1678.0,,H,BAO_0000219,CHO,,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,105.0,449.0
9.0,15332.0,,F,,,Expert,CHEMBL616669,1.0,,,1679.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,105.0,449.0
8.0,15332.0,,F,,,Expert,CHEMBL617040,1.0,,,1680.0,,H,BAO_0000219,CHO,,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,105.0,449.0
8.0,3294.0,,F,,,Autocuration,CHEMBL617041,1.0,,,1681.0,,H,BAO_0000219,CHO,,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,105.0,449.0
8.0,14158.0,,F,,,Expert,CHEMBL617042,1.0,,,1682.0,,H,BAO_0000219,CHO,,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,105.0,449.0
8.0,14956.0,,F,,,Expert,CHEMBL617043,1.0,,,1683.0,,H,BAO_0000219,CHO,,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,105.0,449.0
8.0,12469.0,,F,,,Autocuration,CHEMBL617044,1.0,,,1684.0,,H,BAO_0000019,,,,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,105.0,
8.0,3463.0,,F,,,Expert,CHEMBL617045,1.0,,,1685.0,,H,BAO_0000219,CHO,,,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,105.0,449.0
9.0,15250.0,,F,,,Expert,CHEMBL617046,1.0,,,1686.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,105.0,449.0
9.0,15250.0,,F,,,Expert,CHEMBL617047,1.0,,,1687.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,105.0,449.0
8.0,14956.0,,F,,,Expert,CHEMBL617048,1.0,,,1688.0,,H,BAO_0000019,,,,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,105.0,
8.0,14159.0,,F,,,Autocuration,CHEMBL616897,1.0,,,1689.0,,H,BAO_0000019,,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,105.0,
9.0,14159.0,,F,,,Expert,CHEMBL616898,1.0,,,1690.0,,D,BAO_0000019,,9606.0,,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,105.0,
9.0,14499.0,,F,,,Expert,CHEMBL858201,1.0,,,1691.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,105.0,449.0
8.0,15315.0,,F,,,Autocuration,CHEMBL616899,1.0,,,1692.0,,H,BAO_0000019,,,,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,105.0,
8.0,3294.0,,B,,,Autocuration,CHEMBL616900,1.0,,,1693.0,In vitro,H,BAO_0000219,,,,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,105.0,
8.0,3463.0,,B,,,Expert,CHEMBL616901,1.0,,,1694.0,,H,BAO_0000219,CHO,,,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,105.0,449.0
8.0,15331.0,,B,,,Autocuration,CHEMBL616902,1.0,,,1695.0,,H,BAO_0000357,,,,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,105.0,
9.0,14159.0,,B,,,Expert,CHEMBL616903,1.0,,,1696.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,105.0,449.0
8.0,14158.0,,B,,,Expert,CHEMBL616904,1.0,,,1697.0,,H,BAO_0000219,CHO,,,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,105.0,449.0
8.0,14159.0,,B,,,Autocuration,CHEMBL616905,1.0,,,1698.0,,H,BAO_0000357,,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,105.0,
8.0,15250.0,,B,,,Expert,CHEMBL616906,1.0,,,1699.0,,H,BAO_0000219,CHO,,,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,105.0,449.0
8.0,15250.0,,B,,,Expert,CHEMBL616907,1.0,,,1700.0,,H,BAO_0000219,CHO,,,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,105.0,449.0
8.0,15331.0,,B,,,Expert,CHEMBL616908,1.0,,,1701.0,,H,BAO_0000219,CHO,,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,105.0,449.0
9.0,15332.0,,B,,,Expert,CHEMBL616909,1.0,,,1702.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,105.0,449.0
9.0,14499.0,,B,,,Expert,CHEMBL616910,1.0,,,1703.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,105.0,449.0
8.0,15332.0,,B,,,Expert,CHEMBL616911,1.0,,,1704.0,,H,BAO_0000219,CHO,,,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,105.0,449.0
8.0,14956.0,,B,,,Expert,CHEMBL616912,1.0,,,1705.0,,H,BAO_0000219,CHO,,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,105.0,449.0
8.0,3805.0,,B,,,Autocuration,CHEMBL616913,1.0,,,1706.0,,H,BAO_0000357,,,,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,105.0,
9.0,6011.0,,B,,,Expert,CHEMBL616914,1.0,,,1707.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,105.0,449.0
8.0,16190.0,,B,,,Autocuration,CHEMBL616915,1.0,,,1708.0,,H,BAO_0000219,CHO,,,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,105.0,449.0
8.0,14165.0,,B,,,Autocuration,CHEMBL616916,1.0,,,1709.0,,H,BAO_0000019,,,,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,105.0,
9.0,4234.0,,B,,,Expert,CHEMBL616917,1.0,,,1710.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,105.0,
8.0,15527.0,,B,,,Autocuration,CHEMBL616918,1.0,,,1711.0,,H,BAO_0000357,,,,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,105.0,
8.0,6328.0,,B,,,Expert,CHEMBL616919,1.0,,,1712.0,,H,BAO_0000219,,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,105.0,
8.0,16209.0,,B,,,Autocuration,CHEMBL616920,1.0,,,1713.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,105.0,
8.0,14770.0,,B,,,Autocuration,CHEMBL872914,1.0,,,1714.0,,H,BAO_0000357,,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,105.0,
8.0,2598.0,,B,,,Autocuration,CHEMBL616921,1.0,,,1715.0,,H,BAO_0000357,,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,105.0,
8.0,6897.0,,B,,,Expert,CHEMBL616922,1.0,,,1716.0,,H,BAO_0000357,,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,105.0,
8.0,6013.0,,B,,,Autocuration,CHEMBL616923,1.0,,,1717.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor,,105.0,
8.0,5843.0,,B,,,Expert,CHEMBL616924,1.0,,,1718.0,,H,BAO_0000357,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,105.0,
8.0,14454.0,,B,,,Expert,CHEMBL875909,1.0,,,1719.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,105.0,
8.0,14454.0,,B,,,Autocuration,CHEMBL616925,1.0,,,1720.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,105.0,
8.0,14454.0,,B,,,Autocuration,CHEMBL616926,1.0,,,1721.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,105.0,
8.0,15818.0,,B,,,Autocuration,CHEMBL616927,1.0,,,1722.0,,H,BAO_0000357,,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,105.0,
8.0,13729.0,,F,,,Expert,CHEMBL616928,1.0,,,1723.0,,H,BAO_0000219,CHO-K1,,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,105.0,485.0
9.0,6011.0,,B,,,Expert,CHEMBL616929,1.0,,,1724.0,In vitro,D,BAO_0000219,,9606.0,,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,105.0,
9.0,4234.0,,B,,,Expert,CHEMBL616930,1.0,,,1725.0,,D,BAO_0000357,,9606.0,,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,105.0,
8.0,17085.0,,B,,,Expert,CHEMBL616931,1.0,,,1726.0,,H,BAO_0000019,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,105.0,
8.0,3025.0,,B,,,Autocuration,CHEMBL616932,1.0,,,1727.0,,H,BAO_0000357,,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,105.0,
8.0,15315.0,,B,,,Expert,CHEMBL616933,1.0,,,1728.0,,H,BAO_0000357,,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,105.0,
9.0,14214.0,,B,,,Expert,CHEMBL616934,1.0,,,1729.0,,D,BAO_0000219,,9606.0,,Homo sapiens,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,105.0,
9.0,3804.0,,B,,,Expert,CHEMBL616935,1.0,,,1730.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1D receptor,,105.0,
8.0,16700.0,,B,,,Autocuration,CHEMBL616936,1.0,,,1731.0,,H,BAO_0000357,,,,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,105.0,
9.0,2391.0,,B,,,Expert,CHEMBL616937,1.0,,,1732.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Affinity for 5-hydroxytryptamine 1D receptor subtype,,105.0,
9.0,4175.0,,B,,,Expert,CHEMBL616938,1.0,,,1733.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1D receptor,,105.0,
8.0,17085.0,,B,,,Autocuration,CHEMBL616939,1.0,,,1734.0,,H,BAO_0000019,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,105.0,
8.0,17085.0,,B,,,Expert,CHEMBL616940,1.0,,,1735.0,,H,BAO_0000019,,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,105.0,
9.0,15926.0,,B,,,Expert,CHEMBL616941,1.0,,,1736.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,105.0,
8.0,16312.0,,B,,,Autocuration,CHEMBL616942,1.0,,,1737.0,,H,BAO_0000219,CHO-K1,,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,105.0,485.0
8.0,16312.0,,B,,,Autocuration,CHEMBL616943,1.0,,,1738.0,,H,BAO_0000219,CHO-K1,,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,105.0,485.0
4.0,14956.0,,B,,,Autocuration,CHEMBL616944,1.0,,,1739.0,,H,BAO_0000219,CHO,,,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,104802.0,449.0
8.0,3294.0,,F,,,Autocuration,CHEMBL616945,1.0,,,1740.0,,H,BAO_0000019,,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,105.0,
8.0,12861.0,,B,,,Autocuration,CHEMBL616946,1.0,,,1741.0,,H,BAO_0000357,,,,,Binding activity radioligand.,,105.0,
8.0,12861.0,,B,,,Autocuration,CHEMBL616947,1.0,,,1742.0,,H,BAO_0000019,,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,105.0,
8.0,16312.0,,B,,,Expert,CHEMBL616948,1.0,,,1743.0,,H,BAO_0000219,CHO-K1,,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,105.0,485.0
8.0,5104.0,,B,,,Autocuration,CHEMBL616851,1.0,,,1744.0,,H,BAO_0000357,,,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,105.0,
8.0,5105.0,,B,,,Autocuration,CHEMBL616852,1.0,,,1745.0,,H,BAO_0000357,,,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,105.0,
8.0,14499.0,,B,,,Autocuration,CHEMBL616853,1.0,,,1746.0,,H,BAO_0000357,,,,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,105.0,
9.0,15926.0,,B,,,Expert,CHEMBL616854,1.0,,,1747.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1D receptor,,105.0,
9.0,4540.0,,B,,,Expert,CHEMBL616855,1.0,,,1748.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,105.0,449.0
8.0,15779.0,,B,,,Autocuration,CHEMBL616856,1.0,,,1749.0,,H,BAO_0000219,CHO,,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,105.0,449.0
8.0,15779.0,,B,,,Autocuration,CHEMBL616857,1.0,,,1750.0,,H,BAO_0000219,CHO,,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,105.0,449.0
8.0,6166.0,,B,,,Autocuration,CHEMBL616858,1.0,,,1751.0,,H,BAO_0000357,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,105.0,
8.0,15779.0,,B,,,Autocuration,CHEMBL616859,1.0,,,1752.0,,H,BAO_0000219,CHO,,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,105.0,449.0
8.0,15779.0,,B,,,Autocuration,CHEMBL616860,1.0,,,1753.0,,H,BAO_0000219,CHO,,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,105.0,449.0
8.0,17451.0,,B,,,Autocuration,CHEMBL616861,1.0,,,1754.0,,H,BAO_0000219,HEK293,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,105.0,722.0
8.0,17451.0,,B,,,Autocuration,CHEMBL616541,1.0,,,1755.0,,H,BAO_0000219,HEK293,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,105.0,722.0
8.0,17451.0,,B,,,Autocuration,CHEMBL616542,1.0,,,1756.0,,H,BAO_0000219,HEK293,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,105.0,722.0
8.0,4199.0,,B,,,Autocuration,CHEMBL616543,1.0,,,1757.0,,H,BAO_0000219,CHO,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,105.0,449.0
9.0,14875.0,,B,,,Expert,CHEMBL616544,1.0,,,1758.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1D receptor,,105.0,
8.0,15146.0,,B,,,Autocuration,CHEMBL616545,1.0,,,1759.0,,H,BAO_0000219,CHO,,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,105.0,449.0
8.0,5213.0,,B,,,Autocuration,CHEMBL616546,1.0,,,1760.0,,H,BAO_0000357,,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,105.0,
8.0,14818.0,,B,,,Autocuration,CHEMBL616547,1.0,,,1761.0,,H,BAO_0000219,CHO,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,105.0,449.0
8.0,4829.0,,B,,,Autocuration,CHEMBL616548,1.0,,,1762.0,,H,BAO_0000219,CHO,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,105.0,449.0
8.0,14454.0,,F,,,Expert,CHEMBL616549,1.0,,,1763.0,,H,BAO_0000019,,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,105.0,
8.0,14454.0,,F,,,Expert,CHEMBL616550,1.0,,,1764.0,,H,BAO_0000019,,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,105.0,
8.0,5254.0,,B,,,Autocuration,CHEMBL857066,1.0,,,1765.0,,H,BAO_0000357,,,,,Binding affinity against 5-HT2C receptor,,108.0,
8.0,5254.0,,B,,,Autocuration,CHEMBL616551,1.0,,,1766.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,,108.0,
8.0,10639.0,,B,,,Autocuration,CHEMBL616552,1.0,,,1767.0,,H,BAO_0000357,,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,10577.0,
8.0,10639.0,,F,,,Autocuration,CHEMBL832876,1.0,,,1768.0,,H,BAO_0000019,,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,10577.0,
8.0,12352.0,,B,,,Expert,CHEMBL616553,1.0,,,1769.0,,H,BAO_0000019,,,,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,10577.0,
8.0,9098.0,,B,,,Autocuration,CHEMBL616554,1.0,,,1770.0,,H,BAO_0000357,,,,,Binding affinity towards 5-HT1B was determined,,10577.0,
8.0,14430.0,,B,,,Expert,CHEMBL616555,1.0,,,1771.0,,H,BAO_0000019,,,,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,10577.0,
8.0,13657.0,,B,,,Expert,CHEMBL616556,1.0,,,1772.0,,H,BAO_0000019,,,,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,10577.0,
8.0,13657.0,,B,,,Autocuration,CHEMBL616557,1.0,,,1773.0,,H,BAO_0000019,,,,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,10577.0,
8.0,15854.0,,B,,,Expert,CHEMBL616558,1.0,,,1774.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,10577.0,
9.0,10639.0,,B,,,Expert,CHEMBL616749,1.0,,,1775.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,10577.0,
8.0,10025.0,,B,,,Autocuration,CHEMBL616750,1.0,,,1776.0,,H,BAO_0000357,,,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,10577.0,
8.0,10025.0,,B,,,Autocuration,CHEMBL616751,1.0,,,1777.0,,H,BAO_0000357,,,,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,10577.0,
8.0,14286.0,,B,,,Autocuration,CHEMBL616752,1.0,,,1778.0,,H,BAO_0000249,,,,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,10577.0,
8.0,3651.0,2435.0,B,,,Autocuration,CHEMBL616753,1.0,Striatum,,1779.0,,H,BAO_0000019,,,,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,10577.0,
9.0,14178.0,,B,,,Expert,CHEMBL616754,1.0,,,1780.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,10577.0,
8.0,10639.0,,B,,,Autocuration,CHEMBL616755,1.0,,,1781.0,,H,BAO_0000019,,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,10577.0,
8.0,13605.0,2435.0,B,,,Autocuration,CHEMBL616756,1.0,Striatum,,1782.0,,H,BAO_0000019,,,,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,10577.0,
8.0,5834.0,2435.0,B,,,Autocuration,CHEMBL616757,1.0,Striatum,,1783.0,,H,BAO_0000019,,,,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,10577.0,
8.0,10922.0,2435.0,B,,,Autocuration,CHEMBL616758,1.0,Striatum,,1784.0,,H,BAO_0000357,,,,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,10577.0,
8.0,14286.0,,B,,,Autocuration,CHEMBL616759,1.0,,,1785.0,,H,BAO_0000249,,,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,10577.0,
8.0,11825.0,,B,,,Autocuration,CHEMBL616760,1.0,,,1786.0,,H,BAO_0000357,,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,10577.0,
8.0,14826.0,2435.0,B,,,Autocuration,CHEMBL616761,1.0,Striatum,,1787.0,,H,BAO_0000019,,,,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,10577.0,
8.0,9699.0,2435.0,B,,,Autocuration,CHEMBL616762,1.0,Striatum,,1788.0,,H,BAO_0000019,,,,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,10577.0,
8.0,14423.0,,B,,,Autocuration,CHEMBL616763,1.0,,,1789.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,10577.0,
8.0,10062.0,,B,,,Expert,CHEMBL872909,1.0,,,1790.0,,H,BAO_0000357,,,,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,10577.0,
8.0,10062.0,,B,,,Autocuration,CHEMBL616764,1.0,,,1791.0,,H,BAO_0000357,,,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,10577.0,
9.0,12280.0,,B,,,Expert,CHEMBL616765,1.0,,,1792.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,10577.0,
8.0,15412.0,2435.0,B,,,Autocuration,CHEMBL616766,1.0,Striatum,,1793.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,10577.0,
8.0,15412.0,2435.0,B,,,Autocuration,CHEMBL616767,1.0,Striatum,,1794.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,10577.0,
8.0,10062.0,,B,,,Autocuration,CHEMBL616768,1.0,,,1795.0,,H,BAO_0000357,,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,10577.0,
8.0,11147.0,,B,,,Autocuration,CHEMBL616769,1.0,,,1796.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,10577.0,
8.0,9547.0,,B,,,Autocuration,CHEMBL616770,1.0,,,1797.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,10577.0,
8.0,10444.0,,B,,,Autocuration,CHEMBL616771,1.0,,,1798.0,,H,BAO_0000019,,,,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,10577.0,
8.0,12469.0,2435.0,B,,,Autocuration,CHEMBL616772,1.0,Striatum,,1799.0,,H,BAO_0000019,,,,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,10577.0,
8.0,9098.0,,B,,,Expert,CHEMBL616773,1.0,,,1800.0,,H,BAO_0000019,,,,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,10577.0,
8.0,9098.0,,B,,,Autocuration,CHEMBL616774,1.0,,,1801.0,,H,BAO_0000019,,,,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,10577.0,
8.0,9699.0,,B,,,Autocuration,CHEMBL616775,1.0,,,1802.0,,H,BAO_0000357,,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,10577.0,
8.0,10394.0,,B,,,Autocuration,CHEMBL616776,1.0,,,1803.0,,H,BAO_0000249,,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,10577.0,
8.0,12092.0,,B,,,Autocuration,CHEMBL616777,1.0,,,1804.0,,H,BAO_0000357,,,,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,10577.0,
8.0,16700.0,,B,,,Autocuration,CHEMBL616778,1.0,,,1805.0,,H,BAO_0000357,,,,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,10577.0,
9.0,403.0,,B,,,Expert,CHEMBL616779,1.0,,,1806.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,10577.0,
9.0,12771.0,,B,,,Expert,CHEMBL616780,1.0,,,1807.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1B receptor,,10577.0,
8.0,11642.0,,B,,,Autocuration,CHEMBL616781,1.0,,,1808.0,,H,BAO_0000019,,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,10577.0,
8.0,12953.0,,B,,,Autocuration,CHEMBL616782,1.0,,,1809.0,,H,BAO_0000357,,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,10577.0,
8.0,12953.0,,B,,,Autocuration,CHEMBL616783,1.0,,,1810.0,,H,BAO_0000357,,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,10577.0,
8.0,12953.0,2435.0,B,,,Expert,CHEMBL616784,1.0,Striatum,,1811.0,,H,BAO_0000019,,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,10577.0,
8.0,12953.0,,B,,,Autocuration,CHEMBL616785,1.0,,,1812.0,,H,BAO_0000357,,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,10577.0,
8.0,9737.0,955.0,B,,,Autocuration,CHEMBL857067,1.0,Brain,,1813.0,,H,BAO_0000249,,,,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,10577.0,
8.0,9737.0,,B,,,Autocuration,CHEMBL616786,1.0,,,1814.0,,H,BAO_0000019,,,,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,10577.0,
8.0,9737.0,955.0,B,,,Autocuration,CHEMBL616787,1.0,Brain,,1815.0,,H,BAO_0000249,,,,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,10577.0,
8.0,12827.0,,B,,,Autocuration,CHEMBL616788,1.0,,,1816.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,10577.0,
8.0,5033.0,,B,,,Autocuration,CHEMBL616789,1.0,,,1817.0,,H,BAO_0000357,,,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,10577.0,
9.0,9786.0,,B,,,Expert,CHEMBL616790,1.0,,,1818.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,10577.0,
8.0,13116.0,,B,,,Expert,CHEMBL616791,1.0,,,1819.0,,H,BAO_0000357,,,,,Binding affinity at 5-hydroxytryptamine 1B receptor,,10577.0,
8.0,16429.0,,B,,,Autocuration,CHEMBL616792,1.0,,,1820.0,,H,BAO_0000019,,,,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,10577.0,
9.0,12409.0,,B,,,Expert,CHEMBL616793,1.0,,,1821.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,10577.0,
8.0,15194.0,,B,,,Autocuration,CHEMBL616794,1.0,,,1822.0,,H,BAO_0000357,,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,10577.0,
8.0,15194.0,,B,,,Autocuration,CHEMBL616795,1.0,,,1823.0,,H,BAO_0000357,,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,10577.0,
4.0,5486.0,,B,,,Autocuration,CHEMBL616796,1.0,,,1824.0,,H,BAO_0000019,,,,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,104686.0,
8.0,4639.0,,B,,,Autocuration,CHEMBL616797,1.0,,,1825.0,,H,BAO_0000357,,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,106.0,
8.0,386.0,,B,Brain membranes,,Autocuration,CHEMBL616798,1.0,,,1826.0,,H,BAO_0000249,,,,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,106.0,
8.0,2474.0,,B,,,Autocuration,CHEMBL616799,1.0,,,1827.0,,H,BAO_0000357,,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,106.0,
8.0,6011.0,,B,,,Autocuration,CHEMBL616800,1.0,,,1828.0,,H,BAO_0000357,,,,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,106.0,
8.0,5014.0,,B,,,Autocuration,CHEMBL616801,1.0,,,1829.0,,H,BAO_0000357,,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,106.0,
8.0,17515.0,,B,,,Autocuration,CHEMBL616802,1.0,,,1830.0,,H,BAO_0000357,,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,106.0,
8.0,4373.0,,B,,,Autocuration,CHEMBL616803,1.0,,,1831.0,,H,BAO_0000357,,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,106.0,
8.0,1633.0,,B,,,Expert,CHEMBL857068,1.0,,,1832.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,106.0,
8.0,1633.0,,B,,,Autocuration,CHEMBL616804,1.0,,,1833.0,,H,BAO_0000357,,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,106.0,
8.0,4373.0,,B,,,Autocuration,CHEMBL616805,1.0,,,1834.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,106.0,
8.0,4687.0,,B,,,Autocuration,CHEMBL616806,1.0,,,1835.0,,H,BAO_0000357,,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,106.0,
8.0,11574.0,,B,,,Autocuration,CHEMBL616807,1.0,,,1836.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1B receptor,,106.0,
8.0,10321.0,,B,,,Autocuration,CHEMBL616808,1.0,,,1837.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,106.0,
8.0,15527.0,,B,,,Autocuration,CHEMBL616809,1.0,,,1838.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,106.0,
8.0,17200.0,,B,,,Autocuration,CHEMBL616810,1.0,,,1839.0,,H,BAO_0000357,,,,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,106.0,
4.0,14423.0,,B,,,Autocuration,CHEMBL616811,1.0,,,1840.0,,H,BAO_0000224,,,,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,104802.0,
8.0,5834.0,,B,,,Autocuration,CHEMBL616812,1.0,,,1841.0,,H,BAO_0000357,,9913.0,,Bos taurus,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,108.0,
8.0,11473.0,,B,,,Autocuration,CHEMBL616813,1.0,,,1842.0,,H,BAO_0000357,,9823.0,,Sus scrofa,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,108.0,
8.0,11473.0,,B,,,Autocuration,CHEMBL616814,1.0,,,1843.0,,H,BAO_0000357,,9823.0,,Sus scrofa,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,108.0,
8.0,10639.0,,B,,,Autocuration,CHEMBL616815,1.0,,,1844.0,,H,BAO_0000357,,9823.0,,Sus scrofa,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,108.0,
8.0,10639.0,,B,,,Autocuration,CHEMBL616816,1.0,,,1845.0,,H,BAO_0000357,,9823.0,,Sus scrofa,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,108.0,
8.0,14331.0,,B,,,Autocuration,CHEMBL616817,1.0,,,1846.0,,H,BAO_0000357,,9823.0,,Sus scrofa,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,108.0,
8.0,10796.0,,B,,,Autocuration,CHEMBL616818,1.0,,,1847.0,,H,BAO_0000357,,9823.0,,Sus scrofa,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,108.0,
8.0,9098.0,,B,,,Expert,CHEMBL616819,1.0,,,1848.0,,H,BAO_0000357,,9823.0,,Sus scrofa,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,108.0,
8.0,14331.0,,B,,,Expert,CHEMBL616820,1.0,,,1849.0,,H,BAO_0000357,,9823.0,,Sus scrofa,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,108.0,
8.0,11828.0,,B,,,Expert,CHEMBL616821,1.0,,,1850.0,,H,BAO_0000019,,9823.0,,Sus scrofa,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,108.0,
8.0,11866.0,,B,,,Autocuration,CHEMBL616822,1.0,,,1851.0,,H,BAO_0000357,,9823.0,,Sus scrofa,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,108.0,
8.0,13047.0,,B,,,Autocuration,CHEMBL616823,1.0,,,1852.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,108.0,
9.0,188.0,,B,,,Autocuration,CHEMBL616824,1.0,,,1853.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,12689.0,
9.0,11825.0,,B,,,Autocuration,CHEMBL616825,1.0,,,1854.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,12689.0,
9.0,11825.0,,B,,,Autocuration,CHEMBL616826,1.0,,,1855.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,12689.0,
9.0,11624.0,,B,,,Expert,CHEMBL616827,1.0,,,1856.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,12689.0,
9.0,11139.0,,B,,,Autocuration,CHEMBL616828,1.0,,,1857.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,12689.0,
9.0,11147.0,,B,,,Autocuration,CHEMBL616829,1.0,,,1858.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,12689.0,
9.0,10444.0,,B,,,Autocuration,CHEMBL616830,1.0,,,1859.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,12689.0,
9.0,11624.0,,B,,,Expert,CHEMBL616831,1.0,,,1860.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1C receptor,,12689.0,
9.0,11662.0,,B,,,Autocuration,CHEMBL616832,1.0,,,1861.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,12689.0,
9.0,11662.0,,B,,,Autocuration,CHEMBL616833,1.0,,,1862.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,12689.0,
9.0,11662.0,,B,,,Expert,CHEMBL616834,1.0,,,1863.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,12689.0,
9.0,11662.0,,B,,,Autocuration,CHEMBL829595,1.0,,,1864.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,12689.0,
9.0,9098.0,,B,,,Autocuration,CHEMBL616835,1.0,,,1865.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,12689.0,
9.0,10394.0,,B,,,Autocuration,CHEMBL872910,1.0,,,1866.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,12689.0,
8.0,11933.0,,B,,,Expert,CHEMBL616836,1.0,,,1867.0,,H,BAO_0000357,,,,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,12689.0,
9.0,12092.0,,B,,,Autocuration,CHEMBL616837,1.0,,,1868.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,12689.0,
9.0,12253.0,,B,,,Autocuration,CHEMBL616466,1.0,,,1869.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,12689.0,
9.0,12253.0,,B,,,Autocuration,CHEMBL616467,1.0,,,1870.0,,D,BAO_0000219,HEK293,10116.0,,Rattus norvegicus,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,12689.0,722.0
8.0,1558.0,,B,,,Autocuration,CHEMBL616468,1.0,,,1871.0,,H,BAO_0000357,,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,108.0,
8.0,2474.0,,B,,,Autocuration,CHEMBL616469,1.0,,,1872.0,,H,BAO_0000357,,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,108.0,
8.0,2474.0,,B,,,Autocuration,CHEMBL616470,1.0,,,1873.0,,H,BAO_0000357,,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,108.0,
8.0,11574.0,,B,,,Autocuration,CHEMBL616471,1.0,,,1874.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,,12689.0,
8.0,1558.0,,B,,,Autocuration,CHEMBL616472,1.0,,,1875.0,,H,BAO_0000357,,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,12689.0,
8.0,13944.0,,B,,,Autocuration,CHEMBL616473,1.0,,,1876.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,,12689.0,
8.0,13033.0,,B,,,Autocuration,CHEMBL616474,1.0,,,1877.0,,H,BAO_0000357,,,,,Binding affinity against serotonergic 5-HT1c receptor,,12689.0,
8.0,10321.0,,B,,,Autocuration,CHEMBL616475,1.0,,,1878.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,12689.0,
8.0,11866.0,,B,,,Autocuration,CHEMBL616476,1.0,,,1879.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,12689.0,
8.0,14454.0,,B,,,Autocuration,CHEMBL616477,1.0,,,1880.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,105.0,
4.0,11574.0,,B,,,Autocuration,CHEMBL616478,1.0,,,1881.0,,H,BAO_0000224,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,104686.0,
4.0,11574.0,,B,,,Autocuration,CHEMBL616479,1.0,,,1882.0,,H,BAO_0000224,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,104686.0,
4.0,13631.0,,B,,,Autocuration,CHEMBL616480,1.0,,,1883.0,,H,BAO_0000019,,,,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,104686.0,
5.0,9630.0,,B,,,Autocuration,CHEMBL616481,1.0,,,1884.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,104686.0,
5.0,8822.0,,B,,,Autocuration,CHEMBL616482,1.0,,,1885.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,104686.0,
5.0,9064.0,955.0,B,,,Autocuration,CHEMBL884713,1.0,Brain,,1886.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,104686.0,
4.0,8868.0,,B,,,Autocuration,CHEMBL616483,1.0,,,1887.0,,H,BAO_0000224,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,104686.0,
4.0,9064.0,,B,,,Autocuration,CHEMBL616484,1.0,,,1888.0,,H,BAO_0000224,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,104686.0,
4.0,9806.0,,B,,,Autocuration,CHEMBL616485,1.0,,,1889.0,,H,BAO_0000019,,,,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,104686.0,
4.0,9098.0,,B,,,Autocuration,CHEMBL616486,1.0,,,1890.0,,H,BAO_0000224,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,104686.0,
4.0,8868.0,,B,,,Autocuration,CHEMBL616487,1.0,,,1891.0,,H,BAO_0000224,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,104686.0,
4.0,12765.0,,B,,,Autocuration,CHEMBL616488,1.0,,,1892.0,,H,BAO_0000224,,,,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,104686.0,
4.0,11049.0,,B,,,Autocuration,CHEMBL616489,1.0,,,1893.0,,H,BAO_0000019,,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,104686.0,
4.0,11049.0,,B,,,Autocuration,CHEMBL616490,1.0,,,1894.0,,H,BAO_0000019,,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,104686.0,
4.0,11049.0,,B,,,Autocuration,CHEMBL616491,1.0,,,1895.0,,H,BAO_0000019,,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,104686.0,
4.0,11049.0,,B,,,Autocuration,CHEMBL616492,1.0,,,1896.0,,H,BAO_0000019,,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,104686.0,
4.0,11049.0,,B,,,Autocuration,CHEMBL616493,1.0,,,1897.0,,H,BAO_0000019,,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,104686.0,
4.0,11473.0,,B,,,Autocuration,CHEMBL616494,1.0,,,1898.0,,H,BAO_0000019,,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,104686.0,
4.0,11473.0,,B,,,Autocuration,CHEMBL616495,1.0,,,1899.0,,H,BAO_0000019,,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,104686.0,
4.0,3086.0,,B,,,Autocuration,CHEMBL616496,1.0,,,1900.0,,H,BAO_0000019,,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,104686.0,
4.0,11049.0,,B,,,Autocuration,CHEMBL616497,1.0,,,1901.0,,H,BAO_0000019,,,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,104686.0,
4.0,11049.0,,B,,,Autocuration,CHEMBL616498,1.0,,,1902.0,,H,BAO_0000019,,,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,104686.0,
4.0,10639.0,,B,,,Autocuration,CHEMBL616499,1.0,,,1903.0,,H,BAO_0000019,,,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,104686.0,
4.0,10922.0,,B,,,Autocuration,CHEMBL616500,1.0,,,1904.0,,H,BAO_0000019,,,,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,104686.0,
5.0,9064.0,955.0,B,,,Autocuration,CHEMBL616501,1.0,Brain,,1905.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,104686.0,
4.0,10748.0,955.0,B,,,Autocuration,CHEMBL616502,1.0,Brain,,1906.0,,H,BAO_0000221,,,,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,104686.0,
4.0,11614.0,,B,Membranes,,Autocuration,CHEMBL884529,1.0,,,1907.0,,H,BAO_0000249,,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,104686.0,
4.0,11615.0,,B,Membranes,,Autocuration,CHEMBL616503,1.0,,,1908.0,,H,BAO_0000249,,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,104686.0,
4.0,11615.0,,B,,,Autocuration,CHEMBL616964,1.0,,,1909.0,,H,BAO_0000224,,,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,11614.0,,B,Membranes,,Autocuration,CHEMBL616965,1.0,,,1910.0,,H,BAO_0000249,,,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,104686.0,
4.0,11702.0,,B,,,Autocuration,CHEMBL616966,1.0,,,1911.0,,H,BAO_0000224,,,,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,104686.0,
4.0,11702.0,,B,,,Autocuration,CHEMBL616967,1.0,,,1912.0,,H,BAO_0000224,,,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,104686.0,
5.0,11702.0,,B,,,Autocuration,CHEMBL616968,1.0,,,1913.0,,D,BAO_0000224,,10116.0,,Rattus norvegicus,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,11702.0,,B,,,Autocuration,CHEMBL616969,1.0,,,1914.0,,H,BAO_0000224,,,,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,104686.0,
4.0,13346.0,,B,,,Autocuration,CHEMBL884530,1.0,,,1915.0,,H,BAO_0000019,,,,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,104686.0,
4.0,10025.0,,B,,,Autocuration,CHEMBL616970,1.0,,,1916.0,,H,BAO_0000224,,,,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,10025.0,,B,,,Autocuration,CHEMBL616971,1.0,,,1917.0,,H,BAO_0000224,,,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,104686.0,
4.0,10025.0,,B,,,Autocuration,CHEMBL616972,1.0,,,1918.0,,H,BAO_0000224,,,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,104686.0,
4.0,9036.0,,B,,,Autocuration,CHEMBL616973,1.0,,,1919.0,,H,BAO_0000224,,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,104686.0,
4.0,9036.0,,B,,,Autocuration,CHEMBL616974,1.0,,,1920.0,,H,BAO_0000224,,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,104686.0,
4.0,9161.0,,B,,,Autocuration,CHEMBL616975,1.0,,,1921.0,,H,BAO_0000019,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,104686.0,
4.0,12304.0,,B,,,Autocuration,CHEMBL616976,1.0,,,1922.0,,H,BAO_0000019,,,,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,104686.0,
4.0,13276.0,,B,,,Autocuration,CHEMBL616977,1.0,,,1923.0,,H,BAO_0000224,,,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,104686.0,
4.0,11825.0,,B,,,Autocuration,CHEMBL616978,1.0,,,1924.0,,H,BAO_0000224,,,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,104686.0,
4.0,12443.0,,B,,,Autocuration,CHEMBL616979,1.0,,,1925.0,,H,BAO_0000224,,,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,104686.0,
4.0,13830.0,,B,,,Autocuration,CHEMBL616980,1.0,,,1926.0,,H,BAO_0000224,,,,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,9592.0,,B,Membranes,,Autocuration,CHEMBL616981,1.0,,,1927.0,,H,BAO_0000249,,,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,104686.0,
4.0,9592.0,,B,Membranes,,Autocuration,CHEMBL616982,1.0,,,1928.0,,H,BAO_0000249,,,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,104686.0,
4.0,10881.0,,B,,,Autocuration,CHEMBL616983,1.0,,,1929.0,,H,BAO_0000224,,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,104686.0,
4.0,13605.0,,B,,,Autocuration,CHEMBL616984,1.0,,,1930.0,,H,BAO_0000019,,,,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,104686.0,
5.0,11624.0,,B,,,Autocuration,CHEMBL616985,1.0,,,1931.0,,D,BAO_0000224,,10116.0,,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,4101.0,,B,,,Autocuration,CHEMBL616986,1.0,,,1932.0,,H,BAO_0000224,,,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,104686.0,
4.0,4101.0,,B,,,Autocuration,CHEMBL616987,1.0,,,1933.0,,H,BAO_0000224,,,,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,104686.0,
4.0,15360.0,,B,,,Autocuration,CHEMBL616988,1.0,,,1934.0,,H,BAO_0000019,,,,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,104686.0,
4.0,11576.0,,B,,,Autocuration,CHEMBL617243,1.0,,,1935.0,,H,BAO_0000019,,,,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,104686.0,
4.0,5834.0,,B,,,Autocuration,CHEMBL617244,1.0,,,1936.0,,H,BAO_0000019,,,,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,104686.0,
5.0,2395.0,,B,,,Autocuration,CHEMBL617245,1.0,,,1937.0,,D,BAO_0000219,CHO-K1,10116.0,,Rattus norvegicus,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,104686.0,485.0
4.0,11965.0,,B,Membranes,,Autocuration,CHEMBL617246,1.0,,,1938.0,,H,BAO_0000249,,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,104686.0,
4.0,3967.0,,B,,,Autocuration,CHEMBL617546,1.0,,,1939.0,,H,BAO_0000224,,,,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,104686.0,
4.0,11130.0,,B,Brain membranes,,Autocuration,CHEMBL617547,1.0,,,1940.0,,H,BAO_0000249,,,,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,104686.0,
4.0,13427.0,,B,,,Autocuration,CHEMBL617548,1.0,,,1941.0,In vitro,H,BAO_0000219,,,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,104686.0,
4.0,9443.0,,B,,,Autocuration,CHEMBL617549,1.0,,,1942.0,,H,BAO_0000224,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,9443.0,,B,,,Autocuration,CHEMBL617550,1.0,,,1943.0,,H,BAO_0000224,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,104686.0,
4.0,11825.0,,B,,,Autocuration,CHEMBL617551,1.0,,,1944.0,,H,BAO_0000224,,,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,104686.0,
4.0,12120.0,,B,Membranes,,Autocuration,CHEMBL617552,1.0,,,1945.0,,H,BAO_0000249,,,,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,104686.0,
4.0,12120.0,,B,Membranes,,Autocuration,CHEMBL617553,1.0,,,1946.0,,H,BAO_0000249,,,,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,104686.0,
4.0,11963.0,1515.0,F,,,Autocuration,CHEMBL617554,1.0,Thoracic aorta,,1947.0,,H,BAO_0000019,,,,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,104686.0,
4.0,9069.0,,B,,,Autocuration,CHEMBL617555,1.0,,,1948.0,,H,BAO_0000019,,,,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,8868.0,,B,,,Autocuration,CHEMBL617556,1.0,,,1949.0,,H,BAO_0000224,,,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,104686.0,
8.0,17200.0,,B,,,Autocuration,CHEMBL617557,1.0,,,1950.0,,H,BAO_0000357,,,,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,10624.0,
8.0,17200.0,,B,,,Autocuration,CHEMBL617558,1.0,,,1951.0,,H,BAO_0000357,,,,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,10624.0,
8.0,13969.0,,B,,,Expert,CHEMBL617559,1.0,,,1952.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,17106.0,
9.0,13392.0,,B,,,Expert,CHEMBL617560,1.0,,,1953.0,,D,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 1D receptor,,17106.0,
8.0,1742.0,,B,,,Autocuration,CHEMBL617561,1.0,,,1954.0,,H,BAO_0000249,,,,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,17106.0,
8.0,1742.0,,B,,,Autocuration,CHEMBL617562,1.0,,,1955.0,,H,BAO_0000249,,,,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,17106.0,
8.0,14331.0,2435.0,B,,,Autocuration,CHEMBL617563,1.0,Striatum,,1956.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,17106.0,
8.0,12861.0,,F,,,Autocuration,CHEMBL617564,1.0,,,1957.0,,H,BAO_0000019,,,,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,17106.0,
8.0,12861.0,,B,,,Expert,CHEMBL617565,1.0,,,1958.0,,H,BAO_0000019,,,,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,17106.0,
8.0,12861.0,,B,,,Autocuration,CHEMBL856076,1.0,,,1959.0,,H,BAO_0000357,,,,,Binding activity radioligand.,,17106.0,
8.0,12861.0,,B,,,Autocuration,CHEMBL617566,1.0,,,1960.0,,H,BAO_0000019,,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,17106.0,
8.0,12861.0,,B,,,Expert,CHEMBL875911,1.0,,,1961.0,,H,BAO_0000019,,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,17106.0,
8.0,12861.0,,B,,,Autocuration,CHEMBL617567,1.0,,,1962.0,,H,BAO_0000019,,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,17106.0,
8.0,675.0,,B,,,Autocuration,CHEMBL617568,1.0,,,1963.0,,H,BAO_0000249,,,,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,17106.0,
8.0,12490.0,,B,,,Expert,CHEMBL617569,1.0,,,1964.0,,H,BAO_0000019,,,,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,17106.0,
8.0,11828.0,,B,,,Expert,CHEMBL617570,1.0,,,1965.0,,H,BAO_0000249,,,,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,17106.0,
8.0,11866.0,,B,,,Autocuration,CHEMBL617571,1.0,,,1966.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,17106.0,
8.0,773.0,,B,,,Autocuration,CHEMBL617572,1.0,,,1967.0,,H,BAO_0000357,,9823.0,,Sus scrofa,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,105.0,
8.0,13047.0,,B,,,Expert,CHEMBL617573,1.0,,,1968.0,,H,BAO_0000357,,9986.0,,Oryctolagus cuniculus,The compound was tested for intrinsic activity against 5-HT1D receptor,,105.0,
8.0,13047.0,,B,,,Autocuration,CHEMBL617574,1.0,,,1969.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,105.0,
8.0,13047.0,,B,,,Expert,CHEMBL617575,1.0,,,1970.0,,H,BAO_0000357,,9986.0,,Oryctolagus cuniculus,The compound was tested for binding affinity against 5-HT1D receptor,,105.0,
8.0,188.0,,B,,,Autocuration,CHEMBL617576,1.0,,,1971.0,,H,BAO_0000357,,,,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,10578.0,
8.0,10639.0,,F,,,Autocuration,CHEMBL617577,1.0,,,1972.0,,H,BAO_0000019,,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,10578.0,
8.0,12438.0,,F,,,Autocuration,CHEMBL617578,1.0,,,1973.0,,H,BAO_0000019,,,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,10578.0,
8.0,12438.0,,B,,,Autocuration,CHEMBL617579,1.0,,,1974.0,,H,BAO_0000357,,,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,10578.0,
8.0,15854.0,,B,,,Expert,CHEMBL617580,1.0,,,1975.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,10578.0,
8.0,10394.0,,B,,,Autocuration,CHEMBL617581,1.0,,,1976.0,,H,BAO_0000249,,,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,10578.0,
8.0,12092.0,,B,,,Autocuration,CHEMBL617582,1.0,,,1977.0,,H,BAO_0000357,,,,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,10578.0,
8.0,3389.0,,B,,,Expert,CHEMBL617583,1.0,,,1978.0,,H,BAO_0000019,,,,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,10578.0,
8.0,6011.0,,B,,,Autocuration,CHEMBL617584,1.0,,,1979.0,,H,BAO_0000357,,,,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,105.0,
8.0,4639.0,,B,,,Autocuration,CHEMBL617585,1.0,,,1980.0,,H,BAO_0000357,,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,105.0,
8.0,2474.0,,B,,,Autocuration,CHEMBL875912,1.0,,,1981.0,,H,BAO_0000357,,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,105.0,
8.0,5014.0,,B,,,Autocuration,CHEMBL617586,1.0,,,1982.0,,H,BAO_0000357,,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,105.0,
8.0,17515.0,,B,,,Autocuration,CHEMBL617587,1.0,,,1983.0,,H,BAO_0000357,,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,105.0,
8.0,11866.0,,B,,,Autocuration,CHEMBL617588,1.0,,,1984.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,105.0,
8.0,4687.0,,B,,,Autocuration,CHEMBL857980,1.0,,,1985.0,,H,BAO_0000357,,,,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,105.0,
8.0,12146.0,,B,,,Autocuration,CHEMBL617589,1.0,,,1986.0,,H,BAO_0000357,,,,,Tested against 5-hydroxytryptamine 1D receptor,,105.0,
8.0,10321.0,,B,,,Autocuration,CHEMBL617590,1.0,,,1987.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,105.0,
8.0,13267.0,,B,,,Autocuration,CHEMBL617591,1.0,,,1988.0,,H,BAO_0000219,HEK293,,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,105.0,722.0
9.0,1274.0,,B,,,Expert,CHEMBL617592,1.0,,,1989.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity against 5-Hydroxytryptamine 1D receptor,,105.0,
8.0,15250.0,,B,,,Autocuration,CHEMBL617593,1.0,,,1990.0,,H,BAO_0000357,,,,,,,105.0,
8.0,13706.0,,B,,,Autocuration,CHEMBL617594,1.0,,,1991.0,,H,BAO_0000219,CHO-K1,,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,106.0,485.0
8.0,13706.0,,B,,,Autocuration,CHEMBL617595,1.0,,,1992.0,,H,BAO_0000219,CHO-K1,,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,105.0,485.0
8.0,13706.0,,B,,,Autocuration,CHEMBL617596,1.0,,,1993.0,,H,BAO_0000219,HEK293,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,105.0,722.0
8.0,13706.0,,B,,,Autocuration,CHEMBL617597,1.0,,,1994.0,,H,BAO_0000219,HEK293,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,105.0,722.0
8.0,13047.0,,B,,,Autocuration,CHEMBL617598,1.0,,,1995.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,105.0,
8.0,13366.0,,B,,,Autocuration,CHEMBL872916,1.0,,,1996.0,,H,BAO_0000357,,,,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,105.0,
8.0,13366.0,,B,,,Expert,CHEMBL617599,1.0,,,1997.0,,H,BAO_0000357,,,,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,105.0,
8.0,1558.0,,B,,,Autocuration,CHEMBL617091,1.0,,,1998.0,,H,BAO_0000357,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,105.0,
8.0,12902.0,,B,,,Expert,CHEMBL617092,1.0,,,1999.0,,H,BAO_0000219,CHO-K1,,,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,105.0,485.0
8.0,13706.0,,B,,,Autocuration,CHEMBL617093,1.0,,,2000.0,,H,BAO_0000219,CHO-K1,,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,105.0,485.0
8.0,13706.0,,F,,,Autocuration,CHEMBL617094,1.0,,,2001.0,,H,BAO_0000019,,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,105.0,
8.0,13706.0,,F,,,Autocuration,CHEMBL617095,1.0,,,2002.0,,H,BAO_0000019,,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,105.0,
8.0,14251.0,,F,,,Autocuration,CHEMBL617096,1.0,,,2003.0,,H,BAO_0000019,,,,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,105.0,
8.0,14251.0,,F,,,Autocuration,CHEMBL617097,1.0,,,2004.0,,H,BAO_0000019,,,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,105.0,
8.0,14251.0,,F,,,Autocuration,CHEMBL617098,1.0,,,2005.0,,H,BAO_0000019,,,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,105.0,
8.0,13313.0,,B,,,Autocuration,CHEMBL617301,1.0,,,2006.0,,H,BAO_0000357,,,,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,105.0,
8.0,13313.0,,B,,,Autocuration,CHEMBL617302,1.0,,,2007.0,,H,BAO_0000357,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,105.0,
8.0,13366.0,,B,,,Autocuration,CHEMBL617303,1.0,,,2008.0,,H,BAO_0000357,,,,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,105.0,
8.0,13051.0,,B,,,Expert,CHEMBL617304,1.0,,,2009.0,,H,BAO_0000357,,,,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,105.0,
8.0,12903.0,,B,,,Expert,CHEMBL617305,1.0,,,2010.0,,H,BAO_0000219,CHO,,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,105.0,449.0
9.0,12469.0,,B,,,Autocuration,CHEMBL617306,1.0,,,2011.0,,D,BAO_0000219,,9606.0,,Homo sapiens,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,105.0,
8.0,5619.0,,B,,,Autocuration,CHEMBL617307,1.0,,,2012.0,,H,BAO_0000357,,,,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,17106.0,
8.0,13047.0,,B,,,Autocuration,CHEMBL617308,1.0,,,2013.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,105.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL617309,1.0,,,2014.0,,H,BAO_0000357,,,,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,105.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL617310,1.0,,,2015.0,,H,BAO_0000357,,,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,105.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL617311,1.0,,,2016.0,,H,BAO_0000357,,,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,105.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL617312,1.0,,,2017.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,105.0,
8.0,3269.0,,B,,,Autocuration,CHEMBL617313,1.0,,,2018.0,,H,BAO_0000357,,,,,Affinity against 5-hydroxytryptamine 1D receptor alpha,,105.0,
8.0,12409.0,,B,,,Expert,CHEMBL617314,1.0,,,2019.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,105.0,
8.0,13706.0,,F,,,Autocuration,CHEMBL617315,1.0,,,2020.0,,H,BAO_0000019,,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,106.0,
8.0,13706.0,,B,,,Autocuration,CHEMBL617316,1.0,,,2021.0,,H,BAO_0000219,HEK293,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,106.0,722.0
8.0,13706.0,,B,,,Autocuration,CHEMBL617317,1.0,,,2022.0,,H,BAO_0000219,HEK293,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,106.0,722.0
8.0,12903.0,,B,,,Autocuration,CHEMBL617318,1.0,,,2023.0,,H,BAO_0000219,CHO,,,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,106.0,449.0
8.0,13047.0,,B,,,Autocuration,CHEMBL617319,1.0,,,2024.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,106.0,
9.0,13366.0,,B,,,Expert,CHEMBL617320,1.0,,,2025.0,,D,BAO_0000357,,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,106.0,
9.0,13366.0,,B,,,Expert,CHEMBL617321,1.0,,,2026.0,,D,BAO_0000357,,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,106.0,
9.0,13366.0,,B,,,Expert,CHEMBL617322,1.0,,,2027.0,,D,BAO_0000357,,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,106.0,
8.0,13366.0,,B,,,Autocuration,CHEMBL616862,1.0,,,2028.0,,H,BAO_0000357,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,106.0,
8.0,13366.0,,B,,,Autocuration,CHEMBL616863,1.0,,,2029.0,,H,BAO_0000357,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,106.0,
8.0,12469.0,,B,,,Autocuration,CHEMBL616864,1.0,,,2030.0,,H,BAO_0000219,CHO,,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,106.0,449.0
8.0,13706.0,,B,,,Autocuration,CHEMBL616865,1.0,,,2031.0,,H,BAO_0000219,CHO-K1,,,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,106.0,485.0
8.0,13706.0,,B,,,Autocuration,CHEMBL616866,1.0,,,2032.0,,H,BAO_0000219,CHO-K1,,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,106.0,485.0
8.0,13706.0,,F,,,Autocuration,CHEMBL616867,1.0,,,2033.0,,H,BAO_0000019,,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,106.0,
8.0,12902.0,,B,,,Expert,CHEMBL616868,1.0,,,2034.0,,H,BAO_0000219,CHO-K1,,,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,106.0,485.0
8.0,13051.0,,B,,,Expert,CHEMBL616869,1.0,,,2035.0,,H,BAO_0000357,,,,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,105.0,
8.0,12903.0,,B,,,Expert,CHEMBL616870,1.0,,,2036.0,,H,BAO_0000219,CHO,,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,106.0,449.0
8.0,1558.0,,F,,,Autocuration,CHEMBL616871,1.0,,,2037.0,,H,BAO_0000219,CHO-K1,,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,105.0,485.0
8.0,1558.0,,F,,,Autocuration,CHEMBL616872,1.0,,,2038.0,,H,BAO_0000219,CHO-K1,,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,105.0,485.0
8.0,1558.0,,F,,,Autocuration,CHEMBL616873,1.0,,,2039.0,,H,BAO_0000219,CHO-K1,,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,105.0,485.0
8.0,1558.0,,F,,,Autocuration,CHEMBL616838,1.0,,,2040.0,,H,BAO_0000219,CHO-K1,,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,105.0,485.0
8.0,1558.0,,B,,,Autocuration,CHEMBL616839,1.0,,,2041.0,,H,BAO_0000357,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,105.0,
8.0,13047.0,,B,,,Autocuration,CHEMBL616840,1.0,,,2042.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,106.0,
8.0,13313.0,,B,,,Autocuration,CHEMBL616841,1.0,,,2043.0,,H,BAO_0000357,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,105.0,
8.0,13313.0,,B,,,Autocuration,CHEMBL616842,1.0,,,2044.0,,H,BAO_0000357,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,105.0,
8.0,12409.0,,B,,,Expert,CHEMBL857976,1.0,,,2045.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,105.0,
8.0,15250.0,,B,,,Autocuration,CHEMBL616843,1.0,,,2046.0,,H,BAO_0000219,CHO,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,10618.0,449.0
9.0,1348.0,,B,,,Expert,CHEMBL616844,1.0,,,2047.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,10618.0,
8.0,1348.0,,B,,,Autocuration,CHEMBL616845,1.0,,,2048.0,,H,BAO_0000357,,,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,10618.0,
9.0,4234.0,,B,,,Expert,CHEMBL616846,1.0,,,2049.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,10618.0,
8.0,16209.0,,B,,,Autocuration,CHEMBL616847,1.0,,,2050.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,10618.0,
8.0,10444.0,,B,,,Autocuration,CHEMBL616848,1.0,,,2051.0,,H,BAO_0000019,,,,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,10618.0,
8.0,3935.0,,B,,,Autocuration,CHEMBL616849,1.0,,,2052.0,,H,BAO_0000357,,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,10618.0,
8.0,15818.0,,B,,,Autocuration,CHEMBL872911,1.0,,,2053.0,,H,BAO_0000357,,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,10618.0,
8.0,17085.0,,B,,,Autocuration,CHEMBL616850,1.0,,,2054.0,,H,BAO_0000019,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,10618.0,
9.0,12936.0,,B,,,Expert,CHEMBL616699,1.0,,,2055.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,10618.0,449.0
8.0,6166.0,,B,,,Autocuration,CHEMBL616700,1.0,,,2056.0,,H,BAO_0000357,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,10618.0,
8.0,15779.0,,B,,,Autocuration,CHEMBL616701,1.0,,,2057.0,,H,BAO_0000219,CHO,,,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,10618.0,449.0
8.0,15779.0,,B,,,Autocuration,CHEMBL616702,1.0,,,2058.0,,H,BAO_0000219,CHO,,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,10618.0,449.0
8.0,15779.0,,B,,,Autocuration,CHEMBL616703,1.0,,,2059.0,,H,BAO_0000219,CHO,,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,10618.0,449.0
8.0,13181.0,,B,,,Autocuration,CHEMBL616704,1.0,,,2060.0,,H,BAO_0000357,,,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,10618.0,
8.0,4199.0,,B,,,Autocuration,CHEMBL616705,1.0,,,2061.0,,H,BAO_0000219,CHO,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,10618.0,449.0
8.0,14875.0,,B,,,Autocuration,CHEMBL616706,1.0,,,2062.0,,H,BAO_0000357,,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,10618.0,
8.0,15146.0,,B,,,Autocuration,CHEMBL616707,1.0,,,2063.0,,H,BAO_0000219,CHO,,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,10618.0,449.0
8.0,5213.0,,B,,,Autocuration,CHEMBL616708,1.0,,,2064.0,,H,BAO_0000357,,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,10618.0,
8.0,12146.0,,B,,,Autocuration,CHEMBL616709,1.0,,,2065.0,,H,BAO_0000357,,,,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,10618.0,
8.0,13267.0,,B,,,Autocuration,CHEMBL616710,1.0,,,2066.0,,H,BAO_0000219,CHO,,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,10618.0,449.0
8.0,14818.0,,B,,,Autocuration,CHEMBL616711,1.0,,,2067.0,,H,BAO_0000219,CHO,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,10618.0,449.0
8.0,4829.0,,B,,,Autocuration,CHEMBL616712,1.0,,,2068.0,,H,BAO_0000219,CHO,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,10618.0,449.0
8.0,4373.0,,B,,,Autocuration,CHEMBL616713,1.0,,,2069.0,,H,BAO_0000357,,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,10618.0,
8.0,4373.0,,B,,,Autocuration,CHEMBL616714,1.0,,,2070.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,10618.0,
8.0,14159.0,,B,,,Autocuration,CHEMBL616715,1.0,,,2071.0,,H,BAO_0000357,,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,10618.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL616716,1.0,,,2072.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 1E receptor,,10618.0,
8.0,17085.0,,F,,,Autocuration,CHEMBL616717,1.0,,,2073.0,,H,BAO_0000019,,,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,279.0,
8.0,17085.0,,F,,,Expert,CHEMBL616718,1.0,,,2074.0,,H,BAO_0000019,,,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,279.0,
8.0,16209.0,,F,,,Autocuration,CHEMBL875905,1.0,,,2075.0,,H,BAO_0000019,,,,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,279.0,
8.0,16209.0,,F,,,Autocuration,CHEMBL616719,1.0,,,2076.0,,H,BAO_0000019,,,,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,279.0,
8.0,17085.0,,F,,,Expert,CHEMBL616720,1.0,,,2077.0,,H,BAO_0000019,,,,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,279.0,
8.0,14159.0,,B,,,Autocuration,CHEMBL616721,1.0,,,2078.0,,H,BAO_0000357,,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,279.0,
8.0,15250.0,,B,,,Autocuration,CHEMBL616722,1.0,,,2079.0,,H,BAO_0000219,CHO,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,279.0,449.0
8.0,3805.0,,B,,,Autocuration,CHEMBL616723,1.0,,,2080.0,,H,BAO_0000357,,,,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,279.0,
8.0,16190.0,,B,,,Autocuration,CHEMBL616724,1.0,,,2081.0,,H,BAO_0000219,CHO,,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,279.0,449.0
8.0,16190.0,,B,,,Autocuration,CHEMBL616725,1.0,,,2082.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,279.0,
8.0,16209.0,,B,,,Autocuration,CHEMBL616726,1.0,,,2083.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,279.0,
8.0,16209.0,,B,,,Autocuration,CHEMBL616727,1.0,,,2084.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,279.0,
8.0,16209.0,,B,,,Autocuration,CHEMBL616728,1.0,,,2085.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,279.0,
8.0,6866.0,,B,,,Autocuration,CHEMBL616729,1.0,,,2086.0,,H,BAO_0000357,,,,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,279.0,
8.0,17085.0,,B,,,Expert,CHEMBL616730,1.0,,,2087.0,,H,BAO_0000019,,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,279.0,
8.0,16312.0,,B,,,Autocuration,CHEMBL617125,1.0,,,2088.0,,H,BAO_0000357,,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,279.0,
8.0,6166.0,,B,,,Autocuration,CHEMBL857977,1.0,,,2089.0,,H,BAO_0000357,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,279.0,
8.0,15779.0,,B,,,Autocuration,CHEMBL617126,1.0,,,2090.0,,H,BAO_0000219,CHO,,,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,279.0,449.0
8.0,4199.0,,B,,,Autocuration,CHEMBL617127,1.0,,,2091.0,,H,BAO_0000219,CHO,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,279.0,449.0
8.0,14875.0,,B,,,Autocuration,CHEMBL617128,1.0,,,2092.0,,H,BAO_0000357,,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,279.0,
8.0,15146.0,,B,,,Autocuration,CHEMBL617129,1.0,,,2093.0,,H,BAO_0000219,CHO,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,279.0,449.0
8.0,5213.0,,B,,,Autocuration,CHEMBL617130,1.0,,,2094.0,,H,BAO_0000357,,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,279.0,
8.0,14818.0,,B,,,Autocuration,CHEMBL617131,1.0,,,2095.0,,H,BAO_0000219,CHO,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,279.0,449.0
8.0,4829.0,,B,,,Autocuration,CHEMBL617132,1.0,,,2096.0,,H,BAO_0000219,CHO,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,279.0,449.0
8.0,4829.0,,B,,,Autocuration,CHEMBL617133,1.0,,,2097.0,,H,BAO_0000219,CHO,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,279.0,449.0
8.0,4373.0,,B,,,Autocuration,CHEMBL617134,1.0,,,2098.0,,H,BAO_0000357,,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,279.0,
8.0,4373.0,,B,,,Autocuration,CHEMBL617135,1.0,,,2099.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,279.0,
8.0,5014.0,,B,,,Autocuration,CHEMBL617136,1.0,,,2100.0,,H,BAO_0000357,,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,279.0,
4.0,11662.0,,B,,,Autocuration,CHEMBL617137,1.0,,,2101.0,,H,BAO_0000019,,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,104686.0,
4.0,11662.0,,B,,,Autocuration,CHEMBL617138,1.0,,,2102.0,,H,BAO_0000019,,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,104686.0,
4.0,11662.0,,B,,,Autocuration,CHEMBL617139,1.0,,,2103.0,,H,BAO_0000019,,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,104686.0,
8.0,14093.0,,B,,,Autocuration,CHEMBL617140,1.0,,,2104.0,,H,BAO_0000019,,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,12687.0,
4.0,11200.0,,F,,,Autocuration,CHEMBL617141,1.0,,,2105.0,In vivo,H,BAO_0000218,,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,104686.0,
4.0,11200.0,,F,,,Autocuration,CHEMBL858112,1.0,,,2106.0,,H,BAO_0000019,,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,104686.0,
8.0,12352.0,,B,,,Intermediate,CHEMBL617142,1.0,,,2107.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,17005.0,
0.0,13657.0,,B,,,Autocuration,CHEMBL617143,1.0,,,2108.0,,U,BAO_0000019,,9913.0,,Bos taurus,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,22226.0,
0.0,14331.0,,B,,,Autocuration,CHEMBL617144,1.0,,,2109.0,,U,BAO_0000019,,9913.0,,Bos taurus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,22226.0,
0.0,14331.0,,B,,,Autocuration,CHEMBL617145,1.0,,,2110.0,,U,BAO_0000019,,9913.0,,Bos taurus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,22226.0,
0.0,14331.0,,B,,,Autocuration,CHEMBL617146,1.0,,,2111.0,,U,BAO_0000019,,,,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,22226.0,
4.0,12685.0,,B,,,Autocuration,CHEMBL617147,1.0,,,2112.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,104784.0,
4.0,14389.0,,B,,,Autocuration,CHEMBL617148,1.0,,,2113.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,104784.0,
4.0,14386.0,,B,,,Autocuration,CHEMBL617149,1.0,,,2114.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,104784.0,
4.0,5732.0,,B,,,Autocuration,CHEMBL617150,1.0,,,2115.0,,H,BAO_0000224,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,104784.0,
4.0,16293.0,,B,,,Autocuration,CHEMBL617151,1.0,,,2116.0,,H,BAO_0000224,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,104784.0,
4.0,2078.0,,B,,,Autocuration,CHEMBL617201,1.0,,,2117.0,,H,BAO_0000224,,,,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,104784.0,
8.0,5486.0,,B,,,Autocuration,CHEMBL617202,1.0,,,2118.0,,H,BAO_0000357,,,,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,10209.0,
4.0,11820.0,,B,,,Autocuration,CHEMBL617203,1.0,,,2119.0,In vivo,H,BAO_0000218,,,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,104826.0,
4.0,10297.0,,B,,,Autocuration,CHEMBL617204,1.0,,,2120.0,,H,BAO_0000019,,,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,104826.0,
4.0,13704.0,,B,,,Autocuration,CHEMBL617205,1.0,,,2121.0,,H,BAO_0000224,,,,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,104826.0,
5.0,10297.0,,B,,,Autocuration,CHEMBL617206,1.0,,,2122.0,,D,BAO_0000019,,10090.0,,Mus musculus,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,104826.0,
4.0,11820.0,,B,,,Autocuration,CHEMBL617207,1.0,,,2123.0,In vivo,H,BAO_0000218,,,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,104826.0,
5.0,10297.0,,B,,,Autocuration,CHEMBL617208,1.0,,,2124.0,,D,BAO_0000019,,10090.0,,Mus musculus,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,104826.0,
4.0,11555.0,,B,,,Autocuration,CHEMBL617209,1.0,,,2125.0,,H,BAO_0000224,,,,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,104826.0,
4.0,11555.0,,B,,,Autocuration,CHEMBL617210,1.0,,,2126.0,,H,BAO_0000224,,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,104826.0,
4.0,11555.0,,B,,,Autocuration,CHEMBL617211,1.0,,,2127.0,,H,BAO_0000224,,,,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,104826.0,
5.0,10297.0,,B,,,Autocuration,CHEMBL617212,1.0,,,2128.0,,D,BAO_0000019,,10090.0,,Mus musculus,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,104826.0,
4.0,16688.0,,B,,,Autocuration,CHEMBL617213,1.0,,,2129.0,,H,BAO_0000224,,9823.0,,Sus scrofa,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,104784.0,
4.0,16688.0,,B,,,Autocuration,CHEMBL617214,1.0,,,2130.0,,H,BAO_0000224,,9823.0,,Sus scrofa,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,104784.0,
0.0,5333.0,,B,,,Autocuration,CHEMBL617215,1.0,,,2131.0,,U,BAO_0000221,,,,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,22226.0,
0.0,4437.0,,B,,,Autocuration,CHEMBL617216,1.0,,,2132.0,,U,BAO_0000221,,,,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,22226.0,
8.0,5033.0,,B,,,Autocuration,CHEMBL617217,1.0,,,2133.0,,H,BAO_0000357,,9823.0,,Sus scrofa,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,17005.0,
4.0,15267.0,,B,,,Autocuration,CHEMBL617218,1.0,,,2134.0,,H,BAO_0000019,,,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,15267.0,,B,,,Autocuration,CHEMBL872913,1.0,,,2135.0,,H,BAO_0000019,,,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,11820.0,,B,,,Autocuration,CHEMBL617219,1.0,,,2136.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,104826.0,
4.0,9069.0,,B,,,Autocuration,CHEMBL873482,1.0,,,2137.0,,H,BAO_0000224,,,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,104686.0,
5.0,9162.0,,B,,,Autocuration,CHEMBL617220,1.0,,,2138.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,104686.0,
4.0,9162.0,,B,,,Autocuration,CHEMBL617221,1.0,,,2139.0,,H,BAO_0000019,,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,104686.0,
4.0,9162.0,,B,,,Autocuration,CHEMBL617222,1.0,,,2140.0,,H,BAO_0000019,,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,104686.0,
4.0,10428.0,,F,,,Autocuration,CHEMBL875906,1.0,,,2141.0,,H,BAO_0000019,,,,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,104686.0,
4.0,9628.0,,B,,,Autocuration,CHEMBL617223,1.0,,,2142.0,,H,BAO_0000019,,,,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,104686.0,
4.0,12704.0,,B,,,Autocuration,CHEMBL617224,1.0,,,2143.0,,H,BAO_0000224,,,,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,104686.0,
5.0,15453.0,,B,,,Autocuration,CHEMBL617225,1.0,,,2144.0,,D,BAO_0000224,,10116.0,,Rattus norvegicus,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,104686.0,
4.0,188.0,,B,,,Autocuration,CHEMBL617226,1.0,,,2145.0,,H,BAO_0000224,,,,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,104686.0,
4.0,10349.0,,B,,,Autocuration,CHEMBL617227,1.0,,,2146.0,,H,BAO_0000224,,,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,104686.0,
4.0,10349.0,,B,,,Autocuration,CHEMBL617228,1.0,,,2147.0,,H,BAO_0000224,,,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,104686.0,
4.0,8868.0,,B,,,Autocuration,CHEMBL617229,1.0,,,2148.0,,H,BAO_0000224,,,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,104686.0,
4.0,10025.0,,B,,,Autocuration,CHEMBL617230,1.0,,,2149.0,,H,BAO_0000224,,,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,104686.0,
4.0,10025.0,,B,,,Autocuration,CHEMBL617231,1.0,,,2150.0,,H,BAO_0000224,,,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,104686.0,
4.0,11702.0,,B,,,Autocuration,CHEMBL617232,1.0,,,2151.0,,H,BAO_0000224,,,,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,104686.0,
4.0,11702.0,,B,,,Autocuration,CHEMBL617233,1.0,,,2152.0,,H,BAO_0000224,,,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,11702.0,,B,,,Autocuration,CHEMBL617234,1.0,,,2153.0,,H,BAO_0000224,,,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,104686.0,
4.0,11702.0,,F,,,Autocuration,CHEMBL617235,1.0,,,2154.0,,H,BAO_0000019,,,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,,104686.0,
4.0,11702.0,,F,,,Autocuration,CHEMBL617236,1.0,,,2155.0,,H,BAO_0000019,,,,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,104686.0,
4.0,10085.0,10000000.0,B,,,Autocuration,CHEMBL617237,1.0,Hippocampus,,2156.0,,H,BAO_0000221,,,,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,104686.0,
4.0,10085.0,10000000.0,B,,,Autocuration,CHEMBL617238,1.0,Hippocampus,,2157.0,,H,BAO_0000221,,,,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,104686.0,
5.0,9630.0,955.0,B,,,Autocuration,CHEMBL617239,1.0,Brain,,2158.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,104686.0,
4.0,11070.0,,B,,,Autocuration,CHEMBL617240,1.0,,,2159.0,,H,BAO_0000019,,,,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,104686.0,
4.0,9841.0,,B,Membranes,,Autocuration,CHEMBL617241,1.0,,,2160.0,,H,BAO_0000249,,,,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,104686.0,
4.0,9841.0,,B,Membranes,,Autocuration,CHEMBL875907,1.0,,,2161.0,,H,BAO_0000249,,,,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,104686.0,
4.0,13291.0,,B,,,Autocuration,CHEMBL617242,1.0,,,2162.0,,H,BAO_0000019,,,,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,104686.0,
4.0,10590.0,,F,,,Autocuration,CHEMBL617152,1.0,,,2163.0,,H,BAO_0000019,,,,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,104686.0,
5.0,9064.0,955.0,B,,,Autocuration,CHEMBL617153,1.0,Brain,,2164.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,104686.0,
5.0,12268.0,,B,Membranes,,Autocuration,CHEMBL617154,1.0,,,2165.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,104686.0,
4.0,13508.0,955.0,B,,,Autocuration,CHEMBL617155,1.0,Brain,,2166.0,,H,BAO_0000221,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,104686.0,
4.0,11279.0,,F,,,Autocuration,CHEMBL617156,1.0,,,2167.0,,H,BAO_0000019,,,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,104686.0,
4.0,11200.0,,F,,,Autocuration,CHEMBL617157,1.0,,,2168.0,,H,BAO_0000019,,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,104686.0,
4.0,11200.0,,F,,,Autocuration,CHEMBL617158,1.0,,,2169.0,,H,BAO_0000019,,,,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,104686.0,
4.0,11200.0,,F,,,Autocuration,CHEMBL617159,1.0,,,2170.0,,H,BAO_0000019,,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,104686.0,
4.0,11200.0,,F,,,Autocuration,CHEMBL617160,1.0,,,2171.0,,H,BAO_0000019,,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,104686.0,
4.0,11200.0,,F,,,Autocuration,CHEMBL858113,1.0,,,2172.0,,H,BAO_0000019,,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,104686.0,
4.0,9231.0,955.0,B,,,Autocuration,CHEMBL617247,1.0,Brain,,2173.0,,H,BAO_0000220,,,,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,104686.0,
4.0,9737.0,,B,,,Autocuration,CHEMBL617248,1.0,,,2174.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,104686.0,
4.0,9737.0,955.0,B,,,Autocuration,CHEMBL617249,1.0,Brain,,2175.0,,H,BAO_0000249,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,104686.0,
4.0,9737.0,,B,,,Autocuration,CHEMBL617250,1.0,,,2176.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,104686.0,
4.0,9737.0,,B,,,Autocuration,CHEMBL617251,1.0,,,2177.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,104686.0,
5.0,11828.0,,B,,,Autocuration,CHEMBL617252,1.0,,,2178.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,12253.0,,B,,,Autocuration,CHEMBL617006,1.0,,,2179.0,,H,BAO_0000019,,,,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,104686.0,
4.0,12253.0,,B,,,Autocuration,CHEMBL617007,1.0,,,2180.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,104686.0,
4.0,11279.0,,F,,,Autocuration,CHEMBL617008,1.0,,,2181.0,,H,BAO_0000019,,,,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,104686.0,
4.0,11866.0,,B,,,Autocuration,CHEMBL617009,1.0,,,2182.0,,H,BAO_0000019,,,,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,104686.0,
5.0,14424.0,,B,,,Autocuration,CHEMBL617010,1.0,,,2183.0,,D,BAO_0000224,,10116.0,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,104686.0,
5.0,15180.0,,B,,,Autocuration,CHEMBL857978,1.0,,,2184.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,104686.0,
5.0,15180.0,,B,,,Autocuration,CHEMBL617011,1.0,,,2185.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,104686.0,
5.0,9786.0,,B,,,Autocuration,CHEMBL617012,1.0,,,2186.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,104686.0,
4.0,12132.0,,B,,,Autocuration,CHEMBL617013,1.0,,,2187.0,,H,BAO_0000224,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,104686.0,
4.0,5486.0,,B,,,Autocuration,CHEMBL617014,1.0,,,2188.0,,H,BAO_0000249,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,104686.0,
4.0,15316.0,,B,,,Autocuration,CHEMBL617015,1.0,,,2189.0,,H,BAO_0000019,,,,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,16429.0,,B,,,Autocuration,CHEMBL617016,1.0,,,2190.0,,H,BAO_0000019,,,,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,104686.0,
4.0,14617.0,,B,,,Autocuration,CHEMBL617017,1.0,,,2191.0,,H,BAO_0000224,,,,,pKi value for 5-hydroxytryptamine 2 receptor binding site,,104686.0,
4.0,11351.0,955.0,B,,,Autocuration,CHEMBL617018,1.0,Brain,,2192.0,,H,BAO_0000221,,,,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,104686.0,
4.0,11279.0,,F,,,Autocuration,CHEMBL617019,1.0,,,2193.0,,H,BAO_0000019,,,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,104686.0,
4.0,9523.0,,B,,,Autocuration,CHEMBL617020,1.0,,,2194.0,,H,BAO_0000019,,,,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,105075.0,
4.0,9523.0,,B,,,Autocuration,CHEMBL617021,1.0,,,2195.0,,H,BAO_0000019,,,,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,105075.0,
4.0,9523.0,,B,,,Autocuration,CHEMBL617022,1.0,,,2196.0,,H,BAO_0000019,,,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,105075.0,
4.0,9523.0,,B,,,Autocuration,CHEMBL617023,1.0,,,2197.0,,H,BAO_0000019,,,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,105075.0,
4.0,9523.0,,B,,,Autocuration,CHEMBL617024,1.0,,,2198.0,,H,BAO_0000019,,,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,105075.0,
4.0,9523.0,,B,,,Autocuration,CHEMBL617025,1.0,,,2199.0,,H,BAO_0000019,,,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,105075.0,
4.0,9523.0,,B,,,Autocuration,CHEMBL617026,1.0,,,2200.0,,H,BAO_0000224,,,,,Hill coefficient of compound was determined,,105075.0,
0.0,4771.0,,B,,,Autocuration,CHEMBL617027,1.0,,,2201.0,,U,BAO_0000019,,,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,22226.0,
5.0,5033.0,,B,,,Autocuration,CHEMBL617028,1.0,,,2202.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,104686.0,
8.0,10845.0,,B,,,Expert,CHEMBL617029,1.0,,,2203.0,,H,BAO_0000019,,,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,12687.0,
8.0,10845.0,,B,,,Expert,CHEMBL875908,1.0,,,2204.0,,H,BAO_0000019,,,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,12687.0,
8.0,16288.0,,B,,,Autocuration,CHEMBL617030,1.0,,,2205.0,,H,BAO_0000357,,,,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,12687.0,
8.0,16288.0,,B,,,Autocuration,CHEMBL617031,1.0,,,2206.0,,H,BAO_0000019,,,,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,12687.0,
8.0,16190.0,,B,,,Autocuration,CHEMBL617032,1.0,,,2207.0,,H,BAO_0000019,,,,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,12687.0,
5.0,12463.0,,B,,,Autocuration,CHEMBL617033,1.0,,,2208.0,,D,BAO_0000224,,10116.0,,Rattus norvegicus,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,104686.0,
4.0,9699.0,,B,,,Autocuration,CHEMBL617034,1.0,,,2209.0,,H,BAO_0000224,,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,104686.0,
4.0,9699.0,,B,,,Autocuration,CHEMBL617035,1.0,,,2210.0,,H,BAO_0000224,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,104686.0,
4.0,11662.0,,B,,,Autocuration,CHEMBL617036,1.0,,,2211.0,,H,BAO_0000019,,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,104686.0,
4.0,1205.0,,B,,,Autocuration,CHEMBL617037,1.0,,,2212.0,,H,BAO_0000224,,,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,104784.0,
0.0,11376.0,,B,,,Autocuration,CHEMBL617038,1.0,,,2213.0,,U,BAO_0000219,,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,22226.0,
4.0,11376.0,,B,,,Autocuration,CHEMBL617039,1.0,,,2214.0,,H,BAO_0000219,,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,104784.0,
4.0,4639.0,,B,,,Autocuration,CHEMBL617161,1.0,,,2215.0,,H,BAO_0000224,,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,104784.0,
4.0,2222.0,,B,,,Autocuration,CHEMBL617162,1.0,,,2216.0,,H,BAO_0000224,,,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,104784.0,
4.0,1558.0,,B,,,Autocuration,CHEMBL617163,1.0,,,2217.0,,H,BAO_0000224,,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,104784.0,
4.0,1089.0,,B,,,Autocuration,CHEMBL617164,1.0,,,2218.0,,H,BAO_0000224,,,,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,104784.0,
4.0,386.0,,B,Brain membranes,,Autocuration,CHEMBL617165,1.0,,,2219.0,,H,BAO_0000249,,,,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,104784.0,
4.0,2474.0,,B,,,Autocuration,CHEMBL617166,1.0,,,2220.0,,H,BAO_0000224,,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,104784.0,
4.0,17066.0,,B,,,Autocuration,CHEMBL617167,1.0,,,2221.0,,H,BAO_0000224,,,,,Binding affinity towards 5-HT2 receptor,,104784.0,
4.0,959.0,,B,,,Autocuration,CHEMBL872912,1.0,,,2222.0,,H,BAO_0000224,,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,104784.0,
4.0,6398.0,,B,,,Autocuration,CHEMBL617168,1.0,,,2223.0,,H,BAO_0000224,,,,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,104784.0,
4.0,11889.0,,B,,,Autocuration,CHEMBL617169,1.0,,,2224.0,,H,BAO_0000224,,,,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,104686.0,
4.0,4221.0,,B,,,Autocuration,CHEMBL617170,1.0,,,2225.0,,H,BAO_0000224,,,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,104784.0,
4.0,11026.0,,B,,,Autocuration,CHEMBL617171,1.0,,,2226.0,,H,BAO_0000224,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,104784.0,
4.0,11866.0,,B,,,Autocuration,CHEMBL617172,1.0,,,2227.0,,H,BAO_0000224,,,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,104784.0,
4.0,4221.0,,B,,,Autocuration,CHEMBL617173,1.0,,,2228.0,,H,BAO_0000224,,,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,104784.0,
0.0,13950.0,,B,,,Autocuration,CHEMBL617174,1.0,,,2229.0,,U,BAO_0000019,,,,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,22226.0,
4.0,1263.0,,B,,,Autocuration,CHEMBL617175,1.0,,,2230.0,,H,BAO_0000224,,,,,5-hydroxytryptamine 2 receptor binding affinity,,104784.0,
8.0,13291.0,,B,,,Autocuration,CHEMBL617176,1.0,,,2231.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,17005.0,
8.0,10812.0,,B,,,Autocuration,CHEMBL617177,1.0,,,2232.0,,H,BAO_0000357,,,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,17005.0,
4.0,13020.0,,B,,,Autocuration,CHEMBL617178,1.0,,,2233.0,,H,BAO_0000224,,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,104784.0,
4.0,13021.0,,B,,,Autocuration,CHEMBL617179,1.0,,,2234.0,,H,BAO_0000224,,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,104784.0,
4.0,13020.0,,B,,,Autocuration,CHEMBL617180,1.0,,,2235.0,,H,BAO_0000224,,,,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,104784.0,
8.0,14532.0,,B,,,Autocuration,CHEMBL617181,1.0,,,2236.0,,H,BAO_0000357,,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,17005.0,
8.0,13944.0,,B,,,Autocuration,CHEMBL617182,1.0,,,2237.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor,,17005.0,
8.0,14331.0,,B,,,Autocuration,CHEMBL617183,1.0,,,2238.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor,,17005.0,
8.0,14118.0,,B,,,Autocuration,CHEMBL617184,1.0,,,2239.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,17005.0,
8.0,13033.0,,B,,,Autocuration,CHEMBL617185,1.0,,,2240.0,,H,BAO_0000357,,,,,Binding affinity against serotonergic 5-HT2 receptor,,17005.0,
8.0,10321.0,,B,,,Autocuration,CHEMBL617186,1.0,,,2241.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,17005.0,
8.0,12918.0,,B,,,Autocuration,CHEMBL617187,1.0,,,2242.0,,H,BAO_0000357,,,,,Compound was evaluated for the binding affinity at 5- HT2 receptor,,17005.0,
8.0,15120.0,,B,,,Autocuration,CHEMBL617188,1.0,,,2243.0,,H,BAO_0000357,,,,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,17005.0,
8.0,2613.0,,B,,,Autocuration,CHEMBL617189,1.0,,,2244.0,,H,BAO_0000218,,,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,17005.0,
5.0,13378.0,,B,,,Autocuration,CHEMBL617190,1.0,,,2245.0,,D,BAO_0000224,,9606.0,,Homo sapiens,Inhibitory activity against cloned human 5-HT2 receptor,,104784.0,
5.0,2331.0,,B,,,Autocuration,CHEMBL617191,1.0,,,2246.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,104784.0,449.0
5.0,2331.0,,B,,,Autocuration,CHEMBL617192,1.0,,,2247.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,104784.0,449.0
5.0,2331.0,,B,,,Autocuration,CHEMBL617193,1.0,,,2248.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,104784.0,449.0
5.0,2331.0,,B,,,Autocuration,CHEMBL617194,1.0,,,2249.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,104784.0,449.0
4.0,4170.0,,B,,,Autocuration,CHEMBL617195,1.0,,,2250.0,,H,BAO_0000224,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,104784.0,
4.0,15453.0,,B,,,Autocuration,CHEMBL881830,1.0,,,2251.0,,H,BAO_0000224,,,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,104784.0,
8.0,1479.0,,B,,,Autocuration,CHEMBL617196,1.0,,,2252.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,17005.0,
4.0,11139.0,,B,,,Autocuration,CHEMBL617197,1.0,,,2253.0,,H,BAO_0000224,,,,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,104686.0,
8.0,13969.0,,B,,,Expert,CHEMBL617198,1.0,,,2254.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,17005.0,
8.0,13392.0,,B,,,Expert,CHEMBL873476,1.0,,,2255.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,17005.0,
8.0,14430.0,,B,,,Expert,CHEMBL617199,1.0,,,2256.0,,H,BAO_0000019,,,,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,17005.0,
8.0,13181.0,,B,,,Autocuration,CHEMBL617200,1.0,,,2257.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,107.0,
8.0,17200.0,,B,,,Autocuration,CHEMBL617484,1.0,,,2258.0,,H,BAO_0000357,,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,51.0,
8.0,17200.0,,B,,,Autocuration,CHEMBL617485,1.0,,,2259.0,,H,BAO_0000357,,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,107.0,
8.0,17200.0,,B,,,Autocuration,CHEMBL617486,1.0,,,2260.0,,H,BAO_0000357,,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,51.0,
8.0,13463.0,,B,,,Autocuration,CHEMBL858022,1.0,,,2261.0,,H,BAO_0000357,,,,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,107.0,
8.0,6347.0,,B,,,Autocuration,CHEMBL617049,1.0,,,2262.0,,H,BAO_0000219,CHO,,,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,107.0,449.0
9.0,6857.0,,F,,,Expert,CHEMBL617050,1.0,,,2263.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,107.0,449.0
8.0,4176.0,,F,,,Autocuration,CHEMBL617051,1.0,,,2264.0,,H,BAO_0000219,,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,107.0,
8.0,4176.0,,F,,,Autocuration,CHEMBL617052,1.0,,,2265.0,,H,BAO_0000219,,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,107.0,
8.0,4176.0,,F,,,Autocuration,CHEMBL617053,1.0,,,2266.0,,H,BAO_0000219,,,,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,107.0,
8.0,6347.0,,B,,,Autocuration,CHEMBL617054,1.0,,,2267.0,,H,BAO_0000219,CHO,,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,107.0,449.0
8.0,6347.0,,B,,,Autocuration,CHEMBL617055,1.0,,,2268.0,,H,BAO_0000219,CHO,,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,107.0,449.0
8.0,15331.0,,B,,,Autocuration,CHEMBL882924,1.0,,,2269.0,,H,BAO_0000357,,,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,107.0,
9.0,16146.0,,B,,,Expert,CHEMBL617056,1.0,,,2270.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Inhibition of human 5-hydroxytryptamine 2A receptor,,107.0,
8.0,15250.0,,B,,,Autocuration,CHEMBL617057,1.0,,,2271.0,,H,BAO_0000219,CHO,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,107.0,449.0
8.0,13631.0,,B,,,Expert,CHEMBL617058,1.0,,,2272.0,,H,BAO_0000219,,,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,107.0,
8.0,3805.0,,B,,,Autocuration,CHEMBL617059,1.0,,,2273.0,,H,BAO_0000357,,,,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,107.0,
8.0,4011.0,,B,,,Autocuration,CHEMBL617060,1.0,,,2274.0,,H,BAO_0000219,CHO,,,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,107.0,449.0
8.0,4012.0,,B,,,Expert,CHEMBL617061,1.0,,,2275.0,,H,BAO_0000219,CHO,,,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,107.0,449.0
8.0,6366.0,,B,,,Expert,CHEMBL617062,1.0,,,2276.0,,H,BAO_0000219,L929,,,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,107.0,307.0
8.0,15949.0,,B,,,Expert,CHEMBL617063,1.0,,,2277.0,,H,BAO_0000219,CHO,,,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,107.0,449.0
8.0,14093.0,,F,,,Autocuration,CHEMBL617064,1.0,,,2278.0,,H,BAO_0000019,,,,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,107.0,
8.0,13481.0,,F,,,Autocuration,CHEMBL617065,1.0,,,2279.0,,H,BAO_0000019,,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,107.0,
8.0,6347.0,,B,,,Autocuration,CHEMBL617066,1.0,,,2280.0,,H,BAO_0000219,CHO,,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,107.0,449.0
8.0,6347.0,,B,,,Autocuration,CHEMBL617067,1.0,,,2281.0,,H,BAO_0000219,CHO,,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,107.0,449.0
8.0,14093.0,,F,,,Autocuration,CHEMBL617068,1.0,,,2282.0,,H,BAO_0000019,,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,107.0,
8.0,14093.0,,F,,,Autocuration,CHEMBL617069,1.0,,,2283.0,,H,BAO_0000019,,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,107.0,
8.0,13481.0,,F,,,Autocuration,CHEMBL617070,1.0,,,2284.0,,H,BAO_0000019,,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,107.0,
8.0,14442.0,,B,,,Autocuration,CHEMBL617071,1.0,,,2285.0,,H,BAO_0000357,,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,107.0,
8.0,14442.0,,B,,,Autocuration,CHEMBL872915,1.0,,,2286.0,,H,BAO_0000357,,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,107.0,
8.0,14755.0,,B,,,Autocuration,CHEMBL617072,1.0,,,2287.0,,H,BAO_0000357,,,,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,107.0,
8.0,16441.0,,B,,,Autocuration,CHEMBL617073,1.0,,,2288.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,107.0,
8.0,14744.0,,B,,,Autocuration,CHEMBL617074,1.0,,,2289.0,,H,BAO_0000357,,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,107.0,
8.0,16659.0,,B,,,Expert,CHEMBL617075,1.0,,,2290.0,,H,BAO_0000219,CHO,,,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,107.0,449.0
8.0,3307.0,,B,,,Autocuration,CHEMBL617076,1.0,,,2291.0,,H,BAO_0000357,,,,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,107.0,
9.0,6857.0,,B,,,Expert,CHEMBL617077,1.0,,,2292.0,,D,BAO_0000019,,9606.0,,Homo sapiens,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,107.0,
8.0,5635.0,,B,,,Expert,CHEMBL617078,1.0,,,2293.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,107.0,
9.0,4234.0,,B,,,Expert,CHEMBL617079,1.0,,,2294.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,107.0,
8.0,15527.0,,B,,,Autocuration,CHEMBL617080,1.0,,,2295.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,107.0,
8.0,6588.0,,B,,,Expert,CHEMBL617081,1.0,,,2296.0,,H,BAO_0000219,CHO,,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,107.0,449.0
8.0,13631.0,,B,,,Expert,CHEMBL617082,1.0,,,2297.0,,H,BAO_0000219,,,,,Binding affinity towards human 5-HT2A receptor in BEK cells,,107.0,
8.0,17723.0,,B,,,Autocuration,CHEMBL617083,1.0,,,2298.0,,H,BAO_0000357,,,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,107.0,
8.0,14770.0,,B,,,Autocuration,CHEMBL617084,1.0,,,2299.0,,H,BAO_0000357,,,,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,107.0,
9.0,16293.0,,B,,,Expert,CHEMBL617085,1.0,,,2300.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 2A receptor,,107.0,
8.0,16209.0,,B,,,Autocuration,CHEMBL617086,1.0,,,2301.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,107.0,
8.0,12469.0,,B,,,Autocuration,CHEMBL617087,1.0,,,2302.0,,H,BAO_0000219,,,,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,107.0,
8.0,15363.0,,B,,,Autocuration,CHEMBL617088,1.0,,,2303.0,,H,BAO_0000357,,,,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,107.0,
8.0,15363.0,,B,,,Autocuration,CHEMBL617089,1.0,,,2304.0,,H,BAO_0000357,,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,107.0,
8.0,16441.0,,B,,,Expert,CHEMBL617090,1.0,,,2305.0,,H,BAO_0000019,,,,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,107.0,
8.0,8.0,,B,,,Autocuration,CHEMBL617513,1.0,,,2306.0,,H,BAO_0000357,,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,107.0,
8.0,4176.0,,B,,,Autocuration,CHEMBL617514,1.0,,,2307.0,,H,BAO_0000219,HEK293,,,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,107.0,722.0
8.0,17085.0,,B,,,Autocuration,CHEMBL617515,1.0,,,2308.0,,H,BAO_0000019,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,107.0,
8.0,17200.0,,B,,,Autocuration,CHEMBL617516,1.0,,,2309.0,,H,BAO_0000357,,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,107.0,
9.0,17200.0,,B,,,Expert,CHEMBL617517,1.0,,,2310.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,107.0,
9.0,4013.0,,B,,,Expert,CHEMBL617518,1.0,,,2311.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,107.0,449.0
8.0,5088.0,,B,,,Autocuration,CHEMBL617519,1.0,,,2312.0,,H,BAO_0000357,,,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,107.0,
9.0,5088.0,,B,,,Expert,CHEMBL617520,1.0,,,2313.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,107.0,
8.0,5088.0,,B,,,Autocuration,CHEMBL617521,1.0,,,2314.0,,H,BAO_0000357,,,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,107.0,
9.0,5088.0,,B,,,Expert,CHEMBL617522,1.0,,,2315.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,107.0,
8.0,5088.0,,B,,,Autocuration,CHEMBL617523,1.0,,,2316.0,,H,BAO_0000357,,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,107.0,
8.0,5088.0,,B,,,Autocuration,CHEMBL617524,1.0,,,2317.0,,H,BAO_0000357,,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,107.0,
4.0,9786.0,,B,,,Autocuration,CHEMBL617525,1.0,,,2318.0,,H,BAO_0000019,,,,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,104686.0,
5.0,9205.0,,B,,,Autocuration,CHEMBL617526,1.0,,,2319.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,104686.0,
4.0,11257.0,,B,,,Autocuration,CHEMBL617527,1.0,,,2320.0,,H,BAO_0000224,,,,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,104686.0,
4.0,9362.0,,B,,,Autocuration,CHEMBL617528,1.0,,,2321.0,,H,BAO_0000019,,,,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,104686.0,
4.0,9362.0,,B,,,Autocuration,CHEMBL617529,1.0,,,2322.0,,H,BAO_0000019,,,,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,104686.0,
4.0,10590.0,,B,,,Autocuration,CHEMBL617530,1.0,,,2323.0,,H,BAO_0000224,,,,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,104686.0,
4.0,10468.0,,B,,,Autocuration,CHEMBL617531,1.0,,,2324.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,104686.0,
4.0,13050.0,,B,,,Autocuration,CHEMBL617532,1.0,,,2325.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,104686.0,
4.0,11624.0,,B,,,Autocuration,CHEMBL617533,1.0,,,2326.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,104686.0,
4.0,10468.0,,B,,,Autocuration,CHEMBL617534,1.0,,,2327.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,104686.0,
4.0,10330.0,,B,,,Autocuration,CHEMBL617535,1.0,,,2328.0,,H,BAO_0000224,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,104686.0,
4.0,10062.0,,B,,,Autocuration,CHEMBL617536,1.0,,,2329.0,,H,BAO_0000224,,,,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,104686.0,
4.0,11642.0,,B,,,Autocuration,CHEMBL617537,1.0,,,2330.0,,H,BAO_0000224,,,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,10062.0,,B,,,Autocuration,CHEMBL617538,1.0,,,2331.0,,H,BAO_0000224,,,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,13427.0,,B,,,Autocuration,CHEMBL617539,1.0,,,2332.0,In vitro,H,BAO_0000219,,,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,104686.0,
5.0,12280.0,,B,,,Autocuration,CHEMBL617540,1.0,,,2333.0,,D,BAO_0000224,,10116.0,,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,104686.0,
5.0,4101.0,,B,,,Autocuration,CHEMBL617541,1.0,,,2334.0,,D,BAO_0000224,,10116.0,,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,104686.0,
4.0,10062.0,,B,,,Autocuration,CHEMBL617542,1.0,,,2335.0,,H,BAO_0000224,,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,11147.0,,B,,,Autocuration,CHEMBL617543,1.0,,,2336.0,,H,BAO_0000224,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,104686.0,
5.0,2395.0,,B,,,Autocuration,CHEMBL617544,1.0,,,2337.0,,D,BAO_0000219,CHO-K1,10116.0,,Rattus norvegicus,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,104686.0,485.0
5.0,2395.0,,B,,,Autocuration,CHEMBL617545,1.0,,,2338.0,,D,BAO_0000219,CHO-K1,10116.0,,Rattus norvegicus,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,104686.0,485.0
5.0,9098.0,,B,,,Autocuration,CHEMBL617413,1.0,,,2339.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,104686.0,
4.0,9098.0,,B,,,Autocuration,CHEMBL617414,1.0,,,2340.0,,H,BAO_0000019,,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,104686.0,
5.0,9098.0,,B,,,Autocuration,CHEMBL617415,1.0,,,2341.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,104686.0,
4.0,9443.0,,B,,,Autocuration,CHEMBL617416,1.0,,,2342.0,,H,BAO_0000224,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,9443.0,,B,,,Autocuration,CHEMBL617417,1.0,,,2343.0,,H,BAO_0000224,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,104686.0,
4.0,9699.0,,B,,,Autocuration,CHEMBL617418,1.0,,,2344.0,,H,BAO_0000019,,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,104686.0,
4.0,9699.0,,B,,,Autocuration,CHEMBL617419,1.0,,,2345.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,104686.0,
4.0,9098.0,,B,,,Autocuration,CHEMBL617420,1.0,,,2346.0,,H,BAO_0000224,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,104686.0,
5.0,3070.0,,B,,,Autocuration,CHEMBL617421,1.0,,,2347.0,,D,BAO_0000224,,10116.0,,Rattus norvegicus,Affinity for 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,9547.0,,B,,,Autocuration,CHEMBL617422,1.0,,,2348.0,,H,BAO_0000224,,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,104686.0,
4.0,10444.0,,B,,,Autocuration,CHEMBL617423,1.0,,,2349.0,,H,BAO_0000019,,,,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,104686.0,
4.0,14617.0,,B,,,Autocuration,CHEMBL617424,1.0,,,2350.0,,H,BAO_0000019,,,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,104686.0,
4.0,14617.0,,B,,,Autocuration,CHEMBL617425,1.0,,,2351.0,,H,BAO_0000019,,,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,104686.0,
4.0,11130.0,,B,,,Autocuration,CHEMBL617426,1.0,,,2352.0,,H,BAO_0000224,,,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,104686.0,
4.0,11130.0,,B,,,Autocuration,CHEMBL617427,1.0,,,2353.0,In vivo,H,BAO_0000218,,,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,104686.0,
4.0,14542.0,955.0,B,,,Autocuration,CHEMBL617428,1.0,Brain,,2354.0,,H,BAO_0000221,,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,104686.0,
4.0,2797.0,,B,,,Autocuration,CHEMBL617429,1.0,,,2355.0,,H,BAO_0000224,,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,104686.0,
4.0,11332.0,,B,,,Autocuration,CHEMBL617430,1.0,,,2356.0,,H,BAO_0000019,,,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,104686.0,
4.0,11332.0,,B,,,Autocuration,CHEMBL617431,1.0,,,2357.0,,H,BAO_0000019,,,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,104686.0,
4.0,10752.0,1870.0,B,,,Autocuration,CHEMBL617432,1.0,Frontal cortex,,2358.0,,H,BAO_0000019,,,,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,104686.0,
4.0,1185.0,,B,,,Autocuration,CHEMBL617433,1.0,,,2359.0,,H,BAO_0000224,,,,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,1185.0,,B,,,Autocuration,CHEMBL617434,1.0,,,2360.0,,H,BAO_0000224,,,,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,104686.0,
5.0,11624.0,,B,,,Autocuration,CHEMBL617435,1.0,,,2361.0,,D,BAO_0000224,,10116.0,,Rattus norvegicus,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,104686.0,
4.0,1344.0,,B,,,Autocuration,CHEMBL617436,1.0,,,2362.0,,H,BAO_0000019,,,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,104686.0,
5.0,15453.0,2435.0,B,,,Autocuration,CHEMBL617437,1.0,Striatum,,2363.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,104686.0,
4.0,11662.0,,B,,,Autocuration,CHEMBL617438,1.0,,,2364.0,,H,BAO_0000019,,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,104686.0,
4.0,11662.0,,B,,,Autocuration,CHEMBL617439,1.0,,,2365.0,,H,BAO_0000019,,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,104686.0,
4.0,10796.0,,B,,,Autocuration,CHEMBL617440,1.0,,,2366.0,,H,BAO_0000224,,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,9069.0,,B,,,Autocuration,CHEMBL617441,1.0,,,2367.0,,H,BAO_0000224,,,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,104686.0,
5.0,8814.0,,B,,,Autocuration,CHEMBL872918,1.0,,,2368.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,104686.0,
5.0,8908.0,,B,,,Autocuration,CHEMBL617442,1.0,,,2369.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,104686.0,
4.0,9098.0,,B,,,Autocuration,CHEMBL617443,1.0,,,2370.0,,H,BAO_0000019,,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,104686.0,
4.0,9098.0,,B,,,Autocuration,CHEMBL617444,1.0,,,2371.0,,H,BAO_0000019,,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,104686.0,
4.0,9098.0,,B,,,Autocuration,CHEMBL617445,1.0,,,2372.0,,H,BAO_0000019,,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,104686.0,
4.0,9098.0,,B,,,Autocuration,CHEMBL617446,1.0,,,2373.0,,H,BAO_0000019,,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,104686.0,
4.0,9098.0,,B,,,Autocuration,CHEMBL617447,1.0,,,2374.0,,H,BAO_0000249,,,,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,104686.0,
4.0,9098.0,,B,,,Autocuration,CHEMBL617448,1.0,,,2375.0,,H,BAO_0000019,,,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,104686.0,
4.0,9098.0,,B,,,Autocuration,CHEMBL617449,1.0,,,2376.0,,H,BAO_0000019,,,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,104686.0,
4.0,9161.0,,B,,,Autocuration,CHEMBL617450,1.0,,,2377.0,,H,BAO_0000019,,,,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,104686.0,
4.0,9161.0,,B,,,Autocuration,CHEMBL617451,1.0,,,2378.0,,H,BAO_0000019,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,104686.0,
4.0,9161.0,,B,,,Autocuration,CHEMBL617452,1.0,,,2379.0,,H,BAO_0000019,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,104686.0,
4.0,9161.0,,B,,,Autocuration,CHEMBL617453,1.0,,,2380.0,,H,BAO_0000019,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,104686.0,
4.0,9161.0,,B,,,Autocuration,CHEMBL617660,1.0,,,2381.0,,H,BAO_0000019,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,104686.0,
4.0,9161.0,,B,,,Autocuration,CHEMBL617661,1.0,,,2382.0,,H,BAO_0000019,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,104686.0,
4.0,9161.0,,B,,,Autocuration,CHEMBL617662,1.0,,,2383.0,,H,BAO_0000019,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,104686.0,
4.0,9161.0,,B,,,Autocuration,CHEMBL872919,1.0,,,2384.0,,H,BAO_0000019,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,104686.0,
4.0,9161.0,,B,,,Autocuration,CHEMBL617663,1.0,,,2385.0,,H,BAO_0000019,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,104686.0,
4.0,9161.0,,B,,,Autocuration,CHEMBL617664,1.0,,,2386.0,,H,BAO_0000019,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,104686.0,
4.0,9161.0,,B,,,Autocuration,CHEMBL617665,1.0,,,2387.0,,H,BAO_0000019,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,104686.0,
4.0,9161.0,,B,,,Autocuration,CHEMBL617666,1.0,,,2388.0,,H,BAO_0000019,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,104686.0,
4.0,12094.0,,B,,,Autocuration,CHEMBL617667,1.0,,,2389.0,,H,BAO_0000019,,,,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,104686.0,
4.0,12018.0,,B,,,Autocuration,CHEMBL617668,1.0,,,2390.0,,H,BAO_0000249,,,,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,104686.0,
4.0,10394.0,,B,,,Autocuration,CHEMBL617669,1.0,,,2391.0,,H,BAO_0000249,,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,104686.0,
4.0,15260.0,,B,,,Autocuration,CHEMBL617670,1.0,,,2392.0,,H,BAO_0000224,,,,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,104686.0,
5.0,11624.0,,B,,,Autocuration,CHEMBL617671,1.0,,,2393.0,,D,BAO_0000224,,10116.0,,Rattus norvegicus,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,13654.0,,B,,,Autocuration,CHEMBL617672,1.0,,,2394.0,,H,BAO_0000224,,,,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,9541.0,,B,,,Autocuration,CHEMBL617673,1.0,,,2395.0,,H,BAO_0000019,,,,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,104686.0,
4.0,11933.0,,B,,,Autocuration,CHEMBL617674,1.0,,,2396.0,,H,BAO_0000224,,,,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,104686.0,
4.0,15538.0,,B,,,Autocuration,CHEMBL617675,1.0,,,2397.0,,H,BAO_0000019,,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,104686.0,
4.0,15538.0,,B,,,Autocuration,CHEMBL617676,1.0,,,2398.0,,H,BAO_0000019,,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,104686.0,
4.0,15538.0,,B,,,Autocuration,CHEMBL617677,1.0,,,2399.0,,H,BAO_0000019,,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,104686.0,
5.0,8841.0,,B,,,Autocuration,CHEMBL617678,1.0,,,2400.0,,D,BAO_0000019,,,,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,1455.0,,B,,,Autocuration,CHEMBL617679,1.0,,,2401.0,,H,BAO_0000224,,,,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,104686.0,
4.0,1455.0,,B,,,Autocuration,CHEMBL617680,1.0,,,2402.0,,H,BAO_0000224,,,,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,104686.0,
4.0,11752.0,,B,,,Autocuration,CHEMBL617681,1.0,,,2403.0,,H,BAO_0000019,,,,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,104686.0,
4.0,11642.0,955.0,B,,,Autocuration,CHEMBL617682,1.0,Brain,,2404.0,,H,BAO_0000221,,,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,104686.0,
4.0,12092.0,,B,,,Autocuration,CHEMBL617683,1.0,,,2405.0,,H,BAO_0000224,,,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,104686.0,
4.0,3967.0,,B,,,Autocuration,CHEMBL617684,1.0,,,2406.0,,H,BAO_0000224,,,,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,104686.0,
5.0,12771.0,,B,,,Autocuration,CHEMBL617685,1.0,,,2407.0,,D,BAO_0000224,,10116.0,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,11642.0,,B,,,Autocuration,CHEMBL617686,1.0,,,2408.0,,H,BAO_0000019,,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,104686.0,
4.0,11628.0,,B,,,Autocuration,CHEMBL617687,1.0,,,2409.0,,H,BAO_0000224,,,,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,104686.0,
4.0,13654.0,,B,,,Autocuration,CHEMBL617688,1.0,,,2410.0,,H,BAO_0000224,,,,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,104686.0,
4.0,11200.0,,F,,,Autocuration,CHEMBL617689,1.0,,,2411.0,,H,BAO_0000019,,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,104686.0,
4.0,11200.0,,F,,,Autocuration,CHEMBL617690,1.0,,,2412.0,,H,BAO_0000019,,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,104686.0,
4.0,11200.0,,F,,,Autocuration,CHEMBL617691,1.0,,,2413.0,In vivo,H,BAO_0000218,,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,104686.0,
4.0,11200.0,,F,,,Autocuration,CHEMBL617692,1.0,,,2414.0,In vivo,H,BAO_0000218,,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,104686.0,
4.0,11200.0,,F,,,Autocuration,CHEMBL617693,1.0,,,2415.0,In vivo,H,BAO_0000218,,,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,104686.0,
4.0,11200.0,,F,,,Autocuration,CHEMBL617694,1.0,,,2416.0,In vivo,H,BAO_0000218,,,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,104686.0,
8.0,15436.0,955.0,B,,,Expert,CHEMBL857985,1.0,Brain,,2417.0,,H,BAO_0000221,,,,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,12687.0,
9.0,15436.0,,B,,,Expert,CHEMBL617695,1.0,,,2418.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,12687.0,
8.0,14025.0,,B,,,Autocuration,CHEMBL617696,1.0,,,2419.0,,H,BAO_0000019,,,,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,12687.0,
8.0,4342.0,,B,,,Autocuration,CHEMBL617697,1.0,,,2420.0,,H,BAO_0000357,,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,12687.0,
9.0,13735.0,,B,,,Expert,CHEMBL617257,1.0,,,2421.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,12687.0,
9.0,5816.0,,B,,,Expert,CHEMBL617258,1.0,,,2422.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,12687.0,
8.0,14287.0,,B,,,Expert,CHEMBL617259,1.0,,,2423.0,,H,BAO_0000019,,,,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,12687.0,
8.0,15738.0,,B,,,Autocuration,CHEMBL617260,1.0,,,2424.0,,H,BAO_0000357,,,,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,12687.0,
9.0,15738.0,,B,,,Expert,CHEMBL617261,1.0,,,2425.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,15026.0,,B,,,Autocuration,CHEMBL617262,1.0,,,2426.0,,H,BAO_0000019,,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,12687.0,
8.0,16647.0,,B,,,Expert,CHEMBL617263,1.0,,,2427.0,,H,BAO_0000019,,,,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,12687.0,
8.0,16647.0,,B,,,Autocuration,CHEMBL617264,1.0,,,2428.0,,H,BAO_0000019,,,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,12687.0,
9.0,13345.0,,B,,,Expert,CHEMBL617265,1.0,,,2429.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,1543.0,,B,Membranes,,Autocuration,CHEMBL617266,1.0,,,2430.0,,H,BAO_0000249,,,,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,12444.0,,B,,,Autocuration,CHEMBL617267,1.0,,,2431.0,,H,BAO_0000019,,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,12687.0,
8.0,16404.0,,B,,,Expert,CHEMBL617268,1.0,,,2432.0,,H,BAO_0000019,,,,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,12687.0,
8.0,16404.0,,B,,,Autocuration,CHEMBL617269,1.0,,,2433.0,,H,BAO_0000219,CHO,,,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,12687.0,449.0
8.0,15577.0,,B,,,Expert,CHEMBL617323,1.0,,,2434.0,,H,BAO_0000357,,,,,Kinetic inhibition constant evaluated by measuring serotonergic activity,,12687.0,
8.0,15577.0,,B,,,Autocuration,CHEMBL617324,1.0,,,2435.0,,H,BAO_0000357,,,,,Serotonergic activity of the compound.,,12687.0,
8.0,2495.0,,B,,,Autocuration,CHEMBL617325,1.0,,,2436.0,,H,BAO_0000249,,,,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,12687.0,
9.0,15042.0,,B,,,Expert,CHEMBL617326,1.0,,,2437.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,12687.0,
8.0,15026.0,,B,,,Expert,CHEMBL617327,1.0,,,2438.0,,H,BAO_0000249,,,,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,12687.0,
9.0,12919.0,,F,,,Expert,CHEMBL617328,1.0,,,2439.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,12687.0,
9.0,12919.0,,F,,,Expert,CHEMBL617329,1.0,,,2440.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,12687.0,
9.0,12919.0,,F,,,Expert,CHEMBL617330,1.0,,,2441.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,12687.0,
8.0,15194.0,,B,,,Autocuration,CHEMBL617331,1.0,,,2442.0,,H,BAO_0000357,,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,12687.0,
8.0,15194.0,,B,,,Autocuration,CHEMBL617332,1.0,,,2443.0,,H,BAO_0000357,,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,12687.0,
8.0,4820.0,,B,,,Expert,CHEMBL617333,1.0,,,2444.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,107.0,
8.0,6736.0,,B,,,Autocuration,CHEMBL617334,1.0,,,2445.0,,H,BAO_0000357,,,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,107.0,
8.0,5163.0,,B,,,Autocuration,CHEMBL617335,1.0,,,2446.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,107.0,
8.0,5163.0,,B,,,Autocuration,CHEMBL617336,1.0,,,2447.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,107.0,
8.0,6011.0,,B,,,Autocuration,CHEMBL617337,1.0,,,2448.0,,H,BAO_0000357,,,,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,107.0,
9.0,14294.0,,B,,,Expert,CHEMBL617338,1.0,,,2449.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,107.0,
8.0,5014.0,,B,,,Autocuration,CHEMBL617339,1.0,,,2450.0,,H,BAO_0000357,,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,107.0,
8.0,17066.0,,B,,,Expert,CHEMBL617340,1.0,,,2451.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,107.0,
8.0,17515.0,,B,,,Autocuration,CHEMBL617341,1.0,,,2452.0,,H,BAO_0000357,,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,107.0,
8.0,6736.0,,B,,,Expert,CHEMBL617342,1.0,,,2453.0,,H,BAO_0000357,,,,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,107.0,
8.0,5163.0,,B,,,Expert,CHEMBL617343,1.0,,,2454.0,,H,BAO_0000357,,,,,Affinity for 5-hydroxytryptamine 2A receptor,,107.0,
8.0,16911.0,,B,,,Expert,CHEMBL617344,1.0,,,2455.0,,H,BAO_0000219,NIH3T3,,,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,107.0,723.0
8.0,6841.0,,B,,,Expert,CHEMBL617345,1.0,,,2456.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,107.0,
8.0,6119.0,,B,,,Expert,CHEMBL617346,1.0,,,2457.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,107.0,
8.0,3962.0,,B,,,Autocuration,CHEMBL617347,1.0,,,2458.0,,H,BAO_0000357,,,,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,107.0,
8.0,4373.0,,B,,,Autocuration,CHEMBL617348,1.0,,,2459.0,,H,BAO_0000357,,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,107.0,
8.0,4373.0,,B,,,Autocuration,CHEMBL617349,1.0,,,2460.0,,H,BAO_0000357,,,,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,107.0,
8.0,3962.0,,F,,,Autocuration,CHEMBL617350,1.0,,,2461.0,,H,BAO_0000019,,,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,107.0,
8.0,1633.0,,B,,,Expert,CHEMBL872339,1.0,,,2462.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,107.0,
8.0,4373.0,,B,,,Autocuration,CHEMBL617351,1.0,,,2463.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,107.0,
8.0,6576.0,,B,,,Expert,CHEMBL617352,1.0,,,2464.0,,H,BAO_0000357,,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,107.0,
8.0,4687.0,,B,,,Autocuration,CHEMBL617353,1.0,,,2465.0,,H,BAO_0000357,,,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,107.0,
8.0,16946.0,,B,,,Autocuration,CHEMBL617354,1.0,,,2466.0,,H,BAO_0000357,,,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,107.0,
8.0,14159.0,,B,,,Autocuration,CHEMBL617355,1.0,,,2467.0,,H,BAO_0000357,,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,107.0,
8.0,3032.0,,B,,,Expert,CHEMBL617356,1.0,,,2468.0,,H,BAO_0000219,CHO,10090.0,,Mus musculus,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,107.0,449.0
8.0,16655.0,,B,,,Autocuration,CHEMBL617357,1.0,,,2469.0,,H,BAO_0000357,,,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,107.0,
8.0,13964.0,,B,,,Autocuration,CHEMBL617358,1.0,,,2470.0,,H,BAO_0000357,,,,,Binding affinity at 5-hydroxytryptamine 2A receptor,,107.0,
8.0,16989.0,,B,,,Expert,CHEMBL617359,1.0,,,2471.0,,H,BAO_0000357,,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,107.0,
8.0,16117.0,,B,,,Autocuration,CHEMBL617360,1.0,,,2472.0,,H,BAO_0000357,,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,107.0,
8.0,16700.0,,B,,,Autocuration,CHEMBL875913,1.0,,,2473.0,,H,BAO_0000357,,,,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,107.0,
8.0,3269.0,,B,,,Autocuration,CHEMBL617361,1.0,,,2474.0,,H,BAO_0000357,,,,,Affinity against 5-hydroxytryptamine 2A receptor,,107.0,
9.0,1274.0,,B,,,Expert,CHEMBL617362,1.0,,,2475.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity against 5-Hydroxytryptamine 2A receptor,,107.0,
8.0,1317.0,,B,,,Autocuration,CHEMBL617363,1.0,,,2476.0,,H,BAO_0000357,,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,107.0,
8.0,12146.0,,B,,,Autocuration,CHEMBL617364,1.0,,,2477.0,,H,BAO_0000357,,,,,Tested against 5-hydroxytryptamine 2A receptor,,107.0,
4.0,12652.0,,B,,,Autocuration,CHEMBL617365,1.0,,,2478.0,,H,BAO_0000224,,,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,105075.0,
4.0,12652.0,,B,,,Autocuration,CHEMBL617366,1.0,,,2479.0,,H,BAO_0000224,,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,105075.0,
4.0,12652.0,,B,,,Autocuration,CHEMBL617367,1.0,,,2480.0,,H,BAO_0000224,,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,105075.0,
4.0,12652.0,,B,,,Autocuration,CHEMBL617368,1.0,,,2481.0,,H,BAO_0000224,,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,105075.0,
8.0,16647.0,,B,,,Autocuration,CHEMBL617369,1.0,,,2482.0,,H,BAO_0000357,,,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,107.0,
9.0,15851.0,,B,,,Expert,CHEMBL617370,1.0,,,2483.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,227.0,722.0
9.0,6857.0,,F,,,Expert,CHEMBL617371,1.0,,,2484.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,227.0,449.0
8.0,3805.0,,B,,,Autocuration,CHEMBL617372,1.0,,,2485.0,,H,BAO_0000357,,,,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,227.0,
9.0,6491.0,,B,,,Expert,CHEMBL617373,1.0,,,2486.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,227.0,
8.0,14093.0,,F,,,Autocuration,CHEMBL617374,1.0,,,2487.0,,H,BAO_0000019,,,,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,227.0,
8.0,13481.0,,F,,,Autocuration,CHEMBL617375,1.0,,,2488.0,,H,BAO_0000019,,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,227.0,
8.0,14093.0,,F,,,Autocuration,CHEMBL617376,1.0,,,2489.0,,H,BAO_0000019,,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,227.0,
8.0,14093.0,,F,,,Autocuration,CHEMBL617377,1.0,,,2490.0,,H,BAO_0000019,,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,227.0,
8.0,14093.0,,F,,,Autocuration,CHEMBL617378,1.0,,,2491.0,,H,BAO_0000019,,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,227.0,
8.0,13481.0,,F,,,Autocuration,CHEMBL617379,1.0,,,2492.0,,H,BAO_0000019,,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,227.0,
8.0,14442.0,,B,,,Autocuration,CHEMBL617380,1.0,,,2493.0,,H,BAO_0000357,,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,227.0,
8.0,14442.0,,B,,,Autocuration,CHEMBL617381,1.0,,,2494.0,,H,BAO_0000357,,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,227.0,
8.0,14442.0,,B,,,Autocuration,CHEMBL617382,1.0,,,2495.0,,H,BAO_0000357,,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,227.0,
8.0,12369.0,,B,,,Autocuration,CHEMBL617383,1.0,,,2496.0,,H,BAO_0000357,,,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,107.0,
8.0,12369.0,,B,,,Expert,CHEMBL617384,1.0,,,2497.0,,H,BAO_0000357,,,,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,107.0,
8.0,12369.0,,B,,,Expert,CHEMBL617385,1.0,,,2498.0,,H,BAO_0000357,,,,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,107.0,
8.0,14447.0,,B,,,Autocuration,CHEMBL617386,1.0,,,2499.0,,H,BAO_0000019,,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,107.0,
8.0,14447.0,,B,,,Autocuration,CHEMBL617387,1.0,,,2500.0,,H,BAO_0000019,,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,107.0,
8.0,17451.0,,B,,,Autocuration,CHEMBL617388,1.0,,,2501.0,,H,BAO_0000219,NIH3T3,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,107.0,723.0
8.0,6857.0,,F,,,Autocuration,CHEMBL617389,1.0,,,2502.0,,H,BAO_0000219,CHO,,,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,107.0,449.0
9.0,6857.0,,F,,,Expert,CHEMBL617390,1.0,,,2503.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,107.0,449.0
4.0,5635.0,,B,,,Autocuration,CHEMBL617391,1.0,,,2504.0,,H,BAO_0000224,,,,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,104817.0,
8.0,12861.0,,B,,,Autocuration,CHEMBL617392,1.0,,,2505.0,,H,BAO_0000357,,,,,Binding activity radioligand.,,107.0,
8.0,12861.0,,B,,,Autocuration,CHEMBL617393,1.0,,,2506.0,,H,BAO_0000019,,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,107.0,
8.0,5105.0,,B,,,Autocuration,CHEMBL617394,1.0,,,2507.0,,H,BAO_0000219,L929,,,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,107.0,307.0
8.0,5104.0,,B,,,Expert,CHEMBL617395,1.0,,,2508.0,,H,BAO_0000219,L929,,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,107.0,307.0
8.0,5105.0,,B,,,Expert,CHEMBL617396,1.0,,,2509.0,,H,BAO_0000219,L929,,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,107.0,307.0
8.0,5105.0,,B,,,Autocuration,CHEMBL617397,1.0,,,2510.0,,H,BAO_0000219,L929,,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,107.0,307.0
8.0,5254.0,,B,,,Autocuration,CHEMBL617398,1.0,,,2511.0,,H,BAO_0000357,,,,,Binding affinity against 5-HT2A receptor,,107.0,
8.0,5254.0,,B,,,Autocuration,CHEMBL617399,1.0,,,2512.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor,,107.0,
8.0,13267.0,,B,,,Autocuration,CHEMBL617400,1.0,,,2513.0,,H,BAO_0000219,HEK293,,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,107.0,722.0
8.0,13267.0,,B,,,Autocuration,CHEMBL617401,1.0,,,2514.0,,H,BAO_0000219,HEK293,,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,107.0,722.0
9.0,14157.0,,B,,,Expert,CHEMBL617402,1.0,,,2515.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,107.0,722.0
9.0,12936.0,,B,,,Expert,CHEMBL617403,1.0,,,2516.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,107.0,722.0
8.0,14068.0,,B,,,Expert,CHEMBL617404,1.0,,,2517.0,,H,BAO_0000357,,,,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,107.0,
9.0,12936.0,,B,,,Expert,CHEMBL857981,1.0,,,2518.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,107.0,722.0
9.0,12936.0,,B,,,Expert,CHEMBL617405,1.0,,,2519.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,107.0,722.0
9.0,4540.0,,B,,,Expert,CHEMBL617253,1.0,,,2520.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,107.0,722.0
8.0,6166.0,,B,,,Expert,CHEMBL617254,1.0,,,2521.0,,H,BAO_0000357,,,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,107.0,
8.0,17296.0,,B,,,Autocuration,CHEMBL617255,1.0,,,2522.0,,H,BAO_0000219,HEK293,,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,107.0,722.0
8.0,17296.0,,B,,,Autocuration,CHEMBL617256,1.0,,,2523.0,,H,BAO_0000219,HEK293,,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,107.0,722.0
8.0,17296.0,,B,,,Autocuration,CHEMBL616874,1.0,,,2524.0,,H,BAO_0000219,HEK293,,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,107.0,722.0
9.0,15779.0,,B,,,Expert,CHEMBL616875,1.0,,,2525.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,107.0,722.0
8.0,14391.0,,B,,,Expert,CHEMBL616876,1.0,,,2526.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,107.0,722.0
8.0,15851.0,,B,,,Expert,CHEMBL616877,1.0,,,2527.0,,H,BAO_0000219,HEK293,,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,107.0,722.0
9.0,15851.0,,B,,,Expert,CHEMBL616878,1.0,,,2528.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,107.0,722.0
8.0,3832.0,,B,,,Expert,CHEMBL616879,1.0,,,2529.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,107.0,722.0
8.0,3833.0,,B,,,Expert,CHEMBL616880,1.0,,,2530.0,,H,BAO_0000219,HEK293,,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,107.0,722.0
9.0,12936.0,,B,,,Expert,CHEMBL616881,1.0,,,2531.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,107.0,722.0
8.0,17451.0,,B,,,Autocuration,CHEMBL616882,1.0,,,2532.0,,H,BAO_0000219,NIH3T3,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,107.0,723.0
8.0,17451.0,,B,,,Autocuration,CHEMBL616883,1.0,,,2533.0,,H,BAO_0000219,NIH3T3,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,107.0,723.0
8.0,17451.0,,B,,,Autocuration,CHEMBL616884,1.0,,,2534.0,,H,BAO_0000219,NIH3T3,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,107.0,723.0
8.0,4199.0,,B,,,Autocuration,CHEMBL616885,1.0,,,2535.0,,H,BAO_0000219,HEK293,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,107.0,722.0
8.0,1883.0,,B,,,Autocuration,CHEMBL616886,1.0,,,2536.0,,H,BAO_0000219,CHO-K1,,,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,107.0,485.0
8.0,1883.0,,B,,,Expert,CHEMBL616887,1.0,,,2537.0,,H,BAO_0000219,CHO-K1,,,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,107.0,485.0
9.0,14875.0,,B,,,Expert,CHEMBL616888,1.0,,,2538.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 2A receptor,,107.0,
8.0,15146.0,,B,,,Autocuration,CHEMBL616889,1.0,,,2539.0,,H,BAO_0000219,HEK293,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,107.0,722.0
8.0,5213.0,,B,,,Autocuration,CHEMBL616890,1.0,,,2540.0,,H,BAO_0000219,HEK293,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,107.0,722.0
9.0,16404.0,,B,,,Expert,CHEMBL616891,1.0,,,2541.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,107.0,449.0
8.0,14818.0,,B,,,Autocuration,CHEMBL616892,1.0,,,2542.0,,H,BAO_0000219,HEK293,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,107.0,722.0
8.0,4829.0,,B,,,Autocuration,CHEMBL616893,1.0,,,2543.0,,H,BAO_0000219,HEK293,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,107.0,722.0
8.0,12652.0,,F,,,Autocuration,CHEMBL616894,1.0,,,2544.0,,H,BAO_0000219,NIH3T3,,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,10620.0,723.0
8.0,4682.0,,B,,,Expert,CHEMBL616895,1.0,,,2545.0,,H,BAO_0000219,NIH3T3,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,107.0,723.0
8.0,12652.0,,F,,,Autocuration,CHEMBL616896,1.0,,,2546.0,,H,BAO_0000019,,,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,10620.0,
8.0,4921.0,,B,,,Autocuration,CHEMBL617099,1.0,,,2547.0,,H,BAO_0000357,,,,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,10621.0,
8.0,4921.0,,B,,,Autocuration,CHEMBL617100,1.0,,,2548.0,,H,BAO_0000357,,,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,10621.0,
8.0,16312.0,,B,,,Autocuration,CHEMBL884532,1.0,,,2549.0,,H,BAO_0000357,,9986.0,,Oryctolagus cuniculus,Binding affinity against rabbit aorta 5-HT2A receptor,,107.0,
8.0,14998.0,,B,,,Expert,CHEMBL617101,1.0,,,2550.0,,H,BAO_0000357,,9986.0,,Oryctolagus cuniculus,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,107.0,
8.0,14025.0,,B,,,Expert,CHEMBL617102,1.0,,,2551.0,,H,BAO_0000357,,9986.0,,Oryctolagus cuniculus,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,107.0,
8.0,13047.0,,B,,,Autocuration,CHEMBL617103,1.0,,,2552.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,107.0,
8.0,13047.0,,B,,,Expert,CHEMBL617104,1.0,,,2553.0,,H,BAO_0000357,,9986.0,,Oryctolagus cuniculus,The compound was tested for binding affinity against 5-HT2A receptor,,107.0,
8.0,1883.0,,B,,,Autocuration,CHEMBL857979,1.0,,,2554.0,,H,BAO_0000219,CHO-K1,,,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,10576.0,485.0
8.0,13463.0,,B,,,Autocuration,CHEMBL857502,1.0,,,2555.0,,H,BAO_0000019,,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,12687.0,
8.0,13463.0,,B,,,Autocuration,CHEMBL617105,1.0,,,2556.0,,H,BAO_0000019,,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,12687.0,
8.0,13463.0,945.0,B,,,Autocuration,CHEMBL858021,1.0,Stomach,,2557.0,,H,BAO_0000019,,,,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,12687.0,
9.0,13463.0,945.0,B,,,Expert,CHEMBL875910,1.0,Stomach,,2558.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity for 5-HT 2A in rat stomach fundus,,12687.0,
8.0,13463.0,,B,,,Autocuration,CHEMBL617106,1.0,,,2559.0,,H,BAO_0000019,,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,12687.0,
8.0,16326.0,,B,,,Expert,CHEMBL617107,1.0,,,2560.0,,H,BAO_0000219,NIH3T3,,,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,12687.0,723.0
8.0,14093.0,,F,,,Autocuration,CHEMBL617108,1.0,,,2561.0,,H,BAO_0000019,,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,14093.0,,F,,,Autocuration,CHEMBL617109,1.0,,,2562.0,,H,BAO_0000019,,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,15740.0,,B,,,Autocuration,CHEMBL617110,1.0,,,2563.0,,H,BAO_0000357,,,,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL617111,1.0,,,2564.0,,H,BAO_0000357,,,,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,12687.0,
9.0,17200.0,,F,,,Expert,CHEMBL617112,1.0,,,2565.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,12687.0,
8.0,17133.0,,B,,,Autocuration,CHEMBL617113,1.0,,,2566.0,,H,BAO_0000357,,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,17133.0,,B,,,Autocuration,CHEMBL617114,1.0,,,2567.0,,H,BAO_0000357,,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,17133.0,,B,,,Autocuration,CHEMBL617115,1.0,,,2568.0,,H,BAO_0000357,,,,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,17200.0,,F,,,Autocuration,CHEMBL617116,1.0,,,2569.0,,H,BAO_0000219,,,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,12687.0,
8.0,15363.0,,F,,,Autocuration,CHEMBL617117,1.0,,,2570.0,,H,BAO_0000019,,,,,Efficacy at 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,17200.0,,B,,,Autocuration,CHEMBL617118,1.0,,,2571.0,,H,BAO_0000357,,,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,12687.0,
9.0,17200.0,,B,,,Expert,CHEMBL617119,1.0,,,2572.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,12687.0,
9.0,17200.0,,B,,,Expert,CHEMBL617120,1.0,,,2573.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,12687.0,
9.0,17200.0,,F,,,Expert,CHEMBL617121,1.0,,,2574.0,,D,BAO_0000219,,10116.0,,Rattus norvegicus,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,12687.0,
8.0,17200.0,,F,,,Autocuration,CHEMBL617122,1.0,,,2575.0,,H,BAO_0000219,,,,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,12687.0,
8.0,17211.0,,B,,,Autocuration,CHEMBL617123,1.0,,,2576.0,,H,BAO_0000019,,,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,17331.0,,B,,,Expert,CHEMBL617124,1.0,,,2577.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,12687.0,
8.0,13565.0,,B,,,Expert,CHEMBL617600,1.0,,,2578.0,,H,BAO_0000249,,,,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,12687.0,
8.0,13730.0,,B,,,Expert,CHEMBL617601,1.0,,,2579.0,,H,BAO_0000357,,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,12687.0,
8.0,12416.0,,B,,,Expert,CHEMBL882923,1.0,,,2580.0,,H,BAO_0000019,,,,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,12687.0,
8.0,15295.0,,B,,,Autocuration,CHEMBL617602,1.0,,,2581.0,,H,BAO_0000357,,,,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,1742.0,,B,,,Autocuration,CHEMBL617603,1.0,,,2582.0,,H,BAO_0000019,,,,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,12687.0,
8.0,15295.0,,B,,,Autocuration,CHEMBL617604,1.0,,,2583.0,,H,BAO_0000357,,,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,14970.0,,B,,,Expert,CHEMBL617605,1.0,,,2584.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,12687.0,
8.0,16693.0,,B,,,Expert,CHEMBL617606,1.0,,,2585.0,,H,BAO_0000019,,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,12687.0,
9.0,14776.0,,B,,,Expert,CHEMBL617607,1.0,,,2586.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,14286.0,,B,,,Autocuration,CHEMBL617455,1.0,,,2587.0,,H,BAO_0000249,,,,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,12687.0,
9.0,17200.0,,B,,,Expert,CHEMBL617456,1.0,,,2588.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,12687.0,
8.0,15306.0,,B,,,Expert,CHEMBL617457,1.0,,,2589.0,,H,BAO_0000357,,,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,12687.0,
9.0,14178.0,,B,,,Expert,CHEMBL617458,1.0,,,2590.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,12687.0,
9.0,14229.0,,B,,,Expert,CHEMBL617459,1.0,,,2591.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,12687.0,
8.0,12884.0,,B,,,Expert,CHEMBL617460,1.0,,,2592.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,12687.0,
8.0,13149.0,,B,,,Expert,CHEMBL617461,1.0,,,2593.0,,H,BAO_0000357,,,,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,12687.0,
9.0,15295.0,,B,,,Expert,CHEMBL617462,1.0,,,2594.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,12687.0,
8.0,15740.0,,B,,,Autocuration,CHEMBL617463,1.0,,,2595.0,,H,BAO_0000357,,,,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,12687.0,
8.0,15185.0,,B,,,Autocuration,CHEMBL617464,1.0,,,2596.0,,H,BAO_0000019,,,,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,12687.0,
8.0,15185.0,,B,,,Autocuration,CHEMBL617465,1.0,,,2597.0,,H,BAO_0000019,,,,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,12687.0,
8.0,17529.0,,B,,,Expert,CHEMBL617466,1.0,,,2598.0,,H,BAO_0000019,,,,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,12687.0,
8.0,14826.0,,B,,,Autocuration,CHEMBL617467,1.0,,,2599.0,,H,BAO_0000019,,,,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,12687.0,
8.0,17211.0,,B,,,Expert,CHEMBL617468,1.0,,,2600.0,,H,BAO_0000019,,,,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,12687.0,
8.0,14826.0,,B,,,Autocuration,CHEMBL617469,1.0,,,2601.0,,H,BAO_0000019,,,,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,12687.0,
8.0,14093.0,,B,,,Autocuration,CHEMBL617470,1.0,,,2602.0,,H,BAO_0000019,,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,14093.0,,B,,,Autocuration,CHEMBL617471,1.0,,,2603.0,,H,BAO_0000019,,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,12687.0,
8.0,13246.0,,B,,,Expert,CHEMBL617472,1.0,,,2604.0,,H,BAO_0000219,NIH3T3,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,12687.0,723.0
8.0,13246.0,,B,,,Expert,CHEMBL617473,1.0,,,2605.0,,H,BAO_0000357,,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,12687.0,
9.0,15436.0,,B,,,Expert,CHEMBL617474,1.0,,,2606.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,12687.0,
9.0,15436.0,,B,,,Expert,CHEMBL617475,1.0,,,2607.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,12687.0,
8.0,14442.0,955.0,B,,,Autocuration,CHEMBL617476,1.0,Brain,,2608.0,,H,BAO_0000221,,,,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,12687.0,
8.0,12457.0,,B,,,Expert,CHEMBL617477,1.0,,,2609.0,,H,BAO_0000357,,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,12457.0,,B,,,Expert,CHEMBL617478,1.0,,,2610.0,,H,BAO_0000219,NIH3T3,,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,12687.0,723.0
8.0,14755.0,,F,,,Autocuration,CHEMBL617479,1.0,,,2611.0,,H,BAO_0000221,,,,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,12687.0,
8.0,4707.0,,B,,,Autocuration,CHEMBL617480,1.0,,,2612.0,,H,BAO_0000357,,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,12687.0,
8.0,13297.0,,B,,,Expert,CHEMBL617481,1.0,,,2613.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,17331.0,,B,,,Expert,CHEMBL617482,1.0,,,2614.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,12687.0,
8.0,4664.0,,B,,,Autocuration,CHEMBL617483,1.0,,,2615.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,12687.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL621528,1.0,,,2616.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,12687.0,
9.0,4664.0,,B,,,Expert,CHEMBL621529,1.0,,,2617.0,,D,BAO_0000219,NIH3T3,10116.0,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,12687.0,723.0
8.0,16133.0,,B,,,Expert,CHEMBL621530,1.0,,,2618.0,,H,BAO_0000357,,,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,12687.0,
8.0,16133.0,,B,,,Expert,CHEMBL621531,1.0,,,2619.0,,H,BAO_0000357,,,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,12687.0,
9.0,14060.0,,B,,,Expert,CHEMBL621532,1.0,,,2620.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,16326.0,,B,,,Expert,CHEMBL621533,1.0,,,2621.0,,H,BAO_0000357,,,,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,12687.0,
8.0,16659.0,,B,,,Expert,CHEMBL621534,1.0,,,2622.0,,H,BAO_0000219,CHO,,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,12687.0,449.0
8.0,14776.0,,B,,,Autocuration,CHEMBL621535,1.0,,,2623.0,,H,BAO_0000019,,,,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,12687.0,
8.0,13481.0,,B,,,Autocuration,CHEMBL621536,1.0,,,2624.0,,H,BAO_0000357,,,,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,12687.0,
8.0,17386.0,,B,,,Autocuration,CHEMBL621537,1.0,,,2625.0,,H,BAO_0000357,,,,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,12687.0,
9.0,6611.0,,B,,,Expert,CHEMBL621538,1.0,,,2626.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,14423.0,,B,,,Autocuration,CHEMBL621539,1.0,,,2627.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,12687.0,
8.0,15412.0,,B,,,Autocuration,CHEMBL621540,1.0,,,2628.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,12687.0,
8.0,15412.0,,B,,,Autocuration,CHEMBL621541,1.0,,,2629.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,12687.0,
8.0,6238.0,,B,,,Autocuration,CHEMBL621542,1.0,,,2630.0,,H,BAO_0000019,,,,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,12687.0,
8.0,6648.0,,B,,,Expert,CHEMBL621543,1.0,,,2631.0,,H,BAO_0000357,,,,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,12687.0,
8.0,5667.0,,B,,,Expert,CHEMBL621544,1.0,,,2632.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,12687.0,
9.0,6611.0,,B,,,Expert,CHEMBL621545,1.0,,,2633.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,12687.0,
8.0,13481.0,,B,,,Autocuration,CHEMBL621546,1.0,,,2634.0,,H,BAO_0000357,,,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,12687.0,
8.0,13481.0,,B,,,Autocuration,CHEMBL621547,1.0,,,2635.0,,H,BAO_0000357,,,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,12687.0,
8.0,15558.0,,B,,,Expert,CHEMBL618692,1.0,,,2636.0,,H,BAO_0000219,NIH3T3,,,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,12687.0,723.0
8.0,6013.0,,B,,,Autocuration,CHEMBL618693,1.0,,,2637.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL872922,1.0,,,2638.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,12687.0,
8.0,6013.0,,B,,,Autocuration,CHEMBL618694,1.0,,,2639.0,,H,BAO_0000357,,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,12687.0,
9.0,6013.0,,B,,,Expert,CHEMBL618695,1.0,,,2640.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,12687.0,
8.0,6013.0,,B,,,Autocuration,CHEMBL618696,1.0,,,2641.0,,H,BAO_0000357,,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,12687.0,
8.0,6013.0,,B,,,Expert,CHEMBL618697,1.0,,,2642.0,,H,BAO_0000357,,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,12687.0,
8.0,6013.0,,B,,,Autocuration,CHEMBL618892,1.0,,,2643.0,,H,BAO_0000357,,,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,12687.0,
8.0,6013.0,,B,,,Autocuration,CHEMBL618893,1.0,,,2644.0,,H,BAO_0000357,,,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,12687.0,
8.0,16293.0,,B,,,Autocuration,CHEMBL618894,1.0,,,2645.0,,H,BAO_0000357,,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,17175.0,,B,,,Expert,CHEMBL618895,1.0,,,2646.0,,H,BAO_0000219,NIH3T3,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,12687.0,723.0
9.0,13278.0,,B,,,Expert,CHEMBL618896,1.0,,,2647.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,12687.0,
8.0,3682.0,5383.0,B,,,Autocuration,CHEMBL618897,1.0,Caudate-putamen,,2648.0,,H,BAO_0000019,,,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,12687.0,
8.0,2014.0,,B,,,Autocuration,CHEMBL618898,1.0,,,2649.0,,H,BAO_0000357,,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,12687.0,
8.0,2014.0,,B,,,Autocuration,CHEMBL618899,1.0,,,2650.0,,H,BAO_0000357,,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,12687.0,
8.0,4932.0,,B,,,Autocuration,CHEMBL618900,1.0,,,2651.0,,H,BAO_0000357,,,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,12687.0,
8.0,4932.0,,B,,,Autocuration,CHEMBL618901,1.0,,,2652.0,,H,BAO_0000019,,,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,12687.0,
8.0,3935.0,,B,,,Autocuration,CHEMBL618902,1.0,,,2653.0,,H,BAO_0000357,,,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,12687.0,
9.0,5432.0,10000000.0,B,,,Expert,CHEMBL618903,1.0,Hippocampus,,2654.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,15818.0,,B,,,Autocuration,CHEMBL618904,1.0,,,2655.0,,H,BAO_0000357,,,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,13672.0,,B,,,Autocuration,CHEMBL618905,1.0,,,2656.0,,H,BAO_0000357,,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,12687.0,
8.0,13672.0,,B,,,Autocuration,CHEMBL618906,1.0,,,2657.0,,H,BAO_0000357,,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,12687.0,
8.0,14749.0,,B,,,Expert,CHEMBL618907,1.0,,,2658.0,,H,BAO_0000219,NIH3T3,,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,12687.0,723.0
8.0,13462.0,,B,,,Autocuration,CHEMBL618908,1.0,,,2659.0,,H,BAO_0000019,,,,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,12687.0,
8.0,15740.0,,B,,,Autocuration,CHEMBL617909,1.0,,,2660.0,,H,BAO_0000357,,,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,16647.0,,B,,,Expert,CHEMBL617910,1.0,,,2661.0,,H,BAO_0000019,,,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,12687.0,
8.0,13345.0,955.0,B,,,Autocuration,CHEMBL617911,1.0,Brain,,2662.0,,H,BAO_0000221,,,,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,12687.0,
8.0,16740.0,,B,,,Autocuration,CHEMBL872923,1.0,,,2663.0,,H,BAO_0000249,,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,12687.0,
8.0,16740.0,,B,,,Autocuration,CHEMBL617912,1.0,,,2664.0,,H,BAO_0000249,,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,12687.0,
9.0,15535.0,,B,,,Expert,CHEMBL617913,1.0,,,2665.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,12687.0,
8.0,16740.0,,B,,,Expert,CHEMBL617914,1.0,,,2666.0,,H,BAO_0000249,,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,12687.0,
8.0,16740.0,,B,,,Autocuration,CHEMBL617915,1.0,,,2667.0,,H,BAO_0000249,,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,12687.0,
8.0,16740.0,,B,,,Autocuration,CHEMBL617916,1.0,,,2668.0,,H,BAO_0000249,,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,12687.0,
9.0,4795.0,,B,,,Expert,CHEMBL617917,1.0,,,2669.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,12687.0,
8.0,8.0,,B,,,Expert,CHEMBL617918,1.0,,,2670.0,,H,BAO_0000019,,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,12687.0,
8.0,8.0,,B,,,Autocuration,CHEMBL617919,1.0,,,2671.0,,H,BAO_0000019,,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,12687.0,
9.0,17200.0,,B,,,Expert,CHEMBL617920,1.0,,,2672.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,12687.0,
9.0,2148.0,,B,,,Expert,CHEMBL617921,1.0,,,2673.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,12687.0,
5.0,13345.0,,B,,,Expert,CHEMBL617922,1.0,,,2674.0,,D,BAO_0000224,,10116.0,,Rattus norvegicus,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,105102.0,
8.0,5088.0,,B,,,Autocuration,CHEMBL617923,1.0,,,2675.0,,H,BAO_0000357,,,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,12687.0,
8.0,5088.0,,B,,,Autocuration,CHEMBL617924,1.0,,,2676.0,,H,BAO_0000357,,,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,12687.0,
8.0,17133.0,,B,,,Autocuration,CHEMBL617925,1.0,,,2677.0,,H,BAO_0000357,,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,12687.0,
9.0,17133.0,,B,,,Expert,CHEMBL617926,1.0,,,2678.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,12687.0,
8.0,16532.0,,B,,,Autocuration,CHEMBL617927,1.0,,,2679.0,,H,BAO_0000357,,,,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,12687.0,
8.0,15086.0,,B,,,Autocuration,CHEMBL617928,1.0,,,2680.0,,H,BAO_0000357,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,12687.0,
9.0,2309.0,,B,,,Expert,CHEMBL617929,1.0,,,2681.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,12687.0,
8.0,12953.0,,B,,,Expert,CHEMBL617930,1.0,,,2682.0,,H,BAO_0000019,,,,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,12687.0,
8.0,12953.0,,B,,,Autocuration,CHEMBL617931,1.0,,,2683.0,,H,BAO_0000019,,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,12687.0,
8.0,12953.0,,B,,,Autocuration,CHEMBL617932,1.0,,,2684.0,,H,BAO_0000019,,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,12687.0,
8.0,16659.0,,B,,,Autocuration,CHEMBL617933,1.0,,,2685.0,,H,BAO_0000219,CHO,,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,12687.0,449.0
8.0,16740.0,,B,,,Autocuration,CHEMBL617934,1.0,,,2686.0,,H,BAO_0000019,,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,12687.0,
8.0,16740.0,,B,,,Autocuration,CHEMBL617935,1.0,,,2687.0,,H,BAO_0000019,,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,12687.0,
8.0,17133.0,,B,,,Autocuration,CHEMBL617936,1.0,,,2688.0,,H,BAO_0000357,,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,12687.0,
8.0,17211.0,,B,,,Autocuration,CHEMBL617937,1.0,,,2689.0,,H,BAO_0000019,,,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,12687.0,
8.0,17331.0,,B,,,Autocuration,CHEMBL617938,1.0,,,2690.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,12687.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL617939,1.0,,,2691.0,,H,BAO_0000218,,,,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,12687.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL617940,1.0,,,2692.0,,H,BAO_0000218,,,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,12687.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL617941,1.0,,,2693.0,,H,BAO_0000218,,,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,12687.0,
8.0,15026.0,,B,,,Expert,CHEMBL617942,1.0,,,2694.0,,H,BAO_0000357,,,,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,12687.0,
8.0,15026.0,,B,,,Expert,CHEMBL617943,1.0,,,2695.0,,H,BAO_0000357,,,,,Ratio of pKi of 5-HT2A to that of D2 receptor,,12687.0,
4.0,16404.0,,B,,,Expert,CHEMBL617944,1.0,,,2696.0,,H,BAO_0000224,,,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,105093.0,
4.0,16404.0,,B,,,Expert,CHEMBL617945,1.0,,,2697.0,,H,BAO_0000224,,,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,105093.0,
4.0,16404.0,,B,,,Expert,CHEMBL617946,1.0,,,2698.0,,H,BAO_0000224,,,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,105075.0,
8.0,16404.0,,B,,,Autocuration,CHEMBL617947,1.0,,,2699.0,,H,BAO_0000357,,,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,12687.0,
8.0,16326.0,,B,,,Expert,CHEMBL617948,1.0,,,2700.0,,H,BAO_0000357,,,,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,12687.0,
8.0,15847.0,,F,,,Autocuration,CHEMBL858116,1.0,,,2701.0,,H,BAO_0000019,,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,12687.0,
8.0,15847.0,,F,,,Autocuration,CHEMBL617949,1.0,,,2702.0,,H,BAO_0000019,,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,12687.0,
8.0,15329.0,,F,,,Autocuration,CHEMBL617950,1.0,,,2703.0,,H,BAO_0000019,,,,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,12687.0,
8.0,16404.0,1515.0,F,,,Expert,CHEMBL617951,1.0,Thoracic aorta,,2704.0,,H,BAO_0000019,,,,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,12687.0,
8.0,16404.0,1515.0,F,,,Expert,CHEMBL617952,1.0,Thoracic aorta,,2705.0,,H,BAO_0000019,,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,12687.0,
8.0,16404.0,1515.0,F,,,Autocuration,CHEMBL617953,1.0,Thoracic aorta,,2706.0,,H,BAO_0000019,,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,12687.0,
8.0,12861.0,,B,,,Autocuration,CHEMBL617954,1.0,,,2707.0,,H,BAO_0000357,,,,,Binding activity radioligand.,,12687.0,
8.0,12861.0,,B,,,Expert,CHEMBL617955,1.0,,,2708.0,,H,BAO_0000019,,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,12687.0,
8.0,12861.0,,B,,,Autocuration,CHEMBL857071,1.0,,,2709.0,,H,BAO_0000019,,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,12687.0,
8.0,12490.0,,B,,,Expert,CHEMBL617270,1.0,,,2710.0,,H,BAO_0000019,,,,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,12687.0,
8.0,12827.0,,B,,,Autocuration,CHEMBL617271,1.0,,,2711.0,,H,BAO_0000219,N1E-115,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,12687.0,339.0
8.0,12827.0,,B,,,Autocuration,CHEMBL617272,1.0,,,2712.0,,H,BAO_0000219,N1E-115,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,12687.0,339.0
8.0,12918.0,,B,,,Autocuration,CHEMBL617273,1.0,,,2713.0,,H,BAO_0000019,,,,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,12687.0,
9.0,12919.0,,F,,,Expert,CHEMBL617274,1.0,,,2714.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,12687.0,
8.0,17723.0,,B,,,Autocuration,CHEMBL617275,1.0,,,2715.0,,H,BAO_0000357,,,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,108.0,
8.0,6013.0,,B,,,Autocuration,CHEMBL617276,1.0,,,2716.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,108.0,
8.0,16293.0,,B,,,Autocuration,CHEMBL617277,1.0,,,2717.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,108.0,
8.0,3857.0,,B,,,Expert,CHEMBL617278,1.0,,,2718.0,,H,BAO_0000019,,,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,108.0,
8.0,3857.0,,B,,,Expert,CHEMBL617279,1.0,,,2719.0,,H,BAO_0000019,,,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,108.0,
8.0,3857.0,,B,,,Expert,CHEMBL617280,1.0,,,2720.0,,H,BAO_0000019,,,,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,108.0,
8.0,15363.0,,B,,,Autocuration,CHEMBL617281,1.0,,,2721.0,,H,BAO_0000357,,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,108.0,
8.0,15363.0,,B,,,Autocuration,CHEMBL617282,1.0,,,2722.0,,H,BAO_0000357,,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,108.0,
8.0,16441.0,,B,,,Expert,CHEMBL617283,1.0,,,2723.0,,H,BAO_0000019,,,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,108.0,
8.0,16441.0,,B,,,Expert,CHEMBL617284,1.0,,,2724.0,,H,BAO_0000019,,,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,108.0,
8.0,4176.0,,B,,,Autocuration,CHEMBL617285,1.0,,,2725.0,,H,BAO_0000219,HEK293,,,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,108.0,722.0
8.0,17085.0,,B,,,Autocuration,CHEMBL617286,1.0,,,2726.0,,H,BAO_0000019,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,108.0,
9.0,17200.0,,B,,,Expert,CHEMBL617287,1.0,,,2727.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,108.0,
8.0,5088.0,,B,,,Expert,CHEMBL617288,1.0,,,2728.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,108.0,
8.0,5088.0,,B,,,Autocuration,CHEMBL617289,1.0,,,2729.0,,H,BAO_0000357,,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,108.0,
8.0,5088.0,,B,,,Autocuration,CHEMBL872917,1.0,,,2730.0,,H,BAO_0000357,,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,108.0,
8.0,5088.0,,B,,,Autocuration,CHEMBL617290,1.0,,,2731.0,,H,BAO_0000357,,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,108.0,
8.0,16659.0,,B,,,Autocuration,CHEMBL617291,1.0,,,2732.0,,H,BAO_0000219,CHO,,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,108.0,449.0
8.0,16659.0,,B,,,Autocuration,CHEMBL617292,1.0,,,2733.0,,H,BAO_0000219,CHO,,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,108.0,449.0
8.0,17451.0,,B,,,Autocuration,CHEMBL617293,1.0,,,2734.0,,H,BAO_0000219,NIH3T3,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,108.0,723.0
9.0,6857.0,,F,,,Expert,CHEMBL617294,1.0,,,2735.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,108.0,449.0
8.0,3857.0,,B,,,Expert,CHEMBL617295,1.0,,,2736.0,,H,BAO_0000019,,,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,108.0,
8.0,12861.0,,B,,,Autocuration,CHEMBL617296,1.0,,,2737.0,,H,BAO_0000357,,,,,Binding activity radioligand.,,108.0,
8.0,12861.0,,B,,,Autocuration,CHEMBL617297,1.0,,,2738.0,,H,BAO_0000019,,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,108.0,
8.0,5104.0,,B,,,Expert,CHEMBL617298,1.0,,,2739.0,,H,BAO_0000219,CHO,,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,108.0,449.0
8.0,5105.0,,B,,,Expert,CHEMBL617299,1.0,,,2740.0,,H,BAO_0000219,CHO,,,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,108.0,449.0
8.0,5105.0,,B,,,Autocuration,CHEMBL617300,1.0,,,2741.0,,H,BAO_0000219,CHO,,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,108.0,449.0
8.0,5254.0,,B,,,Autocuration,CHEMBL617454,1.0,,,2742.0,,H,BAO_0000357,,,,,Binding affinity against 5-HT2C receptor,,108.0,
8.0,13267.0,,B,,,Autocuration,CHEMBL617505,1.0,,,2743.0,,H,BAO_0000219,HEK293,,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,108.0,722.0
9.0,14157.0,,B,,,Expert,CHEMBL617506,1.0,,,2744.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,108.0,722.0
9.0,12936.0,,B,,,Expert,CHEMBL617507,1.0,,,2745.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,108.0,722.0
8.0,14068.0,,B,,,Expert,CHEMBL617508,1.0,,,2746.0,,H,BAO_0000357,,,,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,108.0,
9.0,12936.0,,B,,,Expert,CHEMBL857982,1.0,,,2747.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,108.0,722.0
9.0,4540.0,,B,,,Expert,CHEMBL617509,1.0,,,2748.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,108.0,722.0
9.0,4540.0,,B,,,Expert,CHEMBL617510,1.0,,,2749.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,108.0,722.0
8.0,6166.0,,B,,,Autocuration,CHEMBL617511,1.0,,,2750.0,,H,BAO_0000357,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,108.0,
8.0,17296.0,,B,,,Autocuration,CHEMBL617512,1.0,,,2751.0,,H,BAO_0000219,HEK293,,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,108.0,722.0
8.0,17296.0,,B,,,Autocuration,CHEMBL617749,1.0,,,2752.0,,H,BAO_0000219,HEK293,,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,108.0,722.0
8.0,15779.0,,B,,,Autocuration,CHEMBL617750,1.0,,,2753.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,108.0,722.0
8.0,15779.0,,B,,,Autocuration,CHEMBL617751,1.0,,,2754.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,108.0,722.0
8.0,14391.0,,B,,,Expert,CHEMBL617752,1.0,,,2755.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,108.0,722.0
8.0,15779.0,,B,,,Autocuration,CHEMBL617753,1.0,,,2756.0,,H,BAO_0000219,HEK293,,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,108.0,722.0
8.0,15851.0,,B,,,Expert,CHEMBL617754,1.0,,,2757.0,,H,BAO_0000219,HEK293,,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,108.0,722.0
9.0,15851.0,,B,,,Expert,CHEMBL617755,1.0,,,2758.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,108.0,722.0
8.0,15779.0,,B,,,Autocuration,CHEMBL617756,1.0,,,2759.0,,H,BAO_0000219,HEK293,,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,108.0,722.0
8.0,3832.0,,B,,,Expert,CHEMBL617757,1.0,,,2760.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,108.0,722.0
8.0,3833.0,,B,,,Expert,CHEMBL617758,1.0,,,2761.0,,H,BAO_0000219,HEK293,,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,108.0,722.0
8.0,17451.0,,B,,,Autocuration,CHEMBL617759,1.0,,,2762.0,,H,BAO_0000219,NIH3T3,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,108.0,723.0
8.0,4199.0,,B,,,Autocuration,CHEMBL617760,1.0,,,2763.0,,H,BAO_0000219,HEK293,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,108.0,722.0
8.0,1883.0,,B,,,Expert,CHEMBL617761,1.0,,,2764.0,,H,BAO_0000219,CHO-K1,,,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,108.0,485.0
9.0,4321.0,,B,,,Expert,CHEMBL617762,1.0,,,2765.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity against 5-hydroxytryptamine 2C receptor,,108.0,
8.0,14875.0,,B,,,Autocuration,CHEMBL617763,1.0,,,2766.0,,H,BAO_0000357,,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,108.0,
8.0,15146.0,,B,,,Autocuration,CHEMBL857983,1.0,,,2767.0,,H,BAO_0000219,HEK293,,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,108.0,722.0
8.0,5213.0,,B,,,Autocuration,CHEMBL617764,1.0,,,2768.0,,H,BAO_0000219,HEK293,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,108.0,722.0
8.0,16404.0,,B,,,Autocuration,CHEMBL617765,1.0,,,2769.0,,H,BAO_0000219,HeLa,,,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,108.0,308.0
8.0,13267.0,,F,,,Autocuration,CHEMBL617766,1.0,,,2770.0,,H,BAO_0000019,,,,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,108.0,
8.0,13267.0,10000000.0,F,,,Autocuration,CHEMBL617767,1.0,Hippocampus,,2771.0,,H,BAO_0000221,,,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,108.0,
8.0,14818.0,,B,,,Autocuration,CHEMBL617768,1.0,,,2772.0,,H,BAO_0000219,HEK293,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,108.0,722.0
8.0,4829.0,,B,,,Autocuration,CHEMBL617769,1.0,,,2773.0,,H,BAO_0000219,HEK293,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,108.0,722.0
8.0,13463.0,,B,,,Autocuration,CHEMBL858023,1.0,,,2774.0,,H,BAO_0000357,,,,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,11864.0,
8.0,13463.0,945.0,B,,,Autocuration,CHEMBL617770,1.0,Stomach,,2775.0,,H,BAO_0000019,,,,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,11864.0,
8.0,13463.0,945.0,B,,,Autocuration,CHEMBL617771,1.0,Stomach,,2776.0,,H,BAO_0000019,,,,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,11864.0,
8.0,12652.0,,F,,,Autocuration,CHEMBL617772,1.0,,,2777.0,,H,BAO_0000219,A9,,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,11864.0,625.0
8.0,4682.0,,B,,,Autocuration,CHEMBL617773,1.0,,,2778.0,,H,BAO_0000219,NIH3T3,,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,11864.0,723.0
8.0,4682.0,,B,,,Autocuration,CHEMBL617850,1.0,,,2779.0,,H,BAO_0000219,NIH3T3,,,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,11864.0,723.0
8.0,4682.0,,B,,,Autocuration,CHEMBL617851,1.0,,,2780.0,,H,BAO_0000219,NIH3T3,,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,11864.0,723.0
8.0,12652.0,,F,,,Autocuration,CHEMBL617852,1.0,,,2781.0,,H,BAO_0000019,,,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,11864.0,
8.0,13463.0,945.0,B,,,Autocuration,CHEMBL858024,1.0,Stomach,,2782.0,,H,BAO_0000019,,10090.0,,Mus musculus,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,12689.0,
9.0,13463.0,945.0,B,,,Expert,CHEMBL617853,1.0,Stomach,,2783.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,12689.0,
8.0,13969.0,,B,,,Expert,CHEMBL617854,1.0,,,2784.0,,H,BAO_0000357,,,,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,108.0,
8.0,13392.0,,B,,,Expert,CHEMBL873477,1.0,,,2785.0,,H,BAO_0000357,,9823.0,,Sus scrofa,Binding affinity for 5-hydroxytryptamine 2C receptor,,108.0,
8.0,13392.0,,B,,,Expert,CHEMBL617855,1.0,,,2786.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,108.0,
8.0,14430.0,,B,,,Expert,CHEMBL617856,1.0,,,2787.0,,H,BAO_0000019,,,,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,108.0,
8.0,1742.0,,B,,,Autocuration,CHEMBL617857,1.0,,,2788.0,,H,BAO_0000019,,,,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,108.0,
8.0,14286.0,,B,,,Autocuration,CHEMBL617858,1.0,,,2789.0,,H,BAO_0000249,,,,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,108.0,
8.0,5619.0,,B,,,Autocuration,CHEMBL617859,1.0,,,2790.0,,H,BAO_0000357,,,,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,108.0,
8.0,15086.0,,B,,,Autocuration,CHEMBL617860,1.0,,,2791.0,,H,BAO_0000357,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,108.0,
8.0,12861.0,,B,,,Autocuration,CHEMBL617861,1.0,,,2792.0,,H,BAO_0000357,,,,,Binding activity radioligand.,,108.0,
8.0,12861.0,,B,,,Expert,CHEMBL617862,1.0,,,2793.0,,H,BAO_0000019,,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,108.0,
8.0,12861.0,,B,,,Autocuration,CHEMBL617863,1.0,,,2794.0,,H,BAO_0000019,,,,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,108.0,
8.0,12827.0,,B,,,Autocuration,CHEMBL617864,1.0,,,2795.0,,H,BAO_0000249,,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,108.0,
8.0,12827.0,,B,,,Autocuration,CHEMBL617649,1.0,,,2796.0,,H,BAO_0000249,,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,108.0,
8.0,12919.0,,F,,,Expert,CHEMBL617650,1.0,,,2797.0,,H,BAO_0000019,,9823.0,,Sus scrofa,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,108.0,
8.0,12919.0,,F,,,Expert,CHEMBL617651,1.0,,,2798.0,,H,BAO_0000019,,9823.0,,Sus scrofa,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,108.0,
8.0,16429.0,,B,,,Autocuration,CHEMBL617652,1.0,,,2799.0,,H,BAO_0000357,,9823.0,,Sus scrofa,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,108.0,
8.0,773.0,,B,,,Autocuration,CHEMBL857072,1.0,,,2800.0,,H,BAO_0000019,,9823.0,,Sus scrofa,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,108.0,
8.0,5033.0,,B,,,Autocuration,CHEMBL617653,1.0,,,2801.0,,H,BAO_0000357,,9823.0,,Sus scrofa,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,108.0,
8.0,12861.0,,B,,,Autocuration,CHEMBL617654,1.0,,,2802.0,,H,BAO_0000019,,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,12687.0,
8.0,14093.0,,F,,,Autocuration,CHEMBL617655,1.0,,,2803.0,,H,BAO_0000019,,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,12689.0,
8.0,14970.0,,B,,,Expert,CHEMBL617656,1.0,,,2804.0,,H,BAO_0000357,,,,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,12689.0,
8.0,14970.0,,B,,,Autocuration,CHEMBL617657,1.0,,,2805.0,,H,BAO_0000357,,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,12689.0,
8.0,14970.0,,B,,,Autocuration,CHEMBL617658,1.0,,,2806.0,,H,BAO_0000357,,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,12689.0,
9.0,14178.0,,B,,,Expert,CHEMBL617659,1.0,,,2807.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,12689.0,
9.0,14178.0,,B,,,Expert,CHEMBL617838,1.0,,,2808.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,12689.0,
9.0,14229.0,,B,Brain membranes,,Expert,CHEMBL617839,1.0,,,2809.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,12689.0,
8.0,16532.0,,B,,,Autocuration,CHEMBL617840,1.0,,,2810.0,,H,BAO_0000357,,,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,12689.0,
8.0,14826.0,,B,,,Autocuration,CHEMBL617841,1.0,,,2811.0,,H,BAO_0000019,,,,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,12689.0,
8.0,17211.0,,B,,,Autocuration,CHEMBL875915,1.0,,,2812.0,,H,BAO_0000019,,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,12689.0,
8.0,17211.0,,B,,,Expert,CHEMBL617842,1.0,,,2813.0,In vitro,H,BAO_0000219,,,,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,12689.0,
8.0,13246.0,,B,,,Expert,CHEMBL617843,1.0,,,2814.0,,H,BAO_0000219,NIH3T3,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,12689.0,723.0
8.0,13246.0,,B,,,Expert,CHEMBL617844,1.0,,,2815.0,,H,BAO_0000357,,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,12689.0,
8.0,12457.0,,B,,,Expert,CHEMBL617845,1.0,,,2816.0,,H,BAO_0000357,,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,12689.0,
8.0,12457.0,,B,,,Expert,CHEMBL617846,1.0,,,2817.0,,H,BAO_0000219,NIH3T3,,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,12689.0,723.0
8.0,4707.0,,B,,,Autocuration,CHEMBL617847,1.0,,,2818.0,,H,BAO_0000357,,,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,12689.0,
8.0,13297.0,,B,,,Expert,CHEMBL617848,1.0,,,2819.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 2C receptor,,12689.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL617849,1.0,,,2820.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,12689.0,
8.0,16133.0,,B,,,Expert,CHEMBL621507,1.0,,,2821.0,,H,BAO_0000357,,,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,12689.0,
8.0,16326.0,,B,,,Expert,CHEMBL621508,1.0,,,2822.0,,H,BAO_0000357,,,,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,12689.0,
8.0,14423.0,,B,,,Autocuration,CHEMBL621509,1.0,,,2823.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,12689.0,
8.0,15412.0,,B,,,Autocuration,CHEMBL621510,1.0,,,2824.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,12689.0,
8.0,15412.0,,B,,,Autocuration,CHEMBL621511,1.0,,,2825.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,12689.0,
8.0,15558.0,,B,,,Expert,CHEMBL621512,1.0,,,2826.0,,H,BAO_0000219,A9,,,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,12689.0,625.0
8.0,16633.0,,B,,,Autocuration,CHEMBL621513,1.0,,,2827.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,12689.0,
8.0,6013.0,,B,,,Expert,CHEMBL621514,1.0,,,2828.0,,H,BAO_0000357,,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,12689.0,
8.0,17175.0,,B,,,Expert,CHEMBL621515,1.0,,,2829.0,In vitro,H,BAO_0000219,,,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,12689.0,
8.0,12469.0,,B,,,Autocuration,CHEMBL621516,1.0,,,2830.0,,H,BAO_0000219,,,,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,12689.0,
8.0,3682.0,5383.0,B,,,Autocuration,CHEMBL621517,1.0,Caudate-putamen,,2831.0,,H,BAO_0000019,,,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,12689.0,
8.0,4932.0,,B,,,Autocuration,CHEMBL621518,1.0,,,2832.0,,H,BAO_0000357,,,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,12689.0,
8.0,4932.0,,B,,,Autocuration,CHEMBL621519,1.0,,,2833.0,,H,BAO_0000019,,,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,12689.0,
8.0,3935.0,,B,,,Autocuration,CHEMBL621520,1.0,,,2834.0,,H,BAO_0000357,,,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,12689.0,
8.0,15818.0,,B,,,Autocuration,CHEMBL621521,1.0,,,2835.0,,H,BAO_0000357,,,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,12689.0,
8.0,15818.0,,B,,,Autocuration,CHEMBL621522,1.0,,,2836.0,,H,BAO_0000357,,,,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,12689.0,
8.0,14749.0,,B,,,Expert,CHEMBL621523,1.0,,,2837.0,,H,BAO_0000219,,,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,12689.0,
8.0,15740.0,,B,,,Autocuration,CHEMBL621524,1.0,,,2838.0,,H,BAO_0000357,,,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,12689.0,
9.0,17133.0,,B,,,Expert,CHEMBL621525,1.0,,,2839.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,12689.0,
8.0,16532.0,,B,,,Autocuration,CHEMBL872921,1.0,,,2840.0,,H,BAO_0000357,,,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,12689.0,
8.0,12369.0,,B,,,Autocuration,CHEMBL621526,1.0,,,2841.0,,H,BAO_0000357,,,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,12689.0,
8.0,12369.0,,B,,,Expert,CHEMBL621527,1.0,,,2842.0,,H,BAO_0000219,,,,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,12689.0,
9.0,2309.0,,B,,,Expert,CHEMBL617865,1.0,,,2843.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,12689.0,
8.0,12953.0,,B,,,Autocuration,CHEMBL617866,1.0,,,2844.0,,H,BAO_0000357,,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,12689.0,
8.0,12953.0,,B,,,Autocuration,CHEMBL617867,1.0,,,2845.0,,H,BAO_0000019,,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,12689.0,
8.0,12953.0,,B,,,Autocuration,CHEMBL617487,1.0,,,2846.0,,H,BAO_0000357,,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,12689.0,
8.0,12953.0,,B,,,Expert,CHEMBL617488,1.0,,,2847.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,,12689.0,
8.0,17133.0,,B,,,Autocuration,CHEMBL617489,1.0,,,2848.0,,H,BAO_0000357,,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,12689.0,
8.0,17211.0,,B,,,Autocuration,CHEMBL617490,1.0,,,2849.0,,H,BAO_0000019,,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,12689.0,
8.0,17211.0,,B,,,Autocuration,CHEMBL617491,1.0,,,2850.0,,H,BAO_0000019,,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,12689.0,
8.0,14025.0,,B,,,Autocuration,CHEMBL617492,1.0,,,2851.0,,H,BAO_0000019,,,,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,12689.0,
8.0,14998.0,,B,,,Autocuration,CHEMBL617493,1.0,,,2852.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,12689.0,
8.0,4342.0,,B,,,Autocuration,CHEMBL617494,1.0,,,2853.0,,H,BAO_0000357,,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,12689.0,
9.0,13735.0,,B,,,Expert,CHEMBL617495,1.0,,,2854.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,12689.0,
8.0,13181.0,,B,,,Autocuration,CHEMBL617496,1.0,,,2855.0,,H,BAO_0000357,,,,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,12689.0,
8.0,1883.0,,B,,,Autocuration,CHEMBL617497,1.0,,,2856.0,,H,BAO_0000219,CHO-K1,,,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,12689.0,485.0
8.0,15194.0,,B,,,Autocuration,CHEMBL617498,1.0,,,2857.0,,H,BAO_0000357,,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,12689.0,
8.0,15194.0,,B,,,Autocuration,CHEMBL617499,1.0,,,2858.0,,H,BAO_0000357,,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,12689.0,
8.0,14579.0,,F,,,Autocuration,CHEMBL617500,1.0,,,2859.0,,H,BAO_0000019,,,,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,12689.0,
8.0,4639.0,,B,,,Autocuration,CHEMBL617501,1.0,,,2860.0,,H,BAO_0000357,,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,108.0,
8.0,4820.0,,B,,,Expert,CHEMBL617502,1.0,,,2861.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,108.0,
8.0,14442.0,,B,,,Autocuration,CHEMBL617503,1.0,,,2862.0,,H,BAO_0000357,,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,227.0,
8.0,14755.0,,B,,,Autocuration,CHEMBL617504,1.0,,,2863.0,,H,BAO_0000357,,,,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,227.0,
8.0,14744.0,,B,,,Autocuration,CHEMBL617406,1.0,,,2864.0,,H,BAO_0000357,,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,227.0,
9.0,6857.0,,B,,,Expert,CHEMBL617407,1.0,,,2865.0,,D,BAO_0000019,,9606.0,,Homo sapiens,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,227.0,
8.0,16209.0,,B,,,Autocuration,CHEMBL617408,1.0,,,2866.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,227.0,
8.0,15363.0,,B,,,Autocuration,CHEMBL617409,1.0,,,2867.0,,H,BAO_0000357,,,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,227.0,
8.0,15363.0,,B,,,Autocuration,CHEMBL617410,1.0,,,2868.0,,H,BAO_0000357,,,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,227.0,
8.0,15363.0,,B,,,Autocuration,CHEMBL617411,1.0,,,2869.0,,H,BAO_0000357,,,,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,227.0,
8.0,17085.0,,B,,,Autocuration,CHEMBL617412,1.0,,,2870.0,,H,BAO_0000019,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,227.0,
9.0,17200.0,,B,,,Expert,CHEMBL617774,1.0,,,2871.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,227.0,
9.0,15851.0,,B,,,Expert,CHEMBL617775,1.0,,,2872.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,227.0,722.0
9.0,15851.0,,B,,,Expert,CHEMBL617776,1.0,,,2873.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,227.0,722.0
9.0,6857.0,,F,,,Expert,CHEMBL617777,1.0,,,2874.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,227.0,449.0
9.0,6857.0,,F,,,Expert,CHEMBL617778,1.0,,,2875.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,227.0,449.0
8.0,15779.0,,B,,,Autocuration,CHEMBL617779,1.0,,,2876.0,,H,BAO_0000219,HEK293,,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,227.0,722.0
8.0,15851.0,,B,,,Expert,CHEMBL617780,1.0,,,2877.0,,H,BAO_0000219,HEK293,,,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,227.0,722.0
8.0,15779.0,,B,,,Autocuration,CHEMBL617781,1.0,,,2878.0,,H,BAO_0000219,HEK293,,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,227.0,722.0
9.0,14157.0,,B,,,Expert,CHEMBL617782,1.0,,,2879.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,227.0,722.0
9.0,4540.0,,B,,,Expert,CHEMBL617783,1.0,,,2880.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,227.0,722.0
8.0,6166.0,,B,,,Autocuration,CHEMBL617784,1.0,,,2881.0,,H,BAO_0000357,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,227.0,
8.0,15779.0,,B,,,Autocuration,CHEMBL617785,1.0,,,2882.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,227.0,722.0
8.0,14391.0,,B,,,Expert,CHEMBL857984,1.0,,,2883.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,227.0,722.0
8.0,3832.0,,B,,,Expert,CHEMBL617786,1.0,,,2884.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,227.0,722.0
8.0,3833.0,,B,,,Expert,CHEMBL617787,1.0,,,2885.0,,H,BAO_0000219,HEK293,,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,227.0,722.0
9.0,15851.0,,B,,,Expert,CHEMBL617788,1.0,,,2886.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,227.0,722.0
9.0,15851.0,,B,,,Expert,CHEMBL617789,1.0,,,2887.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,227.0,722.0
8.0,4199.0,,B,,,Autocuration,CHEMBL617790,1.0,,,2888.0,,H,BAO_0000219,HEK293,,,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,227.0,722.0
8.0,1883.0,,B,,,Expert,CHEMBL617791,1.0,,,2889.0,,H,BAO_0000219,CHO-K1,,,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,227.0,485.0
8.0,4321.0,,B,,,Expert,CHEMBL617608,1.0,,,2890.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 2B receptor,,227.0,
8.0,15146.0,,B,,,Autocuration,CHEMBL617609,1.0,,,2891.0,,H,BAO_0000219,HEK293,,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,227.0,722.0
8.0,5213.0,,B,,,Autocuration,CHEMBL617610,1.0,,,2892.0,,H,BAO_0000219,HEK293,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,227.0,722.0
8.0,14818.0,,B,,,Autocuration,CHEMBL617611,1.0,,,2893.0,,H,BAO_0000219,HEK293,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,227.0,722.0
8.0,4829.0,,B,,,Autocuration,CHEMBL617612,1.0,,,2894.0,,H,BAO_0000219,HEK293,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,227.0,722.0
8.0,4829.0,,B,,,Autocuration,CHEMBL617613,1.0,,,2895.0,,H,BAO_0000219,HEK293,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,227.0,722.0
8.0,14025.0,,B,,,Autocuration,CHEMBL617614,1.0,,,2896.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,227.0,
8.0,13463.0,945.0,B,,,Expert,CHEMBL617615,1.0,Stomach,,2897.0,,H,BAO_0000019,,,,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,12688.0,
8.0,7259.0,945.0,B,,,Expert,CHEMBL858114,1.0,Stomach,,2898.0,,H,BAO_0000357,,,,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,12688.0,
8.0,7259.0,945.0,B,,,Autocuration,CHEMBL617616,1.0,Stomach,,2899.0,,H,BAO_0000357,,,,,Affinity against serotonergic receptor in the isolated rat stomach fundus,,12688.0,
9.0,7185.0,945.0,F,,,Expert,CHEMBL617617,1.0,Stomach,,2900.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,12688.0,
9.0,7185.0,,F,,,Expert,CHEMBL875914,1.0,,,2901.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Antagonistic against 5-hydroxytryptamine 2B receptor,,12688.0,
8.0,13267.0,945.0,F,,,Autocuration,CHEMBL617618,1.0,Stomach,,2902.0,,H,BAO_0000019,,,,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,12688.0,
9.0,13735.0,945.0,B,,,Expert,CHEMBL617619,1.0,Stomach,,2903.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,12688.0,
8.0,15738.0,,F,,,Autocuration,CHEMBL617620,1.0,,,2904.0,,H,BAO_0000019,,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,12688.0,
8.0,15738.0,,F,,,Autocuration,CHEMBL617621,1.0,,,2905.0,,H,BAO_0000019,,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,12688.0,
8.0,15738.0,,F,,,Autocuration,CHEMBL617622,1.0,,,2906.0,,H,BAO_0000019,,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,12688.0,
9.0,12936.0,945.0,B,,,Expert,CHEMBL617623,1.0,Stomach,,2907.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,12688.0,
9.0,12936.0,945.0,B,,,Expert,CHEMBL617624,1.0,Stomach,,2908.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,12688.0,
9.0,12936.0,945.0,B,,,Expert,CHEMBL617625,1.0,Stomach,,2909.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,12688.0,
9.0,12936.0,945.0,B,,,Expert,CHEMBL617626,1.0,Stomach,,2910.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,12688.0,
8.0,16404.0,945.0,F,,,Autocuration,CHEMBL617627,1.0,Stomach,,2911.0,,H,BAO_0000019,,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,12688.0,
8.0,16404.0,945.0,F,,,Expert,CHEMBL617628,1.0,Stomach,,2912.0,,H,BAO_0000019,,,,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,12688.0,
8.0,16404.0,945.0,F,,,Autocuration,CHEMBL617629,1.0,Stomach,,2913.0,,H,BAO_0000019,,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,12688.0,
8.0,16404.0,945.0,F,,,Autocuration,CHEMBL858115,1.0,Stomach,,2914.0,,H,BAO_0000019,,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,12688.0,
9.0,16404.0,945.0,F,,,Expert,CHEMBL617630,1.0,Stomach,,2915.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,12688.0,
8.0,16404.0,1515.0,F,,,Autocuration,CHEMBL617631,1.0,Thoracic aorta,,2916.0,,H,BAO_0000019,,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,12688.0,
8.0,7483.0,,B,,,Autocuration,CHEMBL617632,1.0,,,2917.0,,H,BAO_0000357,,,,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,12688.0,
8.0,7483.0,,B,,,Expert,CHEMBL617633,1.0,,,2918.0,,H,BAO_0000357,,,,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,12688.0,
8.0,7483.0,,B,,,Autocuration,CHEMBL617634,1.0,,,2919.0,,H,BAO_0000357,,,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,12688.0,
8.0,7483.0,,B,,,Autocuration,CHEMBL617635,1.0,,,2920.0,,H,BAO_0000357,,,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,12688.0,
9.0,16404.0,945.0,F,,,Autocuration,CHEMBL617637,1.0,Stomach,,2922.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,12688.0,
8.0,6347.0,,B,,,Autocuration,CHEMBL617638,1.0,,,2923.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,227.0,
8.0,4373.0,,B,,,Autocuration,CHEMBL617639,1.0,,,2924.0,,H,BAO_0000357,,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,227.0,
8.0,4373.0,,B,,,Autocuration,CHEMBL617640,1.0,,,2925.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,227.0,
8.0,4687.0,,B,,,Autocuration,CHEMBL617641,1.0,,,2926.0,,H,BAO_0000357,,,,,Evaluated for the binding affinity to 5-HT 2B receptor,,227.0,
8.0,16946.0,,B,,,Autocuration,CHEMBL617642,1.0,,,2927.0,,H,BAO_0000357,,,,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,227.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL617643,1.0,,,2928.0,,H,BAO_0000357,,,,,Binding affinities against 5-hydroxytryptamine 2B receptor,,227.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL617644,1.0,,,2929.0,,H,BAO_0000357,,,,,Binding affinities towards 5-hydroxytryptamine 2B receptor,,227.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL617645,1.0,,,2930.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,227.0,
8.0,15026.0,,B,,,Expert,CHEMBL617646,1.0,,,2931.0,,H,BAO_0000357,,,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,108.0,
8.0,15738.0,,B,,,Autocuration,CHEMBL617647,1.0,,,2932.0,,H,BAO_0000357,,9913.0,,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,108.0,
8.0,15738.0,,B,,,Autocuration,CHEMBL617648,1.0,,,2933.0,,H,BAO_0000357,,9913.0,,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,108.0,
8.0,15738.0,,B,,,Autocuration,CHEMBL617875,1.0,,,2934.0,,H,BAO_0000357,,9913.0,,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,108.0,
8.0,15738.0,,B,,,Autocuration,CHEMBL617876,1.0,,,2935.0,,H,BAO_0000357,,9913.0,,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,108.0,
8.0,16404.0,,B,,,Expert,CHEMBL617877,1.0,,,2936.0,,H,BAO_0000357,,9913.0,,Bos taurus,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,108.0,
8.0,15026.0,,B,,,Expert,CHEMBL617878,1.0,,,2937.0,,H,BAO_0000357,,9913.0,,Bos taurus,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,108.0,
8.0,15738.0,,B,,,Autocuration,CHEMBL617879,1.0,,,2938.0,,H,BAO_0000357,,9913.0,,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,108.0,
8.0,16312.0,,B,,,Autocuration,CHEMBL617880,1.0,,,2939.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,108.0,
9.0,5486.0,2435.0,B,,,Intermediate,CHEMBL617881,1.0,Striatum,,2940.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,20033.0,
8.0,5254.0,,B,,,Autocuration,CHEMBL857073,1.0,,,2941.0,,H,BAO_0000357,,,,,Binding affinity against 5-HT1A receptor,,51.0,
8.0,3857.0,,F,,,Expert,CHEMBL617882,1.0,,,2942.0,,H,BAO_0000219,CHO,,,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,108.0,449.0
9.0,6857.0,,F,,,Expert,CHEMBL617883,1.0,,,2943.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,108.0,449.0
8.0,4176.0,,F,,,Autocuration,CHEMBL617884,1.0,,,2944.0,,H,BAO_0000219,,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,108.0,
8.0,6347.0,,B,,,Autocuration,CHEMBL617885,1.0,,,2945.0,,H,BAO_0000219,CHO,,,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,108.0,449.0
8.0,6347.0,,B,,,Autocuration,CHEMBL617886,1.0,,,2946.0,,H,BAO_0000219,CHO,,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,108.0,449.0
9.0,16146.0,,B,,,Expert,CHEMBL617887,1.0,,,2947.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Inhibition of human 5-hydroxytryptamine 2C receptor,,108.0,
8.0,3805.0,,B,,,Autocuration,CHEMBL617888,1.0,,,2948.0,,H,BAO_0000357,,,,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,108.0,
8.0,3857.0,,B,,,Autocuration,CHEMBL617889,1.0,,,2949.0,,H,BAO_0000019,,,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,108.0,
8.0,5635.0,,B,,,Autocuration,CHEMBL617890,1.0,,,2950.0,,H,BAO_0000357,,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,108.0,
8.0,5635.0,,B,,,Autocuration,CHEMBL617891,1.0,,,2951.0,,H,BAO_0000357,,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,108.0,
8.0,5635.0,,B,,,Autocuration,CHEMBL617892,1.0,,,2952.0,,H,BAO_0000357,,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,108.0,
8.0,4012.0,,B,,,Expert,CHEMBL617893,1.0,,,2953.0,,H,BAO_0000219,CHO,,,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,108.0,449.0
8.0,6366.0,,B,,,Expert,CHEMBL617894,1.0,,,2954.0,,H,BAO_0000219,CHO,,,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,108.0,449.0
8.0,15949.0,,B,,,Expert,CHEMBL617895,1.0,,,2955.0,,H,BAO_0000219,CHO,,,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,108.0,449.0
8.0,17211.0,,B,,,Autocuration,CHEMBL617896,1.0,,,2956.0,,H,BAO_0000219,CHO,,,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,108.0,449.0
9.0,6491.0,,B,,,Expert,CHEMBL617897,1.0,,,2957.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,108.0,
8.0,14093.0,,F,,,Autocuration,CHEMBL617898,1.0,,,2958.0,,H,BAO_0000019,,,,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,108.0,
8.0,13481.0,,F,,,Autocuration,CHEMBL617899,1.0,,,2959.0,,H,BAO_0000019,,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,108.0,
8.0,6347.0,,B,,,Expert,CHEMBL617900,1.0,,,2960.0,,H,BAO_0000219,CHO,10116.0,,Rattus norvegicus,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,108.0,449.0
8.0,14093.0,,F,,,Autocuration,CHEMBL617901,1.0,,,2961.0,,H,BAO_0000019,,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,108.0,
8.0,14093.0,,F,,,Autocuration,CHEMBL617902,1.0,,,2962.0,,H,BAO_0000019,,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,108.0,
8.0,13481.0,,F,,,Autocuration,CHEMBL617903,1.0,,,2963.0,,H,BAO_0000019,,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,108.0,
8.0,14442.0,,B,,,Autocuration,CHEMBL617904,1.0,,,2964.0,,H,BAO_0000357,,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,108.0,
8.0,14442.0,,B,,,Autocuration,CHEMBL617905,1.0,,,2965.0,,H,BAO_0000357,,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,108.0,
8.0,14442.0,,B,,,Autocuration,CHEMBL617906,1.0,,,2966.0,,H,BAO_0000357,,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,108.0,
8.0,14755.0,,B,,,Autocuration,CHEMBL617907,1.0,,,2967.0,,H,BAO_0000357,,,,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,108.0,
8.0,14744.0,,B,,,Autocuration,CHEMBL617908,1.0,,,2968.0,,H,BAO_0000357,,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,108.0,
8.0,16659.0,,B,,,Expert,CHEMBL620617,1.0,,,2969.0,,H,BAO_0000219,CHO,,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,108.0,449.0
9.0,6857.0,,B,,,Expert,CHEMBL620618,1.0,,,2970.0,,D,BAO_0000019,,9606.0,,Homo sapiens,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,108.0,
8.0,5635.0,,B,,,Expert,CHEMBL620619,1.0,,,2971.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,108.0,
9.0,4234.0,,B,,,Expert,CHEMBL620620,1.0,,,2972.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,108.0,
8.0,16209.0,,B,,,Autocuration,CHEMBL620621,1.0,,,2973.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,108.0,
7.0,5778.0,,B,Membranes,,Autocuration,CHEMBL872920,1.0,,,2974.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,104698.0,
6.0,5094.0,,B,,,Autocuration,CHEMBL620622,1.0,,,2975.0,,H,BAO_0000223,,,,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,104698.0,
7.0,809.0,,B,,,Autocuration,CHEMBL620623,1.0,,,2976.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,104698.0,
6.0,1578.0,,B,,,Autocuration,CHEMBL620624,1.0,,,2977.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,104698.0,
6.0,809.0,,B,,,Autocuration,CHEMBL620625,1.0,,,2978.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,104698.0,
6.0,12469.0,,B,,,Autocuration,CHEMBL620626,1.0,,,2979.0,,H,BAO_0000219,,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,104698.0,
6.0,14290.0,,B,,,Autocuration,CHEMBL621307,1.0,,,2980.0,,H,BAO_0000019,,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,104698.0,
6.0,14290.0,,B,,,Autocuration,CHEMBL621308,1.0,,,2981.0,,H,BAO_0000019,,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,104698.0,
6.0,10609.0,,B,,,Autocuration,CHEMBL621309,1.0,,,2982.0,,H,BAO_0000223,,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,104698.0,
6.0,10609.0,,B,,,Autocuration,CHEMBL621310,1.0,,,2983.0,,H,BAO_0000223,,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,104698.0,
6.0,10609.0,,B,,,Autocuration,CHEMBL621311,1.0,,,2984.0,,H,BAO_0000223,,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,104698.0,
6.0,15253.0,,B,,,Autocuration,CHEMBL621502,1.0,,,2985.0,,H,BAO_0000249,,,,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,104698.0,
6.0,15253.0,,B,,,Autocuration,CHEMBL621503,1.0,,,2986.0,,H,BAO_0000249,,,,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,104698.0,
6.0,11683.0,,B,Membranes,,Autocuration,CHEMBL621504,1.0,,,2987.0,,H,BAO_0000249,,,,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,104698.0,
6.0,12092.0,,B,,,Autocuration,CHEMBL621505,1.0,,,2988.0,,H,BAO_0000223,,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,104698.0,
6.0,1946.0,,B,,,Autocuration,CHEMBL621506,1.0,,,2989.0,,H,BAO_0000019,,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,104698.0,
6.0,11623.0,,B,,,Autocuration,CHEMBL619781,1.0,,,2990.0,,H,BAO_0000223,,,,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,104698.0,
6.0,11623.0,,B,,,Autocuration,CHEMBL619782,1.0,,,2991.0,,H,BAO_0000223,,,,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,104698.0,
6.0,14788.0,,B,,,Autocuration,CHEMBL619783,1.0,,,2992.0,,H,BAO_0000019,,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,104698.0,
7.0,5432.0,,B,,,Autocuration,CHEMBL619784,1.0,,,2993.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,104698.0,
6.0,14826.0,,B,,,Autocuration,CHEMBL619785,1.0,,,2994.0,,H,BAO_0000249,,,,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,104698.0,
6.0,2222.0,,B,,,Autocuration,CHEMBL619786,1.0,,,2995.0,,H,BAO_0000223,,,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,104698.0,
6.0,11963.0,,B,,,Autocuration,CHEMBL619787,1.0,,,2996.0,,H,BAO_0000019,,,,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,104698.0,
6.0,14145.0,,B,,,Autocuration,CHEMBL872925,1.0,,,2997.0,,H,BAO_0000019,,,,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,104698.0,
6.0,17819.0,,B,,,Autocuration,CHEMBL619788,1.0,,,2998.0,,H,BAO_0000019,,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,104698.0,
6.0,10394.0,,B,,,Autocuration,CHEMBL619789,1.0,,,2999.0,,H,BAO_0000249,,,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,104698.0,
6.0,10394.0,,B,,,Autocuration,CHEMBL619790,1.0,,,3000.0,,H,BAO_0000249,,,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,104698.0,
6.0,15034.0,,B,,,Autocuration,CHEMBL619791,1.0,,,3001.0,,H,BAO_0000019,,,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,104698.0,
6.0,691.0,,B,,,Autocuration,CHEMBL619792,1.0,,,3002.0,,H,BAO_0000019,,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,104698.0,
6.0,12092.0,,B,Membranes,,Autocuration,CHEMBL619793,1.0,,,3003.0,,H,BAO_0000249,,,,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,104698.0,
7.0,11752.0,,B,,,Autocuration,CHEMBL619794,1.0,,,3004.0,,D,BAO_0000223,,10116.0,,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,104698.0,
6.0,11752.0,955.0,B,,,Autocuration,CHEMBL619795,1.0,Brain,,3005.0,,H,BAO_0000221,,,,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,104698.0,
6.0,301.0,,B,,,Autocuration,CHEMBL619796,1.0,,,3006.0,,H,BAO_0000019,,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,104698.0,
6.0,16532.0,,B,,,Autocuration,CHEMBL620448,1.0,,,3007.0,,H,BAO_0000223,,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,104698.0,
6.0,16532.0,,B,,,Autocuration,CHEMBL620449,1.0,,,3008.0,,H,BAO_0000223,,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,104698.0,
6.0,12092.0,,B,,,Autocuration,CHEMBL620450,1.0,,,3009.0,,H,BAO_0000223,,,,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,104698.0,
6.0,11684.0,,B,,,Autocuration,CHEMBL620451,1.0,,,3010.0,,H,BAO_0000223,,,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,104698.0,
6.0,11684.0,,B,,,Autocuration,CHEMBL620631,1.0,,,3011.0,,H,BAO_0000223,,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,104698.0,
6.0,12953.0,,B,,,Autocuration,CHEMBL620632,1.0,,,3012.0,,H,BAO_0000019,,,,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,104698.0,
6.0,12953.0,,B,,,Autocuration,CHEMBL620633,1.0,,,3013.0,,H,BAO_0000019,,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,104698.0,
6.0,12953.0,,B,,,Autocuration,CHEMBL620634,1.0,,,3014.0,,H,BAO_0000223,,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,104698.0,
6.0,12861.0,,B,,,Autocuration,CHEMBL620635,1.0,,,3015.0,,H,BAO_0000019,,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL620636,1.0,,,3016.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL620637,1.0,,,3017.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL620638,1.0,,,3018.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL620639,1.0,,,3019.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL620640,1.0,,,3020.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL620641,1.0,,,3021.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL620642,1.0,,,3022.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL620643,1.0,,,3023.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL620644,1.0,,,3024.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL620645,1.0,,,3025.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL620646,1.0,,,3026.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL620647,1.0,,,3027.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL620648,1.0,,,3028.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL620649,1.0,,,3029.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL620650,1.0,,,3030.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL620651,1.0,,,3031.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL872875,1.0,,,3032.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL620652,1.0,,,3033.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,104698.0,
6.0,10609.0,,F,,,Autocuration,CHEMBL620653,1.0,,,3034.0,,H,BAO_0000019,,,,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,104698.0,
6.0,12861.0,,B,,,Autocuration,CHEMBL857076,1.0,,,3035.0,,H,BAO_0000019,,,,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,104698.0,
7.0,12861.0,,B,,,Autocuration,CHEMBL620654,1.0,,,3036.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,104698.0,
6.0,12861.0,,B,,,Autocuration,CHEMBL620655,1.0,,,3037.0,,H,BAO_0000223,,,,,Binding activity radioligand.,,104698.0,
6.0,10728.0,,B,Brain membranes,,Autocuration,CHEMBL620656,1.0,,,3038.0,,H,BAO_0000249,,,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,104698.0,
6.0,10728.0,,B,Brain membranes,,Autocuration,CHEMBL620657,1.0,,,3039.0,,H,BAO_0000249,,,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,104698.0,
8.0,5163.0,,B,,,Autocuration,CHEMBL620658,1.0,,,3040.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,108.0,
8.0,5163.0,,B,,,Autocuration,CHEMBL620659,1.0,,,3041.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,108.0,
8.0,6011.0,,B,,,Autocuration,CHEMBL620660,1.0,,,3042.0,,H,BAO_0000357,,,,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,108.0,
8.0,5014.0,,B,,,Autocuration,CHEMBL620661,1.0,,,3043.0,,H,BAO_0000357,,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,108.0,
8.0,5635.0,,B,,,Autocuration,CHEMBL620662,1.0,,,3044.0,,H,BAO_0000357,,,,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,108.0,
8.0,5163.0,,B,,,Expert,CHEMBL620663,1.0,,,3045.0,,H,BAO_0000357,,,,,Affinity for 5-hydroxytryptamine 2C receptor,,108.0,
8.0,6841.0,,B,,,Autocuration,CHEMBL620664,1.0,,,3046.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,108.0,
8.0,6119.0,,B,,,Expert,CHEMBL620665,1.0,,,3047.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,108.0,
8.0,4373.0,,B,,,Autocuration,CHEMBL620666,1.0,,,3048.0,,H,BAO_0000357,,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,108.0,
8.0,1633.0,,B,,,Autocuration,CHEMBL620667,1.0,,,3049.0,,H,BAO_0000357,,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,108.0,
8.0,1633.0,,B,,,Expert,CHEMBL620668,1.0,,,3050.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,108.0,
8.0,4373.0,,B,,,Autocuration,CHEMBL620669,1.0,,,3051.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,108.0,
8.0,6576.0,,B,,,Expert,CHEMBL620670,1.0,,,3052.0,,H,BAO_0000357,,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,108.0,
8.0,4687.0,,B,,,Autocuration,CHEMBL620671,1.0,,,3053.0,,H,BAO_0000357,,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,108.0,
8.0,12146.0,,B,,,Autocuration,CHEMBL620672,1.0,,,3054.0,,H,BAO_0000357,,,,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,108.0,
8.0,12146.0,,B,,,Autocuration,CHEMBL620673,1.0,,,3055.0,,H,BAO_0000357,,,,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,108.0,
8.0,16946.0,,B,,,Autocuration,CHEMBL620674,1.0,,,3056.0,,H,BAO_0000357,,,,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,108.0,
8.0,14159.0,,B,,,Autocuration,CHEMBL620675,1.0,,,3057.0,,H,BAO_0000357,,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,108.0,
8.0,16700.0,,B,,,Autocuration,CHEMBL620676,1.0,,,3058.0,,H,BAO_0000357,,,,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,108.0,
8.0,3269.0,,B,,,Autocuration,CHEMBL621382,1.0,,,3059.0,,H,BAO_0000357,,,,,Affinity against 5-hydroxytryptamine 2C receptor,,108.0,
9.0,1274.0,,B,,,Expert,CHEMBL621383,1.0,,,3060.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity against 5-hydroxytryptamine 2C receptor,,108.0,
8.0,1317.0,,B,,,Autocuration,CHEMBL621384,1.0,,,3061.0,,H,BAO_0000357,,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,108.0,
8.0,5834.0,,B,,,Autocuration,CHEMBL621385,1.0,,,3062.0,,H,BAO_0000357,,9913.0,,Bos taurus,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,144.0,
8.0,11147.0,,B,,,Autocuration,CHEMBL617989,1.0,,,3063.0,,H,BAO_0000357,,9913.0,,Bos taurus,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,144.0,
4.0,14145.0,,F,,,Expert,CHEMBL617990,1.0,,,3064.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,104714.0,
4.0,10561.0,2116.0,B,,,Autocuration,CHEMBL875085,1.0,Ileum,,3065.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,104714.0,
4.0,15847.0,,F,,,Autocuration,CHEMBL617991,1.0,,,3066.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,104714.0,
4.0,15847.0,,F,,,Autocuration,CHEMBL617992,1.0,,,3067.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,104714.0,
4.0,10561.0,2116.0,B,,,Autocuration,CHEMBL617993,1.0,Ileum,,3068.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,104714.0,
4.0,11454.0,2116.0,B,,,Autocuration,CHEMBL617994,1.0,Ileum,,3069.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,104714.0,
4.0,4639.0,,F,,,Autocuration,CHEMBL617995,1.0,,,3070.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,104714.0,
4.0,4639.0,,F,,,Autocuration,CHEMBL617996,1.0,,,3071.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,104714.0,
4.0,4639.0,,F,,,Autocuration,CHEMBL617997,1.0,,,3072.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,104714.0,
4.0,4639.0,,F,,,Autocuration,CHEMBL617998,1.0,,,3073.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,104714.0,
4.0,4639.0,,F,,,Autocuration,CHEMBL617999,1.0,,,3074.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,104714.0,
4.0,4639.0,,F,,,Autocuration,CHEMBL618000,1.0,,,3075.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,104714.0,
4.0,15253.0,2116.0,F,,,Autocuration,CHEMBL617815,1.0,Ileum,,3076.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,104714.0,
4.0,15253.0,2116.0,F,,,Autocuration,CHEMBL617816,1.0,Ileum,,3077.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,104714.0,
4.0,11963.0,2116.0,F,,,Autocuration,CHEMBL617817,1.0,Ileum,,3078.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,104714.0,
4.0,1946.0,2116.0,B,,,Autocuration,CHEMBL617818,1.0,Ileum,,3079.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,104714.0,
4.0,1946.0,2116.0,B,,,Autocuration,CHEMBL617819,1.0,Ileum,,3080.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,104714.0,
4.0,12045.0,,B,,,Autocuration,CHEMBL617820,1.0,,,3081.0,,H,BAO_0000223,,10141.0,,Cavia porcellus,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,104714.0,
4.0,1559.0,2116.0,B,,,Autocuration,CHEMBL617821,1.0,Ileum,,3082.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,104714.0,
4.0,273.0,2116.0,F,,,Autocuration,CHEMBL617822,1.0,Ileum,,3083.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,104714.0,
4.0,273.0,2116.0,F,,,Autocuration,CHEMBL617823,1.0,Ileum,,3084.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,104714.0,
4.0,188.0,2116.0,F,,,Autocuration,CHEMBL617824,1.0,Ileum,,3085.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,104714.0,
4.0,12919.0,2116.0,F,,,Autocuration,CHEMBL617825,1.0,Ileum,,3086.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,104714.0,
4.0,12918.0,2116.0,F,,,Autocuration,CHEMBL617826,1.0,Ileum,,3087.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,104714.0,
4.0,1559.0,2116.0,B,,,Autocuration,CHEMBL617827,1.0,Ileum,,3088.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,104714.0,
4.0,273.0,2116.0,F,,,Autocuration,CHEMBL617828,1.0,Ileum,,3089.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,104714.0,
4.0,1559.0,2116.0,B,,,Autocuration,CHEMBL617829,1.0,Ileum,,3090.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,104714.0,
4.0,1559.0,2116.0,B,,,Autocuration,CHEMBL617830,1.0,Ileum,,3091.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,104714.0,
4.0,1559.0,2116.0,B,,,Autocuration,CHEMBL617831,1.0,Ileum,,3092.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,104714.0,
4.0,14424.0,2116.0,B,,,Autocuration,CHEMBL617832,1.0,Ileum,,3093.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,104714.0,
0.0,13181.0,,B,,,Autocuration,CHEMBL617833,1.0,,,3094.0,,U,BAO_0000019,,10141.0,,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,22226.0,
8.0,5486.0,,B,,,Autocuration,CHEMBL617834,1.0,,,3095.0,,H,BAO_0000357,,,,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,51.0,
5.0,6491.0,,B,,,Expert,CHEMBL617835,1.0,,,3096.0,,D,BAO_0000223,,9606.0,,Homo sapiens,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,104714.0,
4.0,6013.0,,B,,,Autocuration,CHEMBL617836,1.0,,,3097.0,,H,BAO_0000223,,,,,Binding affinity towards 5-HT3 receptor,,104714.0,
4.0,12861.0,,B,,,Autocuration,CHEMBL617837,1.0,,,3098.0,,H,BAO_0000223,,,,,Binding activity radioligand.,,104714.0,
4.0,12861.0,,B,,,Autocuration,CHEMBL620392,1.0,,,3099.0,,H,BAO_0000019,,,,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,104714.0,
4.0,5104.0,,B,,,Autocuration,CHEMBL620393,1.0,,,3100.0,,H,BAO_0000223,,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,104714.0,
4.0,5105.0,,B,,,Autocuration,CHEMBL620394,1.0,,,3101.0,,H,BAO_0000223,,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,104714.0,
4.0,5104.0,,B,,,Autocuration,CHEMBL620395,1.0,,,3102.0,,H,BAO_0000223,,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,104714.0,
0.0,3935.0,,B,,,Autocuration,CHEMBL620396,1.0,,,3103.0,,U,BAO_0000019,,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,22226.0,
4.0,13657.0,,B,,,Expert,CHEMBL620582,1.0,,,3104.0,,H,BAO_0000219,NG108-15,,,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,105030.0,433.0
4.0,10369.0,,B,,,Autocuration,CHEMBL620583,1.0,,,3105.0,In vivo,H,BAO_0000218,,,,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,105030.0,
4.0,10369.0,,B,,,Autocuration,CHEMBL620584,1.0,,,3106.0,,H,BAO_0000019,,,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,105030.0,
4.0,12918.0,,B,,,Autocuration,CHEMBL620585,1.0,,,3107.0,,H,BAO_0000224,,,,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,105030.0,
4.0,12918.0,,B,,,Autocuration,CHEMBL620586,1.0,,,3108.0,,H,BAO_0000224,,,,,Compound was evaluated for the binding affinity at 5- HT3 receptor,,105030.0,
4.0,10369.0,,B,,,Autocuration,CHEMBL620587,1.0,,,3109.0,,H,BAO_0000019,,,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,105030.0,
4.0,773.0,,B,,,Autocuration,CHEMBL620588,1.0,,,3110.0,,H,BAO_0000019,,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,105030.0,
4.0,12918.0,,F,,,Autocuration,CHEMBL620589,1.0,,,3111.0,,H,BAO_0000218,,,,,5-hydroxytryptamine 3 receptor agonism in mouse,,105030.0,
4.0,10561.0,,B,,,Autocuration,CHEMBL620590,1.0,,,3112.0,,H,BAO_0000219,,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,105030.0,
4.0,12827.0,,B,,,Autocuration,CHEMBL617956,1.0,,,3113.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,105030.0,
4.0,12827.0,,B,,,Autocuration,CHEMBL617957,1.0,,,3114.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,105030.0,
4.0,12918.0,,B,,,Autocuration,CHEMBL617958,1.0,,,3115.0,,H,BAO_0000224,,,,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,105030.0,
4.0,273.0,,B,,,Autocuration,CHEMBL617959,1.0,,,3116.0,,H,BAO_0000219,,,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,105030.0,
4.0,273.0,,B,,,Autocuration,CHEMBL617960,1.0,,,3117.0,,H,BAO_0000219,,,,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,105030.0,
4.0,10561.0,,B,,,Autocuration,CHEMBL617961,1.0,,,3118.0,,H,BAO_0000224,,,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,105030.0,
4.0,5033.0,,B,,,Autocuration,CHEMBL617962,1.0,,,3119.0,In vitro,H,BAO_0000219,,,,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,105030.0,
4.0,16429.0,,B,,,Autocuration,CHEMBL617963,1.0,,,3120.0,,H,BAO_0000219,N1E-115,,,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,105030.0,339.0
8.0,10322.0,,B,,,Autocuration,CHEMBL617964,1.0,,,3121.0,,H,BAO_0000019,,,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,11765.0,
8.0,14331.0,,B,,,Autocuration,CHEMBL617965,1.0,,,3122.0,,H,BAO_0000219,,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,11765.0,
9.0,13462.0,,B,,,Autocuration,CHEMBL617966,1.0,,,3123.0,,D,BAO_0000357,,10090.0,,Mus musculus,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,10630.0,
8.0,12861.0,,B,,,Autocuration,CHEMBL857074,1.0,,,3124.0,,H,BAO_0000019,,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,17106.0,
8.0,15086.0,,B,,,Autocuration,CHEMBL617967,1.0,,,3125.0,,H,BAO_0000357,,9823.0,,Sus scrofa,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,144.0,
8.0,12861.0,,B,,,Autocuration,CHEMBL617968,1.0,,,3126.0,,H,BAO_0000357,,9823.0,,Sus scrofa,Binding activity radioligand.,,144.0,
4.0,10561.0,,B,,,Autocuration,CHEMBL617969,1.0,,,3127.0,,H,BAO_0000223,,9986.0,,Oryctolagus cuniculus,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,104714.0,
4.0,10561.0,,B,,,Autocuration,CHEMBL617970,1.0,,,3128.0,,H,BAO_0000223,,9986.0,,Oryctolagus cuniculus,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,104714.0,
4.0,10561.0,,B,,,Autocuration,CHEMBL617971,1.0,,,3129.0,,H,BAO_0000223,,9986.0,,Oryctolagus cuniculus,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,104714.0,
4.0,10561.0,,B,,,Autocuration,CHEMBL617972,1.0,,,3130.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,104714.0,
4.0,273.0,,F,,,Autocuration,CHEMBL617973,1.0,,,3131.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,104714.0,
4.0,273.0,,F,,,Autocuration,CHEMBL617974,1.0,,,3132.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,104714.0,
4.0,273.0,2116.0,F,,,Autocuration,CHEMBL617975,1.0,Ileum,,3133.0,,H,BAO_0000221,,9986.0,,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,104714.0,
4.0,273.0,,F,,,Autocuration,CHEMBL617976,1.0,,,3134.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,104714.0,
4.0,273.0,,F,,,Autocuration,CHEMBL617977,1.0,,,3135.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,104714.0,
4.0,273.0,,F,,,Autocuration,CHEMBL617978,1.0,,,3136.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,104714.0,
4.0,273.0,,F,,,Autocuration,CHEMBL617979,1.0,,,3137.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,104714.0,
4.0,13047.0,,B,,,Autocuration,CHEMBL617980,1.0,,,3138.0,,H,BAO_0000219,CHO,9986.0,,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,104714.0,449.0
7.0,1650.0,,B,,,Autocuration,CHEMBL617981,1.0,,,3139.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,104698.0,
8.0,16288.0,,B,,,Autocuration,CHEMBL617982,1.0,,,3140.0,,H,BAO_0000019,,,,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,12020.0,
8.0,16288.0,,B,,,Autocuration,CHEMBL617983,1.0,,,3141.0,,H,BAO_0000357,,,,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,12020.0,
7.0,10254.0,,B,,,Autocuration,CHEMBL617984,1.0,,,3142.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,104698.0,
6.0,14532.0,,B,,,Autocuration,CHEMBL617985,1.0,,,3143.0,,H,BAO_0000019,,,,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,104698.0,
6.0,13392.0,948.0,F,,,Autocuration,CHEMBL617986,1.0,Heart,,3144.0,In vivo,H,BAO_0000218,,,,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,104698.0,
6.0,13392.0,948.0,F,,,Autocuration,CHEMBL617987,1.0,Heart,,3145.0,,H,BAO_0000019,,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,104698.0,
6.0,13392.0,948.0,F,,,Autocuration,CHEMBL617988,1.0,Heart,,3146.0,,H,BAO_0000019,,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,104698.0,
6.0,13392.0,948.0,F,,,Autocuration,CHEMBL617792,1.0,Heart,,3147.0,,H,BAO_0000019,,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,104698.0,
6.0,13392.0,948.0,F,,,Autocuration,CHEMBL617793,1.0,Heart,,3148.0,,H,BAO_0000019,,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,104698.0,
6.0,13392.0,,F,,,Autocuration,CHEMBL617794,1.0,,,3149.0,,H,BAO_0000019,,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,104698.0,
6.0,13392.0,,F,,,Autocuration,CHEMBL617795,1.0,,,3150.0,,H,BAO_0000019,,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,104698.0,
6.0,13392.0,,F,,,Autocuration,CHEMBL617796,1.0,,,3151.0,,H,BAO_0000019,,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,104698.0,
6.0,13392.0,,F,,,Autocuration,CHEMBL617797,1.0,,,3152.0,,H,BAO_0000019,,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,104698.0,
7.0,1089.0,,F,,,Autocuration,CHEMBL617798,1.0,,,3153.0,In vivo,D,BAO_0000218,,10116.0,,Rattus norvegicus,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,104698.0,
6.0,1089.0,,F,,,Autocuration,CHEMBL617799,1.0,,,3154.0,In vivo,H,BAO_0000218,,,,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,104698.0,
7.0,11454.0,,F,,,Autocuration,CHEMBL617800,1.0,,,3155.0,In vivo,D,BAO_0000218,,10116.0,,Rattus norvegicus,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,104698.0,
7.0,11454.0,,F,,,Autocuration,CHEMBL617801,1.0,,,3156.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,104698.0,
7.0,12205.0,,F,,,Autocuration,CHEMBL617802,1.0,,,3157.0,In vivo,D,BAO_0000218,,10116.0,,Rattus norvegicus,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,104698.0,
7.0,1089.0,,F,,,Autocuration,CHEMBL617803,1.0,,,3158.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,104698.0,
6.0,5094.0,,B,,,Autocuration,CHEMBL617804,1.0,,,3159.0,,H,BAO_0000019,,,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,104698.0,
7.0,2622.0,,B,,,Autocuration,CHEMBL617805,1.0,,,3160.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,104698.0,
6.0,245.0,,B,,,Autocuration,CHEMBL617806,1.0,,,3161.0,,H,BAO_0000223,,,,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,104698.0,
6.0,14788.0,,B,,,Autocuration,CHEMBL617807,1.0,,,3162.0,,H,BAO_0000019,,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,104698.0,
6.0,14788.0,,B,,,Autocuration,CHEMBL617808,1.0,,,3163.0,,H,BAO_0000019,,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,104698.0,
6.0,3020.0,,B,,,Autocuration,CHEMBL617809,1.0,,,3164.0,,H,BAO_0000249,,,,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,104698.0,
6.0,1742.0,,B,,,Autocuration,CHEMBL617810,1.0,,,3165.0,,H,BAO_0000019,,,,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,104698.0,
6.0,17394.0,955.0,B,,,Autocuration,CHEMBL617811,1.0,Brain,,3166.0,,H,BAO_0000249,,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,104698.0,
6.0,17394.0,955.0,B,,,Autocuration,CHEMBL617812,1.0,Brain,,3167.0,,H,BAO_0000221,,,,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,104698.0,
6.0,17394.0,,B,,,Autocuration,CHEMBL617813,1.0,,,3168.0,,H,BAO_0000249,,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,104698.0,
6.0,14286.0,,B,,,Autocuration,CHEMBL617814,1.0,,,3169.0,,H,BAO_0000249,,,,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,104698.0,
6.0,14178.0,,B,,,Autocuration,CHEMBL617698,1.0,,,3170.0,,H,BAO_0000019,,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,104698.0,
7.0,14178.0,,B,,,Autocuration,CHEMBL617699,1.0,,,3171.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,104698.0,
7.0,14178.0,,B,,,Autocuration,CHEMBL617700,1.0,,,3172.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,104698.0,
7.0,14178.0,,B,,,Autocuration,CHEMBL617701,1.0,,,3173.0,,D,BAO_0000223,,10116.0,,Rattus norvegicus,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,104698.0,
6.0,15034.0,,B,,,Autocuration,CHEMBL617702,1.0,,,3174.0,,H,BAO_0000019,,,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,104698.0,
6.0,1089.0,,B,Membranes,,Autocuration,CHEMBL617703,1.0,,,3175.0,,H,BAO_0000249,,,,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,104698.0,
7.0,1089.0,,B,,,Autocuration,CHEMBL617704,1.0,,,3176.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,104698.0,
6.0,16532.0,,B,,,Autocuration,CHEMBL617705,1.0,,,3177.0,,H,BAO_0000223,,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,104698.0,
7.0,12801.0,,B,,,Autocuration,CHEMBL617706,1.0,,,3178.0,,D,BAO_0000223,,10116.0,,Rattus norvegicus,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,104698.0,
6.0,15194.0,,B,,,Autocuration,CHEMBL617707,1.0,,,3179.0,,H,BAO_0000219,NG108-15,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,104698.0,433.0
6.0,15194.0,,B,,,Autocuration,CHEMBL617708,1.0,,,3180.0,,H,BAO_0000219,NG108-15,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,104698.0,433.0
6.0,15194.0,,B,,,Autocuration,CHEMBL617709,1.0,,,3181.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,104698.0,
6.0,15194.0,,B,,,Autocuration,CHEMBL617710,1.0,,,3182.0,,H,BAO_0000019,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,104698.0,
6.0,15194.0,,B,,,Autocuration,CHEMBL882925,1.0,,,3183.0,,H,BAO_0000019,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,104698.0,
6.0,15194.0,,B,,,Autocuration,CHEMBL617711,1.0,,,3184.0,,H,BAO_0000019,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,104698.0,
6.0,10610.0,,F,,,Autocuration,CHEMBL617712,1.0,,,3185.0,,H,BAO_0000019,,,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,104698.0,
7.0,10355.0,,F,,,Autocuration,CHEMBL617713,1.0,,,3186.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,104698.0,
6.0,691.0,,F,,,Autocuration,CHEMBL617714,1.0,,,3187.0,,H,BAO_0000019,,,,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,104698.0,
6.0,10611.0,,F,,,Autocuration,CHEMBL617715,1.0,,,3188.0,,H,BAO_0000218,,,,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,104698.0,
6.0,12801.0,,F,,,Autocuration,CHEMBL617716,1.0,,,3189.0,In vivo,H,BAO_0000218,,,,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,104698.0,
6.0,10609.0,,F,,,Autocuration,CHEMBL617717,1.0,,,3190.0,,H,BAO_0000218,,,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617718,1.0,,,3191.0,In vivo,H,BAO_0000218,,,,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617719,1.0,,,3192.0,In vivo,H,BAO_0000218,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617720,1.0,,,3193.0,In vivo,H,BAO_0000218,,,,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,104698.0,
7.0,11454.0,,F,,,Autocuration,CHEMBL617721,1.0,,,3194.0,In vivo,D,BAO_0000218,,10116.0,,Rattus norvegicus,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617722,1.0,,,3195.0,In vivo,H,BAO_0000218,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617723,1.0,,,3196.0,In vivo,H,BAO_0000218,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617724,1.0,,,3197.0,In vivo,H,BAO_0000218,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617725,1.0,,,3198.0,In vivo,H,BAO_0000218,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617726,1.0,,,3199.0,In vivo,H,BAO_0000218,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617727,1.0,,,3200.0,In vivo,H,BAO_0000218,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617728,1.0,,,3201.0,In vivo,H,BAO_0000218,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617729,1.0,,,3202.0,In vivo,H,BAO_0000218,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617730,1.0,,,3203.0,In vivo,H,BAO_0000218,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617731,1.0,,,3204.0,In vivo,H,BAO_0000218,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617732,1.0,,,3205.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617733,1.0,,,3206.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617734,1.0,,,3207.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL872874,1.0,,,3208.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617735,1.0,,,3209.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617736,1.0,,,3210.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617737,1.0,,,3211.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617738,1.0,,,3212.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617739,1.0,,,3213.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617740,1.0,,,3214.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617741,1.0,,,3215.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617742,1.0,,,3216.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617743,1.0,,,3217.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617744,1.0,,,3218.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,11454.0,,F,,,Autocuration,CHEMBL617745,1.0,,,3219.0,In vivo,H,BAO_0000218,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,104698.0,
6.0,670.0,,F,,,Autocuration,CHEMBL617746,1.0,,,3220.0,,H,BAO_0000218,,,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,104698.0,
6.0,670.0,,F,,,Autocuration,CHEMBL617747,1.0,,,3221.0,,H,BAO_0000218,,,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,104698.0,
6.0,10321.0,,F,,,Autocuration,CHEMBL617748,1.0,,,3222.0,In vivo,H,BAO_0000218,,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,104698.0,
6.0,10321.0,,F,,,Autocuration,CHEMBL618909,1.0,,,3223.0,In vivo,H,BAO_0000218,,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,104698.0,
6.0,10321.0,,F,,,Autocuration,CHEMBL618910,1.0,,,3224.0,In vivo,H,BAO_0000218,,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,104698.0,
6.0,10321.0,,F,,,Autocuration,CHEMBL618911,1.0,,,3225.0,In vivo,H,BAO_0000218,,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,104698.0,
6.0,10321.0,,F,,,Autocuration,CHEMBL618912,1.0,,,3226.0,In vivo,H,BAO_0000218,,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,104698.0,
6.0,10322.0,,F,,,Autocuration,CHEMBL618913,1.0,,,3227.0,In vivo,H,BAO_0000218,,,,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,104698.0,
6.0,15412.0,,F,,,Autocuration,CHEMBL618914,1.0,,,3228.0,,H,BAO_0000019,,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,104698.0,
6.0,15412.0,,F,,,Autocuration,CHEMBL618915,1.0,,,3229.0,,H,BAO_0000019,,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,104698.0,
7.0,15412.0,,B,,,Autocuration,CHEMBL618916,1.0,,,3230.0,,D,BAO_0000223,,10116.0,,Rattus norvegicus,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,104698.0,
6.0,15412.0,,F,,,Autocuration,CHEMBL618917,1.0,,,3231.0,,H,BAO_0000019,,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,104698.0,
7.0,15412.0,10000000.0,B,,,Intermediate,CHEMBL618918,1.0,Hippocampus,,3232.0,,D,BAO_0000221,,,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,104698.0,
7.0,15412.0,,B,,,Autocuration,CHEMBL618919,1.0,,,3233.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,104698.0,
7.0,17394.0,,B,,,Autocuration,CHEMBL618920,1.0,,,3234.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,104698.0,
6.0,12457.0,,B,,,Autocuration,CHEMBL618921,1.0,,,3235.0,,H,BAO_0000223,,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,104698.0,
6.0,12457.0,,B,,,Autocuration,CHEMBL618922,1.0,,,3236.0,,H,BAO_0000019,,,,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,104698.0,
6.0,12205.0,,B,,,Autocuration,CHEMBL618923,1.0,,,3237.0,,H,BAO_0000019,,,,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,104698.0,
6.0,14532.0,,B,,,Autocuration,CHEMBL618924,1.0,,,3238.0,,H,BAO_0000019,,,,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,104698.0,
6.0,1122.0,,B,,,Autocuration,CHEMBL618925,1.0,,,3239.0,,H,BAO_0000019,,,,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,104698.0,
6.0,5094.0,,B,,,Autocuration,CHEMBL618926,1.0,,,3240.0,,H,BAO_0000019,,,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,104698.0,
9.0,809.0,2116.0,F,,,Intermediate,CHEMBL618927,1.0,Ileum,,3241.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,20033.0,
9.0,809.0,2116.0,F,,,Intermediate,CHEMBL618928,1.0,Ileum,,3242.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,20033.0,
9.0,14290.0,2116.0,F,,,Intermediate,CHEMBL618929,1.0,Ileum,,3243.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,20033.0,
9.0,14290.0,2116.0,F,,,Intermediate,CHEMBL618930,1.0,Ileum,,3244.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,20033.0,
9.0,14290.0,2116.0,F,,,Intermediate,CHEMBL618931,1.0,Ileum,,3245.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,20033.0,
9.0,14290.0,2116.0,F,,,Intermediate,CHEMBL619594,1.0,Ileum,,3246.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,20033.0,
9.0,14290.0,2116.0,F,,,Intermediate,CHEMBL619595,1.0,Ileum,,3247.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,20033.0,
9.0,13961.0,2116.0,F,,,Intermediate,CHEMBL619596,1.0,Ileum,,3248.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,20033.0,
9.0,13961.0,2116.0,F,,,Intermediate,CHEMBL619755,1.0,Ileum,,3249.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,20033.0,
9.0,809.0,2116.0,F,,,Intermediate,CHEMBL619756,1.0,Ileum,,3250.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,20033.0,
9.0,809.0,2116.0,F,,,Intermediate,CHEMBL619757,1.0,Ileum,,3251.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,20033.0,
9.0,809.0,2116.0,F,,,Intermediate,CHEMBL619758,1.0,Ileum,,3252.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,20033.0,
9.0,14290.0,2116.0,F,,,Intermediate,CHEMBL619759,1.0,Ileum,,3253.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,20033.0,
9.0,14290.0,2116.0,F,,,Intermediate,CHEMBL619760,1.0,Ileum,,3254.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,20033.0,
9.0,14290.0,2116.0,F,,,Intermediate,CHEMBL619761,1.0,Ileum,,3255.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,20033.0,
9.0,14290.0,2116.0,F,,,Intermediate,CHEMBL619762,1.0,Ileum,,3256.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,20033.0,
9.0,14290.0,2116.0,F,,,Intermediate,CHEMBL619763,1.0,Ileum,,3257.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,20033.0,
9.0,14290.0,2116.0,F,,,Intermediate,CHEMBL617868,1.0,Ileum,,3258.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,20033.0,
9.0,15034.0,,B,,,Intermediate,CHEMBL617869,1.0,,,3259.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,20033.0,
9.0,5094.0,2435.0,B,,,Intermediate,CHEMBL882926,1.0,Striatum,,3260.0,,D,BAO_0000249,,10141.0,,Cavia porcellus,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,20033.0,
9.0,5094.0,2435.0,B,,,Intermediate,CHEMBL617870,1.0,Striatum,,3261.0,,D,BAO_0000249,,10141.0,,Cavia porcellus,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,20033.0,
9.0,5399.0,2435.0,B,,,Intermediate,CHEMBL617871,1.0,Striatum,,3262.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,20033.0,
9.0,17394.0,2435.0,B,,,Intermediate,CHEMBL617872,1.0,Striatum,,3263.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,20033.0,
9.0,17394.0,2435.0,B,,,Intermediate,CHEMBL617873,1.0,Striatum,,3264.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,20033.0,
9.0,17394.0,2435.0,B,,,Intermediate,CHEMBL617874,1.0,Striatum,,3265.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,20033.0,
9.0,13961.0,2116.0,F,,,Intermediate,CHEMBL619067,1.0,Ileum,,3266.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,20033.0,
9.0,13961.0,2116.0,F,,,Intermediate,CHEMBL619068,1.0,Ileum,,3267.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,20033.0,
9.0,13961.0,2116.0,F,,,Intermediate,CHEMBL619069,1.0,Ileum,,3268.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,20033.0,
9.0,16946.0,,B,,,Intermediate,CHEMBL619070,1.0,,,3269.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,20033.0,
9.0,16946.0,,B,,,Intermediate,CHEMBL619071,1.0,,,3270.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,20033.0,
9.0,15034.0,,F,,,Intermediate,CHEMBL619072,1.0,,,3271.0,,D,BAO_0000019,,10141.0,,Cavia porcellus,Agonistic activity against 5-hydroxytryptamine 4 receptor,,20033.0,
9.0,15034.0,,F,,,Intermediate,CHEMBL619073,1.0,,,3272.0,,D,BAO_0000019,,10141.0,,Cavia porcellus,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,20033.0,
9.0,12918.0,,F,,,Intermediate,CHEMBL619074,1.0,,,3273.0,,D,BAO_0000019,,10141.0,,Cavia porcellus,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,20033.0,
9.0,16946.0,,B,,,Intermediate,CHEMBL619075,1.0,,,3274.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,20033.0,
9.0,17394.0,2435.0,B,,,Intermediate,CHEMBL619076,1.0,Striatum,,3275.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,20033.0,
9.0,15034.0,2435.0,B,,,Intermediate,CHEMBL619077,1.0,Striatum,,3276.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,20033.0,
9.0,5094.0,2435.0,B,,,Intermediate,CHEMBL619078,1.0,Striatum,,3277.0,,D,BAO_0000249,,10141.0,,Cavia porcellus,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,20033.0,
9.0,5094.0,2435.0,B,,,Intermediate,CHEMBL619079,1.0,Striatum,,3278.0,,D,BAO_0000249,,10141.0,,Cavia porcellus,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,20033.0,
9.0,17358.0,2116.0,B,,,Intermediate,CHEMBL619080,1.0,Ileum,,3279.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,20033.0,
9.0,12953.0,,B,,,Expert,CHEMBL619081,1.0,,,3280.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,20033.0,
9.0,12953.0,,B,,,Intermediate,CHEMBL619082,1.0,,,3281.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,20033.0,
9.0,12953.0,,B,,,Intermediate,CHEMBL619083,1.0,,,3282.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,20033.0,
9.0,12953.0,,B,,,Intermediate,CHEMBL619084,1.0,,,3283.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,20033.0,
9.0,273.0,2116.0,F,,,Intermediate,CHEMBL859397,1.0,Ileum,,3284.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,20033.0,
9.0,12918.0,2116.0,F,,,Intermediate,CHEMBL619085,1.0,Ileum,,3285.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,20033.0,
9.0,12919.0,2116.0,F,,,Intermediate,CHEMBL619086,1.0,Ileum,,3286.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,20033.0,
9.0,273.0,2116.0,F,,,Intermediate,CHEMBL619087,1.0,Ileum,,3287.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,20033.0,
9.0,273.0,2116.0,F,,,Intermediate,CHEMBL619088,1.0,Ileum,,3288.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,20033.0,
9.0,13181.0,,B,,,Intermediate,CHEMBL619089,1.0,,,3289.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,20033.0,
8.0,13181.0,,B,,,Autocuration,CHEMBL619090,1.0,,,3290.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,168.0,
9.0,15034.0,,F,,,Intermediate,CHEMBL619091,1.0,,,3291.0,,D,BAO_0000019,,10141.0,,Cavia porcellus,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,20033.0,
9.0,5033.0,,B,,,Intermediate,CHEMBL619092,1.0,,,3292.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,20033.0,
9.0,1980.0,,B,,,Intermediate,CHEMBL619093,1.0,,,3293.0,,D,BAO_0000019,,10141.0,,Cavia porcellus,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,20033.0,
8.0,13181.0,,B,,,Autocuration,CHEMBL619094,1.0,,,3294.0,,H,BAO_0000219,HEK293,10141.0,,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,168.0,722.0
9.0,14287.0,,B,,,Intermediate,CHEMBL619095,1.0,,,3295.0,,D,BAO_0000019,,10141.0,,Cavia porcellus,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,20033.0,
9.0,1317.0,,B,,,Intermediate,CHEMBL857988,1.0,,,3296.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,20033.0,
9.0,15316.0,,B,,,Intermediate,CHEMBL619096,1.0,,,3297.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,20033.0,
9.0,16429.0,2435.0,B,,,Intermediate,CHEMBL619097,1.0,Striatum,,3298.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,20033.0,
9.0,14818.0,10000000.0,B,,,Intermediate,CHEMBL619098,1.0,Hippocampus,,3299.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,20033.0,
9.0,15194.0,,B,,,Intermediate,CHEMBL619751,1.0,,,3300.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,20033.0,
9.0,15194.0,,B,,,Intermediate,CHEMBL619752,1.0,,,3301.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,20033.0,
9.0,13961.0,2116.0,F,,,Intermediate,CHEMBL875096,1.0,Ileum,,3302.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,20033.0,
8.0,5486.0,,B,,,Autocuration,CHEMBL619004,1.0,,,3303.0,,H,BAO_0000357,,,,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,108.0,
8.0,16209.0,,B,,,Autocuration,CHEMBL619005,1.0,,,3304.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,168.0,
8.0,17085.0,,B,,,Autocuration,CHEMBL619006,1.0,,,3305.0,,H,BAO_0000019,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,168.0,
8.0,4199.0,,B,,,Autocuration,CHEMBL619007,1.0,,,3306.0,,H,BAO_0000219,HeLa,,,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,168.0,308.0
8.0,15146.0,,B,,,Autocuration,CHEMBL619008,1.0,,,3307.0,,H,BAO_0000357,,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,168.0,
8.0,5213.0,,B,,,Autocuration,CHEMBL619009,1.0,,,3308.0,,H,BAO_0000357,,,,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,168.0,
8.0,4829.0,,B,,,Autocuration,CHEMBL619010,1.0,,,3309.0,,H,BAO_0000219,HeLa,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,168.0,308.0
8.0,17358.0,,B,,,Autocuration,CHEMBL619011,1.0,,,3310.0,,H,BAO_0000357,,,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,10622.0,
8.0,17358.0,,B,,,Autocuration,CHEMBL619012,1.0,,,3311.0,,H,BAO_0000357,,,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,10622.0,
8.0,16946.0,,B,,,Autocuration,CHEMBL619013,1.0,,,3312.0,,H,BAO_0000219,,,,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,10622.0,
8.0,17358.0,,B,,,Autocuration,CHEMBL619014,1.0,,,3313.0,,H,BAO_0000357,,,,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,10622.0,
8.0,268.0,2081.0,F,,,Autocuration,CHEMBL857503,1.0,Cardiac atrium,,3314.0,,H,BAO_0000019,,,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,11249.0,
8.0,268.0,2081.0,F,,,Autocuration,CHEMBL619015,1.0,Cardiac atrium,,3315.0,,H,BAO_0000019,,,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,11249.0,
8.0,15086.0,,B,,,Autocuration,CHEMBL619016,1.0,,,3316.0,,H,BAO_0000357,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,11249.0,
8.0,14875.0,10000000.0,B,,,Autocuration,CHEMBL619017,1.0,Hippocampus,,3317.0,,H,BAO_0000221,,,,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,11249.0,
8.0,13267.0,10000000.0,B,,,Autocuration,CHEMBL619018,1.0,Hippocampus,,3318.0,,H,BAO_0000221,,9823.0,,Sus scrofa,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,168.0,
8.0,13047.0,,B,,,Autocuration,CHEMBL619019,1.0,,,3319.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,168.0,
9.0,1650.0,,B,,,Expert,CHEMBL619020,1.0,,,3320.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,10623.0,
8.0,567.0,,F,,,Autocuration,CHEMBL619021,1.0,,,3321.0,,H,BAO_0000019,,,,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,10623.0,
8.0,17358.0,,B,,,Autocuration,CHEMBL619022,1.0,,,3322.0,,H,BAO_0000357,,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,10623.0,
8.0,188.0,,B,,,Autocuration,CHEMBL619023,1.0,,,3323.0,,H,BAO_0000357,,,,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,10623.0,
8.0,670.0,,F,,,Autocuration,CHEMBL619024,1.0,,,3324.0,,H,BAO_0000019,,,,,lntrinsic activity relative to 5-HT receptor,,10623.0,
8.0,204.0,,F,,,Autocuration,CHEMBL619025,1.0,,,3325.0,,H,BAO_0000019,,,,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,10623.0,
8.0,1946.0,,F,,,Expert,CHEMBL619026,1.0,,,3326.0,,H,BAO_0000019,,,,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,10623.0,
8.0,6398.0,,F,,,Autocuration,CHEMBL619027,1.0,,,3327.0,,H,BAO_0000019,,,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,10623.0,
8.0,6398.0,,F,,,Autocuration,CHEMBL619028,1.0,,,3328.0,,H,BAO_0000019,,,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,10623.0,
8.0,17358.0,,F,,,Autocuration,CHEMBL619029,1.0,,,3329.0,,H,BAO_0000019,,,,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,10623.0,
8.0,6398.0,,F,,,Autocuration,CHEMBL619030,1.0,,,3330.0,,H,BAO_0000019,,,,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,10623.0,
8.0,11752.0,,B,,,Expert,CHEMBL619031,1.0,,,3331.0,,H,BAO_0000357,,,,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,10623.0,
8.0,809.0,,F,,,Autocuration,CHEMBL619032,1.0,,,3332.0,,H,BAO_0000019,,,,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,10623.0,
9.0,14178.0,,B,,,Expert,CHEMBL619033,1.0,,,3333.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,10623.0,
8.0,567.0,,B,,,Autocuration,CHEMBL619034,1.0,,,3334.0,,H,BAO_0000357,,,,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,10623.0,
8.0,1946.0,,B,,,Autocuration,CHEMBL619035,1.0,,,3335.0,,H,BAO_0000357,,,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,10623.0,
8.0,1946.0,,B,,,Autocuration,CHEMBL619036,1.0,,,3336.0,,H,BAO_0000357,,,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,10623.0,
9.0,13961.0,,B,,,Expert,CHEMBL619037,1.0,,,3337.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,10623.0,
8.0,6238.0,2435.0,B,,,Autocuration,CHEMBL619038,1.0,Striatum,,3338.0,,H,BAO_0000249,,,,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,10623.0,
8.0,14290.0,,B,,,Autocuration,CHEMBL619039,1.0,,,3339.0,,H,BAO_0000249,,,,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,10623.0,
8.0,14290.0,,B,,,Expert,CHEMBL619040,1.0,,,3340.0,,H,BAO_0000249,,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,10623.0,
9.0,809.0,2435.0,B,,,Expert,CHEMBL619041,1.0,Striatum,,3341.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,10623.0,
8.0,1578.0,2435.0,B,,,Autocuration,CHEMBL619042,1.0,Striatum,,3342.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,10623.0,
8.0,16709.0,2435.0,B,,,Expert,CHEMBL619043,1.0,Striatum,,3343.0,,H,BAO_0000249,,,,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,10623.0,
8.0,1946.0,2435.0,B,,,Expert,CHEMBL619044,1.0,Striatum,,3344.0,,H,BAO_0000019,,,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,10623.0,
8.0,15253.0,2435.0,B,,,Expert,CHEMBL619045,1.0,Striatum,,3345.0,,H,BAO_0000249,,,,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,10623.0,
8.0,4535.0,2435.0,B,,,Expert,CHEMBL619046,1.0,Striatum,,3346.0,,H,BAO_0000249,,,,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,10623.0,
8.0,13961.0,,B,,,Expert,CHEMBL619047,1.0,,,3347.0,,H,BAO_0000249,,,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,10623.0,
8.0,17358.0,955.0,F,,,Autocuration,CHEMBL619048,1.0,Brain,,3348.0,,H,BAO_0000221,,,,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,10623.0,
8.0,15847.0,,F,,,Autocuration,CHEMBL859398,1.0,,,3349.0,,H,BAO_0000019,,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,10623.0,
8.0,15847.0,,F,,,Autocuration,CHEMBL619049,1.0,,,3350.0,,H,BAO_0000019,,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,10623.0,
8.0,670.0,,F,,,Autocuration,CHEMBL857886,1.0,,,3351.0,,H,BAO_0000019,,,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,10623.0,
8.0,670.0,,F,,,Autocuration,CHEMBL619050,1.0,,,3352.0,,H,BAO_0000019,,,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,10623.0,
8.0,1317.0,,F,,,Autocuration,CHEMBL620591,1.0,,,3353.0,,H,BAO_0000019,,,,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,10623.0,
9.0,12936.0,,B,,,Expert,CHEMBL620592,1.0,,,3354.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,10623.0,
8.0,4535.0,2435.0,B,,,Expert,CHEMBL620593,1.0,Striatum,,3355.0,,H,BAO_0000249,,,,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,10623.0,
9.0,14424.0,,F,,,Expert,CHEMBL620594,1.0,,,3356.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,10623.0,
8.0,14424.0,,F,,,Expert,CHEMBL875079,1.0,,,3357.0,,H,BAO_0000019,,,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,10623.0,
8.0,14424.0,,F,,,Expert,CHEMBL620595,1.0,,,3358.0,,H,BAO_0000019,,,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,10623.0,
9.0,14424.0,,F,,,Expert,CHEMBL620596,1.0,,,3359.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,10623.0,
8.0,14424.0,,F,,,Autocuration,CHEMBL620597,1.0,,,3360.0,,H,BAO_0000019,,,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,10623.0,
8.0,14424.0,,F,,,Expert,CHEMBL620598,1.0,,,3361.0,,H,BAO_0000019,,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,10623.0,
8.0,14424.0,,F,,,Expert,CHEMBL620599,1.0,,,3362.0,,H,BAO_0000218,,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,10623.0,
8.0,14424.0,,F,,,Autocuration,CHEMBL620600,1.0,,,3363.0,,H,BAO_0000019,,,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,10623.0,
8.0,1980.0,,F,,,Autocuration,CHEMBL620601,1.0,,,3364.0,,H,BAO_0000019,,10116.0,,Rattus norvegicus,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,168.0,
8.0,4639.0,,F,,,Autocuration,CHEMBL620602,1.0,,,3365.0,,H,BAO_0000019,,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,168.0,
8.0,17358.0,,B,,,Autocuration,CHEMBL620603,1.0,,,3366.0,,H,BAO_0000357,,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,168.0,
8.0,17358.0,,B,,,Autocuration,CHEMBL620604,1.0,,,3367.0,,H,BAO_0000357,,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,168.0,
8.0,17358.0,,B,,,Autocuration,CHEMBL620605,1.0,,,3368.0,,H,BAO_0000357,,,,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,168.0,
8.0,1558.0,,B,,,Autocuration,CHEMBL620606,1.0,,,3369.0,,H,BAO_0000357,,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,168.0,
8.0,17358.0,,F,,,Autocuration,CHEMBL620607,1.0,,,3370.0,,H,BAO_0000019,,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,168.0,
8.0,16117.0,,B,,,Autocuration,CHEMBL620608,1.0,,,3371.0,,H,BAO_0000357,,,,,In vitro binding affinity towards 5-HT4 receptor was determined,,168.0,
8.0,17358.0,,F,,,Autocuration,CHEMBL620609,1.0,,,3372.0,,H,BAO_0000019,,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,168.0,
8.0,17358.0,,F,,,Autocuration,CHEMBL620610,1.0,,,3373.0,,H,BAO_0000019,,,,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,168.0,
8.0,17358.0,,B,,,Autocuration,CHEMBL620611,1.0,,,3374.0,,H,BAO_0000357,,,,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,168.0,
8.0,17358.0,,B,,,Autocuration,CHEMBL620612,1.0,,,3375.0,,H,BAO_0000357,,,,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,168.0,
8.0,17358.0,,B,,,Autocuration,CHEMBL620613,1.0,,,3376.0,,H,BAO_0000357,,,,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,168.0,
8.0,17358.0,,B,,,Autocuration,CHEMBL620614,1.0,,,3377.0,,H,BAO_0000357,,,,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,168.0,
8.0,1274.0,,B,,,Expert,CHEMBL620615,1.0,,,3378.0,,H,BAO_0000357,,,,,Binding affinity against 5-Hydroxytryptamine 4 receptor,,168.0,
6.0,10728.0,,B,Brain membranes,,Autocuration,CHEMBL857075,1.0,,,3379.0,,H,BAO_0000249,,,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,104698.0,
6.0,11695.0,,B,Brain membranes,,Autocuration,CHEMBL620616,1.0,,,3380.0,,H,BAO_0000249,,,,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,104698.0,
6.0,11695.0,,B,Brain membranes,,Autocuration,CHEMBL619411,1.0,,,3381.0,,H,BAO_0000249,,,,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,104698.0,
6.0,12490.0,,B,,,Autocuration,CHEMBL619412,1.0,,,3382.0,,H,BAO_0000019,,,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,104698.0,
7.0,11828.0,,B,,,Autocuration,CHEMBL619413,1.0,,,3383.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,104698.0,
6.0,12253.0,10000000.0,B,,,Autocuration,CHEMBL619414,1.0,Hippocampus,,3384.0,,H,BAO_0000221,,,,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,104698.0,
6.0,10561.0,,B,,,Autocuration,CHEMBL619415,1.0,,,3385.0,,H,BAO_0000019,,,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,104698.0,
6.0,10561.0,,B,,,Autocuration,CHEMBL619416,1.0,,,3386.0,,H,BAO_0000019,,,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,104698.0,
6.0,14432.0,,F,,,Autocuration,CHEMBL619417,1.0,,,3387.0,,H,BAO_0000019,,,,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,104698.0,
7.0,12936.0,,B,,,Autocuration,CHEMBL619418,1.0,,,3388.0,,D,BAO_0000223,,10116.0,,Rattus norvegicus,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,104698.0,
7.0,1274.0,,B,,,Autocuration,CHEMBL619419,1.0,,,3389.0,,D,BAO_0000223,,10116.0,,Rattus norvegicus,Binding affinity against 5-Hydroxytryptamine 3 receptor,,104698.0,
6.0,1980.0,,B,,,Autocuration,CHEMBL619420,1.0,,,3390.0,,H,BAO_0000019,,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,104698.0,
6.0,670.0,,B,,,Autocuration,CHEMBL619421,1.0,,,3391.0,,H,BAO_0000249,,,,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,104698.0,
7.0,968.0,,B,,,Autocuration,CHEMBL619422,1.0,,,3392.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,104698.0,
6.0,14287.0,,B,,,Autocuration,CHEMBL619423,1.0,,,3393.0,,H,BAO_0000019,,,,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,104698.0,
6.0,567.0,,B,,,Autocuration,CHEMBL875080,1.0,,,3394.0,,H,BAO_0000019,,,,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,104698.0,
6.0,13267.0,,B,,,Autocuration,CHEMBL619424,1.0,,,3395.0,,H,BAO_0000019,,,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,104698.0,
6.0,14826.0,,B,,,Autocuration,CHEMBL619425,1.0,,,3396.0,,H,BAO_0000249,,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,104698.0,
6.0,15194.0,,B,,,Autocuration,CHEMBL619426,1.0,,,3397.0,,H,BAO_0000223,,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,104698.0,
6.0,15194.0,,B,,,Autocuration,CHEMBL619427,1.0,,,3398.0,,H,BAO_0000223,,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,104698.0,
7.0,10394.0,,B,,,Autocuration,CHEMBL619645,1.0,,,3399.0,,D,BAO_0000223,,10116.0,,Rattus norvegicus,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,104698.0,
9.0,13657.0,,B,,,Expert,CHEMBL619646,1.0,,,3400.0,,D,BAO_0000249,,,,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,10576.0,
8.0,1879.0,955.0,F,,,Autocuration,CHEMBL619647,1.0,Brain,,3401.0,,H,BAO_0000221,,,,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,12020.0,
8.0,1879.0,,F,,,Autocuration,CHEMBL619648,1.0,,,3402.0,,H,BAO_0000019,,,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,12020.0,
8.0,1879.0,,F,,,Autocuration,CHEMBL619165,1.0,,,3403.0,,H,BAO_0000019,,,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,12020.0,
8.0,204.0,,F,,,Autocuration,CHEMBL620719,1.0,,,3404.0,In vivo,H,BAO_0000218,,,,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,12020.0,
8.0,1879.0,,B,,,Autocuration,CHEMBL872924,1.0,,,3405.0,,H,BAO_0000019,,,,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,12020.0,
8.0,1879.0,,B,,,Autocuration,CHEMBL620720,1.0,,,3406.0,,H,BAO_0000357,,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,12020.0,
8.0,1879.0,,B,,,Autocuration,CHEMBL620721,1.0,,,3407.0,,H,BAO_0000019,,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,12020.0,
8.0,1879.0,,B,,,Autocuration,CHEMBL620722,1.0,,,3408.0,,H,BAO_0000019,,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,12020.0,
6.0,10641.0,,B,,,Autocuration,CHEMBL620723,1.0,,,3409.0,,H,BAO_0000019,,,,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,104698.0,
8.0,773.0,,B,,,Autocuration,CHEMBL620724,1.0,,,3410.0,,H,BAO_0000019,,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,12020.0,
6.0,11952.0,,B,,,Autocuration,CHEMBL620725,1.0,,,3411.0,,H,BAO_0000249,,,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,104698.0,
9.0,14145.0,,F,,,Autocuration,CHEMBL620726,1.0,,,3412.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,12020.0,
8.0,17066.0,,B,,,Expert,CHEMBL620727,1.0,,,3413.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,144.0,
4.0,6398.0,,B,,,Autocuration,CHEMBL620728,1.0,,,3414.0,,H,BAO_0000223,,,,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,104714.0,
0.0,10321.0,,B,,,Autocuration,CHEMBL620729,1.0,,,3415.0,,U,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,22226.0,
4.0,511.0,,F,,,Autocuration,CHEMBL858288,1.0,,,3416.0,,H,BAO_0000019,,,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,104714.0,
4.0,4639.0,,B,,,Autocuration,CHEMBL620730,1.0,,,3417.0,,H,BAO_0000223,,,,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,104714.0,
4.0,4639.0,,B,,,Autocuration,CHEMBL620731,1.0,,,3418.0,,H,BAO_0000223,,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,104714.0,
4.0,4639.0,,F,,,Autocuration,CHEMBL620732,1.0,,,3419.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,104714.0,
4.0,4639.0,,F,,,Autocuration,CHEMBL618042,1.0,,,3420.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,104714.0,
4.0,4639.0,,F,,,Autocuration,CHEMBL618043,1.0,,,3421.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,104714.0,
4.0,1558.0,,B,,,Autocuration,CHEMBL618044,1.0,,,3422.0,,H,BAO_0000223,,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,104714.0,
4.0,268.0,,F,,,Autocuration,CHEMBL618045,1.0,,,3423.0,,H,BAO_0000019,,,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,104714.0,
4.0,2474.0,,B,,,Autocuration,CHEMBL618046,1.0,,,3424.0,,H,BAO_0000223,,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,104714.0,
4.0,5067.0,,F,,,Autocuration,CHEMBL618047,1.0,,,3425.0,,H,BAO_0000019,,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,104714.0,
4.0,5067.0,,F,,,Autocuration,CHEMBL875084,1.0,,,3426.0,,H,BAO_0000019,,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,104714.0,
4.0,5067.0,,F,,,Autocuration,CHEMBL618048,1.0,,,3427.0,,H,BAO_0000019,,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,104714.0,
4.0,5067.0,,B,,,Autocuration,CHEMBL618049,1.0,,,3428.0,,H,BAO_0000223,,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,104714.0,
4.0,5067.0,,F,,,Autocuration,CHEMBL619764,1.0,,,3429.0,,H,BAO_0000019,,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,104714.0,
4.0,5067.0,,F,,,Autocuration,CHEMBL619765,1.0,,,3430.0,,H,BAO_0000019,,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,104714.0,
4.0,5067.0,,F,,,Autocuration,CHEMBL619766,1.0,,,3431.0,,H,BAO_0000019,,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,104714.0,
4.0,5067.0,,B,,,Autocuration,CHEMBL619767,1.0,,,3432.0,,H,BAO_0000223,,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,104714.0,
4.0,5067.0,,B,,,Autocuration,CHEMBL619768,1.0,,,3433.0,,H,BAO_0000223,,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,104714.0,
4.0,5067.0,,F,,,Autocuration,CHEMBL619769,1.0,,,3434.0,,H,BAO_0000019,,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,104714.0,
4.0,5067.0,,B,,,Autocuration,CHEMBL619770,1.0,,,3435.0,,H,BAO_0000223,,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,104714.0,
4.0,5067.0,,B,,,Autocuration,CHEMBL619771,1.0,,,3436.0,,H,BAO_0000223,,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,104714.0,
4.0,14331.0,,B,,,Autocuration,CHEMBL619772,1.0,,,3437.0,,H,BAO_0000219,,,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,104714.0,
4.0,5067.0,,B,,,Autocuration,CHEMBL619773,1.0,,,3438.0,,H,BAO_0000223,,,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,104714.0,
4.0,6179.0,,B,,,Autocuration,CHEMBL619774,1.0,,,3439.0,,H,BAO_0000219,NG108-15,,,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,104714.0,433.0
4.0,4265.0,,B,,,Autocuration,CHEMBL875083,1.0,,,3440.0,,H,BAO_0000019,,,,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,104714.0,
4.0,4265.0,,B,,,Autocuration,CHEMBL620718,1.0,,,3441.0,,H,BAO_0000219,NG108-15,,,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,104714.0,433.0
4.0,17358.0,,B,,,Autocuration,CHEMBL618127,1.0,,,3442.0,,H,BAO_0000223,,,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,104714.0,
4.0,17358.0,,B,,,Autocuration,CHEMBL618128,1.0,,,3443.0,,H,BAO_0000223,,,,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,104714.0,
4.0,13628.0,,B,,,Autocuration,CHEMBL618129,1.0,,,3444.0,In vitro,H,BAO_0000219,,,,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,104714.0,
4.0,4612.0,,B,,,Autocuration,CHEMBL618130,1.0,,,3445.0,,H,BAO_0000223,,,,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,104714.0,
4.0,17358.0,,F,,,Autocuration,CHEMBL618131,1.0,,,3446.0,,H,BAO_0000019,,,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,104714.0,
4.0,4639.0,,F,,,Autocuration,CHEMBL618132,1.0,,,3447.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,104714.0,
4.0,4639.0,,F,,,Autocuration,CHEMBL618133,1.0,,,3448.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,104714.0,
4.0,4639.0,,F,,,Autocuration,CHEMBL618134,1.0,,,3449.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,104714.0,
4.0,4639.0,,F,,,Autocuration,CHEMBL618135,1.0,,,3450.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,104714.0,
4.0,511.0,,B,,,Autocuration,CHEMBL618136,1.0,,,3451.0,,H,BAO_0000223,,,,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,104714.0,
4.0,1479.0,,B,,,Autocuration,CHEMBL618137,1.0,,,3452.0,,H,BAO_0000223,,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,104714.0,
4.0,1317.0,,B,,,Autocuration,CHEMBL618138,1.0,,,3453.0,,H,BAO_0000223,,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,104714.0,
4.0,12146.0,,B,,,Autocuration,CHEMBL618139,1.0,,,3454.0,,H,BAO_0000223,,,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,104714.0,
4.0,12146.0,,B,,,Autocuration,CHEMBL618140,1.0,,,3455.0,,H,BAO_0000223,,,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,104714.0,
4.0,13969.0,,B,,,Autocuration,CHEMBL618141,1.0,,,3456.0,,H,BAO_0000223,,,,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,104714.0,
8.0,13392.0,,B,,,Expert,CHEMBL873478,1.0,,,3457.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,,108.0,
6.0,13392.0,,B,,,Autocuration,CHEMBL618142,1.0,,,3458.0,,H,BAO_0000223,,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,104698.0,
8.0,14159.0,,B,,,Autocuration,CHEMBL618143,1.0,,,3459.0,,H,BAO_0000357,,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,144.0,
8.0,1558.0,,B,,,Autocuration,CHEMBL618144,1.0,,,3460.0,,H,BAO_0000357,,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,144.0,
8.0,16655.0,,B,,,Autocuration,CHEMBL618145,1.0,,,3461.0,,H,BAO_0000357,,,,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,144.0,
4.0,13020.0,,B,,,Autocuration,CHEMBL618146,1.0,,,3462.0,,H,BAO_0000223,,,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,104714.0,
4.0,13021.0,,B,,,Autocuration,CHEMBL618147,1.0,,,3463.0,,H,BAO_0000223,,,,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,104714.0,
4.0,13020.0,,B,,,Autocuration,CHEMBL618148,1.0,,,3464.0,,H,BAO_0000223,,,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,104714.0,
8.0,10321.0,,B,,,Autocuration,CHEMBL618149,1.0,,,3465.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,144.0,
8.0,15818.0,,B,,,Autocuration,CHEMBL872927,1.0,,,3466.0,,H,BAO_0000357,,,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,144.0,
8.0,15818.0,,B,,,Autocuration,CHEMBL618150,1.0,,,3467.0,,H,BAO_0000357,,,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,144.0,
8.0,17358.0,,B,,,Autocuration,CHEMBL618151,1.0,,,3468.0,,H,BAO_0000357,,,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,144.0,
8.0,2222.0,,B,,,Autocuration,CHEMBL875094,1.0,,,3469.0,,H,BAO_0000357,,,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,144.0,
8.0,10322.0,,B,,,Autocuration,CHEMBL618152,1.0,,,3470.0,,H,BAO_0000019,,,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,144.0,
8.0,16117.0,,B,,,Autocuration,CHEMBL618153,1.0,,,3471.0,,H,BAO_0000357,,,,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,144.0,
8.0,17200.0,,B,,,Autocuration,CHEMBL618888,1.0,,,3472.0,,H,BAO_0000357,,,,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,144.0,
8.0,17358.0,,F,,,Autocuration,CHEMBL618889,1.0,,,3473.0,,H,BAO_0000019,,,,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,144.0,
8.0,16700.0,,B,,,Autocuration,CHEMBL618890,1.0,,,3474.0,,H,BAO_0000357,,,,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,144.0,
8.0,1980.0,,B,,,Autocuration,CHEMBL618891,1.0,,,3475.0,,H,BAO_0000019,,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,144.0,
8.0,1980.0,,B,,,Autocuration,CHEMBL619054,1.0,,,3476.0,,H,BAO_0000019,,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,144.0,
4.0,12409.0,,B,,,Autocuration,CHEMBL619055,1.0,,,3477.0,,H,BAO_0000223,,,,,Binding affinity against the 5-hydroxytryptamine 3 receptor,,104714.0,
8.0,4365.0,,B,,,Autocuration,CHEMBL619056,1.0,,,3478.0,,H,BAO_0000357,,,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,144.0,
8.0,4365.0,,F,,,Autocuration,CHEMBL619057,1.0,,,3479.0,,H,BAO_0000019,,,,,Percent efficacy against 5-hydroxytryptamine 3A receptor,,144.0,
8.0,4365.0,,B,,,Autocuration,CHEMBL619058,1.0,,,3480.0,,H,BAO_0000357,,,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,144.0,
9.0,6769.0,,F,,,Expert,CHEMBL619059,1.0,,,3481.0,,D,BAO_0000219,Oocytes,10116.0,,Rattus norvegicus,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,12020.0,
9.0,6769.0,,F,,,Expert,CHEMBL619060,1.0,,,3482.0,,D,BAO_0000219,Oocytes,10116.0,,Rattus norvegicus,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,12020.0,
9.0,6769.0,,F,,,Expert,CHEMBL875095,1.0,,,3483.0,,D,BAO_0000219,Oocytes,10116.0,,Rattus norvegicus,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,12020.0,
9.0,809.0,2116.0,F,,,Intermediate,CHEMBL619061,1.0,Ileum,,3484.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,20033.0,
9.0,809.0,2116.0,F,,,Intermediate,CHEMBL619062,1.0,Ileum,,3485.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,20033.0,
9.0,14290.0,,F,,,Intermediate,CHEMBL619063,1.0,,,3486.0,,D,BAO_0000019,,10141.0,,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,20033.0,
9.0,17358.0,2116.0,B,,,Intermediate,CHEMBL619064,1.0,Ileum,,3487.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,20033.0,
9.0,17358.0,,B,,,Intermediate,CHEMBL619065,1.0,,,3488.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,20033.0,
9.0,17358.0,2116.0,B,,,Intermediate,CHEMBL619066,1.0,Ileum,,3489.0,,D,BAO_0000221,,10141.0,,Cavia porcellus,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,20033.0,
8.0,17386.0,2116.0,B,,,Autocuration,CHEMBL619775,1.0,Ileum,,3490.0,,H,BAO_0000221,,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,10209.0,
8.0,3269.0,,B,,,Autocuration,CHEMBL619776,1.0,,,3491.0,,H,BAO_0000357,,,,,Affinity against 5-hydroxytryptamine 7 receptor,,10209.0,
4.0,7721.0,,B,,,Autocuration,CHEMBL619777,1.0,,,3492.0,,H,BAO_0000224,,10141.0,,Cavia porcellus,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,104841.0,
4.0,7721.0,,B,,,Autocuration,CHEMBL619778,1.0,,,3493.0,,H,BAO_0000224,,10141.0,,Cavia porcellus,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,104841.0,
4.0,9117.0,2116.0,B,,,Autocuration,CHEMBL619779,1.0,Ileum,,3494.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,104841.0,
4.0,7721.0,,B,,,Autocuration,CHEMBL619780,1.0,,,3495.0,,H,BAO_0000224,,10141.0,,Cavia porcellus,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,104841.0,
4.0,7721.0,,B,,,Autocuration,CHEMBL619166,1.0,,,3496.0,,H,BAO_0000224,,10141.0,,Cavia porcellus,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,104841.0,
4.0,15796.0,,F,,,Autocuration,CHEMBL619167,1.0,,,3497.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,104841.0,
4.0,15796.0,,F,,,Autocuration,CHEMBL619168,1.0,,,3498.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,104841.0,
9.0,15650.0,2081.0,B,,,Expert,CHEMBL619169,1.0,Cardiac atrium,,3499.0,,D,BAO_0000219,,9606.0,,Homo sapiens,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,168.0,
9.0,15650.0,2081.0,B,,,Expert,CHEMBL619170,1.0,Cardiac atrium,,3500.0,,D,BAO_0000219,,9606.0,,Homo sapiens,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,168.0,
5.0,6866.0,,F,,,Autocuration,CHEMBL619171,1.0,,,3501.0,,D,BAO_0000019,,9606.0,,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,104841.0,
9.0,15650.0,2081.0,F,,,Expert,CHEMBL619172,1.0,Cardiac atrium,,3502.0,,D,BAO_0000219,,9606.0,,Homo sapiens,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,168.0,
0.0,10063.0,,B,,,Autocuration,CHEMBL619173,1.0,,,3503.0,,U,BAO_0000019,,10090.0,,Mus musculus,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,22226.0,
0.0,12665.0,,B,,,Autocuration,CHEMBL619174,1.0,,,3504.0,,U,BAO_0000019,,10090.0,,Mus musculus,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,22226.0,
4.0,7504.0,,B,,,Autocuration,CHEMBL619175,1.0,,,3505.0,,H,BAO_0000019,,,,,5-hydroxytryptamine receptor binding affinity was determined in rats,,104705.0,
4.0,7504.0,,B,,,Autocuration,CHEMBL619176,1.0,,,3506.0,,H,BAO_0000224,,,,,Binding affinity at rat 5-hydroxytryptamine receptor.,,104705.0,
4.0,7038.0,,B,,,Autocuration,CHEMBL619177,1.0,,,3507.0,,H,BAO_0000019,,,,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,104705.0,
4.0,7626.0,,B,,,Autocuration,CHEMBL619178,1.0,,,3508.0,,H,BAO_0000224,,,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,104705.0,
4.0,7626.0,,B,,,Autocuration,CHEMBL619179,1.0,,,3509.0,,H,BAO_0000224,,,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,104705.0,
4.0,7185.0,945.0,F,,,Autocuration,CHEMBL619180,1.0,Stomach,,3510.0,,H,BAO_0000019,,,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,104705.0,
4.0,7185.0,945.0,F,,,Autocuration,CHEMBL619181,1.0,Stomach,,3511.0,,H,BAO_0000019,,,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,104705.0,
4.0,7185.0,,F,,,Autocuration,CHEMBL619182,1.0,,,3512.0,,H,BAO_0000019,,,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,104705.0,
4.0,6960.0,,B,,,Autocuration,CHEMBL619183,1.0,,,3513.0,,H,BAO_0000224,,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,104705.0,
4.0,6960.0,,B,,,Autocuration,CHEMBL619184,1.0,,,3514.0,,H,BAO_0000224,,,,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,104705.0,
8.0,12416.0,10000000.0,B,,,Autocuration,CHEMBL619185,1.0,Hippocampus,,3515.0,,H,BAO_0000221,,,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,10576.0,
8.0,15753.0,,B,,,Expert,CHEMBL619186,1.0,,,3516.0,,H,BAO_0000357,,,,,Binding affinity for rat 5-hydroxytryptamine transporter.,,12198.0,
4.0,8062.0,,B,,,Autocuration,CHEMBL619187,1.0,,,3517.0,,H,BAO_0000019,,,,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,104705.0,
5.0,9036.0,,B,,,Autocuration,CHEMBL619188,1.0,,,3518.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,104705.0,
5.0,15067.0,,B,,,Autocuration,CHEMBL619189,1.0,,,3519.0,,D,BAO_0000224,,10116.0,,Rattus norvegicus,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,104705.0,
9.0,15753.0,955.0,F,,,Expert,CHEMBL619190,1.0,Brain,,3520.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,12198.0,
9.0,15753.0,2037.0,F,,,Expert,CHEMBL619191,1.0,Cerebellum,,3521.0,,D,BAO_0000221,,10116.0,,Rattus norvegicus,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,12198.0,
5.0,15295.0,,B,,,Autocuration,CHEMBL619192,1.0,,,3522.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,104705.0,
5.0,6347.0,,B,,,Autocuration,CHEMBL619193,1.0,,,3523.0,,D,BAO_0000224,,10116.0,,Rattus norvegicus,Percent binding affinity against 5-hydroxytryptamine receptor,,104705.0,
0.0,6763.0,,B,,,Autocuration,CHEMBL619194,1.0,,,3524.0,,U,BAO_0000019,,,,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,22226.0,
5.0,12092.0,,B,,,Autocuration,CHEMBL619195,1.0,,,3525.0,,D,BAO_0000224,,10116.0,,Rattus norvegicus,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,104705.0,
5.0,1579.0,,B,,,Autocuration,CHEMBL619196,1.0,,,3526.0,,D,BAO_0000224,,10116.0,,Rattus norvegicus,Affinity against 5-hydroxytryptamine receptor was determined,,104705.0,
5.0,1579.0,945.0,B,,,Autocuration,CHEMBL619197,1.0,Stomach,,3527.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,104705.0,
9.0,5963.0,,B,,,Expert,CHEMBL619198,1.0,,,3528.0,In vitro,D,BAO_0000219,,9606.0,,Homo sapiens,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,121.0,
9.0,5963.0,,B,,,Expert,CHEMBL875081,1.0,,,3529.0,In vitro,D,BAO_0000219,,9606.0,,Homo sapiens,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,121.0,
8.0,5030.0,,B,,,Autocuration,CHEMBL884712,1.0,,,3530.0,,H,BAO_0000357,,,,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,18065.0,
8.0,15796.0,,B,,,Expert,CHEMBL884710,1.0,,,3531.0,,H,BAO_0000357,,,,,Inhibition of 5-hydroxytryptamine reuptake,,121.0,
8.0,15413.0,,F,,,Autocuration,CHEMBL619199,1.0,,,3532.0,,H,BAO_0000019,,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,18065.0,
8.0,15413.0,,F,,,Autocuration,CHEMBL619200,1.0,,,3533.0,,H,BAO_0000019,,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,18065.0,
8.0,15413.0,,F,,,Autocuration,CHEMBL619201,1.0,,,3534.0,,H,BAO_0000019,,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,18065.0,
8.0,12409.0,,F,,,Autocuration,CHEMBL619202,1.0,,,3535.0,,H,BAO_0000019,,,,,Tested for 5-hydroxytryptamine receptor uptake,,18065.0,
9.0,16909.0,,B,,,Expert,CHEMBL619203,1.0,,,3536.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,51.0,449.0
9.0,16909.0,,F,,,Expert,CHEMBL619204,1.0,,,3537.0,,D,BAO_0000019,,9606.0,,Homo sapiens,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,51.0,
8.0,15629.0,,B,,,Autocuration,CHEMBL619205,1.0,,,3538.0,,H,BAO_0000249,,9606.0,,Homo sapiens,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,10576.0,
8.0,15629.0,,B,,,Autocuration,CHEMBL619206,1.0,,,3539.0,,H,BAO_0000357,,,,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,10576.0,
8.0,15629.0,,B,,,Expert,CHEMBL619207,1.0,,,3540.0,,H,BAO_0000249,,,,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,10576.0,
8.0,10034.0,2435.0,F,,,Autocuration,CHEMBL619208,1.0,Striatum,,3541.0,,H,BAO_0000019,,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,10825.0,
8.0,10034.0,2435.0,F,,,Autocuration,CHEMBL619209,1.0,Striatum,,3542.0,,H,BAO_0000019,,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,10825.0,
8.0,10034.0,2435.0,F,,,Autocuration,CHEMBL619210,1.0,Striatum,,3543.0,,H,BAO_0000019,,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,10825.0,
8.0,10034.0,2435.0,F,,,Autocuration,CHEMBL619211,1.0,Striatum,,3544.0,,H,BAO_0000019,,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,10825.0,
8.0,10034.0,2435.0,F,,,Autocuration,CHEMBL619212,1.0,Striatum,,3545.0,,H,BAO_0000019,,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,10825.0,
8.0,10034.0,2435.0,F,,,Autocuration,CHEMBL620681,1.0,Striatum,,3546.0,,H,BAO_0000019,,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,10825.0,
8.0,10034.0,2435.0,F,,,Autocuration,CHEMBL620682,1.0,Striatum,,3547.0,,H,BAO_0000019,,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,10825.0,
8.0,10034.0,2435.0,F,,,Autocuration,CHEMBL620683,1.0,Striatum,,3548.0,,H,BAO_0000019,,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,10825.0,
8.0,10034.0,2435.0,F,,,Autocuration,CHEMBL620684,1.0,Striatum,,3549.0,,H,BAO_0000019,,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,10825.0,
8.0,10034.0,2435.0,F,,,Autocuration,CHEMBL620685,1.0,Striatum,,3550.0,,H,BAO_0000019,,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,10825.0,
8.0,10034.0,2435.0,F,,,Autocuration,CHEMBL620686,1.0,Striatum,,3551.0,,H,BAO_0000019,,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,10825.0,
8.0,10034.0,349.0,F,,,Autocuration,CHEMBL620687,1.0,Limbic system,,3552.0,,H,BAO_0000019,,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,10825.0,
8.0,10034.0,349.0,F,,,Autocuration,CHEMBL620688,1.0,Limbic system,,3553.0,,H,BAO_0000019,,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,10825.0,
8.0,10034.0,349.0,F,,,Autocuration,CHEMBL620689,1.0,Limbic system,,3554.0,,H,BAO_0000019,,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,10825.0,
8.0,10034.0,349.0,F,,,Autocuration,CHEMBL620690,1.0,Limbic system,,3555.0,,H,BAO_0000019,,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,10825.0,
8.0,10034.0,349.0,F,,,Autocuration,CHEMBL620691,1.0,Limbic system,,3556.0,,H,BAO_0000019,,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,10825.0,
8.0,10034.0,349.0,F,,,Autocuration,CHEMBL620692,1.0,Limbic system,,3557.0,,H,BAO_0000019,,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,10825.0,
8.0,10034.0,349.0,F,,,Autocuration,CHEMBL620693,1.0,Limbic system,,3558.0,,H,BAO_0000019,,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,10825.0,
8.0,1274.0,,B,,,Expert,CHEMBL620694,1.0,,,3559.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 4 receptor,,168.0,
8.0,17358.0,,F,,,Autocuration,CHEMBL857986,1.0,,,3560.0,,H,BAO_0000019,,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,168.0,
8.0,14532.0,,B,,,Autocuration,CHEMBL620695,1.0,,,3561.0,,H,BAO_0000357,,,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,168.0,
8.0,16989.0,,B,,,Expert,CHEMBL620696,1.0,,,3562.0,,H,BAO_0000357,,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,168.0,
8.0,17200.0,,B,,,Autocuration,CHEMBL620697,1.0,,,3563.0,,H,BAO_0000357,,,,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,168.0,
8.0,15779.0,,B,,,Autocuration,CHEMBL620698,1.0,,,3564.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor,,168.0,
8.0,15779.0,,B,,,Autocuration,CHEMBL620699,1.0,,,3565.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,168.0,
8.0,15779.0,,B,,,Autocuration,CHEMBL620700,1.0,,,3566.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,168.0,
8.0,15650.0,,B,,,Autocuration,CHEMBL620701,1.0,,,3567.0,,H,BAO_0000219,COS-7,,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,168.0,643.0
8.0,15650.0,,B,,,Autocuration,CHEMBL875082,1.0,,,3568.0,,H,BAO_0000219,COS-7,,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,168.0,643.0
8.0,15650.0,,B,,,Autocuration,CHEMBL620702,1.0,,,3569.0,,H,BAO_0000219,COS-7,,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,168.0,643.0
8.0,15650.0,,B,,,Autocuration,CHEMBL620703,1.0,,,3570.0,,H,BAO_0000219,COS-7,,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,168.0,643.0
8.0,17046.0,,B,,,Autocuration,CHEMBL620704,1.0,,,3571.0,,H,BAO_0000219,C6,,,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,168.0,673.0
8.0,17046.0,,B,,,Expert,CHEMBL620705,1.0,,,3572.0,,H,BAO_0000219,C6,,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,168.0,673.0
8.0,15650.0,,B,,,Expert,CHEMBL620706,1.0,,,3573.0,,H,BAO_0000219,C6,,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,168.0,673.0
8.0,17046.0,,B,,,Expert,CHEMBL620707,1.0,,,3574.0,,H,BAO_0000219,C6,,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,168.0,673.0
8.0,17066.0,,B,,,Expert,CHEMBL620708,1.0,,,3575.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 5 receptor,,10624.0,
8.0,17200.0,,B,,,Autocuration,CHEMBL620709,1.0,,,3576.0,,H,BAO_0000357,,,,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,105.0,
9.0,16146.0,,B,,,Expert,CHEMBL620710,1.0,,,3577.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity against 5-hydroxytryptamine 5A receptor,,10624.0,
8.0,15250.0,,B,,,Autocuration,CHEMBL620711,1.0,,,3578.0,,H,BAO_0000219,CHO,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,10624.0,449.0
9.0,6491.0,,B,,,Expert,CHEMBL620712,1.0,,,3579.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,10624.0,
9.0,17066.0,,B,,,Expert,CHEMBL620713,1.0,,,3580.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,10624.0,
9.0,17066.0,,B,,,Expert,CHEMBL620714,1.0,,,3581.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,10624.0,
9.0,4234.0,,B,,,Expert,CHEMBL620715,1.0,,,3582.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,10624.0,
8.0,6013.0,,B,,,Autocuration,CHEMBL620716,1.0,,,3583.0,,H,BAO_0000357,,,,,Binding affinity towards 5-HT5A receptor,,10624.0,
8.0,17175.0,,B,,,Expert,CHEMBL620717,1.0,,,3584.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,10624.0,
8.0,15818.0,,B,,,Autocuration,CHEMBL618072,1.0,,,3585.0,,H,BAO_0000357,,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,10624.0,
8.0,6166.0,,B,,,Autocuration,CHEMBL857987,1.0,,,3586.0,,H,BAO_0000357,,,,,Binding affinity towards cloned human 5-HT5A receptor was determined,,10624.0,
8.0,15779.0,,B,,,Autocuration,CHEMBL618073,1.0,,,3587.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,10624.0,722.0
8.0,15779.0,,B,,,Autocuration,CHEMBL618074,1.0,,,3588.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,10624.0,722.0
8.0,5213.0,,B,,,Autocuration,CHEMBL618075,1.0,,,3589.0,,H,BAO_0000219,HEK293,,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,10624.0,722.0
9.0,17066.0,,B,,,Expert,CHEMBL618076,1.0,,,3590.0,,D,BAO_0000357,,10090.0,,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,10625.0,
9.0,17066.0,,B,,,Expert,CHEMBL618077,1.0,,,3591.0,,D,BAO_0000357,,10090.0,,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,10625.0,
9.0,17066.0,,B,,,Expert,CHEMBL618078,1.0,,,3592.0,,D,BAO_0000357,,10090.0,,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,10625.0,
9.0,17066.0,,B,,,Expert,CHEMBL881821,1.0,,,3593.0,,D,BAO_0000357,,10090.0,,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,10625.0,
9.0,17066.0,,B,,,Expert,CHEMBL618079,1.0,,,3594.0,,D,BAO_0000357,,10090.0,,Mus musculus,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,10625.0,
8.0,17175.0,,B,,,Expert,CHEMBL618080,1.0,,,3595.0,,H,BAO_0000357,,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,10625.0,
8.0,16190.0,,B,,,Autocuration,CHEMBL618081,1.0,,,3596.0,,H,BAO_0000219,HEK293,,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,10576.0,722.0
8.0,16190.0,,B,,,Autocuration,CHEMBL618082,1.0,,,3597.0,,H,BAO_0000219,HEK293,,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,10626.0,722.0
8.0,4820.0,,B,,,Expert,CHEMBL618083,1.0,,,3598.0,,H,BAO_0000357,,,,,Binding affinity towards 5-HT5a receptor,,10624.0,
9.0,17066.0,,B,,,Expert,CHEMBL618084,1.0,,,3599.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 5A receptor,,10624.0,
8.0,17066.0,,B,,,Expert,CHEMBL618085,1.0,,,3600.0,,H,BAO_0000357,,,,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,10624.0,
8.0,17175.0,,B,,,Expert,CHEMBL618086,1.0,,,3601.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,10624.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL875092,1.0,,,3602.0,,H,BAO_0000357,,,,,Binding affinities against 5-hydroxytryptamine 5A receptor,,10624.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL618087,1.0,,,3603.0,,H,BAO_0000357,,,,,Binding affinities towards 5-hydroxytryptamine 5A receptor,,10624.0,
8.0,16700.0,,B,,,Autocuration,CHEMBL872926,1.0,,,3604.0,,H,BAO_0000357,,,,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,10624.0,
4.0,4639.0,,F,,,Autocuration,CHEMBL618088,1.0,,,3605.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,104714.0,
4.0,5486.0,,B,,,Autocuration,CHEMBL618089,1.0,,,3606.0,,H,BAO_0000223,,,,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,104714.0,
9.0,16146.0,,B,,,Expert,CHEMBL618090,1.0,,,3607.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Inhibition of human 5-hydroxytryptamine 6 receptor,,10627.0,
9.0,17273.0,,B,,,Expert,CHEMBL618091,1.0,,,3608.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,10627.0,
8.0,17687.0,,B,,,Autocuration,CHEMBL618092,1.0,,,3609.0,,H,BAO_0000357,,,,,Inhibition against human 5-hydroxytryptamine 6 receptor,,10627.0,
9.0,6491.0,,B,,,Expert,CHEMBL618093,1.0,,,3610.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,10627.0,
8.0,16190.0,,B,,,Expert,CHEMBL618094,1.0,,,3611.0,,H,BAO_0000219,HeLa,,,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,10627.0,308.0
9.0,17066.0,,B,,,Expert,CHEMBL618095,1.0,,,3612.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,10627.0,
9.0,17066.0,,B,,,Expert,CHEMBL875093,1.0,,,3613.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,10627.0,
9.0,17066.0,,B,,,Expert,CHEMBL618096,1.0,,,3614.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,10627.0,
9.0,17066.0,,B,,,Expert,CHEMBL618118,1.0,,,3615.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,10627.0,
9.0,3555.0,,B,,,Expert,CHEMBL618119,1.0,,,3616.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity against 5-hydroxytryptamine 6 receptor,,10627.0,
8.0,5808.0,,B,,,Expert,CHEMBL618120,1.0,,,3617.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,10627.0,
8.0,6013.0,,B,,,Autocuration,CHEMBL618121,1.0,,,3618.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,10627.0,
8.0,15818.0,,B,,,Expert,CHEMBL618122,1.0,,,3619.0,,H,BAO_0000219,HEK293,,,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,10627.0,722.0
8.0,16209.0,,B,,,Autocuration,CHEMBL618123,1.0,,,3620.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,10627.0,
8.0,3935.0,,B,,,Expert,CHEMBL618124,1.0,,,3621.0,,H,BAO_0000219,HEK293,,,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,10627.0,722.0
8.0,15818.0,,B,,,Autocuration,CHEMBL618125,1.0,,,3622.0,,H,BAO_0000357,,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,10627.0,
9.0,3805.0,,B,,,Expert,CHEMBL618126,1.0,,,3623.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,10627.0,722.0
8.0,16441.0,,B,,,Expert,CHEMBL618236,1.0,,,3624.0,,H,BAO_0000019,,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,10627.0,
8.0,16441.0,,B,,,Expert,CHEMBL618237,1.0,,,3625.0,,H,BAO_0000019,,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,10627.0,
8.0,6786.0,,B,,,Expert,CHEMBL618238,1.0,,,3626.0,,H,BAO_0000219,COS-7,,,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,10627.0,643.0
9.0,4234.0,,B,,,Expert,CHEMBL618239,1.0,,,3627.0,,D,BAO_0000357,,9606.0,,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,10627.0,
8.0,17085.0,,B,,,Autocuration,CHEMBL618240,1.0,,,3628.0,,H,BAO_0000019,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,10627.0,
8.0,17200.0,,B,,,Autocuration,CHEMBL618241,1.0,,,3629.0,,H,BAO_0000357,,,,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,10627.0,
8.0,17451.0,,B,,,Autocuration,CHEMBL859399,1.0,,,3630.0,,H,BAO_0000219,HEK293,,,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,10627.0,722.0
8.0,3935.0,,F,,,Autocuration,CHEMBL618242,1.0,,,3631.0,,H,BAO_0000019,,,,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,10627.0,
8.0,5033.0,,B,,,Autocuration,CHEMBL857991,1.0,,,3632.0,,H,BAO_0000357,,,,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,10627.0,
8.0,4540.0,,B,,,Expert,CHEMBL619951,1.0,,,3633.0,,H,BAO_0000357,,,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,10627.0,
9.0,4540.0,,B,,,Expert,CHEMBL619952,1.0,,,3634.0,,D,BAO_0000219,HeLa,9606.0,,Homo sapiens,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,10627.0,308.0
9.0,4540.0,,B,,,Expert,CHEMBL619953,1.0,,,3635.0,,D,BAO_0000219,HeLa,9606.0,,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,10627.0,308.0
8.0,17296.0,,B,,,Autocuration,CHEMBL619954,1.0,,,3636.0,,H,BAO_0000219,HeLa,,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,10627.0,308.0
8.0,17296.0,,B,,,Autocuration,CHEMBL619955,1.0,,,3637.0,,H,BAO_0000219,HeLa,,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,10627.0,308.0
8.0,17296.0,,B,,,Autocuration,CHEMBL619956,1.0,,,3638.0,,H,BAO_0000219,HeLa,,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,10627.0,308.0
8.0,15779.0,,B,,,Autocuration,CHEMBL619957,1.0,,,3639.0,,H,BAO_0000219,CHO,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,10627.0,449.0
8.0,15779.0,,B,,,Autocuration,CHEMBL619958,1.0,,,3640.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,10627.0,722.0
8.0,15779.0,,B,,,Autocuration,CHEMBL620627,1.0,,,3641.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,10627.0,722.0
8.0,15779.0,,B,,,Autocuration,CHEMBL620628,1.0,,,3642.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,10627.0,722.0
8.0,15779.0,,B,,,Autocuration,CHEMBL620629,1.0,,,3643.0,,H,BAO_0000219,HeLa,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,10627.0,308.0
8.0,6166.0,,B,,,Autocuration,CHEMBL620630,1.0,,,3644.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,10627.0,
8.0,17451.0,,B,,,Autocuration,CHEMBL620782,1.0,,,3645.0,,H,BAO_0000219,HeLa,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,10627.0,308.0
8.0,15316.0,,B,,,Autocuration,CHEMBL620783,1.0,,,3646.0,,H,BAO_0000357,,,,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,10627.0,
8.0,4199.0,,B,,,Expert,CHEMBL620784,1.0,,,3647.0,,H,BAO_0000357,,,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,10627.0,
8.0,15146.0,,B,,,Expert,CHEMBL620785,1.0,,,3648.0,,H,BAO_0000219,HeLa,,,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,10627.0,308.0
8.0,5213.0,,B,,,Autocuration,CHEMBL857992,1.0,,,3649.0,,H,BAO_0000357,,,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,10627.0,
8.0,16429.0,,B,,,Autocuration,CHEMBL620786,1.0,,,3650.0,,H,BAO_0000219,,,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,10627.0,
8.0,14818.0,,B,,,Autocuration,CHEMBL620787,1.0,,,3651.0,,H,BAO_0000219,HeLa,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,10627.0,308.0
8.0,4829.0,,B,,,Autocuration,CHEMBL620788,1.0,,,3652.0,,H,BAO_0000219,HeLa,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,10627.0,308.0
8.0,4829.0,,B,,,Autocuration,CHEMBL620789,1.0,,,3653.0,,H,BAO_0000219,HeLa,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,10627.0,308.0
8.0,4829.0,,B,,,Autocuration,CHEMBL620790,1.0,,,3654.0,,H,BAO_0000219,HeLa,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,10627.0,308.0
8.0,15250.0,,B,,,Autocuration,CHEMBL620791,1.0,,,3655.0,,H,BAO_0000219,CHO,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,10628.0,449.0
8.0,14423.0,,B,,,Autocuration,CHEMBL620792,1.0,,,3656.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,10628.0,
8.0,15086.0,,B,,,Autocuration,CHEMBL620793,1.0,,,3657.0,,H,BAO_0000357,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,10628.0,
8.0,4342.0,,B,,,Autocuration,CHEMBL620794,1.0,,,3658.0,,H,BAO_0000357,,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,10628.0,
9.0,16190.0,,B,,,Autocuration,CHEMBL620795,1.0,,,3659.0,,D,BAO_0000219,HeLa,9606.0,,Homo sapiens,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,10627.0,308.0
8.0,4820.0,,B,,,Expert,CHEMBL620796,1.0,,,3660.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,10627.0,
8.0,4639.0,,B,,,Autocuration,CHEMBL620797,1.0,,,3661.0,,H,BAO_0000357,,,,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,10627.0,
9.0,17066.0,,F,,,Expert,CHEMBL620798,1.0,,,3662.0,,D,BAO_0000019,,9606.0,,Homo sapiens,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,10627.0,
8.0,6011.0,,B,,,Autocuration,CHEMBL620799,1.0,,,3663.0,,H,BAO_0000357,,,,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,10627.0,
8.0,17066.0,,B,,,Expert,CHEMBL620800,1.0,,,3664.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,10627.0,
8.0,17515.0,,B,,,Autocuration,CHEMBL620801,1.0,,,3665.0,,H,BAO_0000357,,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,10627.0,
8.0,5014.0,,B,,,Autocuration,CHEMBL875100,1.0,,,3666.0,,H,BAO_0000357,,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,10627.0,
8.0,4373.0,,B,,,Autocuration,CHEMBL620802,1.0,,,3667.0,,H,BAO_0000357,,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,10627.0,
8.0,17066.0,,F,,,Expert,CHEMBL620803,1.0,,,3668.0,,H,BAO_0000019,,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,10627.0,
8.0,17066.0,,F,,,Expert,CHEMBL620804,1.0,,,3669.0,,H,BAO_0000019,,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,10627.0,
8.0,4373.0,,B,,,Autocuration,CHEMBL620805,1.0,,,3670.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,10627.0,
8.0,4687.0,,B,,,Autocuration,CHEMBL620806,1.0,,,3671.0,,H,BAO_0000357,,,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,10627.0,
8.0,16946.0,,B,,,Autocuration,CHEMBL620807,1.0,,,3672.0,,H,BAO_0000357,,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,10627.0,
8.0,16946.0,,B,,,Autocuration,CHEMBL620808,1.0,,,3673.0,,H,BAO_0000357,,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,10627.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL620809,1.0,,,3674.0,,H,BAO_0000357,,,,,Binding affinities against 5-hydroxytryptamine 6 receptor,,10627.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL620810,1.0,,,3675.0,,H,BAO_0000357,,,,,Binding affinities towards 5-hydroxytryptamine 6 receptor,,10627.0,
9.0,17066.0,,B,,,Expert,CHEMBL620811,1.0,,,3676.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 6 receptor,,10627.0,
8.0,16700.0,,B,,,Autocuration,CHEMBL620812,1.0,,,3677.0,,H,BAO_0000357,,,,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,10627.0,
8.0,3269.0,,B,,,Autocuration,CHEMBL620813,1.0,,,3678.0,,H,BAO_0000357,,,,,Affinity against 5-hydroxytryptamine 6 receptor,,10627.0,
8.0,5486.0,,B,,,Autocuration,CHEMBL620814,1.0,,,3679.0,,H,BAO_0000357,,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,10627.0,
9.0,16146.0,,B,,,Expert,CHEMBL620815,1.0,,,3680.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Inhibition of human 5-hydroxytryptamine 7 receptor,,10209.0,
8.0,5014.0,,B,,,Autocuration,CHEMBL620816,1.0,,,3681.0,,H,BAO_0000219,HEK293,,,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,10209.0,722.0
8.0,15463.0,,B,,,Autocuration,CHEMBL620817,1.0,,,3682.0,,H,BAO_0000357,,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,10209.0,
8.0,3805.0,,B,,,Autocuration,CHEMBL620818,1.0,,,3683.0,,H,BAO_0000357,,,,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,10209.0,
8.0,5014.0,,B,,,Expert,CHEMBL620819,1.0,,,3684.0,,H,BAO_0000219,HEK293,,,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,10209.0,722.0
9.0,6491.0,,B,,,Expert,CHEMBL620820,1.0,,,3685.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,10209.0,
8.0,16190.0,,B,,,Autocuration,CHEMBL620821,1.0,,,3686.0,,H,BAO_0000219,CHO,,,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,10209.0,449.0
9.0,17066.0,,B,,,Expert,CHEMBL620822,1.0,,,3687.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,10209.0,
9.0,17066.0,,B,,,Expert,CHEMBL620823,1.0,,,3688.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,10209.0,
9.0,3555.0,,B,,,Expert,CHEMBL620824,1.0,,,3689.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity against 5-hydroxytryptamine 7 receptor,,10209.0,
8.0,6588.0,,B,,,Expert,CHEMBL620825,1.0,,,3690.0,,H,BAO_0000219,CHO,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,10209.0,449.0
8.0,15463.0,,B,,,Autocuration,CHEMBL872930,1.0,,,3691.0,,H,BAO_0000357,,,,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,10209.0,
8.0,6013.0,,B,,,Autocuration,CHEMBL620826,1.0,,,3692.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,10209.0,
8.0,16209.0,,B,,,Autocuration,CHEMBL620827,1.0,,,3693.0,,H,BAO_0000357,,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,10209.0,
8.0,3935.0,,B,,,Autocuration,CHEMBL620828,1.0,,,3694.0,,H,BAO_0000357,,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,10209.0,
8.0,15818.0,,B,,,Autocuration,CHEMBL620829,1.0,,,3695.0,,H,BAO_0000357,,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,10209.0,
8.0,5014.0,,B,,,Expert,CHEMBL620830,1.0,,,3696.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,10209.0,722.0
8.0,16441.0,,B,,,Expert,CHEMBL620831,1.0,,,3697.0,,H,BAO_0000019,,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,10209.0,
8.0,16441.0,,B,,,Expert,CHEMBL620832,1.0,,,3698.0,,H,BAO_0000019,,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,10209.0,
9.0,4234.0,,B,,,Expert,CHEMBL621548,1.0,,,3699.0,,D,BAO_0000357,,9606.0,,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,10209.0,
8.0,17085.0,,B,,,Autocuration,CHEMBL621549,1.0,,,3700.0,,H,BAO_0000019,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,10209.0,
8.0,17200.0,,B,,,Autocuration,CHEMBL621550,1.0,,,3701.0,,H,BAO_0000357,,,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,10209.0,
8.0,17451.0,,B,,,Autocuration,CHEMBL621551,1.0,,,3702.0,,H,BAO_0000219,CHO,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,10209.0,449.0
8.0,17085.0,,B,,,Autocuration,CHEMBL621552,1.0,,,3703.0,,H,BAO_0000019,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,10209.0,
8.0,5104.0,,B,,,Autocuration,CHEMBL857077,1.0,,,3704.0,,H,BAO_0000357,,,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,10209.0,
8.0,5104.0,,B,,,Autocuration,CHEMBL618158,1.0,,,3705.0,,H,BAO_0000357,,,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,10209.0,
9.0,5033.0,,B,,,Expert,CHEMBL618159,1.0,,,3706.0,,D,BAO_0000219,COS-7,9606.0,,Homo sapiens,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,10209.0,643.0
8.0,5486.0,,B,,,Autocuration,CHEMBL875101,1.0,,,3707.0,,H,BAO_0000219,COS-7,,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,10209.0,643.0
9.0,4540.0,,B,,,Expert,CHEMBL618160,1.0,,,3708.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,10209.0,722.0
8.0,6166.0,,B,,,Expert,CHEMBL618161,1.0,,,3709.0,,H,BAO_0000357,,,,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,10209.0,
8.0,17342.0,,B,,,Expert,CHEMBL618162,1.0,,,3710.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,10209.0,722.0
8.0,17342.0,,B,,,Expert,CHEMBL618163,1.0,,,3711.0,,H,BAO_0000357,,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,10209.0,
8.0,17296.0,,B,,,Autocuration,CHEMBL618164,1.0,,,3712.0,,H,BAO_0000357,,,,,Binding affinity against 5-hydroxytryptamine 7 human receptors,,10209.0,
8.0,16429.0,,B,,,Expert,CHEMBL618165,1.0,,,3713.0,,H,BAO_0000219,,,,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,10209.0,
8.0,15779.0,,B,,,Autocuration,CHEMBL618166,1.0,,,3714.0,,H,BAO_0000219,HEK293,,,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,10209.0,722.0
8.0,15779.0,,B,,,Autocuration,CHEMBL857989,1.0,,,3715.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,10209.0,722.0
8.0,15779.0,,B,,,Autocuration,CHEMBL619888,1.0,,,3716.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,10209.0,722.0
8.0,15779.0,,B,,,Autocuration,CHEMBL619889,1.0,,,3717.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,10209.0,722.0
8.0,15779.0,,B,,,Autocuration,CHEMBL619890,1.0,,,3718.0,,H,BAO_0000219,HEK293,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,10209.0,722.0
8.0,17451.0,,B,,,Autocuration,CHEMBL619891,1.0,,,3719.0,,H,BAO_0000219,CHO,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,10209.0,449.0
8.0,4199.0,,B,,,Autocuration,CHEMBL619892,1.0,,,3720.0,,H,BAO_0000219,HEK293,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,10209.0,722.0
9.0,4199.0,,B,,,Expert,CHEMBL619893,1.0,,,3721.0,,D,BAO_0000219,HEK293,,,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,10209.0,722.0
8.0,4199.0,,B,,,Autocuration,CHEMBL619894,1.0,,,3722.0,,H,BAO_0000219,HEK293,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,10209.0,722.0
9.0,3680.0,,B,,,Intermediate,CHEMBL619895,1.0,,,3723.0,,D,BAO_0000219,HEK293,,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,10209.0,722.0
9.0,3680.0,,B,,,Intermediate,CHEMBL619896,1.0,,,3724.0,,D,BAO_0000357,,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,10209.0,
8.0,15316.0,,B,,,Autocuration,CHEMBL619897,1.0,,,3725.0,,H,BAO_0000219,COS-7,,,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,10209.0,643.0
8.0,15146.0,,B,,,Autocuration,CHEMBL619898,1.0,,,3726.0,,H,BAO_0000219,HEK293,,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,10209.0,722.0
8.0,5213.0,,B,,,Expert,CHEMBL619899,1.0,,,3727.0,,H,BAO_0000219,HEK293,,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,10209.0,722.0
8.0,5213.0,,B,,,Autocuration,CHEMBL619900,1.0,,,3728.0,,H,BAO_0000219,HEK293,,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,10209.0,722.0
9.0,14818.0,,B,,,Expert,CHEMBL619901,1.0,,,3729.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,10209.0,722.0
8.0,14818.0,,B,,,Autocuration,CHEMBL620580,1.0,,,3730.0,,H,BAO_0000219,HEK293,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,10209.0,722.0
8.0,14818.0,,B,,,Autocuration,CHEMBL620581,1.0,,,3731.0,,H,BAO_0000219,HEK293,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,10209.0,722.0
8.0,4829.0,,B,,,Autocuration,CHEMBL620733,1.0,,,3732.0,,H,BAO_0000219,HEK293,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,10209.0,722.0
9.0,17200.0,,B,,,Autocuration,CHEMBL620734,1.0,,,3733.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,10209.0,
9.0,17066.0,,B,,,Expert,CHEMBL620735,1.0,,,3734.0,,D,BAO_0000357,,10090.0,,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,10022.0,
8.0,14025.0,,B,,,Autocuration,CHEMBL620736,1.0,,,3735.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,10209.0,
8.0,15250.0,,B,,,Autocuration,CHEMBL620737,1.0,,,3736.0,,H,BAO_0000219,CHO,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,11923.0,449.0
8.0,16372.0,,B,,,Autocuration,CHEMBL620738,1.0,,,3737.0,,H,BAO_0000219,CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,11923.0,449.0
8.0,16372.0,,B,,,Autocuration,CHEMBL620739,1.0,,,3738.0,,H,BAO_0000219,CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,11923.0,449.0
8.0,16372.0,,B,,,Autocuration,CHEMBL620740,1.0,,,3739.0,,H,BAO_0000219,CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,11923.0,449.0
8.0,16372.0,,B,,,Autocuration,CHEMBL620741,1.0,,,3740.0,,H,BAO_0000219,CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,11923.0,449.0
8.0,16372.0,,B,,,Autocuration,CHEMBL620742,1.0,,,3741.0,,H,BAO_0000219,CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,11923.0,449.0
8.0,16372.0,,B,,,Autocuration,CHEMBL620743,1.0,,,3742.0,,H,BAO_0000219,CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,11923.0,449.0
8.0,16372.0,,B,,,Autocuration,CHEMBL620744,1.0,,,3743.0,,H,BAO_0000219,CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,11923.0,449.0
8.0,16372.0,,B,,,Autocuration,CHEMBL620745,1.0,,,3744.0,,H,BAO_0000219,CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,11923.0,449.0
8.0,16372.0,,B,,,Autocuration,CHEMBL620746,1.0,,,3745.0,,H,BAO_0000219,CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,11923.0,449.0
8.0,16372.0,,B,,,Autocuration,CHEMBL620747,1.0,,,3746.0,,H,BAO_0000219,CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,11923.0,449.0
8.0,16372.0,,B,,,Autocuration,CHEMBL620748,1.0,,,3747.0,,H,BAO_0000219,CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,11923.0,449.0
8.0,16372.0,,B,,,Autocuration,CHEMBL620749,1.0,,,3748.0,,H,BAO_0000219,CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,11923.0,449.0
8.0,17066.0,,B,,,Expert,CHEMBL620750,1.0,,,3749.0,,H,BAO_0000357,,,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,11923.0,
9.0,17066.0,,B,,,Expert,CHEMBL620751,1.0,,,3750.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,11923.0,
8.0,17386.0,,B,,,Expert,CHEMBL620752,1.0,,,3751.0,,H,BAO_0000357,,,,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,11923.0,
8.0,14423.0,,B,,,Autocuration,CHEMBL872929,1.0,,,3752.0,,H,BAO_0000019,,,,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,11923.0,
9.0,15874.0,,B,,,Expert,CHEMBL620753,1.0,,,3753.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,11923.0,
9.0,15874.0,,B,,,Expert,CHEMBL620754,1.0,,,3754.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,11923.0,
9.0,16372.0,,B,,,Expert,CHEMBL620755,1.0,,,3755.0,,D,BAO_0000219,CHO,10116.0,,Rattus norvegicus,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,11923.0,449.0
8.0,4622.0,,B,,,Autocuration,CHEMBL620756,1.0,,,3756.0,,H,BAO_0000357,,,,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,11923.0,
8.0,15086.0,,B,,,Autocuration,CHEMBL620757,1.0,,,3757.0,,H,BAO_0000357,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,11923.0,
8.0,16372.0,,B,,,Autocuration,CHEMBL620758,1.0,,,3758.0,,H,BAO_0000219,CHO,,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,11923.0,449.0
8.0,16372.0,,B,,,Autocuration,CHEMBL620759,1.0,,,3759.0,,H,BAO_0000219,CHO,,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,11923.0,449.0
8.0,16372.0,,B,,,Autocuration,CHEMBL620760,1.0,,,3760.0,,H,BAO_0000219,CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,11923.0,449.0
8.0,16372.0,,B,,,Autocuration,CHEMBL620761,1.0,,,3761.0,,H,BAO_0000219,CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,11923.0,449.0
8.0,17386.0,2116.0,F,,,Autocuration,CHEMBL620762,1.0,Ileum,,3762.0,,H,BAO_0000221,,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,11923.0,
8.0,17386.0,2116.0,F,,,Autocuration,CHEMBL620763,1.0,Ileum,,3763.0,,H,BAO_0000221,,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,11923.0,
8.0,17386.0,2116.0,F,,,Autocuration,CHEMBL620764,1.0,Ileum,,3764.0,,H,BAO_0000221,,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,11923.0,
9.0,5831.0,,B,Membranes,,Expert,CHEMBL857990,1.0,,,3765.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,11923.0,
8.0,4342.0,,B,,,Autocuration,CHEMBL620765,1.0,,,3766.0,,H,BAO_0000357,,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,11923.0,
8.0,17319.0,,B,,,Expert,CHEMBL620766,1.0,,,3767.0,,H,BAO_0000357,,,,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,11923.0,
8.0,17342.0,1898.0,B,,,Expert,CHEMBL620767,1.0,Hypothalamus,,3768.0,,H,BAO_0000019,,,,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,11923.0,
8.0,17342.0,,B,,,Autocuration,CHEMBL620768,1.0,,,3769.0,,H,BAO_0000357,,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,11923.0,
8.0,3680.0,1898.0,B,,,Expert,CHEMBL619051,1.0,Hypothalamus,,3770.0,,H,BAO_0000249,,,,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,11923.0,
8.0,3680.0,,B,,,Expert,CHEMBL619052,1.0,,,3771.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,11923.0,
9.0,17319.0,,F,,,Expert,CHEMBL619053,1.0,,,3772.0,,D,BAO_0000219,HEK293,10116.0,,Rattus norvegicus,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,11923.0,722.0
9.0,17319.0,,F,,,Expert,CHEMBL619703,1.0,,,3773.0,,D,BAO_0000219,HEK293,10116.0,,Rattus norvegicus,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,11923.0,722.0
9.0,17319.0,,F,,,Autocuration,CHEMBL619704,1.0,,,3774.0,,D,BAO_0000219,HEK293,10116.0,,Rattus norvegicus,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,11923.0,722.0
8.0,4820.0,,B,,,Expert,CHEMBL619851,1.0,,,3775.0,,H,BAO_0000357,,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,10209.0,
8.0,4639.0,,B,,,Autocuration,CHEMBL619852,1.0,,,3776.0,,H,BAO_0000357,,,,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,10209.0,
8.0,6011.0,,B,,,Autocuration,CHEMBL619853,1.0,,,3777.0,,H,BAO_0000357,,,,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,10209.0,
9.0,17066.0,,B,,,Expert,CHEMBL619854,1.0,,,3778.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,10209.0,
8.0,17066.0,,B,,,Expert,CHEMBL619855,1.0,,,3779.0,,H,BAO_0000357,,,,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,10209.0,
8.0,17515.0,,B,,,Autocuration,CHEMBL619856,1.0,,,3780.0,,H,BAO_0000357,,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,10209.0,
8.0,4373.0,,B,,,Autocuration,CHEMBL619857,1.0,,,3781.0,,H,BAO_0000357,,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,10209.0,
8.0,17066.0,,F,,,Expert,CHEMBL619858,1.0,,,3782.0,,H,BAO_0000019,,,,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,10209.0,
8.0,4373.0,,B,,,Autocuration,CHEMBL619859,1.0,,,3783.0,,H,BAO_0000357,,,,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,10209.0,
8.0,4373.0,,B,,,Autocuration,CHEMBL619860,1.0,,,3784.0,,H,BAO_0000357,,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,10209.0,
8.0,4687.0,,B,,,Autocuration,CHEMBL619861,1.0,,,3785.0,,H,BAO_0000357,,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,10209.0,
8.0,17342.0,,B,,,Expert,CHEMBL619862,1.0,,,3786.0,,H,BAO_0000357,,,,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,10209.0,
8.0,16946.0,,B,,,Autocuration,CHEMBL619863,1.0,,,3787.0,,H,BAO_0000357,,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,10209.0,
8.0,16946.0,,B,,,Autocuration,CHEMBL619864,1.0,,,3788.0,,H,BAO_0000357,,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,10209.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL872928,1.0,,,3789.0,,H,BAO_0000357,,,,,Binding affinities against 5-hydroxytryptamine 7 receptor,,10209.0,
8.0,16633.0,,B,,,Autocuration,CHEMBL619865,1.0,,,3790.0,,H,BAO_0000357,,,,,Binding affinities towards 5-hydroxytryptamine 7 receptor,,10209.0,
8.0,17066.0,,B,,,Expert,CHEMBL619866,1.0,,,3791.0,,H,BAO_0000357,,,,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,10209.0,
8.0,16700.0,,B,,,Autocuration,CHEMBL619867,1.0,,,3792.0,,H,BAO_0000357,,,,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,10209.0,
8.0,17386.0,2116.0,B,,,Autocuration,CHEMBL619868,1.0,Ileum,,3793.0,,H,BAO_0000221,,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,10209.0,
8.0,14080.0,,F,,,Autocuration,CHEMBL619869,1.0,,,3794.0,,H,BAO_0000019,,,,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,55.0,
9.0,14080.0,,F,,,Expert,CHEMBL619870,1.0,,,3795.0,,D,BAO_0000019,,9606.0,,Homo sapiens,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,55.0,
8.0,409.0,,B,,,Autocuration,CHEMBL619871,1.0,,,3796.0,,H,BAO_0000357,,,,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,55.0,
8.0,409.0,,B,,,Autocuration,CHEMBL619872,1.0,,,3797.0,,H,BAO_0000357,,,,,In vitro inhibition of human recombinant lipoxygenase enzyme,,55.0,
8.0,409.0,,B,,,Autocuration,CHEMBL619873,1.0,,,3798.0,,H,BAO_0000357,,,,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,55.0,
8.0,11090.0,178.0,B,,,Expert,CHEMBL619874,1.0,Blood,,3799.0,,H,BAO_0000357,,,,,Inhibition of 5-lipoxygenase in human whole blood.,,55.0,
8.0,11090.0,178.0,B,,,Expert,CHEMBL619875,1.0,Blood,,3800.0,,H,BAO_0000357,,,,,Inhibition of 5-lipoxygenase in human whole blood.,,55.0,
8.0,948.0,,B,,,Autocuration,CHEMBL619876,1.0,,,3801.0,,H,BAO_0000357,,,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,55.0,
8.0,948.0,,B,,,Autocuration,CHEMBL619877,1.0,,,3802.0,,H,BAO_0000357,,,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,55.0,
8.0,13622.0,,F,,,Expert,CHEMBL619878,1.0,,,3803.0,,H,BAO_0000219,,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,55.0,
8.0,13622.0,178.0,F,,,Autocuration,CHEMBL619879,1.0,Blood,,3804.0,,H,BAO_0000019,,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,55.0,
8.0,9637.0,,B,,,Autocuration,CHEMBL619880,1.0,,,3805.0,,H,BAO_0000357,,,,,In vitro inhibition of 5-lipoxygenase from human polymorphs,,55.0,
8.0,11320.0,,B,,,Autocuration,CHEMBL619881,1.0,,,3806.0,,H,BAO_0000357,,,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,55.0,
8.0,11320.0,,B,,,Expert,CHEMBL619882,1.0,,,3807.0,,H,BAO_0000357,,,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,55.0,
8.0,6838.0,,B,,,Autocuration,CHEMBL619883,1.0,,,3808.0,,H,BAO_0000357,,,,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,55.0,
9.0,17667.0,178.0,B,,,Expert,CHEMBL619884,1.0,Blood,,3809.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,55.0,
8.0,12703.0,,B,,,Autocuration,CHEMBL619885,1.0,,,3810.0,,H,BAO_0000357,,,,,In vitro potency against human 5-Lipoxygenase,,55.0,
9.0,14312.0,,F,,,Expert,CHEMBL619886,1.0,,,3811.0,,D,BAO_0000019,,9606.0,,Homo sapiens,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,55.0,
8.0,14312.0,178.0,F,,,Autocuration,CHEMBL619887,1.0,Blood,,3812.0,,H,BAO_0000019,,,,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,55.0,
8.0,5364.0,,F,,,Autocuration,CHEMBL875097,1.0,,,3813.0,,H,BAO_0000019,,,,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,55.0,
8.0,951.0,,B,,,Autocuration,CHEMBL618001,1.0,,,3814.0,,H,BAO_0000219,,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,55.0,
8.0,951.0,,B,,,Autocuration,CHEMBL618002,1.0,,,3815.0,,H,BAO_0000219,,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,55.0,
8.0,951.0,,B,,,Autocuration,CHEMBL618003,1.0,,,3816.0,,H,BAO_0000219,,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,55.0,
8.0,951.0,,B,,,Autocuration,CHEMBL618004,1.0,,,3817.0,,H,BAO_0000219,,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,55.0,
8.0,12365.0,,B,,,Autocuration,CHEMBL618005,1.0,,,3818.0,,H,BAO_0000219,,,,,Inhibition of human 5-lipoxygenase in human cells,,55.0,
8.0,10603.0,,B,,,Expert,CHEMBL618006,1.0,,,3819.0,,H,BAO_0000357,,,,,Inhibition of human neutrophil 5-lipoxygenase,,55.0,
8.0,10501.0,,B,,,Autocuration,CHEMBL875086,1.0,,,3820.0,,H,BAO_0000019,,,,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,55.0,
8.0,12281.0,178.0,B,,,Expert,CHEMBL618007,1.0,Blood,,3821.0,,H,BAO_0000357,,,,,Inhibition of 5-lipoxygenase from human whole blood,,55.0,
8.0,2567.0,,B,,,Autocuration,CHEMBL618008,1.0,,,3822.0,,H,BAO_0000357,,,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,55.0,
8.0,2567.0,,B,,,Autocuration,CHEMBL618009,1.0,,,3823.0,,H,BAO_0000219,,,,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,55.0,
8.0,10193.0,,B,,,Expert,CHEMBL618010,1.0,,,3824.0,,H,BAO_0000357,,,,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,55.0,
8.0,10193.0,,B,,,Autocuration,CHEMBL618011,1.0,,,3825.0,,H,BAO_0000357,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,55.0,
8.0,13623.0,,B,,,Expert,CHEMBL618012,1.0,,,3826.0,,H,BAO_0000357,,,,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,55.0,
8.0,12780.0,,B,,,Autocuration,CHEMBL882927,1.0,,,3827.0,,H,BAO_0000357,,,,,Tested against 5-lipoxygenase,,55.0,
8.0,12780.0,,B,,,Autocuration,CHEMBL618013,1.0,,,3828.0,,H,BAO_0000357,,,,,Tested for activity against 5-Lipoxygenase (5-LO),,55.0,
8.0,12780.0,,B,,,Autocuration,CHEMBL618014,1.0,,,3829.0,,H,BAO_0000357,,,,,Tested for activity against 5-lipoxygenase,,55.0,
8.0,11966.0,,B,,,Autocuration,CHEMBL618015,1.0,,,3830.0,,H,BAO_0000357,,,,,Tested for inhibition of 5-HPETE production by human 5-LO,,55.0,
8.0,5364.0,,F,,,Autocuration,CHEMBL618016,1.0,,,3831.0,,H,BAO_0000019,,,,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,55.0,
8.0,13165.0,,B,,,Expert,CHEMBL618017,1.0,,,3832.0,,H,BAO_0000357,,,,,Inhibition of Human 5-lipoxygenase,,55.0,
8.0,5364.0,,B,,,Autocuration,CHEMBL618018,1.0,,,3833.0,,H,BAO_0000019,,,,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,55.0,
8.0,11311.0,,B,,,Autocuration,CHEMBL875087,1.0,,,3834.0,,H,BAO_0000219,,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,55.0,
8.0,11311.0,,B,,,Autocuration,CHEMBL618019,1.0,,,3835.0,,H,BAO_0000219,,,,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,55.0,
8.0,14863.0,,B,,,Autocuration,CHEMBL618020,1.0,,,3836.0,,H,BAO_0000019,,,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,55.0,
8.0,14863.0,,B,,,Autocuration,CHEMBL618021,1.0,,,3837.0,,H,BAO_0000019,,,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,55.0,
8.0,11087.0,178.0,B,,,Autocuration,CHEMBL618022,1.0,Blood,,3838.0,,H,BAO_0000357,,,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,55.0,
8.0,455.0,,B,,,Autocuration,CHEMBL618023,1.0,,,3839.0,,H,BAO_0000357,,,,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,55.0,
8.0,13183.0,,B,,,Autocuration,CHEMBL618024,1.0,,,3840.0,,H,BAO_0000357,,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,55.0,
8.0,10319.0,,B,,,Expert,CHEMBL873950,1.0,,,3841.0,,H,BAO_0000019,,,,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,55.0,
8.0,10193.0,,B,,,Autocuration,CHEMBL618025,1.0,,,3842.0,,H,BAO_0000357,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,55.0,
8.0,951.0,,B,,,Autocuration,CHEMBL618026,1.0,,,3843.0,,H,BAO_0000219,,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,55.0,
8.0,951.0,,B,,,Autocuration,CHEMBL618027,1.0,,,3844.0,,H,BAO_0000219,,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,55.0,
8.0,951.0,,B,,,Autocuration,CHEMBL618028,1.0,,,3845.0,,H,BAO_0000219,,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,55.0,
8.0,951.0,,B,,,Autocuration,CHEMBL618029,1.0,,,3846.0,,H,BAO_0000219,,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,55.0,
8.0,9859.0,,B,,,Expert,CHEMBL618030,1.0,,,3847.0,,H,BAO_0000357,,,,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,55.0,
8.0,9859.0,,B,,,Expert,CHEMBL618031,1.0,,,3848.0,,H,BAO_0000357,,,,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,55.0,
8.0,9859.0,,B,,,Autocuration,CHEMBL618032,1.0,,,3849.0,,H,BAO_0000357,,,,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,55.0,
8.0,2567.0,,B,,,Autocuration,CHEMBL618033,1.0,,,3850.0,,H,BAO_0000357,,,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,55.0,
8.0,10193.0,,B,,,Autocuration,CHEMBL618034,1.0,,,3851.0,,H,BAO_0000357,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,55.0,
8.0,10193.0,,B,,,Autocuration,CHEMBL875088,1.0,,,3852.0,,H,BAO_0000357,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,55.0,
8.0,949.0,,B,,,Autocuration,CHEMBL618035,1.0,,,3853.0,,H,BAO_0000019,,,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,55.0,
8.0,949.0,,B,,,Autocuration,CHEMBL618036,1.0,,,3854.0,,H,BAO_0000019,,,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,55.0,
8.0,10603.0,,B,,,Expert,CHEMBL618037,1.0,,,3855.0,,H,BAO_0000357,,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,55.0,
8.0,10603.0,,B,,,Expert,CHEMBL618038,1.0,,,3856.0,,H,BAO_0000357,,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,55.0,
8.0,10603.0,,F,,,Autocuration,CHEMBL618761,1.0,,,3857.0,,H,BAO_0000019,,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,55.0,
8.0,10603.0,,B,,,Expert,CHEMBL618762,1.0,,,3858.0,,H,BAO_0000357,,,,,Inhibition of lipoxygenase at the concentration of 0.1 uM,,55.0,
8.0,10603.0,,B,,,Expert,CHEMBL618763,1.0,,,3859.0,,H,BAO_0000357,,,,,Inhibition of lipoxygenase at the concentration of 1 uM,,55.0,
8.0,10193.0,,B,,,Autocuration,CHEMBL618764,1.0,,,3860.0,,H,BAO_0000357,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,55.0,
9.0,14580.0,,B,,,Expert,CHEMBL618765,1.0,,,3861.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Inhibition of 5-Lipoxygenase (5-LOX),,55.0,
8.0,11090.0,,B,,,Expert,CHEMBL618766,1.0,,,3862.0,,H,BAO_0000357,,,,,Inhibition of 5-lipoxygenase in mouse macrophages.,,17087.0,
8.0,11090.0,,B,,,Expert,CHEMBL618767,1.0,,,3863.0,,H,BAO_0000357,,,,,Inhibition of 5-lipoxygenase in mouse macrophages.,,17087.0,
8.0,6339.0,,B,,,Autocuration,CHEMBL619380,1.0,,,3864.0,,H,BAO_0000357,,,,,Inhibitory activity against lipoxygenase-2 in mice,,17087.0,
8.0,6339.0,,B,,,Expert,CHEMBL619381,1.0,,,3865.0,,H,BAO_0000357,,,,,Inhibitory activity against murine lipoxygenase-2.,,17087.0,
9.0,12281.0,,B,,,Expert,CHEMBL619382,1.0,,,3866.0,,D,BAO_0000357,,10090.0,,Mus musculus,Inhibition of 5-lipoxygenase from mouse macrophage,,17087.0,
8.0,11311.0,,B,,,Autocuration,CHEMBL619383,1.0,,,3867.0,,H,BAO_0000357,,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,17087.0,
8.0,11089.0,,B,,,Autocuration,CHEMBL619384,1.0,,,3868.0,,H,BAO_0000019,,9823.0,,Sus scrofa,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,55.0,
8.0,10091.0,,B,,,Autocuration,CHEMBL619385,1.0,,,3869.0,,H,BAO_0000019,,9823.0,,Sus scrofa,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,55.0,
8.0,14352.0,,B,,,Autocuration,CHEMBL882928,1.0,,,3870.0,,H,BAO_0000019,,9986.0,,Oryctolagus cuniculus,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,55.0,
9.0,13329.0,,B,,,Expert,CHEMBL619386,1.0,,,3871.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,12166.0,
8.0,13329.0,,B,,,Autocuration,CHEMBL619387,1.0,,,3872.0,,H,BAO_0000019,,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,12166.0,
8.0,13329.0,,B,,,Autocuration,CHEMBL619388,1.0,,,3873.0,,H,BAO_0000019,,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,12166.0,
8.0,13329.0,,B,,,Autocuration,CHEMBL619389,1.0,,,3874.0,,H,BAO_0000019,,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,12166.0,
8.0,13329.0,,B,,,Expert,CHEMBL619390,1.0,,,3875.0,,H,BAO_0000019,,,,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,12166.0,
8.0,13329.0,,B,,,Expert,CHEMBL619391,1.0,,,3876.0,,H,BAO_0000019,,,,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,12166.0,
8.0,13329.0,,B,,,Autocuration,CHEMBL619392,1.0,,,3877.0,,H,BAO_0000019,,,,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,12166.0,
8.0,11311.0,,B,,,Autocuration,CHEMBL619393,1.0,,,3878.0,,H,BAO_0000019,,,,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,12166.0,
8.0,11311.0,,B,,,Autocuration,CHEMBL619394,1.0,,,3879.0,,H,BAO_0000019,,,,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,12166.0,
8.0,105.0,,B,,,Autocuration,CHEMBL619395,1.0,,,3880.0,,H,BAO_0000219,RBL-1,,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,12166.0,702.0
8.0,105.0,,B,,,Autocuration,CHEMBL619396,1.0,,,3881.0,,H,BAO_0000219,RBL-1,,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,12166.0,702.0
8.0,9138.0,,B,,,Autocuration,CHEMBL619397,1.0,,,3882.0,,H,BAO_0000357,,,,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,12166.0,
8.0,9138.0,,B,,,Autocuration,CHEMBL619398,1.0,,,3883.0,,H,BAO_0000357,,,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,12166.0,
8.0,9138.0,,B,,,Autocuration,CHEMBL619399,1.0,,,3884.0,,H,BAO_0000357,,,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,12166.0,
8.0,14427.0,,B,,,Autocuration,CHEMBL619400,1.0,,,3885.0,,H,BAO_0000357,,,,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,12166.0,
8.0,13329.0,,B,,,Autocuration,CHEMBL619401,1.0,,,3886.0,,H,BAO_0000019,,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,12166.0,
8.0,13329.0,,B,,,Autocuration,CHEMBL619402,1.0,,,3887.0,,H,BAO_0000019,,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,12166.0,
9.0,14427.0,,B,,,Expert,CHEMBL619403,1.0,,,3888.0,,D,BAO_0000219,RBL-2H3,10116.0,,Rattus norvegicus,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,12166.0,663.0
8.0,14427.0,,B,,,Autocuration,CHEMBL619404,1.0,,,3889.0,,H,BAO_0000357,,,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,12166.0,
8.0,14427.0,,B,,,Autocuration,CHEMBL619405,1.0,,,3890.0,,H,BAO_0000357,,,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,12166.0,
8.0,10293.0,,B,,,Expert,CHEMBL619406,1.0,,,3891.0,,H,BAO_0000219,RBL-1,,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,12166.0,702.0
9.0,338.0,,B,,,Expert,CHEMBL619407,1.0,,,3892.0,,D,BAO_0000219,RBL-1,10116.0,,Rattus norvegicus,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,12166.0,702.0
8.0,303.0,,B,,,Autocuration,CHEMBL619408,1.0,,,3893.0,,H,BAO_0000357,,,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,12166.0,
8.0,303.0,,B,,,Autocuration,CHEMBL619409,1.0,,,3894.0,,H,BAO_0000219,RBL-1,,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,12166.0,702.0
8.0,9247.0,,B,,,Expert,CHEMBL619410,1.0,,,3895.0,,H,BAO_0000219,RBL-1,,,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,12166.0,702.0
8.0,9247.0,,B,,,Autocuration,CHEMBL619753,1.0,,,3896.0,,H,BAO_0000219,RBL-1,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,12166.0,702.0
8.0,137.0,,B,,,Autocuration,CHEMBL619754,1.0,,,3897.0,,H,BAO_0000219,RBL-1,,,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,12166.0,702.0
8.0,11481.0,,B,,,Expert,CHEMBL619903,1.0,,,3898.0,,H,BAO_0000357,,,,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,12166.0,
8.0,11481.0,,B,,,Expert,CHEMBL619904,1.0,,,3899.0,,H,BAO_0000357,,,,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,12166.0,
8.0,9029.0,,B,,,Expert,CHEMBL619905,1.0,,,3900.0,,H,BAO_0000357,,,,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,12166.0,
8.0,1701.0,,B,,,Autocuration,CHEMBL619906,1.0,,,3901.0,,H,BAO_0000019,,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,12166.0,
8.0,1701.0,,B,,,Autocuration,CHEMBL619907,1.0,,,3902.0,,H,BAO_0000019,,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,12166.0,
8.0,1701.0,,B,,,Autocuration,CHEMBL619908,1.0,,,3903.0,,H,BAO_0000019,,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,12166.0,
8.0,1701.0,,B,,,Autocuration,CHEMBL619909,1.0,,,3904.0,,H,BAO_0000019,,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,12166.0,
8.0,13358.0,,F,,,Expert,CHEMBL619910,1.0,,,3905.0,,H,BAO_0000219,RBL-1,,,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,12166.0,702.0
8.0,1175.0,,B,,,Expert,CHEMBL882929,1.0,,,3906.0,,H,BAO_0000219,RBL-1,,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,12166.0,702.0
8.0,8797.0,,B,,,Expert,CHEMBL619911,1.0,,,3907.0,,H,BAO_0000219,RBL-1,,,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,12166.0,702.0
8.0,8797.0,,B,,,Autocuration,CHEMBL619912,1.0,,,3908.0,,H,BAO_0000019,,,,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,12166.0,
9.0,577.0,,B,,,Expert,CHEMBL619913,1.0,,,3909.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,12166.0,
8.0,9295.0,,B,,,Expert,CHEMBL619914,1.0,,,3910.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibitory activity against RBL-1 5-LO,,12166.0,702.0
8.0,9295.0,,B,,,Autocuration,CHEMBL619915,1.0,,,3911.0,,H,BAO_0000219,RBL-1,,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,12166.0,702.0
8.0,9295.0,,B,,,Autocuration,CHEMBL619916,1.0,,,3912.0,,H,BAO_0000219,RBL-1,,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,12166.0,702.0
8.0,9295.0,,B,,,Autocuration,CHEMBL619917,1.0,,,3913.0,,H,BAO_0000218,,,,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,12166.0,
8.0,9295.0,,B,,,Autocuration,CHEMBL619918,1.0,,,3914.0,,H,BAO_0000357,,,,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,12166.0,
8.0,216.0,,B,,,Autocuration,CHEMBL619919,1.0,,,3915.0,,H,BAO_0000218,,,,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,12166.0,
8.0,11090.0,,B,,,Autocuration,CHEMBL883710,1.0,,,3916.0,,H,BAO_0000219,RBL-1,,,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,12166.0,702.0
8.0,11090.0,178.0,B,,,Autocuration,CHEMBL619920,1.0,Blood,,3917.0,,H,BAO_0000019,,,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,12166.0,
8.0,10091.0,,B,,,Expert,CHEMBL619921,1.0,,,3918.0,,H,BAO_0000357,,,,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,12166.0,
8.0,10274.0,,F,,,Autocuration,CHEMBL619922,1.0,,,3919.0,,H,BAO_0000019,,,,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,12166.0,
8.0,13622.0,,F,,,Autocuration,CHEMBL619923,1.0,,,3920.0,,H,BAO_0000219,,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,12166.0,
8.0,12118.0,,B,,,Expert,CHEMBL619924,1.0,,,3921.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,12166.0,702.0
8.0,12576.0,,B,,,Expert,CHEMBL619925,1.0,,,3922.0,,H,BAO_0000357,,,,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,12166.0,
8.0,9546.0,,B,,,Expert,CHEMBL619926,1.0,,,3923.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,12166.0,702.0
8.0,9521.0,,B,,,Autocuration,CHEMBL619927,1.0,,,3924.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,12166.0,702.0
8.0,10626.0,,B,,,Expert,CHEMBL619928,1.0,,,3925.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL619929,1.0,,,3926.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL875089,1.0,,,3927.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL619930,1.0,,,3928.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL619931,1.0,,,3929.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL619932,1.0,,,3930.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL619933,1.0,,,3931.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL619934,1.0,,,3932.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL619935,1.0,,,3933.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL619936,1.0,,,3934.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL619937,1.0,,,3935.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL619938,1.0,,,3936.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL619939,1.0,,,3937.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL619940,1.0,,,3938.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL875090,1.0,,,3939.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL619941,1.0,,,3940.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL619942,1.0,,,3941.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL883711,1.0,,,3942.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL619943,1.0,,,3943.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL619944,1.0,,,3944.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL619945,1.0,,,3945.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL619946,1.0,,,3946.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL619947,1.0,,,3947.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL619948,1.0,,,3948.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL619949,1.0,,,3949.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,12166.0,702.0
8.0,9401.0,,B,,,Expert,CHEMBL619950,1.0,,,3950.0,,H,BAO_0000019,,,,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,12166.0,
8.0,10325.0,,B,,,Autocuration,CHEMBL618050,1.0,,,3951.0,,H,BAO_0000019,,,,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,12166.0,
8.0,1556.0,,F,,,Expert,CHEMBL875091,1.0,,,3952.0,,H,BAO_0000219,RBL-2H3,,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,12166.0,663.0
8.0,1556.0,,F,,,Expert,CHEMBL618051,1.0,,,3953.0,,H,BAO_0000219,RBL-2H3,,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,12166.0,663.0
9.0,961.0,,B,,,Expert,CHEMBL618052,1.0,,,3954.0,,D,BAO_0000219,RBL-1,10116.0,,Rattus norvegicus,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,12166.0,702.0
8.0,6838.0,,B,,,Autocuration,CHEMBL618053,1.0,,,3955.0,,H,BAO_0000019,,,,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,12166.0,
8.0,10325.0,,B,,,Expert,CHEMBL618054,1.0,,,3956.0,,H,BAO_0000019,,,,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,12166.0,
9.0,9209.0,,B,,,Expert,CHEMBL618055,1.0,,,3957.0,,D,BAO_0000219,RBL-1,10116.0,,Rattus norvegicus,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,12166.0,702.0
8.0,11520.0,,B,,,Expert,CHEMBL618056,1.0,,,3958.0,,H,BAO_0000219,RBL-1,,,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,12166.0,702.0
8.0,137.0,,B,,,Autocuration,CHEMBL618057,1.0,,,3959.0,,H,BAO_0000357,,,,,In vitro inhibitory activity against 5-lipoxygenase was determined,,12166.0,
8.0,4717.0,,B,,,Autocuration,CHEMBL618058,1.0,,,3960.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,12166.0,702.0
8.0,10636.0,,B,,,Expert,CHEMBL618059,1.0,,,3961.0,,H,BAO_0000219,RBL-1,,,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,12166.0,702.0
9.0,14312.0,,F,,,Expert,CHEMBL618060,1.0,,,3962.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,12166.0,
8.0,1203.0,,B,,,Autocuration,CHEMBL618061,1.0,,,3963.0,,H,BAO_0000219,RBL-1,,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,12166.0,702.0
8.0,1203.0,,B,,,Autocuration,CHEMBL618062,1.0,,,3964.0,,H,BAO_0000019,,,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,12166.0,
8.0,13622.0,,B,,,Expert,CHEMBL618063,1.0,,,3965.0,,H,BAO_0000219,RBL-1,,,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,12166.0,702.0
8.0,9793.0,,B,,,Autocuration,CHEMBL618064,1.0,,,3966.0,,H,BAO_0000357,,,,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,12166.0,
9.0,1143.0,,B,,,Expert,CHEMBL618065,1.0,,,3967.0,,D,BAO_0000219,RBL-1,10116.0,,Rattus norvegicus,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,12166.0,702.0
9.0,11854.0,,B,,,Expert,CHEMBL618066,1.0,,,3968.0,,D,BAO_0000219,RBL-1,10116.0,,Rattus norvegicus,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,12166.0,702.0
8.0,3595.0,,B,,,Autocuration,CHEMBL618067,1.0,,,3969.0,,H,BAO_0000219,RBL-1,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,12166.0,702.0
8.0,3595.0,,B,,,Autocuration,CHEMBL618068,1.0,,,3970.0,,H,BAO_0000219,RBL-1,,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,12166.0,702.0
9.0,10501.0,,B,,,Expert,CHEMBL618069,1.0,,,3971.0,,D,BAO_0000219,RBL-1,10116.0,,Rattus norvegicus,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,12166.0,702.0
8.0,12526.0,,B,,,Expert,CHEMBL618070,1.0,,,3972.0,,H,BAO_0000219,RBL-1,,,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,12166.0,702.0
8.0,10034.0,349.0,F,,,Autocuration,CHEMBL618071,1.0,Limbic system,,3973.0,,H,BAO_0000019,,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,10825.0,
8.0,10034.0,349.0,F,,,Autocuration,CHEMBL619247,1.0,Limbic system,,3974.0,,H,BAO_0000019,,,,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,10825.0,
8.0,10034.0,,F,,,Autocuration,CHEMBL619248,1.0,,,3975.0,,H,BAO_0000019,,,,,Approximate dose levels for a half maximal reduction of 5-HTP levels,,10825.0,
8.0,10046.0,10000000.0,B,,,Autocuration,CHEMBL619249,1.0,Hippocampus,,3976.0,,H,BAO_0000221,,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,10576.0,
8.0,10046.0,10000000.0,B,,,Autocuration,CHEMBL619250,1.0,Hippocampus,,3977.0,,H,BAO_0000221,,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,10576.0,
8.0,10046.0,,B,,,Autocuration,CHEMBL619251,1.0,,,3978.0,,H,BAO_0000019,,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,10577.0,
8.0,12079.0,178.0,F,,,Autocuration,CHEMBL619252,1.0,Blood,,3979.0,,H,BAO_0000019,,9615.0,,Canis lupus familiaris,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,55.0,
8.0,12079.0,178.0,F,,,Autocuration,CHEMBL619253,1.0,Blood,,3980.0,,H,BAO_0000019,,,,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,55.0,
8.0,11311.0,,B,,,Autocuration,CHEMBL619254,1.0,,,3981.0,,H,BAO_0000219,,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,12166.0,
8.0,12338.0,,B,,,Expert,CHEMBL619255,1.0,,,3982.0,,H,BAO_0000219,,,,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,17140.0,
8.0,12143.0,,B,,,Expert,CHEMBL619256,1.0,,,3983.0,,H,BAO_0000219,,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,17140.0,
8.0,12143.0,,B,,,Autocuration,CHEMBL875418,1.0,,,3984.0,,H,BAO_0000219,,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,17140.0,
8.0,12143.0,,B,,,Expert,CHEMBL619257,1.0,,,3985.0,,H,BAO_0000219,,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,17140.0,
8.0,12143.0,,B,,,Autocuration,CHEMBL619258,1.0,,,3986.0,,H,BAO_0000219,,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,17140.0,
8.0,12365.0,,B,,,Expert,CHEMBL619259,1.0,,,3987.0,,H,BAO_0000357,,,,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,17140.0,
8.0,13500.0,,B,,,Expert,CHEMBL619260,1.0,,,3988.0,,H,BAO_0000357,,,,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,17140.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL619261,1.0,Blood,,3989.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL619263,1.0,Blood,,3990.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL619264,1.0,Blood,,3991.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL619265,1.0,Blood,,3992.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL619266,1.0,Blood,,3993.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL619902,1.0,Blood,,3994.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620058,1.0,Blood,,3995.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620059,1.0,Blood,,3996.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620060,1.0,Blood,,3997.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620061,1.0,Blood,,3998.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620062,1.0,Blood,,3999.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620063,1.0,Blood,,4000.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620064,1.0,Blood,,4001.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620065,1.0,Blood,,4002.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620066,1.0,Blood,,4003.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620067,1.0,Blood,,4004.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620068,1.0,Blood,,4005.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620069,1.0,Blood,,4006.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620070,1.0,Blood,,4007.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620071,1.0,Blood,,4008.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620072,1.0,Blood,,4009.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620036,1.0,Blood,,4010.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL857702,1.0,Blood,,4011.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620037,1.0,Blood,,4012.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620038,1.0,Blood,,4013.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620039,1.0,Blood,,4014.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620040,1.0,Blood,,4015.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620041,1.0,Blood,,4016.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620042,1.0,Blood,,4017.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620043,1.0,Blood,,4018.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620044,1.0,Blood,,4019.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620045,1.0,Blood,,4020.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620046,1.0,Blood,,4021.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620047,1.0,Blood,,4022.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620048,1.0,Blood,,4023.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL857703,1.0,Blood,,4024.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620049,1.0,Blood,,4025.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620050,1.0,Blood,,4026.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL620051,1.0,Blood,,4027.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL619213,1.0,Blood,,4028.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL619214,1.0,Blood,,4029.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL619804,1.0,Blood,,4030.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL619805,1.0,Blood,,4031.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL619806,1.0,Blood,,4032.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL619807,1.0,Blood,,4033.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,12832.0,178.0,F,,,Autocuration,CHEMBL619808,1.0,Blood,,4034.0,In vivo,H,BAO_0000218,,9615.0,,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,3595.0,,B,,,Autocuration,CHEMBL619809,1.0,,,4035.0,,H,BAO_0000218,,9615.0,,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,55.0,
8.0,3595.0,,B,,,Autocuration,CHEMBL619810,1.0,,,4036.0,,H,BAO_0000218,,9615.0,,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,55.0,
8.0,3595.0,,B,,,Autocuration,CHEMBL619811,1.0,,,4037.0,,H,BAO_0000218,,9615.0,,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,55.0,
8.0,3595.0,,B,,,Autocuration,CHEMBL620769,1.0,,,4038.0,,H,BAO_0000218,,9615.0,,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,55.0,
8.0,3595.0,,B,,,Autocuration,CHEMBL620770,1.0,,,4039.0,,H,BAO_0000218,,9615.0,,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,55.0,
8.0,3595.0,,B,,,Autocuration,CHEMBL620771,1.0,,,4040.0,,H,BAO_0000218,,9615.0,,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,55.0,
8.0,3595.0,,B,,,Autocuration,CHEMBL620772,1.0,,,4041.0,,H,BAO_0000218,,9615.0,,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,55.0,
8.0,3595.0,,B,,,Autocuration,CHEMBL620773,1.0,,,4042.0,,H,BAO_0000218,,9615.0,,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,55.0,
8.0,9203.0,,B,,,Autocuration,CHEMBL620774,1.0,,,4043.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,Ability to inhibit 5-lipoxygenase in guinea pig,,55.0,
8.0,82.0,,B,,,Expert,CHEMBL620775,1.0,,,4044.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,55.0,
8.0,11090.0,,B,,,Autocuration,CHEMBL620776,1.0,,,4045.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,55.0,
8.0,12832.0,178.0,B,,,Autocuration,CHEMBL620777,1.0,Blood,,4046.0,,H,BAO_0000218,,10141.0,,Cavia porcellus,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,55.0,
8.0,1065.0,,B,,,Autocuration,CHEMBL620778,1.0,,,4047.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,55.0,
8.0,1065.0,,B,,,Autocuration,CHEMBL620779,1.0,,,4048.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,55.0,
8.0,12832.0,,B,,,Expert,CHEMBL621500,1.0,,,4049.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,55.0,
8.0,12832.0,,B,,,Expert,CHEMBL621501,1.0,,,4050.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,55.0,
8.0,12832.0,,B,,,Autocuration,CHEMBL618098,1.0,,,4051.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,55.0,
8.0,10504.0,,B,,,Autocuration,CHEMBL618099,1.0,,,4052.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,55.0,
8.0,7788.0,,B,,,Autocuration,CHEMBL618100,1.0,,,4053.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,Inhibitory activity against 5-lipoxygenase,,55.0,
8.0,10001.0,,B,,,Autocuration,CHEMBL618101,1.0,,,4054.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,55.0,
8.0,10193.0,,B,,,Autocuration,CHEMBL618102,1.0,,,4055.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,55.0,
8.0,13243.0,,B,,,Autocuration,CHEMBL618103,1.0,,,4056.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,55.0,
8.0,13243.0,,B,,,Autocuration,CHEMBL618104,1.0,,,4057.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,Inhibitory activity uM,,55.0,
8.0,969.0,,B,,,Autocuration,CHEMBL883712,1.0,,,4058.0,,H,BAO_0000219,,10141.0,,Cavia porcellus,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,55.0,
8.0,10001.0,,B,,,Autocuration,CHEMBL618105,1.0,,,4059.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,Inhibitory activity against 5-lipoxygenase at 10 uM,,55.0,
8.0,7788.0,,B,,,Autocuration,CHEMBL618106,1.0,,,4060.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,55.0,
8.0,10001.0,,B,,,Autocuration,CHEMBL618107,1.0,,,4061.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,55.0,
8.0,10193.0,,B,,,Autocuration,CHEMBL618108,1.0,,,4062.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,55.0,
8.0,13243.0,,B,,,Autocuration,CHEMBL618109,1.0,,,4063.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,Inhibitory activity uM,,55.0,
8.0,13243.0,,B,,,Autocuration,CHEMBL618110,1.0,,,4064.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,55.0,
8.0,13243.0,,B,,,Expert,CHEMBL618111,1.0,,,4065.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,Inhibitory activity uM,,55.0,
8.0,13243.0,,F,,,Autocuration,CHEMBL618112,1.0,,,4066.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Inhibitory activity uM,,55.0,
8.0,10504.0,,B,,,Autocuration,CHEMBL618113,1.0,,,4067.0,,H,BAO_0000019,,10141.0,,Cavia porcellus,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,55.0,
8.0,7788.0,,B,,,Autocuration,CHEMBL618114,1.0,,,4068.0,,H,BAO_0000357,,10141.0,,Cavia porcellus,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,55.0,
8.0,10546.0,2116.0,F,,,Expert,CHEMBL620871,1.0,Ileum,,4069.0,,H,BAO_0000221,,10141.0,,Cavia porcellus,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,55.0,
8.0,13183.0,,B,,,Autocuration,CHEMBL620872,1.0,,,4070.0,,H,BAO_0000357,,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,55.0,
8.0,13183.0,,B,,,Autocuration,CHEMBL620873,1.0,,,4071.0,,H,BAO_0000357,,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,55.0,
8.0,2578.0,,B,,,Autocuration,CHEMBL620874,1.0,,,4072.0,,H,BAO_0000357,,,,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,55.0,
8.0,12780.0,,B,,,Expert,CHEMBL620875,1.0,,,4073.0,,H,BAO_0000357,,,,,In vitro inhibition of human 5-Lipoxygenase.,,55.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL620876,1.0,Liver,,4074.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL620877,1.0,Liver,,4075.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL857854,1.0,Liver,,4076.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL620878,1.0,Liver,,4077.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL620879,1.0,Liver,,4078.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL620880,1.0,Liver,,4079.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL620881,1.0,Liver,,4080.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL620882,1.0,Liver,,4081.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL620883,1.0,Liver,,4082.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL620884,1.0,Liver,,4083.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL620885,1.0,Liver,,4084.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL620886,1.0,Liver,,4085.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL620887,1.0,Liver,,4086.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618039,1.0,Liver,,4087.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618040,1.0,Liver,,4088.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618041,1.0,Liver,,4089.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618216,1.0,Liver,,4090.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618217,1.0,Liver,,4091.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618218,1.0,Liver,,4092.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618219,1.0,Liver,,4093.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618220,1.0,Liver,,4094.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618221,1.0,Liver,,4095.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618222,1.0,Liver,,4096.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618223,1.0,Liver,,4097.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618224,1.0,Liver,,4098.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618225,1.0,Liver,,4099.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618226,1.0,Liver,,4100.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618227,1.0,Liver,,4101.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618228,1.0,Liver,,4102.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618229,1.0,Liver,,4103.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618230,1.0,Liver,,4104.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618231,1.0,Liver,,4105.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618232,1.0,Liver,,4106.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618233,1.0,Liver,,4107.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618234,1.0,Liver,,4108.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618235,1.0,Liver,,4109.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618115,1.0,Liver,,4110.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618116,1.0,Liver,,4111.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL618117,1.0,Liver,,4112.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL619968,1.0,Liver,,4113.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL619969,1.0,Liver,,4114.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL619970,1.0,Liver,,4115.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL619971,1.0,Liver,,4116.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL619972,1.0,Liver,,4117.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL619973,1.0,Liver,,4118.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL619974,1.0,Liver,,4119.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL619975,1.0,Liver,,4120.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,22226.0,
0.0,7411.0,,B,Microsomes,,Autocuration,CHEMBL619976,1.0,,,4121.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL619977,1.0,Liver,,4122.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL619978,1.0,Liver,,4123.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL619979,1.0,Liver,,4124.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL619980,1.0,Liver,,4125.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL619981,1.0,Liver,,4126.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,22226.0,
1.0,10797.0,,F,,,Intermediate,CHEMBL619982,1.0,,,4127.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,In vitro inhibition of 7226/S myeloma cancer cell line,,80433.0,741.0
1.0,6881.0,,F,,,Intermediate,CHEMBL619983,1.0,,,4128.0,,N,BAO_0000219,BEL-7404 tumor cell line,9606.0,,Homo sapiens,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,80698.0,993.0
1.0,3838.0,,F,,,Intermediate,CHEMBL620031,1.0,,,4129.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,80640.0,391.0
1.0,3838.0,,F,,,Intermediate,CHEMBL620032,1.0,,,4130.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,80640.0,391.0
1.0,12981.0,,F,,,Expert,CHEMBL620033,1.0,,,4131.0,,N,BAO_0000219,V79,10029.0,,Cricetulus griseus,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,81264.0,505.0
1.0,12981.0,,F,,,Expert,CHEMBL620034,1.0,,,4132.0,,N,BAO_0000219,V79,10029.0,,Cricetulus griseus,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,81264.0,505.0
1.0,7653.0,,F,,,Intermediate,CHEMBL620035,1.0,,,4133.0,,N,BAO_0000219,7800C1 cell line,10116.0,,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,80635.0,1119.0
1.0,7653.0,,F,,,Intermediate,CHEMBL618318,1.0,,,4134.0,,N,BAO_0000219,7800C1 cell line,10116.0,,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,80635.0,1119.0
1.0,7653.0,,F,,,Intermediate,CHEMBL618319,1.0,,,4135.0,,N,BAO_0000219,7800C1 cell line,10116.0,,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,80635.0,1119.0
1.0,7653.0,,F,,,Intermediate,CHEMBL618320,1.0,,,4136.0,,N,BAO_0000219,7800C1 cell line,10116.0,,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,80635.0,1119.0
1.0,7653.0,,F,,,Intermediate,CHEMBL618321,1.0,,,4137.0,,N,BAO_0000219,7800C1 cell line,10116.0,,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,80635.0,1119.0
1.0,7653.0,,F,,,Intermediate,CHEMBL883118,1.0,,,4138.0,,N,BAO_0000219,7800C1 cell line,10116.0,,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,80635.0,1119.0
1.0,17229.0,,F,,,Intermediate,CHEMBL883795,1.0,,,4139.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,In vitro antitumor activity against renal 786-0 tumor cell lines,,80640.0,391.0
1.0,12858.0,,F,,,Intermediate,CHEMBL618322,1.0,,,4140.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Cytotoxic activity against 786-0 Renal cancer cell line,,80640.0,391.0
1.0,16325.0,,F,,,Intermediate,CHEMBL618323,1.0,,,4141.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,80640.0,391.0
1.0,16325.0,,F,,,Intermediate,CHEMBL618324,1.0,,,4142.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,80640.0,391.0
1.0,5858.0,,F,,,Intermediate,CHEMBL618325,1.0,,,4143.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,In vitro antitumor activity against human renal 786-0 cell line,,80640.0,391.0
1.0,16325.0,,F,,,Intermediate,CHEMBL875416,1.0,,,4144.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Inhibition of Renal cancer in 786-0 cancer cell lines,,80640.0,391.0
1.0,14696.0,,F,,,Intermediate,CHEMBL618326,1.0,,,4145.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,80640.0,391.0
1.0,3786.0,,F,,,Intermediate,CHEMBL618327,1.0,,,4146.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,80640.0,391.0
1.0,14696.0,,F,,,Intermediate,CHEMBL619215,1.0,,,4147.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,inhibition of the growth of renal cancer(786-0) cell line,,80640.0,391.0
1.0,14769.0,,F,,,Intermediate,CHEMBL619216,1.0,,,4148.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,80640.0,391.0
1.0,15354.0,,F,,,Intermediate,CHEMBL619217,1.0,,,4149.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,80640.0,391.0
1.0,14255.0,,F,,,Intermediate,CHEMBL619218,1.0,,,4150.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,The IC50 value was measured on 786-0 cell line in ovarian tumor,,80640.0,391.0
1.0,14255.0,,F,,,Intermediate,CHEMBL619219,1.0,,,4151.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,80640.0,391.0
1.0,14255.0,,F,,,Intermediate,CHEMBL619220,1.0,,,4152.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,The IC50 value was measured on 786-0 cell line in renal tumor type.,,80640.0,391.0
1.0,14696.0,,F,,,Intermediate,CHEMBL619221,1.0,,,4153.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,80640.0,391.0
1.0,12016.0,,F,,,Intermediate,CHEMBL619222,1.0,,,4154.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Tested for cytotoxic activity against renal cancer 786-0 cell line,,80640.0,391.0
1.0,2597.0,,F,,,Intermediate,CHEMBL857454,1.0,,,4155.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Compound was tested for growth inhibitory activity against 786-0 cell line,,80640.0,391.0
8.0,12526.0,,B,,,Autocuration,CHEMBL619223,1.0,,,4156.0,,H,BAO_0000219,RBL-1,,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,12166.0,702.0
8.0,12526.0,,B,,,Autocuration,CHEMBL619224,1.0,,,4157.0,,H,BAO_0000219,RBL-1,,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,12166.0,702.0
8.0,14799.0,,B,,,Autocuration,CHEMBL619225,1.0,,,4158.0,,H,BAO_0000019,,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,12166.0,
8.0,3595.0,,B,,,Expert,CHEMBL619226,1.0,,,4159.0,,H,BAO_0000219,RBL-1,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,12166.0,702.0
8.0,3595.0,,B,,,Expert,CHEMBL619227,1.0,,,4160.0,,H,BAO_0000219,RBL-1,,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,12166.0,702.0
8.0,12767.0,,B,,,Autocuration,CHEMBL619228,1.0,,,4161.0,,H,BAO_0000357,,,,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,12166.0,
8.0,10997.0,,B,,,Autocuration,CHEMBL619229,1.0,,,4162.0,,H,BAO_0000219,,,,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,12166.0,
8.0,11388.0,,B,,,Autocuration,CHEMBL619230,1.0,,,4163.0,,H,BAO_0000219,RBL-1,,,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,12166.0,702.0
8.0,167.0,,B,,,Autocuration,CHEMBL619231,1.0,,,4164.0,,H,BAO_0000357,,,,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,12166.0,
8.0,167.0,,B,,,Autocuration,CHEMBL619232,1.0,,,4165.0,,H,BAO_0000357,,,,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,12166.0,
8.0,13744.0,,B,,,Expert,CHEMBL619233,1.0,,,4166.0,,H,BAO_0000357,,,,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,12166.0,
8.0,1630.0,,B,,,Autocuration,CHEMBL619234,1.0,,,4167.0,,H,BAO_0000357,,,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,12166.0,
8.0,1630.0,,B,,,Autocuration,CHEMBL619235,1.0,,,4168.0,,H,BAO_0000357,,,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,12166.0,
9.0,969.0,,B,,,Expert,CHEMBL619236,1.0,,,4169.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,12166.0,
8.0,13621.0,,B,,,Autocuration,CHEMBL619237,1.0,,,4170.0,,H,BAO_0000219,RBL-1,,,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,12166.0,702.0
8.0,10089.0,,B,,,Autocuration,CHEMBL619238,1.0,,,4171.0,,H,BAO_0000357,,,,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,12166.0,
8.0,10193.0,,B,,,Expert,CHEMBL619239,1.0,,,4172.0,,H,BAO_0000357,,,,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,12166.0,
8.0,11966.0,,B,,,Autocuration,CHEMBL619240,1.0,,,4173.0,,H,BAO_0000357,,,,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,12166.0,
8.0,12251.0,,B,,,Autocuration,CHEMBL875417,1.0,,,4174.0,,H,BAO_0000019,,,,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,12166.0,
8.0,211.0,,B,,,Autocuration,CHEMBL619241,1.0,,,4175.0,,H,BAO_0000219,RBL-1,,,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,12166.0,702.0
8.0,12251.0,,F,,,Expert,CHEMBL619242,1.0,,,4176.0,,H,BAO_0000019,,,,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,12166.0,
8.0,12495.0,,B,,,Autocuration,CHEMBL883796,1.0,,,4177.0,,H,BAO_0000219,RBL-1,,,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,12166.0,702.0
8.0,414.0,,B,,,Autocuration,CHEMBL619243,1.0,,,4178.0,,H,BAO_0000357,,,,,Tested for its inhibitory activity against 5-lipoxygenase,,12166.0,
8.0,414.0,,B,,,Autocuration,CHEMBL619244,1.0,,,4179.0,,H,BAO_0000357,,,,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,12166.0,
8.0,10325.0,,B,,,Expert,CHEMBL619245,1.0,,,4180.0,,H,BAO_0000019,,,,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,12166.0,
8.0,11966.0,,B,,,Expert,CHEMBL619246,1.0,,,4181.0,,H,BAO_0000019,,,,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,12166.0,
8.0,165.0,,B,,,Expert,CHEMBL619984,1.0,,,4182.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,12166.0,702.0
8.0,165.0,,B,,,Autocuration,CHEMBL619985,1.0,,,4183.0,,H,BAO_0000219,RBL-1,,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,12166.0,702.0
8.0,165.0,,B,,,Autocuration,CHEMBL619986,1.0,,,4184.0,,H,BAO_0000219,RBL-1,,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,12166.0,702.0
8.0,165.0,,B,,,Expert,CHEMBL619987,1.0,,,4185.0,,H,BAO_0000219,RBL-1,,,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,12166.0,702.0
8.0,11311.0,,B,,,Autocuration,CHEMBL619988,1.0,,,4186.0,,H,BAO_0000218,,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,12166.0,
8.0,11311.0,,B,,,Autocuration,CHEMBL619989,1.0,,,4187.0,,H,BAO_0000219,RBL-1,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,12166.0,702.0
8.0,11311.0,,B,,,Autocuration,CHEMBL619990,1.0,,,4188.0,,H,BAO_0000219,RBL-1,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,12166.0,702.0
8.0,11311.0,,B,,,Autocuration,CHEMBL619991,1.0,,,4189.0,,H,BAO_0000219,,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,12166.0,
8.0,11311.0,,B,,,Autocuration,CHEMBL619992,1.0,,,4190.0,,H,BAO_0000219,,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,12166.0,
8.0,11311.0,,B,,,Autocuration,CHEMBL619993,1.0,,,4191.0,In vivo,H,BAO_0000218,,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,12166.0,
8.0,11311.0,,F,,,Autocuration,CHEMBL619994,1.0,,,4192.0,,H,BAO_0000219,RBL-2H3,,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,12166.0,663.0
8.0,11311.0,,F,,,Autocuration,CHEMBL619995,1.0,,,4193.0,,H,BAO_0000219,RBL-2H3,,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,12166.0,663.0
8.0,11311.0,,B,,,Autocuration,CHEMBL619996,1.0,,,4194.0,,H,BAO_0000019,,,,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,12166.0,
8.0,11732.0,,B,,,Autocuration,CHEMBL619997,1.0,,,4195.0,,H,BAO_0000019,,,,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,12166.0,
8.0,11732.0,,B,,,Expert,CHEMBL619998,1.0,,,4196.0,,H,BAO_0000019,,,,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,12166.0,
8.0,11087.0,,B,,,Expert,CHEMBL619999,1.0,,,4197.0,,H,BAO_0000019,,,,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,12166.0,
8.0,11087.0,,B,,,Autocuration,CHEMBL620000,1.0,,,4198.0,,H,BAO_0000019,,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,12166.0,
8.0,11087.0,,B,,,Autocuration,CHEMBL620001,1.0,,,4199.0,,H,BAO_0000219,RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,12166.0,702.0
9.0,11087.0,,B,,,Expert,CHEMBL620002,1.0,,,4200.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,12166.0,
8.0,496.0,,B,,,Autocuration,CHEMBL620003,1.0,,,4201.0,,H,BAO_0000219,RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,12166.0,702.0
8.0,13986.0,,F,,,Expert,CHEMBL620004,1.0,,,4202.0,,H,BAO_0000219,RBL-1,,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,12166.0,702.0
8.0,11520.0,,B,,,Autocuration,CHEMBL874063,1.0,,,4203.0,,H,BAO_0000357,,,,,Compound was evaluated for the inhibition of 5-lipoxygenase,,12166.0,
8.0,10293.0,,B,,,Autocuration,CHEMBL620005,1.0,,,4204.0,,H,BAO_0000219,RBL-1,,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,12166.0,702.0
8.0,303.0,,B,,,Autocuration,CHEMBL620006,1.0,,,4205.0,,H,BAO_0000219,RBL-1,,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,12166.0,702.0
8.0,303.0,,B,,,Autocuration,CHEMBL620007,1.0,,,4206.0,,H,BAO_0000219,RBL-1,,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,12166.0,702.0
8.0,9247.0,,B,,,Autocuration,CHEMBL620008,1.0,,,4207.0,,H,BAO_0000219,RBL-1,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,12166.0,702.0
9.0,9247.0,,B,,,Expert,CHEMBL620009,1.0,,,4208.0,,D,BAO_0000219,RBL-1,10116.0,,Rattus norvegicus,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,12166.0,702.0
8.0,9247.0,,B,,,Autocuration,CHEMBL620010,1.0,,,4209.0,,H,BAO_0000219,RBL-1,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,12166.0,702.0
8.0,9247.0,,B,,,Autocuration,CHEMBL620011,1.0,,,4210.0,,H,BAO_0000219,RBL-1,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,12166.0,702.0
8.0,9247.0,,B,,,Autocuration,CHEMBL620677,1.0,,,4211.0,,H,BAO_0000219,RBL-1,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,12166.0,702.0
8.0,9247.0,,B,,,Autocuration,CHEMBL620678,1.0,,,4212.0,,H,BAO_0000219,RBL-1,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,12166.0,702.0
8.0,9247.0,,B,,,Autocuration,CHEMBL620679,1.0,,,4213.0,,H,BAO_0000219,RBL-1,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,12166.0,702.0
8.0,9247.0,,B,,,Autocuration,CHEMBL620680,1.0,,,4214.0,,H,BAO_0000219,RBL-1,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,12166.0,702.0
9.0,11481.0,,B,,,Expert,CHEMBL620838,1.0,,,4215.0,,D,BAO_0000357,,10116.0,,Rattus norvegicus,Inhibitory activity against 5-lipoxygenase at 10 uM,,12166.0,
8.0,105.0,,B,,,Autocuration,CHEMBL620839,1.0,,,4216.0,,H,BAO_0000357,,,,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,12166.0,
8.0,9029.0,,B,,,Expert,CHEMBL620840,1.0,,,4217.0,,H,BAO_0000357,,,,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,12166.0,
8.0,1175.0,,B,,,Expert,CHEMBL620841,1.0,,,4218.0,,H,BAO_0000219,RBL-1,,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,12166.0,702.0
8.0,12118.0,,B,,,Autocuration,CHEMBL620842,1.0,,,4219.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,12166.0,702.0
8.0,12118.0,,B,,,Autocuration,CHEMBL620843,1.0,,,4220.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,12166.0,702.0
8.0,12118.0,,B,,,Autocuration,CHEMBL620844,1.0,,,4221.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,12166.0,702.0
8.0,9225.0,,B,,,Autocuration,CHEMBL620845,1.0,,,4222.0,,H,BAO_0000219,RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,12166.0,702.0
8.0,9401.0,,B,,,Autocuration,CHEMBL620846,1.0,,,4223.0,,H,BAO_0000019,,,,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,12166.0,
8.0,137.0,,B,,,Autocuration,CHEMBL873951,1.0,,,4224.0,,H,BAO_0000357,,,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,12166.0,
8.0,137.0,,B,,,Autocuration,CHEMBL620847,1.0,,,4225.0,,H,BAO_0000357,,,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,12166.0,
8.0,4717.0,,B,,,Autocuration,CHEMBL620848,1.0,,,4226.0,,H,BAO_0000219,RBL-1,,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,12166.0,702.0
8.0,3595.0,,B,,,Autocuration,CHEMBL620849,1.0,,,4227.0,,H,BAO_0000219,RBL-1,,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,12166.0,702.0
8.0,10501.0,,B,,,Autocuration,CHEMBL620850,1.0,,,4228.0,,H,BAO_0000219,RBL-1,,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,12166.0,702.0
8.0,10501.0,,B,,,Autocuration,CHEMBL620851,1.0,,,4229.0,,H,BAO_0000219,RBL-1,,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,12166.0,702.0
8.0,10501.0,,B,,,Autocuration,CHEMBL620852,1.0,,,4230.0,,H,BAO_0000219,RBL-1,,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,12166.0,702.0
8.0,12526.0,,B,,,Autocuration,CHEMBL875098,1.0,,,4231.0,,H,BAO_0000219,RBL-1,,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,12166.0,702.0
9.0,14799.0,,B,,,Expert,CHEMBL620853,1.0,,,4232.0,,D,BAO_0000219,RBL-1,10116.0,,Rattus norvegicus,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,12166.0,702.0
8.0,14799.0,,B,,,Autocuration,CHEMBL620854,1.0,,,4233.0,,H,BAO_0000019,,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,12166.0,
8.0,3595.0,,B,,,Autocuration,CHEMBL620855,1.0,,,4234.0,,H,BAO_0000219,RBL-1,,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,12166.0,702.0
8.0,3595.0,,B,,,Expert,CHEMBL839884,1.0,,,4235.0,,H,BAO_0000219,RBL-1,,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,12166.0,702.0
8.0,12526.0,,B,,,Autocuration,CHEMBL620856,1.0,,,4236.0,,H,BAO_0000219,RBL-1,,,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,12166.0,702.0
8.0,12526.0,,B,,,Autocuration,CHEMBL620857,1.0,,,4237.0,,H,BAO_0000219,RBL-1,,,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,12166.0,702.0
8.0,10193.0,,B,,,Autocuration,CHEMBL620858,1.0,,,4238.0,,H,BAO_0000019,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,12166.0,
8.0,10193.0,,B,,,Autocuration,CHEMBL620859,1.0,,,4239.0,,H,BAO_0000019,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,12166.0,
8.0,10193.0,,B,,,Autocuration,CHEMBL620860,1.0,,,4240.0,,H,BAO_0000019,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,12166.0,
8.0,10193.0,,B,,,Autocuration,CHEMBL620861,1.0,,,4241.0,,H,BAO_0000019,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,12166.0,
8.0,9138.0,,B,,,Expert,CHEMBL620862,1.0,,,4242.0,,H,BAO_0000357,,,,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,12166.0,
8.0,9138.0,,B,,,Autocuration,CHEMBL620863,1.0,,,4243.0,,H,BAO_0000357,,,,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,12166.0,
8.0,11966.0,,B,,,Autocuration,CHEMBL620864,1.0,,,4244.0,,H,BAO_0000019,,,,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,12166.0,
8.0,165.0,,B,,,Autocuration,CHEMBL620865,1.0,,,4245.0,,H,BAO_0000219,RBL-1,,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,12166.0,702.0
8.0,165.0,,B,,,Autocuration,CHEMBL620866,1.0,,,4246.0,,H,BAO_0000219,RBL-1,,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,12166.0,702.0
8.0,11311.0,,B,,,Autocuration,CHEMBL620867,1.0,,,4247.0,,H,BAO_0000219,RBL-2H3,,,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,12166.0,663.0
8.0,11311.0,,B,,,Autocuration,CHEMBL620868,1.0,,,4248.0,,H,BAO_0000219,RBL-2H3,,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,12166.0,663.0
8.0,11311.0,,F,,,Autocuration,CHEMBL620869,1.0,,,4249.0,,H,BAO_0000219,RBL-2H3,,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,12166.0,663.0
8.0,11311.0,,F,,,Autocuration,CHEMBL873952,1.0,,,4250.0,,H,BAO_0000019,,,,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,12166.0,
8.0,11311.0,,B,,,Autocuration,CHEMBL875099,1.0,,,4251.0,,H,BAO_0000357,,,,,The compound was tested for inhibition of isolated 5-lipoxygenase,,12166.0,
8.0,11311.0,,F,,,Autocuration,CHEMBL620870,1.0,,,4252.0,,H,BAO_0000219,RBL-2H3,,,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,12166.0,663.0
8.0,11087.0,,B,,,Autocuration,CHEMBL618261,1.0,,,4253.0,,H,BAO_0000019,,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,12166.0,
8.0,11087.0,,B,,,Autocuration,CHEMBL618262,1.0,,,4254.0,,H,BAO_0000019,,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,12166.0,
8.0,11087.0,,B,,,Autocuration,CHEMBL619428,1.0,,,4255.0,,H,BAO_0000019,,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,12166.0,
8.0,11087.0,,B,,,Autocuration,CHEMBL619429,1.0,,,4256.0,,H,BAO_0000019,,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,12166.0,
8.0,11087.0,,B,,,Autocuration,CHEMBL619430,1.0,,,4257.0,,H,BAO_0000019,,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,12166.0,
8.0,496.0,,B,,,Autocuration,CHEMBL620017,1.0,,,4258.0,,H,BAO_0000219,RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,12166.0,702.0
8.0,496.0,,B,,,Autocuration,CHEMBL620018,1.0,,,4259.0,,H,BAO_0000219,RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,12166.0,702.0
8.0,13986.0,,F,,,Autocuration,CHEMBL620019,1.0,,,4260.0,,H,BAO_0000219,RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,12166.0,702.0
8.0,13986.0,,F,,,Autocuration,CHEMBL620020,1.0,,,4261.0,,H,BAO_0000219,RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,12166.0,702.0
8.0,13986.0,,F,,,Autocuration,CHEMBL620021,1.0,,,4262.0,,H,BAO_0000219,RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,12166.0,702.0
8.0,13986.0,,F,,,Autocuration,CHEMBL620022,1.0,,,4263.0,,H,BAO_0000219,RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,12166.0,702.0
8.0,13986.0,,F,,,Autocuration,CHEMBL620023,1.0,,,4264.0,,H,BAO_0000219,RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,12166.0,702.0
8.0,13986.0,,F,,,Autocuration,CHEMBL620024,1.0,,,4265.0,,H,BAO_0000219,RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,12166.0,702.0
8.0,13986.0,,F,,,Autocuration,CHEMBL620025,1.0,,,4266.0,,H,BAO_0000219,RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,12166.0,702.0
8.0,13986.0,,F,,,Autocuration,CHEMBL620026,1.0,,,4267.0,,H,BAO_0000219,RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,12166.0,702.0
8.0,13986.0,,F,,,Autocuration,CHEMBL620027,1.0,,,4268.0,,H,BAO_0000219,RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,12166.0,702.0
9.0,13986.0,,F,,,Expert,CHEMBL620028,1.0,,,4269.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,12166.0,
8.0,10193.0,,B,,,Autocuration,CHEMBL620029,1.0,,,4270.0,,H,BAO_0000357,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,12166.0,
8.0,9295.0,,B,,,Autocuration,CHEMBL620030,1.0,,,4271.0,,H,BAO_0000357,,,,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,12166.0,
8.0,4717.0,,B,,,Autocuration,CHEMBL875415,1.0,,,4272.0,,H,BAO_0000219,RBL-1,,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,12166.0,702.0
8.0,4717.0,,B,,,Autocuration,CHEMBL618256,1.0,,,4273.0,,H,BAO_0000219,RBL-1,,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,12166.0,702.0
8.0,11854.0,,B,,,Autocuration,CHEMBL618257,1.0,,,4274.0,,H,BAO_0000219,RBL-1,,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,12166.0,702.0
8.0,11854.0,,B,,,Autocuration,CHEMBL618258,1.0,,,4275.0,,H,BAO_0000219,RBL-1,,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,12166.0,702.0
8.0,11854.0,,B,,,Autocuration,CHEMBL618259,1.0,,,4276.0,,H,BAO_0000219,RBL-1,,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,12166.0,702.0
8.0,10193.0,,B,,,Autocuration,CHEMBL618260,1.0,,,4277.0,,H,BAO_0000019,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,12166.0,
8.0,9295.0,,B,,,Autocuration,CHEMBL618215,1.0,,,4278.0,,H,BAO_0000219,RBL-1,,,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,12166.0,702.0
8.0,9295.0,,B,,,Autocuration,CHEMBL618390,1.0,,,4279.0,,H,BAO_0000219,RBL-1,,,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,12166.0,702.0
8.0,9295.0,,B,,,Autocuration,CHEMBL618391,1.0,,,4280.0,,H,BAO_0000219,RBL-1,,,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,12166.0,702.0
8.0,9295.0,,B,,,Autocuration,CHEMBL618392,1.0,,,4281.0,,H,BAO_0000219,RBL-1,,,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,12166.0,702.0
8.0,165.0,,B,,,Autocuration,CHEMBL618393,1.0,,,4282.0,,H,BAO_0000219,RBL-1,,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,12166.0,702.0
8.0,11311.0,,B,,,Autocuration,CHEMBL618394,1.0,,,4283.0,,H,BAO_0000219,,,,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,12166.0,
8.0,10489.0,,B,,,Expert,CHEMBL618395,1.0,,,4284.0,,H,BAO_0000219,RBL-1,9606.0,,Homo sapiens,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,12166.0,702.0
9.0,10489.0,,B,,,Expert,CHEMBL618396,1.0,,,4285.0,,D,BAO_0000219,RBL-1,10116.0,,Rattus norvegicus,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,12166.0,702.0
9.0,10489.0,,B,,,Expert,CHEMBL858253,1.0,,,4286.0,,D,BAO_0000219,RBL-1,10116.0,,Rattus norvegicus,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,12166.0,702.0
9.0,14799.0,,B,,,Autocuration,CHEMBL618397,1.0,,,4287.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,12166.0,
8.0,9295.0,,B,,,Autocuration,CHEMBL618398,1.0,,,4288.0,,H,BAO_0000357,,3847.0,,Glycine max,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,12054.0,
0.0,16811.0,,B,,,Autocuration,CHEMBL618399,1.0,,,4289.0,,U,BAO_0000019,,,,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,22226.0,
8.0,168.0,,B,,,Expert,CHEMBL618400,1.0,,,4290.0,,H,BAO_0000357,,,,,In vitro inhibition of 5-Lipoxygenase; Inactive.,,55.0,
8.0,6309.0,,B,,,Autocuration,CHEMBL618401,1.0,,,4291.0,,H,BAO_0000357,,,,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,55.0,
8.0,6309.0,,B,,,Autocuration,CHEMBL618402,1.0,,,4292.0,,H,BAO_0000357,,,,,Inhibitory concentration against 5-lipoxygenase; No inhibition,,55.0,
8.0,3092.0,,B,,,Autocuration,CHEMBL876400,1.0,,,4293.0,,H,BAO_0000219,RBL-1,,,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,55.0,702.0
8.0,168.0,,B,,,Expert,CHEMBL618403,1.0,,,4294.0,,H,BAO_0000357,,,,,Inhibitory activity against 5-lipoxygenase.,,55.0,
8.0,168.0,,B,,,Autocuration,CHEMBL618404,1.0,,,4295.0,,H,BAO_0000357,,,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,55.0,
8.0,168.0,,B,,,Autocuration,CHEMBL618405,1.0,,,4296.0,,H,BAO_0000357,,,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,55.0,
8.0,168.0,,B,,,Autocuration,CHEMBL618406,1.0,,,4297.0,,H,BAO_0000357,,,,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,55.0,
8.0,12338.0,,F,,,Expert,CHEMBL618407,1.0,,,4298.0,,H,BAO_0000019,,,,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,55.0,
8.0,4501.0,,B,,,Autocuration,CHEMBL618408,1.0,,,4299.0,,H,BAO_0000357,,,,,Tested for the inhibitory activity against 5-lipoxygenase,,55.0,
8.0,1132.0,,B,,,Autocuration,CHEMBL618409,1.0,,,4300.0,,H,BAO_0000357,,,,,Compound was tested for its inhibitory activity against 5-lipoxygenase,,55.0,
8.0,2117.0,,B,,,Autocuration,CHEMBL618410,1.0,,,4301.0,,H,BAO_0000357,,,,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,55.0,
8.0,168.0,,B,,,Autocuration,CHEMBL618411,1.0,,,4302.0,,H,BAO_0000357,,,,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,55.0,
8.0,168.0,,B,,,Autocuration,CHEMBL618412,1.0,,,4303.0,,H,BAO_0000357,,,,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,55.0,
8.0,13575.0,,B,,,Autocuration,CHEMBL618413,1.0,,,4304.0,,H,BAO_0000219,RBL-1,,,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,12166.0,702.0
8.0,11089.0,,B,,,Autocuration,CHEMBL618414,1.0,,,4305.0,,H,BAO_0000357,,,,,,,12166.0,
8.0,216.0,,B,,,Autocuration,CHEMBL618415,1.0,,,4306.0,,H,BAO_0000357,,,,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,10102.0,
8.0,13165.0,,B,,,Autocuration,CHEMBL618416,1.0,,,4307.0,,H,BAO_0000019,,,,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,10102.0,
8.0,3278.0,,B,,,Autocuration,CHEMBL876401,1.0,,,4308.0,,H,BAO_0000357,,,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,10102.0,
8.0,3278.0,,B,,,Expert,CHEMBL618417,1.0,,,4309.0,,H,BAO_0000357,,,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,10102.0,
8.0,11966.0,,B,,,Autocuration,CHEMBL618418,1.0,,,4310.0,,H,BAO_0000357,,,,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,10102.0,
8.0,175.0,,B,,,Autocuration,CHEMBL618419,1.0,,,4311.0,,H,BAO_0000357,,,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,10102.0,
8.0,175.0,,B,,,Autocuration,CHEMBL618420,1.0,,,4312.0,,H,BAO_0000357,,,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,10102.0,
8.0,13449.0,,B,,,Autocuration,CHEMBL618421,1.0,,,4313.0,,H,BAO_0000357,,,,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,10102.0,
8.0,12014.0,,B,,,Autocuration,CHEMBL618422,1.0,,,4314.0,,H,BAO_0000019,,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,11238.0,
8.0,12014.0,,B,,,Autocuration,CHEMBL618423,1.0,,,4315.0,,H,BAO_0000019,,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,11238.0,
8.0,12014.0,,B,,,Autocuration,CHEMBL618424,1.0,,,4316.0,,H,BAO_0000019,,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,11238.0,
2.0,99.0,,B,,,Intermediate,CHEMBL618425,1.0,,,4317.0,,S,BAO_0000220,,,,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,100284.0,
0.0,4349.0,,F,,,Autocuration,CHEMBL618426,1.0,,,4318.0,,U,BAO_0000019,,9606.0,,Homo sapiens,The dark toxicity against 543 human galactophore carcinoma cells,,22226.0,
1.0,4071.0,,F,,,Expert,CHEMBL618427,1.0,,,4319.0,,N,BAO_0000219,Panel (56 tumour cell lines),9606.0,,Homo sapiens,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,80623.0,390.0
1.0,17589.0,,F,,,Expert,CHEMBL618428,1.0,,,4320.0,,N,BAO_0000219,5637,9606.0,,Homo sapiens,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,80008.0,345.0
1.0,15002.0,,F,,,Intermediate,CHEMBL618429,1.0,,,4321.0,,N,BAO_0000219,5637,9606.0,,Homo sapiens,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,80008.0,345.0
1.0,13958.0,,F,,,Intermediate,CHEMBL618430,1.0,,,4322.0,,N,BAO_0000219,5637,9606.0,,Homo sapiens,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,80008.0,345.0
1.0,17589.0,,F,,,Expert,CHEMBL618431,1.0,,,4323.0,,N,BAO_0000219,5637,9606.0,,Homo sapiens,Growth inhibition against human 5637 cell lines,,80008.0,345.0
1.0,16748.0,,F,,,Expert,CHEMBL883799,1.0,,,4324.0,,N,BAO_0000219,5637,9606.0,,Homo sapiens,Antitumor activity against human bladder carcinoma 5637 cells.,,80008.0,345.0
1.0,16747.0,,F,,,Intermediate,CHEMBL618432,1.0,,,4325.0,,N,BAO_0000219,5637,9606.0,,Homo sapiens,Antitumor activity against human bladder carcinoma 5637 cells,,80008.0,345.0
1.0,16747.0,,F,,,Intermediate,CHEMBL618433,1.0,,,4326.0,,N,BAO_0000219,5637,9606.0,,Homo sapiens,Antitumor activity against human bladder carcinoma 5637 cells,,80008.0,345.0
9.0,15285.0,,B,,,Expert,CHEMBL618434,1.0,,,4327.0,,D,BAO_0000357,,9913.0,,Bos taurus,In vitro inhibition of bovine trypsin(Trp).,,10443.0,
8.0,3726.0,,B,,,Expert,CHEMBL618435,1.0,,,4328.0,,H,BAO_0000219,CV-1,9527.0,,Cercopithecidae,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,240.0,407.0
8.0,5033.0,,B,,,Autocuration,CHEMBL876402,1.0,,,4329.0,,H,BAO_0000357,,,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,10577.0,
6.0,11756.0,,F,,,Autocuration,CHEMBL618436,1.0,,,4330.0,,H,BAO_0000019,,,,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,104698.0,
0.0,11953.0,,F,,,Autocuration,CHEMBL618437,1.0,,,4331.0,In vivo,U,BAO_0000218,,,,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,22226.0,
9.0,5033.0,,B,,,Intermediate,CHEMBL618438,1.0,,,4332.0,,D,BAO_0000357,,10141.0,,Cavia porcellus,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,20033.0,
8.0,11347.0,,A,Microsomes,,Expert,CHEMBL883800,1.0,,,4333.0,,H,BAO_0000251,,10116.0,,Rattus norvegicus,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,17045.0,
8.0,11347.0,,A,Microsomes,,Expert,CHEMBL618439,1.0,,,4334.0,,H,BAO_0000251,,10116.0,,Rattus norvegicus,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,17045.0,
0.0,1229.0,,F,,,Intermediate,CHEMBL618440,1.0,,,4335.0,,U,BAO_0000019,,,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,22226.0,
0.0,1229.0,,F,,,Intermediate,CHEMBL618441,1.0,,,4336.0,,U,BAO_0000019,,,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,22226.0,
8.0,17588.0,,B,,,Expert,CHEMBL618442,1.0,,,4337.0,,H,BAO_0000019,,5691.0,,Trypanosoma brucei,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,11938.0,
8.0,17588.0,,B,,,Autocuration,CHEMBL618443,1.0,,,4338.0,,H,BAO_0000019,,5691.0,,Trypanosoma brucei,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,11938.0,
8.0,17588.0,,B,,,Expert,CHEMBL619158,1.0,,,4339.0,,H,BAO_0000019,,9940.0,,Ovis aries,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,11938.0,
8.0,17588.0,,B,,,Autocuration,CHEMBL620974,1.0,,,4340.0,,H,BAO_0000019,,9940.0,,Ovis aries,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,11938.0,
8.0,16485.0,,B,,,Autocuration,CHEMBL620975,1.0,,,4341.0,,H,BAO_0000357,,,,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,11938.0,
0.0,4337.0,,F,,,Intermediate,CHEMBL620976,1.0,,,4342.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Average inhibitory concentration against 60 human cell lines was reported,,22226.0,
0.0,4112.0,,F,,,Expert,CHEMBL620977,1.0,,,4343.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,22226.0,
1.0,16160.0,,F,,,Intermediate,CHEMBL620978,1.0,,,4344.0,,N,BAO_0000219,Panel NCI-60 (60 carcinoma cell lines),9606.0,,Homo sapiens,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,80315.0,542.0
1.0,16160.0,,F,,,Intermediate,CHEMBL620979,1.0,,,4345.0,,N,BAO_0000219,Panel NCI-60 (60 carcinoma cell lines),9606.0,,Homo sapiens,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,80315.0,542.0
1.0,17376.0,,F,,,Expert,CHEMBL620980,1.0,,,4346.0,,N,BAO_0000219,Panel NCI-60 (60 carcinoma cell lines),,,,In vitro mean growth inhibitory activity against 60-cell panel,,80315.0,542.0
1.0,17376.0,,F,,,Expert,CHEMBL620981,1.0,,,4347.0,,N,BAO_0000219,Panel NCI-60 (60 carcinoma cell lines),,,,In vitro mean growth lethal concentration against 60-cell panel,,80315.0,542.0
1.0,17376.0,,F,,,Expert,CHEMBL620982,1.0,,,4348.0,,N,BAO_0000219,Panel NCI-60 (60 carcinoma cell lines),,,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,80315.0,542.0
1.0,17376.0,,F,,,Expert,CHEMBL620983,1.0,,,4349.0,,N,BAO_0000219,Panel NCI-60 (60 carcinoma cell lines),,,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,80315.0,542.0
4.0,3241.0,,F,,,Autocuration,CHEMBL620984,1.0,,,4350.0,,H,BAO_0000019,,,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,104775.0,
4.0,3241.0,,F,,,Autocuration,CHEMBL620985,1.0,,,4351.0,,H,BAO_0000019,,,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,104775.0,
8.0,3725.0,,B,,,Expert,CHEMBL620986,1.0,,,4352.0,,H,BAO_0000357,,,,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,275.0,
1.0,10805.0,,F,,,Expert,CHEMBL620987,1.0,,,4353.0,,N,BAO_0000218,,5833.0,,Plasmodium falciparum,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,50425.0,
1.0,10805.0,,F,,,Expert,CHEMBL620988,1.0,,,4354.0,,N,BAO_0000218,,5833.0,,Plasmodium falciparum,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,50425.0,
1.0,10805.0,,F,,,Expert,CHEMBL620989,1.0,,,4355.0,,N,BAO_0000218,,5833.0,,Plasmodium falciparum,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,50425.0,
1.0,10805.0,,F,,,Expert,CHEMBL620990,1.0,,,4356.0,,N,BAO_0000218,,5833.0,,Plasmodium falciparum,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,50425.0,
1.0,10805.0,,F,,,Intermediate,CHEMBL620991,1.0,,,4357.0,,N,BAO_0000218,,5833.0,,Plasmodium falciparum,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,50425.0,
1.0,10144.0,,F,,,Intermediate,CHEMBL620992,1.0,,,4358.0,,N,BAO_0000218,6C3HED,10090.0,,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,80628.0,850.0
1.0,10144.0,,F,,,Intermediate,CHEMBL620993,1.0,,,4359.0,,N,BAO_0000218,6C3HED,10090.0,,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,80628.0,850.0
1.0,10144.0,,F,,,Intermediate,CHEMBL620994,1.0,,,4360.0,,N,BAO_0000218,6C3HED,10090.0,,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,80628.0,850.0
1.0,10144.0,,F,,,Intermediate,CHEMBL620995,1.0,,,4361.0,,N,BAO_0000218,6C3HED,10090.0,,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,80628.0,850.0
1.0,10144.0,,F,,,Intermediate,CHEMBL620996,1.0,,,4362.0,,N,BAO_0000218,6C3HED,10090.0,,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,80628.0,850.0
1.0,10144.0,,F,,,Intermediate,CHEMBL875581,1.0,,,4363.0,,N,BAO_0000218,6C3HED,10090.0,,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,80628.0,850.0
0.0,10685.0,,F,,,Autocuration,CHEMBL620997,1.0,,,4364.0,In vivo,U,BAO_0000218,,10090.0,,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,22224.0,
0.0,10685.0,,F,,,Autocuration,CHEMBL620998,1.0,,,4365.0,In vivo,U,BAO_0000218,,10090.0,,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,22224.0,
0.0,10685.0,,F,,,Autocuration,CHEMBL620999,1.0,,,4366.0,In vivo,U,BAO_0000218,,10090.0,,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,22224.0,
0.0,10685.0,,F,,,Autocuration,CHEMBL621000,1.0,,,4367.0,In vivo,U,BAO_0000218,,10090.0,,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,22224.0,
0.0,10685.0,,F,,,Autocuration,CHEMBL621001,1.0,,,4368.0,In vivo,U,BAO_0000218,,10090.0,,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,22224.0,
0.0,10685.0,,F,,,Autocuration,CHEMBL621002,1.0,,,4369.0,In vivo,U,BAO_0000218,,10090.0,,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,22224.0,
0.0,10685.0,,F,,,Autocuration,CHEMBL621003,1.0,,,4370.0,In vivo,U,BAO_0000218,,10090.0,,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,22224.0,
0.0,10685.0,,F,,,Autocuration,CHEMBL621004,1.0,,,4371.0,In vivo,U,BAO_0000218,,10090.0,,Mus musculus,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,22224.0,
0.0,10685.0,,F,,,Autocuration,CHEMBL621005,1.0,,,4372.0,In vivo,U,BAO_0000218,,10090.0,,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,22224.0,
0.0,10685.0,,F,,,Autocuration,CHEMBL621006,1.0,,,4373.0,In vivo,U,BAO_0000218,,10090.0,,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,22224.0,
0.0,10685.0,,F,,,Autocuration,CHEMBL621007,1.0,,,4374.0,In vivo,U,BAO_0000218,,10090.0,,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,22224.0,
0.0,10144.0,,F,,,Autocuration,CHEMBL621008,1.0,,,4375.0,,U,BAO_0000218,,10090.0,,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,22224.0,
0.0,10144.0,,F,,,Autocuration,CHEMBL621009,1.0,,,4376.0,,U,BAO_0000218,,10090.0,,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,22224.0,
0.0,10144.0,,F,,,Autocuration,CHEMBL857705,1.0,,,4377.0,,U,BAO_0000218,,10090.0,,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,22224.0,
0.0,10144.0,,F,,,Autocuration,CHEMBL619828,1.0,,,4378.0,,U,BAO_0000218,,10090.0,,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,22224.0,
0.0,10685.0,,F,,,Autocuration,CHEMBL619829,1.0,,,4379.0,,U,BAO_0000218,,10090.0,,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,22224.0,
0.0,10685.0,,F,,,Autocuration,CHEMBL619830,1.0,,,4380.0,,U,BAO_0000218,,10090.0,,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,22224.0,
0.0,10685.0,,F,,,Autocuration,CHEMBL619831,1.0,,,4381.0,,U,BAO_0000218,,10090.0,,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,22224.0,
0.0,10685.0,,F,,,Autocuration,CHEMBL619832,1.0,,,4382.0,,U,BAO_0000218,,10090.0,,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,22224.0,
0.0,10685.0,,A,,,Autocuration,CHEMBL619833,1.0,,,4383.0,,U,BAO_0000218,,10090.0,,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,22224.0,
0.0,10685.0,,A,,,Autocuration,CHEMBL619834,1.0,,,4384.0,,U,BAO_0000218,,10090.0,,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,22224.0,
0.0,10685.0,,A,,,Autocuration,CHEMBL619835,1.0,,,4385.0,,U,BAO_0000218,,10090.0,,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,22224.0,
0.0,10685.0,,A,,,Autocuration,CHEMBL619836,1.0,,,4386.0,,U,BAO_0000218,,10090.0,,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,22224.0,
1.0,8831.0,,F,,,Intermediate,CHEMBL619837,1.0,,,4387.0,,N,BAO_0000218,6C3HED,10090.0,,Mus musculus,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,80628.0,850.0
0.0,11704.0,,F,,,Autocuration,CHEMBL619838,1.0,,,4388.0,In vivo,U,BAO_0000218,,,,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,22224.0,
1.0,11704.0,,A,,,Intermediate,CHEMBL619839,1.0,,,4389.0,,N,BAO_0000218,,10090.0,,Mus musculus,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,50594.0,
1.0,10685.0,,F,,,Intermediate,CHEMBL619840,1.0,,,4390.0,In vivo,N,BAO_0000218,6C3HED,10090.0,,Mus musculus,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,,80628.0,850.0
1.0,10685.0,,F,,,Intermediate,CHEMBL619841,1.0,,,4391.0,In vivo,N,BAO_0000218,6C3HED,10090.0,,Mus musculus,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,,80628.0,850.0
1.0,11368.0,,F,,,Expert,CHEMBL857704,1.0,,,4392.0,,N,BAO_0000218,6C3HED,10090.0,,Mus musculus,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,80628.0,850.0
1.0,11368.0,,F,,,Intermediate,CHEMBL619842,1.0,,,4393.0,,N,BAO_0000218,6C3HED,10090.0,,Mus musculus,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,80628.0,850.0
1.0,11368.0,,F,,,Expert,CHEMBL619843,1.0,,,4394.0,,N,BAO_0000218,6C3HED,10090.0,,Mus musculus,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,80628.0,850.0
0.0,17763.0,,B,,,Autocuration,CHEMBL619844,1.0,,,4395.0,,U,BAO_0000019,,1280.0,,Staphylococcus aureus,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL857855,1.0,Liver,,4396.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL619845,1.0,Liver,,4397.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL619846,1.0,Liver,,4398.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL619847,1.0,Liver,,4399.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL619848,1.0,Liver,,4400.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL620893,1.0,Liver,,4401.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL620894,1.0,Liver,,4402.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL620895,1.0,Liver,,4403.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL620896,1.0,Liver,,4404.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL620897,1.0,Liver,,4405.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL620898,1.0,Liver,,4406.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,22226.0,
0.0,7411.0,2107.0,B,Microsomes,,Autocuration,CHEMBL620899,1.0,Liver,,4407.0,,U,BAO_0000251,,10116.0,,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,22226.0,
0.0,347.0,1969.0,A,,,Autocuration,CHEMBL620900,1.0,Plasma,,4408.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,The apparent total plasma clearance in monkey,,22224.0,
0.0,3341.0,,A,,,Autocuration,CHEMBL620901,1.0,,,4409.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Compound was evaluated for Hepatic clearance in monkey,,22224.0,
0.0,17853.0,,A,,,Autocuration,CHEMBL620902,1.0,,,4410.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Lower clearance in monkey (i.v.) at 0.5 mpk,,22224.0,
0.0,4514.0,,A,,,Autocuration,CHEMBL620903,1.0,,,4411.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Plasma clearance in rhesus monkey,,22224.0,
0.0,6062.0,,A,,,Autocuration,CHEMBL620904,1.0,,,4412.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,22224.0,
0.0,6821.0,,A,,,Autocuration,CHEMBL620905,1.0,,,4413.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Plasma clearance of compound was determined in monkey,,22224.0,
0.0,6057.0,,A,,,Autocuration,CHEMBL620906,1.0,,,4414.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Plasma clearance was calculated in rhesus monkey,,22224.0,
0.0,5145.0,,A,,,Autocuration,CHEMBL875420,1.0,,,4415.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Plasma clearance in rhesus monkey,,22224.0,
0.0,6641.0,,A,,,Autocuration,CHEMBL620907,1.0,,,4416.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,22224.0,
0.0,5472.0,,A,,,Autocuration,CHEMBL620908,1.0,,,4417.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Plasma clearance was evaluated in rhesus,,22224.0,
0.0,4257.0,,A,,,Autocuration,CHEMBL620909,1.0,,,4418.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,22224.0,
0.0,5546.0,,A,,,Autocuration,CHEMBL620910,1.0,,,4419.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,22224.0,
0.0,5334.0,,A,,,Autocuration,CHEMBL620911,1.0,,,4420.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,22224.0,
0.0,5334.0,,A,,,Autocuration,CHEMBL620912,1.0,,,4421.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,22224.0,
0.0,17509.0,,A,,,Autocuration,CHEMBL620913,1.0,,,4422.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,22224.0,
0.0,6535.0,,A,,,Autocuration,CHEMBL620914,1.0,,,4423.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Cmax in monkey after administration of 1 mg/kg iv,,22224.0,
0.0,5668.0,,A,,,Autocuration,CHEMBL620915,1.0,,,4424.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Cmax was determine after peroral administration at 10 mpk in Rhesus,,22224.0,
0.0,5922.0,,A,,,Autocuration,CHEMBL620916,1.0,,,4425.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Cmax in cynomolgus monkey by iv administration,,22224.0,
0.0,5922.0,,A,,,Autocuration,CHEMBL620917,1.0,,,4426.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Cmax in cynomolgus monkey by po administration,,22224.0,
0.0,6078.0,,A,,,Autocuration,CHEMBL620918,1.0,,,4427.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Cmax value evaluated in monkey,,22224.0,
0.0,2661.0,,A,,,Autocuration,CHEMBL620919,1.0,,,4428.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,22224.0,
0.0,3249.0,1969.0,A,,,Autocuration,CHEMBL620920,1.0,Plasma,,4429.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,,22224.0,
0.0,3249.0,1969.0,A,,,Autocuration,CHEMBL620921,1.0,Plasma,,4430.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,,22224.0,
0.0,5553.0,1969.0,A,,,Autocuration,CHEMBL620922,1.0,Plasma,,4431.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Maximal plasma concentration in squirrel monkeys,,22224.0,
0.0,1916.0,,A,,,Autocuration,CHEMBL620923,1.0,,,4432.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,22224.0,
0.0,6227.0,1969.0,A,,,Autocuration,CHEMBL620924,1.0,Plasma,,4433.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,,22224.0,
0.0,4809.0,,A,,,Autocuration,CHEMBL620925,1.0,,,4434.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL620926,1.0,,,4435.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL620927,1.0,,,4436.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL620928,1.0,,,4437.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL620929,1.0,,,4438.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,22224.0,
0.0,6221.0,1969.0,A,,,Autocuration,CHEMBL620930,1.0,Plasma,,4439.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,,22224.0,
0.0,167.0,,A,,,Autocuration,CHEMBL620931,1.0,,,4440.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,22224.0,
0.0,167.0,,A,,,Autocuration,CHEMBL620932,1.0,,,4441.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,22224.0,
0.0,4257.0,,A,,,Autocuration,CHEMBL620933,1.0,,,4442.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Absolute bioavailability was evaluated in monkey,,22224.0,
0.0,6221.0,,A,,,Autocuration,CHEMBL620934,1.0,,,4443.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,22224.0,
0.0,17667.0,,A,,,Autocuration,CHEMBL620935,1.0,,,4444.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,22224.0,
0.0,17267.0,,A,,,Autocuration,CHEMBL620936,1.0,,,4445.0,In vivo,U,BAO_0000218,,9544.0,,Macaca mulatta,Bioavailability of compound was determined in rhesus monkey,,22224.0,
0.0,4256.0,,A,,,Autocuration,CHEMBL620937,1.0,,,4446.0,In vivo,U,BAO_0000218,,38020.0,,marmosets,Bioavailability determined after oral administration in marmoset,,22224.0,
0.0,4256.0,,A,,,Autocuration,CHEMBL620938,1.0,,,4447.0,In vivo,U,BAO_0000218,,9541.0,,Macaca fascicularis,Oral bioavailability in cynomolgus monkey,,22224.0,
0.0,17853.0,,A,,,Autocuration,CHEMBL620939,1.0,,,4448.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Bioavailability in monkey (p.o.) at 2.0 mpk,,22224.0,
0.0,16365.0,,A,,,Autocuration,CHEMBL620940,1.0,,,4449.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Bioavailability was evaluated after oral administration in monkey,,22224.0,
0.0,1916.0,,A,,,Autocuration,CHEMBL620941,1.0,,,4450.0,In vivo,U,BAO_0000218,,9541.0,,Macaca fascicularis,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,22224.0,
0.0,5334.0,,A,,,Autocuration,CHEMBL620942,1.0,,,4451.0,In vivo,U,BAO_0000218,,9544.0,,Macaca mulatta,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,22224.0,
0.0,5334.0,,A,,,Autocuration,CHEMBL620943,1.0,,,4452.0,In vivo,U,BAO_0000218,,9544.0,,Macaca mulatta,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,22224.0,
0.0,17592.0,,A,,,Autocuration,CHEMBL620944,1.0,,,4453.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Bioavailability of the compound was determined in monkey,,22224.0,
0.0,1399.0,,A,,,Autocuration,CHEMBL620945,1.0,,,4454.0,In vivo,U,BAO_0000218,,9521.0,,Saimiri sciureus,Bioavailability in squirrel monkey (dose 5 mg/kg),,22224.0,
0.0,4809.0,,A,,,Autocuration,CHEMBL620946,1.0,,,4455.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,22224.0,
0.0,3341.0,,A,,,Autocuration,CHEMBL620947,1.0,,,4456.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Oral bioavailability in monkey,,22224.0,
0.0,64.0,,A,,,Autocuration,CHEMBL620948,1.0,,,4457.0,In vivo,U,BAO_0000218,,9521.0,,Saimiri sciureus,Compound was tested for bioavailability in squirrel monkey,,22224.0,
0.0,5005.0,,A,,,Autocuration,CHEMBL620949,1.0,,,4458.0,In vivo,U,BAO_0000218,,9544.0,,Macaca mulatta,Oral bioavailability in Rhesus monkey,,22224.0,
0.0,5005.0,,A,,,Autocuration,CHEMBL620950,1.0,,,4459.0,In vivo,U,BAO_0000218,,9544.0,,Macaca mulatta,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,22224.0,
0.0,5237.0,,A,,,Autocuration,CHEMBL620951,1.0,,,4460.0,In vivo,U,BAO_0000218,,9541.0,,Macaca fascicularis,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,22224.0,
0.0,5237.0,,A,,,Autocuration,CHEMBL620952,1.0,,,4461.0,In vivo,U,BAO_0000218,,9541.0,,Macaca fascicularis,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,22224.0,
0.0,5302.0,,A,,,Autocuration,CHEMBL875421,1.0,,,4462.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Oral bioavailability in monkey (dose 5 mg/kg),,22224.0,
0.0,17667.0,,A,,,Autocuration,CHEMBL620953,1.0,,,4463.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Oral bioavailability of compound at 5 mg/kg in monkey,,22224.0,
1.0,6161.0,,A,,,Intermediate,CHEMBL873491,1.0,,,4464.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,50588.0,
1.0,6161.0,,A,,,Intermediate,CHEMBL620954,1.0,,,4465.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,50588.0,
1.0,3854.0,1969.0,A,,,Intermediate,CHEMBL620955,1.0,Plasma,,4466.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma half life determined,,50588.0,
1.0,993.0,1969.0,A,,,Intermediate,CHEMBL618097,1.0,Plasma,,4467.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma half life in dog,,50588.0,
1.0,4514.0,1969.0,A,,,Intermediate,CHEMBL618268,1.0,Plasma,,4468.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma half-life in Beagle dogs,,50588.0,
1.0,5334.0,1969.0,A,,,Intermediate,CHEMBL618269,1.0,Plasma,,4469.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,50588.0,
1.0,5334.0,1969.0,A,,,Intermediate,CHEMBL618270,1.0,Plasma,,4470.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),,50588.0,
1.0,1466.0,,A,,,Intermediate,CHEMBL618271,1.0,,,4471.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,50588.0,
1.0,1466.0,,A,,,Intermediate,CHEMBL873493,1.0,,,4472.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,50588.0,
1.0,5313.0,,A,,,Intermediate,CHEMBL621031,1.0,,,4473.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Tested for the half life period in dog,,50588.0,
1.0,5313.0,,A,,,Intermediate,CHEMBL621032,1.0,,,4474.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Tested for the half life period in dog at dosage of 10 mpk,,50588.0,
1.0,3880.0,,A,,,Intermediate,CHEMBL621033,1.0,,,4475.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,The compound was tested for half life in dog,,50588.0,
1.0,3639.0,1969.0,A,,,Intermediate,CHEMBL621034,1.0,Plasma,,4476.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,50588.0,
1.0,3880.0,,A,,,Intermediate,CHEMBL621035,1.0,,,4477.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,The half life was determined,,50588.0,
1.0,3918.0,1969.0,A,,,Intermediate,CHEMBL621036,1.0,Plasma,,4478.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,The plasma half-life in dogs,,50588.0,
1.0,16452.0,1969.0,A,,,Intermediate,CHEMBL621037,1.0,Plasma,,4479.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,50588.0,
1.0,17796.0,,A,,,Intermediate,CHEMBL619812,1.0,,,4480.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dog,,50588.0,
1.0,5983.0,,A,,,Intermediate,CHEMBL619813,1.0,,,4481.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,50588.0,
1.0,1466.0,,A,,,Intermediate,CHEMBL873335,1.0,,,4482.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,50588.0,
1.0,16456.0,,A,,,Intermediate,CHEMBL619814,1.0,,,4483.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,50588.0,
1.0,6113.0,,A,,,Expert,CHEMBL619815,1.0,,,4484.0,In vivo,N,BAO_0000218,,9669.0,,Mustela putorius furo,Cmax in ferrets after 30 mg/kg oral dose,,50506.0,
1.0,6113.0,,F,,,Expert,CHEMBL619816,1.0,,,4485.0,In vivo,N,BAO_0000218,,9669.0,,Mustela putorius furo,Emesis in ferrets at 30 mg/kg oral dose,,50506.0,
0.0,17796.0,,A,,,Autocuration,CHEMBL619817,1.0,,,4486.0,In vivo,U,BAO_0000218,,9541.0,,Macaca fascicularis,Bioavailability in cynomolgus monkey,,22224.0,
1.0,17796.0,,A,,,Intermediate,CHEMBL619818,1.0,,,4487.0,In vivo,N,BAO_0000218,,9541.0,,Macaca fascicularis,Volume of distribution in cynomolgus,,100710.0,
0.0,5308.0,1969.0,A,,,Autocuration,CHEMBL619819,1.0,Plasma,,4488.0,,U,BAO_0000218,,10141.0,,Cavia porcellus,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,22224.0,
0.0,4877.0,,A,,,Autocuration,CHEMBL619820,1.0,,,4489.0,,U,BAO_0000218,,10141.0,,Cavia porcellus,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,22224.0,
0.0,4876.0,,A,,,Autocuration,CHEMBL875419,1.0,,,4490.0,,U,BAO_0000218,,10141.0,,Cavia porcellus,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,22224.0,
0.0,4878.0,1969.0,A,,,Autocuration,CHEMBL619821,1.0,Plasma,,4491.0,In vivo,U,BAO_0000218,,10141.0,,Cavia porcellus,AUC in guinea pig after 3mg/kg oral dose,,22224.0,
0.0,5308.0,,A,,,Autocuration,CHEMBL619822,1.0,,,4492.0,In vivo,U,BAO_0000218,,10141.0,,Cavia porcellus,Bioavailability in guinea pig was tested,,22224.0,
0.0,4877.0,,A,,,Autocuration,CHEMBL619823,1.0,,,4493.0,In vivo,U,BAO_0000218,,10141.0,,Cavia porcellus,Tested for oral bioavailability in guinea pig at 5 mg/kg,,22224.0,
0.0,4876.0,,A,,,Autocuration,CHEMBL619824,1.0,,,4494.0,In vivo,U,BAO_0000218,,10141.0,,Cavia porcellus,Tested for the oral bioavailability of the compound,,22224.0,
0.0,4876.0,,A,,,Autocuration,CHEMBL619825,1.0,,,4495.0,In vivo,U,BAO_0000218,,10141.0,,Cavia porcellus,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,22224.0,
0.0,5308.0,,A,,,Autocuration,CHEMBL619826,1.0,,,4496.0,In vivo,U,BAO_0000218,,10141.0,,Cavia porcellus,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,22224.0,
0.0,4877.0,2048.0,A,,,Autocuration,CHEMBL619827,1.0,Lung,,4497.0,In vivo,U,BAO_0000218,,10141.0,,Cavia porcellus,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,22224.0,
0.0,4878.0,,A,,,Autocuration,CHEMBL618167,1.0,,,4498.0,In vivo,U,BAO_0000218,,10141.0,,Cavia porcellus,Cmax in guinea pig after 3mg/kg oral dose,,22224.0,
0.0,5689.0,178.0,A,,,Autocuration,CHEMBL618168,1.0,Blood,,4499.0,,U,BAO_0000019,,10141.0,,Cavia porcellus,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,22224.0,
0.0,5689.0,955.0,A,,,Autocuration,CHEMBL618169,1.0,Brain,,4500.0,,U,BAO_0000019,,10141.0,,Cavia porcellus,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,22224.0,
0.0,5689.0,,A,,,Autocuration,CHEMBL618170,1.0,,,4501.0,,U,BAO_0000019,,10141.0,,Cavia porcellus,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,22224.0,
0.0,5689.0,160.0,A,,,Autocuration,CHEMBL618171,1.0,Intestine,,4502.0,,U,BAO_0000019,,10141.0,,Cavia porcellus,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,22224.0,
0.0,5689.0,2113.0,A,,,Autocuration,CHEMBL618172,1.0,Kidney,,4503.0,,U,BAO_0000019,,10141.0,,Cavia porcellus,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,22224.0,
0.0,5689.0,2107.0,A,,,Autocuration,CHEMBL618173,1.0,Liver,,4504.0,,U,BAO_0000019,,10141.0,,Cavia porcellus,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,22224.0,
0.0,5689.0,,A,,,Autocuration,CHEMBL618174,1.0,,,4505.0,,U,BAO_0000019,,10141.0,,Cavia porcellus,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,22224.0,
0.0,5689.0,2106.0,A,,,Autocuration,CHEMBL875408,1.0,Spleen,,4506.0,,U,BAO_0000019,,10141.0,,Cavia porcellus,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,22224.0,
0.0,14465.0,,A,,,Autocuration,CHEMBL839827,1.0,,,4507.0,In vivo,U,BAO_0000218,,10141.0,,Cavia porcellus,Elimination T1/2 in Guinea pig (PO dose),,22224.0,
0.0,5689.0,,A,,,Autocuration,CHEMBL618175,1.0,,,4508.0,,U,BAO_0000019,,10141.0,,Cavia porcellus,Partition coefficient was measured as -log (counts per min ),,22224.0,
0.0,611.0,,A,,,Autocuration,CHEMBL618176,1.0,,,4509.0,In vivo,U,BAO_0000218,,10141.0,,Cavia porcellus,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,22224.0,
0.0,611.0,,A,,,Autocuration,CHEMBL618177,1.0,,,4510.0,In vivo,U,BAO_0000218,,10141.0,,Cavia porcellus,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,22224.0,
0.0,14465.0,,A,,,Autocuration,CHEMBL618178,1.0,,,4511.0,In vivo,U,BAO_0000218,,10141.0,,Cavia porcellus,Elimination T1/2 in Guinea pig (PO dose),,22224.0,
0.0,4876.0,,A,,,Autocuration,CHEMBL618179,1.0,,,4512.0,In vivo,U,BAO_0000218,,10141.0,,Cavia porcellus,"Tested for the half life period of the compound, intravenously",,22224.0,
0.0,5689.0,,A,,,Autocuration,CHEMBL873489,1.0,,,4513.0,,U,BAO_0000019,,10141.0,,Cavia porcellus,Half-life was measured,,22224.0,
0.0,7515.0,,A,,,Autocuration,CHEMBL618180,1.0,,,4514.0,,U,BAO_0000019,,10141.0,,Cavia porcellus,The time required for onset of inotropy after addition of a single dose of delta F75,,22224.0,
0.0,17667.0,,A,,,Autocuration,CHEMBL618181,1.0,,,4515.0,In vivo,U,BAO_0000218,,10141.0,,Cavia porcellus,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,22224.0,
0.0,17667.0,,A,,,Autocuration,CHEMBL618182,1.0,,,4516.0,In vivo,U,BAO_0000218,,10141.0,,Cavia porcellus,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,22224.0,
0.0,4727.0,,A,,,Autocuration,CHEMBL618183,1.0,,,4517.0,In vivo,U,BAO_0000218,,10029.0,,Cricetulus griseus,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,22224.0,
1.0,10107.0,,A,,,Intermediate,CHEMBL618184,1.0,,,4518.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594.0,
1.0,10107.0,,A,,,Intermediate,CHEMBL618185,1.0,,,4519.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,50594.0,
1.0,10107.0,,A,,,Intermediate,CHEMBL618186,1.0,,,4520.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594.0,
1.0,10107.0,,A,,,Intermediate,CHEMBL618187,1.0,,,4521.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594.0,
1.0,10107.0,,A,,,Intermediate,CHEMBL618188,1.0,,,4522.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,50594.0,
1.0,10107.0,,A,,,Intermediate,CHEMBL875409,1.0,,,4523.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594.0,
1.0,10107.0,,A,,,Intermediate,CHEMBL618189,1.0,,,4524.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594.0,
1.0,3655.0,178.0,A,,,Intermediate,CHEMBL618190,1.0,Blood,,4525.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,,50594.0,
1.0,3655.0,178.0,A,,,Intermediate,CHEMBL618191,1.0,Blood,,4526.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,,50594.0,
1.0,3655.0,178.0,A,,,Intermediate,CHEMBL618192,1.0,Blood,,4527.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,,50594.0,
1.0,3655.0,10000001.0,A,,,Intermediate,CHEMBL618193,1.0,Bone,,4528.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,,50594.0,
1.0,3655.0,10000001.0,A,,,Intermediate,CHEMBL618194,1.0,Bone,,4529.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,,50594.0,
1.0,3655.0,10000001.0,A,,,Intermediate,CHEMBL618195,1.0,Bone,,4530.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,,50594.0,
1.0,3655.0,955.0,A,,,Intermediate,CHEMBL618196,1.0,Brain,,4531.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,,50594.0,
1.0,3655.0,955.0,A,,,Intermediate,CHEMBL618197,1.0,Brain,,4532.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,,50594.0,
1.0,3655.0,955.0,A,,,Intermediate,CHEMBL618198,1.0,Brain,,4533.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,,50594.0,
1.0,3655.0,948.0,A,,,Intermediate,CHEMBL618199,1.0,Heart,,4534.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,,50594.0,
1.0,3655.0,948.0,A,,,Intermediate,CHEMBL618200,1.0,Heart,,4535.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,,50594.0,
1.0,3655.0,948.0,A,,,Intermediate,CHEMBL618201,1.0,Heart,,4536.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,,50594.0,
1.0,3655.0,160.0,A,,,Intermediate,CHEMBL618202,1.0,Intestine,,4537.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,,50594.0,
1.0,3655.0,160.0,A,,,Intermediate,CHEMBL618203,1.0,Intestine,,4538.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,,50594.0,
1.0,3655.0,160.0,A,,,Intermediate,CHEMBL618204,1.0,Intestine,,4539.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,,50594.0,
1.0,3655.0,2113.0,A,,,Intermediate,CHEMBL618205,1.0,Kidney,,4540.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,,50594.0,
1.0,3655.0,2113.0,A,,,Intermediate,CHEMBL618206,1.0,Kidney,,4541.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,,50594.0,
1.0,3655.0,2113.0,A,,,Intermediate,CHEMBL618207,1.0,Kidney,,4542.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,,50594.0,
1.0,3655.0,2107.0,A,,,Intermediate,CHEMBL618208,1.0,Liver,,4543.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,,50594.0,
1.0,3655.0,2107.0,A,,,Intermediate,CHEMBL618932,1.0,Liver,,4544.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,,50594.0,
1.0,3655.0,2107.0,A,,,Intermediate,CHEMBL618933,1.0,Liver,,4545.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,,50594.0,
1.0,3655.0,2048.0,A,,,Intermediate,CHEMBL618934,1.0,Lung,,4546.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,,50594.0,
1.0,3655.0,2048.0,A,,,Intermediate,CHEMBL618935,1.0,Lung,,4547.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,,50594.0,
1.0,3655.0,2048.0,A,,,Intermediate,CHEMBL618936,1.0,Lung,,4548.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,,50594.0,
1.0,3655.0,2385.0,A,,,Intermediate,CHEMBL618937,1.0,Muscle tissue,,4549.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,,50594.0,
1.0,3655.0,2385.0,A,,,Intermediate,CHEMBL618938,1.0,Muscle tissue,,4550.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,,50594.0,
1.0,3655.0,2385.0,A,,,Intermediate,CHEMBL619104,1.0,Muscle tissue,,4551.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,,50594.0,
1.0,3655.0,2106.0,A,,,Intermediate,CHEMBL619105,1.0,Spleen,,4552.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,,50594.0,
1.0,3655.0,2106.0,A,,,Intermediate,CHEMBL619106,1.0,Spleen,,4553.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,,50594.0,
1.0,3655.0,2106.0,A,,,Intermediate,CHEMBL619107,1.0,Spleen,,4554.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,,50594.0,
1.0,3655.0,945.0,A,,,Intermediate,CHEMBL875410,1.0,Stomach,,4555.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,,50594.0,
1.0,3655.0,945.0,A,,,Intermediate,CHEMBL619108,1.0,Stomach,,4556.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,,50594.0,
1.0,3655.0,945.0,A,,,Intermediate,CHEMBL619109,1.0,Stomach,,4557.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,,50594.0,
1.0,16597.0,,A,,,Intermediate,CHEMBL619110,1.0,,,4558.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,50594.0,
1.0,16597.0,,F,,,Intermediate,CHEMBL619111,1.0,,,4559.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,50594.0,
1.0,16597.0,,A,,,Intermediate,CHEMBL619112,1.0,,,4560.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,50594.0,
1.0,16597.0,,A,,,Intermediate,CHEMBL619113,1.0,,,4561.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,MRT value at a dose of 10 mg/kg peroral administration in mice.,,50594.0,
1.0,17764.0,,A,,,Intermediate,CHEMBL619114,1.0,,,4562.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL619115,1.0,,,4563.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,50594.0,
1.0,3830.0,,F,,,Intermediate,CHEMBL619116,1.0,,,4564.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,81034.0,478.0
1.0,3829.0,,F,,,Intermediate,CHEMBL619117,1.0,,,4565.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,81034.0,478.0
1.0,2040.0,,F,,,Intermediate,CHEMBL619118,1.0,,,4566.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cell lines.,,81034.0,478.0
1.0,15684.0,,F,,,Intermediate,CHEMBL619119,1.0,,,4567.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,81034.0,478.0
1.0,15684.0,,F,,,Intermediate,CHEMBL619120,1.0,,,4568.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,81034.0,478.0
1.0,15684.0,,F,,,Intermediate,CHEMBL619121,1.0,,,4569.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,81034.0,478.0
1.0,15684.0,,F,,,Intermediate,CHEMBL619122,1.0,,,4570.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,81034.0,478.0
1.0,15684.0,,F,,,Intermediate,CHEMBL619123,1.0,,,4571.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,81034.0,478.0
1.0,15684.0,,F,,,Intermediate,CHEMBL619124,1.0,,,4572.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,81034.0,478.0
1.0,2859.0,,F,,,Intermediate,CHEMBL619125,1.0,,,4573.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cell line,,81034.0,478.0
1.0,5618.0,,F,,,Intermediate,CHEMBL875411,1.0,,,4574.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro inhibitory activity against human tumor cell line A2780,,81034.0,478.0
1.0,15684.0,,F,,,Intermediate,CHEMBL619126,1.0,,,4575.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,81034.0,478.0
1.0,15684.0,,F,,,Intermediate,CHEMBL619127,1.0,,,4576.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,81034.0,478.0
1.0,15684.0,,F,,,Intermediate,CHEMBL619128,1.0,,,4577.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,81034.0,478.0
1.0,15684.0,,F,,,Intermediate,CHEMBL619129,1.0,,,4578.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,81034.0,478.0
1.0,2113.0,,F,,,Intermediate,CHEMBL619130,1.0,,,4579.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,81034.0,478.0
1.0,2113.0,,F,,,Intermediate,CHEMBL619131,1.0,,,4580.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,81034.0,478.0
1.0,16745.0,,F,,,Intermediate,CHEMBL619132,1.0,,,4581.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,81034.0,478.0
1.0,16597.0,,F,,,Expert,CHEMBL619133,1.0,,,4582.0,,N,BAO_0000218,A2780,9606.0,,Homo sapiens,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,81034.0,478.0
1.0,15684.0,,F,,,Intermediate,CHEMBL619134,1.0,,,4583.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,81034.0,478.0
1.0,15684.0,,F,,,Intermediate,CHEMBL619135,1.0,,,4584.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,81034.0,478.0
1.0,2040.0,,F,,,Intermediate,CHEMBL619136,1.0,,,4585.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,81034.0,478.0
1.0,2040.0,,F,,,Intermediate,CHEMBL619137,1.0,,,4586.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Relative resistance factor in A2780 cisplatin-resistant line,,81034.0,478.0
1.0,16165.0,,F,,,Intermediate,CHEMBL883713,1.0,,,4587.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,81034.0,478.0
1.0,16165.0,,F,,,Intermediate,CHEMBL875412,1.0,,,4588.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,81034.0,478.0
1.0,16597.0,,F,,,Expert,CHEMBL619138,1.0,,,4589.0,,N,BAO_0000218,A2780,9606.0,,Homo sapiens,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,81034.0,478.0
1.0,16597.0,,F,,,Expert,CHEMBL619262,1.0,,,4590.0,,N,BAO_0000218,A2780,9606.0,,Homo sapiens,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,81034.0,478.0
1.0,3992.0,,F,,,Intermediate,CHEMBL619139,1.0,,,4591.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,81034.0,478.0
1.0,10553.0,,F,,,Intermediate,CHEMBL619140,1.0,,,4592.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,81034.0,478.0
1.0,15608.0,,F,,,Intermediate,CHEMBL619141,1.0,,,4593.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,81034.0,478.0
1.0,15608.0,,F,,,Intermediate,CHEMBL619142,1.0,,,4594.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,81034.0,478.0
1.0,15608.0,,F,,,Intermediate,CHEMBL619143,1.0,,,4595.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,81034.0,478.0
1.0,15608.0,,F,,,Intermediate,CHEMBL619144,1.0,,,4596.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,81034.0,478.0
1.0,15608.0,,F,,,Intermediate,CHEMBL619145,1.0,,,4597.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,81034.0,478.0
1.0,15608.0,,F,,,Intermediate,CHEMBL619146,1.0,,,4598.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,81034.0,478.0
1.0,15569.0,,F,,,Intermediate,CHEMBL619147,1.0,,,4599.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,81034.0,478.0
1.0,17420.0,,F,,,Intermediate,CHEMBL619148,1.0,,,4600.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Antiproliferative effect of compound on A2780/DX cell line,,81034.0,478.0
1.0,17420.0,,F,,,Intermediate,CHEMBL619149,1.0,,,4601.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,81034.0,478.0
1.0,15099.0,,F,,,Intermediate,CHEMBL619150,1.0,,,4602.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,81034.0,478.0
1.0,15099.0,,F,,,Intermediate,CHEMBL619151,1.0,,,4603.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,81034.0,478.0
1.0,17672.0,,F,,,Intermediate,CHEMBL883794,1.0,,,4604.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,81034.0,478.0
1.0,17672.0,,F,,,Intermediate,CHEMBL619152,1.0,,,4605.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,81034.0,478.0
1.0,17270.0,,F,,,Intermediate,CHEMBL619153,1.0,,,4606.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro cytotoxicity against A2780ADR cell line,,81034.0,478.0
1.0,17270.0,,F,,,Intermediate,CHEMBL619154,1.0,,,4607.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro cytotoxicity against A2780CIS cell line,,81034.0,478.0
1.0,5574.0,,F,,,Intermediate,CHEMBL619155,1.0,,,4608.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,81034.0,478.0
1.0,2113.0,,F,,,Intermediate,CHEMBL619156,1.0,,,4609.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,81034.0,478.0
1.0,16913.0,,F,,,Intermediate,CHEMBL619157,1.0,,,4610.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,81034.0,478.0
1.0,16913.0,,F,,,Intermediate,CHEMBL619797,1.0,,,4611.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,81034.0,478.0
0.0,17839.0,,A,,,Autocuration,CHEMBL619798,1.0,,,4612.0,In vivo,U,BAO_0000218,,9544.0,,Macaca mulatta,Oral bioavailability of compound in rhesus macaques,,22224.0,
0.0,6821.0,,A,,,Autocuration,CHEMBL619799,1.0,,,4613.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Oral bioavailability in monkey,,22224.0,
0.0,6078.0,,A,,,Autocuration,CHEMBL619800,1.0,,,4614.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Oral bioavailability evaluated in monkey,,22224.0,
0.0,6535.0,,A,,,Autocuration,CHEMBL619801,1.0,,,4615.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,22224.0,
0.0,4449.0,,A,,,Autocuration,CHEMBL619802,1.0,,,4616.0,In vivo,U,BAO_0000218,,9544.0,,Macaca mulatta,Oral bioavailability in Rhesus monkey,,22224.0,
0.0,6057.0,,A,,,Autocuration,CHEMBL619803,1.0,,,4617.0,In vivo,U,BAO_0000218,,9544.0,,Macaca mulatta,Oral bioavailability was calculated in rhesus monkey,,22224.0,
0.0,5922.0,,A,,,Autocuration,CHEMBL619965,1.0,,,4618.0,In vivo,U,BAO_0000218,,9541.0,,Macaca fascicularis,Oral bioavailability in cynomolgus monkey,,22224.0,
0.0,5940.0,,A,,,Autocuration,CHEMBL619966,1.0,,,4619.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Oral bioavailability in monkey,,22224.0,
0.0,6265.0,,A,,,Autocuration,CHEMBL619967,1.0,,,4620.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Oral bioavailability in monkey,,22224.0,
0.0,6265.0,,A,,,Autocuration,CHEMBL620073,1.0,,,4621.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Oral bioavailability in monkey (dose 1 mg/kg),,22224.0,
0.0,6265.0,,A,,,Autocuration,CHEMBL620074,1.0,,,4622.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Oral bioavailability in monkey (dose 5 mg/kg),,22224.0,
0.0,5940.0,,A,,,Autocuration,CHEMBL620075,1.0,,,4623.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Oral bioavailability in monkey,,22224.0,
0.0,5940.0,,A,,,Autocuration,CHEMBL620076,1.0,,,4624.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Oral bioavailability in monkey,,22224.0,
0.0,4514.0,,A,,,Autocuration,CHEMBL620077,1.0,,,4625.0,In vivo,U,BAO_0000218,,9544.0,,Macaca mulatta,Oral bioavailability in rhesus monkey,,22224.0,
0.0,5546.0,,A,,,Autocuration,CHEMBL620078,1.0,,,4626.0,In vivo,U,BAO_0000218,,9544.0,,Macaca mulatta,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,22224.0,
0.0,5553.0,,A,,,Autocuration,CHEMBL620079,1.0,,,4627.0,In vivo,U,BAO_0000218,,9521.0,,Saimiri sciureus,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,22224.0,
0.0,6641.0,,A,,,Autocuration,CHEMBL620080,1.0,,,4628.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,22224.0,
0.0,5472.0,,A,,,Autocuration,CHEMBL620081,1.0,,,4629.0,In vivo,U,BAO_0000218,,9544.0,,Macaca mulatta,Oral bioavailability in Rhesus monkey,,22224.0,
0.0,5668.0,,A,,,Autocuration,CHEMBL620082,1.0,,,4630.0,In vivo,U,BAO_0000218,,9544.0,,Macaca mulatta,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,22224.0,
0.0,5711.0,,A,,,Autocuration,CHEMBL620083,1.0,,,4631.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Oral bioavailability in monkey at 10 mg/kg of the compound,,22224.0,
0.0,5145.0,,A,,,Autocuration,CHEMBL620084,1.0,,,4632.0,In vivo,U,BAO_0000218,,9544.0,,Macaca mulatta,Bioavailability in Rhesus monkey,,22224.0,
0.0,3443.0,,A,,,Autocuration,CHEMBL620085,1.0,,,4633.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224.0,
0.0,3443.0,,A,,,Autocuration,CHEMBL874595,1.0,,,4634.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224.0,
0.0,3249.0,,A,,,Autocuration,CHEMBL873352,1.0,,,4635.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,22224.0,
0.0,3249.0,,A,,,Autocuration,CHEMBL620086,1.0,,,4636.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL620087,1.0,,,4637.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL620088,1.0,,,4638.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL620089,1.0,,,4639.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,22224.0,
0.0,4809.0,,A,,,Autocuration,CHEMBL620090,1.0,,,4640.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,22224.0,
0.0,4809.0,,A,,,Autocuration,CHEMBL620091,1.0,,,4641.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,22224.0,
0.0,14294.0,,A,Microsomes,,Autocuration,CHEMBL620092,1.0,,,4642.0,,U,BAO_0000251,,9527.0,,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,22224.0,
0.0,14294.0,,A,Microsomes,,Autocuration,CHEMBL620093,1.0,,,4643.0,,U,BAO_0000251,,9527.0,,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,22224.0,
0.0,14294.0,,A,Microsomes,,Autocuration,CHEMBL620094,1.0,,,4644.0,,U,BAO_0000251,,9527.0,,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,22224.0,
0.0,14294.0,,A,Microsomes,,Autocuration,CHEMBL620095,1.0,,,4645.0,,U,BAO_0000251,,9527.0,,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,22224.0,
0.0,3443.0,,A,,,Autocuration,CHEMBL620096,1.0,,,4646.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224.0,
0.0,3443.0,,A,,,Autocuration,CHEMBL620097,1.0,,,4647.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224.0,
0.0,11271.0,,A,,,Autocuration,CHEMBL620098,1.0,,,4648.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,22224.0,
0.0,3443.0,,A,,,Autocuration,CHEMBL620099,1.0,,,4649.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224.0,
0.0,3443.0,,A,,,Autocuration,CHEMBL620100,1.0,,,4650.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224.0,
0.0,6821.0,,A,,,Autocuration,CHEMBL620101,1.0,,,4651.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Elimination Half-life of compound was determined in monkey,,22224.0,
0.0,17267.0,,A,,,Autocuration,CHEMBL620102,1.0,,,4652.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Half life of compound was determined in rhesus monkey,,22224.0,
0.0,5819.0,1969.0,A,,,Autocuration,CHEMBL620103,1.0,Plasma,,4653.0,,U,BAO_0000366,,9527.0,,Cercopithecidae,Half life in monkey plasma,,22224.0,
0.0,5819.0,1969.0,A,,,Autocuration,CHEMBL620104,1.0,Plasma,,4654.0,,U,BAO_0000366,,9527.0,,Cercopithecidae,Half life in monkey plasma; Not detected,,22224.0,
0.0,1916.0,,A,,,Autocuration,CHEMBL874596,1.0,,,4655.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,22224.0,
0.0,17509.0,,A,,,Autocuration,CHEMBL873490,1.0,,,4656.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,22224.0,
0.0,1399.0,,A,,,Autocuration,CHEMBL620105,1.0,,,4657.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Terminal half life of the compound.,,22224.0,
0.0,1916.0,,A,,,Autocuration,CHEMBL620780,1.0,,,4658.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,22224.0,
0.0,4809.0,,A,,,Autocuration,CHEMBL620781,1.0,,,4659.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,22224.0,
0.0,5546.0,,A,,,Autocuration,CHEMBL620956,1.0,,,4660.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,22224.0,
0.0,3443.0,1088.0,A,,,Autocuration,CHEMBL620957,1.0,Urine,,4661.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224.0,
0.0,3443.0,1088.0,A,,,Autocuration,CHEMBL620958,1.0,Urine,,4662.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224.0,
0.0,4257.0,,A,,,Autocuration,CHEMBL620959,1.0,,,4663.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,22224.0,
0.0,6221.0,,A,,,Autocuration,CHEMBL620960,1.0,,,4664.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,22224.0,
0.0,5472.0,,A,,,Autocuration,CHEMBL620961,1.0,,,4665.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Volume of distribution was evaluated in rhesus,,22224.0,
0.0,4727.0,,A,,,Autocuration,CHEMBL620962,1.0,,,4666.0,In vivo,U,BAO_0000218,,10029.0,,Cricetulus griseus,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,22224.0,
0.0,4727.0,,A,,,Autocuration,CHEMBL620963,1.0,,,4667.0,In vivo,U,BAO_0000218,,10029.0,,Cricetulus griseus,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,22224.0,
0.0,4727.0,,A,,,Autocuration,CHEMBL620964,1.0,,,4668.0,In vivo,U,BAO_0000218,,10029.0,,Cricetulus griseus,Bioavailability in hamster was determined,,22224.0,
0.0,4727.0,,A,,,Autocuration,CHEMBL620965,1.0,,,4669.0,In vivo,U,BAO_0000218,,10029.0,,Cricetulus griseus,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,22224.0,
0.0,4727.0,,A,,,Autocuration,CHEMBL620966,1.0,,,4670.0,In vivo,U,BAO_0000218,,10029.0,,Cricetulus griseus,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,22224.0,
0.0,4727.0,178.0,A,,,Autocuration,CHEMBL620967,1.0,Blood,,4671.0,,U,BAO_0000221,,10029.0,,Cricetulus griseus,Half life of compound was determined in hamster blood,,22224.0,
0.0,1452.0,,A,,,Autocuration,CHEMBL620968,1.0,,,4672.0,,U,BAO_0000019,,9823.0,,Sus scrofa,Michaelis-Menten constant of the compound.,,22224.0,
0.0,1452.0,,A,,,Autocuration,CHEMBL874597,1.0,,,4673.0,,U,BAO_0000019,,9823.0,,Sus scrofa,Vmax value was measured at 0 uM concentration of silyl ether.,,22224.0,
0.0,1452.0,,A,,,Autocuration,CHEMBL620969,1.0,,,4674.0,,U,BAO_0000019,,9823.0,,Sus scrofa,Vmax value was measured at 10 uM concentration of silyl ether.,,22224.0,
0.0,1452.0,,A,,,Autocuration,CHEMBL620970,1.0,,,4675.0,,U,BAO_0000019,,9823.0,,Sus scrofa,Vmax value was measured at 5 uM concentration of silyl ether.,,22224.0,
9.0,11706.0,,B,,,Expert,CHEMBL620971,1.0,,,4676.0,,D,BAO_0000357,,9606.0,,Homo sapiens,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,235.0,
0.0,1916.0,,A,,,Autocuration,CHEMBL620972,1.0,,,4677.0,,U,BAO_0000218,,9606.0,,Homo sapiens,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,22224.0,
0.0,17791.0,,A,,,Autocuration,CHEMBL620973,1.0,,,4678.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Compound was evaluated for area under the curve expressed as (h*ug/ml),,22224.0,
0.0,7766.0,,A,,,Autocuration,CHEMBL618243,1.0,,,4679.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Active metabolite of ifosfamide determined in humans; A-Active,,22224.0,
0.0,6567.0,,A,,,Autocuration,CHEMBL618244,1.0,,,4680.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,22224.0,
0.0,6567.0,,A,,,Autocuration,CHEMBL618245,1.0,,,4681.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,22224.0,
0.0,6567.0,,A,,,Autocuration,CHEMBL618246,1.0,,,4682.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,22224.0,
0.0,6567.0,,A,,,Autocuration,CHEMBL618247,1.0,,,4683.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,22224.0,
0.0,17791.0,,A,,,Autocuration,CHEMBL618248,1.0,,,4684.0,,U,BAO_0000218,,9606.0,,Homo sapiens,Compound was evaluated for oral bioavailability in human,,22224.0,
0.0,7766.0,1088.0,A,,,Autocuration,CHEMBL618249,1.0,Urine,,4685.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Metabolite of ifosfamide determined in urine; NF-Not found,,22224.0,
0.0,6852.0,,A,,,Autocuration,CHEMBL618250,1.0,,,4686.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,22224.0,
0.0,6852.0,,A,,,Autocuration,CHEMBL874598,1.0,,,4687.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,22224.0,
0.0,6852.0,,A,,,Autocuration,CHEMBL618251,1.0,,,4688.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,22224.0,
0.0,6852.0,,A,,,Autocuration,CHEMBL618252,1.0,,,4689.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,22224.0,
0.0,6852.0,,A,,,Autocuration,CHEMBL618253,1.0,,,4690.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,22224.0,
0.0,6852.0,,A,,,Autocuration,CHEMBL618254,1.0,,,4691.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,22224.0,
0.0,6852.0,,A,,,Autocuration,CHEMBL618255,1.0,,,4692.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Percent of compound in healthy individuals (Group D),,22224.0,
0.0,4397.0,2107.0,A,Microsomes,,Autocuration,CHEMBL618983,1.0,Liver,,4693.0,,U,BAO_0000251,,9606.0,,Homo sapiens,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,22224.0,
0.0,17409.0,,A,,,Autocuration,CHEMBL618984,1.0,,,4694.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Binding towards human plasma protein at 10 uM,,22224.0,
0.0,17409.0,,A,,,Autocuration,CHEMBL618985,1.0,,,4695.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Binding towards human plasma protein at 100 uM,,22224.0,
0.0,17176.0,,A,,,Autocuration,CHEMBL618986,1.0,,,4696.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Human plasma protein binding activity was determined,,22224.0,
0.0,15444.0,,A,,,Autocuration,CHEMBL618987,1.0,,,4697.0,,U,BAO_0000019,,9606.0,,Homo sapiens,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,22224.0,
0.0,17267.0,,A,,,Autocuration,CHEMBL618988,1.0,,,4698.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Percent binding of compound towards human plasma protein was determined,,22224.0,
0.0,5944.0,2107.0,A,Microsomes,,Autocuration,CHEMBL618989,1.0,Liver,,4699.0,In vitro,U,BAO_0000251,,9606.0,,Homo sapiens,Plasma clearance in human liver microsomes,,22224.0,
0.0,5668.0,2107.0,A,Microsomes,,Autocuration,CHEMBL618990,1.0,Liver,,4700.0,In vitro,U,BAO_0000251,,9606.0,,Homo sapiens,In vitro intrinsic clearance in human liver microsome,,22224.0,
0.0,5669.0,2107.0,A,Microsomes,,Autocuration,CHEMBL618991,1.0,Liver,,4701.0,In vitro,U,BAO_0000251,,9606.0,,Homo sapiens,In vitro intrinsic clearance in human liver microsome,,22224.0,
0.0,5041.0,,A,Microsomes,,Autocuration,CHEMBL876725,1.0,,,4702.0,In vitro,U,BAO_0000251,,9606.0,,Homo sapiens,In vitro microsome metabolism clearance in human was determined,,22224.0,
0.0,5041.0,,A,Microsomes,,Autocuration,CHEMBL618992,1.0,,,4703.0,In vitro,U,BAO_0000251,,9606.0,,Homo sapiens,In vitro microsome metabolism clearance in human was determined; High,,22224.0,
0.0,5041.0,,A,Microsomes,,Autocuration,CHEMBL618993,1.0,,,4704.0,In vitro,U,BAO_0000251,,9606.0,,Homo sapiens,In vitro microsome metabolism clearance in human was determined; ND denotes no data,,22224.0,
0.0,5676.0,2107.0,A,Microsomes,,Autocuration,CHEMBL618994,1.0,Liver,,4705.0,In vitro,U,BAO_0000251,,9606.0,,Homo sapiens,Pharmacokinetic property (clearance) in human liver microsome,,22224.0,
0.0,5944.0,2107.0,A,Microsomes,,Autocuration,CHEMBL618995,1.0,Liver,,4706.0,In vitro,U,BAO_0000251,,9606.0,,Homo sapiens,Plasma clearance in human liver microsomes,,22224.0,
0.0,17538.0,2107.0,A,Microsomes,,Autocuration,CHEMBL618996,1.0,Liver,,4707.0,In vitro,U,BAO_0000251,,9606.0,,Homo sapiens,In vitro clearance in human liver microsomes,,22224.0,
0.0,6331.0,2107.0,A,Microsomes,,Autocuration,CHEMBL618997,1.0,Liver,,4708.0,In vitro,U,BAO_0000251,,9606.0,,Homo sapiens,Intrinsic clearance in human liver microsomes was determined,,22224.0,
0.0,5948.0,2107.0,A,Microsomes,,Autocuration,CHEMBL618998,1.0,Liver,,4709.0,In vitro,U,BAO_0000251,,9606.0,,Homo sapiens,Intrinsic clearance in human liver microsomes was determined,,22224.0,
0.0,5965.0,,A,,,Autocuration,CHEMBL618999,1.0,,,4710.0,In vivo,U,BAO_0000218,,9606.0,,Homo sapiens,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,22224.0,
0.0,1916.0,,A,,,Autocuration,CHEMBL620223,1.0,,,4711.0,In vivo,U,BAO_0000218,,9606.0,,Homo sapiens,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,22224.0,
0.0,5965.0,,A,,,Autocuration,CHEMBL620224,1.0,,,4712.0,,U,BAO_0000218,,9606.0,,Homo sapiens,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,22224.0,
0.0,1299.0,,A,,,Autocuration,CHEMBL620225,1.0,,,4713.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Stability in human plasma 2 hr after incubation expressed as percent concentration,,22224.0,
0.0,1299.0,,A,,,Autocuration,CHEMBL620226,1.0,,,4714.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Stability in human plasma 4 hr after incubation expressed as percent concentration,,22224.0,
0.0,7766.0,1088.0,A,,,Autocuration,CHEMBL620227,1.0,Urine,,4715.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,22224.0,
0.0,7766.0,1088.0,A,,,Autocuration,CHEMBL876726,1.0,Urine,,4716.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,22224.0,
0.0,7766.0,1088.0,A,,,Autocuration,CHEMBL620228,1.0,Urine,,4717.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,22224.0,
0.0,7766.0,1088.0,A,,,Autocuration,CHEMBL620229,1.0,Urine,,4718.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,22224.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL620230,1.0,,,4719.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL620231,1.0,,,4720.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL620232,1.0,,,4721.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL620233,1.0,,,4722.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,50594.0,
1.0,14294.0,,A,,,Intermediate,CHEMBL620234,1.0,,,4723.0,,N,BAO_0000218,,10090.0,,Mus musculus,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,50594.0,
1.0,14294.0,,A,,,Intermediate,CHEMBL620235,1.0,,,4724.0,,N,BAO_0000218,,10090.0,,Mus musculus,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,50594.0,
1.0,14294.0,,A,,,Intermediate,CHEMBL620236,1.0,,,4725.0,,N,BAO_0000218,,10090.0,,Mus musculus,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,50594.0,
1.0,6251.0,2107.0,A,,,Intermediate,CHEMBL620237,1.0,Liver,,4726.0,,N,BAO_0000218,,10090.0,,Mus musculus,In vitro metabolic potential in mouse liver microsomes,,50594.0,
1.0,17582.0,,A,,,Intermediate,CHEMBL620238,1.0,,,4727.0,,N,BAO_0000218,,10090.0,,Mus musculus,Ability of compound to bind to plasma protein was evaluated in HSA cells,,50594.0,
1.0,17811.0,2369.0,A,,,Intermediate,CHEMBL620239,1.0,Adrenal gland,,4728.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,50594.0,
1.0,17811.0,955.0,A,,,Intermediate,CHEMBL620240,1.0,Brain,,4729.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,50594.0,
1.0,17811.0,955.0,A,,,Intermediate,CHEMBL620241,1.0,Brain,,4730.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,50594.0,
1.0,17811.0,,A,,,Intermediate,CHEMBL876727,1.0,,,4731.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,50594.0,
1.0,17811.0,2113.0,A,,,Intermediate,CHEMBL620242,1.0,Kidney,,4732.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,50594.0,
1.0,17811.0,,A,,,Intermediate,CHEMBL620243,1.0,,,4733.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,50594.0,
1.0,5288.0,,A,,,Intermediate,CHEMBL620244,1.0,,,4734.0,,N,BAO_0000218,,10090.0,,Mus musculus,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,50594.0,
1.0,2717.0,1977.0,A,,,Intermediate,CHEMBL620245,1.0,Serum,,4735.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,50594.0,
1.0,2717.0,1977.0,A,,,Intermediate,CHEMBL620246,1.0,Serum,,4736.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,50594.0,
1.0,2717.0,1977.0,A,,,Intermediate,CHEMBL620247,1.0,Serum,,4737.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,50594.0,
1.0,17753.0,1969.0,A,,,Intermediate,CHEMBL620248,1.0,Plasma,,4738.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Half life of compound was determined in plasma of mice at 24 mg/Kg,,50594.0,
1.0,17753.0,1969.0,A,,,Intermediate,CHEMBL873497,1.0,Plasma,,4739.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Half life of compound was determined in plasma of mice at 40 mg/Kg,,50594.0,
1.0,17753.0,1969.0,A,,,Intermediate,CHEMBL620249,1.0,Plasma,,4740.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Half life of compound was determined in plasma of mice at 5 mg/Kg,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL620250,1.0,,,4741.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Half life after intraperitoneal administration in mice at 18 uM/kg,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL620251,1.0,,,4742.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Half life after intraperitoneal administration in mice at 23 uM/kg,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL620252,1.0,,,4743.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Half life after intraperitoneal administration in mice at 25 uM/kg,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL620253,1.0,,,4744.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Half life after intraperitoneal administration in mice at 26 uM/kg,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL620254,1.0,,,4745.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Half life after intravenous administration in mice at 23 uM/kg,,50594.0,
1.0,17764.0,,A,,,Intermediate,CHEMBL620255,1.0,,,4746.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Half life after intravenous administration in mice at 24 uM/kg,,50594.0,
1.0,16597.0,,A,,,Intermediate,CHEMBL620256,1.0,,,4747.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,50594.0,
1.0,2675.0,,A,,,Intermediate,CHEMBL876728,1.0,,,4748.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,50594.0,
1.0,2675.0,,A,,,Intermediate,CHEMBL620257,1.0,,,4749.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Maximum time required to reach Cp max was evaluated in mice after oral administration,,50594.0,
1.0,16597.0,,A,,,Intermediate,CHEMBL620258,1.0,,,4750.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,50594.0,
1.0,4890.0,,A,,,Intermediate,CHEMBL620259,1.0,,,4751.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,50594.0,
1.0,429.0,,A,,,Intermediate,CHEMBL620260,1.0,,,4752.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,50594.0,
1.0,17837.0,178.0,A,,,Intermediate,CHEMBL620261,1.0,Blood,,4753.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,,50594.0,
1.0,16597.0,,A,,,Intermediate,CHEMBL620262,1.0,,,4754.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Half life at a dose of 10 mg/kg intravenous administration in mice.,,50594.0,
1.0,16597.0,,A,,,Intermediate,CHEMBL620263,1.0,,,4755.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Half life at a dose of 10 mg/kg peroral administration in mice.,,50594.0,
1.0,6619.0,,A,,,Intermediate,CHEMBL620264,1.0,,,4756.0,,N,BAO_0000218,,10090.0,,Mus musculus,Half life in ob/ob mice,,50594.0,
1.0,4066.0,,A,,,Intermediate,CHEMBL620265,1.0,,,4757.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,50594.0,
1.0,4239.0,,A,,,Intermediate,CHEMBL620266,1.0,,,4758.0,,N,BAO_0000218,,10090.0,,Mus musculus,Half-life was measured in mouse,,50594.0,
1.0,5969.0,,A,,,Intermediate,CHEMBL620267,1.0,,,4759.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,50594.0,
1.0,8999.0,,A,,,Intermediate,CHEMBL619364,1.0,,,4760.0,,N,BAO_0000218,,10090.0,,Mus musculus,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,50594.0,
1.0,8999.0,,A,,,Intermediate,CHEMBL619365,1.0,,,4761.0,,N,BAO_0000218,,10090.0,,Mus musculus,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,50594.0,
1.0,17641.0,955.0,A,,,Intermediate,CHEMBL619366,1.0,Brain,,4762.0,,N,BAO_0000218,,10090.0,,Mus musculus,T2 in brain of mice at the oral dose of 50 mg/kg,,50594.0,
1.0,17641.0,2113.0,A,,,Intermediate,CHEMBL619367,1.0,Kidney,,4763.0,,N,BAO_0000218,,10090.0,,Mus musculus,T2 in kidney of mice at the oral dose of 50 mg/kg,,50594.0,
1.0,17641.0,2107.0,A,,,Intermediate,CHEMBL619368,1.0,Liver,,4764.0,,N,BAO_0000218,,10090.0,,Mus musculus,T2 in liver of mice at the oral dose of 50 mg/kg,,50594.0,
1.0,17641.0,2048.0,A,,,Intermediate,CHEMBL619369,1.0,Lung,,4765.0,,N,BAO_0000218,,10090.0,,Mus musculus,T2 in lungs of mice at the oral dose of 50 mg/kg,,50594.0,
1.0,17641.0,2106.0,A,,,Intermediate,CHEMBL876729,1.0,Spleen,,4766.0,,N,BAO_0000218,,10090.0,,Mus musculus,T2 in spleen of mice at the oral dose of 50 mg/kg,,50594.0,
1.0,16597.0,,A,,,Intermediate,CHEMBL619370,1.0,,,4767.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,50594.0,
1.0,4890.0,,A,,,Intermediate,CHEMBL619371,1.0,,,4768.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,50594.0,
1.0,429.0,,A,,,Intermediate,CHEMBL619372,1.0,,,4769.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,50594.0,
1.0,429.0,,A,,,Intermediate,CHEMBL620012,1.0,,,4770.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,50594.0,
1.0,5969.0,,A,,,Intermediate,CHEMBL620013,1.0,,,4771.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,50594.0,
1.0,16913.0,,F,,,Intermediate,CHEMBL620014,1.0,,,4772.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,81034.0,478.0
1.0,16913.0,,F,,,Intermediate,CHEMBL620015,1.0,,,4773.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,81034.0,478.0
1.0,16913.0,,F,,,Intermediate,CHEMBL621010,1.0,,,4774.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,81034.0,478.0
1.0,16913.0,,F,,,Intermediate,CHEMBL621011,1.0,,,4775.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,81034.0,478.0
1.0,16913.0,,F,,,Intermediate,CHEMBL621012,1.0,,,4776.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,81034.0,478.0
1.0,16913.0,,F,,,Intermediate,CHEMBL621013,1.0,,,4777.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,81034.0,478.0
1.0,17270.0,,F,,,Intermediate,CHEMBL621014,1.0,,,4778.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro cytotoxicity against A2780TAX cell line,,81034.0,478.0
1.0,5618.0,,F,,,Intermediate,CHEMBL618154,1.0,,,4779.0,,N,BAO_0000219,A2780cisR,9606.0,,Homo sapiens,In vitro inhibitory activity against human tumor cell line A2780cis,,80017.0,481.0
1.0,17777.0,,F,,,Expert,CHEMBL618155,1.0,,,4780.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,81034.0,478.0
1.0,16112.0,,F,,,Intermediate,CHEMBL618156,1.0,,,4781.0,,N,BAO_0000219,A2780cisR,9606.0,,Homo sapiens,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,80017.0,481.0
1.0,15748.0,,F,,,Intermediate,CHEMBL618157,1.0,,,4782.0,,N,BAO_0000219,A2780cisR,9606.0,,Homo sapiens,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,80017.0,481.0
1.0,6633.0,,F,,,Intermediate,CHEMBL618328,1.0,,,4783.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,81034.0,478.0
1.0,16930.0,,F,,,Intermediate,CHEMBL618329,1.0,,,4784.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,81034.0,478.0
1.0,17496.0,,F,,,Intermediate,CHEMBL618330,1.0,,,4785.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,81034.0,478.0
1.0,12989.0,,F,,,Expert,CHEMBL618331,1.0,,,4786.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro antitumor activity against A2780cisR cell line.,,81034.0,478.0
1.0,4840.0,,F,,,Intermediate,CHEMBL618332,1.0,,,4787.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,81034.0,478.0
1.0,12989.0,,F,,,Expert,CHEMBL618333,1.0,,,4788.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,81034.0,478.0
1.0,16745.0,,F,,,Intermediate,CHEMBL618334,1.0,,,4789.0,,N,BAO_0000219,A2780cisR,9606.0,,Homo sapiens,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,80017.0,481.0
1.0,16597.0,,F,,,Expert,CHEMBL618335,1.0,,,4790.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,81034.0,478.0
9.0,16547.0,,B,,,Expert,CHEMBL618336,1.0,,,4791.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,11736.0,
8.0,16547.0,,F,,,Expert,CHEMBL618337,1.0,,,4792.0,,H,BAO_0000019,,,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,11736.0,
9.0,16547.0,,F,,,Expert,CHEMBL618338,1.0,,,4793.0,,D,BAO_0000019,,10116.0,,Rattus norvegicus,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,11736.0,
9.0,15856.0,,F,,,Expert,CHEMBL618339,1.0,,,4794.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,278.0,722.0
9.0,15856.0,,F,,,Expert,CHEMBL618340,1.0,,,4795.0,,D,BAO_0000219,HEK293,9606.0,,Homo sapiens,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,278.0,722.0
9.0,16547.0,,B,,,Expert,CHEMBL618341,1.0,,,4796.0,,D,BAO_0000019,,10090.0,,Mus musculus,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,11831.0,
8.0,16547.0,,F,,,Expert,CHEMBL618342,1.0,,,4797.0,,H,BAO_0000019,,,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,11831.0,
9.0,16547.0,,F,,,Expert,CHEMBL618343,1.0,,,4798.0,,D,BAO_0000019,,10090.0,,Mus musculus,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,11831.0,
8.0,17402.0,,B,,,Expert,CHEMBL621038,1.0,,,4799.0,,H,BAO_0000357,,,,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,280.0,
0.0,11746.0,,F,,,Autocuration,CHEMBL621039,1.0,,,4800.0,,U,BAO_0000219,T-cells,9606.0,,Homo sapiens,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,22226.0,574.0
0.0,11746.0,,F,,,Autocuration,CHEMBL621040,1.0,,,4801.0,,U,BAO_0000219,T-cells,9606.0,,Homo sapiens,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,22226.0,574.0
1.0,5455.0,,F,,,Intermediate,CHEMBL621041,1.0,,,4802.0,,N,BAO_0000219,A-375,9606.0,,Homo sapiens,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,80018.0,455.0
1.0,2068.0,,F,,,Intermediate,CHEMBL621042,1.0,,,4803.0,,N,BAO_0000219,A-375,9606.0,,Homo sapiens,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,80018.0,455.0
1.0,2683.0,,F,,,Intermediate,CHEMBL621043,1.0,,,4804.0,,N,BAO_0000219,A-375,9606.0,,Homo sapiens,In vitro antitumor activity against A375cell line extracted form melanoma,,80018.0,455.0
1.0,15313.0,,F,,,Expert,CHEMBL621044,1.0,,,4805.0,,N,BAO_0000219,A-375,9606.0,,Homo sapiens,Inhibition of cell growth in (A375) melan cell line,,80018.0,455.0
1.0,13739.0,,F,,,Intermediate,CHEMBL621045,1.0,,,4806.0,,N,BAO_0000219,A-375,9606.0,,Homo sapiens,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,80018.0,455.0
1.0,13739.0,,F,,,Intermediate,CHEMBL621046,1.0,,,4807.0,,N,BAO_0000219,A-375,9606.0,,Homo sapiens,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,80018.0,455.0
1.0,14750.0,,F,,,Intermediate,CHEMBL621047,1.0,,,4808.0,,N,BAO_0000219,A-375,9606.0,,Homo sapiens,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,80018.0,455.0
1.0,14777.0,,F,,,Intermediate,CHEMBL621048,1.0,,,4809.0,,N,BAO_0000219,A-427,9606.0,,Homo sapiens,Antiproliferative activity measured against A427 human lung carcinoma,,80019.0,797.0
1.0,14777.0,,F,,,Intermediate,CHEMBL883798,1.0,,,4810.0,,N,BAO_0000219,A-427,9606.0,,Homo sapiens,Antiproliferative activity measured against A427 human lung carcinoma,,80019.0,797.0
1.0,17672.0,,F,,,Intermediate,CHEMBL621049,1.0,,,4811.0,,N,BAO_0000219,A-427,9606.0,,Homo sapiens,Cytotoxicity against lung carcinoma A427 tumor cell lines,,80019.0,797.0
1.0,14368.0,,F,,,Intermediate,CHEMBL621050,1.0,,,4812.0,,N,BAO_0000219,A-427,9606.0,,Homo sapiens,Inhibition of large cell lung carcinoma (A427),,80019.0,797.0
1.0,14368.0,,F,,,Intermediate,CHEMBL621051,1.0,,,4813.0,,N,BAO_0000219,A-427,9606.0,,Homo sapiens,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,80019.0,797.0
1.0,13866.0,,F,,,Intermediate,CHEMBL621052,1.0,,,4814.0,,N,BAO_0000219,A-427,9606.0,,Homo sapiens,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,80019.0,797.0
1.0,2545.0,,F,,,Intermediate,CHEMBL621053,1.0,,,4815.0,,N,BAO_0000219,A-427,9606.0,,Homo sapiens,Inhibitory concentration in human lung carcinoma A427 cell line,,80019.0,797.0
1.0,2545.0,,F,,,Intermediate,CHEMBL621054,1.0,,,4816.0,,N,BAO_0000219,A-427,9606.0,,Homo sapiens,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,80019.0,797.0
0.0,6062.0,,A,,,Autocuration,CHEMBL621055,1.0,,,4817.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,22224.0,
0.0,4578.0,,A,,,Autocuration,CHEMBL876398,1.0,,,4818.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Tested for volume of distribution upon iv administration to african green monkey,,22224.0,
0.0,17592.0,,A,,,Autocuration,CHEMBL621056,1.0,,,4819.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Volume of distribution in monkey,,22224.0,
0.0,5005.0,,A,,,Autocuration,CHEMBL621057,1.0,,,4820.0,In vivo,U,BAO_0000218,,9544.0,,Macaca mulatta,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,22224.0,
0.0,5005.0,,A,,,Autocuration,CHEMBL621058,1.0,,,4821.0,In vivo,U,BAO_0000218,,9544.0,,Macaca mulatta,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,22224.0,
0.0,5922.0,,A,,,Autocuration,CHEMBL621059,1.0,,,4822.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Pharmacokinetic property(Vdss) in cynomolgus monkey,,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL621060,1.0,,,4823.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,The distribution volume after intravenous administration in cynomolgus monkeys,,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL621061,1.0,,,4824.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL621062,1.0,,,4825.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,22224.0,
0.0,6057.0,,A,,,Autocuration,CHEMBL621063,1.0,,,4826.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Volume displacement was calculated in rhesus monkey,,22224.0,
0.0,5145.0,,A,,,Autocuration,CHEMBL621064,1.0,,,4827.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Volume of distribution in steady state was determined in rhesus monkey,,22224.0,
0.0,6821.0,,A,,,Autocuration,CHEMBL621065,1.0,,,4828.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Volume of distribution of compound was determined in monkey,,22224.0,
0.0,5334.0,,A,,,Autocuration,CHEMBL621066,1.0,,,4829.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,22224.0,
0.0,5334.0,,A,,,Autocuration,CHEMBL621067,1.0,,,4830.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,22224.0,
0.0,6641.0,,A,,,Autocuration,CHEMBL621068,1.0,,,4831.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,22224.0,
0.0,2661.0,,A,,,Autocuration,CHEMBL876399,1.0,,,4832.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,22224.0,
0.0,6535.0,,A,,,Autocuration,CHEMBL621069,1.0,,,4833.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Volume distribution in monkey after administration of 1 mg/kg iv,,22224.0,
0.0,4809.0,,A,,,Autocuration,CHEMBL621070,1.0,,,4834.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,22224.0,
0.0,6062.0,,A,,,Autocuration,CHEMBL621071,1.0,,,4835.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,22224.0,
0.0,3443.0,,A,,,Autocuration,CHEMBL621072,1.0,,,4836.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224.0,
0.0,4578.0,,A,,,Autocuration,CHEMBL618209,1.0,,,4837.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Oral systemic bioavailability upon iv administration to african green monkey,,22224.0,
0.0,4809.0,,A,,,Autocuration,CHEMBL618210,1.0,,,4838.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,22224.0,
0.0,11271.0,,A,,,Autocuration,CHEMBL618211,1.0,,,4839.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Baboon plasma free fraction. ,,22224.0,
0.0,6057.0,,A,,,Autocuration,CHEMBL618212,1.0,,,4840.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Area under the curve was calculated in rhesus monkey after iv administration,,22224.0,
0.0,6057.0,,A,,,Autocuration,CHEMBL618213,1.0,,,4841.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Area under the curve was calculated in rhesus monkey after peroral administration,,22224.0,
0.0,17853.0,,A,,,Autocuration,CHEMBL618214,1.0,,,4842.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,22224.0,
0.0,5302.0,,A,,,Autocuration,CHEMBL873492,1.0,,,4843.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half life period in monkey after 5 mg/kg dose,,22224.0,
0.0,4257.0,,A,,,Autocuration,CHEMBL618272,1.0,,,4844.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,22224.0,
0.0,4257.0,,A,,,Autocuration,CHEMBL618273,1.0,,,4845.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,22224.0,
0.0,13501.0,1969.0,A,,,Autocuration,CHEMBL618274,1.0,Plasma,,4846.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,22224.0,
0.0,5394.0,,A,,,Autocuration,CHEMBL618275,1.0,,,4847.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,22224.0,
0.0,2661.0,,A,,,Autocuration,CHEMBL618276,1.0,,,4848.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,22224.0,
0.0,3341.0,,A,,,Autocuration,CHEMBL618277,1.0,,,4849.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Compound was evaluated for terminal half life in monkey,,22224.0,
0.0,3045.0,,A,,,Autocuration,CHEMBL618278,1.0,,,4850.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,22224.0,
0.0,5005.0,1969.0,A,,,Autocuration,CHEMBL618279,1.0,Plasma,,4851.0,In vivo,U,BAO_0000218,,9544.0,,Macaca mulatta,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,22224.0,
0.0,4847.0,,A,,,Autocuration,CHEMBL618280,1.0,,,4852.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Half life of compound was determined in squirrel monkey,,22224.0,
0.0,4256.0,,A,,,Autocuration,CHEMBL618281,1.0,,,4853.0,In vivo,U,BAO_0000218,,9541.0,,Macaca fascicularis,Half life after iv administration in cynomolgus monkey,,22224.0,
0.0,6535.0,1969.0,A,,,Autocuration,CHEMBL618282,1.0,Plasma,,4854.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half life in monkey plasma after administration of 1 mg/kg iv,,22224.0,
0.0,6057.0,,A,,,Autocuration,CHEMBL618283,1.0,,,4855.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Half life was calculated in rhesus monkey,,22224.0,
0.0,17592.0,,A,,,Autocuration,CHEMBL618284,1.0,,,4856.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Half life in monkey,,22224.0,
0.0,6641.0,,A,,,Autocuration,CHEMBL618285,1.0,,,4857.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,22224.0,
0.0,5472.0,,A,,,Autocuration,CHEMBL618286,1.0,,,4858.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Half life was evaluated in rhesus,,22224.0,
0.0,6221.0,,A,,,Autocuration,CHEMBL618287,1.0,,,4859.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,22224.0,
0.0,5668.0,,A,,,Autocuration,CHEMBL618288,1.0,,,4860.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half life period was determine after peroral administration at 10 mpk in Rhesus,,22224.0,
0.0,4809.0,,A,,,Autocuration,CHEMBL876393,1.0,,,4861.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,22224.0,
0.0,5546.0,,A,,,Autocuration,CHEMBL618289,1.0,,,4862.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,22224.0,
0.0,5553.0,,A,,,Autocuration,CHEMBL618290,1.0,,,4863.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,22224.0,
0.0,6078.0,,A,,,Autocuration,CHEMBL618291,1.0,,,4864.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Half-life was calculated in monkey,,22224.0,
0.0,5147.0,,A,,,Autocuration,CHEMBL618292,1.0,,,4865.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Half-life in Squirrel monkey,,22224.0,
0.0,5145.0,,A,,,Autocuration,CHEMBL618293,1.0,,,4866.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Half-life in rhesus monkey,,22224.0,
0.0,6062.0,,A,,,Autocuration,CHEMBL618294,1.0,,,4867.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half-life was measured in monkey after an iv dose of 1 mg/kg,,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL618295,1.0,,,4868.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half-life period after intravenous administration in cynomolgus monkeys,,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL618296,1.0,,,4869.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half-life period after oral administration in cynomolgus monkeys,,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL618297,1.0,,,4870.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,22224.0,
0.0,7766.0,1088.0,A,,,Autocuration,CHEMBL618298,1.0,Urine,,4871.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,22224.0,
0.0,7766.0,1088.0,A,,,Autocuration,CHEMBL618299,1.0,Urine,,4872.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,22224.0,
0.0,7766.0,1088.0,A,,,Autocuration,CHEMBL618300,1.0,Urine,,4873.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,22224.0,
0.0,7766.0,1088.0,A,,,Autocuration,CHEMBL618301,1.0,Urine,,4874.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,22224.0,
0.0,7766.0,1088.0,A,,,Autocuration,CHEMBL618302,1.0,Urine,,4875.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,22224.0,
0.0,7766.0,1088.0,A,,,Autocuration,CHEMBL876394,1.0,Urine,,4876.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,22224.0,
0.0,7766.0,1088.0,A,,,Autocuration,CHEMBL618303,1.0,Urine,,4877.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,22224.0,
0.0,7766.0,1088.0,A,,,Autocuration,CHEMBL618304,1.0,Urine,,4878.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,22224.0,
0.0,1916.0,,A,,,Autocuration,CHEMBL618305,1.0,,,4879.0,In vivo,U,BAO_0000218,,9606.0,,Homo sapiens,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,22224.0,
0.0,16643.0,,A,,,Autocuration,CHEMBL618306,1.0,,,4880.0,In vivo,U,BAO_0000218,,9606.0,,Homo sapiens,Oral bioavailability in human,,22224.0,
0.0,17248.0,,A,,,Autocuration,CHEMBL618307,1.0,,,4881.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Compound was tested for human plasma protein binding,,22224.0,
0.0,17248.0,,A,,,Autocuration,CHEMBL618308,1.0,,,4882.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Compound was tested for human plasma protein binding; Not determined,,22224.0,
0.0,6241.0,,A,,,Autocuration,CHEMBL618309,1.0,,,4883.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Protein binding activity of compound in human plasma; % Free,,22224.0,
0.0,17716.0,,A,,,Autocuration,CHEMBL618310,1.0,,,4884.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Unbound fraction (plasma),,22224.0,
0.0,17605.0,1969.0,A,,,Autocuration,CHEMBL873353,1.0,Plasma,,4885.0,,U,BAO_0000366,,9606.0,,Homo sapiens,Half life for the hydrolysis of compound in human blood serum,,22224.0,
0.0,17625.0,1969.0,A,,,Autocuration,CHEMBL618311,1.0,Plasma,,4886.0,,U,BAO_0000366,,9606.0,,Homo sapiens,Half life period in human plasma using phosphate buffer (0.08 M),,22224.0,
0.0,17625.0,1969.0,A,,,Autocuration,CHEMBL618312,1.0,Plasma,,4887.0,,U,BAO_0000366,,9606.0,,Homo sapiens,Half life period in human plasma using phosphate buffer (0.1 M),,22224.0,
0.0,17747.0,1969.0,A,,,Autocuration,CHEMBL618313,1.0,Plasma,,4888.0,,U,BAO_0000366,,9606.0,,Homo sapiens,Half-life in human plasma was determined,,22224.0,
0.0,15613.0,,A,,,Autocuration,CHEMBL618314,1.0,,,4889.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,22224.0,
0.0,354.0,,A,,,Autocuration,CHEMBL618315,1.0,,,4890.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,22224.0,
0.0,3741.0,,A,,,Autocuration,CHEMBL618316,1.0,,,4891.0,,U,BAO_0000019,,9606.0,,Homo sapiens,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,22224.0,
0.0,3741.0,,A,,,Autocuration,CHEMBL618317,1.0,,,4892.0,,U,BAO_0000019,,9606.0,,Homo sapiens,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,22224.0,
0.0,3741.0,,A,,,Autocuration,CHEMBL620138,1.0,,,4893.0,,U,BAO_0000019,,9606.0,,Homo sapiens,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,22224.0,
0.0,17599.0,,A,,,Autocuration,CHEMBL858280,1.0,,,4894.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Partition coefficient (logP),,22224.0,
0.0,5486.0,,A,,,Autocuration,CHEMBL620139,1.0,,,4895.0,,U,BAO_0000019,,9606.0,,Homo sapiens,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,22224.0,
0.0,5600.0,,A,Microsomes,,Autocuration,CHEMBL620140,1.0,,,4896.0,,U,BAO_0000251,,9606.0,,Homo sapiens,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,22224.0,
0.0,14294.0,,A,,,Autocuration,CHEMBL620141,1.0,,,4897.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,22224.0,
0.0,14294.0,,A,,,Autocuration,CHEMBL620142,1.0,,,4898.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,22224.0,
0.0,14294.0,,A,,,Autocuration,CHEMBL620143,1.0,,,4899.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,22224.0,
0.0,14294.0,,A,Microsomes,,Autocuration,CHEMBL620144,1.0,,,4900.0,,U,BAO_0000251,,9606.0,,Homo sapiens,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,22224.0,
0.0,14294.0,,A,Microsomes,,Autocuration,CHEMBL620145,1.0,,,4901.0,,U,BAO_0000251,,9606.0,,Homo sapiens,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,22224.0,
0.0,14294.0,,A,Microsomes,,Autocuration,CHEMBL620146,1.0,,,4902.0,,U,BAO_0000251,,9606.0,,Homo sapiens,Metabolism of compound in human microsomes; Trace,,22224.0,
0.0,6260.0,2107.0,A,Microsomes,,Autocuration,CHEMBL620147,1.0,Liver,,4903.0,,U,BAO_0000251,,9606.0,,Homo sapiens,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,,22224.0,
0.0,6187.0,,A,Microsomes,,Autocuration,CHEMBL620148,1.0,,,4904.0,,U,BAO_0000251,,9606.0,,Homo sapiens,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,22224.0,
0.0,6251.0,2107.0,A,Microsomes,,Autocuration,CHEMBL620149,1.0,Liver,,4905.0,,U,BAO_0000251,,9606.0,,Homo sapiens,In vitro metabolic potential in human liver microsomes,,22224.0,
0.0,3246.0,,A,,,Autocuration,CHEMBL876412,1.0,,,4906.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,22224.0,
0.0,17313.0,,A,,,Autocuration,CHEMBL619352,1.0,,,4907.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Tested for human plasma protein binding of the compound; Not tested,,22224.0,
0.0,6227.0,,A,,,Autocuration,CHEMBL619353,1.0,,,4908.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Compound was tested for percent protein binding (PB) in human,,22224.0,
0.0,5530.0,1969.0,A,,,Autocuration,CHEMBL619354,1.0,Plasma,,4909.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Protein binding in human plasma,,22224.0,
0.0,6108.0,,A,,,Autocuration,CHEMBL619355,1.0,,,4910.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Permeability coefficient (B to A) in Caco-2 cell,,22224.0,
0.0,6108.0,,A,,,Autocuration,CHEMBL619356,1.0,,,4911.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,22224.0,
0.0,2774.0,,A,,,Autocuration,CHEMBL619357,1.0,,,4912.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,22224.0,
0.0,16643.0,,A,,,Autocuration,CHEMBL619358,1.0,,,4913.0,,U,BAO_0000019,,9606.0,,Homo sapiens,In vitro rate of absorption observed as Caco-2 permeability in humans,,22224.0,
0.0,17582.0,,A,,,Autocuration,CHEMBL619359,1.0,,,4914.0,,U,BAO_0000219,Caco-2,9606.0,,Homo sapiens,Cellular permeability of compound was determined in Caco-2 cells; High,,22224.0,495.0
0.0,6838.0,,A,,,Autocuration,CHEMBL619360,1.0,,,4915.0,,U,BAO_0000219,Caco-2,9606.0,,Homo sapiens,Permeability in Caco-2 cells of compound,,22224.0,495.0
0.0,6108.0,,A,,,Autocuration,CHEMBL619361,1.0,,,4916.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Permeability coefficient (A to B) in Caco-2 cell,,22224.0,
0.0,6108.0,,A,,,Autocuration,CHEMBL619362,1.0,,,4917.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Permeability coefficient (B to A) in Caco-2 cell,,22224.0,
0.0,6108.0,,A,,,Autocuration,CHEMBL619363,1.0,,,4918.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Permeability coefficient (Papp) (Caco-2 cell monolayer),,22224.0,
0.0,2146.0,,A,,,Autocuration,CHEMBL618942,1.0,,,4919.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,22224.0,
0.0,4514.0,,A,,,Autocuration,CHEMBL618943,1.0,,,4920.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Compound was tested for protein binding in human plasma,,22224.0,
0.0,6108.0,,A,,,Autocuration,CHEMBL618944,1.0,,,4921.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,22224.0,
0.0,7766.0,1088.0,A,,,Autocuration,CHEMBL618945,1.0,Urine,,4922.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,22224.0,
1.0,5969.0,,A,,,Intermediate,CHEMBL618946,1.0,,,4923.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,50594.0,
1.0,3277.0,,A,,,Intermediate,CHEMBL876413,1.0,,,4924.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,50594.0,
1.0,3802.0,,A,,,Intermediate,CHEMBL618947,1.0,,,4925.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,50594.0,
1.0,2862.0,1969.0,A,,,Intermediate,CHEMBL618948,1.0,Plasma,,4926.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Time taken to reach maximum concentration in plasma upon oral administration in mouse,,50594.0,
1.0,6348.0,1969.0,A,,,Intermediate,CHEMBL618949,1.0,Plasma,,4927.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL618950,1.0,,,4928.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Tmax after intraperitoneal administration in mice at 23 uM/kg,,50594.0,
1.0,5781.0,,A,,,Intermediate,CHEMBL618951,1.0,,,4929.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Tmax after oral administration at 30 mg/kg in ICR mouse,,50594.0,
1.0,17764.0,,A,,,Intermediate,CHEMBL618952,1.0,,,4930.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Tmax after peroral administration in mice at 2.4 uM/kg,,50594.0,
1.0,4066.0,,A,,,Intermediate,CHEMBL618953,1.0,,,4931.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,50594.0,
1.0,17641.0,955.0,A,,,Intermediate,CHEMBL618954,1.0,Brain,,4932.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Tmax in brain of mice at the oral dose of 50 mg/kg,,50594.0,
1.0,17641.0,2113.0,A,,,Intermediate,CHEMBL618955,1.0,Kidney,,4933.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Tmax in kidney of mice at the oral dose of 50 mg/kg,,50594.0,
1.0,17641.0,2107.0,A,,,Intermediate,CHEMBL618956,1.0,Liver,,4934.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Tmax in liver of mice at the oral dose of 50 mg/kg,,50594.0,
1.0,17641.0,2048.0,A,,,Intermediate,CHEMBL618957,1.0,Lung,,4935.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Tmax in lungs of mice at the oral dose of 50 mg/kg,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL618958,1.0,,,4936.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Tmax in mice at 18 uM/kg i.p. administration,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL618959,1.0,,,4937.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Tmax in mice at 23 uM/kg i.v. administration,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL618960,1.0,,,4938.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Tmax in mice at 25 uM/kg i.p. administration,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL876723,1.0,,,4939.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Tmax in mice at 26 uM/kg i.p. administration,,50594.0,
1.0,17641.0,2106.0,A,,,Intermediate,CHEMBL618961,1.0,Spleen,,4940.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Tmax in spleen of mice at the oral dose of 50 mg/kg,,50594.0,
1.0,16597.0,,A,,,Intermediate,CHEMBL618962,1.0,,,4941.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,50594.0,
1.0,16597.0,,A,,,Intermediate,CHEMBL618963,1.0,,,4942.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,50594.0,
1.0,5951.0,,A,,,Intermediate,CHEMBL618964,1.0,,,4943.0,,N,BAO_0000218,,10090.0,,Mus musculus,Tmax value in IRC mice,,50594.0,
1.0,5506.0,,A,,,Intermediate,CHEMBL618965,1.0,,,4944.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,50594.0,
1.0,5506.0,,A,,,Intermediate,CHEMBL618966,1.0,,,4945.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,50594.0,
1.0,429.0,1088.0,A,,,Intermediate,CHEMBL618967,1.0,Urine,,4946.0,,N,BAO_0000218,,10090.0,,Mus musculus,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,50594.0,
1.0,429.0,1088.0,A,,,Intermediate,CHEMBL618968,1.0,Urine,,4947.0,,N,BAO_0000218,,10090.0,,Mus musculus,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,50594.0,
1.0,4066.0,1088.0,A,,,Intermediate,CHEMBL618969,1.0,Urine,,4948.0,,N,BAO_0000218,,10090.0,,Mus musculus,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,50594.0,
1.0,17734.0,,A,,,Intermediate,CHEMBL618970,1.0,,,4949.0,,N,BAO_0000218,,10090.0,,Mus musculus,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,50594.0,
1.0,17734.0,,A,,,Intermediate,CHEMBL618971,1.0,,,4950.0,,N,BAO_0000218,,10090.0,,Mus musculus,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,50594.0,
1.0,6062.0,,A,,,Intermediate,CHEMBL618972,1.0,,,4951.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,50594.0,
1.0,5969.0,,A,,,Intermediate,CHEMBL618973,1.0,,,4952.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,50594.0,
1.0,5969.0,,A,,,Intermediate,CHEMBL618974,1.0,,,4953.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,50594.0,
1.0,5969.0,,A,,,Intermediate,CHEMBL618975,1.0,,,4954.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,50594.0,
1.0,5980.0,,A,,,Intermediate,CHEMBL618976,1.0,,,4955.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Vd in mice,,50594.0,
1.0,17592.0,,A,,,Intermediate,CHEMBL618977,1.0,,,4956.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Volume of distribution in mouse,,50594.0,
1.0,6348.0,,A,,,Intermediate,CHEMBL876724,1.0,,,4957.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,50594.0,
1.0,17753.0,,A,,,Intermediate,CHEMBL618978,1.0,,,4958.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,50594.0,
1.0,17753.0,,A,,,Intermediate,CHEMBL618979,1.0,,,4959.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,50594.0,
1.0,17753.0,,A,,,Intermediate,CHEMBL618980,1.0,,,4960.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,50594.0,
1.0,4239.0,,A,,,Intermediate,CHEMBL618981,1.0,,,4961.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Pharmacokinetic property (vdss) was measured in mouse,,50594.0,
1.0,2862.0,,A,,,Intermediate,CHEMBL618982,1.0,,,4962.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Value distribution upon iv administration in mouse,,50594.0,
1.0,17734.0,,A,,,Intermediate,CHEMBL620150,1.0,,,4963.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,50594.0,
1.0,2675.0,,A,,,Intermediate,CHEMBL620151,1.0,,,4964.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Volume of distribution was evaluated in mice after intravenous administration,,50594.0,
1.0,2675.0,,A,,,Intermediate,CHEMBL620152,1.0,,,4965.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Volume of distribution was evaluated in mice after oral administration,,50594.0,
1.0,17837.0,,A,,,Intermediate,CHEMBL620153,1.0,,,4966.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,50594.0,
1.0,5727.0,,A,,,Intermediate,CHEMBL876395,1.0,,,4967.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Steady state volume of distribution was determined in mice,,50594.0,
1.0,17852.0,,A,,,Intermediate,CHEMBL620154,1.0,,,4968.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Volume distribution (steady state) of compound was determined in mouse,,50594.0,
1.0,17764.0,,A,,,Intermediate,CHEMBL620155,1.0,,,4969.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,50594.0,
1.0,16597.0,,A,,,Intermediate,CHEMBL620156,1.0,,,4970.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,50594.0,
1.0,6062.0,,A,,,Intermediate,CHEMBL620157,1.0,,,4971.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,50594.0,
1.0,16438.0,2113.0,A,,,Intermediate,CHEMBL620158,1.0,Kidney,,4972.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of compound (oxidized form) in in kidney tissue,,50594.0,
1.0,16438.0,178.0,A,,,Intermediate,CHEMBL620159,1.0,Blood,,4973.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,,50594.0,
1.0,16438.0,178.0,A,,,Intermediate,CHEMBL620160,1.0,Blood,,4974.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,50594.0,
1.0,16438.0,178.0,A,,,Intermediate,CHEMBL620161,1.0,Blood,,4975.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,50594.0,
1.0,10708.0,,F,,,Intermediate,CHEMBL620162,1.0,,,4976.0,,N,BAO_0000219,A-427,9606.0,,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,80019.0,797.0
1.0,16597.0,,F,,,Expert,CHEMBL620163,1.0,,,4977.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Inhibition of A431 human squamous cell carcinoma cell proliferation,,80852.0,500.0
1.0,16062.0,,F,,,Expert,CHEMBL620833,1.0,,,4978.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,80852.0,500.0
1.0,16062.0,,F,,,Expert,CHEMBL876396,1.0,,,4979.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,80852.0,500.0
1.0,16958.0,,F,,,Expert,CHEMBL620834,1.0,,,4980.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,80852.0,500.0
1.0,6700.0,,F,,,Expert,CHEMBL620835,1.0,,,4981.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Inhibition of A431 human carcinoma cell proliferation,,80852.0,500.0
1.0,17226.0,,F,,,Expert,CHEMBL620836,1.0,,,4982.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,80852.0,500.0
1.0,6828.0,,F,,,Intermediate,CHEMBL620837,1.0,,,4983.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,80852.0,500.0
1.0,12314.0,,F,,,Intermediate,CHEMBL621017,1.0,,,4984.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,In vitro cytotoxicity against epidermoid carcinoma cell line,,80852.0,500.0
9.0,13412.0,,F,,,Expert,CHEMBL621018,1.0,,,4985.0,,D,BAO_0000218,A-431,9606.0,,Homo sapiens,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,9.0,500.0
1.0,13299.0,,F,,,Intermediate,CHEMBL621019,1.0,,,4986.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Antiproliferative activity of compound was measured on human tumor cell line A431.,,80852.0,500.0
1.0,17420.0,,F,,,Intermediate,CHEMBL621020,1.0,,,4987.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,80852.0,500.0
1.0,13678.0,,F,,,Intermediate,CHEMBL621021,1.0,,,4988.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,80852.0,500.0
8.0,14171.0,,F,,,Expert,CHEMBL621022,1.0,,,4989.0,,H,BAO_0000219,A-431,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,9.0,500.0
1.0,6333.0,,F,,,Expert,CHEMBL621023,1.0,,,4990.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Tested for antiproliferative activity against human A431 cells,,80852.0,500.0
9.0,2356.0,,F,,,Expert,CHEMBL621024,1.0,,,4991.0,,D,BAO_0000219,A-431,9606.0,,Homo sapiens,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,9.0,500.0
1.0,15578.0,,F,,,Expert,CHEMBL621025,1.0,,,4992.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,80852.0,500.0
1.0,5126.0,,F,,,Expert,CHEMBL621026,1.0,,,4993.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Inhibition of A431 cell proliferation,,80852.0,500.0
1.0,6844.0,,F,,,Expert,CHEMBL621027,1.0,,,4994.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Cytotoxic effect on A431 human epidermoid carcinoma cells,,80852.0,500.0
1.0,6844.0,,F,,,Expert,CHEMBL876397,1.0,,,4995.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,80852.0,500.0
1.0,4925.0,,F,,,Intermediate,CHEMBL883797,1.0,,,4996.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,80852.0,500.0
1.0,4925.0,,F,,,Intermediate,CHEMBL621028,1.0,,,4997.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,80852.0,500.0
1.0,13978.0,,F,,,Intermediate,CHEMBL621029,1.0,,,4998.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,80852.0,500.0
1.0,16786.0,,F,,,Intermediate,CHEMBL621030,1.0,,,4999.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,80852.0,500.0
8.0,13412.0,,F,,,Expert,CHEMBL621147,1.0,,,5000.0,,H,BAO_0000219,A-431,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,9.0,500.0
1.0,17824.0,,F,,,Intermediate,CHEMBL621148,1.0,,,5001.0,,N,BAO_0000218,A-431,9606.0,,Homo sapiens,In vivo antiproliferative activity against A431 cell line,,80852.0,500.0
9.0,12751.0,,F,,,Expert,CHEMBL621149,1.0,,,5002.0,,D,BAO_0000219,A-431,9606.0,,Homo sapiens,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,9.0,500.0
1.0,12380.0,,F,,,Expert,CHEMBL621150,1.0,,,5003.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Inhibition of A431 human epidermoid carcinoma cell proliferation,,80852.0,500.0
9.0,4959.0,,F,,,Expert,CHEMBL621151,1.0,,,5004.0,,D,BAO_0000219,A-431,9606.0,,Homo sapiens,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,9.0,500.0
1.0,6333.0,,F,,,Intermediate,CHEMBL621152,1.0,,,5005.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,80852.0,500.0
1.0,6333.0,,F,,,Intermediate,CHEMBL621153,1.0,,,5006.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,80852.0,500.0
1.0,6333.0,,F,,,Intermediate,CHEMBL884000,1.0,,,5007.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,80852.0,500.0
9.0,5296.0,,F,,,Expert,CHEMBL621154,1.0,,,5008.0,,D,BAO_0000019,,9606.0,,Homo sapiens,Inhibition of EGFR overexpressing A431 cell proliferation,,9.0,
1.0,12624.0,,F,,,Expert,CHEMBL621155,1.0,,,5009.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Inhibition of A431 cell proliferation,,80852.0,500.0
9.0,14926.0,,F,,,Expert,CHEMBL621156,1.0,,,5010.0,,D,BAO_0000219,A-431,9606.0,,Homo sapiens,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,9.0,500.0
9.0,14926.0,,F,,,Expert,CHEMBL621157,1.0,,,5011.0,,D,BAO_0000219,A-431,9606.0,,Homo sapiens,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,9.0,500.0
8.0,14926.0,,F,,,Expert,CHEMBL621158,1.0,,,5012.0,,H,BAO_0000219,A-431,,,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,9.0,500.0
1.0,15144.0,,F,,,Intermediate,CHEMBL621159,1.0,,,5013.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,80852.0,500.0
1.0,15144.0,,F,,,Intermediate,CHEMBL621160,1.0,,,5014.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,80852.0,500.0
1.0,5245.0,,F,,,Intermediate,CHEMBL621161,1.0,,,5015.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,80852.0,500.0
1.0,5245.0,,F,,,Intermediate,CHEMBL621162,1.0,,,5016.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,80852.0,500.0
1.0,5245.0,,F,,,Intermediate,CHEMBL621163,1.0,,,5017.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,80852.0,500.0
1.0,5245.0,,F,,,Intermediate,CHEMBL621164,1.0,,,5018.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,80852.0,500.0
1.0,5245.0,,F,,,Intermediate,CHEMBL621165,1.0,,,5019.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,80852.0,500.0
0.0,5922.0,,A,,,Autocuration,CHEMBL619159,1.0,,,5020.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Half-life period in cynomolgus monkey,,22224.0,
0.0,1116.0,1969.0,A,,,Autocuration,CHEMBL619160,1.0,Plasma,,5021.0,In vitro,U,BAO_0000366,,9527.0,,Cercopithecidae,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",,22224.0,
0.0,17853.0,,A,,,Autocuration,CHEMBL619161,1.0,,,5022.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Longer half-life in monkey (i.v.) at 0.5 mpk,,22224.0,
0.0,993.0,1969.0,A,,,Autocuration,CHEMBL619162,1.0,Plasma,,5023.0,,U,BAO_0000366,,9527.0,,Cercopithecidae,Plasma half life in monkey,,22224.0,
0.0,4514.0,1969.0,A,,,Autocuration,CHEMBL619163,1.0,Plasma,,5024.0,,U,BAO_0000366,,9527.0,,Cercopithecidae,Plasma half-life in rhesus monkey,,22224.0,
0.0,5334.0,1969.0,A,,,Autocuration,CHEMBL619164,1.0,Plasma,,5025.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,22224.0,
0.0,5334.0,1969.0,A,,,Autocuration,CHEMBL619320,1.0,Plasma,,5026.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,22224.0,
0.0,4578.0,,A,,,Autocuration,CHEMBL619321,1.0,,,5027.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Tested for half life upon iv administration to african green monkey,,22224.0,
0.0,2661.0,,A,,,Autocuration,CHEMBL873336,1.0,,,5028.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL619322,1.0,,,5029.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL619323,1.0,,,5030.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL619324,1.0,,,5031.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,The time for peak concentration value after oral administration in cynomolgus monkeys,,22224.0,
0.0,11271.0,,A,,,Autocuration,CHEMBL619325,1.0,,,5032.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,22224.0,
0.0,11271.0,,A,,,Autocuration,CHEMBL876411,1.0,,,5033.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,22224.0,
0.0,11271.0,,A,,,Autocuration,CHEMBL619326,1.0,,,5034.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,22224.0,
0.0,11271.0,,A,,,Autocuration,CHEMBL619327,1.0,,,5035.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,22224.0,
0.0,11271.0,,A,,,Autocuration,CHEMBL619328,1.0,,,5036.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,22224.0,
0.0,11271.0,,A,,,Autocuration,CHEMBL619329,1.0,,,5037.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,22224.0,
0.0,11271.0,,A,,,Autocuration,CHEMBL619330,1.0,,,5038.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,22224.0,
0.0,11271.0,,A,,,Autocuration,CHEMBL619331,1.0,,,5039.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,22224.0,
0.0,11271.0,,A,,,Autocuration,CHEMBL619332,1.0,,,5040.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,22224.0,
0.0,11271.0,,A,,,Autocuration,CHEMBL619333,1.0,,,5041.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,22224.0,
0.0,11271.0,,A,,,Autocuration,CHEMBL619334,1.0,,,5042.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,22224.0,
0.0,11271.0,,A,,,Autocuration,CHEMBL619335,1.0,,,5043.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,22224.0,
0.0,11271.0,,A,,,Autocuration,CHEMBL619336,1.0,,,5044.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,22224.0,
0.0,11271.0,,A,,,Autocuration,CHEMBL619337,1.0,,,5045.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,22224.0,
0.0,11271.0,,A,,,Autocuration,CHEMBL619338,1.0,,,5046.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,22224.0,
0.0,11271.0,,A,,,Autocuration,CHEMBL619339,1.0,,,5047.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,22224.0,
1.0,5809.0,,A,,,Intermediate,CHEMBL619340,1.0,,,5048.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Bioavailability in rat (cannulated) (dose 2 mg/kg),,50597.0,
1.0,17720.0,1969.0,A,,,Intermediate,CHEMBL873496,1.0,Plasma,,5049.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,50597.0,
1.0,3546.0,1969.0,A,,,Intermediate,CHEMBL619341,1.0,Plasma,,5050.0,,N,BAO_0000218,,10116.0,,Rattus norvegicus,AUC value in rat after IV administration at a dose of 10 mg/kg,,50597.0,
1.0,3546.0,1969.0,A,,,Intermediate,CHEMBL619342,1.0,Plasma,,5051.0,,N,BAO_0000218,,10116.0,,Rattus norvegicus,AUC value in rat after oral administration at a dose of 10 mg/kg,,50597.0,
1.0,3546.0,,A,,,Intermediate,CHEMBL619343,1.0,,,5052.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Cmax value in rat after oral administration at a dose of 10 mg/kg,,50597.0,
1.0,3546.0,,A,,,Intermediate,CHEMBL619344,1.0,,,5053.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,50597.0,
1.0,3546.0,,A,,,Intermediate,CHEMBL619345,1.0,,,5054.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Tmax value in rat after oral administration at a dose of 10 mg/kg,,50597.0,
1.0,3546.0,,A,,,Intermediate,CHEMBL619346,1.0,,,5055.0,,N,BAO_0000218,,10116.0,,Rattus norvegicus,Vc value in rat after IV administration at a dose of 10 mg/kg,,50597.0,
1.0,3546.0,,A,,,Intermediate,CHEMBL619347,1.0,,,5056.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Half life period in rat after IV administration at a dose of 10 mg/kg,,50597.0,
0.0,10625.0,,A,,,Autocuration,CHEMBL619348,1.0,,,5057.0,,U,BAO_0000019,,9557.0,,Papio hamadryas,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,22224.0,
0.0,10625.0,,A,,,Autocuration,CHEMBL619349,1.0,,,5058.0,,U,BAO_0000019,,9557.0,,Papio hamadryas,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,22224.0,
0.0,10625.0,,A,,,Autocuration,CHEMBL619350,1.0,,,5059.0,,U,BAO_0000019,,9557.0,,Papio hamadryas,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,22224.0,
0.0,10625.0,,A,,,Autocuration,CHEMBL619351,1.0,,,5060.0,,U,BAO_0000019,,9557.0,,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,22224.0,
0.0,10625.0,,A,,,Autocuration,CHEMBL875953,1.0,,,5061.0,,U,BAO_0000019,,9557.0,,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,22224.0,
0.0,10625.0,,A,,,Autocuration,CHEMBL621716,1.0,,,5062.0,,U,BAO_0000019,,9557.0,,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,22224.0,
0.0,10625.0,,A,,,Autocuration,CHEMBL621717,1.0,,,5063.0,,U,BAO_0000019,,9557.0,,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,22224.0,
0.0,10625.0,,A,,,Autocuration,CHEMBL621718,1.0,,,5064.0,,U,BAO_0000019,,9557.0,,Papio hamadryas,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,22224.0,
0.0,3510.0,,A,,,Autocuration,CHEMBL621719,1.0,,,5065.0,,U,BAO_0000019,,9615.0,,beagle,Area under curve after 1 mpk peroral administration to beagles,,22224.0,
0.0,3510.0,,A,,,Autocuration,CHEMBL621720,1.0,,,5066.0,,U,BAO_0000019,,9615.0,,beagle,Area under curve after 2 mpk peroral administration to beagles,,22224.0,
0.0,3510.0,,A,,,Autocuration,CHEMBL621721,1.0,,,5067.0,In vivo,U,BAO_0000218,,9615.0,,beagle,Cmax value after 1 mpk peroral administration to beagles,,22224.0,
0.0,7766.0,1088.0,A,,,Autocuration,CHEMBL621722,1.0,Urine,,5068.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,22224.0,
0.0,7766.0,1088.0,A,,,Autocuration,CHEMBL621723,1.0,Urine,,5069.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,22224.0,
0.0,7766.0,1088.0,A,,,Autocuration,CHEMBL621724,1.0,Urine,,5070.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,22224.0,
0.0,7766.0,1088.0,A,,,Autocuration,CHEMBL623443,1.0,Urine,,5071.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,22224.0,
0.0,7766.0,1088.0,A,,,Autocuration,CHEMBL623444,1.0,Urine,,5072.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,22224.0,
0.0,7766.0,1088.0,A,,,Autocuration,CHEMBL623445,1.0,Urine,,5073.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,22224.0,
0.0,7766.0,1088.0,A,,,Autocuration,CHEMBL623446,1.0,Urine,,5074.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,22224.0,
0.0,16643.0,2107.0,A,Microsomes,,Autocuration,CHEMBL623447,1.0,Liver,,5075.0,,U,BAO_0000251,,9606.0,,Homo sapiens,Metabolic stability observed at 30 min after administration in human liver microsomes,,22224.0,
0.0,6852.0,,A,,,Autocuration,CHEMBL623448,1.0,,,5076.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,22224.0,
0.0,6852.0,,A,,,Autocuration,CHEMBL623449,1.0,,,5077.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,22224.0,
0.0,6852.0,,A,,,Autocuration,CHEMBL623450,1.0,,,5078.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,22224.0,
0.0,6567.0,2107.0,A,Microsomes,,Autocuration,CHEMBL623451,1.0,Liver,,5079.0,,U,BAO_0000251,,9606.0,,Homo sapiens,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",,22224.0,
0.0,6570.0,,A,,,Autocuration,CHEMBL623452,1.0,,,5080.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Metabolic stability (% remaining at 30 mins) in human S9.,,22224.0,
0.0,6570.0,,A,,,Autocuration,CHEMBL623453,1.0,,,5081.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,22224.0,
0.0,5237.0,2107.0,A,Microsomes,,Autocuration,CHEMBL623454,1.0,Liver,,5082.0,,U,BAO_0000251,,9606.0,,Homo sapiens,Percent parent compound remaining after 20 min incubation with human liver microsomes,,22224.0,
0.0,5237.0,2107.0,A,Microsomes,,Autocuration,CHEMBL623455,1.0,Liver,,5083.0,,U,BAO_0000251,,9606.0,,Homo sapiens,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,,22224.0,
0.0,5237.0,2107.0,A,Microsomes,,Autocuration,CHEMBL624371,1.0,Liver,,5084.0,,U,BAO_0000251,,9606.0,,Homo sapiens,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,,22224.0,
0.0,5202.0,,A,,,Autocuration,CHEMBL624372,1.0,,,5085.0,,U,BAO_0000218,,9606.0,,Homo sapiens,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,22224.0,
0.0,5481.0,,A,,,Autocuration,CHEMBL624373,1.0,,,5086.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,22224.0,
0.0,5481.0,,A,,,Autocuration,CHEMBL624374,1.0,,,5087.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Percent remaining in human plasma after incubation for 60 min at 37 C.,,22224.0,
0.0,3956.0,,A,,,Autocuration,CHEMBL624556,1.0,,,5088.0,,U,BAO_0000019,,9606.0,,Homo sapiens,The percent remaining in human plasma after 30 min was determined,,22224.0,
0.0,5074.0,1969.0,A,,,Autocuration,CHEMBL624557,1.0,Plasma,,5089.0,,U,BAO_0000366,,9606.0,,Homo sapiens,Conversion rate of the prodrug in human plasma,,22224.0,
0.0,5074.0,1969.0,A,,,Autocuration,CHEMBL624558,1.0,Plasma,,5090.0,,U,BAO_0000366,,9606.0,,Homo sapiens,Conversion rate of the prodrug in human plasma; ND means no data,,22224.0,
0.0,4727.0,178.0,A,,,Autocuration,CHEMBL624559,1.0,Blood,,5091.0,,U,BAO_0000221,,9606.0,,Homo sapiens,Half life of compound was determined in human blood,,22224.0,
0.0,5965.0,,A,,,Autocuration,CHEMBL624560,1.0,,,5092.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Half life of compound was determined in man with once daily dosing,,22224.0,
0.0,5732.0,,A,Microsomes,,Autocuration,CHEMBL624561,1.0,,,5093.0,In vitro,U,BAO_0000251,,9606.0,,Homo sapiens,Half life in human microsomes,,22224.0,
0.0,5819.0,1969.0,A,,,Autocuration,CHEMBL624562,1.0,Plasma,,5094.0,,U,BAO_0000366,,9606.0,,Homo sapiens,Half life in human plasma,,22224.0,
0.0,5819.0,1969.0,A,,,Autocuration,CHEMBL624563,1.0,Plasma,,5095.0,,U,BAO_0000366,,9606.0,,Homo sapiens,Half life in human plasma; Not detected,,22224.0,
0.0,1916.0,,A,,,Autocuration,CHEMBL624564,1.0,,,5096.0,In vivo,U,BAO_0000218,,9606.0,,Homo sapiens,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,22224.0,
0.0,6597.0,2107.0,A,Microsomes,,Autocuration,CHEMBL624565,1.0,Liver,,5097.0,In vitro,U,BAO_0000251,,9606.0,,Homo sapiens,Half-life for oxidative metabolic stability was determined using rat liver microsomes,,22224.0,
0.0,5229.0,1969.0,A,,,Autocuration,CHEMBL875152,1.0,Plasma,,5098.0,,U,BAO_0000366,,9606.0,,Homo sapiens,Half-life in human plasma,,22224.0,
0.0,5229.0,1969.0,A,,,Autocuration,CHEMBL624566,1.0,Plasma,,5099.0,,U,BAO_0000366,,9606.0,,Homo sapiens,Half-life of the parent prodrug in plasma,,22224.0,
0.0,2192.0,1969.0,A,,,Autocuration,CHEMBL873805,1.0,Plasma,,5100.0,In vitro,U,BAO_0000366,,9606.0,,Homo sapiens,In vitro half life in human plasma was determined,,22224.0,
0.0,3032.0,2107.0,A,Microsomes,,Autocuration,CHEMBL624567,1.0,Liver,,5101.0,In vitro,U,BAO_0000251,,9606.0,,Homo sapiens,The compound was tested In Vitro for half life in human liver microsomes.,,22224.0,
0.0,1916.0,,A,,,Autocuration,CHEMBL624568,1.0,,,5102.0,In vivo,U,BAO_0000218,,9606.0,,Homo sapiens,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,22224.0,
0.0,17716.0,,A,,,Autocuration,CHEMBL624569,1.0,,,5103.0,In vivo,U,BAO_0000218,,9606.0,,Homo sapiens,Observed volume of distribution,,22224.0,
0.0,15778.0,,A,,,Autocuration,CHEMBL624570,1.0,,,5104.0,In vivo,U,BAO_0000218,,9606.0,,Homo sapiens,Oral bioavailability in human,,22224.0,
0.0,17313.0,,A,,,Autocuration,CHEMBL624571,1.0,,,5105.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Tested for human plasma protein binding of the compound,,22224.0,
0.0,4231.0,,A,,,Autocuration,CHEMBL624572,1.0,,,5106.0,,U,BAO_0000019,,9606.0,,Homo sapiens,"First order rate constant, k was determined in human plasma",,22224.0,
0.0,4755.0,,A,,,Autocuration,CHEMBL624573,1.0,,,5107.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Observed rate constant in 80% human plasma at 37 degree Centigrade,,22224.0,
0.0,4755.0,,A,,,Autocuration,CHEMBL875153,1.0,,,5108.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Observed rate constant in 80% human plasma at 37 degree Centigrade,,22224.0,
0.0,16907.0,2107.0,A,Microsomes,,Autocuration,CHEMBL624574,1.0,Liver,,5109.0,,U,BAO_0000251,,9606.0,,Homo sapiens,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,22224.0,
0.0,10839.0,,A,,,Autocuration,CHEMBL624575,1.0,,,5110.0,,U,BAO_0000019,,9606.0,,Homo sapiens,The compound was tested for the plasma binding in human,,22224.0,
0.0,10839.0,,A,,,Autocuration,CHEMBL624576,1.0,,,5111.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Plasma protein binding (human),,22224.0,
0.0,3199.0,2107.0,A,Microsomes,,Autocuration,CHEMBL624577,1.0,Liver,,5112.0,In vitro,U,BAO_0000251,,9606.0,,Homo sapiens,Compound was evaluated for half-life in human liver microsomes,,22224.0,
0.0,1345.0,178.0,A,,,Autocuration,CHEMBL624578,1.0,Blood,,5113.0,In vitro,U,BAO_0000221,,9606.0,,Homo sapiens,Half life measured in vitro for its stability in human blood,,22224.0,
0.0,4297.0,1977.0,A,,,Autocuration,CHEMBL622796,1.0,Serum,,5114.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Half life in human serum,,22224.0,
0.0,4297.0,1977.0,A,,,Autocuration,CHEMBL622797,1.0,Serum,,5115.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Half life in human serum; ND=not determined,,22224.0,
0.0,4297.0,,A,,,Autocuration,CHEMBL622798,1.0,,,5116.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Half life were determined in CEM-SS cell extract in decomposition step 1,,22224.0,
0.0,4297.0,,A,,,Autocuration,CHEMBL622799,1.0,,,5117.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Half life were determined in CEM-SS cell extract in decomposition step 2,,22224.0,
0.0,4231.0,1969.0,A,,,Autocuration,CHEMBL622800,1.0,Plasma,,5118.0,,U,BAO_0000366,,9606.0,,Homo sapiens,Half life of the in human plasma,,22224.0,
0.0,5633.0,,A,S9,,Autocuration,CHEMBL622801,1.0,,,5119.0,In vitro,U,BAO_0000220,,9606.0,,Homo sapiens,Half life period in human hepatic S9 fraction was determined,,22224.0,
0.0,5633.0,2107.0,A,Microsomes,,Autocuration,CHEMBL622802,1.0,Liver,,5120.0,In vitro,U,BAO_0000251,,9606.0,,Homo sapiens,Half life period in human liver microsome was determined,,22224.0,
0.0,17791.0,,A,,,Autocuration,CHEMBL622803,1.0,,,5121.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Half life period was determined; 6-7,,22224.0,
0.0,17791.0,,A,,,Autocuration,CHEMBL875154,1.0,,,5122.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Half life period was evaluated in human,,22224.0,
0.0,3160.0,1969.0,A,,,Autocuration,CHEMBL622804,1.0,Plasma,,5123.0,,U,BAO_0000366,,9606.0,,Homo sapiens,Half life time in human plasma,,22224.0,
1.0,16438.0,955.0,A,,,Intermediate,CHEMBL622805,1.0,Brain,,5124.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,50594.0,
1.0,16438.0,948.0,A,,,Intermediate,CHEMBL622611,1.0,Heart,,5125.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,50594.0,
1.0,16438.0,948.0,A,,,Intermediate,CHEMBL622612,1.0,Heart,,5126.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,50594.0,
1.0,16438.0,2113.0,A,,,Intermediate,CHEMBL875160,1.0,Kidney,,5127.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,50594.0,
1.0,16438.0,2113.0,A,,,Intermediate,CHEMBL622613,1.0,Kidney,,5128.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,50594.0,
1.0,16438.0,2113.0,A,,,Intermediate,CHEMBL622614,1.0,Kidney,,5129.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,50594.0,
1.0,16438.0,2107.0,A,,,Intermediate,CHEMBL622615,1.0,Liver,,5130.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,50594.0,
1.0,16438.0,2107.0,A,,,Intermediate,CHEMBL622616,1.0,Liver,,5131.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,,50594.0,
1.0,16438.0,2107.0,A,,,Intermediate,CHEMBL622617,1.0,Liver,,5132.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,50594.0,
1.0,16438.0,2106.0,A,,,Intermediate,CHEMBL622618,1.0,Spleen,,5133.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,,50594.0,
1.0,16438.0,2106.0,A,,,Intermediate,CHEMBL622619,1.0,Spleen,,5134.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,50594.0,
1.0,16438.0,2106.0,A,,,Intermediate,CHEMBL622620,1.0,Spleen,,5135.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,50594.0,
1.0,16438.0,955.0,A,,,Intermediate,CHEMBL622621,1.0,Brain,,5136.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,50594.0,
1.0,16438.0,178.0,A,,,Intermediate,CHEMBL622622,1.0,Blood,,5137.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of compound (oxidized form) in blood tissue,,50594.0,
1.0,16438.0,178.0,A,,,Intermediate,CHEMBL622623,1.0,Blood,,5138.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,50594.0,
1.0,16438.0,178.0,A,,,Intermediate,CHEMBL622624,1.0,Blood,,5139.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,50594.0,
1.0,16438.0,178.0,A,,,Intermediate,CHEMBL622625,1.0,Blood,,5140.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,50594.0,
1.0,16438.0,178.0,A,,,Intermediate,CHEMBL622626,1.0,Blood,,5141.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,50594.0,
1.0,16438.0,178.0,A,,,Intermediate,CHEMBL622627,1.0,Blood,,5142.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,50594.0,
1.0,16438.0,955.0,A,,,Intermediate,CHEMBL622628,1.0,Brain,,5143.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of compound (oxidized form) in brain tissue of mice,,50594.0,
1.0,16438.0,955.0,A,,,Intermediate,CHEMBL622629,1.0,Brain,,5144.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,50594.0,
1.0,16438.0,955.0,A,,,Intermediate,CHEMBL622630,1.0,Brain,,5145.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,50594.0,
1.0,16438.0,955.0,A,,,Intermediate,CHEMBL622631,1.0,Brain,,5146.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,50594.0,
1.0,16438.0,955.0,A,,,Intermediate,CHEMBL622632,1.0,Brain,,5147.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,50594.0,
1.0,16438.0,955.0,A,,,Intermediate,CHEMBL622633,1.0,Brain,,5148.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",,50594.0,
1.0,16438.0,948.0,A,,,Intermediate,CHEMBL622634,1.0,Heart,,5149.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of compound (oxidized form) in heart tissue of mice,,50594.0,
1.0,16438.0,948.0,A,,,Intermediate,CHEMBL622635,1.0,Heart,,5150.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,50594.0,
1.0,16438.0,948.0,A,,,Intermediate,CHEMBL875161,1.0,Heart,,5151.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,50594.0,
1.0,16438.0,948.0,A,,,Intermediate,CHEMBL622636,1.0,Heart,,5152.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,50594.0,
1.0,16438.0,948.0,A,,,Intermediate,CHEMBL623335,1.0,Heart,,5153.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,50594.0,
1.0,16438.0,948.0,A,,,Intermediate,CHEMBL623336,1.0,Heart,,5154.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,50594.0,
1.0,16438.0,2113.0,A,,,Intermediate,CHEMBL623337,1.0,Kidney,,5155.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,50594.0,
1.0,16438.0,2113.0,A,,,Intermediate,CHEMBL623338,1.0,Kidney,,5156.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,50594.0,
1.0,16438.0,2113.0,A,,,Intermediate,CHEMBL623339,1.0,Kidney,,5157.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,50594.0,
1.0,16438.0,2113.0,A,,,Intermediate,CHEMBL623524,1.0,Kidney,,5158.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,50594.0,
1.0,16438.0,2113.0,A,,,Intermediate,CHEMBL623525,1.0,Kidney,,5159.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,50594.0,
1.0,16438.0,2107.0,A,,,Intermediate,CHEMBL623526,1.0,Liver,,5160.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of compound (oxidized form) in liver tissue,,50594.0,
1.0,16438.0,2107.0,A,,,Intermediate,CHEMBL623527,1.0,Liver,,5161.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,50594.0,
1.0,16438.0,2107.0,A,,,Intermediate,CHEMBL623528,1.0,Liver,,5162.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,50594.0,
1.0,5245.0,,F,,,Intermediate,CHEMBL624615,1.0,,,5163.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,80852.0,500.0
1.0,5245.0,,F,,,Intermediate,CHEMBL621672,1.0,,,5164.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,80852.0,500.0
1.0,16289.0,,F,,,Expert,CHEMBL621673,1.0,,,5165.0,,N,BAO_0000218,A-431,,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,80852.0,500.0
1.0,16289.0,,F,,,Expert,CHEMBL621674,1.0,,,5166.0,,N,BAO_0000218,A-431,,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,80852.0,500.0
9.0,16093.0,,F,,,Expert,CHEMBL884002,1.0,,,5167.0,,D,BAO_0000219,A-431,9606.0,,Homo sapiens,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,9.0,500.0
1.0,16825.0,,F,,,Intermediate,CHEMBL621850,1.0,,,5168.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,80852.0,500.0
1.0,4848.0,,F,,,Intermediate,CHEMBL621851,1.0,,,5169.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,80852.0,500.0
9.0,14827.0,,F,,,Expert,CHEMBL621852,1.0,,,5170.0,,D,BAO_0000219,A-431,9606.0,,Homo sapiens,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,9.0,500.0
9.0,14827.0,,F,,,Expert,CHEMBL621853,1.0,,,5171.0,,D,BAO_0000219,A-431,9606.0,,Homo sapiens,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,9.0,500.0
1.0,16289.0,,F,,,Expert,CHEMBL621854,1.0,,,5172.0,,N,BAO_0000218,A-431,,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,80852.0,500.0
1.0,16289.0,,F,,,Expert,CHEMBL621855,1.0,,,5173.0,,N,BAO_0000218,A-431,,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,80852.0,500.0
1.0,16289.0,,F,,,Expert,CHEMBL623724,1.0,,,5174.0,,N,BAO_0000218,A-431,,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,80852.0,500.0
1.0,16289.0,,F,,,Expert,CHEMBL623725,1.0,,,5175.0,,N,BAO_0000218,A-431,,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,80852.0,500.0
1.0,16289.0,,F,,,Expert,CHEMBL623726,1.0,,,5176.0,,N,BAO_0000218,A-431,,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,80852.0,500.0
9.0,16289.0,,F,,,Expert,CHEMBL623727,1.0,,,5177.0,,D,BAO_0000219,A-431,9606.0,,Homo sapiens,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,9.0,500.0
8.0,16289.0,,F,,,Expert,CHEMBL623728,1.0,,,5178.0,,H,BAO_0000219,A-431,,,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,9.0,500.0
1.0,16289.0,,F,,,Expert,CHEMBL623729,1.0,,,5179.0,,N,BAO_0000218,A-431,,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,80852.0,500.0
1.0,16289.0,,F,,,Expert,CHEMBL623730,1.0,,,5180.0,,N,BAO_0000218,A-431,,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,80852.0,500.0
1.0,16289.0,,F,,,Expert,CHEMBL623731,1.0,,,5181.0,,N,BAO_0000218,A-431,,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,80852.0,500.0
1.0,14555.0,,F,,,Expert,CHEMBL623732,1.0,,,5182.0,,N,BAO_0000218,A-431,10090.0,,Mus musculus,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,80852.0,500.0
1.0,14555.0,,F,,,Expert,CHEMBL623733,1.0,,,5183.0,,N,BAO_0000218,A-431,10090.0,,Mus musculus,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,80852.0,500.0
1.0,14555.0,,F,,,Expert,CHEMBL623734,1.0,,,5184.0,,N,BAO_0000218,A-431,10090.0,,Mus musculus,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,80852.0,500.0
1.0,14555.0,,F,,,Expert,CHEMBL623735,1.0,,,5185.0,,N,BAO_0000218,A-431,10090.0,,Mus musculus,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,80852.0,500.0
1.0,1937.0,,F,,,Expert,CHEMBL623736,1.0,,,5186.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,80852.0,500.0
1.0,13739.0,,F,,,Intermediate,CHEMBL623737,1.0,,,5187.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,80852.0,500.0
1.0,3558.0,,F,,,Intermediate,CHEMBL623738,1.0,,,5188.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,80852.0,500.0
1.0,3558.0,,F,,,Intermediate,CHEMBL875168,1.0,,,5189.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Dose giving a 50% decrease in the living cell number (A437 cells),,80852.0,500.0
1.0,17686.0,,F,,,Expert,CHEMBL623739,1.0,,,5190.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro inhibitory concentration against proliferation of A459 cell line.,,80682.0,646.0
1.0,5305.0,,F,,,Intermediate,CHEMBL623740,1.0,,,5191.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,80682.0,646.0
1.0,3614.0,,F,,,Intermediate,CHEMBL624424,1.0,,,5192.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,80682.0,646.0
1.0,17229.0,,F,,,Intermediate,CHEMBL624425,1.0,,,5193.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,In vitro antitumor activity against renal A498 tumor cell lines,,80021.0,624.0
1.0,15935.0,,F,,,Intermediate,CHEMBL624426,1.0,,,5194.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,80021.0,624.0
1.0,15935.0,,F,,,Intermediate,CHEMBL624427,1.0,,,5195.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,80021.0,624.0
1.0,15560.0,,F,,,Intermediate,CHEMBL624428,1.0,,,5196.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,80021.0,624.0
1.0,13891.0,,F,,,Intermediate,CHEMBL624429,1.0,,,5197.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,80021.0,624.0
1.0,13891.0,,F,,,Intermediate,CHEMBL624620,1.0,,,5198.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,80021.0,624.0
1.0,13788.0,,F,,,Intermediate,CHEMBL624621,1.0,,,5199.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Cytotoxicity on kidney carcinoma (A-498) cell line,,80021.0,624.0
1.0,15403.0,,F,,,Intermediate,CHEMBL624622,1.0,,,5200.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Compound was evaluated against Human cell line renal A498,,80021.0,624.0
1.0,1009.0,,F,,,Intermediate,CHEMBL624623,1.0,,,5201.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Compound was tested for inhibition of A498 human renal cancer cell line,,80021.0,624.0
1.0,1043.0,,F,,,Intermediate,CHEMBL874365,1.0,,,5202.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Growth inhibitory activity against A498 human cancer cell line,,80021.0,624.0
1.0,5858.0,,F,,,Intermediate,CHEMBL624624,1.0,,,5203.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,In vitro antitumor activity against human renal A498 cell line,,80021.0,624.0
1.0,5958.0,,F,,,Intermediate,CHEMBL624625,1.0,,,5204.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,In vitro cytotoxic activity against renal (A498) cell line,,80021.0,624.0
1.0,5506.0,,F,,,Intermediate,CHEMBL624626,1.0,,,5205.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,In vitro cytotoxic activity against human renal cancer (A498) cell line,,80021.0,624.0
1.0,12781.0,,F,,,Intermediate,CHEMBL624627,1.0,,,5206.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Tested for cytostatic activity against renal A498 cell line,,80021.0,624.0
1.0,14399.0,,F,,,Intermediate,CHEMBL883157,1.0,,,5207.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,80021.0,624.0
1.0,5958.0,,F,,,Expert,CHEMBL624628,1.0,,,5208.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,80021.0,624.0
0.0,3510.0,,A,,,Autocuration,CHEMBL624629,1.0,,,5209.0,In vivo,U,BAO_0000218,,9615.0,,beagle,Cmax value after 2 mpk peroral administration to beagles,,22224.0,
0.0,3510.0,,A,,,Autocuration,CHEMBL623551,1.0,,,5210.0,In vivo,U,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability,beagle,22224.0,
0.0,3510.0,,A,,,Autocuration,CHEMBL623552,1.0,,,5211.0,In vivo,U,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability after 1 mpk peroral administration to beagles,beagle,22224.0,
0.0,3510.0,,A,,,Autocuration,CHEMBL623553,1.0,,,5212.0,In vivo,U,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability after 2 mpk peroral administration to beagles,beagle,22224.0,
0.0,3085.0,,A,,,Autocuration,CHEMBL623554,1.0,,,5213.0,,U,BAO_0000019,,9913.0,,Bos taurus,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,22224.0,
0.0,3085.0,,A,,,Autocuration,CHEMBL623555,1.0,,,5214.0,,U,BAO_0000019,,9913.0,,Bos taurus,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,22224.0,
0.0,3085.0,,A,,,Autocuration,CHEMBL623556,1.0,,,5215.0,,U,BAO_0000019,,9913.0,,Bos taurus,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,22224.0,
0.0,9372.0,,A,,,Autocuration,CHEMBL623557,1.0,,,5216.0,,U,BAO_0000019,,9913.0,,Bos taurus,Solubility against bovine alpha-chymotrypsin,,22224.0,
0.0,3085.0,,A,,,Autocuration,CHEMBL623558,1.0,,,5217.0,,U,BAO_0000019,,9913.0,,Bos taurus,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,22224.0,
0.0,3085.0,,A,,,Autocuration,CHEMBL623559,1.0,,,5218.0,,U,BAO_0000019,,9913.0,,Bos taurus,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,22224.0,
0.0,1469.0,2106.0,A,,,Autocuration,CHEMBL623560,1.0,Spleen,,5219.0,,U,BAO_0000221,,9913.0,,Bos taurus,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,22224.0,
0.0,4297.0,,A,,,Autocuration,CHEMBL623561,1.0,,,5220.0,,U,BAO_0000019,,9913.0,,Bos taurus,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,22224.0,
0.0,4297.0,,A,,,Autocuration,CHEMBL623562,1.0,,,5221.0,,U,BAO_0000019,,9913.0,,Bos taurus,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,22224.0,
0.0,17585.0,,A,,,Autocuration,CHEMBL623563,1.0,,,5222.0,,U,BAO_0000019,,9913.0,,Bos taurus,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,22224.0,
0.0,1336.0,2106.0,A,,,Autocuration,CHEMBL623564,1.0,Spleen,,5223.0,,U,BAO_0000221,,9913.0,,Bos taurus,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,22224.0,
0.0,3085.0,,A,,,Autocuration,CHEMBL873806,1.0,,,5224.0,,U,BAO_0000019,,9913.0,,Bos taurus,Half life in presence of 2 mg/mL BSA at pH 8.8,,22224.0,
0.0,2857.0,,A,,,Autocuration,CHEMBL623565,1.0,,,5225.0,,U,BAO_0000019,,9913.0,,Bos taurus,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,22224.0,
0.0,2857.0,,A,,,Autocuration,CHEMBL623566,1.0,,,5226.0,,U,BAO_0000019,,9913.0,,Bos taurus,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,22224.0,
0.0,2857.0,,A,,,Autocuration,CHEMBL623567,1.0,,,5227.0,,U,BAO_0000019,,9913.0,,Bos taurus,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,22224.0,
0.0,1540.0,,A,,,Autocuration,CHEMBL623568,1.0,,,5228.0,,U,BAO_0000019,,9913.0,,Bos taurus,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,22224.0,
1.0,6316.0,1969.0,A,,,Intermediate,CHEMBL623569,1.0,Plasma,,5229.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,50588.0,
1.0,17594.0,1969.0,A,,,Intermediate,CHEMBL623570,1.0,Plasma,,5230.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,AUC after administration at 100 mg/kg/day in dogs,,50588.0,
1.0,4953.0,1969.0,A,,,Intermediate,CHEMBL624254,1.0,Plasma,,5231.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,50588.0,
1.0,16907.0,1969.0,A,,,Intermediate,CHEMBL624255,1.0,Plasma,,5232.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,AUC value after 15 mg/kg iv dose in Dogs,,50588.0,
1.0,16907.0,1969.0,A,,,Intermediate,CHEMBL624256,1.0,Plasma,,5233.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,AUC value after 30 mg/kg po dose in Dogs,,50588.0,
1.0,2959.0,1969.0,A,,,Intermediate,CHEMBL624257,1.0,Plasma,,5234.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,AUC value after administration of 4 mg/Kg oral dose in dog,,50588.0,
1.0,17594.0,1969.0,A,,,Intermediate,CHEMBL624258,1.0,Plasma,,5235.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,50588.0,
1.0,5356.0,,A,,,Intermediate,CHEMBL875277,1.0,,,5236.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,50588.0,
1.0,16807.0,,A,,,Intermediate,CHEMBL622667,1.0,,,5237.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,50588.0,
1.0,4527.0,,A,,,Intermediate,CHEMBL622668,1.0,,,5238.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,50588.0,
1.0,4527.0,,A,,,Intermediate,CHEMBL622669,1.0,,,5239.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,50588.0,
1.0,15660.0,,A,,,Intermediate,CHEMBL622670,1.0,,,5240.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,50588.0,
1.0,15660.0,,A,,,Intermediate,CHEMBL622671,1.0,,,5241.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve determined in dogs after oral administration of 10 mg/kg,,50588.0,
1.0,5802.0,,A,,,Intermediate,CHEMBL622672,1.0,,,5242.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,50588.0,
1.0,3598.0,,A,,,Expert,CHEMBL622673,1.0,,,5243.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,50588.0,
1.0,3598.0,,A,,,Expert,CHEMBL622674,1.0,,,5244.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,50588.0,
1.0,5944.0,,A,,,Intermediate,CHEMBL622675,1.0,,,5245.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,50588.0,
1.0,5944.0,,A,,,Intermediate,CHEMBL622676,1.0,,,5246.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,50588.0,
1.0,5944.0,,A,,,Intermediate,CHEMBL622677,1.0,,,5247.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,50588.0,
1.0,5944.0,,A,,,Intermediate,CHEMBL622678,1.0,,,5248.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,50588.0,
1.0,4186.0,,A,,,Intermediate,CHEMBL622679,1.0,,,5249.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,50588.0,
1.0,5007.0,,A,,,Intermediate,CHEMBL622680,1.0,,,5250.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,50588.0,
1.0,5668.0,,A,,,Intermediate,CHEMBL622681,1.0,,,5251.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve was determine after peroral administration at 10 mpk in dog,,50588.0,
1.0,5668.0,,A,,,Intermediate,CHEMBL875278,1.0,,,5252.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve was determine after peroral administration at 5 mpk in dog,,50588.0,
1.0,5006.0,,A,,,Intermediate,CHEMBL622682,1.0,,,5253.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve was determined,,50588.0,
1.0,5006.0,,A,,,Intermediate,CHEMBL622683,1.0,,,5254.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve in dogs,,50588.0,
1.0,3771.0,,A,,,Intermediate,CHEMBL622684,1.0,,,5255.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve in dogs at 10 mg/kg dose fo oral administration,,50588.0,
1.0,3771.0,,A,,,Intermediate,CHEMBL622685,1.0,,,5256.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,50588.0,
1.0,3771.0,,A,,,Intermediate,CHEMBL622686,1.0,,,5257.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,50588.0,
1.0,1916.0,,A,,,Intermediate,CHEMBL618344,1.0,,,5258.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,50588.0,
1.0,5302.0,,A,,,Intermediate,CHEMBL875582,1.0,,,5259.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve value in dog at a dose of 5 mg/kg,,50588.0,
1.0,5600.0,,A,,,Intermediate,CHEMBL618345,1.0,,,5260.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve was determined after 0.1 mg/kg iv administration in dog,,50588.0,
1.0,5600.0,,A,,,Intermediate,CHEMBL618346,1.0,,,5261.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve was determined after 0.3 mg/kg po administration in dog,,50588.0,
1.0,17764.0,,A,,,Intermediate,CHEMBL618347,1.0,,,5262.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,50588.0,
1.0,4368.0,,A,,,Intermediate,CHEMBL618348,1.0,,,5263.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,50588.0,
0.0,5318.0,,A,,,Autocuration,CHEMBL618349,1.0,,,5264.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,22224.0,
0.0,5318.0,,A,,,Autocuration,CHEMBL618350,1.0,,,5265.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,22224.0,
0.0,5318.0,,A,,,Autocuration,CHEMBL618351,1.0,,,5266.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,22224.0,
0.0,5318.0,,A,,,Autocuration,CHEMBL618352,1.0,,,5267.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,22224.0,
0.0,14518.0,178.0,A,,,Autocuration,CHEMBL873494,1.0,Blood,,5268.0,,U,BAO_0000221,,9606.0,,Homo sapiens,Time taken to reduce 50% of the concentration of compound in blood plasma,,22224.0,
0.0,2209.0,1969.0,A,,,Autocuration,CHEMBL618353,1.0,Plasma,,5269.0,,U,BAO_0000366,,9606.0,,Homo sapiens,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,22224.0,
0.0,6787.0,1969.0,A,,,Autocuration,CHEMBL618354,1.0,Plasma,,5270.0,,U,BAO_0000366,,9606.0,,Homo sapiens,Half life in human plasma,,22224.0,
0.0,4898.0,1969.0,A,,,Autocuration,CHEMBL875583,1.0,Plasma,,5271.0,,U,BAO_0000366,,9606.0,,Homo sapiens,Half life in human plasma was reported,,22224.0,
0.0,6072.0,1977.0,A,,,Autocuration,CHEMBL618355,1.0,Serum,,5272.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Half life in human serum,,22224.0,
0.0,16907.0,1969.0,A,,,Autocuration,CHEMBL618356,1.0,Plasma,,5273.0,,U,BAO_0000366,,9606.0,,Homo sapiens,Half life upon exposure to human plasma,,22224.0,
0.0,5656.0,,A,Microsomes,,Autocuration,CHEMBL618357,1.0,,,5274.0,In vitro,U,BAO_0000251,,9606.0,,Homo sapiens,t1/2 in human microsomes,,22224.0,
0.0,4755.0,1969.0,A,,,Autocuration,CHEMBL618358,1.0,Plasma,,5275.0,,U,BAO_0000366,,9606.0,,Homo sapiens,Half life period in 80% human plasma at 37 degree Centigrade,,22224.0,
0.0,17503.0,14.0,A,,,Autocuration,CHEMBL618359,1.0,Zone of skin,,5276.0,,U,BAO_0000221,,9606.0,,Homo sapiens,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,22224.0,
0.0,12357.0,1969.0,A,,,Autocuration,CHEMBL618360,1.0,Plasma,,5277.0,In vitro,U,BAO_0000366,,9606.0,,Homo sapiens,Half-life measured in in vitro Cathepsin B assay in human plasma,,22224.0,
0.0,3076.0,,A,,,Autocuration,CHEMBL618361,1.0,,,5278.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,22224.0,
0.0,6410.0,2107.0,A,Microsomes,,Autocuration,CHEMBL618362,1.0,Liver,,5279.0,In vitro,U,BAO_0000251,,9606.0,,Homo sapiens,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,,22224.0,
0.0,3741.0,1969.0,A,,,Autocuration,CHEMBL618363,1.0,Plasma,,5280.0,,U,BAO_0000366,,9606.0,,Homo sapiens,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,22224.0,
0.0,3741.0,1969.0,A,,,Autocuration,CHEMBL618364,1.0,Plasma,,5281.0,,U,BAO_0000366,,9606.0,,Homo sapiens,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,22224.0,
0.0,3741.0,1969.0,A,,,Autocuration,CHEMBL875584,1.0,Plasma,,5282.0,,U,BAO_0000366,,9606.0,,Homo sapiens,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,22224.0,
0.0,1540.0,,A,,,Autocuration,CHEMBL618365,1.0,,,5283.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Half-life in the CEM cell extracts,,22224.0,
0.0,2905.0,1969.0,A,,,Autocuration,CHEMBL873495,1.0,Plasma,,5284.0,,U,BAO_0000366,,9606.0,,Homo sapiens,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,22224.0,
0.0,2905.0,1969.0,A,,,Autocuration,CHEMBL618366,1.0,Plasma,,5285.0,,U,BAO_0000366,,9606.0,,Homo sapiens,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,22224.0,
0.0,5523.0,,A,,,Autocuration,CHEMBL618367,1.0,,,5286.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Half-life was determined,,22224.0,
0.0,1499.0,178.0,A,,,Autocuration,CHEMBL618368,1.0,Blood,,5287.0,,U,BAO_0000221,,9606.0,,Homo sapiens,Half-life (human blood stability),,22224.0,
0.0,1499.0,178.0,A,,,Autocuration,CHEMBL618369,1.0,Blood,,5288.0,,U,BAO_0000221,,9606.0,,Homo sapiens,Half-life (human blood stability); no data,,22224.0,
0.0,17065.0,1969.0,A,,,Autocuration,CHEMBL618370,1.0,Plasma,,5289.0,,U,BAO_0000366,,9606.0,,Homo sapiens,Half-life in human plasma,,22224.0,
0.0,6861.0,,A,,,Autocuration,CHEMBL618371,1.0,,,5290.0,,U,BAO_0000019,,9606.0,,Homo sapiens,CYP3A4 metabolism half-life (t1/2),,22224.0,
0.0,1499.0,178.0,A,,,Autocuration,CHEMBL618372,1.0,Blood,,5291.0,,U,BAO_0000221,,9606.0,,Homo sapiens,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,22224.0,
0.0,530.0,1969.0,A,,,Autocuration,CHEMBL618373,1.0,Plasma,,5292.0,In vitro,U,BAO_0000366,,9606.0,,Homo sapiens,In vitro half life in human plasma,,22224.0,
0.0,1116.0,1969.0,A,,,Autocuration,CHEMBL618374,1.0,Plasma,,5293.0,In vitro,U,BAO_0000366,,9606.0,,Homo sapiens,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",,22224.0,
0.0,6695.0,1969.0,A,,,Autocuration,CHEMBL618375,1.0,Plasma,,5294.0,In vitro,U,BAO_0000366,,9606.0,,Homo sapiens,In vitro hydrolysis in human plasma,,22224.0,
0.0,6695.0,1969.0,A,,,Autocuration,CHEMBL618376,1.0,Plasma,,5295.0,In vitro,U,BAO_0000366,,9606.0,,Homo sapiens,In vitro hydrolysis in human plasma; no data,,22224.0,
0.0,10.0,2107.0,A,Microsomes,,Autocuration,CHEMBL618377,1.0,Liver,,5296.0,In vitro,U,BAO_0000251,,9606.0,,Homo sapiens,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,,22224.0,
0.0,993.0,1969.0,A,,,Autocuration,CHEMBL618378,1.0,Plasma,,5297.0,,U,BAO_0000366,,9606.0,,Homo sapiens,Plasma half life in human,,22224.0,
0.0,15429.0,1969.0,A,,,Autocuration,CHEMBL618379,1.0,Plasma,,5298.0,,U,BAO_0000366,,9606.0,,Homo sapiens,Stability after incubation with human plasma (at 37 degree C),,22224.0,
0.0,1675.0,1969.0,A,,,Autocuration,CHEMBL618380,1.0,Plasma,,5299.0,,U,BAO_0000366,,9606.0,,Homo sapiens,T1/2 was evaluated in human plasma,,22224.0,
0.0,2209.0,1969.0,A,,,Autocuration,CHEMBL618381,1.0,Plasma,,5300.0,,U,BAO_0000366,,9606.0,,Homo sapiens,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,22224.0,
0.0,2209.0,1969.0,A,,,Autocuration,CHEMBL618382,1.0,Plasma,,5301.0,,U,BAO_0000366,,9606.0,,Homo sapiens,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,22224.0,
0.0,5318.0,,A,,,Autocuration,CHEMBL618383,1.0,,,5302.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,22224.0,
0.0,2412.0,,A,,,Autocuration,CHEMBL618384,1.0,,,5303.0,In vitro,U,BAO_0000019,,9606.0,,Homo sapiens,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,22224.0,
0.0,2412.0,,A,,,Autocuration,CHEMBL618385,1.0,,,5304.0,In vitro,U,BAO_0000019,,9606.0,,Homo sapiens,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,22224.0,
0.0,2906.0,1969.0,A,,,Autocuration,CHEMBL619099,1.0,Plasma,,5305.0,,U,BAO_0000366,,9606.0,,Homo sapiens,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,22224.0,
0.0,2906.0,1969.0,A,,,Autocuration,CHEMBL619100,1.0,Plasma,,5306.0,,U,BAO_0000366,,9606.0,,Homo sapiens,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,22224.0,
0.0,5495.0,,A,,,Autocuration,CHEMBL619101,1.0,,,5307.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Time taken for 50% to be consumed by serum PON1 was determined,,22224.0,
0.0,5495.0,,A,,,Autocuration,CHEMBL619102,1.0,,,5308.0,,U,BAO_0000019,,9606.0,,Homo sapiens,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,22224.0,
0.0,4397.0,2107.0,A,Microsomes,,Autocuration,CHEMBL619103,1.0,Liver,,5309.0,,U,BAO_0000251,,9606.0,,Homo sapiens,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,22224.0,
0.0,2413.0,,A,,,Autocuration,CHEMBL619268,1.0,,,5310.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,22224.0,
0.0,2413.0,,A,,,Autocuration,CHEMBL619269,1.0,,,5311.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,22224.0,
0.0,2413.0,,A,,,Autocuration,CHEMBL619270,1.0,,,5312.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,22224.0,
0.0,2413.0,,A,,,Autocuration,CHEMBL619271,1.0,,,5313.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,22224.0,
0.0,2413.0,,A,,,Autocuration,CHEMBL875585,1.0,,,5314.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,22224.0,
0.0,2413.0,,A,,,Autocuration,CHEMBL619272,1.0,,,5315.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,22224.0,
1.0,6058.0,,F,,,Intermediate,CHEMBL619273,1.0,,,5316.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Compound tested for growth inhibition of renal cancer cell line 786-0,,80640.0,391.0
1.0,17708.0,,F,,,Intermediate,CHEMBL619274,1.0,,,5317.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,80640.0,391.0
1.0,14017.0,,F,,,Expert,CHEMBL619275,1.0,,,5318.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,80640.0,391.0
1.0,16818.0,,F,,,Intermediate,CHEMBL619276,1.0,,,5319.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,80640.0,391.0
1.0,16818.0,,F,,,Intermediate,CHEMBL619277,1.0,,,5320.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,80640.0,391.0
1.0,16818.0,,F,,,Intermediate,CHEMBL619278,1.0,,,5321.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,80640.0,391.0
1.0,11970.0,,F,,,Intermediate,CHEMBL619279,1.0,,,5322.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,80640.0,391.0
1.0,12400.0,,F,,,Intermediate,CHEMBL858458,1.0,,,5323.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,80640.0,391.0
1.0,12888.0,,F,,,Expert,CHEMBL619280,1.0,,,5324.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Cytotoxic effect on renal cancer line 786-0,,80640.0,391.0
1.0,15300.0,,F,,,Intermediate,CHEMBL619281,1.0,,,5325.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,80640.0,391.0
1.0,14769.0,,F,,,Intermediate,CHEMBL619282,1.0,,,5326.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,80640.0,391.0
1.0,15895.0,,F,,,Intermediate,CHEMBL619283,1.0,,,5327.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,80640.0,391.0
1.0,17376.0,,F,,,Intermediate,CHEMBL619284,1.0,,,5328.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,80640.0,391.0
1.0,14882.0,,F,,,Intermediate,CHEMBL619285,1.0,,,5329.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,80640.0,391.0
1.0,14882.0,,F,,,Intermediate,CHEMBL619286,1.0,,,5330.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,80640.0,391.0
1.0,15176.0,,F,,,Intermediate,CHEMBL619287,1.0,,,5331.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,80640.0,391.0
1.0,12696.0,,F,,,Intermediate,CHEMBL857455,1.0,,,5332.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,80640.0,391.0
1.0,2496.0,,F,,,Intermediate,CHEMBL883801,1.0,,,5333.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,80640.0,391.0
1.0,11831.0,,F,,,Intermediate,CHEMBL619288,1.0,,,5334.0,,N,BAO_0000219,791T cell line,9606.0,,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,80641.0,972.0
1.0,11831.0,,F,,,Intermediate,CHEMBL619289,1.0,,,5335.0,,N,BAO_0000219,791T cell line,9606.0,,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,80641.0,972.0
1.0,11831.0,,F,,,Intermediate,CHEMBL619290,1.0,,,5336.0,,N,BAO_0000219,791T cell line,9606.0,,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,80641.0,972.0
1.0,11831.0,,F,,,Intermediate,CHEMBL619291,1.0,,,5337.0,,N,BAO_0000219,791T cell line,9606.0,,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,80641.0,972.0
1.0,11831.0,,F,,,Intermediate,CHEMBL619292,1.0,,,5338.0,,N,BAO_0000219,791T cell line,9606.0,,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,80641.0,972.0
1.0,11831.0,,F,,,Intermediate,CHEMBL619293,1.0,,,5339.0,,N,BAO_0000219,791T cell line,9606.0,,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,80641.0,972.0
1.0,11831.0,,F,,,Intermediate,CHEMBL619294,1.0,,,5340.0,,N,BAO_0000219,791T cell line,9606.0,,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,80641.0,972.0
1.0,11831.0,,F,,,Intermediate,CHEMBL619295,1.0,,,5341.0,,N,BAO_0000219,791T cell line,9606.0,,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,80641.0,972.0
1.0,11831.0,,F,,,Intermediate,CHEMBL619296,1.0,,,5342.0,,N,BAO_0000219,791T cell line,9606.0,,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,80641.0,972.0
1.0,11831.0,,F,,,Intermediate,CHEMBL619297,1.0,,,5343.0,,N,BAO_0000219,791T cell line,9606.0,,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,80641.0,972.0
1.0,12782.0,,F,,,Intermediate,CHEMBL619298,1.0,,,5344.0,,N,BAO_0000219,786-0,9606.0,,Homo sapiens,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,80640.0,391.0
0.0,1229.0,,F,,,Intermediate,CHEMBL619299,1.0,,,5345.0,,U,BAO_0000019,,,,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,22226.0,
1.0,15313.0,,F,,,Expert,CHEMBL619300,1.0,,,5346.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,80433.0,741.0
1.0,15313.0,,F,,,Expert,CHEMBL619301,1.0,,,5347.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,80433.0,741.0
1.0,11544.0,,F,,,Intermediate,CHEMBL619302,1.0,,,5348.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL619303,1.0,,,5349.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL619304,1.0,,,5350.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL857706,1.0,,,5351.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL619305,1.0,,,5352.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL619306,1.0,,,5353.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL619307,1.0,,,5354.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL619308,1.0,,,5355.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL619309,1.0,,,5356.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL619310,1.0,,,5357.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,80433.0,741.0
1.0,14769.0,,F,,,Intermediate,CHEMBL619311,1.0,,,5358.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,80021.0,624.0
1.0,15354.0,,F,,,Intermediate,CHEMBL619312,1.0,,,5359.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Compound was tested for the growth inhibition of A498 renal tumor cell line,,80021.0,624.0
1.0,17445.0,,F,,,Intermediate,CHEMBL619313,1.0,,,5360.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,80021.0,624.0
1.0,4337.0,,F,,,Intermediate,CHEMBL619314,1.0,,,5361.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,In vitro inhibitory concentration against renal cancer cell line A498,,80021.0,624.0
1.0,15277.0,,F,,,Intermediate,CHEMBL619959,1.0,,,5362.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Cytotoxicity against A 498 tumor cell line,,80021.0,624.0
1.0,4812.0,,F,,,Intermediate,CHEMBL619960,1.0,,,5363.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,In vitro antitumor activity against A498 human cancer cell line,,80021.0,624.0
1.0,4812.0,,F,,,Intermediate,CHEMBL619961,1.0,,,5364.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,80021.0,624.0
1.0,4995.0,,F,,,Intermediate,CHEMBL619962,1.0,,,5365.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Inhibitory dose required against A498 human tumor cell lines,,80021.0,624.0
1.0,5847.0,,F,,,Intermediate,CHEMBL875586,1.0,,,5366.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Anticancer activity against one renal cancer (A498 cell line),,80021.0,624.0
1.0,6557.0,,F,,,Intermediate,CHEMBL619963,1.0,,,5367.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,In vitro cytotoxicity against melanoma A498 cell line,,80021.0,624.0
1.0,2597.0,,F,,,Intermediate,CHEMBL619964,1.0,,,5368.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Compound was tested for growth inhibitory activity against A498 cell line,,80021.0,624.0
1.0,6058.0,,F,,,Intermediate,CHEMBL620108,1.0,,,5369.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Compound tested for growth inhibition of renal cancer cell line A498,,80021.0,624.0
1.0,17708.0,,F,,,Intermediate,CHEMBL620109,1.0,,,5370.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,80021.0,624.0
1.0,15176.0,,F,,,Intermediate,CHEMBL620110,1.0,,,5371.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,80021.0,624.0
1.0,15300.0,,F,,,Intermediate,CHEMBL620111,1.0,,,5372.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,80021.0,624.0
1.0,11970.0,,F,,,Intermediate,CHEMBL620112,1.0,,,5373.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Tested for cytotoxicity against A498 cell lines in renal cancer,,80021.0,624.0
1.0,12400.0,,F,,,Intermediate,CHEMBL620113,1.0,,,5374.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,80021.0,624.0
1.0,12888.0,,F,,,Expert,CHEMBL620114,1.0,,,5375.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Cytotoxic effect on renal cancer lines A498,,80021.0,624.0
1.0,3030.0,,F,,,Intermediate,CHEMBL620115,1.0,,,5376.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,80021.0,624.0
1.0,14769.0,,F,,,Intermediate,CHEMBL620116,1.0,,,5377.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,80021.0,624.0
1.0,17376.0,,F,,,Intermediate,CHEMBL620117,1.0,,,5378.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,80021.0,624.0
1.0,16558.0,,F,,,Intermediate,CHEMBL620118,1.0,,,5379.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,80021.0,624.0
1.0,5194.0,,F,,,Intermediate,CHEMBL620119,1.0,,,5380.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,80021.0,624.0
1.0,10708.0,,F,,,Intermediate,CHEMBL620120,1.0,,,5381.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,80021.0,624.0
1.0,16880.0,,F,,,Expert,CHEMBL620121,1.0,,,5382.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,80682.0,646.0
1.0,10196.0,,F,,,Intermediate,CHEMBL620122,1.0,,,5383.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Antitumor activity against A549 human lung carcinoma cell line,,80682.0,646.0
1.0,10196.0,,F,,,Intermediate,CHEMBL620123,1.0,,,5384.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,80682.0,646.0
1.0,10196.0,,F,,,Intermediate,CHEMBL620124,1.0,,,5385.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,80682.0,646.0
1.0,12083.0,,F,,,Intermediate,CHEMBL620125,1.0,,,5386.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,80682.0,646.0
1.0,16464.0,,F,,,Expert,CHEMBL620126,1.0,,,5387.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,80682.0,646.0
1.0,16464.0,,F,,,Intermediate,CHEMBL883027,1.0,,,5388.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,80682.0,646.0
1.0,16470.0,,F,,,Expert,CHEMBL620127,1.0,,,5389.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line,,80682.0,646.0
1.0,16470.0,,F,,,Intermediate,CHEMBL620128,1.0,,,5390.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,80682.0,646.0
1.0,16470.0,,F,,,Intermediate,CHEMBL620129,1.0,,,5391.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line),,80682.0,646.0
1.0,16470.0,,F,,,Intermediate,CHEMBL620130,1.0,,,5392.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,80682.0,646.0
1.0,16582.0,,F,,,Expert,CHEMBL620131,1.0,,,5393.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,80682.0,646.0
1.0,15935.0,,F,,,Intermediate,CHEMBL620132,1.0,,,5394.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,80682.0,646.0
1.0,15935.0,,F,,,Intermediate,CHEMBL620133,1.0,,,5395.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,80682.0,646.0
1.0,16597.0,,F,,,Expert,CHEMBL620134,1.0,,,5396.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of A549 human lung carcinoma cell proliferation,,80682.0,646.0
1.0,17376.0,,F,,,Intermediate,CHEMBL620135,1.0,,,5397.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory activity against A549 lung adenocarcinoma cell line,,80682.0,646.0
1.0,16496.0,,F,,,Intermediate,CHEMBL620136,1.0,,,5398.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,80682.0,646.0
1.0,16152.0,,F,,,Intermediate,CHEMBL620137,1.0,,,5399.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,80682.0,646.0
1.0,16152.0,,F,,,Intermediate,CHEMBL620268,1.0,,,5400.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,80682.0,646.0
1.0,16464.0,,F,,,Intermediate,CHEMBL620269,1.0,,,5401.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,80682.0,646.0
1.0,2288.0,,F,,,Intermediate,CHEMBL620270,1.0,,,5402.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,80682.0,646.0
1.0,17350.0,,F,,,Intermediate,CHEMBL620271,1.0,,,5403.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,80682.0,646.0
1.0,4090.0,,F,,,Expert,CHEMBL620272,1.0,,,5404.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of A549 cancer cell proliferation,,80682.0,646.0
1.0,4090.0,,F,,,Expert,CHEMBL620273,1.0,,,5405.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of A549 cancer cell proliferation (Not tested),,80682.0,646.0
1.0,17350.0,,F,,,Intermediate,CHEMBL620274,1.0,,,5406.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,80682.0,646.0
1.0,4197.0,,F,,,Intermediate,CHEMBL620275,1.0,,,5407.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,80682.0,646.0
1.0,17072.0,,F,,,Intermediate,CHEMBL620276,1.0,,,5408.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Antiproliferative potency determined as inhibitory concentration against A549 cells,,80682.0,646.0
1.0,17072.0,,F,,,Intermediate,CHEMBL620277,1.0,,,5409.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,80682.0,646.0
1.0,5194.0,,F,,,Intermediate,CHEMBL620278,1.0,,,5410.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity against Renal cell lines A549 was determined,,80682.0,646.0
1.0,4257.0,,A,,,Intermediate,CHEMBL620279,1.0,,,5411.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve was determined in dog after a 3 mg/kg of oral dose,,50588.0,
1.0,6123.0,,A,,,Intermediate,CHEMBL620280,1.0,,,5412.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve was determined in dog after oral administration at 1 mg/kg,,50588.0,
1.0,1337.0,,A,,,Intermediate,CHEMBL620281,1.0,,,5413.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,50588.0,
1.0,1337.0,,A,,,Intermediate,CHEMBL620282,1.0,,,5414.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,50588.0,
1.0,8833.0,,A,,,Intermediate,CHEMBL621134,1.0,,,5415.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,50588.0,
1.0,8833.0,,A,,,Intermediate,CHEMBL621135,1.0,,,5416.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,50588.0,
1.0,8833.0,,A,,,Intermediate,CHEMBL621136,1.0,,,5417.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,50588.0,
1.0,8833.0,,A,,,Intermediate,CHEMBL621137,1.0,,,5418.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,50588.0,
1.0,17657.0,1969.0,A,,,Intermediate,CHEMBL621138,1.0,Plasma,,5419.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under plasma concentration time curve in dog upon oral administration,,50588.0,
1.0,17650.0,1969.0,A,,,Intermediate,CHEMBL875587,1.0,Plasma,,5420.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,50588.0,
1.0,1977.0,,A,,,Intermediate,CHEMBL621139,1.0,,,5421.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,50588.0,
1.0,1977.0,,A,,,Intermediate,CHEMBL621140,1.0,,,5422.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,50588.0,
1.0,3132.0,,A,,,Intermediate,CHEMBL621141,1.0,,,5423.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under the curve for the compound was obtained when tested in dog,,50588.0,
1.0,5473.0,,A,,,Intermediate,CHEMBL621142,1.0,,,5424.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under the curve at a dose of 1 mg/kg,,50588.0,
1.0,5474.0,,A,,,Intermediate,CHEMBL621143,1.0,,,5425.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under the curve at a dose of 1 mg/kg (oral),,50588.0,
1.0,5474.0,,A,,,Intermediate,CHEMBL621144,1.0,,,5426.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under the curve at i.v. dose of 0.2 mg/kg,,50588.0,
1.0,6062.0,,A,,,Intermediate,CHEMBL621145,1.0,,,5427.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,50588.0,
1.0,4709.0,,A,,,Intermediate,CHEMBL621146,1.0,,,5428.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,50588.0,
1.0,2652.0,,A,,,Intermediate,CHEMBL622567,1.0,,,5429.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,50588.0,
1.0,2652.0,,A,,,Intermediate,CHEMBL622568,1.0,,,5430.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,50588.0,
1.0,2877.0,,A,,,Intermediate,CHEMBL622569,1.0,,,5431.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was evaluated for area under the curve in dog blood.,,50588.0,
1.0,5444.0,,A,,,Intermediate,CHEMBL622570,1.0,,,5432.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,50588.0,
1.0,5130.0,1969.0,A,,,Intermediate,CHEMBL622571,1.0,Plasma,,5433.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,AUC in dog after oral dose (1 mg/kg),,50588.0,
1.0,6265.0,,A,,,Intermediate,CHEMBL622572,1.0,,,5434.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,50588.0,
1.0,4657.0,,A,,,Intermediate,CHEMBL622573,1.0,,,5435.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,50588.0,
1.0,16367.0,,A,,,Intermediate,CHEMBL622574,1.0,,,5436.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic parameter AUC after intravenous administration to dogs,,50588.0,
1.0,16367.0,,A,,,Intermediate,CHEMBL622575,1.0,,,5437.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic parameter AUC after oral administration to dogs,,50588.0,
1.0,9579.0,,A,,,Intermediate,CHEMBL622576,1.0,,,5438.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,50588.0,
1.0,9579.0,,A,,,Intermediate,CHEMBL622577,1.0,,,5439.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,50588.0,
1.0,5983.0,,A,,,Intermediate,CHEMBL622578,1.0,,,5440.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,50588.0,
1.0,6241.0,,A,,,Intermediate,CHEMBL622579,1.0,,,5441.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,50588.0,
1.0,5313.0,,A,,,Intermediate,CHEMBL622580,1.0,,,5442.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,50588.0,
1.0,5313.0,,A,,,Intermediate,CHEMBL622581,1.0,,,5443.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,50588.0,
1.0,6642.0,,A,,,Intermediate,CHEMBL622582,1.0,,,5444.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,50588.0,
1.0,6642.0,,A,,,Intermediate,CHEMBL622583,1.0,,,5445.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,50588.0,
1.0,6641.0,,A,,,Intermediate,CHEMBL622584,1.0,,,5446.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral AUCN in dog (dosed at 0.5 mpk iv ),,50588.0,
1.0,6642.0,,A,,,Intermediate,CHEMBL622585,1.0,,,5447.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral AUCN in dog (dosed at 0.5 mpk iv ),,50588.0,
1.0,17791.0,,A,,,Intermediate,CHEMBL622586,1.0,,,5448.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was evaluated for oral bioavailability in dog; 90-100,,50588.0,
1.0,17655.0,,A,,,Intermediate,CHEMBL623281,1.0,,,5449.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,50588.0,
1.0,17655.0,,A,,,Intermediate,CHEMBL623282,1.0,,,5450.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,50588.0,
1.0,6596.0,,A,,,Intermediate,CHEMBL623283,1.0,,,5451.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,PAPP (membrane permeability) in dog kidney cell monolayer assay,,50588.0,
1.0,3880.0,,A,,,Intermediate,CHEMBL623284,1.0,,,5452.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,16367.0,,A,,,Intermediate,CHEMBL623285,1.0,,,5453.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,50588.0,
1.0,17409.0,1969.0,A,,,Intermediate,CHEMBL623463,1.0,Plasma,,5454.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma protein binding towards dog plasma at 10 uM,,50588.0,
1.0,17409.0,1969.0,A,,,Intermediate,CHEMBL875952,1.0,Plasma,,5455.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma protein binding towards dog plasma at 100 uM,,50588.0,
1.0,2959.0,,A,,,Intermediate,CHEMBL621705,1.0,,,5456.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog (dose 4 mg/kg p.o.),,50588.0,
1.0,13501.0,,A,,,Intermediate,CHEMBL621706,1.0,,,5457.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,50588.0,
1.0,4527.0,,A,,,Intermediate,CHEMBL621707,1.0,,,5458.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,50588.0,
1.0,15145.0,,A,,,Intermediate,CHEMBL621708,1.0,,,5459.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dogs,,50588.0,
1.0,4219.0,,A,,,Intermediate,CHEMBL621709,1.0,,,5460.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability,,50588.0,
1.0,17538.0,,A,,,Intermediate,CHEMBL621710,1.0,,,5461.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),,50588.0,
1.0,17538.0,,A,,,Intermediate,CHEMBL621711,1.0,,,5462.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,50588.0,
1.0,1466.0,,A,,,Intermediate,CHEMBL621712,1.0,,,5463.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog (dose 10.0 mg/kg p.o.),,50588.0,
1.0,17650.0,,A,,,Intermediate,CHEMBL621713,1.0,,,5464.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,50588.0,
1.0,3132.0,,A,,,Intermediate,CHEMBL621714,1.0,,,5465.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,50588.0,
0.0,2413.0,,A,,,Autocuration,CHEMBL621715,1.0,,,5466.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,22224.0,
0.0,2413.0,2107.0,A,,,Autocuration,CHEMBL623717,1.0,Liver,,5467.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,22224.0,
0.0,2413.0,2107.0,A,,,Autocuration,CHEMBL623718,1.0,Liver,,5468.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,22224.0,
0.0,2413.0,2107.0,A,,,Autocuration,CHEMBL623719,1.0,Liver,,5469.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,22224.0,
0.0,2413.0,,A,,,Autocuration,CHEMBL623720,1.0,,,5470.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,22224.0,
0.0,2413.0,,A,,,Autocuration,CHEMBL623721,1.0,,,5471.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,22224.0,
0.0,2413.0,2385.0,A,,,Autocuration,CHEMBL623722,1.0,Muscle tissue,,5472.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,22224.0,
0.0,2413.0,2385.0,A,,,Autocuration,CHEMBL623723,1.0,Muscle tissue,,5473.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,22224.0,
0.0,2413.0,2385.0,A,,,Autocuration,CHEMBL618543,1.0,Muscle tissue,,5474.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,22224.0,
0.0,2413.0,2106.0,A,,,Autocuration,CHEMBL618544,1.0,Spleen,,5475.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,22224.0,
0.0,2413.0,2106.0,A,,,Autocuration,CHEMBL875155,1.0,Spleen,,5476.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,22224.0,
0.0,2413.0,,A,,,Autocuration,CHEMBL618545,1.0,,,5477.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,22224.0,
0.0,2413.0,,A,,,Autocuration,CHEMBL618546,1.0,,,5478.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,22224.0,
0.0,2413.0,,A,,,Autocuration,CHEMBL623529,1.0,,,5479.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,22224.0,
0.0,2413.0,,A,,,Autocuration,CHEMBL623530,1.0,,,5480.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,22224.0,
0.0,2413.0,,A,,,Autocuration,CHEMBL621764,1.0,,,5481.0,,U,BAO_0000218,,10095.0,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,22224.0,
0.0,17827.0,,A,,,Autocuration,CHEMBL621765,1.0,,,5482.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,22224.0,
0.0,17827.0,2037.0,A,,,Autocuration,CHEMBL621766,1.0,Cerebellum,,5483.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,22224.0,
0.0,17827.0,1870.0,A,,,Autocuration,CHEMBL621767,1.0,Frontal cortex,,5484.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,22224.0,
0.0,17827.0,,A,,,Autocuration,CHEMBL621768,1.0,,,5485.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,22224.0,
0.0,17827.0,2435.0,A,,,Autocuration,CHEMBL621769,1.0,Striatum,,5486.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,22224.0,
0.0,17827.0,,A,,,Autocuration,CHEMBL621770,1.0,,,5487.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,22224.0,
0.0,17827.0,2037.0,A,,,Autocuration,CHEMBL621771,1.0,Cerebellum,,5488.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,22224.0,
0.0,17827.0,1870.0,A,,,Autocuration,CHEMBL621772,1.0,Frontal cortex,,5489.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,22224.0,
0.0,17827.0,,A,,,Autocuration,CHEMBL621773,1.0,,,5490.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,22224.0,
0.0,17827.0,2435.0,A,,,Autocuration,CHEMBL621774,1.0,Striatum,,5491.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,22224.0,
0.0,17791.0,,A,,,Autocuration,CHEMBL621775,1.0,,,5492.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Compound was evaluated for oral bioavailability in rats,,22224.0,
0.0,17667.0,1969.0,A,,,Autocuration,CHEMBL621776,1.0,Plasma,,5493.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,,22224.0,
0.0,17791.0,,A,,,Autocuration,CHEMBL621777,1.0,,,5494.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Half life period was evaluated in monkey,,22224.0,
0.0,110.0,,A,,,Autocuration,CHEMBL875162,1.0,,,5495.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half-life in rhesus monkeys by intravenous administration of dose,,22224.0,
1.0,5781.0,1969.0,A,,,Intermediate,CHEMBL621778,1.0,Plasma,,5496.0,,N,BAO_0000218,,10090.0,,Mus musculus,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,50594.0,
1.0,17734.0,1969.0,A,,,Intermediate,CHEMBL621779,1.0,Plasma,,5497.0,,N,BAO_0000218,,10090.0,,Mus musculus,AUC after intraperitoneal administration of 100 mg/kg in mice,,50594.0,
1.0,17718.0,1969.0,A,,,Intermediate,CHEMBL622479,1.0,Plasma,,5498.0,,N,BAO_0000218,,10090.0,,Mus musculus,AUC value was determined after oral administration,,50594.0,
1.0,4573.0,,A,,,Intermediate,CHEMBL622480,1.0,,,5499.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,50594.0,
1.0,3277.0,,A,,,Intermediate,CHEMBL622481,1.0,,,5500.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,50594.0,
1.0,2862.0,,A,,,Intermediate,CHEMBL622482,1.0,,,5501.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve by ioral administration in mouse,,50594.0,
1.0,2862.0,,A,,,Intermediate,CHEMBL622483,1.0,,,5502.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve by iv administration in mouse,,50594.0,
1.0,5951.0,,A,,,Intermediate,CHEMBL622484,1.0,,,5503.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve at 0-8 hr in IRC mice after peroral administration,,50594.0,
1.0,17729.0,,A,,,Intermediate,CHEMBL622641,1.0,,,5504.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,50594.0,
1.0,17728.0,,A,,,Intermediate,CHEMBL622642,1.0,,,5505.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,50594.0,
1.0,17728.0,,A,,,Intermediate,CHEMBL622643,1.0,,,5506.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,50594.0,
1.0,17729.0,,A,,,Intermediate,CHEMBL622644,1.0,,,5507.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,50594.0,
1.0,9424.0,,F,,,Intermediate,CHEMBL622645,1.0,,,5508.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL622646,1.0,,,5509.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL621238,1.0,,,5510.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL621239,1.0,,,5511.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL621240,1.0,,,5512.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL621241,1.0,,,5513.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL621242,1.0,,,5514.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL620350,1.0,,,5515.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL620351,1.0,,,5516.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL620352,1.0,,,5517.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL620353,1.0,,,5518.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL620354,1.0,,,5519.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL620355,1.0,,,5520.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL620356,1.0,,,5521.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL620357,1.0,,,5522.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,80433.0,741.0
1.0,9424.0,,F,,,Intermediate,CHEMBL620358,1.0,,,5523.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,80433.0,741.0
1.0,9424.0,,F,,,Expert,CHEMBL620359,1.0,,,5524.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,80433.0,741.0
1.0,11544.0,,F,,,Intermediate,CHEMBL620360,1.0,,,5525.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,80433.0,741.0
1.0,17378.0,,F,,,Intermediate,CHEMBL620361,1.0,,,5526.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Cytotoxicity of compound against 8226/DOX1V cells,,80433.0,741.0
1.0,17378.0,,F,,,Intermediate,CHEMBL620362,1.0,,,5527.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Cytotoxicity of compound against 8226/S cells,,80433.0,741.0
1.0,17079.0,,F,,,Intermediate,CHEMBL620363,1.0,,,5528.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Inhibitory concentration against 8226 myeloma cancer cell line,,80433.0,741.0
1.0,17079.0,,F,,,Intermediate,CHEMBL620364,1.0,,,5529.0,,N,BAO_0000219,RPMI-8226,9606.0,,Homo sapiens,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,80433.0,741.0
1.0,13466.0,,F,,,Intermediate,CHEMBL620365,1.0,,,5530.0,,N,BAO_0000219,833K,9606.0,,Homo sapiens,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,80647.0,854.0
1.0,13466.0,,F,,,Intermediate,CHEMBL620366,1.0,,,5531.0,,N,BAO_0000219,833K,9606.0,,Homo sapiens,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,80647.0,854.0
1.0,2392.0,,F,,,Expert,CHEMBL620367,1.0,,,5532.0,,N,BAO_0000219,833K,9606.0,,Homo sapiens,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,80647.0,854.0
1.0,2392.0,,F,,,Intermediate,CHEMBL620368,1.0,,,5533.0,,N,BAO_0000219,833K,9606.0,,Homo sapiens,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,80647.0,854.0
0.0,6608.0,,B,,,Autocuration,CHEMBL620369,1.0,,,5534.0,,U,BAO_0000019,,,,,Inhibitory activity against caspase-1,,22226.0,
8.0,10199.0,,B,,,Autocuration,CHEMBL620370,1.0,,,5535.0,,H,BAO_0000357,,1351.0,,Enterococcus faecalis,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,45.0,
1.0,17749.0,,F,,,Intermediate,CHEMBL620371,1.0,,,5536.0,,N,BAO_0000219,8701-BC,9606.0,,Homo sapiens,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,80648.0,705.0
1.0,17749.0,,F,,,Intermediate,CHEMBL620372,1.0,,,5537.0,,N,BAO_0000219,8701-BC,9606.0,,Homo sapiens,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,80648.0,705.0
0.0,1229.0,,F,,,Intermediate,CHEMBL876492,1.0,,,5538.0,,U,BAO_0000019,,,,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,22226.0,
0.0,1229.0,,F,,,Intermediate,CHEMBL620373,1.0,,,5539.0,,U,BAO_0000019,,,,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,22226.0,
0.0,1229.0,,F,,,Intermediate,CHEMBL620374,1.0,,,5540.0,,U,BAO_0000019,,,,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,22226.0,
0.0,6390.0,,B,,,Autocuration,CHEMBL620375,1.0,,,5541.0,,U,BAO_0000019,,,,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,22226.0,
0.0,16219.0,,F,,,Autocuration,CHEMBL857902,1.0,,,5542.0,,U,BAO_0000019,,1314.0,,Streptococcus pyogenes,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,22226.0,
0.0,16219.0,,F,,,Autocuration,CHEMBL620376,1.0,,,5543.0,,U,BAO_0000019,,1314.0,,Streptococcus pyogenes,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,22226.0,
8.0,17043.0,,B,,,Autocuration,CHEMBL620377,1.0,,,5544.0,,H,BAO_0000357,,,,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,11922.0,
1.0,6929.0,,F,,,Intermediate,CHEMBL620378,1.0,,,5545.0,,N,BAO_0000219,KB ,9606.0,,Homo sapiens,Tested for in vitro cytotoxic potency of compound in 9KB assay,,81115.0,324.0
1.0,6929.0,,A,,,Intermediate,CHEMBL620379,1.0,,,5546.0,,N,BAO_0000219,KB ,9606.0,,Homo sapiens,Tested for in vitro cytotoxic potency of compound in 9KB assay,,81115.0,324.0
0.0,7083.0,,F,,,Autocuration,CHEMBL620380,1.0,,,5547.0,,U,BAO_0000219,,9606.0,,Homo sapiens,In vitro cytotoxicity of compound was tested against 9KB cells.,,22226.0,
1.0,12446.0,,F,,,Intermediate,CHEMBL884006,1.0,,,5548.0,,N,BAO_0000219,9L,10116.0,,Rattus norvegicus,Cytotoxic concentration against 9L cells was determined on day 3,,80653.0,392.0
1.0,15345.0,,F,,,Expert,CHEMBL620381,1.0,,,5549.0,,N,BAO_0000219,9L,10116.0,,Rattus norvegicus,Tested in vitro for anticancer activity against 9L cells,,80653.0,392.0
1.0,15345.0,,F,,,Expert,CHEMBL620382,1.0,,,5550.0,,N,BAO_0000219,9L,10116.0,,Rattus norvegicus,Tested in vitro for anticancer activity against 9L cells; Not determined,,80653.0,392.0
1.0,6301.0,,F,,,Intermediate,CHEMBL620383,1.0,,,5551.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,80682.0,646.0
1.0,4833.0,,F,,,Intermediate,CHEMBL876493,1.0,,,5552.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,80682.0,646.0
1.0,4833.0,,F,,,Intermediate,CHEMBL620384,1.0,,,5553.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,80682.0,646.0
1.0,4833.0,,F,,,Intermediate,CHEMBL620385,1.0,,,5554.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,80682.0,646.0
1.0,13330.0,,F,,,Expert,CHEMBL620386,1.0,,,5555.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity against human lung carcinoma A549 cell line,,80682.0,646.0
9.0,17517.0,,F,,,Expert,CHEMBL620387,1.0,,,5556.0,,D,BAO_0000219,A549,9606.0,,Homo sapiens,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,25.0,646.0
9.0,17517.0,,F,,,Expert,CHEMBL621404,1.0,,,5557.0,,D,BAO_0000219,A549,9606.0,,Homo sapiens,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,25.0,646.0
1.0,14425.0,,F,,,Intermediate,CHEMBL621405,1.0,,,5558.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"In vitro growth inhibition of A549, lung carcinoma",,80682.0,646.0
1.0,14425.0,,F,,,Intermediate,CHEMBL621406,1.0,,,5559.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"In vitro growth inhibition of A549, lung carcinoma.",,80682.0,646.0
1.0,5228.0,,F,,,Expert,CHEMBL621407,1.0,,,5560.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,80682.0,646.0
1.0,5351.0,,F,,,Intermediate,CHEMBL621408,1.0,,,5561.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic activity against human lung cancer A549 cell line was determined,,80682.0,646.0
1.0,12198.0,,F,,,Expert,CHEMBL885345,1.0,,,5562.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,80682.0,646.0
1.0,13891.0,,F,,,Intermediate,CHEMBL621409,1.0,,,5563.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,80682.0,646.0
1.0,5677.0,,F,,,Expert,CHEMBL876034,1.0,,,5564.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity in A549 (human carcinoma) cell line.,,80682.0,646.0
1.0,13788.0,,F,,,Intermediate,CHEMBL621410,1.0,,,5565.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity on lung carcinoma (A-549) cell line,,80682.0,646.0
1.0,13384.0,,F,,,Expert,CHEMBL621411,1.0,,,5566.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,80682.0,646.0
1.0,6726.0,,F,,,Intermediate,CHEMBL621412,1.0,,,5567.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Effective dose of compound against replication of A549 cell line was evaluated,,80682.0,646.0
1.0,3455.0,,F,,,Expert,CHEMBL621413,1.0,,,5568.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,80682.0,646.0
1.0,5726.0,,F,,,Intermediate,CHEMBL621414,1.0,,,5569.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,80682.0,646.0
1.0,5726.0,,F,,,Intermediate,CHEMBL621415,1.0,,,5570.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,80682.0,646.0
1.0,3936.0,,F,,,Intermediate,CHEMBL621416,1.0,,,5571.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,The compound was evaluated for antiproliferative activity against A549 cell line,,80682.0,646.0
1.0,14991.0,,F,,,Intermediate,CHEMBL621417,1.0,,,5572.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,80682.0,646.0
1.0,5243.0,,F,,,Intermediate,CHEMBL621418,1.0,,,5573.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Concentration required for growth inhibition of human lung carcinoma cell line A549,,80682.0,646.0
1.0,12858.0,,F,,,Intermediate,CHEMBL621419,1.0,,,5574.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,80682.0,646.0
1.0,6776.0,,F,,,Intermediate,CHEMBL621420,1.0,,,5575.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Growth inhibition against A549 cell line was evaluated,,80682.0,646.0
1.0,16558.0,,F,,,Intermediate,CHEMBL875823,1.0,,,5576.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,80682.0,646.0
1.0,4583.0,,F,,,Expert,CHEMBL621421,1.0,,,5577.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,80682.0,646.0
1.0,13514.0,,F,,,Intermediate,CHEMBL621422,1.0,,,5578.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,80682.0,646.0
1.0,15166.0,,F,,,Expert,CHEMBL884014,1.0,,,5579.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Chemosensitivity against DT-diaphorase rich A549 cell lines,,80682.0,646.0
1.0,13873.0,,F,,,Intermediate,CHEMBL621423,1.0,,,5580.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,80682.0,646.0
1.0,6447.0,,F,,,Expert,CHEMBL621424,1.0,,,5581.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,80682.0,646.0
1.0,2068.0,,F,,,Intermediate,CHEMBL621425,1.0,,,5582.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,80682.0,646.0
1.0,1863.0,,F,,,Expert,CHEMBL621426,1.0,,,5583.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,80682.0,646.0
1.0,13873.0,,F,,,Intermediate,CHEMBL621427,1.0,,,5584.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,80682.0,646.0
1.0,13873.0,,F,,,Intermediate,CHEMBL621428,1.0,,,5585.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,80682.0,646.0
1.0,13873.0,,F,,,Expert,CHEMBL621429,1.0,,,5586.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,80682.0,646.0
1.0,579.0,,F,,,Intermediate,CHEMBL621430,1.0,,,5587.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,80682.0,646.0
1.0,579.0,,F,,,Intermediate,CHEMBL621431,1.0,,,5588.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,80682.0,646.0
1.0,4584.0,,F,,,Intermediate,CHEMBL621432,1.0,,,5589.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,80682.0,646.0
1.0,5421.0,,F,,,Expert,CHEMBL621433,1.0,,,5590.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,80682.0,646.0
1.0,5421.0,,F,,,Intermediate,CHEMBL875824,1.0,,,5591.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,80682.0,646.0
1.0,5421.0,,F,,,Intermediate,CHEMBL621434,1.0,,,5592.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,80682.0,646.0
1.0,5421.0,,F,,,Intermediate,CHEMBL621435,1.0,,,5593.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,80682.0,646.0
1.0,14188.0,,F,,,Intermediate,CHEMBL621436,1.0,,,5594.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,80682.0,646.0
1.0,14188.0,,F,,,Intermediate,CHEMBL621437,1.0,,,5595.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,80682.0,646.0
1.0,15354.0,,F,,,Intermediate,CHEMBL621438,1.0,,,5596.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested for the growth inhibition of A549 lung tumor cell line,,80682.0,646.0
1.0,14253.0,,F,,,Expert,CHEMBL621439,1.0,,,5597.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,80682.0,646.0
1.0,13873.0,,F,,,Intermediate,CHEMBL621440,1.0,,,5598.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,80682.0,646.0
1.0,3043.0,,A,,,Intermediate,CHEMBL621441,1.0,,,5599.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (conscious),,50588.0,
1.0,3045.0,,A,,,Intermediate,CHEMBL621442,1.0,,,5600.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was evaluated for the oral bioavailability after oral administration in dog.,,50588.0,
1.0,3022.0,,A,,,Intermediate,CHEMBL621443,1.0,,,5601.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,50588.0,
1.0,4453.0,,A,,,Intermediate,CHEMBL621444,1.0,,,5602.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,1696.0,,A,,,Intermediate,CHEMBL625133,1.0,,,5603.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,5045.0,,A,,,Intermediate,CHEMBL625134,1.0,,,5604.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,5356.0,,A,,,Intermediate,CHEMBL625135,1.0,,,5605.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (fasted),,50588.0,
1.0,17764.0,,A,,,Intermediate,CHEMBL625136,1.0,,,5606.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,50588.0,
1.0,6448.0,,A,,,Intermediate,CHEMBL625137,1.0,,,5607.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,1475.0,,A,,,Intermediate,CHEMBL625138,1.0,,,5608.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,3788.0,,A,,,Intermediate,CHEMBL625139,1.0,,,5609.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Percent bioavailability in dog,,50588.0,
1.0,3639.0,,A,,,Intermediate,CHEMBL872264,1.0,,,5610.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,50588.0,
1.0,13397.0,,A,,,Intermediate,CHEMBL625140,1.0,,,5611.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,2137.0,,A,,,Intermediate,CHEMBL624436,1.0,,,5612.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,The compound was evaluated for bioavailability in dogs; 34-44,,50588.0,
1.0,2959.0,,A,,,Intermediate,CHEMBL624437,1.0,,,5613.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog (dose 4 mg/kg p.o.),,50588.0,
1.0,6448.0,,A,,,Intermediate,CHEMBL872261,1.0,,,5614.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,6084.0,,A,,,Intermediate,CHEMBL624438,1.0,,,5615.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,8 hour trough Blood level in dog was measured after administration of compound,,50588.0,
1.0,3639.0,1969.0,A,,,Intermediate,CHEMBL624439,1.0,Plasma,,5616.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,,50588.0,
1.0,6316.0,,A,,,Intermediate,CHEMBL624440,1.0,,,5617.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,C24 after oral administration at 5 mg/kg,,50588.0,
1.0,5238.0,,A,,,Intermediate,CHEMBL624441,1.0,,,5618.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Clearance after oral and iv dosing in dogs,,50588.0,
1.0,17796.0,1969.0,A,,,Intermediate,CHEMBL624442,1.0,Plasma,,5619.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Clearance of the drug was measured in the plasma of dog,,50588.0,
1.0,2652.0,,A,,,Intermediate,CHEMBL624443,1.0,,,5620.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,50588.0,
1.0,5654.0,,A,,,Intermediate,CHEMBL624444,1.0,,,5621.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,50588.0,
1.0,6621.0,,A,,,Intermediate,CHEMBL624445,1.0,,,5622.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Clearance of compound was determined in dogs,,50588.0,
1.0,6505.0,,A,,,Intermediate,CHEMBL624446,1.0,,,5623.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Clearance on i.v. administration of 2 mg/kg was measured in dog,,50588.0,
1.0,5802.0,,A,,,Intermediate,CHEMBL624447,1.0,,,5624.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,50588.0,
1.0,17267.0,,A,,,Intermediate,CHEMBL624448,1.0,,,5625.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance in dog was determined,,50588.0,
1.0,4521.0,,A,,,Intermediate,CHEMBL624449,1.0,,,5626.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,50588.0,
1.0,6535.0,,A,,,Intermediate,CHEMBL624450,1.0,,,5627.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance in dog after administration of 0.25 mg/kg iv,,50588.0,
1.0,6535.0,,A,,,Intermediate,CHEMBL875942,1.0,,,5628.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance in dog after administration of 1 mg/kg iv,,50588.0,
1.0,6535.0,,A,,,Intermediate,CHEMBL624451,1.0,,,5629.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance in dogs,,50588.0,
1.0,5542.0,,A,,,Intermediate,CHEMBL624452,1.0,,,5630.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,50588.0,
1.0,5199.0,,A,,,Intermediate,CHEMBL624453,1.0,,,5631.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,50588.0,
1.0,16907.0,,A,,,Intermediate,CHEMBL624454,1.0,,,5632.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance after 15 mg/kg iv dose in Dogs,,50588.0,
1.0,16907.0,,A,,,Intermediate,CHEMBL624455,1.0,,,5633.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance after 30 mg/kg po dose in Dogs,,50588.0,
1.0,16367.0,,A,,,Intermediate,CHEMBL624456,1.0,,,5634.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma administration to dogs,,50588.0,
1.0,5505.0,,A,,,Intermediate,CHEMBL624457,1.0,,,5635.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance was determined,,50588.0,
1.0,6215.0,,A,,,Intermediate,CHEMBL624458,1.0,,,5636.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,50588.0,
1.0,1466.0,,A,,,Intermediate,CHEMBL624459,1.0,,,5637.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,50588.0,
2.0,5007.0,2107.0,A,Microsomes,,Intermediate,CHEMBL624460,1.0,Liver,,5638.0,In vitro,S,BAO_0000251,,9606.0,,Homo sapiens,Intrinsic clearance in human liver microsomes,,102164.0,
2.0,5007.0,2107.0,A,Microsomes,,Intermediate,CHEMBL624461,1.0,Liver,,5639.0,In vitro,S,BAO_0000251,,9606.0,,Homo sapiens,Intrinsic clearance in human liver microsomes,,102164.0,
1.0,16452.0,,A,,,Intermediate,CHEMBL875943,1.0,,,5640.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,50588.0,
1.0,16452.0,,A,,,Intermediate,CHEMBL624462,1.0,,,5641.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,50588.0,
1.0,16452.0,,A,,,Intermediate,CHEMBL624463,1.0,,,5642.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Clearance in dog (dose 1 mg/kg i.v.),,50588.0,
1.0,6221.0,,A,,,Intermediate,CHEMBL624464,1.0,,,5643.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,50588.0,
1.0,5007.0,,A,,,Intermediate,CHEMBL624465,1.0,,,5644.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,50588.0,
1.0,5668.0,,A,,,Intermediate,CHEMBL624466,1.0,,,5645.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance after peroral administration at 10 mpk in dog,,50588.0,
1.0,5668.0,,A,,,Intermediate,CHEMBL624467,1.0,,,5646.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance after peroral administration at 5 mpk in dog,,50588.0,
1.0,5668.0,,A,,,Intermediate,CHEMBL624468,1.0,,,5647.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance after peroral administration at 5 mg/kg in dog,,50588.0,
1.0,15660.0,,A,,,Intermediate,CHEMBL624469,1.0,,,5648.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance was measured in dog,,50588.0,
1.0,15660.0,,A,,,Intermediate,CHEMBL624470,1.0,,,5649.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance was measured in dog,,50588.0,
1.0,5983.0,,A,,,Intermediate,CHEMBL624471,1.0,,,5650.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,50588.0,
1.0,5600.0,,A,,,Intermediate,CHEMBL624472,1.0,,,5651.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Total clearance was determined after 0.1 mg/kg iv administration in dog,,50588.0,
1.0,17764.0,,A,,,Intermediate,CHEMBL622775,1.0,,,5652.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,50588.0,
1.0,6039.0,,A,,,Intermediate,CHEMBL622776,1.0,,,5653.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,50588.0,
1.0,6039.0,,A,,,Intermediate,CHEMBL622777,1.0,,,5654.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,50588.0,
1.0,6039.0,,A,,,Intermediate,CHEMBL622778,1.0,,,5655.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,50588.0,
1.0,4368.0,,A,,,Intermediate,CHEMBL622779,1.0,,,5656.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Clearance by intravenous administration of 1.2 mg/kg in dog,,50588.0,
1.0,4305.0,,A,,,Intermediate,CHEMBL622780,1.0,,,5657.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Clearance by iv administration in dogs at a dose of 1 mg/kg,,50588.0,
1.0,1918.0,1969.0,A,,,Intermediate,CHEMBL622781,1.0,Plasma,,5658.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Clearance value was evaluated in dog plasma,,50588.0,
1.0,6005.0,,A,,,Intermediate,CHEMBL622782,1.0,,,5659.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,50588.0,
1.0,4839.0,1969.0,A,,,Intermediate,CHEMBL622783,1.0,Plasma,,5660.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was tested for plasma clearance in dog,,50588.0,
1.0,4239.0,,A,,,Intermediate,CHEMBL622784,1.0,,,5661.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic property (Plasma clearance) was measured in dog,,50588.0,
1.0,17729.0,,A,,,Intermediate,CHEMBL622785,1.0,,,5662.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,50594.0,
1.0,17728.0,,A,,,Intermediate,CHEMBL622786,1.0,,,5663.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,50594.0,
1.0,5302.0,,A,,,Intermediate,CHEMBL622787,1.0,,,5664.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve value in mouse at a dose of 10 mg/kg,,50594.0,
1.0,5506.0,,A,,,Intermediate,CHEMBL875949,1.0,,,5665.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,50594.0,
1.0,5506.0,,A,,,Intermediate,CHEMBL622788,1.0,,,5666.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL622789,1.0,,,5667.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL622790,1.0,,,5668.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL622791,1.0,,,5669.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL622792,1.0,,,5670.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,50594.0,
1.0,17764.0,,A,,,Intermediate,CHEMBL622793,1.0,,,5671.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,50594.0,
1.0,17753.0,,A,,,Intermediate,CHEMBL622794,1.0,,,5672.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve was determined for the compound at 24 mg/Kg,,50594.0,
1.0,17753.0,,A,,,Intermediate,CHEMBL622795,1.0,,,5673.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve was determined for the compound at 40 mg/Kg,,50594.0,
1.0,17753.0,,A,,,Intermediate,CHEMBL621803,1.0,,,5674.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under curve was determined for the compound at 5 mg/Kg,,50594.0,
1.0,3132.0,,A,,,Intermediate,CHEMBL621804,1.0,,,5675.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under the curve for the compound is obtained at dose 25 mg/kg,,50594.0,
1.0,3132.0,,A,,,Intermediate,CHEMBL621805,1.0,,,5676.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under the curve for the compound was obtained when tested in mouse,,50594.0,
1.0,17837.0,,A,,,Intermediate,CHEMBL621806,1.0,,,5677.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,50594.0,
1.0,17837.0,,A,,,Intermediate,CHEMBL621807,1.0,,,5678.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,50594.0,
1.0,6062.0,,A,,,Intermediate,CHEMBL621808,1.0,,,5679.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,50594.0,
1.0,4066.0,,A,,,Intermediate,CHEMBL621809,1.0,,,5680.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,50594.0,
1.0,16597.0,,A,,,Intermediate,CHEMBL621810,1.0,,,5681.0,,N,BAO_0000218,,10090.0,,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,50594.0,
1.0,14239.0,,A,,,Intermediate,CHEMBL875164,1.0,,,5682.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,50594.0,
1.0,14239.0,,A,,,Intermediate,CHEMBL621811,1.0,,,5683.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,50594.0,
1.0,4890.0,,A,,,Intermediate,CHEMBL621812,1.0,,,5684.0,,N,BAO_0000218,,10090.0,,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,50594.0,
1.0,429.0,,A,,,Intermediate,CHEMBL621813,1.0,,,5685.0,,N,BAO_0000218,,10090.0,,Mus musculus,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,50594.0,
1.0,429.0,,A,,,Intermediate,CHEMBL621814,1.0,,,5686.0,,N,BAO_0000218,,10090.0,,Mus musculus,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,50594.0,
1.0,5969.0,,A,,,Intermediate,CHEMBL621815,1.0,,,5687.0,,N,BAO_0000218,,10090.0,,Mus musculus,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,50594.0,
1.0,5969.0,,A,,,Intermediate,CHEMBL621816,1.0,,,5688.0,,N,BAO_0000218,,10090.0,,Mus musculus,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,50594.0,
1.0,5969.0,,A,,,Intermediate,CHEMBL621817,1.0,,,5689.0,,N,BAO_0000218,,10090.0,,Mus musculus,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,50594.0,
1.0,6091.0,,A,,,Intermediate,CHEMBL621818,1.0,,,5690.0,,N,BAO_0000218,,10090.0,,Mus musculus,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,50594.0,
1.0,6091.0,,A,,,Intermediate,CHEMBL621819,1.0,,,5691.0,,N,BAO_0000218,,10090.0,,Mus musculus,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,50594.0,
1.0,6091.0,,A,,,Intermediate,CHEMBL621820,1.0,,,5692.0,,N,BAO_0000218,,10090.0,,Mus musculus,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,50594.0,
1.0,6091.0,,A,,,Intermediate,CHEMBL621821,1.0,,,5693.0,,N,BAO_0000218,,10090.0,,Mus musculus,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,50594.0,
1.0,6178.0,,A,,,Intermediate,CHEMBL621822,1.0,,,5694.0,,N,BAO_0000218,,10090.0,,Mus musculus,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,50594.0,
1.0,6178.0,,A,,,Intermediate,CHEMBL619474,1.0,,,5695.0,,N,BAO_0000218,,10090.0,,Mus musculus,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,50594.0,
1.0,6619.0,,A,,,Intermediate,CHEMBL619475,1.0,,,5696.0,,N,BAO_0000218,,10090.0,,Mus musculus,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,50594.0,
1.0,6619.0,,A,,,Intermediate,CHEMBL619476,1.0,,,5697.0,,N,BAO_0000218,,10090.0,,Mus musculus,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,50594.0,
1.0,3760.0,,A,,,Intermediate,CHEMBL619477,1.0,,,5698.0,,N,BAO_0000218,,10090.0,,Mus musculus,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,50594.0,
1.0,3760.0,,A,,,Intermediate,CHEMBL619478,1.0,,,5699.0,,N,BAO_0000218,,10090.0,,Mus musculus,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,50594.0,
1.0,3760.0,,A,,,Intermediate,CHEMBL619479,1.0,,,5700.0,,N,BAO_0000218,,10090.0,,Mus musculus,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,50594.0,
1.0,3760.0,,A,,,Intermediate,CHEMBL619480,1.0,,,5701.0,,N,BAO_0000218,,10090.0,,Mus musculus,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,50594.0,
1.0,3192.0,,A,,,Intermediate,CHEMBL619481,1.0,,,5702.0,,N,BAO_0000218,,10090.0,,Mus musculus,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,50594.0,
1.0,3192.0,,A,,,Intermediate,CHEMBL619482,1.0,,,5703.0,,N,BAO_0000218,,10090.0,,Mus musculus,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,50594.0,
1.0,2675.0,,A,,,Intermediate,CHEMBL619483,1.0,,,5704.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under the curve was evaluated in mice after intravenous administration,,50594.0,
1.0,2675.0,,A,,,Intermediate,CHEMBL619484,1.0,,,5705.0,,N,BAO_0000218,,10090.0,,Mus musculus,Area under the curve was evaluated in mice after oral administration,,50594.0,
1.0,16597.0,1969.0,A,,,Intermediate,CHEMBL619485,1.0,Plasma,,5706.0,,N,BAO_0000218,,10090.0,,Mus musculus,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,50594.0,
1.0,16597.0,1969.0,A,,,Intermediate,CHEMBL619486,1.0,Plasma,,5707.0,,N,BAO_0000218,,10090.0,,Mus musculus,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,50594.0,
1.0,16597.0,,A,,,Intermediate,CHEMBL619487,1.0,,,5708.0,,N,BAO_0000218,,10090.0,,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,50594.0,
1.0,17734.0,,A,,,Intermediate,CHEMBL619488,1.0,,,5709.0,,N,BAO_0000218,,10090.0,,Mus musculus,AUMC after intraperitoneal administration of 100 mg/kg in mice,,50594.0,
1.0,7767.0,178.0,A,,,Intermediate,CHEMBL620106,1.0,Blood,,5710.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,,50594.0,
1.0,15345.0,,F,,,Intermediate,CHEMBL620107,1.0,,,5711.0,,N,BAO_0000219,9L,,,,The compound was tested in vitro for anticancer activity against 9L cells,,80653.0,392.0
0.0,2181.0,,F,,,Autocuration,CHEMBL620283,1.0,,,5712.0,,U,BAO_0000019,,10116.0,,Rattus norvegicus,Anti proliferation activity determined; Weak effect,,22226.0,
0.0,2181.0,,F,,,Autocuration,CHEMBL875176,1.0,,,5713.0,,U,BAO_0000219,,10116.0,,Rattus norvegicus,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,22226.0,
0.0,2181.0,,F,,,Autocuration,CHEMBL620284,1.0,,,5714.0,,U,BAO_0000219,,10116.0,,Rattus norvegicus,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,22226.0,
0.0,2181.0,,F,,,Autocuration,CHEMBL623515,1.0,,,5715.0,,U,BAO_0000219,,10116.0,,Rattus norvegicus,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,22226.0,
0.0,10486.0,,F,,,Autocuration,CHEMBL623516,1.0,,,5716.0,,U,BAO_0000019,,10090.0,,Mus musculus,The cytotoxic activity was in vitro tested by 9PS assay method,,22226.0,
0.0,10486.0,,F,,,Autocuration,CHEMBL623517,1.0,,,5717.0,,U,BAO_0000019,,10090.0,,Mus musculus,The cytotoxic activity was in vitro tested by 9PS assay method.,,22226.0,
0.0,15508.0,,A,,,Autocuration,CHEMBL857878,1.0,,,5718.0,,U,BAO_0000019,,,,,Partition coefficient (logD6.5),,22224.0,
1.0,5242.0,,F,,,Expert,CHEMBL623518,1.0,,,5719.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,81034.0,478.0
1.0,16167.0,,F,,,Intermediate,CHEMBL624195,1.0,,,5720.0,,N,BAO_0000219,A-375,9606.0,,Homo sapiens,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,80018.0,455.0
1.0,4782.0,,F,,,Expert,CHEMBL624196,1.0,,,5721.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,80852.0,500.0
9.0,16093.0,,F,,,Expert,CHEMBL624197,1.0,,,5722.0,,D,BAO_0000219,A-431,9606.0,,Homo sapiens,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,9.0,500.0
1.0,2596.0,,F,,,Intermediate,CHEMBL624198,1.0,,,5723.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,80021.0,624.0
1.0,2596.0,,F,,,Intermediate,CHEMBL621287,1.0,,,5724.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,in vitro cytotoxicity against A 498 cancer cell line,,80021.0,624.0
1.0,3239.0,,F,,,Intermediate,CHEMBL621288,1.0,,,5725.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,80021.0,624.0
1.0,1847.0,,F,,,Intermediate,CHEMBL876496,1.0,,,5726.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Cytotoxic activity against A 498 renal cancer cell lines.,,80021.0,624.0
1.0,10553.0,,F,,,Intermediate,CHEMBL621289,1.0,,,5727.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,80021.0,624.0
0.0,16219.0,,F,,,Autocuration,CHEMBL621290,1.0,,,5728.0,,U,BAO_0000019,,1280.0,,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,22226.0,
0.0,16219.0,,F,,,Autocuration,CHEMBL621291,1.0,,,5729.0,,U,BAO_0000019,,1280.0,,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,22226.0,
0.0,16219.0,,F,,,Autocuration,CHEMBL621292,1.0,,,5730.0,,U,BAO_0000019,,1280.0,,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,22226.0,
0.0,16219.0,,F,,,Autocuration,CHEMBL621293,1.0,,,5731.0,,U,BAO_0000019,,1280.0,,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,22226.0,
1.0,4782.0,,F,,,Intermediate,CHEMBL621294,1.0,,,5732.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory concentration required against A 549 lung cancer cell line,,80682.0,646.0
1.0,11805.0,,F,,,Intermediate,CHEMBL621295,1.0,,,5733.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,80682.0,646.0
1.0,11805.0,,F,,,Intermediate,CHEMBL884007,1.0,,,5734.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,80682.0,646.0
1.0,2007.0,,F,,,Intermediate,CHEMBL621296,1.0,,,5735.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against lung cancer A 549 cell lines,,80682.0,646.0
1.0,4594.0,,F,,,Intermediate,CHEMBL621297,1.0,,,5736.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested for its cytotoxicity against A 549 cell line,,80682.0,646.0
1.0,6018.0,,F,,,Expert,CHEMBL839828,1.0,,,5737.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,80682.0,646.0
1.0,6018.0,,F,,,Intermediate,CHEMBL620397,1.0,,,5738.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,80682.0,646.0
1.0,3599.0,,F,,,Expert,CHEMBL620398,1.0,,,5739.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,80682.0,646.0
1.0,2551.0,,F,,,Intermediate,CHEMBL620399,1.0,,,5740.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,80682.0,646.0
1.0,16132.0,,F,,,Expert,CHEMBL620400,1.0,,,5741.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro inhibition of A549 (human lung cancer) cell growth.,,80682.0,646.0
1.0,16132.0,,F,,,Intermediate,CHEMBL620401,1.0,,,5742.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,80682.0,646.0
1.0,2551.0,,F,,,Expert,CHEMBL620402,1.0,,,5743.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,80682.0,646.0
1.0,2551.0,,F,,,Expert,CHEMBL620403,1.0,,,5744.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,80682.0,646.0
0.0,11913.0,,F,,,Autocuration,CHEMBL620404,1.0,,,5745.0,,U,BAO_0000218,,,,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,22226.0,
4.0,12621.0,,F,,,Autocuration,CHEMBL620405,1.0,,,5746.0,In vivo,H,BAO_0000218,,,,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,104694.0,
4.0,12621.0,,F,,,Autocuration,CHEMBL620406,1.0,,,5747.0,In vivo,H,BAO_0000218,,,,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,104694.0,
4.0,12621.0,,F,,,Autocuration,CHEMBL620407,1.0,,,5748.0,In vivo,H,BAO_0000218,,,,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,104694.0,
4.0,12621.0,,F,,,Autocuration,CHEMBL620408,1.0,,,5749.0,In vivo,H,BAO_0000218,,,,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,104694.0,
4.0,12621.0,,F,,,Autocuration,CHEMBL620409,1.0,,,5750.0,In vivo,H,BAO_0000218,,,,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,104694.0,
1.0,3600.0,,F,,,Expert,CHEMBL620410,1.0,,,5751.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Inhibition of A-498 human Renal cell proliferation,,80021.0,624.0
0.0,1796.0,,F,,,Autocuration,CHEMBL620411,1.0,,,5752.0,,U,BAO_0000019,,10116.0,,Rattus norvegicus,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,22226.0,
0.0,1796.0,,F,,,Autocuration,CHEMBL620412,1.0,,,5753.0,,U,BAO_0000019,,10116.0,,Rattus norvegicus,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,22226.0,
0.0,1796.0,,F,,,Autocuration,CHEMBL876596,1.0,,,5754.0,,U,BAO_0000019,,10116.0,,Rattus norvegicus,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,22226.0,
1.0,16464.0,,F,,,Expert,CHEMBL620413,1.0,,,5755.0,,N,BAO_0000219,A 172,9606.0,,Homo sapiens,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,80012.0,622.0
1.0,16464.0,,F,,,Intermediate,CHEMBL620414,1.0,,,5756.0,,N,BAO_0000219,A 172,9606.0,,Homo sapiens,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,80012.0,622.0
1.0,16464.0,,F,,,Intermediate,CHEMBL620415,1.0,,,5757.0,,N,BAO_0000219,A 172,9606.0,,Homo sapiens,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,80012.0,622.0
1.0,13617.0,,F,,,Expert,CHEMBL620416,1.0,,,5758.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,80682.0,646.0
1.0,4584.0,,F,,,Intermediate,CHEMBL620417,1.0,,,5759.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,80682.0,646.0
1.0,13799.0,,F,,,Expert,CHEMBL620418,1.0,,,5760.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic activity evaluated against A549 tumor cells,,80682.0,646.0
1.0,16726.0,,F,,,Intermediate,CHEMBL620419,1.0,,,5761.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,80682.0,646.0
1.0,16109.0,,F,,,Intermediate,CHEMBL620420,1.0,,,5762.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,80682.0,646.0
1.0,16109.0,,F,,,Intermediate,CHEMBL620421,1.0,,,5763.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,80682.0,646.0
1.0,15474.0,,F,,,Intermediate,CHEMBL620422,1.0,,,5764.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,80682.0,646.0
1.0,6851.0,,F,,,Intermediate,CHEMBL620423,1.0,,,5765.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity of compound against A549 cell line,,80682.0,646.0
1.0,17534.0,,F,,,Expert,CHEMBL620424,1.0,,,5766.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity against human lung cell carcinoma A549 cell line,,80682.0,646.0
1.0,2621.0,,F,,,Intermediate,CHEMBL620425,1.0,,,5767.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,80682.0,646.0
1.0,830.0,,F,,,Intermediate,CHEMBL620426,1.0,,,5768.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,80682.0,646.0
1.0,14255.0,,F,,,Intermediate,CHEMBL620427,1.0,,,5769.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,80682.0,646.0
1.0,14255.0,,F,,,Intermediate,CHEMBL620428,1.0,,,5770.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,80682.0,646.0
1.0,1590.0,,F,,,Intermediate,CHEMBL620429,1.0,,,5771.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,80682.0,646.0
1.0,6146.0,,F,,,Expert,CHEMBL620430,1.0,,,5772.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,80682.0,646.0
1.0,17427.0,,F,,,Expert,CHEMBL839887,1.0,,,5773.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,80682.0,646.0
1.0,5280.0,,F,,,Intermediate,CHEMBL620431,1.0,,,5774.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,80682.0,646.0
1.0,16786.0,,F,,,Intermediate,CHEMBL884010,1.0,,,5775.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,80682.0,646.0
1.0,5895.0,,F,,,Intermediate,CHEMBL620538,1.0,,,5776.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against A549 (human lung cancer),,80682.0,646.0
1.0,14297.0,,F,,,Expert,CHEMBL620539,1.0,,,5777.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,80682.0,646.0
1.0,17824.0,,F,,,Intermediate,CHEMBL623373,1.0,,,5778.0,,N,BAO_0000218,A549,9606.0,,Homo sapiens,In vivo antiproliferative activity against A549 cell line,,80682.0,646.0
1.0,14368.0,,F,,,Intermediate,CHEMBL623374,1.0,,,5779.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of non-small-cell lung adenocarcinoma (A549),,80682.0,646.0
1.0,14368.0,,F,,,Intermediate,CHEMBL623375,1.0,,,5780.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,80682.0,646.0
1.0,14254.0,,F,,,Intermediate,CHEMBL623376,1.0,,,5781.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,80682.0,646.0
1.0,15897.0,,F,,,Intermediate,CHEMBL623377,1.0,,,5782.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,80682.0,646.0
1.0,13866.0,,F,,,Intermediate,CHEMBL623378,1.0,,,5783.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,80682.0,646.0
1.0,13370.0,,F,,,Intermediate,CHEMBL623379,1.0,,,5784.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,80682.0,646.0
1.0,4862.0,,F,,,Intermediate,CHEMBL623380,1.0,,,5785.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory activity against A549 lung cancer cell line,,80682.0,646.0
1.0,4862.0,,F,,,Intermediate,CHEMBL623381,1.0,,,5786.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,80682.0,646.0
1.0,4862.0,,F,,,Intermediate,CHEMBL623382,1.0,,,5787.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,80682.0,646.0
1.0,15970.0,,F,,,Intermediate,CHEMBL623383,1.0,,,5788.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory concentration against A549 (lung cancer) cell line,,80682.0,646.0
1.0,17713.0,,F,,,Expert,CHEMBL623384,1.0,,,5789.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,80682.0,646.0
1.0,4833.0,,F,,,Intermediate,CHEMBL623385,1.0,,,5790.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,80682.0,646.0
1.0,13736.0,,F,,,Expert,CHEMBL623386,1.0,,,5791.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Activity against A549 cancer cell line.,,80682.0,646.0
1.0,4312.0,,F,,,Intermediate,CHEMBL884105,1.0,,,5792.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,The compound was evaluated for cytotoxicity against A549 cell line,,80682.0,646.0
1.0,5421.0,,F,,,Intermediate,CHEMBL623387,1.0,,,5793.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,80682.0,646.0
1.0,5421.0,,F,,,Intermediate,CHEMBL621568,1.0,,,5794.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,80682.0,646.0
1.0,14717.0,,F,,,Intermediate,CHEMBL621569,1.0,,,5795.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Growth inhibitory activity was measured for human A549 tumor cell line.,,80682.0,646.0
1.0,4634.0,,F,,,Intermediate,CHEMBL621570,1.0,,,5796.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory activity against A549 lung cancer cell line,,80682.0,646.0
1.0,1149.0,,F,,,Intermediate,CHEMBL621571,1.0,,,5797.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory activity against A549 cell line; inactive,,80682.0,646.0
1.0,5421.0,,F,,,Expert,CHEMBL621572,1.0,,,5798.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,80682.0,646.0
1.0,5421.0,,F,,,Expert,CHEMBL621573,1.0,,,5799.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,80682.0,646.0
1.0,5421.0,,F,,,Intermediate,CHEMBL621574,1.0,,,5800.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,80682.0,646.0
1.0,3320.0,,F,,,Intermediate,CHEMBL621575,1.0,,,5801.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,80682.0,646.0
1.0,3320.0,,F,,,Intermediate,CHEMBL621576,1.0,,,5802.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,80682.0,646.0
1.0,3320.0,,F,,,Intermediate,CHEMBL621577,1.0,,,5803.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,80682.0,646.0
1.0,3320.0,,F,,,Intermediate,CHEMBL621578,1.0,,,5804.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,80682.0,646.0
1.0,3320.0,,F,,,Intermediate,CHEMBL621579,1.0,,,5805.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,80682.0,646.0
1.0,5726.0,,F,,,Intermediate,CHEMBL621580,1.0,,,5806.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,80682.0,646.0
1.0,17800.0,,A,,,Intermediate,CHEMBL621581,1.0,,,5807.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance (in vivo) in mongrel dogs was determined,,50588.0,
1.0,5985.0,,A,,,Intermediate,CHEMBL621582,1.0,,,5808.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance was measured in dog,,50588.0,
1.0,5530.0,,A,,,Intermediate,CHEMBL621583,1.0,,,5809.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,50588.0,
1.0,5530.0,,A,,,Intermediate,CHEMBL621584,1.0,,,5810.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,50588.0,
1.0,4839.0,1969.0,A,,,Intermediate,CHEMBL621585,1.0,Plasma,,5811.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Tested for plasma clearance in dog,,50588.0,
1.0,3639.0,,A,,,Intermediate,CHEMBL621586,1.0,,,5812.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,The compound was tested for clearance in dog plasma.,,50588.0,
1.0,4838.0,,A,,,Intermediate,CHEMBL875835,1.0,,,5813.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,50588.0,
1.0,4137.0,,A,,,Intermediate,CHEMBL621587,1.0,,,5814.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,50588.0,
1.0,5017.0,1969.0,A,,,Intermediate,CHEMBL621588,1.0,Plasma,,5815.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,50588.0,
1.0,17538.0,2107.0,A,Microsomes,,Intermediate,CHEMBL621589,1.0,Liver,,5816.0,In vitro,N,BAO_0000218,,9615.0,,Canis lupus familiaris,In vitro clearance in dog liver microsomes,,50588.0,
1.0,6161.0,,A,,,Intermediate,CHEMBL621590,1.0,,,5817.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,50588.0,
1.0,6161.0,,A,,,Intermediate,CHEMBL621591,1.0,,,5818.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,50588.0,
1.0,1696.0,,A,,,Intermediate,CHEMBL621592,1.0,,,5819.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance in dog,,50588.0,
1.0,6762.0,,A,,,Intermediate,CHEMBL621593,1.0,,,5820.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Clearance rate in dog,,50588.0,
1.0,5932.0,1969.0,A,,,Intermediate,CHEMBL621594,1.0,Plasma,,5821.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,50588.0,
1.0,6305.0,,A,,,Intermediate,CHEMBL621595,1.0,,,5822.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Clearance in dogs,,50588.0,
1.0,4942.0,,A,,,Intermediate,CHEMBL621596,1.0,,,5823.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance in dogs,,50588.0,
1.0,4219.0,,A,,,Intermediate,CHEMBL621597,1.0,,,5824.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance was determined,,50588.0,
1.0,17853.0,,A,,,Intermediate,CHEMBL621598,1.0,,,5825.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Lower clearance in dog (i.v.) at 0.5 mpk,,50588.0,
1.0,4514.0,,A,,,Intermediate,CHEMBL621599,1.0,,,5826.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance in Beagle dogs,,50588.0,
1.0,6448.0,,A,,,Intermediate,CHEMBL875836,1.0,,,5827.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance (Clp) in dog,,50588.0,
1.0,6227.0,,A,,,Intermediate,CHEMBL621600,1.0,,,5828.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,50588.0,
1.0,6227.0,,A,,,Intermediate,CHEMBL621601,1.0,,,5829.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance (pharmacokinetic parameter) in dog was determined,,50588.0,
1.0,6062.0,,A,,,Intermediate,CHEMBL618474,1.0,,,5830.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,50588.0,
1.0,6821.0,,A,,,Intermediate,CHEMBL618475,1.0,,,5831.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance of compound was determined in dog,,50588.0,
1.0,4709.0,,A,,,Intermediate,CHEMBL624524,1.0,,,5832.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance after intravenous administration of 1 mg/kg in dog,,50588.0,
1.0,4521.0,,A,,,Intermediate,CHEMBL624525,1.0,,,5833.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,50588.0,
1.0,5374.0,,A,,,Intermediate,CHEMBL624526,1.0,,,5834.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance in dog was determined,,50588.0,
1.0,6057.0,,A,,,Intermediate,CHEMBL624527,1.0,,,5835.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance was calculated in dog,,50588.0,
1.0,4727.0,,A,,,Intermediate,CHEMBL624528,1.0,,,5836.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance at the dose of 2 mg/kg in dog,,50588.0,
1.0,5145.0,,A,,,Intermediate,CHEMBL624529,1.0,,,5837.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance in dog,,50588.0,
1.0,17657.0,,A,,,Intermediate,CHEMBL624530,1.0,,,5838.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance in dog,,50588.0,
1.0,17657.0,,A,,,Intermediate,CHEMBL624531,1.0,,,5839.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance in dog; Unable to calculate,,50588.0,
1.0,5145.0,,A,,,Intermediate,CHEMBL624532,1.0,,,5840.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance in rhesus monkey,,50588.0,
1.0,6642.0,,A,,,Intermediate,CHEMBL624533,1.0,,,5841.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,50588.0,
1.0,6641.0,,A,,,Intermediate,CHEMBL624534,1.0,,,5842.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,50588.0,
1.0,6642.0,,A,,,Intermediate,CHEMBL624535,1.0,,,5843.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,50588.0,
1.0,5472.0,,A,,,Intermediate,CHEMBL624536,1.0,,,5844.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance was evaluated in dog,,50588.0,
1.0,5472.0,,A,,,Intermediate,CHEMBL624537,1.0,,,5845.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance was evaluated in dog; Not tested,,50588.0,
1.0,5472.0,,A,,,Intermediate,CHEMBL624538,1.0,,,5846.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance was evaluated in rhesus,,50588.0,
1.0,5472.0,,A,,,Intermediate,CHEMBL624539,1.0,,,5847.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance was evaluated in rhesus; Not tested,,50588.0,
1.0,4257.0,,A,,,Intermediate,CHEMBL624540,1.0,,,5848.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,50588.0,
1.0,6679.0,,A,,,Intermediate,CHEMBL624541,1.0,,,5849.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,50588.0,
1.0,5546.0,,A,,,Intermediate,CHEMBL624542,1.0,,,5850.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,50588.0,
1.0,6348.0,,A,,,Intermediate,CHEMBL624543,1.0,,,5851.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,50588.0,
1.0,5474.0,,A,,,Intermediate,CHEMBL624544,1.0,,,5852.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Clearance value at a dose of 0.2 mg/kg i.v.,,50588.0,
1.0,6316.0,1969.0,A,,,Intermediate,CHEMBL624545,1.0,Plasma,,5853.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,,50588.0,
1.0,17594.0,,A,,,Intermediate,CHEMBL624546,1.0,,,5854.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax after oral dose of compound at 3 mg/kg in dogs,,50588.0,
1.0,17594.0,,A,,,Intermediate,CHEMBL875957,1.0,,,5855.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax after single intravenous bolus of 1 mg/kg in dogs,,50588.0,
1.0,5802.0,,A,,,Intermediate,CHEMBL624547,1.0,,,5856.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,50588.0,
1.0,6535.0,,A,,,Intermediate,CHEMBL624548,1.0,,,5857.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,50588.0,
1.0,6535.0,,A,,,Intermediate,CHEMBL624549,1.0,,,5858.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax in dog after administration of 1 mg/kg iv,,50588.0,
1.0,1466.0,1969.0,A,,,Intermediate,CHEMBL624550,1.0,Plasma,,5859.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,,50588.0,
1.0,6505.0,,A,,,Intermediate,CHEMBL621613,1.0,,,5860.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax on p.o. administration of 10 mg/kg was measured in dog,,50588.0,
1.0,5668.0,,A,,,Intermediate,CHEMBL621614,1.0,,,5861.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax was determine after peroral administration at 10 mpk in dog,,50588.0,
1.0,5668.0,,A,,,Intermediate,CHEMBL623431,1.0,,,5862.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax was determine after peroral administration at 5 mpk in dog,,50588.0,
1.0,5668.0,,A,,,Intermediate,CHEMBL623432,1.0,,,5863.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax was determine after peroral administration at 5 mg/kg in dog,,50588.0,
1.0,5600.0,,A,,,Intermediate,CHEMBL623433,1.0,,,5864.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax after 0.3 mg/kg po administration in dog,,50588.0,
1.0,17764.0,,A,,,Intermediate,CHEMBL623434,1.0,,,5865.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax after peroral administration in dogs at 2.4 uM/kg,,50588.0,
1.0,6123.0,,A,,,Intermediate,CHEMBL623435,1.0,,,5866.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax in dog after oral administration at 1 mg/kg,,50588.0,
1.0,6123.0,,A,,,Intermediate,CHEMBL623436,1.0,,,5867.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,50588.0,
1.0,6757.0,,A,,,Intermediate,CHEMBL875958,1.0,,,5868.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,50588.0,
1.0,16907.0,,A,,,Intermediate,CHEMBL623437,1.0,,,5869.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax value after 15 mg/kg iv dose in Dogs,,50588.0,
1.0,7767.0,178.0,A,,,Intermediate,CHEMBL623438,1.0,Blood,,5870.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,178.0,A,,,Intermediate,CHEMBL623439,1.0,Blood,,5871.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,10000001.0,A,,,Intermediate,CHEMBL623440,1.0,Bone,,5872.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,10000001.0,A,,,Intermediate,CHEMBL623441,1.0,Bone,,5873.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,10000001.0,A,,,Intermediate,CHEMBL623442,1.0,Bone,,5874.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,,A,,,Intermediate,CHEMBL623469,1.0,,,5875.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,,A,,,Intermediate,CHEMBL623470,1.0,,,5876.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,,A,,,Intermediate,CHEMBL623471,1.0,,,5877.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,948.0,A,,,Intermediate,CHEMBL623472,1.0,Heart,,5878.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,948.0,A,,,Intermediate,CHEMBL623473,1.0,Heart,,5879.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,948.0,A,,,Intermediate,CHEMBL623474,1.0,Heart,,5880.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,2113.0,A,,,Intermediate,CHEMBL623475,1.0,Kidney,,5881.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,2113.0,A,,,Intermediate,CHEMBL623476,1.0,Kidney,,5882.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,2113.0,A,,,Intermediate,CHEMBL623477,1.0,Kidney,,5883.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,160.0,A,,,Intermediate,CHEMBL621896,1.0,Intestine,,5884.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,160.0,A,,,Intermediate,CHEMBL621897,1.0,Intestine,,5885.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,160.0,A,,,Intermediate,CHEMBL621898,1.0,Intestine,,5886.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,2107.0,A,,,Intermediate,CHEMBL621899,1.0,Liver,,5887.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,2107.0,A,,,Intermediate,CHEMBL621900,1.0,Liver,,5888.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,2107.0,A,,,Intermediate,CHEMBL621901,1.0,Liver,,5889.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,2048.0,A,,,Intermediate,CHEMBL621902,1.0,Lung,,5890.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,2048.0,A,,,Intermediate,CHEMBL621903,1.0,Lung,,5891.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,2048.0,A,,,Intermediate,CHEMBL622587,1.0,Lung,,5892.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,2385.0,A,,,Intermediate,CHEMBL620285,1.0,Muscle tissue,,5893.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,2385.0,A,,,Intermediate,CHEMBL875285,1.0,Muscle tissue,,5894.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,2385.0,A,,,Intermediate,CHEMBL620286,1.0,Muscle tissue,,5895.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,,A,,,Intermediate,CHEMBL620287,1.0,,,5896.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,,A,,,Intermediate,CHEMBL620288,1.0,,,5897.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,,A,,,Intermediate,CHEMBL620289,1.0,,,5898.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,160.0,A,,,Intermediate,CHEMBL620290,1.0,Intestine,,5899.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,160.0,A,,,Intermediate,CHEMBL620291,1.0,Intestine,,5900.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,160.0,A,,,Intermediate,CHEMBL620292,1.0,Intestine,,5901.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,2106.0,A,,,Intermediate,CHEMBL620293,1.0,Spleen,,5902.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,2106.0,A,,,Intermediate,CHEMBL620294,1.0,Spleen,,5903.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,2106.0,A,,,Intermediate,CHEMBL618614,1.0,Spleen,,5904.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,945.0,A,,,Intermediate,CHEMBL618615,1.0,Stomach,,5905.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,945.0,A,,,Intermediate,CHEMBL618616,1.0,Stomach,,5906.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,2036.0,,F,,,Expert,CHEMBL618617,1.0,,,5907.0,,N,BAO_0000219,A 172,9606.0,,Homo sapiens,Cytotoxicity against A-172 human tumor cell lines,,80012.0,622.0
1.0,2357.0,,F,,,Intermediate,CHEMBL618618,1.0,,,5908.0,,N,BAO_0000219,A 172,9606.0,,Homo sapiens,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,80012.0,622.0
1.0,1457.0,,F,,,Intermediate,CHEMBL618619,1.0,,,5909.0,,N,BAO_0000219,A204,9606.0,,Homo sapiens,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,80014.0,623.0
1.0,4379.0,,F,,,Intermediate,CHEMBL618620,1.0,,,5910.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Tested for antiproliferative activity against A-2780 tumoral cell line,,81034.0,478.0
1.0,1093.0,,F,,,Intermediate,CHEMBL618621,1.0,,,5911.0,,N,BAO_0000219,A-375,9606.0,,Homo sapiens,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,80018.0,455.0
1.0,12152.0,,F,,,Intermediate,CHEMBL618622,1.0,,,5912.0,,N,BAO_0000219,A-375,9606.0,,Homo sapiens,Tested in vitro against A-375 cell line human melanoma,,80018.0,455.0
1.0,16464.0,,F,,,Expert,CHEMBL618623,1.0,,,5913.0,,N,BAO_0000219,A-427,9606.0,,Homo sapiens,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,80019.0,797.0
1.0,16464.0,,F,,,Intermediate,CHEMBL618624,1.0,,,5914.0,,N,BAO_0000219,A-427,9606.0,,Homo sapiens,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,80019.0,797.0
1.0,16582.0,,F,,,Expert,CHEMBL618625,1.0,,,5915.0,,N,BAO_0000219,A-427,9606.0,,Homo sapiens,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,80019.0,797.0
1.0,16464.0,,F,,,Intermediate,CHEMBL618626,1.0,,,5916.0,,N,BAO_0000219,A-427,9606.0,,Homo sapiens,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,80019.0,797.0
1.0,10413.0,,F,,,Intermediate,CHEMBL618627,1.0,,,5917.0,,N,BAO_0000219,A-427,9606.0,,Homo sapiens,Antitumor activity on A-427 lung carcinoma cell lines,,80019.0,797.0
1.0,6418.0,,F,,,Intermediate,CHEMBL618628,1.0,,,5918.0,,N,BAO_0000219,A-427,9606.0,,Homo sapiens,Cytotoxic activity against human A-427 lung tumor cell line,,80019.0,797.0
1.0,17134.0,,F,,,Expert,CHEMBL618629,1.0,,,5919.0,,N,BAO_0000219,A-427,9606.0,,Homo sapiens,In vitro antitumor effects against human A-427 cell lines.,,80019.0,797.0
1.0,16132.0,,F,,,Expert,CHEMBL618630,1.0,,,5920.0,,N,BAO_0000219,A-427,9606.0,,Homo sapiens,In vitro inhibition of A-427 (human lung cancer) cell growth.,,80019.0,797.0
1.0,16132.0,,F,,,Intermediate,CHEMBL618631,1.0,,,5921.0,,N,BAO_0000219,A-427,9606.0,,Homo sapiens,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,80019.0,797.0
1.0,16780.0,,F,,,Intermediate,CHEMBL618632,1.0,,,5922.0,,N,BAO_0000219,A-427,9606.0,,Homo sapiens,Cytotoxic activity of compound against A-427 lung human tumor cell line,,80019.0,797.0
1.0,4085.0,,F,,,Expert,CHEMBL618633,1.0,,,5923.0,,N,BAO_0000219,A-431,9606.0,,Homo sapiens,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,80852.0,500.0
1.0,1276.0,,F,,,Intermediate,CHEMBL619315,1.0,,,5924.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,80021.0,624.0
1.0,3498.0,,F,,,Expert,CHEMBL619316,1.0,,,5925.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,80021.0,624.0
1.0,1169.0,,F,,,Intermediate,CHEMBL619317,1.0,,,5926.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Cytotoxicity against human kidney carcinoma A-498cell lines,,80021.0,624.0
1.0,4450.0,,F,,,Intermediate,CHEMBL619318,1.0,,,5927.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,80021.0,624.0
1.0,3311.0,,F,,,Intermediate,CHEMBL619319,1.0,,,5928.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,80021.0,624.0
1.0,4461.0,,F,,,Intermediate,CHEMBL619739,1.0,,,5929.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Antitumor cytotoxic activity against A-498 cell line was determined,,80021.0,624.0
1.0,3311.0,,F,,,Intermediate,CHEMBL619740,1.0,,,5930.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,80021.0,624.0
1.0,3311.0,,F,,,Intermediate,CHEMBL883158,1.0,,,5931.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,80021.0,624.0
1.0,1457.0,,F,,,Intermediate,CHEMBL884012,1.0,,,5932.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,80021.0,624.0
1.0,3664.0,,F,,,Intermediate,CHEMBL619741,1.0,,,5933.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,80021.0,624.0
1.0,15895.0,,F,,,Intermediate,CHEMBL619742,1.0,,,5934.0,,N,BAO_0000219,A498,9606.0,,Homo sapiens,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,80021.0,624.0
1.0,11843.0,,F,,,Intermediate,CHEMBL876610,1.0,,,5935.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,80682.0,646.0
1.0,11843.0,,F,,,Intermediate,CHEMBL619743,1.0,,,5936.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,80682.0,646.0
1.0,17705.0,,F,,,Intermediate,CHEMBL619744,1.0,,,5937.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro antiproliferative activity against human A-549 NSCL cell line,,80682.0,646.0
1.0,17705.0,,F,,,Intermediate,CHEMBL619745,1.0,,,5938.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,80682.0,646.0
1.0,4369.0,,F,,,Intermediate,CHEMBL619746,1.0,,,5939.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,80682.0,646.0
1.0,4369.0,,F,,,Intermediate,CHEMBL619747,1.0,,,5940.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,80682.0,646.0
1.0,4369.0,,F,,,Intermediate,CHEMBL619748,1.0,,,5941.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,80682.0,646.0
1.0,4369.0,,F,,,Intermediate,CHEMBL619749,1.0,,,5942.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,80682.0,646.0
1.0,4369.0,,F,,,Intermediate,CHEMBL619750,1.0,,,5943.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,80682.0,646.0
1.0,4369.0,,F,,,Intermediate,CHEMBL624014,1.0,,,5944.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,80682.0,646.0
1.0,4369.0,,F,,,Intermediate,CHEMBL624015,1.0,,,5945.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,80682.0,646.0
1.0,4787.0,,F,,,Expert,CHEMBL885344,1.0,,,5946.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,80682.0,646.0
1.0,4787.0,,F,,,Intermediate,CHEMBL623224,1.0,,,5947.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,80682.0,646.0
1.0,6513.0,,F,,,Intermediate,CHEMBL623225,1.0,,,5948.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic activity against A-549 cell line,,80682.0,646.0
1.0,6690.0,,F,,,Intermediate,CHEMBL622698,1.0,,,5949.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,80682.0,646.0
1.0,6690.0,,F,,,Intermediate,CHEMBL622699,1.0,,,5950.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,80682.0,646.0
1.0,12263.0,,F,,,Expert,CHEMBL622700,1.0,,,5951.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,80682.0,646.0
1.0,1054.0,,F,,,Intermediate,CHEMBL622701,1.0,,,5952.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,80682.0,646.0
1.0,1359.0,,F,,,Intermediate,CHEMBL622702,1.0,,,5953.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,80682.0,646.0
1.0,3547.0,,F,,,Intermediate,CHEMBL622703,1.0,,,5954.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic activity against human lung carcinoma (A-549) cell line,,80682.0,646.0
1.0,5771.0,,F,,,Expert,CHEMBL622704,1.0,,,5955.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic activity towards A-549 cells,,80682.0,646.0
1.0,14425.0,,F,,,Intermediate,CHEMBL622705,1.0,,,5956.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma.",,80682.0,646.0
1.0,14425.0,,F,,,Intermediate,CHEMBL622706,1.0,,,5957.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma",,80682.0,646.0
1.0,14425.0,,F,,,Intermediate,CHEMBL622707,1.0,,,5958.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma.",,80682.0,646.0
1.0,14425.0,,F,,,Intermediate,CHEMBL622708,1.0,,,5959.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,80682.0,646.0
1.0,5280.0,,F,,,Intermediate,CHEMBL622709,1.0,,,5960.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,80682.0,646.0
1.0,15176.0,,F,,,Intermediate,CHEMBL622710,1.0,,,5961.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,80682.0,646.0
1.0,15300.0,,F,,,Intermediate,CHEMBL622711,1.0,,,5962.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,80682.0,646.0
1.0,17824.0,,F,,,Intermediate,CHEMBL622712,1.0,,,5963.0,,N,BAO_0000218,A549,9606.0,,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,80682.0,646.0
1.0,17824.0,,F,,,Intermediate,CHEMBL622713,1.0,,,5964.0,,N,BAO_0000218,A549,9606.0,,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,80682.0,646.0
1.0,17824.0,,F,,,Intermediate,CHEMBL622714,1.0,,,5965.0,,N,BAO_0000218,A549,9606.0,,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,80682.0,646.0
1.0,17824.0,,F,,,Intermediate,CHEMBL622715,1.0,,,5966.0,,N,BAO_0000218,A549,9606.0,,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,80682.0,646.0
1.0,17824.0,,F,,,Intermediate,CHEMBL622716,1.0,,,5967.0,,N,BAO_0000218,A549,9606.0,,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,80682.0,646.0
1.0,17824.0,,F,,,Intermediate,CHEMBL622717,1.0,,,5968.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,80682.0,646.0
1.0,17528.0,,F,,,Intermediate,CHEMBL622718,1.0,,,5969.0,,N,BAO_0000218,A549,9606.0,,Homo sapiens,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,80682.0,646.0
1.0,6870.0,,F,,,Expert,CHEMBL622719,1.0,,,5970.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,80682.0,646.0
1.0,6870.0,,F,,,Intermediate,CHEMBL622720,1.0,,,5971.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,80682.0,646.0
1.0,6870.0,,F,,,Intermediate,CHEMBL622721,1.0,,,5972.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,80682.0,646.0
1.0,6870.0,,F,,,Intermediate,CHEMBL622722,1.0,,,5973.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,80682.0,646.0
1.0,16726.0,,F,,,Intermediate,CHEMBL876030,1.0,,,5974.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,80682.0,646.0
1.0,6170.0,,F,,,Intermediate,CHEMBL620206,1.0,,,5975.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,80682.0,646.0
1.0,6583.0,,F,,,Expert,CHEMBL620207,1.0,,,5976.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,80682.0,646.0
1.0,6583.0,,F,,,Expert,CHEMBL620208,1.0,,,5977.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,80682.0,646.0
1.0,6583.0,,F,,,Expert,CHEMBL620209,1.0,,,5978.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,80682.0,646.0
1.0,6583.0,,F,,,Expert,CHEMBL620210,1.0,,,5979.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,80682.0,646.0
1.0,6583.0,,F,,,Expert,CHEMBL621639,1.0,,,5980.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,80682.0,646.0
1.0,17321.0,,F,,,Intermediate,CHEMBL621640,1.0,,,5981.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,80682.0,646.0
1.0,17528.0,,F,,,Expert,CHEMBL621641,1.0,,,5982.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,80682.0,646.0
1.0,12888.0,,F,,,Expert,CHEMBL621642,1.0,,,5983.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,80682.0,646.0
1.0,4312.0,,F,,,Intermediate,CHEMBL621643,1.0,,,5984.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,80682.0,646.0
1.0,4312.0,,F,,,Intermediate,CHEMBL621644,1.0,,,5985.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,80682.0,646.0
1.0,4312.0,,F,,,Intermediate,CHEMBL621645,1.0,,,5986.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,80682.0,646.0
1.0,17737.0,,F,,,Intermediate,CHEMBL621646,1.0,,,5987.0,,N,BAO_0000219,A549,10090.0,,Mus musculus,In vitro antiproliferative activity against A549 cell line,,80682.0,646.0
1.0,6630.0,,F,,,Intermediate,CHEMBL621647,1.0,,,5988.0,,N,BAO_0000219,A549,,,,Synergism with indomethacin in A549 cells,,80682.0,646.0
1.0,6630.0,,F,,,Intermediate,CHEMBL621648,1.0,,,5989.0,,N,BAO_0000219,A549,,,,Synergism with tolmetin in A549 cells,,80682.0,646.0
1.0,6630.0,,F,,,Intermediate,CHEMBL621649,1.0,,,5990.0,,N,BAO_0000219,A549,,,,Synergism with sulindac in A549 cells,,80682.0,646.0
1.0,6630.0,,F,,,Intermediate,CHEMBL621650,1.0,,,5991.0,,N,BAO_0000219,A549,,,,Antagonism of indomethacin in A549 cells,,80682.0,646.0
1.0,6630.0,,F,,,Intermediate,CHEMBL621651,1.0,,,5992.0,,N,BAO_0000219,A549,,,,Antagonism of sulindac in A549 cells,,80682.0,646.0
1.0,6630.0,,F,,,Intermediate,CHEMBL621652,1.0,,,5993.0,,N,BAO_0000219,A549,,,,Antagonism of tolmetin in A549 cells,,80682.0,646.0
1.0,6630.0,,F,,,Intermediate,CHEMBL621653,1.0,,,5994.0,,N,BAO_0000219,A549,,,,Synergism with indomethacin in A549 cells,,80682.0,646.0
1.0,6630.0,,F,,,Intermediate,CHEMBL621654,1.0,,,5995.0,,N,BAO_0000219,A549,,,,Synergism with sulindac in A549 cells,,80682.0,646.0
1.0,6630.0,,F,,,Intermediate,CHEMBL621655,1.0,,,5996.0,,N,BAO_0000219,A549,,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,80682.0,646.0
1.0,16907.0,,A,,,Intermediate,CHEMBL621656,1.0,,,5997.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax value after 30 mg/kg po dose in Dogs,,50588.0,
1.0,5944.0,,A,,,Intermediate,CHEMBL621657,1.0,,,5998.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,50588.0,
1.0,5944.0,,A,,,Intermediate,CHEMBL621658,1.0,,,5999.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,50588.0,
1.0,5944.0,,A,,,Intermediate,CHEMBL621659,1.0,,,6000.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,50588.0,
1.0,5944.0,,A,,,Intermediate,CHEMBL621660,1.0,,,6001.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,50588.0,
1.0,2959.0,,A,,,Intermediate,CHEMBL621661,1.0,,,6002.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax value after administration of 4 mg/Kg oral dose in dog,,50588.0,
1.0,6241.0,,A,,,Intermediate,CHEMBL621662,1.0,,,6003.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax value in dog,,50588.0,
1.0,6241.0,,A,,,Intermediate,CHEMBL621663,1.0,,,6004.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax value in dogs after oral administration at 1 mg/kg,,50588.0,
1.0,2652.0,,A,,,Intermediate,CHEMBL621664,1.0,,,6005.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,50588.0,
1.0,1806.0,1969.0,A,,,Intermediate,CHEMBL621665,1.0,Plasma,,6006.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,,50588.0,
1.0,1806.0,1969.0,A,,,Intermediate,CHEMBL621666,1.0,Plasma,,6007.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,,50588.0,
1.0,1021.0,,A,,,Intermediate,CHEMBL621667,1.0,,,6008.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Concentration maxima after oral dosing in dogs,,50588.0,
1.0,1021.0,,A,,,Intermediate,CHEMBL876738,1.0,,,6009.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Concentration maxima after oral dosing in dogs; not available,,50588.0,
1.0,1021.0,,A,,,Intermediate,CHEMBL621668,1.0,,,6010.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Concentration maxima after oral dosing in dogs; not available,,50588.0,
1.0,5444.0,,A,,,Intermediate,CHEMBL621669,1.0,,,6011.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,50588.0,
1.0,5444.0,,A,,,Intermediate,CHEMBL621670,1.0,,,6012.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,50588.0,
1.0,5444.0,,A,,,Intermediate,CHEMBL621671,1.0,,,6013.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,In vivo maximal concentration was calculated at 1 mg/kg in dog,,50588.0,
1.0,5444.0,,A,,,Intermediate,CHEMBL622360,1.0,,,6014.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,50588.0,
1.0,5444.0,,A,,,Intermediate,CHEMBL622361,1.0,,,6015.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,50588.0,
1.0,5130.0,1969.0,A,,,Intermediate,CHEMBL622362,1.0,Plasma,,6016.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax in dog plasma after oral dose (1 mg/kg),,50588.0,
1.0,3249.0,1969.0,A,,,Intermediate,CHEMBL622363,1.0,Plasma,,6017.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,,50588.0,
1.0,5473.0,1969.0,A,,,Intermediate,CHEMBL622364,1.0,Plasma,,6018.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximal plasma concentration at a dose of 1 mg/kg,,50588.0,
1.0,5474.0,1969.0,A,,,Intermediate,CHEMBL622365,1.0,Plasma,,6019.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximal plasma concentration at a dose of 1 mg/kg (oral),,50588.0,
1.0,4657.0,1969.0,A,,,Intermediate,CHEMBL622533,1.0,Plasma,,6020.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,,50588.0,
1.0,3031.0,,A,,,Intermediate,CHEMBL622534,1.0,,,6021.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum concentration of compound in dog was evaluated.,,50588.0,
1.0,4527.0,,A,,,Intermediate,CHEMBL622535,1.0,,,6022.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,50588.0,
1.0,4186.0,,A,,,Intermediate,CHEMBL876739,1.0,,,6023.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,50588.0,
1.0,5007.0,,A,,,Intermediate,CHEMBL622536,1.0,,,6024.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,50588.0,
1.0,3132.0,1969.0,A,,,Intermediate,CHEMBL622537,1.0,Plasma,,6025.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum concentration obtained in dog plasma was determined,,50588.0,
1.0,5006.0,,A,,,Intermediate,CHEMBL622538,1.0,,,6026.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum concentration was determined,,50588.0,
1.0,4727.0,,A,,,Intermediate,CHEMBL627867,1.0,,,6027.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum concentration at the dose of 2 mg/kg in dog,,50588.0,
1.0,1916.0,,A,,,Intermediate,CHEMBL627868,1.0,,,6028.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,50588.0,
1.0,1918.0,1969.0,A,,,Intermediate,CHEMBL627869,1.0,Plasma,,6029.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum concentration was evaluated in dog plasma,,50588.0,
1.0,3045.0,,A,,,Intermediate,CHEMBL627870,1.0,,,6030.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum concentration was evaluated after 75 min after administration in dog,,50588.0,
1.0,9579.0,1969.0,A,,,Intermediate,CHEMBL627871,1.0,Plasma,,6031.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum plasma concentration determined in dog after oral administration of 17b,,50588.0,
1.0,9579.0,1969.0,A,,,Intermediate,CHEMBL627872,1.0,Plasma,,6032.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum plasma concentration determined in dog after oral administration of 2b,,50588.0,
1.0,933.0,1969.0,A,,,Intermediate,CHEMBL627873,1.0,Plasma,,6033.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum plasma concentration in dog,,50588.0,
1.0,17839.0,1969.0,A,,,Intermediate,CHEMBL627874,1.0,Plasma,,6034.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,,50588.0,
1.0,17839.0,1969.0,A,,,Intermediate,CHEMBL627875,1.0,Plasma,,6035.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,,50588.0,
1.0,17839.0,1969.0,A,,,Intermediate,CHEMBL627876,1.0,Plasma,,6036.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,,50588.0,
1.0,17839.0,1969.0,A,,,Intermediate,CHEMBL627877,1.0,Plasma,,6037.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,,50588.0,
1.0,6348.0,1969.0,A,,,Intermediate,CHEMBL627878,1.0,Plasma,,6038.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,50588.0,
1.0,16367.0,1969.0,A,,,Intermediate,CHEMBL627879,1.0,Plasma,,6039.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,,50588.0,
1.0,1337.0,1969.0,A,,,Intermediate,CHEMBL875355,1.0,Plasma,,6040.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,50588.0,
1.0,1337.0,1969.0,A,,,Intermediate,CHEMBL627880,1.0,Plasma,,6041.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,50588.0,
1.0,5199.0,1969.0,A,,,Intermediate,CHEMBL627881,1.0,Plasma,,6042.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,50588.0,
1.0,17650.0,1969.0,A,,,Intermediate,CHEMBL627882,1.0,Plasma,,6043.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,50588.0,
1.0,6679.0,1969.0,A,,,Intermediate,CHEMBL627883,1.0,Plasma,,6044.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,50588.0,
1.0,5356.0,1969.0,A,,,Intermediate,CHEMBL628526,1.0,Plasma,,6045.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,,50588.0,
1.0,5356.0,1969.0,A,,,Intermediate,CHEMBL628527,1.0,Plasma,,6046.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,,50588.0,
1.0,6227.0,1969.0,A,,,Intermediate,CHEMBL628528,1.0,Plasma,,6047.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,,50588.0,
1.0,6227.0,1969.0,A,,,Intermediate,CHEMBL628529,1.0,Plasma,,6048.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,,50588.0,
1.0,6227.0,1969.0,A,,,Intermediate,CHEMBL628530,1.0,Plasma,,6049.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,,50588.0,
1.0,6227.0,1969.0,A,,,Intermediate,CHEMBL625243,1.0,Plasma,,6050.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,,50588.0,
1.0,3598.0,1969.0,A,,,Expert,CHEMBL625244,1.0,Plasma,,6051.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,,50588.0,
1.0,4368.0,,A,,,Intermediate,CHEMBL625245,1.0,,,6052.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,50588.0,
1.0,6265.0,,A,,,Intermediate,CHEMBL625246,1.0,,,6053.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,50588.0,
1.0,7767.0,945.0,A,,,Intermediate,CHEMBL625247,1.0,Stomach,,6054.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,1088.0,A,,,Intermediate,CHEMBL625248,1.0,Urine,,6055.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594.0,
1.0,7767.0,1088.0,A,,,Intermediate,CHEMBL625249,1.0,Urine,,6056.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,,50594.0,
1.0,7767.0,1088.0,A,,,Intermediate,CHEMBL625250,1.0,Urine,,6057.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,,50594.0,
1.0,17811.0,,A,,,Intermediate,CHEMBL625251,1.0,,,6058.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,50594.0,
1.0,17811.0,,A,,,Intermediate,CHEMBL875356,1.0,,,6059.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,50594.0,
1.0,17827.0,,A,,,Intermediate,CHEMBL625252,1.0,,,6060.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,50594.0,
1.0,17827.0,178.0,A,,,Intermediate,CHEMBL625253,1.0,Blood,,6061.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,50594.0,
1.0,17827.0,,A,,,Intermediate,CHEMBL625254,1.0,,,6062.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,50594.0,
1.0,17827.0,,A,,,Intermediate,CHEMBL625255,1.0,,,6063.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,50594.0,
1.0,17827.0,,A,,,Intermediate,CHEMBL625256,1.0,,,6064.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,50594.0,
1.0,17827.0,178.0,A,,,Intermediate,CHEMBL625257,1.0,Blood,,6065.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,50594.0,
1.0,17827.0,178.0,A,,,Intermediate,CHEMBL625258,1.0,Blood,,6066.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,50594.0,
1.0,17827.0,,A,,,Intermediate,CHEMBL625259,1.0,,,6067.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound was evaluated for washout rate in mice (Radiolabeled compound),,50594.0,
1.0,17827.0,,A,,,Intermediate,CHEMBL625260,1.0,,,6068.0,,N,BAO_0000218,,10090.0,,Mus musculus,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,50594.0,
1.0,17827.0,,A,,,Intermediate,CHEMBL625261,1.0,,,6069.0,,N,BAO_0000218,,10090.0,,Mus musculus,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,50594.0,
1.0,17827.0,,A,,,Intermediate,CHEMBL625262,1.0,,,6070.0,,N,BAO_0000218,,10090.0,,Mus musculus,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,50594.0,
1.0,17827.0,,A,,,Intermediate,CHEMBL622639,1.0,,,6071.0,,N,BAO_0000218,,10090.0,,Mus musculus,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,50594.0,
1.0,17257.0,,A,,,Intermediate,CHEMBL622640,1.0,,,6072.0,,N,BAO_0000218,,10090.0,,Mus musculus,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,50594.0,
1.0,17257.0,,A,,,Intermediate,CHEMBL622812,1.0,,,6073.0,,N,BAO_0000218,,10090.0,,Mus musculus,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,50594.0,
1.0,17257.0,,A,,,Intermediate,CHEMBL622813,1.0,,,6074.0,,N,BAO_0000218,,10090.0,,Mus musculus,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,50594.0,
1.0,17257.0,,A,,,Intermediate,CHEMBL622814,1.0,,,6075.0,,N,BAO_0000218,,10090.0,,Mus musculus,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,50594.0,
1.0,17827.0,,A,,,Intermediate,CHEMBL622815,1.0,,,6076.0,,N,BAO_0000218,,10090.0,,Mus musculus,Time at maximum activity in mice (Radiolabeled compound),,50594.0,
1.0,3760.0,,A,,,Intermediate,CHEMBL625342,1.0,,,6077.0,,N,BAO_0000218,,10090.0,,Mus musculus,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,50594.0,
1.0,3760.0,,A,,,Intermediate,CHEMBL625343,1.0,,,6078.0,,N,BAO_0000218,,10090.0,,Mus musculus,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,50594.0,
1.0,17409.0,,A,,,Intermediate,CHEMBL877591,1.0,,,6079.0,,N,BAO_0000218,,10090.0,,Mus musculus,Binding towards mouse plasma protein at 10 uM,,50594.0,
1.0,17409.0,,A,,,Intermediate,CHEMBL625344,1.0,,,6080.0,,N,BAO_0000218,,10090.0,,Mus musculus,Binding towards mouse plasma protein at 100 uM,,50594.0,
1.0,2675.0,,A,,,Intermediate,CHEMBL625345,1.0,,,6081.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Bioavailability was evaluated in mice after intravenous administration,,50594.0,
1.0,2675.0,,A,,,Intermediate,CHEMBL625346,1.0,,,6082.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Bioavailability was evaluated in mice after oral administration,,50594.0,
1.0,3132.0,,A,,,Intermediate,CHEMBL625347,1.0,,,6083.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,50594.0,
1.0,3132.0,,A,,,Intermediate,CHEMBL625348,1.0,,,6084.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,50594.0,
1.0,16597.0,,A,,,Intermediate,CHEMBL625349,1.0,,,6085.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,50594.0,
1.0,2862.0,,A,,,Intermediate,CHEMBL625350,1.0,,,6086.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Oral bioavailability in mouse,,50594.0,
1.0,17764.0,,A,,,Intermediate,CHEMBL882952,1.0,,,6087.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,50594.0,
1.0,846.0,955.0,A,,,Intermediate,CHEMBL625351,1.0,Brain,,6088.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,955.0,A,,,Intermediate,CHEMBL625352,1.0,Brain,,6089.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,955.0,A,,,Intermediate,CHEMBL877592,1.0,Brain,,6090.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,955.0,A,,,Intermediate,CHEMBL625353,1.0,Brain,,6091.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,955.0,A,,,Intermediate,CHEMBL625354,1.0,Brain,,6092.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,955.0,A,,,Intermediate,CHEMBL626019,1.0,Brain,,6093.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,948.0,A,,,Intermediate,CHEMBL626020,1.0,Heart,,6094.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,948.0,A,,,Intermediate,CHEMBL626021,1.0,Heart,,6095.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,948.0,A,,,Intermediate,CHEMBL626022,1.0,Heart,,6096.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,948.0,A,,,Intermediate,CHEMBL626192,1.0,Heart,,6097.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,1276.0,,F,,,Intermediate,CHEMBL626193,1.0,,,6098.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,80682.0,646.0
1.0,3498.0,,F,,,Expert,CHEMBL626194,1.0,,,6099.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,80682.0,646.0
1.0,1169.0,,F,,,Intermediate,CHEMBL626195,1.0,,,6100.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity against human lung carcinoma A-549 cell lines,,80682.0,646.0
1.0,4450.0,,F,,,Intermediate,CHEMBL626196,1.0,,,6101.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,80682.0,646.0
1.0,358.0,,F,,,Intermediate,CHEMBL626197,1.0,,,6102.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549,,80682.0,646.0
1.0,358.0,,F,,,Intermediate,CHEMBL626198,1.0,,,6103.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,80682.0,646.0
1.0,358.0,,F,,,Intermediate,CHEMBL626199,1.0,,,6104.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,80682.0,646.0
1.0,358.0,,F,,,Intermediate,CHEMBL626200,1.0,,,6105.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,80682.0,646.0
1.0,358.0,,F,,,Intermediate,CHEMBL626201,1.0,,,6106.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,80682.0,646.0
1.0,358.0,,F,,,Intermediate,CHEMBL626202,1.0,,,6107.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,80682.0,646.0
1.0,358.0,,F,,,Intermediate,CHEMBL626203,1.0,,,6108.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,80682.0,646.0
1.0,15167.0,,F,,,Intermediate,CHEMBL626204,1.0,,,6109.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against A-549 human lung cancer cells,,80682.0,646.0
1.0,4139.0,,F,,,Intermediate,CHEMBL624701,1.0,,,6110.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,80682.0,646.0
1.0,833.0,,F,,,Intermediate,CHEMBL624702,1.0,,,6111.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,80682.0,646.0
1.0,15718.0,,F,,,Expert,CHEMBL624703,1.0,,,6112.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,80682.0,646.0
1.0,12373.0,,F,,,Intermediate,CHEMBL624704,1.0,,,6113.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,80682.0,646.0
1.0,637.0,,F,,,Intermediate,CHEMBL624705,1.0,,,6114.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,80682.0,646.0
1.0,14867.0,,F,,,Expert,CHEMBL624706,1.0,,,6115.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,80682.0,646.0
1.0,4461.0,,F,,,Intermediate,CHEMBL624707,1.0,,,6116.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Antitumor cytotoxic activity against A-549 cell line was determined,,80682.0,646.0
1.0,5406.0,,F,,,Intermediate,CHEMBL624708,1.0,,,6117.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,80682.0,646.0
1.0,4457.0,,F,,,Intermediate,CHEMBL624709,1.0,,,6118.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,80682.0,646.0
1.0,1386.0,,F,,,Expert,CHEMBL884107,1.0,,,6119.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,80682.0,646.0
1.0,3265.0,,F,,,Intermediate,CHEMBL624710,1.0,,,6120.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Antitumoral activity was assayed against A-549 cell line,,80682.0,646.0
1.0,2359.0,,F,,,Intermediate,CHEMBL624711,1.0,,,6121.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,80682.0,646.0
1.0,4457.0,,F,,,Intermediate,CHEMBL624712,1.0,,,6122.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,80682.0,646.0
1.0,12454.0,,F,,,Expert,CHEMBL624713,1.0,,,6123.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,80682.0,646.0
1.0,1481.0,,F,,,Intermediate,CHEMBL624714,1.0,,,6124.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested for inhibition of cell growth of A-549 cells,,80682.0,646.0
1.0,1750.0,,F,,,Intermediate,CHEMBL624715,1.0,,,6125.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,80682.0,646.0
1.0,5065.0,,F,,,Intermediate,CHEMBL624716,1.0,,,6126.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,80682.0,646.0
1.0,808.0,,F,,,Expert,CHEMBL619505,1.0,,,6127.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against A549-human lung carcinoma cells.,,80682.0,646.0
1.0,16364.0,,F,,,Expert,CHEMBL619506,1.0,,,6128.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,80682.0,646.0
1.0,1847.0,,F,,,Intermediate,CHEMBL619507,1.0,,,6129.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic activity against A-549 cell lines.,,80682.0,646.0
1.0,1747.0,,F,,,Expert,CHEMBL619508,1.0,,,6130.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,80682.0,646.0
1.0,1003.0,,F,,,Intermediate,CHEMBL619509,1.0,,,6131.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity against human A549 non small cell lung cell lines,,80682.0,646.0
1.0,15313.0,,F,,,Expert,CHEMBL619510,1.0,,,6132.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of cell growth in (A-549) lung cell line,,80682.0,646.0
1.0,3122.0,,F,,,Intermediate,CHEMBL619511,1.0,,,6133.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,80682.0,646.0
1.0,16049.0,,F,,,Intermediate,CHEMBL619512,1.0,,,6134.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro antitumor activity against A-549 tumor cells.,,80682.0,646.0
1.0,17134.0,,F,,,Expert,CHEMBL619513,1.0,,,6135.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro antitumor effects against human A-549 cell lines.,,80682.0,646.0
1.0,6406.0,,F,,,Intermediate,CHEMBL619514,1.0,,,6136.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxic activity of compound against A-549 cell line,,80682.0,646.0
1.0,627.0,,F,,,Intermediate,CHEMBL619515,1.0,,,6137.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,80682.0,646.0
1.0,12307.0,,F,,,Intermediate,CHEMBL619516,1.0,,,6138.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,80682.0,646.0
1.0,17861.0,,F,,,Intermediate,CHEMBL884005,1.0,,,6139.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,80682.0,646.0
1.0,6682.0,,F,,,Expert,CHEMBL619517,1.0,,,6140.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,80682.0,646.0
1.0,6663.0,,F,,,Intermediate,CHEMBL619518,1.0,,,6141.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory concentration of compound against A-549 cell line,,80682.0,646.0
1.0,2454.0,,F,,,Intermediate,CHEMBL619519,1.0,,,6142.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,80682.0,646.0
1.0,14709.0,,F,,,Intermediate,CHEMBL876489,1.0,,,6143.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,cytotoxic activity against leukemia (A-549) cancer cell line,,80682.0,646.0
1.0,15718.0,,F,,,Expert,CHEMBL619520,1.0,,,6144.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,80682.0,646.0
1.0,15718.0,,F,,,Intermediate,CHEMBL619521,1.0,,,6145.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,80682.0,646.0
1.0,17130.0,,F,,,Intermediate,CHEMBL619522,1.0,,,6146.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,80682.0,646.0
1.0,17130.0,,F,,,Intermediate,CHEMBL619523,1.0,,,6147.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,80682.0,646.0
1.0,17130.0,,F,,,Intermediate,CHEMBL619524,1.0,,,6148.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,80682.0,646.0
1.0,17130.0,,F,,,Intermediate,CHEMBL619525,1.0,,,6149.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,80682.0,646.0
1.0,6630.0,,F,,,Intermediate,CHEMBL619526,1.0,,,6150.0,,N,BAO_0000219,A549,,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,80682.0,646.0
1.0,16726.0,,F,,,Intermediate,CHEMBL619527,1.0,,,6151.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,80682.0,646.0
1.0,17846.0,,F,,,Intermediate,CHEMBL619528,1.0,,,6152.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity against A549 cells; No cytotoxicity,,80682.0,646.0
1.0,3415.0,,F,,,Expert,CHEMBL619529,1.0,,,6153.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity against human lung carcinoma (A549) cell lines,,80682.0,646.0
1.0,3415.0,,F,,,Expert,CHEMBL619530,1.0,,,6154.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,80682.0,646.0
1.0,5609.0,,F,,,Intermediate,CHEMBL876490,1.0,,,6155.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro anticancer activity against human lung (A549) cell line,,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL619531,1.0,,,6156.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL619532,1.0,,,6157.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL619533,1.0,,,6158.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL619534,1.0,,,6159.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL620164,1.0,,,6160.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL620165,1.0,,,6161.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,80682.0,646.0
1.0,16295.0,,F,,,Expert,CHEMBL620166,1.0,,,6162.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of A549 human lung tumor cell proliferation,,80682.0,646.0
1.0,16825.0,,F,,,Intermediate,CHEMBL620167,1.0,,,6163.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,80682.0,646.0
1.0,3439.0,,F,,,Expert,CHEMBL620168,1.0,,,6164.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against human tumor cell line A549,,80682.0,646.0
1.0,10870.0,,F,,,Intermediate,CHEMBL620338,1.0,,,6165.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,80682.0,646.0
1.0,4845.0,,F,,,Intermediate,CHEMBL620339,1.0,,,6166.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,80682.0,646.0
1.0,5822.0,,F,,,Intermediate,CHEMBL620340,1.0,,,6167.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,80682.0,646.0
1.0,5822.0,,F,,,Intermediate,CHEMBL620341,1.0,,,6168.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,80682.0,646.0
1.0,5822.0,,F,,,Intermediate,CHEMBL876491,1.0,,,6169.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,80682.0,646.0
1.0,16381.0,,F,,,Intermediate,CHEMBL620342,1.0,,,6170.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,80682.0,646.0
1.0,16381.0,,F,,,Intermediate,CHEMBL620343,1.0,,,6171.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,80682.0,646.0
1.0,16381.0,,F,,,Intermediate,CHEMBL620344,1.0,,,6172.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,80682.0,646.0
1.0,5609.0,,F,,,Intermediate,CHEMBL620345,1.0,,,6173.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro anticancer activity against human lung (A549) cell line,,80682.0,646.0
1.0,4644.0,,F,,,Intermediate,CHEMBL620346,1.0,,,6174.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,80682.0,646.0
1.0,4644.0,,F,,,Intermediate,CHEMBL620347,1.0,,,6175.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,80682.0,646.0
1.0,4644.0,,F,,,Intermediate,CHEMBL620348,1.0,,,6176.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,80682.0,646.0
1.0,4644.0,,F,,,Intermediate,CHEMBL620349,1.0,,,6177.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,80682.0,646.0
1.0,5822.0,,F,,,Intermediate,CHEMBL618667,1.0,,,6178.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,80682.0,646.0
1.0,3415.0,,F,,,Expert,CHEMBL618668,1.0,,,6179.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Percentage inhibition of human lung carcinoma (A549) cell lines,,80682.0,646.0
1.0,16726.0,,F,,,Intermediate,CHEMBL876031,1.0,,,6180.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL618759,1.0,,,6181.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL618760,1.0,,,6182.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL619000,1.0,,,6183.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL619001,1.0,,,6184.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL619002,1.0,,,6185.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL619003,1.0,,,6186.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL619597,1.0,,,6187.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL619598,1.0,,,6188.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL619599,1.0,,,6189.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL619600,1.0,,,6190.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,80682.0,646.0
1.0,16726.0,,F,,,Intermediate,CHEMBL619601,1.0,,,6191.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL619602,1.0,,,6192.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL619603,1.0,,,6193.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL619604,1.0,,,6194.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL619605,1.0,,,6195.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,80682.0,646.0
1.0,6084.0,,A,,,Intermediate,CHEMBL619606,1.0,,,6196.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,50588.0,
1.0,6084.0,,A,,,Intermediate,CHEMBL876032,1.0,,,6197.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic activity (Cmax) in dog,,50588.0,
1.0,4809.0,,A,,,Intermediate,CHEMBL619607,1.0,,,6198.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,50588.0,
1.0,5983.0,,A,,,Intermediate,CHEMBL619608,1.0,,,6199.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,50588.0,
1.0,6251.0,,A,,,Intermediate,CHEMBL619609,1.0,,,6200.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,50588.0,
1.0,5932.0,1969.0,A,,,Intermediate,CHEMBL619610,1.0,Plasma,,6201.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax in dog plasma after 30mg/kg oral dose,,50588.0,
1.0,4273.0,178.0,A,,,Intermediate,CHEMBL619611,1.0,Blood,,6202.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Tested for the peak blood level in dog,,50588.0,
1.0,5313.0,,A,,,Intermediate,CHEMBL619612,1.0,,,6203.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,50588.0,
1.0,5313.0,,A,,,Intermediate,CHEMBL619613,1.0,,,6204.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,50588.0,
1.0,6221.0,178.0,A,,,Intermediate,CHEMBL619614,1.0,Blood,,6205.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,,50588.0,
1.0,4709.0,,A,,,Intermediate,CHEMBL619615,1.0,,,6206.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,50588.0,
1.0,167.0,,A,,,Intermediate,CHEMBL619616,1.0,,,6207.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,50588.0,
1.0,6241.0,1969.0,A,,,Intermediate,CHEMBL619617,1.0,Plasma,,6208.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Final plasma concentration in dogs after oral administration at 1 mg/kg,,50588.0,
1.0,344.0,,A,,,Intermediate,CHEMBL619618,1.0,,,6209.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,50588.0,
1.0,344.0,,A,,,Intermediate,CHEMBL876033,1.0,,,6210.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,50588.0,
1.0,344.0,,A,,,Intermediate,CHEMBL619619,1.0,,,6211.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,50588.0,
1.0,2189.0,,A,,,Intermediate,CHEMBL619620,1.0,,,6212.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,50588.0,
1.0,2189.0,1088.0,A,,,Intermediate,CHEMBL619621,1.0,Urine,,6213.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,50588.0,
1.0,2189.0,1088.0,A,,,Intermediate,CHEMBL619622,1.0,Urine,,6214.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,50588.0,
1.0,2189.0,1088.0,A,,,Intermediate,CHEMBL618874,1.0,Urine,,6215.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,50588.0,
1.0,4257.0,,A,,,Intermediate,CHEMBL618875,1.0,,,6216.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Absolute bioavailability was evaluated in dog,,50588.0,
1.0,6221.0,,A,,,Intermediate,CHEMBL618876,1.0,,,6217.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,50588.0,
1.0,6215.0,,A,,,Intermediate,CHEMBL618877,1.0,,,6218.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,50588.0,
1.0,17267.0,,A,,,Intermediate,CHEMBL618878,1.0,,,6219.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog,,50588.0,
1.0,6621.0,,A,,,Intermediate,CHEMBL618879,1.0,,,6220.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog,,50588.0,
1.0,3854.0,,A,,,Intermediate,CHEMBL618880,1.0,,,6221.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability after intravenous administration in dogs,,50588.0,
1.0,3854.0,,A,,,Intermediate,CHEMBL618881,1.0,,,6222.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability after peroral administration in dogs,,50588.0,
1.0,5007.0,,A,,,Intermediate,CHEMBL618882,1.0,,,6223.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,50588.0,
1.0,4333.0,,A,,,Intermediate,CHEMBL624226,1.0,,,6224.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,50588.0,
1.0,4333.0,1969.0,A,,,Intermediate,CHEMBL624227,1.0,Plasma,,6225.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,,50588.0,
1.0,5006.0,,A,,,Intermediate,CHEMBL624228,1.0,,,6226.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability,,50588.0,
1.0,5199.0,,A,,,Intermediate,CHEMBL624229,1.0,,,6227.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability,,50588.0,
1.0,4368.0,,A,,,Intermediate,CHEMBL624230,1.0,,,6228.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,50588.0,
1.0,3771.0,,A,,,Intermediate,CHEMBL624231,1.0,,,6229.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog,,50588.0,
1.0,4953.0,,A,,,Intermediate,CHEMBL624232,1.0,,,6230.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog,,50588.0,
1.0,5064.0,,A,,,Intermediate,CHEMBL625127,1.0,,,6231.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog,,50588.0,
1.0,17657.0,,A,,,Intermediate,CHEMBL625128,1.0,,,6232.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog,,50588.0,
1.0,17796.0,,A,,,Intermediate,CHEMBL621675,1.0,,,6233.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog,,50588.0,
1.0,17853.0,,A,,,Intermediate,CHEMBL621676,1.0,,,6234.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog (p.o.) at 2.0 mpk,,50588.0,
1.0,4521.0,,A,,,Intermediate,CHEMBL621677,1.0,,,6235.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,50588.0,
1.0,4521.0,,A,,,Intermediate,CHEMBL621678,1.0,,,6236.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,50588.0,
1.0,5006.0,,A,,,Intermediate,CHEMBL621679,1.0,,,6237.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog,,50588.0,
1.0,16365.0,,A,,,Intermediate,CHEMBL621680,1.0,,,6238.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability was evaluated after oral administration in dog,,50588.0,
1.0,1916.0,,A,,,Intermediate,CHEMBL621681,1.0,,,6239.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,50588.0,
1.0,1918.0,,A,,,Intermediate,CHEMBL876740,1.0,,,6240.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability was evaluated in dog,,50588.0,
1.0,4239.0,,A,,,Intermediate,CHEMBL621682,1.0,,,6241.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog,,50588.0,
1.0,6505.0,,A,,,Intermediate,CHEMBL621683,1.0,,,6242.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog,,50588.0,
1.0,5334.0,,A,,,Intermediate,CHEMBL621684,1.0,,,6243.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,50588.0,
1.0,5334.0,,A,,,Intermediate,CHEMBL621685,1.0,,,6244.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,50588.0,
1.0,4809.0,,A,,,Intermediate,CHEMBL621686,1.0,,,6245.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,50588.0,
1.0,6348.0,,A,,,Intermediate,CHEMBL621687,1.0,,,6246.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,50588.0,
1.0,6005.0,,A,,,Intermediate,CHEMBL621688,1.0,,,6247.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,50588.0,
1.0,17804.0,,A,,,Intermediate,CHEMBL621689,1.0,,,6248.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability of compound in dog was determined after peroral administration,,50588.0,
1.0,3184.0,,A,,,Intermediate,CHEMBL621690,1.0,,,6249.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,1806.0,,A,,,Intermediate,CHEMBL621691,1.0,,,6250.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,50588.0,
1.0,1806.0,,A,,,Intermediate,CHEMBL875941,1.0,,,6251.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,50588.0,
1.0,1806.0,,A,,,Intermediate,CHEMBL621692,1.0,,,6252.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,50588.0,
1.0,4839.0,,A,,,Intermediate,CHEMBL621693,1.0,,,6253.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog,,50588.0,
1.0,5017.0,,A,,,Intermediate,CHEMBL621694,1.0,,,6254.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,50588.0,
1.0,846.0,948.0,A,,,Intermediate,CHEMBL621695,1.0,Heart,,6255.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,948.0,A,,,Intermediate,CHEMBL621696,1.0,Heart,,6256.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,2113.0,A,,,Intermediate,CHEMBL621697,1.0,Kidney,,6257.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,2113.0,A,,,Intermediate,CHEMBL621698,1.0,Kidney,,6258.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,2113.0,A,,,Intermediate,CHEMBL623420,1.0,Kidney,,6259.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,2113.0,A,,,Intermediate,CHEMBL623421,1.0,Kidney,,6260.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,2113.0,A,,,Intermediate,CHEMBL623422,1.0,Kidney,,6261.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,2113.0,A,,,Intermediate,CHEMBL623423,1.0,Kidney,,6262.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,2107.0,A,,,Intermediate,CHEMBL623424,1.0,Liver,,6263.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,2107.0,A,,,Intermediate,CHEMBL623425,1.0,Liver,,6264.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,2107.0,A,,,Intermediate,CHEMBL623426,1.0,Liver,,6265.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,2107.0,A,,,Intermediate,CHEMBL623427,1.0,Liver,,6266.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,2107.0,A,,,Intermediate,CHEMBL623428,1.0,Liver,,6267.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,2107.0,A,,,Intermediate,CHEMBL875947,1.0,Liver,,6268.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,2048.0,A,,,Intermediate,CHEMBL623429,1.0,Lung,,6269.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,2048.0,A,,,Intermediate,CHEMBL623430,1.0,Lung,,6270.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,2048.0,A,,,Intermediate,CHEMBL622588,1.0,Lung,,6271.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,2048.0,A,,,Intermediate,CHEMBL622589,1.0,Lung,,6272.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,2048.0,A,,,Intermediate,CHEMBL622751,1.0,Lung,,6273.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,846.0,2048.0,A,,,Intermediate,CHEMBL622752,1.0,Lung,,6274.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,50594.0,
1.0,6599.0,,A,,,Intermediate,CHEMBL622753,1.0,,,6275.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL622647,1.0,,,6276.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL875163,1.0,,,6277.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL622648,1.0,,,6278.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL622649,1.0,,,6279.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,50594.0,42.0
1.0,6599.0,955.0,A,,,Intermediate,CHEMBL622650,1.0,Brain,,6280.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,,50594.0,42.0
1.0,6599.0,955.0,A,,,Intermediate,CHEMBL622651,1.0,Brain,,6281.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,,50594.0,42.0
1.0,6599.0,955.0,A,,,Intermediate,CHEMBL622652,1.0,Brain,,6282.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,,50594.0,42.0
1.0,6599.0,955.0,A,,,Intermediate,CHEMBL622653,1.0,Brain,,6283.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,,50594.0,42.0
1.0,6599.0,955.0,A,,,Intermediate,CHEMBL622654,1.0,Brain,,6284.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,,50594.0,42.0
1.0,6599.0,948.0,A,,,Intermediate,CHEMBL622655,1.0,Heart,,6285.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,,50594.0,42.0
1.0,6599.0,948.0,A,,,Intermediate,CHEMBL622656,1.0,Heart,,6286.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,,50594.0,42.0
1.0,6599.0,948.0,A,,,Intermediate,CHEMBL622657,1.0,Heart,,6287.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,,50594.0,42.0
1.0,6599.0,948.0,A,,,Intermediate,CHEMBL622658,1.0,Heart,,6288.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,,50594.0,42.0
1.0,6599.0,948.0,A,,,Intermediate,CHEMBL622659,1.0,Heart,,6289.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,,50594.0,42.0
1.0,6599.0,2113.0,A,,,Intermediate,CHEMBL624630,1.0,Kidney,,6290.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,,50594.0,42.0
1.0,6599.0,2113.0,A,,,Intermediate,CHEMBL624631,1.0,Kidney,,6291.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,,50594.0,42.0
1.0,6599.0,2113.0,A,,,Intermediate,CHEMBL624632,1.0,Kidney,,6292.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,,50594.0,42.0
1.0,17130.0,,F,,,Intermediate,CHEMBL624633,1.0,,,6293.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,80682.0,646.0
1.0,17130.0,,F,,,Intermediate,CHEMBL624634,1.0,,,6294.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,80682.0,646.0
1.0,17130.0,,F,,,Intermediate,CHEMBL624635,1.0,,,6295.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,80682.0,646.0
1.0,17130.0,,F,,,Intermediate,CHEMBL624636,1.0,,,6296.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,80682.0,646.0
1.0,3263.0,,F,,,Expert,CHEMBL857055,1.0,,,6297.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,80682.0,646.0
1.0,6663.0,,F,,,Expert,CHEMBL624637,1.0,,,6298.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,80682.0,646.0
1.0,6663.0,,F,,,Expert,CHEMBL624638,1.0,,,6299.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,80682.0,646.0
1.0,6663.0,,F,,,Expert,CHEMBL874366,1.0,,,6300.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,80682.0,646.0
1.0,6663.0,,F,,,Expert,CHEMBL624639,1.0,,,6301.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,80682.0,646.0
1.0,6663.0,,F,,,Expert,CHEMBL624640,1.0,,,6302.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,80682.0,646.0
1.0,6663.0,,F,,,Intermediate,CHEMBL624641,1.0,,,6303.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,80682.0,646.0
1.0,6663.0,,F,,,Intermediate,CHEMBL624642,1.0,,,6304.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,80682.0,646.0
1.0,6663.0,,F,,,Intermediate,CHEMBL624643,1.0,,,6305.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,80682.0,646.0
1.0,6663.0,,F,,,Intermediate,CHEMBL624644,1.0,,,6306.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,80682.0,646.0
1.0,6663.0,,F,,,Intermediate,CHEMBL624645,1.0,,,6307.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,80682.0,646.0
1.0,3983.0,,F,,,Intermediate,CHEMBL619445,1.0,,,6308.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,The compound was evaluated for its cytotoxic potency against A-549 cell line,,80682.0,646.0
1.0,11141.0,,F,,,Expert,CHEMBL839886,1.0,,,6309.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,80682.0,646.0
1.0,5076.0,,F,,,Intermediate,CHEMBL619446,1.0,,,6310.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic activity of compound against A-549 tumor cell line.,,80682.0,646.0
1.0,3311.0,,F,,,Intermediate,CHEMBL619447,1.0,,,6311.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,80682.0,646.0
1.0,3311.0,,F,,,Intermediate,CHEMBL619448,1.0,,,6312.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,80682.0,646.0
1.0,3311.0,,F,,,Intermediate,CHEMBL619449,1.0,,,6313.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,80682.0,646.0
1.0,5076.0,,F,,,Intermediate,CHEMBL619450,1.0,,,6314.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,80682.0,646.0
1.0,4150.0,,F,,,Intermediate,CHEMBL619451,1.0,,,6315.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,80682.0,646.0
1.0,2150.0,,F,,,Expert,CHEMBL619452,1.0,,,6316.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,80682.0,646.0
1.0,4644.0,,F,,,Intermediate,CHEMBL619453,1.0,,,6317.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,80682.0,646.0
1.0,263.0,,F,,,Intermediate,CHEMBL874367,1.0,,,6318.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,80682.0,646.0
1.0,11333.0,,F,,,Intermediate,CHEMBL619454,1.0,,,6319.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic concentration against A-549 tumor cells.,,80682.0,646.0
1.0,11333.0,,F,,,Intermediate,CHEMBL619455,1.0,,,6320.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,80682.0,646.0
1.0,15895.0,,F,,,Intermediate,CHEMBL619456,1.0,,,6321.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,80682.0,646.0
1.0,16677.0,,F,,,Expert,CHEMBL619457,1.0,,,6322.0,,N,BAO_0000218,,470.0,,Acinetobacter baumannii,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,50191.0,
1.0,10624.0,,F,,,Intermediate,CHEMBL619458,1.0,,,6323.0,,N,BAO_0000218,,471.0,,Acinetobacter calcoaceticus,Activity against Acinetobacter calcoaceticus (AC54),,50192.0,
1.0,16717.0,,F,,,Expert,CHEMBL619459,1.0,,,6324.0,,N,BAO_0000218,,5059.0,,Aspergillus flavus,In vitro antifungal activity against Aspergillus flavus CM74,,50274.0,
1.0,16717.0,,F,,,Expert,CHEMBL619460,1.0,,,6325.0,,N,BAO_0000218,,5059.0,,Aspergillus flavus,In vitro antifungal activity against Aspergillus flavus CM74,,50274.0,
1.0,5513.0,,F,,,Intermediate,CHEMBL619461,1.0,,,6326.0,,N,BAO_0000218,,746128.0,,Aspergillus fumigatus,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,50416.0,
1.0,15962.0,,F,,,Intermediate,CHEMBL619462,1.0,,,6327.0,,N,BAO_0000218,,746128.0,,Aspergillus fumigatus,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,50416.0,
1.0,15962.0,,F,,,Intermediate,CHEMBL620388,1.0,,,6328.0,,N,BAO_0000218,,746128.0,,Aspergillus fumigatus,Antimicrobial activity against Aspergillus fumigatus (MIC),,50416.0,
1.0,15962.0,,F,,,Intermediate,CHEMBL620389,1.0,,,6329.0,,N,BAO_0000218,,746128.0,,Aspergillus fumigatus,Antimicrobial activity against Aspergillus fumigatus (MIC),,50416.0,
1.0,15962.0,,F,,,Intermediate,CHEMBL620390,1.0,,,6330.0,,N,BAO_0000218,,746128.0,,Aspergillus fumigatus,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,50416.0,
1.0,16717.0,,F,,,Expert,CHEMBL620391,1.0,,,6331.0,,N,BAO_0000218,,746128.0,,Aspergillus fumigatus,In vitro antifungal activity against Aspergillus fumigatus 48238E,,50416.0,
1.0,16717.0,,F,,,Expert,CHEMBL621073,1.0,,,6332.0,,N,BAO_0000218,,746128.0,,Aspergillus fumigatus,In vitro antifungal activity against Aspergillus fumigatus 48238E,,50416.0,
1.0,8117.0,,F,,,Intermediate,CHEMBL621074,1.0,,,6333.0,,N,BAO_0000218,,1655.0,,Actinomyces naeslundii,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,50296.0,
1.0,8117.0,,F,,,Intermediate,CHEMBL621075,1.0,,,6334.0,,N,BAO_0000218,,1656.0,,Actinomyces viscosus,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,50366.0,
1.0,15472.0,,F,,,Intermediate,CHEMBL619554,1.0,,,6335.0,,N,BAO_0000218,,6277.0,,Acanthocheilonema viteae,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,50535.0,
1.0,15472.0,,F,,,Intermediate,CHEMBL619555,1.0,,,6336.0,,N,BAO_0000218,,6277.0,,Acanthocheilonema viteae,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,50535.0,
1.0,16443.0,,F,,,Intermediate,CHEMBL619556,1.0,,,6337.0,,N,BAO_0000218,,714.0,,Aggregatibacter actinomycetemcomitans,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,50169.0,
1.0,16443.0,,F,,,Intermediate,CHEMBL619557,1.0,,,6338.0,,N,BAO_0000218,,714.0,,Aggregatibacter actinomycetemcomitans,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,50169.0,
1.0,16443.0,,F,,,Intermediate,CHEMBL619558,1.0,,,6339.0,,N,BAO_0000218,,714.0,,Aggregatibacter actinomycetemcomitans,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,50169.0,
1.0,17206.0,,F,,,Intermediate,CHEMBL619559,1.0,,,6340.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL619560,1.0,,,6341.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,80682.0,646.0
1.0,16381.0,,F,,,Intermediate,CHEMBL619561,1.0,,,6342.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,80682.0,646.0
1.0,16381.0,,F,,,Intermediate,CHEMBL619562,1.0,,,6343.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,80682.0,646.0
1.0,16381.0,,F,,,Intermediate,CHEMBL619563,1.0,,,6344.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,80682.0,646.0
1.0,16381.0,,F,,,Intermediate,CHEMBL857457,1.0,,,6345.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,GI values against A549 cells (lung cancer),,80682.0,646.0
1.0,17206.0,,F,,,Intermediate,CHEMBL619564,1.0,,,6346.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,80682.0,646.0
1.0,16325.0,,F,,,Intermediate,CHEMBL619565,1.0,,,6347.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory activity against A549 human adenocarcinoma,,80682.0,646.0
1.0,10708.0,,F,,,Intermediate,CHEMBL619566,1.0,,,6348.0,,N,BAO_0000218,A549,9606.0,,Homo sapiens,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,80682.0,646.0
1.0,10708.0,,F,,,Intermediate,CHEMBL619567,1.0,,,6349.0,,N,BAO_0000218,A549,9606.0,,Homo sapiens,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,80682.0,646.0
1.0,17376.0,,F,,,Intermediate,CHEMBL619568,1.0,,,6350.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory activity against A549 lung adenocarcinoma cell line,,80682.0,646.0
1.0,17376.0,,F,,,Intermediate,CHEMBL619569,1.0,,,6351.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,80682.0,646.0
1.0,17488.0,,F,,,Intermediate,CHEMBL619570,1.0,,,6352.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity against human A549 lung cells,,80682.0,646.0
1.0,17404.0,,F,,,Intermediate,CHEMBL619571,1.0,,,6353.0,,N,BAO_0000218,A549,9606.0,,Homo sapiens,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,80682.0,646.0
1.0,10958.0,,F,,,Expert,CHEMBL619572,1.0,,,6354.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Growth inhibition of A549 (human lung carcinoma) cell line.,,80682.0,646.0
1.0,17099.0,,F,,,Expert,CHEMBL619573,1.0,,,6355.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Effective dose required for inhibitory activity against A549 human tumor cell line.,,80682.0,646.0
1.0,17099.0,,F,,,Intermediate,CHEMBL619574,1.0,,,6356.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,80682.0,646.0
1.0,4096.0,,F,,,Intermediate,CHEMBL619575,1.0,,,6357.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,80682.0,646.0
1.0,4096.0,,F,,,Expert,CHEMBL619576,1.0,,,6358.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,80682.0,646.0
1.0,4096.0,,F,,,Intermediate,CHEMBL619577,1.0,,,6359.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,80682.0,646.0
1.0,2525.0,,F,,,Intermediate,CHEMBL619578,1.0,,,6360.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro inhibitory activity against A549 tumor cell culture,,80682.0,646.0
1.0,2525.0,,F,,,Intermediate,CHEMBL884009,1.0,,,6361.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,80682.0,646.0
1.0,5302.0,,F,,,Intermediate,CHEMBL619579,1.0,,,6362.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,80682.0,646.0
1.0,16325.0,,F,,,Intermediate,CHEMBL619580,1.0,,,6363.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,80682.0,646.0
1.0,16939.0,,F,,,Intermediate,CHEMBL619581,1.0,,,6364.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,80682.0,646.0
1.0,17229.0,,F,,,Intermediate,CHEMBL619582,1.0,,,6365.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,80682.0,646.0
1.0,17380.0,,F,,,Intermediate,CHEMBL619583,1.0,,,6366.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,80682.0,646.0
1.0,17380.0,,F,,,Intermediate,CHEMBL876502,1.0,,,6367.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,80682.0,646.0
1.0,1903.0,,F,,,Intermediate,CHEMBL619584,1.0,,,6368.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,80682.0,646.0
1.0,3838.0,,F,,,Intermediate,CHEMBL619585,1.0,,,6369.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,80682.0,646.0
1.0,14696.0,,F,,,Intermediate,CHEMBL619586,1.0,,,6370.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,80682.0,646.0
1.0,3838.0,,F,,,Intermediate,CHEMBL619587,1.0,,,6371.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,80682.0,646.0
1.0,1522.0,,F,,,Intermediate,CHEMBL619588,1.0,,,6372.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,80682.0,646.0
1.0,12400.0,,F,,,Intermediate,CHEMBL619589,1.0,,,6373.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,80682.0,646.0
1.0,14696.0,,F,,,Intermediate,CHEMBL619590,1.0,,,6374.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,80682.0,646.0
1.0,14769.0,,F,,,Intermediate,CHEMBL619591,1.0,,,6375.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,80682.0,646.0
1.0,14696.0,,F,,,Intermediate,CHEMBL619592,1.0,,,6376.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,80682.0,646.0
1.0,1888.0,,F,,,Intermediate,CHEMBL619593,1.0,,,6377.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,80682.0,646.0
1.0,12016.0,,F,,,Intermediate,CHEMBL620217,1.0,,,6378.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,80682.0,646.0
1.0,6058.0,,F,,,Intermediate,CHEMBL620218,1.0,,,6379.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,80682.0,646.0
1.0,17708.0,,F,,,Intermediate,CHEMBL620219,1.0,,,6380.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,80682.0,646.0
1.0,12301.0,,F,,,Intermediate,CHEMBL620220,1.0,,,6381.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Antitumor activity against A549/ATCC cell line,,80682.0,646.0
1.0,11970.0,,F,,,Intermediate,CHEMBL625141,1.0,,,6382.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,80682.0,646.0
1.0,11818.0,,F,,,Expert,CHEMBL625142,1.0,,,6383.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro cytotoxicity against A549/ATCC cell line.,,80682.0,646.0
1.0,12400.0,,F,,,Intermediate,CHEMBL625143,1.0,,,6384.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,80682.0,646.0
1.0,3381.0,,F,,,Intermediate,CHEMBL625144,1.0,,,6385.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,80682.0,646.0
1.0,17376.0,,F,,,Intermediate,CHEMBL622474,1.0,,,6386.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,80682.0,646.0
1.0,10708.0,,F,,,Intermediate,CHEMBL884104,1.0,,,6387.0,,N,BAO_0000219,A549,9606.0,,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,80682.0,646.0
0.0,2964.0,,F,,,Autocuration,CHEMBL622475,1.0,,,6388.0,,U,BAO_0000219,,9606.0,,Homo sapiens,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,22226.0,
0.0,5005.0,,A,,,Intermediate,CHEMBL622476,1.0,,,6389.0,In vivo,U,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was tested for oral bioavailability in dogs,,22224.0,
1.0,6229.0,,A,,,Intermediate,CHEMBL875831,1.0,,,6390.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,50588.0,
1.0,6229.0,,A,,,Intermediate,CHEMBL622477,1.0,,,6391.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,50588.0,
1.0,5374.0,,A,,,Intermediate,CHEMBL622478,1.0,,,6392.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,5374.0,,A,,,Intermediate,CHEMBL623172,1.0,,,6393.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was tested for the oral bioavailability in dog; No availability,,50588.0,
1.0,6265.0,,A,,,Intermediate,CHEMBL623173,1.0,,,6394.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg),,50588.0,
1.0,5654.0,,A,,,Intermediate,CHEMBL623174,1.0,,,6395.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,50588.0,
1.0,5654.0,,A,,,Intermediate,CHEMBL623175,1.0,,,6396.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,50588.0,
1.0,16456.0,,A,,,Intermediate,CHEMBL623340,1.0,,,6397.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,50588.0,
1.0,5302.0,,A,,,Intermediate,CHEMBL623341,1.0,,,6398.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg),,50588.0,
1.0,3624.0,,A,,,Intermediate,CHEMBL623342,1.0,,,6399.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,50588.0,
1.0,16452.0,,A,,,Intermediate,CHEMBL623343,1.0,,,6400.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability of active FTIs in dogs,,50588.0,
1.0,5802.0,,A,,,Intermediate,CHEMBL623344,1.0,,,6401.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,50588.0,
1.0,3598.0,,A,,,Expert,CHEMBL623345,1.0,,,6402.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,50588.0,
1.0,17839.0,,A,,,Intermediate,CHEMBL875832,1.0,,,6403.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,6762.0,,A,,,Intermediate,CHEMBL623346,1.0,,,6404.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,6821.0,,A,,,Intermediate,CHEMBL623347,1.0,,,6405.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,6821.0,,A,,,Intermediate,CHEMBL623348,1.0,,,6406.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability of compound was determined in dog; Not tested,,50588.0,
1.0,5210.0,,A,,,Intermediate,CHEMBL623349,1.0,,,6407.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,6227.0,,A,,,Intermediate,CHEMBL623350,1.0,,,6408.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability (10 mg/kg) was determined in dog,,50588.0,
1.0,761.0,,A,,,Intermediate,CHEMBL623351,1.0,,,6409.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability,,50588.0,
1.0,761.0,,A,,,Intermediate,CHEMBL623352,1.0,,,6410.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,50588.0,
1.0,761.0,,A,,,Intermediate,CHEMBL623353,1.0,,,6411.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability administered in solution in rats,,50588.0,
1.0,16907.0,,A,,,Intermediate,CHEMBL875833,1.0,,,6412.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability after 30 mg/kg po dose in Dogs,,50588.0,
1.0,5474.0,,A,,,Intermediate,CHEMBL623354,1.0,,,6413.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability at a dose of 1 mg/kg in dogs,,50588.0,
1.0,6535.0,,A,,,Intermediate,CHEMBL623355,1.0,,,6414.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (dose 1 mg/kg p.o.),,50588.0,
1.0,6535.0,,A,,,Intermediate,CHEMBL623356,1.0,,,6415.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in Dog; ND = not determined,,50588.0,
1.0,3352.0,,A,,,Intermediate,CHEMBL623357,1.0,,,6416.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,6168.0,,A,,,Intermediate,CHEMBL623358,1.0,,,6417.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,5988.0,,A,,,Intermediate,CHEMBL623359,1.0,,,6418.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,4942.0,,A,,,Intermediate,CHEMBL623360,1.0,,,6419.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,4942.0,,A,,,Intermediate,CHEMBL623361,1.0,,,6420.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dogs; No data,,50588.0,
1.0,14541.0,,A,,,Intermediate,CHEMBL623362,1.0,,,6421.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability measured in dogs,,50588.0,
1.0,4449.0,,A,,,Intermediate,CHEMBL623363,1.0,,,6422.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,6057.0,,A,,,Intermediate,CHEMBL623364,1.0,,,6423.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability was calculated in dog,,50588.0,
1.0,5600.0,,A,,,Intermediate,CHEMBL875834,1.0,,,6424.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability after 0.3 mg/kg po administration in dog,,50588.0,
1.0,5542.0,,A,,,Intermediate,CHEMBL623365,1.0,,,6425.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (i.v. dosing),,50588.0,
1.0,5542.0,,A,,,Intermediate,CHEMBL623366,1.0,,,6426.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,5546.0,,A,,,Intermediate,CHEMBL623367,1.0,,,6427.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,50588.0,
1.0,4514.0,,A,,,Intermediate,CHEMBL623368,1.0,,,6428.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in Beagle dogs,,50588.0,
1.0,3624.0,,A,,,Intermediate,CHEMBL623369,1.0,,,6429.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,3854.0,,A,,,Intermediate,CHEMBL623370,1.0,,,6430.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,5836.0,,A,,,Intermediate,CHEMBL623371,1.0,,,6431.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,5940.0,,A,,,Intermediate,CHEMBL623372,1.0,,,6432.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,6168.0,,A,,,Intermediate,CHEMBL621351,1.0,,,6433.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,6227.0,,A,,,Intermediate,CHEMBL621352,1.0,,,6434.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,6251.0,,A,,,Intermediate,CHEMBL621353,1.0,,,6435.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,6448.0,,A,,,Intermediate,CHEMBL621354,1.0,,,6436.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,6647.0,,A,,,Intermediate,CHEMBL621355,1.0,,,6437.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,5940.0,,A,,,Intermediate,CHEMBL621356,1.0,,,6438.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,933.0,,A,,,Intermediate,CHEMBL621357,1.0,,,6439.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,5210.0,,A,,,Intermediate,CHEMBL621358,1.0,,,6440.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,6642.0,,A,,,Intermediate,CHEMBL621359,1.0,,,6441.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,50588.0,
1.0,6641.0,,A,,,Intermediate,CHEMBL621360,1.0,,,6442.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,50588.0,
1.0,6642.0,,A,,,Intermediate,CHEMBL621361,1.0,,,6443.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,50588.0,
1.0,5472.0,,A,,,Intermediate,CHEMBL621362,1.0,,,6444.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,5985.0,,A,,,Intermediate,CHEMBL621363,1.0,,,6445.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,15660.0,,A,,,Intermediate,CHEMBL621364,1.0,,,6446.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,5530.0,,A,,,Intermediate,CHEMBL621166,1.0,,,6447.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,50588.0,
1.0,5530.0,,A,,,Intermediate,CHEMBL621167,1.0,,,6448.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (dose 1 mg/kg i.v.),,50588.0,
1.0,6305.0,,A,,,Intermediate,CHEMBL621168,1.0,,,6449.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability (F) in dogs,,50588.0,
1.0,5210.0,,A,,,Intermediate,CHEMBL621169,1.0,,,6450.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,5238.0,,A,,,Intermediate,CHEMBL875950,1.0,,,6451.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog,,50588.0,
1.0,5668.0,,A,,,Intermediate,CHEMBL621170,1.0,,,6452.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),,50588.0,
1.0,5668.0,,A,,,Intermediate,CHEMBL621171,1.0,,,6453.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability after peroral administration at 5 mpk in Dog,,50588.0,
1.0,5668.0,,A,,,Intermediate,CHEMBL621172,1.0,,,6454.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg),,50588.0,
1.0,6084.0,,A,,,Intermediate,CHEMBL621173,1.0,,,6455.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),,50588.0,
1.0,6599.0,2113.0,A,,,Intermediate,CHEMBL621174,1.0,Kidney,,6456.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,,50594.0,42.0
1.0,6599.0,2113.0,A,,,Intermediate,CHEMBL621175,1.0,Kidney,,6457.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,,50594.0,42.0
1.0,6599.0,2107.0,A,,,Intermediate,CHEMBL621176,1.0,Liver,,6458.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,,50594.0,42.0
1.0,6599.0,2107.0,A,,,Intermediate,CHEMBL621177,1.0,Liver,,6459.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,,50594.0,42.0
1.0,6599.0,2107.0,A,,,Intermediate,CHEMBL621178,1.0,Liver,,6460.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,,50594.0,42.0
1.0,6599.0,2107.0,A,,,Intermediate,CHEMBL621179,1.0,Liver,,6461.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,,50594.0,42.0
1.0,6599.0,2107.0,A,,,Intermediate,CHEMBL621180,1.0,Liver,,6462.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,,50594.0,42.0
1.0,6599.0,2048.0,A,,,Intermediate,CHEMBL875951,1.0,Lung,,6463.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,,50594.0,42.0
1.0,6599.0,2048.0,A,,,Intermediate,CHEMBL621181,1.0,Lung,,6464.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,,50594.0,42.0
1.0,6599.0,2048.0,A,,,Intermediate,CHEMBL621182,1.0,Lung,,6465.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,,50594.0,42.0
1.0,6599.0,2048.0,A,,,Intermediate,CHEMBL621183,1.0,Lung,,6466.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,,50594.0,42.0
1.0,6599.0,2048.0,A,,,Intermediate,CHEMBL621184,1.0,Lung,,6467.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL621185,1.0,,,6468.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL621186,1.0,,,6469.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL621187,1.0,,,6470.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL621188,1.0,,,6471.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL621189,1.0,,,6472.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,50594.0,42.0
1.0,6599.0,2106.0,A,,,Intermediate,CHEMBL621190,1.0,Spleen,,6473.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,,50594.0,42.0
1.0,6599.0,2106.0,A,,,Intermediate,CHEMBL618520,1.0,Spleen,,6474.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,,50594.0,42.0
1.0,6599.0,2106.0,A,,,Intermediate,CHEMBL621739,1.0,Spleen,,6475.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,,50594.0,42.0
1.0,6599.0,2106.0,A,,,Intermediate,CHEMBL621740,1.0,Spleen,,6476.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,,50594.0,42.0
1.0,6599.0,2106.0,A,,,Intermediate,CHEMBL621741,1.0,Spleen,,6477.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL621742,1.0,,,6478.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL621743,1.0,,,6479.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL621744,1.0,,,6480.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL621745,1.0,,,6481.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL621746,1.0,,,6482.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL621747,1.0,,,6483.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL621748,1.0,,,6484.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL621749,1.0,,,6485.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL621750,1.0,,,6486.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL621751,1.0,,,6487.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,50594.0,42.0
1.0,6599.0,948.0,A,,,Intermediate,CHEMBL621752,1.0,Heart,,6488.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,,50594.0,42.0
1.0,6599.0,948.0,A,,,Intermediate,CHEMBL621753,1.0,Heart,,6489.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,,50594.0,42.0
1.0,6599.0,948.0,A,,,Intermediate,CHEMBL875955,1.0,Heart,,6490.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,,50594.0,42.0
1.0,6599.0,948.0,A,,,Intermediate,CHEMBL621754,1.0,Heart,,6491.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,,50594.0,42.0
1.0,6599.0,948.0,A,,,Intermediate,CHEMBL621755,1.0,Heart,,6492.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,,50594.0,42.0
1.0,6599.0,2107.0,A,,,Intermediate,CHEMBL621756,1.0,Liver,,6493.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,,50594.0,42.0
1.0,6599.0,2107.0,A,,,Intermediate,CHEMBL624199,1.0,Liver,,6494.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,,50594.0,42.0
1.0,6599.0,2107.0,A,,,Intermediate,CHEMBL624200,1.0,Liver,,6495.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,,50594.0,42.0
1.0,6599.0,2107.0,A,,,Intermediate,CHEMBL624375,1.0,Liver,,6496.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,,50594.0,42.0
1.0,6599.0,2107.0,A,,,Intermediate,CHEMBL624376,1.0,Liver,,6497.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,,50594.0,42.0
1.0,6599.0,2048.0,A,,,Intermediate,CHEMBL624377,1.0,Lung,,6498.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,,50594.0,42.0
1.0,6599.0,2048.0,A,,,Intermediate,CHEMBL624378,1.0,Lung,,6499.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,,50594.0,42.0
1.0,12269.0,,F,,,Intermediate,CHEMBL857901,1.0,,,6500.0,,N,BAO_0000218,,107673.0,,aeinetobacter anitrotap,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,50067.0,
1.0,12269.0,,F,,,Intermediate,CHEMBL875274,1.0,,,6501.0,,N,BAO_0000218,,107673.0,,Acinetobacter calcoaceticus subsp. anitratus,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,50067.0,
1.0,12269.0,,F,,,Intermediate,CHEMBL624379,1.0,,,6502.0,,N,BAO_0000218,,107673.0,,Acinetobacter calcoaceticus subsp. anitratus,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,50067.0,
1.0,12269.0,,F,,,Intermediate,CHEMBL624380,1.0,,,6503.0,,N,BAO_0000218,,107673.0,,aeinetobacter anitrotap,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,50067.0,
1.0,10624.0,,F,,,Intermediate,CHEMBL624381,1.0,,,6504.0,,N,BAO_0000218,,471.0,,Acinetobacter calcoaceticus,Activity against Acinetobacter calcoaceticus (AC54),,50192.0,
1.0,17216.0,,F,,,Intermediate,CHEMBL624382,1.0,,,6505.0,,N,BAO_0000218,,28377.0,,Anolis carolinensis,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,50714.0,
1.0,17216.0,,F,,,Intermediate,CHEMBL624383,1.0,,,6506.0,,N,BAO_0000218,,28377.0,,Anolis carolinensis,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,50714.0,
1.0,9560.0,,F,,,Intermediate,CHEMBL624384,1.0,,,6507.0,,N,BAO_0000218,,1655.0,,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii 631,,50296.0,
1.0,9560.0,,F,,,Intermediate,CHEMBL624385,1.0,,,6508.0,,N,BAO_0000218,,1655.0,,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii B74,,50296.0,
1.0,9560.0,,F,,,Intermediate,CHEMBL624386,1.0,,,6509.0,,N,BAO_0000218,,1655.0,,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,50296.0,
1.0,9560.0,,F,,,Intermediate,CHEMBL624387,1.0,,,6510.0,,N,BAO_0000218,,1655.0,,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,50296.0,
1.0,9560.0,,F,,,Intermediate,CHEMBL624388,1.0,,,6511.0,,N,BAO_0000218,,1655.0,,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii 631,,50296.0,
1.0,9560.0,,F,,,Intermediate,CHEMBL624389,1.0,,,6512.0,,N,BAO_0000218,,1655.0,,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii N/9,,50296.0,
1.0,9560.0,,F,,,Intermediate,CHEMBL624390,1.0,,,6513.0,,N,BAO_0000218,,1655.0,,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii B74,,50296.0,
1.0,9560.0,,F,,,Intermediate,CHEMBL875275,1.0,,,6514.0,,N,BAO_0000218,,1655.0,,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii N/3,,50296.0,
1.0,114.0,,F,,,Intermediate,CHEMBL624391,1.0,,,6515.0,,N,BAO_0000218,,85549.0,,Artemia salina,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,50056.0,
1.0,114.0,,F,,,Intermediate,CHEMBL623636,1.0,,,6516.0,,N,BAO_0000218,,85549.0,,Artemia salina,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,50056.0,
1.0,10841.0,,F,,,Intermediate,CHEMBL623637,1.0,,,6517.0,,N,BAO_0000218,,6253.0,,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,50532.0,
1.0,10841.0,,F,,,Intermediate,CHEMBL623638,1.0,,,6518.0,,N,BAO_0000218,,6253.0,,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,50532.0,
1.0,10841.0,,F,,,Intermediate,CHEMBL623639,1.0,,,6519.0,,N,BAO_0000218,,6253.0,,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,50532.0,
1.0,10841.0,,F,,,Intermediate,CHEMBL623640,1.0,,,6520.0,,N,BAO_0000218,,6253.0,,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,50532.0,
1.0,10841.0,,F,,,Intermediate,CHEMBL623641,1.0,,,6521.0,,N,BAO_0000218,,6253.0,,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,50532.0,
1.0,10841.0,,F,,,Intermediate,CHEMBL623642,1.0,,,6522.0,,N,BAO_0000218,,6253.0,,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,50532.0,
1.0,10841.0,,F,,,Intermediate,CHEMBL623643,1.0,,,6523.0,,N,BAO_0000218,,6253.0,,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,50532.0,
1.0,10841.0,,F,,,Intermediate,CHEMBL623644,1.0,,,6524.0,,N,BAO_0000218,,6253.0,,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,50532.0,
1.0,10841.0,,F,,,Intermediate,CHEMBL623645,1.0,,,6525.0,,N,BAO_0000218,,6253.0,,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,50532.0,
1.0,10841.0,,F,,,Intermediate,CHEMBL623646,1.0,,,6526.0,,N,BAO_0000218,,6253.0,,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,50532.0,
1.0,10841.0,,F,,,Intermediate,CHEMBL623647,1.0,,,6527.0,,N,BAO_0000218,,6253.0,,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,50532.0,
1.0,10841.0,,F,,,Intermediate,CHEMBL623648,1.0,,,6528.0,,N,BAO_0000218,,6253.0,,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,50532.0,
1.0,8117.0,,F,,,Intermediate,CHEMBL623649,1.0,,,6529.0,,N,BAO_0000218,,1656.0,,Actinomyces viscosus,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,50366.0,
1.0,8117.0,,F,,,Intermediate,CHEMBL623650,1.0,,,6530.0,,N,BAO_0000218,,1656.0,,Actinomyces viscosus,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,50366.0,
1.0,9560.0,,F,,,Intermediate,CHEMBL623651,1.0,,,6531.0,,N,BAO_0000218,,1656.0,,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,50366.0,
1.0,9560.0,,F,,,Expert,CHEMBL623652,1.0,,,6532.0,,N,BAO_0000218,,1656.0,,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus M-100,,50366.0,
1.0,9560.0,,F,,,Intermediate,CHEMBL623653,1.0,,,6533.0,,N,BAO_0000218,,1656.0,,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus M-626,,50366.0,
1.0,9560.0,,F,,,Intermediate,CHEMBL623654,1.0,,,6534.0,,N,BAO_0000218,,1656.0,,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus T14V,,50366.0,
1.0,9560.0,,F,,,Intermediate,CHEMBL623655,1.0,,,6535.0,,N,BAO_0000218,,1656.0,,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus 8A06,,50366.0,
1.0,9560.0,,F,,,Intermediate,CHEMBL623656,1.0,,,6536.0,,N,BAO_0000218,,1656.0,,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus M-100,,50366.0,
1.0,9560.0,,F,,,Expert,CHEMBL623657,1.0,,,6537.0,,N,BAO_0000218,,1656.0,,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,50366.0,
1.0,9560.0,,F,,,Intermediate,CHEMBL623658,1.0,,,6538.0,,N,BAO_0000218,,1656.0,,Actinomyces viscosus,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,50366.0,
1.0,9560.0,,F,,,Intermediate,CHEMBL623659,1.0,,,6539.0,,N,BAO_0000218,,1656.0,,Actinomyces viscosus,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,50366.0,
1.0,9560.0,,F,,,Intermediate,CHEMBL623660,1.0,,,6540.0,,N,BAO_0000218,,1656.0,,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus 626,,50366.0,
1.0,9560.0,,F,,,Intermediate,CHEMBL623661,1.0,,,6541.0,,N,BAO_0000218,,1656.0,,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus T14V,,50366.0,
1.0,10986.0,,F,,,Intermediate,CHEMBL875281,1.0,,,6542.0,,N,BAO_0000218,,6277.0,,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,50535.0,
1.0,10986.0,,F,,,Intermediate,CHEMBL623662,1.0,,,6543.0,,N,BAO_0000218,,6277.0,,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,50535.0,
1.0,10986.0,,F,,,Intermediate,CHEMBL623663,1.0,,,6544.0,,N,BAO_0000218,,6277.0,,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,50535.0,
1.0,10986.0,,F,,,Intermediate,CHEMBL623664,1.0,,,6545.0,,N,BAO_0000218,,6277.0,,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,50535.0,
1.0,10986.0,,F,,,Intermediate,CHEMBL623665,1.0,,,6546.0,,N,BAO_0000218,,6277.0,,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,50535.0,
1.0,10708.0,,F,,,Intermediate,CHEMBL621856,1.0,,,6547.0,,N,BAO_0000219,A673,9606.0,,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,80023.0,165.0
1.0,10708.0,,F,,,Intermediate,CHEMBL620432,1.0,,,6548.0,,N,BAO_0000219,A704,9606.0,,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,80661.0,645.0
0.0,416.0,,F,,,Autocuration,CHEMBL620433,1.0,,,6549.0,,U,BAO_0000219,,10116.0,,Rattus norvegicus,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,22226.0,
1.0,14354.0,,F,,,Intermediate,CHEMBL620434,1.0,,,6550.0,,N,BAO_0000219,A9,10090.0,,Mus musculus,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,80024.0,625.0
1.0,14354.0,,F,,,Intermediate,CHEMBL620435,1.0,,,6551.0,,N,BAO_0000219,A9,10090.0,,Mus musculus,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,80024.0,625.0
1.0,5116.0,,F,,,Intermediate,CHEMBL620436,1.0,,,6552.0,,N,BAO_0000219,A9,9606.0,,Homo sapiens,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,80024.0,625.0
1.0,5116.0,,F,,,Intermediate,CHEMBL876597,1.0,,,6553.0,,N,BAO_0000219,A9,9606.0,,Homo sapiens,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,80024.0,625.0
1.0,15694.0,,F,,,Expert,CHEMBL620437,1.0,,,6554.0,,N,BAO_0000219,Human ovarian carcinoma cell line,9606.0,,Homo sapiens,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,81037.0,874.0
1.0,13038.0,,F,,,Expert,CHEMBL620438,1.0,,,6555.0,,N,BAO_0000219,A9,10090.0,,Mus musculus,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,80024.0,625.0
1.0,13038.0,,F,,,Expert,CHEMBL620439,1.0,,,6556.0,,N,BAO_0000219,A9,10090.0,,Mus musculus,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,80024.0,625.0
1.0,10923.0,,F,,,Expert,CHEMBL619657,1.0,,,6557.0,,N,BAO_0000219,A9,10090.0,,Mus musculus,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,80024.0,625.0
1.0,10923.0,,F,,,Intermediate,CHEMBL619658,1.0,,,6558.0,,N,BAO_0000219,A9,10090.0,,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,80024.0,625.0
1.0,10923.0,,F,,,Intermediate,CHEMBL619659,1.0,,,6559.0,,N,BAO_0000219,A9,10090.0,,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,80024.0,625.0
8.0,10923.0,,F,,,Expert,CHEMBL619660,1.0,,,6560.0,,H,BAO_0000019,,,,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,10649.0,
1.0,10923.0,,F,,,Intermediate,CHEMBL619661,1.0,,,6561.0,,N,BAO_0000219,A9,10090.0,,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,80024.0,625.0
1.0,10923.0,,F,,,Intermediate,CHEMBL619662,1.0,,,6562.0,,N,BAO_0000219,A9,10090.0,,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,80024.0,625.0
1.0,8158.0,,F,,,Intermediate,CHEMBL619663,1.0,,,6563.0,,N,BAO_0000219,AA6,10029.0,,Cricetulus griseus,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,80663.0,975.0
0.0,15494.0,,F,,,Autocuration,CHEMBL619664,1.0,,,6564.0,,U,BAO_0000219,,9606.0,,Homo sapiens,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,22226.0,
0.0,15494.0,,F,,,Autocuration,CHEMBL619665,1.0,,,6565.0,,U,BAO_0000219,,9606.0,,Homo sapiens,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,22226.0,
1.0,12348.0,,F,,,Intermediate,CHEMBL883244,1.0,,,6566.0,,N,BAO_0000219,AA5,9606.0,,Homo sapiens,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,80662.0,974.0
1.0,12348.0,,F,,,Intermediate,CHEMBL884011,1.0,,,6567.0,,N,BAO_0000219,AA5,9606.0,,Homo sapiens,Cytotoxicity was measured against AA5/HIV-1(IIIB),,80662.0,974.0
1.0,2726.0,,F,,,Intermediate,CHEMBL619666,1.0,,,6568.0,,N,BAO_0000219,AA5,9606.0,,Homo sapiens,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,80662.0,974.0
1.0,2726.0,,F,,,Intermediate,CHEMBL619667,1.0,,,6569.0,,N,BAO_0000219,U-937,9606.0,,Homo sapiens,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,80566.0,379.0
1.0,10747.0,,F,,,Intermediate,CHEMBL619668,1.0,,,6570.0,,N,BAO_0000219,UV4,10029.0,,Cricetulus griseus,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,80578.0,274.0
1.0,11005.0,,F,,,Expert,CHEMBL619669,1.0,,,6571.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,80089.0,185.0
1.0,12687.0,,F,,,Intermediate,CHEMBL876608,1.0,,,6572.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Average intracellular compound concentration when the hypoxic SER=1.6,,80089.0,185.0
1.0,12687.0,,F,,,Intermediate,CHEMBL619670,1.0,,,6573.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Average intracellular compound concentration when the hypoxic SER=1.6.,,80089.0,185.0
1.0,12687.0,,F,,,Intermediate,CHEMBL619671,1.0,,,6574.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,80089.0,185.0
1.0,12687.0,,F,,,Intermediate,CHEMBL619672,1.0,,,6575.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,80089.0,185.0
1.0,12687.0,,F,,,Intermediate,CHEMBL619673,1.0,,,6576.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,80089.0,185.0
1.0,13436.0,,F,,,Intermediate,CHEMBL619674,1.0,,,6577.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,80089.0,185.0
1.0,13435.0,,F,,,Intermediate,CHEMBL619675,1.0,,,6578.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,80089.0,185.0
1.0,13302.0,,F,,,Intermediate,CHEMBL619676,1.0,,,6579.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,80089.0,185.0
1.0,12687.0,,F,,,Intermediate,CHEMBL619677,1.0,,,6580.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,80089.0,185.0
1.0,12687.0,,A,,,Intermediate,CHEMBL619678,1.0,,,6581.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,80089.0,185.0
1.0,12687.0,,A,,,Intermediate,CHEMBL619679,1.0,,,6582.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,80089.0,185.0
1.0,12878.0,,A,,,Expert,CHEMBL619680,1.0,,,6583.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,80089.0,185.0
1.0,12878.0,,A,,,Intermediate,CHEMBL621457,1.0,,,6584.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,80089.0,185.0
1.0,14367.0,,F,,,Expert,CHEMBL876609,1.0,,,6585.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,80089.0,185.0
1.0,14367.0,,F,,,Intermediate,CHEMBL621458,1.0,,,6586.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,80089.0,185.0
1.0,12398.0,,F,,,Expert,CHEMBL621459,1.0,,,6587.0,,N,BAO_0000219,CHO-AA8,36483.0,,hampster,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,80089.0,185.0
1.0,12878.0,,F,,,Expert,CHEMBL621460,1.0,,,6588.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Aerobic growth inhibition in Chinese hamster cell line AA8,,80089.0,185.0
1.0,13820.0,,F,,,Expert,CHEMBL621461,1.0,,,6589.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,80089.0,185.0
1.0,13436.0,,F,,,Expert,CHEMBL621462,1.0,,,6590.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Inhibition of growth under aerobic conditions in AA8 cells,,80089.0,185.0
1.0,6084.0,,A,,,Intermediate,CHEMBL621463,1.0,,,6591.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),,50588.0,
1.0,5711.0,,A,,,Intermediate,CHEMBL621464,1.0,,,6592.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog at 10 mg/kg of the compound,,50588.0,
1.0,4353.0,,A,,,Intermediate,CHEMBL621465,1.0,,,6593.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (dose 5 uM/kg),,50588.0,
1.0,4353.0,,A,,,Intermediate,CHEMBL621466,1.0,,,6594.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (dose 5 uM/kg),,50588.0,
1.0,17800.0,,A,,,Intermediate,CHEMBL621467,1.0,,,6595.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (mongrel),,50588.0,
1.0,3994.0,,A,,,Intermediate,CHEMBL621468,1.0,,,6596.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),,50588.0,
1.0,3994.0,,F,,,Intermediate,CHEMBL876734,1.0,,,6597.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),,50588.0,
1.0,5145.0,,A,,,Intermediate,CHEMBL618476,1.0,,,6598.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog,,50588.0,
1.0,16452.0,,A,,,Intermediate,CHEMBL618477,1.0,,,6599.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog (dose 1 mg/kg i.v.),,50588.0,
1.0,16452.0,,A,,,Intermediate,CHEMBL618478,1.0,,,6600.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,50588.0,
1.0,5983.0,,A,,,Intermediate,CHEMBL618479,1.0,,,6601.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,50588.0,
1.0,4273.0,,A,,,Intermediate,CHEMBL618480,1.0,,,6602.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog,,50588.0,
1.0,12500.0,,A,,,Intermediate,CHEMBL618481,1.0,,,6603.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog (dose 3-10 mg/kg),,50588.0,
1.0,12500.0,1969.0,A,,,Intermediate,CHEMBL618482,1.0,Plasma,,6604.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,The compound was tested for bioavailability of compound in plasma of dog; Complete,,50588.0,
1.0,3639.0,,A,,,Intermediate,CHEMBL618483,1.0,,,6605.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,3880.0,,A,,,Intermediate,CHEMBL618484,1.0,,,6606.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,4838.0,,A,,,Intermediate,CHEMBL618485,1.0,,,6607.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog,,50588.0,
1.0,15600.0,,A,,,Intermediate,CHEMBL618486,1.0,,,6608.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,oral bioavailability was measured in dogs,,50588.0,
1.0,17248.0,,A,,,Intermediate,CHEMBL618487,1.0,,,6609.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was tested for plasma protein binding in dog; Not determined,,50588.0,
1.0,17248.0,,A,,,Intermediate,CHEMBL618488,1.0,,,6610.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was tested for plasma protein binding of dog,,50588.0,
1.0,17248.0,,A,,,Intermediate,CHEMBL876735,1.0,,,6611.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was tested for plasma protein binding of dog; Not determined,,50588.0,
1.0,17443.0,,A,,,Intermediate,CHEMBL618489,1.0,,,6612.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,50588.0,
1.0,4186.0,,A,,,Intermediate,CHEMBL618490,1.0,,,6613.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,50588.0,
1.0,3749.0,,A,,,Intermediate,CHEMBL618491,1.0,,,6614.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life was determined,,50588.0,
1.0,3249.0,,A,,,Intermediate,CHEMBL618492,1.0,,,6615.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,50588.0,
1.0,3022.0,,A,,,Intermediate,CHEMBL873354,1.0,,,6616.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life was evaluated in dog,,50588.0,
1.0,3749.0,,A,,,Intermediate,CHEMBL618493,1.0,,,6617.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life was determined,,50588.0,
1.0,2517.0,,A,,,Intermediate,CHEMBL618494,1.0,,,6618.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,50588.0,
1.0,2517.0,948.0,A,,,Intermediate,CHEMBL618495,1.0,Heart,,6619.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),,50588.0,
1.0,2517.0,2113.0,A,,,Intermediate,CHEMBL618496,1.0,Kidney,,6620.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),,50588.0,
1.0,2517.0,2107.0,A,,,Intermediate,CHEMBL618497,1.0,Liver,,6621.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),,50588.0,
1.0,2517.0,2048.0,A,,,Intermediate,CHEMBL618498,1.0,Lung,,6622.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),,50588.0,
1.0,2517.0,2106.0,A,,,Intermediate,CHEMBL618499,1.0,Spleen,,6623.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),,50588.0,
1.0,3639.0,,A,,,Intermediate,CHEMBL876736,1.0,,,6624.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,LogP in dog,,50588.0,
1.0,6227.0,,A,,,Intermediate,CHEMBL618500,1.0,,,6625.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Partition coefficient (logP),,50588.0,
1.0,6227.0,,A,,,Intermediate,CHEMBL857831,1.0,,,6626.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Partition coefficient in dog,,50588.0,
1.0,17764.0,,A,,,Intermediate,CHEMBL618501,1.0,,,6627.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,50588.0,
1.0,4809.0,,A,,,Intermediate,CHEMBL618502,1.0,,,6628.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,50588.0,
1.0,5600.0,,A,,,Intermediate,CHEMBL618503,1.0,,,6629.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,50588.0,
1.0,14294.0,,A,,,Intermediate,CHEMBL618504,1.0,,,6630.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,50588.0,
1.0,14294.0,,A,,,Intermediate,CHEMBL618505,1.0,,,6631.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,50588.0,
1.0,14294.0,,A,,,Intermediate,CHEMBL618506,1.0,,,6632.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Metabolism of compound in dog S9 microsomes; Trace,,50588.0,
1.0,6251.0,2107.0,A,,,Intermediate,CHEMBL618507,1.0,Liver,,6633.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,In vitro metabolic potential in dog liver microsomes,,50588.0,
1.0,3748.0,,A,,,Intermediate,CHEMBL876737,1.0,,,6634.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,50588.0,
1.0,2713.0,,A,,,Intermediate,CHEMBL618508,1.0,,,6635.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,6512.0,,A,,,Intermediate,CHEMBL618509,1.0,,,6636.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,6679.0,,A,,,Intermediate,CHEMBL618510,1.0,,,6637.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,50588.0,
1.0,3749.0,,A,,,Intermediate,CHEMBL618511,1.0,,,6638.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,The compound was tested for bioavailability in dogs,,50588.0,
1.0,3749.0,,A,,,Intermediate,CHEMBL618512,1.0,,,6639.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,The compound was tested for oral bioavailability in dogs,,50588.0,
1.0,6742.0,,A,,,Intermediate,CHEMBL618513,1.0,,,6640.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog,,50588.0,
1.0,6227.0,,A,,,Intermediate,CHEMBL618514,1.0,,,6641.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was tested for percent protein binding (PB) in dog,,50588.0,
1.0,6874.0,,A,,,Intermediate,CHEMBL620052,1.0,,,6642.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,50588.0,
1.0,2877.0,1969.0,A,,,Intermediate,CHEMBL620053,1.0,Plasma,,6643.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was evaluated for plasma clearance.,,50588.0,
1.0,12500.0,1969.0,A,,,Intermediate,CHEMBL620054,1.0,Plasma,,6644.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,The compound was tested for plasma clearance in dog,,50588.0,
1.0,12500.0,1969.0,A,,,Intermediate,CHEMBL620055,1.0,Plasma,,6645.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,,50588.0,
1.0,4709.0,,A,,,Intermediate,CHEMBL620056,1.0,,,6646.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,50588.0,
1.0,5542.0,2107.0,A,,,Intermediate,CHEMBL620057,1.0,Liver,,6647.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,In vitro relative rate of metabolism was determined in dog liver microsomes,,50588.0,
1.0,17594.0,,A,,,Intermediate,CHEMBL618939,1.0,,,6648.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,50588.0,
1.0,2652.0,,A,,,Intermediate,CHEMBL618940,1.0,,,6649.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,50588.0,
1.0,17764.0,,A,,,Intermediate,CHEMBL618941,1.0,,,6650.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life after intravenous administration in dogs at 1.2 uM/kg,,50588.0,
1.0,6599.0,2048.0,A,,,Intermediate,CHEMBL624473,1.0,Lung,,6651.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,,50594.0,42.0
1.0,6599.0,2048.0,A,,,Intermediate,CHEMBL624474,1.0,Lung,,6652.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,,50594.0,42.0
1.0,6599.0,2048.0,A,,,Intermediate,CHEMBL624475,1.0,Lung,,6653.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL624476,1.0,,,6654.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL623478,1.0,,,6655.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL623479,1.0,,,6656.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL623480,1.0,,,6657.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,50594.0,42.0
1.0,6599.0,,A,,,Intermediate,CHEMBL623481,1.0,,,6658.0,,N,BAO_0000218,CCRF S-180,10090.0,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,50594.0,42.0
1.0,17641.0,955.0,A,,,Intermediate,CHEMBL623482,1.0,Brain,,6659.0,,N,BAO_0000218,,10090.0,,Mus musculus,C2 in brain of mice at the oral dose of 50 mg/kg,,50594.0,
1.0,17641.0,2113.0,A,,,Intermediate,CHEMBL623483,1.0,Kidney,,6660.0,,N,BAO_0000218,,10090.0,,Mus musculus,C2 in kidney of mice at the oral dose of 50 mg/kg,,50594.0,
1.0,17641.0,2107.0,A,,,Intermediate,CHEMBL623484,1.0,Liver,,6661.0,,N,BAO_0000218,,10090.0,,Mus musculus,C2 in liver of mice at the oral dose of 50 mg/kg,,50594.0,
1.0,17641.0,2048.0,A,,,Intermediate,CHEMBL623485,1.0,Lung,,6662.0,,N,BAO_0000218,,10090.0,,Mus musculus,C2 in lungs of mice at the oral dose of 50 mg/kg,,50594.0,
1.0,17641.0,2106.0,A,,,Intermediate,CHEMBL623486,1.0,Spleen,,6663.0,,N,BAO_0000218,,10090.0,,Mus musculus,C2 in spleen of mice at the oral dose of 50 mg/kg,,50594.0,
1.0,17852.0,,A,,,Intermediate,CHEMBL623487,1.0,,,6664.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Plasma clearance in mouse,,50594.0,
1.0,17764.0,,A,,,Intermediate,CHEMBL623488,1.0,,,6665.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Clearance of compound after intravenous administration in mice at 24 uM/kg,,50594.0,
1.0,17837.0,,A,,,Intermediate,CHEMBL623489,1.0,,,6666.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Clearance from mouse blood following i.v. administration of 10 mg/kg,,50594.0,
1.0,2675.0,,A,,,Intermediate,CHEMBL875157,1.0,,,6667.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Clearance was evaluated in mice after intravenous administration,,50594.0,
1.0,2675.0,,A,,,Intermediate,CHEMBL623490,1.0,,,6668.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Clearance was evaluated in mice after oral administration,,50594.0,
1.0,4239.0,,A,,,Intermediate,CHEMBL623491,1.0,,,6669.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Pharmacokinetic property (Plasma clearance) was measured in mouse,,50594.0,
1.0,17753.0,,A,,,Intermediate,CHEMBL623492,1.0,,,6670.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Plasma clearance of compound was determined at 40 mg/Kg,,50594.0,
1.0,17753.0,,A,,,Intermediate,CHEMBL623493,1.0,,,6671.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Plasma clearance of at 24 mg/Kg,,50594.0,
1.0,17753.0,,A,,,Intermediate,CHEMBL623494,1.0,,,6672.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Plasma clearance at 24 mg/Kg,,50594.0,
1.0,17753.0,,A,,,Intermediate,CHEMBL623495,1.0,,,6673.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Plasma clearance at 5 mg/Kg,,50594.0,
1.0,5727.0,,A,,,Intermediate,CHEMBL623496,1.0,,,6674.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Plasma clearance in mice,,50594.0,
1.0,2862.0,,A,,,Intermediate,CHEMBL623497,1.0,,,6675.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Plasma clearance value upon iv administration in mouse,,50594.0,
1.0,5980.0,1969.0,A,,,Intermediate,CHEMBL623498,1.0,Plasma,,6676.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Total plasma clearance in mice,,50594.0,
1.0,17592.0,,A,,,Intermediate,CHEMBL623499,1.0,,,6677.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Clearance in mouse,,50594.0,
1.0,17718.0,,A,,,Intermediate,CHEMBL623500,1.0,,,6678.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Clearance value was determined,,50594.0,
1.0,16597.0,,A,,,Intermediate,CHEMBL623501,1.0,,,6679.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,50594.0,
0.0,17384.0,,P,,,Intermediate,CHEMBL875158,1.0,,,6680.0,,U,BAO_0000100,,,,,Calculated partition coefficient (clogP),,22229.0,
1.0,6062.0,,A,,,Intermediate,CHEMBL623502,1.0,,,6681.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,50594.0,
1.0,17734.0,,A,,,Intermediate,CHEMBL623503,1.0,,,6682.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,50594.0,
1.0,6348.0,,A,,,Intermediate,CHEMBL623504,1.0,,,6683.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,50594.0,
1.0,5969.0,,A,,,Intermediate,CHEMBL623505,1.0,,,6684.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,50594.0,
1.0,5969.0,,A,,,Intermediate,CHEMBL623506,1.0,,,6685.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,50594.0,
1.0,5969.0,,A,,,Intermediate,CHEMBL623507,1.0,,,6686.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,50594.0,
1.0,16597.0,,A,,,Intermediate,CHEMBL623508,1.0,,,6687.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,50594.0,
1.0,5781.0,,A,,,Intermediate,CHEMBL623509,1.0,,,6688.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Cmax after oral administration at 30 mg/kg in ICR mouse,,50594.0,
1.0,17764.0,,A,,,Intermediate,CHEMBL875159,1.0,,,6689.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Cmax after peroral administration in mice at 2.4 uM/kg,,50594.0,
1.0,17641.0,955.0,A,,,Intermediate,CHEMBL623510,1.0,Brain,,6690.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Cmax in brain of mice at the oral dose of 50 mg/kg,,50594.0,
1.0,17641.0,2113.0,A,,,Intermediate,CHEMBL623511,1.0,Kidney,,6691.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Cmax in kidney of mice at the oral dose of 50 mg/kg,,50594.0,
1.0,17641.0,2107.0,A,,,Intermediate,CHEMBL623512,1.0,Liver,,6692.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Cmax in liver of mice at the oral dose of 50 mg/kg,,50594.0,
1.0,17641.0,2048.0,A,,,Intermediate,CHEMBL623513,1.0,Lung,,6693.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Cmax in lungs of mice at the oral dose of 50 mg/kg,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL623514,1.0,,,6694.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Cmax in mice at 18 uM/kg i.p. administration,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL622609,1.0,,,6695.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Cmax in mice at 23 uM/kg i.v. administration,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL622610,1.0,,,6696.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Cmax in mice at 24 uM/kg i.p. administration,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL621823,1.0,,,6697.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Cmax in mice at 25 uM/kg i.p. administration,,50594.0,
1.0,17764.0,,F,,,Intermediate,CHEMBL621824,1.0,,,6698.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Cmax in mice at 26 uM/kg i.p. administration,,50594.0,
1.0,17641.0,2106.0,A,,,Intermediate,CHEMBL621825,1.0,Spleen,,6699.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Cmax in spleen of mice at the oral dose of 50 mg/kg,,50594.0,
1.0,16597.0,,A,,,Intermediate,CHEMBL621826,1.0,,,6700.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,50594.0,
1.0,16597.0,,A,,,Intermediate,CHEMBL621827,1.0,,,6701.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,50594.0,
1.0,5727.0,,A,,,Intermediate,CHEMBL621828,1.0,,,6702.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Cmax value was determined,,50594.0,
1.0,5951.0,,A,,,Intermediate,CHEMBL621829,1.0,,,6703.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Cmax value in IRC mice,,50594.0,
1.0,5506.0,,A,,,Intermediate,CHEMBL621830,1.0,,,6704.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,50594.0,
1.0,5506.0,,A,,,Intermediate,CHEMBL621831,1.0,,,6705.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,50594.0,
1.0,14239.0,1969.0,A,,,Intermediate,CHEMBL621832,1.0,Plasma,,6706.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,50594.0,
1.0,4890.0,1969.0,A,,,Intermediate,CHEMBL624579,1.0,Plasma,,6707.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",,50594.0,
1.0,429.0,,A,,,Intermediate,CHEMBL624580,1.0,,,6708.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,50594.0,
1.0,10986.0,,F,,,Intermediate,CHEMBL624581,1.0,,,6709.0,,N,BAO_0000218,,6277.0,,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,50535.0,
1.0,10986.0,,F,,,Intermediate,CHEMBL624582,1.0,,,6710.0,,N,BAO_0000218,,6277.0,,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,50535.0,
1.0,10986.0,,F,,,Intermediate,CHEMBL624583,1.0,,,6711.0,,N,BAO_0000218,,6277.0,,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,50535.0,
1.0,13227.0,,F,,,Intermediate,CHEMBL624584,1.0,,,6712.0,,N,BAO_0000219,A-375,9606.0,,Homo sapiens,Inhibitory activity against human tumor cell line A0375 melanoma.,,80018.0,455.0
9.0,4481.0,,B,Brain membranes,,Expert,CHEMBL624585,1.0,,,6713.0,,D,BAO_0000249,,10116.0,,Rattus norvegicus,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,12512.0,
9.0,16931.0,,F,,,Expert,CHEMBL875165,1.0,,,6714.0,,D,BAO_0000019,,9606.0,,Homo sapiens,Forskolin-induced cAMP production at human A1 adenosine receptor,,114.0,
8.0,3850.0,,F,,,Autocuration,CHEMBL619490,1.0,,,6715.0,,H,BAO_0000219,CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,114.0,449.0
8.0,3850.0,,F,,,Autocuration,CHEMBL619491,1.0,,,6716.0,,H,BAO_0000219,CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,114.0,449.0
8.0,3850.0,,F,,,Expert,CHEMBL619492,1.0,,,6717.0,,H,BAO_0000219,CHO,,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,114.0,449.0
8.0,3850.0,,F,,,Expert,CHEMBL619493,1.0,,,6718.0,,H,BAO_0000219,CHO,,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,114.0,449.0
8.0,3850.0,,F,,,Autocuration,CHEMBL619494,1.0,,,6719.0,,H,BAO_0000219,CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,114.0,449.0
8.0,3850.0,,F,,,Autocuration,CHEMBL619495,1.0,,,6720.0,,H,BAO_0000219,CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,114.0,449.0
8.0,3850.0,,F,,,Autocuration,CHEMBL619496,1.0,,,6721.0,,H,BAO_0000219,CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,114.0,449.0
9.0,3850.0,,F,,,Expert,CHEMBL619497,1.0,,,6722.0,,D,BAO_0000219,CHO,9606.0,,Homo sapiens,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,114.0,449.0
8.0,3850.0,,F,,,Autocuration,CHEMBL619498,1.0,,,6723.0,,H,BAO_0000219,CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,114.0,449.0
8.0,3850.0,,F,,,Autocuration,CHEMBL619499,1.0,,,6724.0,,H,BAO_0000219,CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,114.0,449.0
8.0,3850.0,,F,,,Expert,CHEMBL619500,1.0,,,6725.0,,H,BAO_0000219,CHO,,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,114.0,449.0
8.0,3850.0,,F,,,Autocuration,CHEMBL619501,1.0,,,6726.0,,H,BAO_0000219,CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,114.0,449.0
8.0,3850.0,,F,,,Expert,CHEMBL619502,1.0,,,6727.0,,H,BAO_0000219,CHO,,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,114.0,449.0
8.0,3850.0,,F,,,Autocuration,CHEMBL619503,1.0,,,6728.0,,H,BAO_0000219,CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,114.0,449.0
8.0,3850.0,,F,,,Autocuration,CHEMBL619504,1.0,,,6729.0,,H,BAO_0000219,CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,114.0,449.0
8.0,3850.0,,F,,,Autocuration,CHEMBL621298,1.0,,,6730.0,,H,BAO_0000219,CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,114.0,449.0
8.0,3850.0,,F,,,Expert,CHEMBL621299,1.0,,,6731.0,,H,BAO_0000219,CHO,,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,114.0,449.0
8.0,3850.0,,F,,,Autocuration,CHEMBL621300,1.0,,,6732.0,,H,BAO_0000219,CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,114.0,449.0
8.0,3850.0,,F,,,Autocuration,CHEMBL621301,1.0,,,6733.0,,H,BAO_0000219,CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,114.0,449.0
8.0,3850.0,,F,,,Expert,CHEMBL621302,1.0,,,6734.0,,H,BAO_0000219,CHO,,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,114.0,449.0
1.0,12680.0,,F,,,Intermediate,CHEMBL621303,1.0,,,6735.0,,N,BAO_0000219,A10,9986.0,,Oryctolagus cuniculus,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,80013.0,164.0
0.0,1313.0,,F,,,Autocuration,CHEMBL621304,1.0,,,6736.0,,U,BAO_0000219,A10,10116.0,,Rattus norvegicus,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,22226.0,164.0
0.0,1313.0,,F,,,Autocuration,CHEMBL621305,1.0,,,6737.0,,U,BAO_0000219,A10,10116.0,,Rattus norvegicus,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,22226.0,164.0
1.0,17567.0,,F,,,Intermediate,CHEMBL621306,1.0,,,6738.0,,N,BAO_0000219,A10,10116.0,,Rattus norvegicus,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,80013.0,164.0
1.0,17567.0,,F,,,Intermediate,CHEMBL618444,1.0,,,6739.0,,N,BAO_0000219,A10,10116.0,,Rattus norvegicus,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,80013.0,164.0
1.0,11819.0,,F,,,Intermediate,CHEMBL618445,1.0,,,6740.0,,N,BAO_0000219,A10,10116.0,,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,80013.0,164.0
1.0,13436.0,,F,,,Intermediate,CHEMBL618446,1.0,,,6741.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,80089.0,185.0
1.0,12687.0,,F,,,Intermediate,CHEMBL618447,1.0,,,6742.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,80089.0,185.0
1.0,12651.0,,F,,,Intermediate,CHEMBL618448,1.0,,,6743.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,80089.0,185.0
1.0,13300.0,,F,,,Intermediate,CHEMBL618449,1.0,,,6744.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,80089.0,185.0
1.0,15296.0,,F,,,Intermediate,CHEMBL618637,1.0,,,6745.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,80089.0,185.0
1.0,15328.0,,F,,,Intermediate,CHEMBL618638,1.0,,,6746.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,80089.0,185.0
1.0,13302.0,,F,,,Intermediate,CHEMBL618639,1.0,,,6747.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,80089.0,185.0
1.0,14367.0,,F,,,Expert,CHEMBL618640,1.0,,,6748.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,80089.0,185.0
1.0,17002.0,,F,,,Expert,CHEMBL618641,1.0,,,6749.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,80089.0,185.0
1.0,13436.0,,F,,,Intermediate,CHEMBL618642,1.0,,,6750.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,80089.0,185.0
1.0,13435.0,,F,,,Intermediate,CHEMBL618643,1.0,,,6751.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Inhibitory activity against aerobic growth of AA8 cells.,,80089.0,185.0
1.0,10503.0,,A,,,Intermediate,CHEMBL884013,1.0,,,6752.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,80089.0,185.0
1.0,10503.0,,F,,,Expert,CHEMBL622723,1.0,,,6753.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,80089.0,185.0
1.0,10503.0,,F,,,Intermediate,CHEMBL622724,1.0,,,6754.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,80089.0,185.0
1.0,15090.0,,F,,,Expert,CHEMBL622725,1.0,,,6755.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,80089.0,185.0
1.0,10368.0,,F,,,Expert,CHEMBL622726,1.0,,,6756.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Cytotoxicity against AA8 cell line,,80089.0,185.0
1.0,12651.0,,F,,,Intermediate,CHEMBL622727,1.0,,,6757.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,80089.0,185.0
1.0,12687.0,,A,,,Intermediate,CHEMBL622728,1.0,,,6758.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,80089.0,185.0
1.0,12687.0,,F,,,Intermediate,CHEMBL622729,1.0,,,6759.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,80089.0,185.0
1.0,12687.0,,A,,,Intermediate,CHEMBL622730,1.0,,,6760.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,80089.0,185.0
1.0,1890.0,,F,,,Intermediate,CHEMBL622731,1.0,,,6761.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,80089.0,185.0
1.0,10747.0,,F,,,Intermediate,CHEMBL622732,1.0,,,6762.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,80089.0,185.0
1.0,10747.0,,F,,,Intermediate,CHEMBL622733,1.0,,,6763.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,80089.0,185.0
0.0,11616.0,,F,,,Autocuration,CHEMBL622734,1.0,,,6764.0,,U,BAO_0000218,,10029.0,,Cricetulus griseus,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,22224.0,
1.0,11616.0,,F,,,Expert,CHEMBL622735,1.0,,,6765.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,80089.0,185.0
0.0,3471.0,,F,,,Autocuration,CHEMBL618746,1.0,,,6766.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,22224.0,185.0
0.0,3471.0,,F,,,Autocuration,CHEMBL618747,1.0,,,6767.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,22224.0,185.0
0.0,3471.0,,F,,,Autocuration,CHEMBL620540,1.0,,,6768.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,22224.0,185.0
0.0,3471.0,,F,,,Autocuration,CHEMBL620541,1.0,,,6769.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,22224.0,185.0
0.0,3471.0,,F,,,Autocuration,CHEMBL620542,1.0,,,6770.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,22224.0,185.0
0.0,3471.0,,F,,,Autocuration,CHEMBL620543,1.0,,,6771.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,22224.0,185.0
0.0,3471.0,,F,,,Autocuration,CHEMBL618832,1.0,,,6772.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,22224.0,185.0
1.0,11616.0,,F,,,Expert,CHEMBL618833,1.0,,,6773.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Concentration required to reduce AA8 cell survival by 10%,,80089.0,185.0
0.0,2656.0,,F,,,Autocuration,CHEMBL618834,1.0,,,6774.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,22224.0,185.0
0.0,10518.0,,F,,,Autocuration,CHEMBL618835,1.0,,,6775.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,22224.0,185.0
0.0,10518.0,,F,,,Autocuration,CHEMBL618836,1.0,,,6776.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,22224.0,185.0
0.0,10518.0,,F,,,Autocuration,CHEMBL618837,1.0,,,6777.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,22224.0,185.0
0.0,10518.0,,F,,,Autocuration,CHEMBL618838,1.0,,,6778.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,22224.0,185.0
0.0,16156.0,,F,,,Autocuration,CHEMBL618839,1.0,,,6779.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,22224.0,185.0
0.0,2656.0,,F,,,Autocuration,CHEMBL618840,1.0,,,6780.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,22224.0,185.0
0.0,11005.0,,F,,,Autocuration,CHEMBL618841,1.0,,,6781.0,,U,BAO_0000019,,10029.0,,Cricetulus griseus,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,22224.0,
0.0,11942.0,,F,,,Autocuration,CHEMBL618842,1.0,,,6782.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,22224.0,185.0
0.0,2128.0,,F,,,Autocuration,CHEMBL618843,1.0,,,6783.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,22224.0,185.0
1.0,16907.0,,A,,,Intermediate,CHEMBL618844,1.0,,,6784.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period after 15 mg/kg iv dose in Dogs,,50588.0,
1.0,16907.0,,A,,,Intermediate,CHEMBL618845,1.0,,,6785.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period after 30 mg/kg po dose in Dogs,,50588.0,
1.0,9579.0,,A,,,Intermediate,CHEMBL618846,1.0,,,6786.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life was measured after oral 2b administration (tested in 6 dogs),,50588.0,
1.0,9579.0,,A,,,Intermediate,CHEMBL618847,1.0,,,6787.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life was measured in dog after oral 17b administration,,50588.0,
1.0,9579.0,,A,,,Intermediate,CHEMBL618848,1.0,,,6788.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,50588.0,
1.0,9579.0,,A,,,Intermediate,CHEMBL618849,1.0,,,6789.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,50588.0,
1.0,16907.0,,A,,,Intermediate,CHEMBL618850,1.0,,,6790.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Tmax value after 15 mg/kg iv dose in Dogs,,50588.0,
1.0,16907.0,,A,,,Intermediate,CHEMBL618851,1.0,,,6791.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Tmax value after 30 mg/kg po dose in Dogs,,50588.0,
1.0,3184.0,,A,,,Intermediate,CHEMBL873815,1.0,,,6792.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was evaluated for its half life when administered intravenously in dog,,50588.0,
1.0,5017.0,1969.0,A,,,Intermediate,CHEMBL618852,1.0,Plasma,,6793.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,50588.0,
1.0,6821.0,,A,,,Intermediate,CHEMBL618853,1.0,,,6794.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Elimination Half-life of compound was determined in dog,,50588.0,
1.0,17839.0,,A,,,Intermediate,CHEMBL618854,1.0,,,6795.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life of compound in dog following oral administration,,50588.0,
1.0,17267.0,,A,,,Intermediate,CHEMBL618855,1.0,,,6796.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life of compound was determined in dog,,50588.0,
1.0,4727.0,178.0,A,,,Intermediate,CHEMBL618856,1.0,Blood,,6797.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life of compound was determined in dog blood,,50588.0,
1.0,5238.0,,A,,,Intermediate,CHEMBL875827,1.0,,,6798.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life after oral and iv dosing in dogs,,50588.0,
1.0,4942.0,,A,,,Intermediate,CHEMBL618857,1.0,,,6799.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dogs in hours,,50588.0,
1.0,6505.0,,A,,,Intermediate,CHEMBL618858,1.0,,,6800.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life on i.v. administration of 2 mg/kg was measured in dog,,50588.0,
1.0,5130.0,,A,,,Intermediate,CHEMBL618859,1.0,,,6801.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,t1/2 in dog after oral dose (1 mg/kg),,50588.0,
1.0,1475.0,,A,,,Intermediate,CHEMBL618860,1.0,,,6802.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life was evaluated in dog,,50588.0,
1.0,17804.0,,A,,,Intermediate,CHEMBL618861,1.0,,,6803.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period of compound was determined after intravenous administration at 2 mg/kg,,50588.0,
1.0,17804.0,,A,,,Intermediate,CHEMBL622539,1.0,,,6804.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period of compound was determined after peroral administration at 2 mg/kg,,50588.0,
1.0,6084.0,,A,,,Intermediate,CHEMBL622540,1.0,,,6805.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period (10 mg/kg) was determined in dog,,50588.0,
1.0,6084.0,,A,,,Intermediate,CHEMBL873803,1.0,,,6806.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period (10 mg/kg) was determined in dog,,50588.0,
1.0,5542.0,,A,,,Intermediate,CHEMBL873804,1.0,,,6807.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,50588.0,
1.0,5542.0,,A,,,Intermediate,CHEMBL624311,1.0,,,6808.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period by po administration in dog at a dose of 0.3 mg/kg,,50588.0,
1.0,6084.0,,A,,,Intermediate,CHEMBL624312,1.0,,,6809.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period in dog,,50588.0,
1.0,6241.0,,A,,,Intermediate,CHEMBL624313,1.0,,,6810.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period in dogs after oral administration at 1 mg/kg,,50588.0,
1.0,1916.0,,A,,,Intermediate,CHEMBL624314,1.0,,,6811.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,50588.0,
1.0,6621.0,,A,,,Intermediate,CHEMBL624315,1.0,,,6812.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life of compound was determined in dogs,,50588.0,
1.0,1696.0,1969.0,A,,,Intermediate,CHEMBL624316,1.0,Plasma,,6813.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life in dog plasma,,50588.0,
1.0,17800.0,,A,,,Intermediate,CHEMBL624317,1.0,,,6814.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life in mongrel dogs was determined,,50588.0,
1.0,17657.0,,A,,,Intermediate,CHEMBL624318,1.0,,,6815.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life in dog upon oral administration,,50588.0,
1.0,17657.0,,A,,,Intermediate,CHEMBL624319,1.0,,,6816.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life in dog upon oral administration; Unable to calculate,,50588.0,
1.0,4239.0,,A,,,Intermediate,CHEMBL624496,1.0,,,6817.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life was measured in dog,,50588.0,
1.0,5985.0,,A,,,Intermediate,CHEMBL624497,1.0,,,6818.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life was measured in dog,,50588.0,
1.0,9932.0,,A,,,Intermediate,CHEMBL624498,1.0,,,6819.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,50588.0,
1.0,5199.0,,A,,,Intermediate,CHEMBL624499,1.0,,,6820.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral half life was determined,,50588.0,
1.0,5199.0,1969.0,A,,,Intermediate,CHEMBL624500,1.0,Plasma,,6821.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,,50588.0,
1.0,1475.0,1969.0,A,,,Intermediate,CHEMBL624501,1.0,Plasma,,6822.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma half life was evaluated,,50588.0,
1.0,1475.0,1969.0,A,,,Intermediate,CHEMBL623666,1.0,Plasma,,6823.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma half life was evaluated in Dog,,50588.0,
1.0,1475.0,1969.0,A,,,Intermediate,CHEMBL623667,1.0,Plasma,,6824.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma half life was evaluated in dog,,50588.0,
1.0,6316.0,,A,,,Intermediate,CHEMBL623668,1.0,,,6825.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,T1/2 (Half-life) was after oral administration at 5 mg/kg,,50588.0,
1.0,4883.0,,A,,,Intermediate,CHEMBL623669,1.0,,,6826.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Tested for the half life value in dog,,50588.0,
1.0,4727.0,,A,,,Intermediate,CHEMBL623670,1.0,,,6827.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum time at the dose of 2 mg/kg in dog,,50588.0,
1.0,1916.0,,A,,,Intermediate,CHEMBL623671,1.0,,,6828.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,50588.0,
1.0,1337.0,178.0,A,,,Intermediate,CHEMBL875945,1.0,Blood,,6829.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,50588.0,
1.0,1337.0,178.0,A,,,Intermediate,CHEMBL623672,1.0,Blood,,6830.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,50588.0,
1.0,6265.0,,A,,,Intermediate,CHEMBL623673,1.0,,,6831.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,50588.0,
1.0,4809.0,,A,,,Intermediate,CHEMBL623674,1.0,,,6832.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,50588.0,
1.0,5983.0,,A,,,Intermediate,CHEMBL623675,1.0,,,6833.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,50588.0,
1.0,5313.0,,A,,,Intermediate,CHEMBL872526,1.0,,,6834.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,50588.0,
1.0,5313.0,,A,,,Intermediate,CHEMBL623676,1.0,,,6835.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,50588.0,
1.0,17650.0,1969.0,A,,,Intermediate,CHEMBL623677,1.0,Plasma,,6836.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,50588.0,
1.0,5199.0,1969.0,A,,,Intermediate,CHEMBL623678,1.0,Plasma,,6837.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,50588.0,
1.0,933.0,1969.0,A,,,Intermediate,CHEMBL623679,1.0,Plasma,,6838.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Time taken for maximum plasma concentration in dog,,50588.0,
1.0,16367.0,,A,,,Intermediate,CHEMBL623680,1.0,,,6839.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Time to reach Cmax after oral administration to dogs,,50588.0,
1.0,6348.0,1969.0,A,,,Intermediate,CHEMBL623681,1.0,Plasma,,6840.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,50588.0,
1.0,6316.0,,A,,,Intermediate,CHEMBL623682,1.0,,,6841.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,50588.0,
1.0,6215.0,,A,,,Intermediate,CHEMBL623683,1.0,,,6842.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Tmax after peroral administration (1 mg/kg) was determined in dog,,50588.0,
1.0,3598.0,,A,,,Expert,CHEMBL623684,1.0,,,6843.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,50588.0,
1.0,4527.0,,A,,,Intermediate,CHEMBL622745,1.0,,,6844.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,50588.0,
1.0,17764.0,,A,,,Intermediate,CHEMBL622746,1.0,,,6845.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Tmax after peroral administration in dogs at 2.4 uM/kg,,50588.0,
1.0,5969.0,,A,,,Intermediate,CHEMBL622747,1.0,,,6846.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,In vivo Cmax in mice at dose of 100 mg/kg,,50594.0,
1.0,5969.0,,A,,,Intermediate,CHEMBL622748,1.0,,,6847.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,In vivo Cmax in mice at dose of 50 mg/kg,,50594.0,
1.0,4573.0,,A,,,Intermediate,CHEMBL622749,1.0,,,6848.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,50594.0,
1.0,3277.0,1969.0,A,,,Intermediate,CHEMBL622750,1.0,Plasma,,6849.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,50594.0,
1.0,17734.0,1969.0,A,,,Intermediate,CHEMBL623411,1.0,Plasma,,6850.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,,50594.0,
1.0,3132.0,1969.0,A,,,Intermediate,CHEMBL875946,1.0,Plasma,,6851.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Maximum concentration obtained in mouse plasma was determined,,50594.0,
1.0,3132.0,1969.0,A,,,Intermediate,CHEMBL623412,1.0,Plasma,,6852.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,,50594.0,
1.0,6348.0,1969.0,A,,,Intermediate,CHEMBL623413,1.0,Plasma,,6853.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,50594.0,
1.0,17729.0,1969.0,A,,,Intermediate,CHEMBL623414,1.0,Plasma,,6854.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,,50594.0,
1.0,17729.0,1969.0,A,,,Intermediate,CHEMBL623415,1.0,Plasma,,6855.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,,50594.0,
1.0,17729.0,1969.0,A,,,Intermediate,CHEMBL623416,1.0,Plasma,,6856.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,,50594.0,
1.0,17728.0,1969.0,A,,,Intermediate,CHEMBL623417,1.0,Plasma,,6857.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,,50594.0,
1.0,17728.0,1969.0,A,,,Intermediate,CHEMBL623418,1.0,Plasma,,6858.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,,50594.0,
1.0,17728.0,1969.0,A,,,Intermediate,CHEMBL623419,1.0,Plasma,,6859.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,,50594.0,
1.0,4066.0,,A,,,Intermediate,CHEMBL622816,1.0,,,6860.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,50594.0,
1.0,6178.0,,A,,,Intermediate,CHEMBL623313,1.0,,,6861.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,50594.0,
1.0,6178.0,,A,,,Intermediate,CHEMBL623314,1.0,,,6862.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,50594.0,
1.0,3760.0,,A,,,Intermediate,CHEMBL876788,1.0,,,6863.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,50594.0,
1.0,3760.0,,A,,,Intermediate,CHEMBL623315,1.0,,,6864.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,50594.0,
1.0,3760.0,,A,,,Intermediate,CHEMBL623316,1.0,,,6865.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,50594.0,
1.0,3760.0,,A,,,Intermediate,CHEMBL623317,1.0,,,6866.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,50594.0,
1.0,5961.0,,A,,,Intermediate,CHEMBL623319,1.0,,,6868.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Cmax in male mice after 2 mg/kg oral dose,,50594.0,
1.0,6137.0,,A,,,Intermediate,CHEMBL623320,1.0,,,6869.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,50594.0,
1.0,3802.0,,A,,,Intermediate,CHEMBL623321,1.0,,,6870.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,50594.0,
1.0,3535.0,,A,,,Intermediate,CHEMBL623322,1.0,,,6871.0,,N,BAO_0000218,,10090.0,,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,50594.0,
1.0,3535.0,,A,,,Intermediate,CHEMBL623323,1.0,,,6872.0,,N,BAO_0000218,,10090.0,,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,50594.0,
1.0,3535.0,,A,,,Intermediate,CHEMBL623324,1.0,,,6873.0,,N,BAO_0000218,,10090.0,,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,50594.0,
1.0,3535.0,,A,,,Intermediate,CHEMBL623325,1.0,,,6874.0,,N,BAO_0000218,,10090.0,,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,50594.0,
1.0,3535.0,,A,,,Intermediate,CHEMBL623326,1.0,,,6875.0,,N,BAO_0000218,,10090.0,,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,50594.0,
1.0,3535.0,,A,,,Intermediate,CHEMBL623327,1.0,,,6876.0,,N,BAO_0000218,,10090.0,,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,50594.0,
1.0,2862.0,1969.0,A,,,Intermediate,CHEMBL623328,1.0,Plasma,,6877.0,,N,BAO_0000218,,10090.0,,Mus musculus,Maximum concentration in plasma upon oral administration in mouse,,50594.0,
1.0,2675.0,1969.0,A,,,Intermediate,CHEMBL623329,1.0,Plasma,,6878.0,,N,BAO_0000218,,10090.0,,Mus musculus,Maximum plasma concentration was evaluated in mice after oral administration,,50594.0,
1.0,2675.0,1969.0,A,,,Intermediate,CHEMBL623330,1.0,Plasma,,6879.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,,50594.0,
1.0,5399.0,,A,,,Intermediate,CHEMBL876789,1.0,,,6880.0,,N,BAO_0000218,,10090.0,,Mus musculus,Dose at which the compound induced fecal excretion in mice,,50594.0,
1.0,11819.0,,F,,,Expert,CHEMBL623333,1.0,,,6893.0,,N,BAO_0000219,A10,10116.0,,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,80013.0,164.0
1.0,11819.0,,F,,,Expert,CHEMBL623334,1.0,,,6894.0,,N,BAO_0000219,A10,10116.0,,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,80013.0,164.0
1.0,11819.0,,F,,,Expert,CHEMBL627536,1.0,,,6895.0,,N,BAO_0000219,A10,10116.0,,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,80013.0,164.0
1.0,11819.0,,F,,,Expert,CHEMBL627537,1.0,,,6896.0,,N,BAO_0000219,A10,10116.0,,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,80013.0,164.0
1.0,16361.0,,F,,,Intermediate,CHEMBL627538,1.0,,,6897.0,,N,BAO_0000219,A10,10116.0,,Rattus norvegicus,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,80013.0,164.0
1.0,2288.0,,F,,,Intermediate,CHEMBL884106,1.0,,,6898.0,,N,BAO_0000219,A121,9606.0,,Homo sapiens,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,80655.0,393.0
1.0,10404.0,,F,,,Intermediate,CHEMBL625294,1.0,,,6899.0,,N,BAO_0000219,A121,9606.0,,Homo sapiens,Anticancer activity against human ovarian carcinoma A121 cells,,80655.0,393.0
1.0,14790.0,,F,,,Intermediate,CHEMBL625295,1.0,,,6900.0,,N,BAO_0000219,A121,9606.0,,Homo sapiens,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,80655.0,393.0
1.0,14790.0,,F,,,Intermediate,CHEMBL625296,1.0,,,6901.0,,N,BAO_0000219,A121,9606.0,,Homo sapiens,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,80655.0,393.0
1.0,14253.0,,F,,,Expert,CHEMBL625297,1.0,,,6902.0,,N,BAO_0000219,A121,9606.0,,Homo sapiens,Growth inhibition of human ovarian carcinoma (A121) cell line,,80655.0,393.0
1.0,13617.0,,F,,,Expert,CHEMBL625298,1.0,,,6903.0,,N,BAO_0000219,A121,9606.0,,Homo sapiens,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,80655.0,393.0
1.0,1003.0,,F,,,Intermediate,CHEMBL625960,1.0,,,6904.0,,N,BAO_0000219,A121,9606.0,,Homo sapiens,Cytotoxicity against human A121 ovarian cells,,80655.0,393.0
1.0,830.0,,F,,,Intermediate,CHEMBL625961,1.0,,,6905.0,,N,BAO_0000219,A121,9606.0,,Homo sapiens,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,80655.0,393.0
1.0,12307.0,,F,,,Intermediate,CHEMBL625962,1.0,,,6906.0,,N,BAO_0000219,A121,9606.0,,Homo sapiens,In vitro cytotoxicity against human ovarian carcinoma A21,,80655.0,393.0
1.0,14254.0,,F,,,Intermediate,CHEMBL624717,1.0,,,6907.0,,N,BAO_0000219,A121,9606.0,,Homo sapiens,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,80655.0,393.0
1.0,13370.0,,F,,,Intermediate,CHEMBL624718,1.0,,,6908.0,,N,BAO_0000219,A121,9606.0,,Homo sapiens,Inhibitory activity of compound against human A121 ovarian cell line.,,80655.0,393.0
1.0,14790.0,,F,,,Intermediate,CHEMBL624719,1.0,,,6909.0,,N,BAO_0000219,A121,9606.0,,Homo sapiens,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,80655.0,393.0
1.0,3614.0,,F,,,Intermediate,CHEMBL624720,1.0,,,6910.0,,N,BAO_0000219,A121,9606.0,,Homo sapiens,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,80655.0,393.0
1.0,2664.0,,F,,,Intermediate,CHEMBL624721,1.0,,,6911.0,,N,BAO_0000219,A 172,9606.0,,Homo sapiens,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,80012.0,622.0
1.0,2037.0,,F,,,Expert,CHEMBL624722,1.0,,,6912.0,,N,BAO_0000219,A 172,9606.0,,Homo sapiens,In vitro cytotoxicity against A172 human tumor cell lines.,,80012.0,622.0
1.0,14539.0,,F,,,Intermediate,CHEMBL877597,1.0,,,6913.0,,N,BAO_0000219,A 172,9606.0,,Homo sapiens,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,80012.0,622.0
1.0,2836.0,,F,,,Intermediate,CHEMBL624723,1.0,,,6914.0,,N,BAO_0000219,A 172,9606.0,,Homo sapiens,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,80012.0,622.0
1.0,10708.0,,F,,,Intermediate,CHEMBL624724,1.0,,,6915.0,,N,BAO_0000219,A 172,9606.0,,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,80012.0,622.0
4.0,8975.0,,B,,,Autocuration,CHEMBL624725,1.0,,,6916.0,,H,BAO_0000224,,9615.0,,Canis lupus familiaris,Association constant against A2 adenosine receptor,,104729.0,
1.0,7645.0,,F,,,Intermediate,CHEMBL624726,1.0,,,6917.0,,N,BAO_0000219,A2,,,fish,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,80656.0,1085.0
5.0,11377.0,,B,,,Autocuration,CHEMBL857535,1.0,,,6918.0,,D,BAO_0000224,,10116.0,,Rattus norvegicus,Ratio of Ki for adenosine A2 and A1 receptor binding,,104713.0,
1.0,13528.0,,F,,,Expert,CHEMBL624727,1.0,,,6919.0,,N,BAO_0000219,A204,9606.0,,Homo sapiens,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,80014.0,623.0
1.0,10160.0,,F,,,Expert,CHEMBL624728,1.0,,,6920.0,,N,BAO_0000219,A204,9606.0,,Homo sapiens,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,80014.0,623.0
1.0,15144.0,,F,,,Intermediate,CHEMBL624729,1.0,,,6921.0,,N,BAO_0000219,A2058,9606.0,,Homo sapiens,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,80015.0,404.0
1.0,13160.0,,F,,,Intermediate,CHEMBL624730,1.0,,,6922.0,,N,BAO_0000219,A253 cell line,9606.0,,Homo sapiens,Growth inhibition against Human squamous cell line(A 253),,80657.0,973.0
1.0,12898.0,,F,,,Intermediate,CHEMBL624731,1.0,,,6923.0,,N,BAO_0000219,A253 cell line,9606.0,,Homo sapiens,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,80657.0,973.0
1.0,13069.0,,F,,,Intermediate,CHEMBL624732,1.0,,,6924.0,,N,BAO_0000219,A253 cell line,9606.0,,Homo sapiens,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,80657.0,973.0
1.0,15984.0,,F,,,Intermediate,CHEMBL883245,1.0,,,6925.0,,N,BAO_0000219,A253 cell line,9606.0,,Homo sapiens,Growth inhibition of A253 cell lines.,,80657.0,973.0
1.0,15564.0,,F,,,Intermediate,CHEMBL624733,1.0,,,6926.0,,N,BAO_0000219,A253 cell line,9606.0,,Homo sapiens,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,80657.0,973.0
1.0,15564.0,,F,,,Intermediate,CHEMBL624734,1.0,,,6927.0,,N,BAO_0000219,A253 cell line,9606.0,,Homo sapiens,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,80657.0,973.0
1.0,15564.0,,F,,,Intermediate,CHEMBL624735,1.0,,,6928.0,,N,BAO_0000219,A253 cell line,9606.0,,Homo sapiens,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,80657.0,973.0
1.0,4720.0,,F,,,Intermediate,CHEMBL621780,1.0,,,6929.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,81034.0,478.0
1.0,16112.0,,F,,,Intermediate,CHEMBL877598,1.0,,,6930.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,81034.0,478.0
1.0,16597.0,,F,,,Expert,CHEMBL621781,1.0,,,6931.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,81034.0,478.0
1.0,16378.0,,F,,,Intermediate,CHEMBL621782,1.0,,,6932.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Cytotoxicity against human cancer cell lines A2780 (ovarian),,81034.0,478.0
1.0,16085.0,,F,,,Expert,CHEMBL621783,1.0,,,6933.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,81034.0,478.0
1.0,16317.0,,F,,,Intermediate,CHEMBL621784,1.0,,,6934.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,81034.0,478.0
1.0,15748.0,,F,,,Intermediate,CHEMBL621785,1.0,,,6935.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,81034.0,478.0
1.0,16597.0,,F,,,Expert,CHEMBL621968,1.0,,,6936.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,81034.0,478.0
1.0,16597.0,,F,,,Expert,CHEMBL621969,1.0,,,6937.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,81034.0,478.0
1.0,16597.0,,F,,,Expert,CHEMBL621970,1.0,,,6938.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,81034.0,478.0
1.0,15608.0,,F,,,Intermediate,CHEMBL621971,1.0,,,6939.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,81034.0,478.0
1.0,15608.0,,F,,,Intermediate,CHEMBL621972,1.0,,,6940.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,81034.0,478.0
1.0,15608.0,,F,,,Intermediate,CHEMBL884108,1.0,,,6941.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,81034.0,478.0
0.0,15296.0,,F,,,Autocuration,CHEMBL623826,1.0,,,6942.0,,U,BAO_0000019,,10029.0,,Cricetulus griseus,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,22224.0,
0.0,10251.0,,A,,,Autocuration,CHEMBL623827,1.0,,,6943.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,22224.0,185.0
0.0,10251.0,,F,,,Autocuration,CHEMBL623828,1.0,,,6944.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,22224.0,185.0
0.0,10251.0,,F,,,Autocuration,CHEMBL623829,1.0,,,6945.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,22224.0,185.0
0.0,10251.0,,F,,,Autocuration,CHEMBL623830,1.0,,,6946.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,22224.0,185.0
0.0,11858.0,,F,,,Autocuration,CHEMBL623831,1.0,,,6947.0,,U,BAO_0000019,,10029.0,,Cricetulus griseus,Growth inhibition against CHO-derived cell line AA8,,22224.0,
0.0,11858.0,,F,,,Autocuration,CHEMBL623832,1.0,,,6948.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,22224.0,185.0
1.0,11616.0,,F,,,Expert,CHEMBL623833,1.0,,,6949.0,,N,BAO_0000219,CHO-AA8,36483.0,,hampster,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,80089.0,185.0
1.0,11616.0,,F,,,Expert,CHEMBL623834,1.0,,,6950.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,80089.0,185.0
0.0,10518.0,,F,,,Autocuration,CHEMBL623835,1.0,,,6951.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,22224.0,185.0
0.0,11396.0,,F,,,Autocuration,CHEMBL623836,1.0,,,6952.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,22224.0,185.0
0.0,10518.0,,F,,,Autocuration,CHEMBL623837,1.0,,,6953.0,,U,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,22224.0,185.0
1.0,11616.0,,F,,,Expert,CHEMBL623838,1.0,,,6954.0,,N,BAO_0000219,CHO-AA8,10029.0,,Cricetulus griseus,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,80089.0,185.0
8.0,14837.0,,F,,,Autocuration,CHEMBL623839,1.0,,,6955.0,,H,BAO_0000019,,,,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,12675.0,
8.0,14837.0,,F,,,Autocuration,CHEMBL623840,1.0,,,6956.0,,H,BAO_0000019,,,,,Number of binding sites (n) of isolated serum protein AAG,,12675.0,
3.0,16037.0,,B,,,Intermediate,CHEMBL623841,1.0,,,6957.0,,M,BAO_0000225,,,,,Association constant for binding to AATT duplex,,22222.0,
1.0,16597.0,,F,,,Expert,CHEMBL623842,1.0,,,6958.0,,N,BAO_0000219,ABAE,9606.0,,Homo sapiens,Inhibition of ABAE human fibroblast cell proliferation,,100090.0,416.0
1.0,8831.0,,F,,,Intermediate,CHEMBL623843,1.0,,,6959.0,,N,BAO_0000218,AC755,10090.0,,Mus musculus,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,80668.0,1064.0
9.0,13419.0,,F,,,Expert,CHEMBL618669,1.0,,,6960.0,,D,BAO_0000218,,9986.0,,Oryctolagus cuniculus,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,102444.0,
9.0,13419.0,,F,,,Expert,CHEMBL618670,1.0,,,6961.0,In vivo,D,BAO_0000218,,9986.0,,Oryctolagus cuniculus,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,102444.0,
8.0,15778.0,,B,,,Autocuration,CHEMBL618671,1.0,,,6962.0,,H,BAO_0000357,,,,,Inhibitory activity against angiotensin-converting enzyme (ACE).,,69.0,
8.0,15778.0,,B,,,Autocuration,CHEMBL618672,1.0,,,6963.0,,H,BAO_0000357,,,,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,69.0,
1.0,12988.0,,F,,,Intermediate,CHEMBL618673,1.0,,,6964.0,,N,BAO_0000219,ACH-2 cell line,9606.0,,Homo sapiens,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,80669.0,978.0
1.0,12988.0,,F,,,Intermediate,CHEMBL618674,1.0,,,6965.0,,N,BAO_0000219,ACH-2 cell line,9606.0,,Homo sapiens,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,80669.0,978.0
0.0,12988.0,,F,,,Autocuration,CHEMBL618675,1.0,,,6966.0,,U,BAO_0000219,T cell line,11676.0,,Human immunodeficiency virus 1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,22224.0,998.0
0.0,12988.0,,F,,,Autocuration,CHEMBL618676,1.0,,,6967.0,,U,BAO_0000219,T cell line,11676.0,,Human immunodeficiency virus 1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,22224.0,998.0
0.0,12988.0,,F,,,Autocuration,CHEMBL618677,1.0,,,6968.0,,U,BAO_0000219,T cell line,11676.0,,Human immunodeficiency virus 1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,22224.0,998.0
1.0,11843.0,,F,,,Intermediate,CHEMBL618678,1.0,,,6969.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Inhibition of growth of renal cancer ACHN cell line,,80025.0,626.0
1.0,16939.0,,F,,,Intermediate,CHEMBL618679,1.0,,,6970.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Inhibition of growth of ACHN renal cancer cell line,,80025.0,626.0
1.0,4782.0,,F,,,Intermediate,CHEMBL618680,1.0,,,6971.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Inhibitory concentration required against ACHN renal cancer cell line,,80025.0,626.0
1.0,6310.0,,F,,,Expert,CHEMBL618681,1.0,,,6972.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Concentration required to inhibit growth of human renal (ACHN) cell line,,80025.0,626.0
1.0,6310.0,,F,,,Intermediate,CHEMBL618682,1.0,,,6973.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,80025.0,626.0
1.0,12858.0,,F,,,Intermediate,CHEMBL618683,1.0,,,6974.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Cytotoxic activity against ACHN Renal cancer cell line,,80025.0,626.0
1.0,17380.0,,F,,,Intermediate,CHEMBL618684,1.0,,,6975.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Cytotoxicity evaluation against ACHN renal cancer cells,,80025.0,626.0
1.0,5858.0,,F,,,Intermediate,CHEMBL618685,1.0,,,6976.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,In vitro antitumor activity against human renal ACHN cell line,,80025.0,626.0
1.0,3838.0,,F,,,Intermediate,CHEMBL876499,1.0,,,6977.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,80025.0,626.0
1.0,3838.0,,F,,,Intermediate,CHEMBL618686,1.0,,,6978.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,80025.0,626.0
1.0,5406.0,,F,,,Intermediate,CHEMBL618687,1.0,,,6979.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,80025.0,626.0
1.0,4071.0,,F,,,Intermediate,CHEMBL618688,1.0,,,6980.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,80025.0,626.0
1.0,4071.0,,F,,,Expert,CHEMBL618689,1.0,,,6981.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,80025.0,626.0
1.0,4071.0,,F,,,Intermediate,CHEMBL618690,1.0,,,6982.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,80025.0,626.0
1.0,15002.0,,F,,,Intermediate,CHEMBL618691,1.0,,,6983.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,80025.0,626.0
1.0,14769.0,,F,,,Intermediate,CHEMBL619373,1.0,,,6984.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,80025.0,626.0
1.0,13958.0,,F,,,Intermediate,CHEMBL884008,1.0,,,6985.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,80025.0,626.0
1.0,1665.0,,F,,,Intermediate,CHEMBL619374,1.0,,,6986.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,80025.0,626.0
1.0,15354.0,,F,,,Intermediate,CHEMBL619375,1.0,,,6987.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,80025.0,626.0
1.0,15354.0,,F,,,Intermediate,CHEMBL619376,1.0,,,6988.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,80025.0,626.0
1.0,13978.0,,F,,,Intermediate,CHEMBL619377,1.0,,,6989.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,80025.0,626.0
1.0,6798.0,,F,,,Intermediate,CHEMBL619378,1.0,,,6990.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,80025.0,626.0
1.0,2959.0,,A,,,Intermediate,CHEMBL872527,1.0,,,6991.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Tmax value after administration of 4 mg/Kg oral dose in dog,,50588.0,
1.0,9932.0,,A,,,Intermediate,CHEMBL876500,1.0,,,6992.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,50588.0,
1.0,5546.0,,A,,,Intermediate,CHEMBL619379,1.0,,,6993.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,50588.0,
1.0,16907.0,,A,,,Intermediate,CHEMBL619538,1.0,,,6994.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume distribution after 15 mg/kg iv dose in Dogs,,50588.0,
1.0,16907.0,,A,,,Intermediate,CHEMBL619539,1.0,,,6995.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume distribution after 30 mg/kg po dose in Dogs,,50588.0,
1.0,4257.0,,A,,,Intermediate,CHEMBL619540,1.0,,,6996.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,50588.0,
1.0,4305.0,,A,,,Intermediate,CHEMBL619541,1.0,,,6997.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,50588.0,
1.0,5472.0,,A,,,Intermediate,CHEMBL619542,1.0,,,6998.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume of distribution was evaluated in dog,,50588.0,
1.0,6062.0,,A,,,Intermediate,CHEMBL619543,1.0,,,6999.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,50588.0,
1.0,3598.0,,A,,,Expert,CHEMBL619544,1.0,,,7000.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,50588.0,
1.0,12500.0,,A,,,Intermediate,CHEMBL619545,1.0,,,7001.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,The compound was tested for volume of distribution in dog,,50588.0,
1.0,12500.0,,A,,,Intermediate,CHEMBL619546,1.0,,,7002.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,50588.0,
1.0,6227.0,,A,,,Intermediate,CHEMBL619547,1.0,,,7003.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Vd (1 mg/kg) was determined in dog (in vivo),,50588.0,
1.0,6227.0,,A,,,Intermediate,CHEMBL619548,1.0,,,7004.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Vd in dog,,50588.0,
1.0,4219.0,,A,,,Intermediate,CHEMBL619549,1.0,,,7005.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume distribution was determined,,50588.0,
1.0,1696.0,,A,,,Intermediate,CHEMBL619550,1.0,,,7006.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume of distribution in dog,,50588.0,
1.0,5542.0,,A,,,Intermediate,CHEMBL876501,1.0,,,7007.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume of distribution by as 4 fold increase by iv administration in dogs,,50588.0,
1.0,5199.0,,A,,,Intermediate,CHEMBL619551,1.0,,,7008.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,50588.0,
1.0,6348.0,,A,,,Intermediate,CHEMBL619552,1.0,,,7009.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,50588.0,
1.0,4727.0,,A,,,Intermediate,CHEMBL619553,1.0,,,7010.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume distribution at the dose of 2 mg/kg in dog,,50588.0,
1.0,16367.0,,A,,,Intermediate,CHEMBL618722,1.0,,,7011.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Steady state volume of distribution was determined,,50588.0,
1.0,2652.0,,A,,,Intermediate,CHEMBL618723,1.0,,,7012.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,50588.0,
1.0,16452.0,,A,,,Intermediate,CHEMBL618724,1.0,,,7013.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,50588.0,
1.0,16452.0,,A,,,Intermediate,CHEMBL618725,1.0,,,7014.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,50588.0,
1.0,16452.0,,A,,,Intermediate,CHEMBL618726,1.0,,,7015.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog (dose 1 mg/kg i.v.),,50588.0,
1.0,5334.0,,A,,,Intermediate,CHEMBL618727,1.0,,,7016.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,50588.0,
1.0,4239.0,,A,,,Intermediate,CHEMBL624233,1.0,,,7017.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic property (vdss) was measured in dog,,50588.0,
1.0,4709.0,,A,,,Intermediate,CHEMBL624234,1.0,,,7018.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,50588.0,
1.0,5600.0,,A,,,Intermediate,CHEMBL624235,1.0,,,7019.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Vdss was determined after iv 0.1 mg/kg administration in dog,,50588.0,
1.0,6057.0,,A,,,Intermediate,CHEMBL624236,1.0,,,7020.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume displacement was calculated in dog,,50588.0,
1.0,5654.0,,A,,,Intermediate,CHEMBL624237,1.0,,,7021.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,50588.0,
1.0,5505.0,,A,,,Intermediate,CHEMBL624238,1.0,,,7022.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume distribution constant was determined,,50588.0,
1.0,4527.0,,A,,,Intermediate,CHEMBL624239,1.0,,,7023.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume distribution at a dose of 1 uM/kg in dog was determined,,50588.0,
1.0,4521.0,,A,,,Intermediate,CHEMBL875829,1.0,,,7024.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,50588.0,
1.0,4521.0,,A,,,Intermediate,CHEMBL624240,1.0,,,7025.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,50588.0,
1.0,15660.0,,A,,,Intermediate,CHEMBL624241,1.0,,,7026.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume distribution (Vdss) was measured in dog,,50588.0,
1.0,15660.0,,A,,,Intermediate,CHEMBL624242,1.0,,,7027.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume distribution (Vdss) was measured in dog,,50588.0,
1.0,6679.0,,A,,,Intermediate,CHEMBL624243,1.0,,,7028.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,50588.0,
1.0,5145.0,,A,,,Intermediate,CHEMBL624244,1.0,,,7029.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume of distribution in steady state was determined in dog,,50588.0,
1.0,6821.0,,A,,,Intermediate,CHEMBL624245,1.0,,,7030.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume of distribution of compound was determined in dog,,50588.0,
1.0,4137.0,,A,,,Intermediate,CHEMBL624246,1.0,,,7031.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,50588.0,
1.0,5334.0,,A,,,Intermediate,CHEMBL624247,1.0,,,7032.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,50588.0,
1.0,15660.0,,A,,,Intermediate,CHEMBL624248,1.0,,,7033.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume of distribution (Vdss) was measured in dog,,50588.0,
1.0,6642.0,,A,,,Intermediate,CHEMBL624249,1.0,,,7034.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,50588.0,
1.0,6641.0,,A,,,Intermediate,CHEMBL624250,1.0,,,7035.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,50588.0,
1.0,6642.0,,A,,,Intermediate,CHEMBL624251,1.0,,,7036.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,50588.0,
1.0,11659.0,,A,,,Intermediate,CHEMBL624252,1.0,,,7037.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Maximum rate of depolarization of the upstroke of the action potential,,50588.0,
1.0,6448.0,,A,,,Intermediate,CHEMBL624253,1.0,,,7038.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Steady state volume distribution in dog,,50588.0,
1.0,5474.0,,A,,,Intermediate,CHEMBL624950,1.0,,,7039.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,50588.0,
1.0,1466.0,,A,,,Intermediate,CHEMBL624951,1.0,,,7040.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,50588.0,
1.0,6535.0,,A,,,Intermediate,CHEMBL875830,1.0,,,7041.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,50588.0,
1.0,6535.0,,A,,,Intermediate,CHEMBL624952,1.0,,,7042.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume distribution in dog after administration of 1 mg/kg iv,,50588.0,
1.0,17764.0,,A,,,Intermediate,CHEMBL624953,1.0,,,7043.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,50588.0,
1.0,6215.0,,A,,,Intermediate,CHEMBL624954,1.0,,,7044.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,50588.0,
1.0,6505.0,,A,,,Intermediate,CHEMBL624955,1.0,,,7045.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Vss on i.v. administration of 2 mg/kg was measured in dog,,50588.0,
1.0,3639.0,,A,,,Intermediate,CHEMBL624956,1.0,,,7046.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Vss was determined,,50588.0,
1.0,3639.0,,A,,,Intermediate,CHEMBL625129,1.0,,,7047.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Vss in dog,,50588.0,
1.0,6062.0,,A,,,Intermediate,CHEMBL625130,1.0,,,7048.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,50588.0,
1.0,4942.0,,A,,,Intermediate,CHEMBL625131,1.0,,,7049.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume distribution in dogs,,50588.0,
1.0,17796.0,,A,,,Intermediate,CHEMBL625132,1.0,,,7050.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Volume of distribution in dog,,50588.0,
1.0,4883.0,,A,,,Intermediate,CHEMBL872263,1.0,,,7051.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Tested for the oral bioavailability in dog,,50588.0,
1.0,17837.0,,A,,,Intermediate,CHEMBL624336,1.0,,,7060.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,50594.0,
1.0,17729.0,,A,,,Intermediate,CHEMBL624337,1.0,,,7061.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,50594.0,
1.0,17729.0,,A,,,Intermediate,CHEMBL624338,1.0,,,7062.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,50594.0,
1.0,4239.0,,A,,,Intermediate,CHEMBL624339,1.0,,,7063.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Bioavailability was measured in mouse,,50594.0,
1.0,17592.0,,A,,,Intermediate,CHEMBL624340,1.0,,,7064.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Bioavailability in mouse,,50594.0,
1.0,6348.0,,A,,,Intermediate,CHEMBL624341,1.0,,,7065.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,50594.0,
1.0,2801.0,,A,,,Intermediate,CHEMBL624342,1.0,,,7066.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Bioavailability in mouse,,50594.0,
1.0,2801.0,,A,,,Intermediate,CHEMBL624343,1.0,,,7067.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,50594.0,
1.0,17718.0,,A,,,Intermediate,CHEMBL624344,1.0,,,7068.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Oral bioavailability in mouse,,50594.0,
1.0,5727.0,,A,,,Intermediate,CHEMBL624345,1.0,,,7069.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Oral availability at 50 mg/kg po in male mice,,50594.0,
1.0,5302.0,,A,,,Intermediate,CHEMBL624346,1.0,,,7070.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Oral bioavailability in mouse (dose 10 mg/kg),,50594.0,
1.0,3598.0,,A,,,Expert,CHEMBL624347,1.0,,,7071.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,50594.0,
1.0,5961.0,,A,,,Intermediate,CHEMBL624348,1.0,,,7072.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,50594.0,
1.0,6091.0,,A,,,Intermediate,CHEMBL622754,1.0,,,7074.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Oral bioavailability in mouse,,50594.0,
1.0,6091.0,,A,,,Intermediate,CHEMBL622755,1.0,,,7075.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Oral bioavailability in vivo in mice;ND=Not determined,,50594.0,
1.0,5711.0,,A,,,Intermediate,CHEMBL622756,1.0,,,7076.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Oral bioavailability in mouse at 10 mg/kg of the compound,,50594.0,
1.0,17728.0,,A,,,Intermediate,CHEMBL622757,1.0,,,7077.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,50594.0,
1.0,17728.0,,A,,,Intermediate,CHEMBL622758,1.0,,,7078.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,50594.0,
1.0,3802.0,,A,,,Intermediate,CHEMBL622759,1.0,,,7079.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Tested for bioavailability of the compound,,50594.0,
1.0,3802.0,,A,,,Intermediate,CHEMBL622760,1.0,,,7080.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Tested for half life at the dose of 10 mg/kg when administered intravenously,,50594.0,
1.0,14029.0,1969.0,A,,,Intermediate,CHEMBL622761,1.0,Plasma,,7081.0,,N,BAO_0000218,,10090.0,,Mus musculus,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,50594.0,
1.0,14029.0,1969.0,A,,,Intermediate,CHEMBL622762,1.0,Plasma,,7082.0,,N,BAO_0000218,,10090.0,,Mus musculus,The plasma half life of compound was determined on heparin prepared by human plasma. ,,50594.0,
1.0,14029.0,1969.0,A,,,Intermediate,CHEMBL622763,1.0,Plasma,,7083.0,,N,BAO_0000218,,10090.0,,Mus musculus,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,50594.0,
1.0,14029.0,1969.0,A,,,Intermediate,CHEMBL622764,1.0,Plasma,,7084.0,,N,BAO_0000218,,10090.0,,Mus musculus,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,50594.0,
1.0,14029.0,1969.0,A,,,Intermediate,CHEMBL622765,1.0,Plasma,,7085.0,,N,BAO_0000218,,10090.0,,Mus musculus,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,50594.0,
1.0,17753.0,,F,,,Intermediate,CHEMBL622766,1.0,,,7086.0,,N,BAO_0000218,,10090.0,,Mus musculus,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,50594.0,
1.0,17753.0,,A,,,Intermediate,CHEMBL622767,1.0,,,7087.0,,N,BAO_0000218,,10090.0,,Mus musculus,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,50594.0,
1.0,17753.0,,A,,,Intermediate,CHEMBL622768,1.0,,,7088.0,,N,BAO_0000218,,10090.0,,Mus musculus,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,50594.0,
1.0,10107.0,178.0,A,,,Intermediate,CHEMBL875948,1.0,Blood,,7089.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594.0,
1.0,10107.0,178.0,A,,,Intermediate,CHEMBL622769,1.0,Blood,,7090.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,50594.0,
1.0,10107.0,178.0,A,,,Intermediate,CHEMBL622770,1.0,Blood,,7091.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594.0,
1.0,10107.0,178.0,A,,,Intermediate,CHEMBL622771,1.0,Blood,,7092.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594.0,
1.0,10107.0,178.0,A,,,Intermediate,CHEMBL622772,1.0,Blood,,7093.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594.0,
1.0,10107.0,178.0,A,,,Intermediate,CHEMBL622773,1.0,Blood,,7094.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594.0,
1.0,10107.0,178.0,A,,,Intermediate,CHEMBL622774,1.0,Blood,,7095.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594.0,
1.0,10107.0,10000001.0,A,,,Intermediate,CHEMBL621725,1.0,Bone,,7096.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594.0,
1.0,10107.0,10000001.0,A,,,Intermediate,CHEMBL621726,1.0,Bone,,7097.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,50594.0,
1.0,15608.0,,F,,,Intermediate,CHEMBL621727,1.0,,,7098.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,81034.0,478.0
1.0,3290.0,,F,,,Expert,CHEMBL622413,1.0,,,7099.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,81034.0,478.0
1.0,2859.0,,F,,,Intermediate,CHEMBL622414,1.0,,,7100.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cell line,,81034.0,478.0
1.0,15688.0,,F,,,Expert,CHEMBL622415,1.0,,,7101.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Inhibition of A2780 cell clonogenic assay,,81034.0,478.0
1.0,5642.0,,F,,,Expert,CHEMBL884001,1.0,,,7102.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Cytotoxic effect on ovarian cancer cell line (A2780),,81034.0,478.0
1.0,6633.0,,F,,,Intermediate,CHEMBL622416,1.0,,,7103.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,81034.0,478.0
1.0,3906.0,,F,,,Intermediate,CHEMBL622417,1.0,,,7104.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,81034.0,478.0
1.0,6788.0,,F,,,Expert,CHEMBL622590,1.0,,,7105.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,81034.0,478.0
1.0,17582.0,,F,,,Expert,CHEMBL622591,1.0,,,7106.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Antiproliferative activity against human A2780 cells,,81034.0,478.0
1.0,17764.0,,F,,,Expert,CHEMBL622592,1.0,,,7107.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Inhibition of human A2780 cell proliferation,,81034.0,478.0
1.0,17764.0,,F,,,Expert,CHEMBL622593,1.0,,,7108.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,81034.0,478.0
1.0,17764.0,,F,,,Expert,CHEMBL622594,1.0,,,7109.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Inhibition of human A2780 cell proliferation (No data),,81034.0,478.0
1.0,2815.0,,F,,,Intermediate,CHEMBL622595,1.0,,,7110.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,81034.0,478.0
1.0,16930.0,,F,,,Intermediate,CHEMBL622596,1.0,,,7111.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound was evaluated against human Ovarian carcinoma cell line A2780,,81034.0,478.0
1.0,17777.0,,F,,,Expert,CHEMBL622597,1.0,,,7112.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Growth inhibition against A2780 wild-type ovarian cell lines,,81034.0,478.0
1.0,17777.0,,F,,,Intermediate,CHEMBL622598,1.0,,,7113.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,81034.0,478.0
5.0,16936.0,,F,,,Autocuration,CHEMBL622599,1.0,,,7114.0,,D,BAO_0000019,,9606.0,,Homo sapiens,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,104766.0,
1.0,13759.0,,F,,,Intermediate,CHEMBL622600,1.0,,,7115.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,81034.0,478.0
1.0,13759.0,,F,,,Intermediate,CHEMBL622601,1.0,,,7116.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,81034.0,478.0
1.0,13759.0,,F,,,Intermediate,CHEMBL622602,1.0,,,7117.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,81034.0,478.0
1.0,13759.0,,F,,,Intermediate,CHEMBL622603,1.0,,,7118.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,81034.0,478.0
1.0,15292.0,,F,,,Intermediate,CHEMBL622604,1.0,,,7119.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,81034.0,478.0
1.0,15292.0,,F,,,Intermediate,CHEMBL622605,1.0,,,7120.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,81034.0,478.0
1.0,15069.0,,F,,,Expert,CHEMBL622606,1.0,,,7121.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro inhibition of human ovarian cell line A2780,,81034.0,478.0
1.0,15069.0,,F,,,Expert,CHEMBL619463,1.0,,,7122.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,81034.0,478.0
1.0,14073.0,,F,,,Intermediate,CHEMBL619464,1.0,,,7123.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,81034.0,478.0
1.0,14553.0,,F,,,Expert,CHEMBL619465,1.0,,,7124.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Concentration required to inhibit A2780-cell growth by 50%,,81034.0,478.0
1.0,13040.0,,F,,,Expert,CHEMBL619466,1.0,,,7125.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,81034.0,478.0
1.0,6891.0,,F,,,Expert,CHEMBL619467,1.0,,,7126.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Cytotoxic effect on human ovarian (A2780) cancer cell line,,81034.0,478.0
1.0,15569.0,,F,,,Intermediate,CHEMBL619468,1.0,,,7127.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,81034.0,478.0
1.0,14190.0,,F,,,Expert,CHEMBL619469,1.0,,,7128.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,81034.0,478.0
1.0,15014.0,,F,,,Expert,CHEMBL619470,1.0,,,7129.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,81034.0,478.0
1.0,15014.0,,F,,,Intermediate,CHEMBL619471,1.0,,,7130.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,81034.0,478.0
1.0,17496.0,,F,,,Intermediate,CHEMBL619472,1.0,,,7131.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Cytotoxicity against human ovarian carcinoma A2780 cell line,,81034.0,478.0
1.0,13617.0,,F,,,Intermediate,CHEMBL619473,1.0,,,7132.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,81034.0,478.0
1.0,13617.0,,F,,,Intermediate,CHEMBL874368,1.0,,,7133.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,81034.0,478.0
1.0,13617.0,,F,,,Intermediate,CHEMBL884003,1.0,,,7134.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,81034.0,478.0
1.0,13617.0,,F,,,Intermediate,CHEMBL622690,1.0,,,7135.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,81034.0,478.0
1.0,17672.0,,F,,,Intermediate,CHEMBL622691,1.0,,,7136.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,81034.0,478.0
1.0,4544.0,,F,,,Intermediate,CHEMBL622692,1.0,,,7137.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,81034.0,478.0
1.0,4544.0,,F,,,Intermediate,CHEMBL623406,1.0,,,7138.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,81034.0,478.0
1.0,16317.0,,F,,,Intermediate,CHEMBL884004,1.0,,,7139.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,81034.0,478.0
1.0,15099.0,,F,,,Intermediate,CHEMBL623407,1.0,,,7140.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,81034.0,478.0
1.0,13978.0,,F,,,Intermediate,CHEMBL623408,1.0,,,7141.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,81034.0,478.0
1.0,12989.0,,F,,,Expert,CHEMBL623409,1.0,,,7142.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro antitumor activity against A2780 cell line.,,81034.0,478.0
1.0,5574.0,,F,,,Intermediate,CHEMBL623410,1.0,,,7143.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,81034.0,478.0
1.0,13528.0,,F,,,Expert,CHEMBL623576,1.0,,,7144.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,81034.0,478.0
1.0,12782.0,,F,,,Intermediate,CHEMBL623577,1.0,,,7145.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,80025.0,626.0
1.0,14255.0,,F,,,Intermediate,CHEMBL623578,1.0,,,7146.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,The IC50 value was measured on ACHN cell line in renal tumor type.,,80025.0,626.0
1.0,16364.0,,F,,,Intermediate,CHEMBL623579,1.0,,,7147.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,80025.0,626.0
1.0,17376.0,,F,,,Expert,CHEMBL623580,1.0,,,7148.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,In vitro lethal concentration against most sensitive ACHN cell line,,80025.0,626.0
1.0,12016.0,,F,,,Intermediate,CHEMBL623581,1.0,,,7149.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Tested for cytotoxic activity against renal cancer ACHN cell line,,80025.0,626.0
1.0,6058.0,,F,,,Intermediate,CHEMBL857456,1.0,,,7150.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Compound tested for growth inhibition of renal cancer cell line ACHN,,80025.0,626.0
1.0,17708.0,,F,,,Intermediate,CHEMBL623582,1.0,,,7151.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,80025.0,626.0
1.0,15176.0,,F,,,Intermediate,CHEMBL623583,1.0,,,7152.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,80025.0,626.0
1.0,2806.0,,F,,,Intermediate,CHEMBL623584,1.0,,,7153.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,In vitro anticancer activity against ACHN renal cancer cell line,,80025.0,626.0
1.0,15300.0,,F,,,Intermediate,CHEMBL623585,1.0,,,7154.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,80025.0,626.0
1.0,16364.0,,F,,,Intermediate,CHEMBL623586,1.0,,,7155.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Percent selectivity was evaluated in renal ACHN cell lines,,80025.0,626.0
1.0,13859.0,,F,,,Intermediate,CHEMBL623587,1.0,,,7156.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,In vitro inhibitory activity against renal ACHN cancer cell line,,80025.0,626.0
1.0,11970.0,,F,,,Intermediate,CHEMBL875279,1.0,,,7157.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Tested for cytotoxicity against ACHN cell lines in renal cancer,,80025.0,626.0
1.0,2450.0,,F,,,Intermediate,CHEMBL623588,1.0,,,7158.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,80025.0,626.0
1.0,12696.0,,F,,,Intermediate,CHEMBL623589,1.0,,,7159.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,80025.0,626.0
1.0,12400.0,,F,,,Intermediate,CHEMBL623590,1.0,,,7160.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,80025.0,626.0
1.0,12888.0,,F,,,Expert,CHEMBL623591,1.0,,,7161.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Cytotoxic effect on renal cancer line ACHN,,80025.0,626.0
1.0,3156.0,,F,,,Intermediate,CHEMBL623592,1.0,,,7162.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,80025.0,626.0
1.0,3381.0,,F,,,Intermediate,CHEMBL623593,1.0,,,7163.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,In vitro inhibition of Renal Cancer ACHN cell lines,,80025.0,626.0
1.0,16747.0,,F,,,Intermediate,CHEMBL623594,1.0,,,7164.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Antitumor activity against human renal adenocarcinoma ACHN cells,,80025.0,626.0
1.0,16748.0,,F,,,Expert,CHEMBL621833,1.0,,,7165.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Antitumor activity against human renal adenocarcinoma ACHN cells.,,80025.0,626.0
1.0,12062.0,,F,,,Intermediate,CHEMBL621834,1.0,,,7166.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,80025.0,626.0
1.0,14769.0,,F,,,Intermediate,CHEMBL621835,1.0,,,7167.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,80025.0,626.0
1.0,15895.0,,F,,,Intermediate,CHEMBL621836,1.0,,,7168.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,80025.0,626.0
1.0,17376.0,,F,,,Intermediate,CHEMBL621837,1.0,,,7169.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,80025.0,626.0
1.0,14882.0,,F,,,Intermediate,CHEMBL875280,1.0,,,7170.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,80025.0,626.0
1.0,14882.0,,F,,,Intermediate,CHEMBL621838,1.0,,,7171.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,80025.0,626.0
1.0,15661.0,,F,,,Intermediate,CHEMBL621839,1.0,,,7172.0,,N,BAO_0000219,ACHN,9606.0,,Homo sapiens,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,80025.0,626.0
0.0,9680.0,,A,,,Autocuration,CHEMBL621840,1.0,,,7173.0,,U,BAO_0000019,,,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,22224.0,
8.0,14579.0,,F,,,Autocuration,CHEMBL621841,1.0,,,7174.0,,H,BAO_0000019,,,,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,10647.0,
1.0,17290.0,,F,,,Expert,CHEMBL622979,1.0,,,7175.0,,N,BAO_0000218,HEL,10358.0,,Cytomegalovirus,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,50529.0,468.0
1.0,17290.0,,F,,,Intermediate,CHEMBL876595,1.0,,,7176.0,,N,BAO_0000218,,10358.0,,Cytomegalovirus,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,50529.0,
8.0,15891.0,,B,,,Autocuration,CHEMBL620221,1.0,,,7177.0,,H,BAO_0000357,,,,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,12159.0,
8.0,15890.0,,B,,,Autocuration,CHEMBL620222,1.0,,,7178.0,,H,BAO_0000357,,,,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,12159.0,
1.0,3801.0,,F,,,Intermediate,CHEMBL620506,1.0,,,7179.0,,N,BAO_0000219,ADDP cell line,9913.0,,Bos taurus,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,80670.0,979.0
1.0,9222.0,,F,,,Intermediate,CHEMBL620507,1.0,,,7180.0,,N,BAO_0000219,ADJ/PC6,10090.0,,Mus musculus,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,80671.0,980.0
1.0,9222.0,,F,,,Intermediate,CHEMBL620508,1.0,,,7181.0,,N,BAO_0000219,ADJ/PC6,10090.0,,Mus musculus,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,80671.0,980.0
1.0,7257.0,,F,,,Intermediate,CHEMBL620509,1.0,,,7182.0,,N,BAO_0000219,ADJ/PC6,10090.0,,Mus musculus,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,80671.0,980.0
1.0,7257.0,,F,,,Intermediate,CHEMBL620510,1.0,,,7183.0,,N,BAO_0000219,ADJ/PC6,10090.0,,Mus musculus,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,80671.0,980.0
1.0,7257.0,,A,,,Intermediate,CHEMBL620511,1.0,,,7184.0,,N,BAO_0000219,ADJ/PC6,10090.0,,Mus musculus,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,80671.0,980.0
1.0,8084.0,,F,,,Intermediate,CHEMBL620512,1.0,,,7185.0,,N,BAO_0000219,ADJ/PC6,10090.0,,Mus musculus,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,80671.0,980.0
0.0,14943.0,,F,,,Autocuration,CHEMBL620513,1.0,,,7186.0,,U,BAO_0000019,,10090.0,,Mus musculus,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,22224.0,
0.0,14943.0,,F,,,Autocuration,CHEMBL620514,1.0,,,7187.0,,U,BAO_0000019,,10090.0,,Mus musculus,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,22224.0,
0.0,14943.0,,F,,,Autocuration,CHEMBL620515,1.0,,,7188.0,,U,BAO_0000019,,10090.0,,Mus musculus,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,22224.0,
0.0,10524.0,,A,,,Autocuration,CHEMBL620516,1.0,,,7189.0,In vivo,U,BAO_0000218,,1423.0,,Bacillus subtilis,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,22224.0,
1.0,3546.0,1969.0,A,,,Intermediate,CHEMBL620517,1.0,Plasma,,7190.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,AUC value in dog after IV administration at a dose of 5 mg/kg,,50588.0,
1.0,3546.0,1969.0,A,,,Intermediate,CHEMBL620518,1.0,Plasma,,7191.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,AUC value in dog after oral administration at a dose of 5 mg/kg,,50588.0,
1.0,3546.0,,A,,,Intermediate,CHEMBL620519,1.0,,,7192.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Cmax value in dog after oral administration at a dose of 5 mg/kg,,50588.0,
1.0,3546.0,,A,,,Intermediate,CHEMBL621386,1.0,,,7193.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,50588.0,
1.0,3546.0,,A,,,Intermediate,CHEMBL621387,1.0,,,7194.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Tmax value in dog after oral administration at a dose of 5 mg/kg,,50588.0,
1.0,3184.0,,A,,,Intermediate,CHEMBL621388,1.0,,,7195.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was evaluated for its clearance when administered intravenously in dog,,50588.0,
1.0,16456.0,,A,,,Intermediate,CHEMBL621389,1.0,,,7196.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,50588.0,
1.0,4809.0,,A,,,Intermediate,CHEMBL621390,1.0,,,7197.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,50588.0,
0.0,4219.0,,P,,,Intermediate,CHEMBL621391,1.0,,,7198.0,,U,BAO_0000100,,,,,Calculated partition coefficient (clogP),,22229.0,
1.0,3748.0,,A,,,Intermediate,CHEMBL621392,1.0,,,7199.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dog,,50588.0,
1.0,3132.0,,A,,,Intermediate,CHEMBL621393,1.0,,,7200.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Time taken for EC90 was determined when tested in dog,,50588.0,
1.0,4219.0,,A,,,Intermediate,CHEMBL621394,1.0,,,7201.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life (iv) was determined,,50588.0,
1.0,16907.0,2107.0,A,,,Intermediate,CHEMBL621395,1.0,Liver,,7202.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,50588.0,
1.0,6057.0,,A,,,Intermediate,CHEMBL621396,1.0,,,7203.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under the curve was calculated in dog after iv administration,,50588.0,
1.0,6057.0,,A,,,Intermediate,CHEMBL621397,1.0,,,7204.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Area under the curve was calculated in dog after peroral administration,,50588.0,
1.0,17853.0,,A,,,Intermediate,CHEMBL621398,1.0,,,7205.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,50588.0,
1.0,3639.0,,A,,,Intermediate,CHEMBL618818,1.0,,,7206.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,pKa was evaluated in dog,,50588.0,
1.0,14541.0,,A,,,Intermediate,CHEMBL618819,1.0,,,7207.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,50588.0,
1.0,16456.0,,A,,,Intermediate,CHEMBL618820,1.0,,,7208.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,50588.0,
1.0,16456.0,,A,,,Intermediate,CHEMBL873810,1.0,,,7209.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,50588.0,
1.0,2652.0,,A,,,Intermediate,CHEMBL876606,1.0,,,7210.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,50588.0,
1.0,3624.0,,A,,,Intermediate,CHEMBL618821,1.0,,,7211.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was evaluated for the half-life (t 1/2) in hours,,50588.0,
1.0,1337.0,178.0,A,,,Intermediate,CHEMBL618822,1.0,Blood,,7212.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,50588.0,
1.0,1337.0,178.0,A,,,Intermediate,CHEMBL618823,1.0,Blood,,7213.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,50588.0,
1.0,4709.0,,A,,,Intermediate,CHEMBL618824,1.0,,,7214.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life after intravenous administration of 1 mg/kg in dog,,50588.0,
1.0,15660.0,,A,,,Intermediate,CHEMBL618825,1.0,,,7215.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life was measured in dog,,50588.0,
1.0,5302.0,,A,,,Intermediate,CHEMBL618826,1.0,,,7216.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period in dog after 5 mg/kg dose,,50588.0,
1.0,17791.0,,A,,,Intermediate,CHEMBL618827,1.0,,,7217.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period was evaluated in dog; 4-4.8,,50588.0,
1.0,6348.0,,A,,,Intermediate,CHEMBL618828,1.0,,,7218.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,50588.0,
1.0,4257.0,,A,,,Intermediate,CHEMBL618829,1.0,,,7219.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life was determined in dog after a3 mg/kg of iv dose,,50588.0,
1.0,3771.0,,A,,,Intermediate,CHEMBL618830,1.0,,,7220.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life was determined,,50588.0,
1.0,6305.0,,A,,,Intermediate,CHEMBL618831,1.0,,,7221.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dogs,,50588.0,
1.0,13501.0,1969.0,A,,,Intermediate,CHEMBL619489,1.0,Plasma,,7222.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,,50588.0,
1.0,17594.0,,A,,,Intermediate,CHEMBL619649,1.0,,,7223.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,50588.0,
1.0,3045.0,,A,,,Intermediate,CHEMBL876607,1.0,,,7224.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was evaluated for the half life period after iv administration in Beagle dog.,,50588.0,
1.0,3043.0,,A,,,Intermediate,CHEMBL619650,1.0,,,7225.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was evaluated for the half life period after oral administration in conscious dog.,,50588.0,
1.0,4839.0,,A,,,Intermediate,CHEMBL619651,1.0,,,7226.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was tested for half life in dog,,50588.0,
1.0,4839.0,,A,,,Intermediate,CHEMBL619652,1.0,,,7227.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Compound was tested for its half life in dog,,50588.0,
1.0,5802.0,,A,,,Intermediate,CHEMBL619653,1.0,,,7228.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,50588.0,
1.0,17839.0,,A,,,Intermediate,CHEMBL619654,1.0,,,7229.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life of compound in dog was determined,,50588.0,
1.0,4219.0,,A,,,Intermediate,CHEMBL619655,1.0,,,7230.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life (iv) was determined,,50588.0,
1.0,13966.0,178.0,A,,,Intermediate,CHEMBL619656,1.0,Blood,,7231.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,50588.0,
1.0,3994.0,1969.0,A,,,Intermediate,CHEMBL873812,1.0,Plasma,,7232.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,50588.0,
1.0,3994.0,1969.0,F,,,Intermediate,CHEMBL621365,1.0,Plasma,,7233.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,50588.0,
1.0,4453.0,,A,,,Intermediate,CHEMBL621366,1.0,,,7234.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dog,,50588.0,
1.0,6535.0,1969.0,A,,,Intermediate,CHEMBL621367,1.0,Plasma,,7235.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dog plasma,,50588.0,
1.0,6535.0,1969.0,A,,,Intermediate,CHEMBL621368,1.0,Plasma,,7236.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dog plasma after administration of 0.25 mg/kg iv,,50588.0,
1.0,6535.0,1969.0,A,,,Intermediate,CHEMBL621369,1.0,Plasma,,7237.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dog plasma after administration of 1 mg/kg iv,,50588.0,
1.0,3132.0,1969.0,A,,,Intermediate,CHEMBL621370,1.0,Plasma,,7238.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dog plasma was determined at dose 10 mg/kg,,50588.0,
1.0,5374.0,,A,,,Intermediate,CHEMBL621371,1.0,,,7239.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dog was determined,,50588.0,
1.0,5007.0,,A,,,Intermediate,CHEMBL621372,1.0,,,7240.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,50588.0,
1.0,16907.0,1969.0,A,,,Intermediate,CHEMBL621373,1.0,Plasma,,7241.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life upon exposure to human plasma,,50588.0,
1.0,6057.0,,A,,,Intermediate,CHEMBL621374,1.0,,,7242.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life was calculated in dog,,50588.0,
1.0,5006.0,,A,,,Intermediate,CHEMBL621375,1.0,,,7243.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life was determined,,50588.0,
1.0,5473.0,,A,,,Intermediate,CHEMBL621376,1.0,,,7244.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life was determined,,50588.0,
1.0,4368.0,,A,,,Intermediate,CHEMBL619624,1.0,,,7245.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life by intravenous administration of 1.2 mg/kg in dog,,50588.0,
1.0,6448.0,,A,,,Intermediate,CHEMBL875840,1.0,,,7246.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dog,,50588.0,
1.0,4353.0,,A,,,Intermediate,CHEMBL619625,1.0,,,7247.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dog after intra venous administration of the compound,,50588.0,
1.0,4353.0,,A,,,Intermediate,CHEMBL619626,1.0,,,7248.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dog after intra venous administration of the compound; ND means Not determined,,50588.0,
1.0,4353.0,,A,,,Intermediate,CHEMBL619627,1.0,,,7249.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dog after po administration of the compound,,50588.0,
1.0,4353.0,,A,,,Intermediate,CHEMBL873817,1.0,,,7250.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dog after po administration of the compound; ND means Not determined,,50588.0,
1.0,6265.0,,A,,,Intermediate,CHEMBL619628,1.0,,,7251.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dog at the single oral dose of 1 mg/kg,,50588.0,
1.0,5006.0,,A,,,Intermediate,CHEMBL619629,1.0,,,7252.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dogs,,50588.0,
1.0,5356.0,,A,,,Intermediate,CHEMBL619630,1.0,,,7253.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,50588.0,
1.0,405.0,,A,,,Intermediate,CHEMBL619631,1.0,,,7254.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in rat,,50588.0,
1.0,6642.0,,A,,,Intermediate,CHEMBL619632,1.0,,,7255.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,50588.0,
1.0,10107.0,10000001.0,A,,,Intermediate,CHEMBL619633,1.0,Bone,,7256.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594.0,
1.0,10107.0,10000001.0,A,,,Intermediate,CHEMBL875841,1.0,Bone,,7257.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594.0,
1.0,10107.0,10000001.0,A,,,Intermediate,CHEMBL619634,1.0,Bone,,7258.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594.0,
1.0,10107.0,10000001.0,A,,,Intermediate,CHEMBL619635,1.0,Bone,,7259.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594.0,
1.0,10107.0,10000001.0,A,,,Intermediate,CHEMBL619636,1.0,Bone,,7260.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594.0,
1.0,10107.0,10000004.0,A,,,Intermediate,CHEMBL619637,1.0,Gut,,7261.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594.0,
1.0,10107.0,10000004.0,A,,,Intermediate,CHEMBL619638,1.0,Gut,,7262.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,50594.0,
1.0,10107.0,10000004.0,A,,,Intermediate,CHEMBL619639,1.0,Gut,,7263.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594.0,
1.0,10107.0,10000004.0,A,,,Intermediate,CHEMBL619640,1.0,Gut,,7264.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594.0,
1.0,10107.0,10000004.0,A,,,Intermediate,CHEMBL619641,1.0,Gut,,7265.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594.0,
1.0,10107.0,10000004.0,A,,,Intermediate,CHEMBL619642,1.0,Gut,,7266.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594.0,
1.0,10107.0,10000004.0,A,,,Intermediate,CHEMBL619643,1.0,Gut,,7267.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594.0,
1.0,10107.0,948.0,A,,,Intermediate,CHEMBL619644,1.0,Heart,,7268.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594.0,
1.0,10107.0,948.0,A,,,Intermediate,CHEMBL621112,1.0,Heart,,7269.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,50594.0,
1.0,10107.0,948.0,A,,,Intermediate,CHEMBL621113,1.0,Heart,,7270.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594.0,
1.0,10107.0,948.0,A,,,Intermediate,CHEMBL621114,1.0,Heart,,7271.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594.0,
1.0,10107.0,948.0,A,,,Intermediate,CHEMBL621115,1.0,Heart,,7272.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594.0,
1.0,10107.0,948.0,A,,,Intermediate,CHEMBL621116,1.0,Heart,,7273.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594.0,
1.0,10107.0,948.0,A,,,Intermediate,CHEMBL621117,1.0,Heart,,7274.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594.0,
1.0,10107.0,2113.0,A,,,Intermediate,CHEMBL621118,1.0,Kidney,,7275.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594.0,
1.0,10107.0,2113.0,A,,,Intermediate,CHEMBL621119,1.0,Kidney,,7276.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,50594.0,
1.0,10107.0,2113.0,A,,,Intermediate,CHEMBL621120,1.0,Kidney,,7277.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594.0,
1.0,10107.0,2113.0,A,,,Intermediate,CHEMBL621757,1.0,Kidney,,7278.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594.0,
1.0,10107.0,2113.0,A,,,Intermediate,CHEMBL621758,1.0,Kidney,,7279.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594.0,
1.0,10107.0,2113.0,A,,,Intermediate,CHEMBL621759,1.0,Kidney,,7280.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594.0,
1.0,10107.0,2113.0,A,,,Intermediate,CHEMBL621760,1.0,Kidney,,7281.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594.0,
1.0,10107.0,2107.0,A,,,Intermediate,CHEMBL621761,1.0,Liver,,7282.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594.0,
1.0,10107.0,2107.0,A,,,Intermediate,CHEMBL621762,1.0,Liver,,7283.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,50594.0,
1.0,10107.0,2107.0,A,,,Intermediate,CHEMBL621763,1.0,Liver,,7284.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594.0,
1.0,10107.0,2107.0,A,,,Intermediate,CHEMBL624502,1.0,Liver,,7285.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594.0,
1.0,10107.0,2107.0,A,,,Intermediate,CHEMBL624503,1.0,Liver,,7286.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594.0,
1.0,10107.0,2107.0,A,,,Intermediate,CHEMBL624504,1.0,Liver,,7287.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594.0,
1.0,10107.0,2107.0,A,,,Intermediate,CHEMBL624505,1.0,Liver,,7288.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594.0,
1.0,10107.0,2048.0,A,,,Intermediate,CHEMBL624506,1.0,Lung,,7289.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594.0,
1.0,5895.0,,F,,,Intermediate,CHEMBL624507,1.0,,,7290.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro cytotoxicity against A2780 (human ovarian cancer),,81034.0,478.0
1.0,6338.0,,F,,,Intermediate,CHEMBL624508,1.0,,,7291.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,81034.0,478.0
1.0,15163.0,,F,,,Intermediate,CHEMBL624509,1.0,,,7292.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,81034.0,478.0
1.0,15163.0,,F,,,Intermediate,CHEMBL624510,1.0,,,7293.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,81034.0,478.0
1.0,15000.0,,F,,,Expert,CHEMBL875956,1.0,,,7294.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,81034.0,478.0
1.0,15000.0,,F,,,Expert,CHEMBL839885,1.0,,,7295.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,81034.0,478.0
1.0,14729.0,,F,,,Expert,CHEMBL624511,1.0,,,7296.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,81034.0,478.0
1.0,17270.0,,F,,,Intermediate,CHEMBL624512,1.0,,,7297.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro cytotoxicity against A2780 cell line,,81034.0,478.0
1.0,5685.0,,F,,,Intermediate,CHEMBL624513,1.0,,,7298.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,81034.0,478.0
1.0,3563.0,,F,,,Intermediate,CHEMBL624514,1.0,,,7299.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,81034.0,478.0
1.0,17753.0,,F,,,Intermediate,CHEMBL618547,1.0,,,7300.0,,N,BAO_0000218,A2780,9606.0,,Homo sapiens,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,81034.0,478.0
1.0,16317.0,,F,,,Intermediate,CHEMBL618548,1.0,,,7301.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,81034.0,478.0
1.0,16936.0,,F,,,Intermediate,CHEMBL618549,1.0,,,7302.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Inhibition of tubulin polymerization in analogy of ca.,,81034.0,478.0
1.0,3801.0,,F,,,Intermediate,CHEMBL618550,1.0,,,7303.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,81034.0,478.0
1.0,6181.0,,F,,,Expert,CHEMBL618551,1.0,,,7304.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Cytotoxic effect in ovarian cancer cell line (A2780),,81034.0,478.0
1.0,5318.0,,F,,,Intermediate,CHEMBL618552,1.0,,,7305.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,81034.0,478.0
1.0,4840.0,,F,,,Intermediate,CHEMBL618553,1.0,,,7306.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Tested for the cytotoxicity in A2780 ovarian cell line,,81034.0,478.0
1.0,15748.0,,F,,,Intermediate,CHEMBL618554,1.0,,,7307.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,81034.0,478.0
1.0,15748.0,,F,,,Intermediate,CHEMBL618555,1.0,,,7308.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,81034.0,478.0
1.0,15748.0,,F,,,Intermediate,CHEMBL618556,1.0,,,7309.0,,N,BAO_0000219,A2780cisR,,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,80017.0,481.0
1.0,15748.0,,F,,,Intermediate,CHEMBL618557,1.0,,,7310.0,,N,BAO_0000219,A2780cisR,,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,80017.0,481.0
1.0,15748.0,,F,,,Intermediate,CHEMBL618558,1.0,,,7311.0,,N,BAO_0000219,A2780cisR,,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,80017.0,481.0
1.0,15748.0,,F,,,Intermediate,CHEMBL618559,1.0,,,7312.0,,N,BAO_0000219,A2780cisR,,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,80017.0,481.0
1.0,17753.0,,F,,,Intermediate,CHEMBL618560,1.0,,,7313.0,,N,BAO_0000218,A2780,9606.0,,Homo sapiens,In vivo log of cells killed after administration of compound in A2780 cell line,,81034.0,478.0
1.0,17753.0,,F,,,Intermediate,CHEMBL618561,1.0,,,7314.0,In vivo,N,BAO_0000218,A2780,9606.0,,Homo sapiens,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,,81034.0,478.0
1.0,16936.0,,F,,,Intermediate,CHEMBL618562,1.0,,,7315.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,81034.0,478.0
1.0,16936.0,,F,,,Intermediate,CHEMBL618563,1.0,,,7316.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,81034.0,478.0
1.0,16936.0,,F,,,Intermediate,CHEMBL618564,1.0,,,7317.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,81034.0,478.0
1.0,16936.0,,F,,,Intermediate,CHEMBL618565,1.0,,,7318.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,81034.0,478.0
1.0,17528.0,,F,,,Intermediate,CHEMBL618566,1.0,,,7319.0,,N,BAO_0000218,A2780,9606.0,,Homo sapiens,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,81034.0,478.0
1.0,6633.0,,F,,,Intermediate,CHEMBL618567,1.0,,,7320.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,81034.0,478.0
1.0,15000.0,,F,,,Expert,CHEMBL618568,1.0,,,7321.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,81034.0,478.0
1.0,17528.0,,F,,,Expert,CHEMBL618569,1.0,,,7322.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,81034.0,478.0
1.0,16936.0,,F,,,Intermediate,CHEMBL621857,1.0,,,7323.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,81034.0,478.0
1.0,16936.0,,F,,,Intermediate,CHEMBL621858,1.0,,,7324.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,81034.0,478.0
1.0,16936.0,,F,,,Intermediate,CHEMBL621859,1.0,,,7325.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,81034.0,478.0
1.0,16936.0,,F,,,Intermediate,CHEMBL621860,1.0,,,7326.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,81034.0,478.0
1.0,16936.0,,F,,,Intermediate,CHEMBL621861,1.0,,,7327.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,81034.0,478.0
1.0,16936.0,,F,,,Expert,CHEMBL621862,1.0,,,7328.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,81034.0,478.0
1.0,16936.0,,F,,,Intermediate,CHEMBL621863,1.0,,,7329.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,81034.0,478.0
1.0,16936.0,,F,,,Intermediate,CHEMBL621864,1.0,,,7330.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,81034.0,478.0
1.0,16936.0,,F,,,Intermediate,CHEMBL621865,1.0,,,7331.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,81034.0,478.0
1.0,17737.0,,F,,,Intermediate,CHEMBL621866,1.0,,,7332.0,,N,BAO_0000219,A2780,10090.0,,Mus musculus,In vitro antiproliferative activity against A2780 cell line,,81034.0,478.0
1.0,17764.0,,F,,,Expert,CHEMBL621867,1.0,,,7333.0,,N,BAO_0000219,A2780,10090.0,,Mus musculus,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,81034.0,478.0
1.0,3830.0,,F,,,Intermediate,CHEMBL621868,1.0,,,7334.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,81034.0,478.0
1.0,3829.0,,F,,,Intermediate,CHEMBL875282,1.0,,,7335.0,,N,BAO_0000219,A2780,9606.0,,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,81034.0,478.0
1.0,3546.0,,A,,,Intermediate,CHEMBL621869,1.0,,,7336.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Vc value in dog after IV administration at a dose of 5 mg/kg,,50588.0,
1.0,3546.0,,A,,,Intermediate,CHEMBL621870,1.0,,,7337.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period in dog after IV administration at a dose of 5 mg/kg,,50588.0,
0.0,5668.0,,A,,,Autocuration,CHEMBL621871,1.0,,,7338.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,22224.0,
0.0,3443.0,1969.0,A,,,Autocuration,CHEMBL621243,1.0,Plasma,,7339.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224.0,
0.0,3443.0,1969.0,A,,,Autocuration,CHEMBL621244,1.0,Plasma,,7340.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224.0,
0.0,4256.0,,A,,,Autocuration,CHEMBL621245,1.0,,,7341.0,In vivo,U,BAO_0000218,,9541.0,,Macaca fascicularis,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,22224.0,
0.0,4256.0,,A,,,Autocuration,CHEMBL621246,1.0,,,7342.0,In vivo,U,BAO_0000218,,9541.0,,Macaca fascicularis,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,22224.0,
0.0,4256.0,,A,,,Autocuration,CHEMBL621247,1.0,,,7343.0,In vivo,U,BAO_0000218,,9541.0,,Macaca fascicularis,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,22224.0,
0.0,4256.0,,A,,,Autocuration,CHEMBL618386,1.0,,,7344.0,In vivo,U,BAO_0000218,,10116.0,,Rattus norvegicus,Oral Bioavailability in rat,,22224.0,
0.0,1916.0,,A,,,Autocuration,CHEMBL618387,1.0,,,7345.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,22224.0,
0.0,5302.0,,A,,,Autocuration,CHEMBL618388,1.0,,,7346.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Area under curve value in monkey at a dose of 5 mg/kg,,22224.0,
0.0,4257.0,,A,,,Autocuration,CHEMBL618389,1.0,,,7347.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL618574,1.0,,,7348.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL618575,1.0,,,7349.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL618576,1.0,,,7350.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,22224.0,
0.0,6078.0,,A,,,Autocuration,CHEMBL618577,1.0,,,7351.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,22224.0,
0.0,6078.0,,A,,,Autocuration,CHEMBL876487,1.0,,,7352.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,22224.0,
0.0,6062.0,,A,,,Autocuration,CHEMBL618578,1.0,,,7353.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,22224.0,
0.0,2661.0,,A,,,Autocuration,CHEMBL618579,1.0,,,7354.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,22224.0,
0.0,2661.0,,A,,,Autocuration,CHEMBL618580,1.0,,,7355.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,22224.0,
0.0,5394.0,,A,,,Autocuration,CHEMBL618581,1.0,,,7356.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,22224.0,
0.0,4397.0,,A,,,Autocuration,CHEMBL618582,1.0,,,7357.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,22224.0,
0.0,17509.0,,A,,,Autocuration,CHEMBL618583,1.0,,,7358.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,22224.0,
0.0,17509.0,,A,,,Autocuration,CHEMBL618584,1.0,,,7359.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,22224.0,
0.0,6641.0,,A,,,Autocuration,CHEMBL618585,1.0,,,7360.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL618586,1.0,,,7361.0,,U,BAO_0000218,,9527.0,,Cercopithecidae,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,22224.0,
0.0,3443.0,,A,,,Autocuration,CHEMBL618587,1.0,,,7362.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224.0,
0.0,3443.0,,A,,,Autocuration,CHEMBL618588,1.0,,,7363.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224.0,
0.0,17409.0,,A,,,Autocuration,CHEMBL618589,1.0,,,7364.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Binding towards monkey plasma protein at 10 uM,,22224.0,
0.0,17409.0,,A,,,Autocuration,CHEMBL618590,1.0,,,7365.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Binding towards monkey plasma protein at 100 uM,,22224.0,
0.0,1052.0,,A,,,Autocuration,CHEMBL872262,1.0,,,7366.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Apparent bioavailability in squirrel monkey was determined,,22224.0,
0.0,13501.0,,A,,,Autocuration,CHEMBL618591,1.0,,,7367.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,22224.0,
0.0,17509.0,,A,,,Autocuration,CHEMBL618592,1.0,,,7368.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Bioavailability in monkey (dose 2 mg/kg),,22224.0,
0.0,5394.0,,A,,,Autocuration,CHEMBL876488,1.0,,,7369.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,22224.0,
0.0,2661.0,,A,,,Autocuration,CHEMBL618593,1.0,,,7370.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,22224.0,
0.0,11219.0,,A,,,Autocuration,CHEMBL618594,1.0,,,7371.0,In vivo,U,BAO_0000218,,9443.0,,monkey,Bioavailability in monkey (i.d. dosing),,22224.0,
0.0,3045.0,,A,,,Autocuration,CHEMBL618595,1.0,,,7372.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,22224.0,
0.0,17796.0,,A,,,Autocuration,CHEMBL621469,1.0,,,7373.0,,U,BAO_0000019,,9527.0,,Cercopithecidae,Clearance of the drug was measured in cynomolgus,,22224.0,
0.0,1399.0,,A,,,Autocuration,CHEMBL621470,1.0,,,7374.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,22224.0,
0.0,2661.0,,A,,,Autocuration,CHEMBL621471,1.0,,,7375.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,22224.0,
0.0,5005.0,1969.0,A,,,Autocuration,CHEMBL621472,1.0,Plasma,,7376.0,In vivo,U,BAO_0000218,,9544.0,,Macaca mulatta,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,22224.0,
0.0,17267.0,,A,,,Autocuration,CHEMBL621473,1.0,,,7377.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Plasma clearance in rhesus monkey was determined,,22224.0,
0.0,6535.0,,A,,,Autocuration,CHEMBL621474,1.0,,,7378.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Plasma clearance in monkey after administration of 1 mg/kg iv,,22224.0,
0.0,5922.0,,A,,,Autocuration,CHEMBL621475,1.0,,,7379.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Plasma clearance in cynomolgus monkey,,22224.0,
0.0,6221.0,,A,,,Autocuration,CHEMBL621476,1.0,,,7380.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,22224.0,
0.0,5668.0,,A,,,Autocuration,CHEMBL624290,1.0,,,7381.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Plasma clearance after peroral administration at 10 mpk in Rhesus,,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL624291,1.0,,,7382.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,The total clearance was determined after intravenous administration in cynomolgus monkeys,,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL624292,1.0,,,7383.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,22224.0,
0.0,5355.0,,A,,,Autocuration,CHEMBL624293,1.0,,,7384.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,22224.0,
0.0,4578.0,,A,,,Autocuration,CHEMBL624294,1.0,,,7385.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Tested for Clearance upon iv administration to african green monkey,,22224.0,
0.0,17592.0,,A,,,Autocuration,CHEMBL624295,1.0,,,7386.0,In vivo,U,BAO_0000218,,9527.0,,Cercopithecidae,Clearance in monkey,,22224.0,
1.0,6641.0,,A,,,Intermediate,CHEMBL624296,1.0,,,7387.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,50588.0,
1.0,6642.0,,A,,,Intermediate,CHEMBL624297,1.0,,,7388.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,50588.0,
1.0,16367.0,,A,,,Intermediate,CHEMBL624298,1.0,,,7389.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life was evaluated after intravenous administration to dogs,,50588.0,
1.0,5472.0,,A,,,Intermediate,CHEMBL624299,1.0,,,7390.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life was evaluated in dog,,50588.0,
1.0,5474.0,,A,,,Intermediate,CHEMBL624300,1.0,,,7391.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life was evaluated in dog,,50588.0,
1.0,5654.0,,A,,,Intermediate,CHEMBL624301,1.0,,,7392.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,50588.0,
1.0,6227.0,,A,,,Intermediate,CHEMBL624302,1.0,,,7393.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,50588.0,
1.0,6227.0,,A,,,Intermediate,CHEMBL876026,1.0,,,7394.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period after intravenous administration in dog,,50588.0,
1.0,6221.0,,A,,,Intermediate,CHEMBL624303,1.0,,,7395.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period after oral administration (2.5 mg/kg) in dog was determined,,50588.0,
1.0,4527.0,,A,,,Intermediate,CHEMBL624304,1.0,,,7396.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period at a dose of 1 uM/kg in dog was determined,,50588.0,
1.0,5668.0,,A,,,Intermediate,CHEMBL624305,1.0,,,7397.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period was determine after peroral administration at 10 mpk in dog,,50588.0,
1.0,5668.0,,A,,,Intermediate,CHEMBL624306,1.0,,,7398.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period was determine after peroral administration at 5 mpk in dog,,50588.0,
1.0,3854.0,,A,,,Intermediate,CHEMBL624307,1.0,,,7399.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period was determined,,50588.0,
1.0,5505.0,,A,,,Intermediate,CHEMBL624308,1.0,,,7400.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period was determined,,50588.0,
1.0,6251.0,,A,,,Intermediate,CHEMBL624309,1.0,,,7401.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period by iv administration in dog at a dose of 6 mg/kg,,50588.0,
1.0,1918.0,,A,,,Intermediate,CHEMBL624310,1.0,,,7402.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period was evaluated in dog,,50588.0,
1.0,5546.0,,A,,,Intermediate,CHEMBL625003,1.0,,,7403.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,50588.0,
1.0,4809.0,,A,,,Intermediate,CHEMBL625004,1.0,,,7404.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,50588.0,
1.0,6215.0,,A,,,Intermediate,CHEMBL625005,1.0,,,7405.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,50588.0,
1.0,4527.0,,A,,,Intermediate,CHEMBL873813,1.0,,,7406.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,50588.0,
1.0,17594.0,,A,,,Intermediate,CHEMBL625006,1.0,,,7407.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life after oral dose of compound at 3 mg/kg in dogs,,50588.0,
1.0,17839.0,,A,,,Intermediate,CHEMBL625007,1.0,,,7408.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,50588.0,
1.0,17839.0,,A,,,Intermediate,CHEMBL876027,1.0,,,7409.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,50588.0,
1.0,17839.0,,A,,,Intermediate,CHEMBL625008,1.0,,,7410.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,50588.0,
1.0,17839.0,,A,,,Intermediate,CHEMBL625009,1.0,,,7411.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 1 mg/kg,,50588.0,
1.0,5210.0,1969.0,A,,,Intermediate,CHEMBL625010,1.0,Plasma,,7412.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life of compound in plasma of dog was determined,,50588.0,
1.0,5210.0,,A,,,Intermediate,CHEMBL625011,1.0,,,7413.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life of compound was determined in dogs,,50588.0,
1.0,2959.0,,A,,,Intermediate,CHEMBL621553,1.0,,,7414.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life after administration of 4 mg/Kg oral dose in dog,,50588.0,
1.0,4137.0,,A,,,Intermediate,CHEMBL621554,1.0,,,7415.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life after intravenous administration of 1 mg/kg/h in dog,,50588.0,
1.0,5064.0,,A,,,Intermediate,CHEMBL621555,1.0,,,7416.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life in Dog,,50588.0,
1.0,5147.0,,A,,,Intermediate,CHEMBL621556,1.0,,,7417.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life in Dog,,50588.0,
1.0,5145.0,,A,,,Intermediate,CHEMBL621557,1.0,,,7418.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life in dog,,50588.0,
1.0,6123.0,,A,,,Intermediate,CHEMBL621558,1.0,,,7419.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life in dog after oral administration at 1 mg/kg,,50588.0,
1.0,6123.0,,A,,,Intermediate,CHEMBL621559,1.0,,,7420.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,50588.0,
1.0,4333.0,,A,,,Intermediate,CHEMBL621560,1.0,,,7421.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life in dogs,,50588.0,
1.0,4333.0,,A,,,Intermediate,CHEMBL876028,1.0,,,7422.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life in dogs; ND indicates not determined,,50588.0,
1.0,12500.0,1969.0,A,,,Intermediate,CHEMBL621561,1.0,Plasma,,7423.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life in plasma of dog,,50588.0,
1.0,12500.0,1969.0,A,,,Intermediate,CHEMBL621562,1.0,Plasma,,7424.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life in plasma of dog at dose of 3-10 mgkg,,50588.0,
1.0,6005.0,,A,,,Intermediate,CHEMBL621563,1.0,,,7425.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,50588.0,
1.0,6062.0,,A,,,Intermediate,CHEMBL621564,1.0,,,7426.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life was measured in dog after an iv dose of 1 mg/kg,,50588.0,
1.0,17650.0,,A,,,Intermediate,CHEMBL621565,1.0,,,7427.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life was measured in dogs after an oral dose of 10 uM/kg,,50588.0,
1.0,5530.0,,A,,,Intermediate,CHEMBL621566,1.0,,,7428.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,50588.0,
1.0,5530.0,,A,,,Intermediate,CHEMBL621567,1.0,,,7429.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,50588.0,
1.0,5600.0,,A,,,Intermediate,CHEMBL622978,1.0,,,7430.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life of the compound after 0.3 mg/kg po administration in dog,,50588.0,
1.0,6039.0,,A,,,Intermediate,CHEMBL873814,1.0,,,7431.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,50588.0,
1.0,6039.0,,A,,,Intermediate,CHEMBL623219,1.0,,,7432.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,50588.0,
1.0,6039.0,,A,,,Intermediate,CHEMBL624477,1.0,,,7433.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,50588.0,
1.0,6227.0,,A,,,Intermediate,CHEMBL624478,1.0,,,7434.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,t1/2 in dog,,50588.0,
1.0,14541.0,,A,,,Intermediate,CHEMBL624479,1.0,,,7435.0,,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life period measured in dogs,,50588.0,
1.0,4521.0,,A,,,Intermediate,CHEMBL624480,1.0,,,7436.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,50588.0,
1.0,4521.0,,A,,,Intermediate,CHEMBL623595,1.0,,,7437.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,50588.0,
1.0,6679.0,,A,,,Intermediate,CHEMBL623596,1.0,,,7438.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,50588.0,
1.0,1116.0,1969.0,A,,,Intermediate,CHEMBL623597,1.0,Plasma,,7439.0,In vitro,N,BAO_0000218,,9615.0,,Canis lupus familiaris,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",,50588.0,
1.0,5444.0,,A,,,Intermediate,CHEMBL623598,1.0,,,7440.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,In vivo half life period was calculated at 1 mg/kg in dog,,50588.0,
1.0,5444.0,,A,,,Intermediate,CHEMBL623599,1.0,,,7441.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,50588.0,
1.0,17853.0,,A,,,Intermediate,CHEMBL623600,1.0,,,7442.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Longer half-life in dog (i.v.) at 0.5 mpk,,50588.0,
1.0,4353.0,,A,,,Intermediate,CHEMBL623601,1.0,,,7443.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Oral bioavailability in dog (dose 5 uM/kg),,50588.0,
1.0,16452.0,,A,,,Intermediate,CHEMBL623602,1.0,,,7444.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,50588.0,
1.0,16452.0,,A,,,Intermediate,CHEMBL623603,1.0,,,7445.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,50588.0,
1.0,16452.0,,A,,,Intermediate,CHEMBL623604,1.0,,,7446.0,In vivo,N,BAO_0000218,,9615.0,,Canis lupus familiaris,Bioavailability in dog (dose 1 mg/kg i.v.),,50588.0,
1.0,10107.0,2048.0,A,,,Intermediate,CHEMBL623605,1.0,Lung,,7447.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,50594.0,
1.0,10107.0,2048.0,A,,,Intermediate,CHEMBL623606,1.0,Lung,,7448.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594.0,
1.0,10107.0,2048.0,A,,,Intermediate,CHEMBL623607,1.0,Lung,,7449.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594.0,
1.0,10107.0,2048.0,A,,,Intermediate,CHEMBL623608,1.0,Lung,,7450.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594.0,
1.0,10107.0,2048.0,A,,,Intermediate,CHEMBL623609,1.0,Lung,,7451.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594.0,
1.0,10107.0,2048.0,A,,,Intermediate,CHEMBL623610,1.0,Lung,,7452.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594.0,
1.0,10107.0,2385.0,A,,,Intermediate,CHEMBL623611,1.0,Muscle tissue,,7453.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594.0,
1.0,10107.0,2385.0,A,,,Intermediate,CHEMBL623612,1.0,Muscle tissue,,7454.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,50594.0,
1.0,10107.0,2385.0,A,,,Intermediate,CHEMBL623613,1.0,Muscle tissue,,7455.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594.0,
1.0,10107.0,2385.0,A,,,Intermediate,CHEMBL623614,1.0,Muscle tissue,,7456.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594.0,
1.0,10107.0,2385.0,A,,,Intermediate,CHEMBL623615,1.0,Muscle tissue,,7457.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594.0,
1.0,10107.0,2385.0,A,,,Intermediate,CHEMBL623616,1.0,Muscle tissue,,7458.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594.0,
1.0,10107.0,2385.0,A,,,Intermediate,CHEMBL623617,1.0,Muscle tissue,,7459.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594.0,
1.0,10107.0,14.0,A,,,Intermediate,CHEMBL875944,1.0,Zone of skin,,7460.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594.0,
1.0,10107.0,14.0,A,,,Intermediate,CHEMBL623618,1.0,Zone of skin,,7461.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,50594.0,
1.0,10107.0,14.0,A,,,Intermediate,CHEMBL623619,1.0,Zone of skin,,7462.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594.0,
1.0,10107.0,14.0,A,,,Intermediate,CHEMBL623620,1.0,Zone of skin,,7463.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594.0,
1.0,10107.0,14.0,A,,,Intermediate,CHEMBL623621,1.0,Zone of skin,,7464.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594.0,
1.0,10107.0,14.0,A,,,Intermediate,CHEMBL623622,1.0,Zone of skin,,7465.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594.0,
1.0,10107.0,14.0,A,,,Intermediate,CHEMBL623623,1.0,Zone of skin,,7466.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594.0,
1.0,10107.0,2106.0,A,,,Intermediate,CHEMBL623624,1.0,Spleen,,7467.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594.0,
1.0,10107.0,2106.0,A,,,Intermediate,CHEMBL618521,1.0,Spleen,,7468.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,50594.0,
1.0,10107.0,2106.0,A,,,Intermediate,CHEMBL618522,1.0,Spleen,,7469.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594.0,
1.0,10107.0,2106.0,A,,,Intermediate,CHEMBL618523,1.0,Spleen,,7470.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594.0,
1.0,10107.0,2106.0,A,,,Intermediate,CHEMBL618524,1.0,Spleen,,7471.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594.0,
1.0,10107.0,2106.0,A,,,Intermediate,CHEMBL618525,1.0,Spleen,,7472.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594.0,
1.0,10107.0,2106.0,A,,,Intermediate,CHEMBL624586,1.0,Spleen,,7473.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594.0,
1.0,10107.0,945.0,A,,,Intermediate,CHEMBL624587,1.0,Stomach,,7474.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594.0,
1.0,10107.0,945.0,A,,,Intermediate,CHEMBL624588,1.0,Stomach,,7475.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,50594.0,
1.0,10107.0,945.0,A,,,Intermediate,CHEMBL624589,1.0,Stomach,,7476.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594.0,
1.0,10107.0,945.0,A,,,Intermediate,CHEMBL624590,1.0,Stomach,,7477.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594.0,
1.0,10107.0,945.0,A,,,Intermediate,CHEMBL624591,1.0,Stomach,,7478.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594.0,
1.0,10107.0,945.0,A,,,Intermediate,CHEMBL624592,1.0,Stomach,,7479.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594.0,
1.0,10107.0,945.0,A,,,Intermediate,CHEMBL624593,1.0,Stomach,,7480.0,In vivo,N,BAO_0000218,,10090.0,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594.0,
1.0,4689.0,,A,,,Intermediate,CHEMBL624594,1.0,,,7481.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Oral bioavailability in rat,,50597.0,
1.0,4950.0,,A,,,Intermediate,CHEMBL624595,1.0,,,7482.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Tested for the bioavailability in rat,,50597.0,
1.0,5328.0,,A,,,Intermediate,CHEMBL624596,1.0,,,7483.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,50597.0,
1.0,406.0,,A,,,Intermediate,CHEMBL624597,1.0,,,7484.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Bioavailability in rat,,50597.0,
1.0,12500.0,,A,,,Intermediate,CHEMBL624598,1.0,,,7485.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Bioavailability in rat,,50597.0,
1.0,12500.0,,A,,,Intermediate,CHEMBL624599,1.0,,,7486.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Bioavailability in rat (dose 3-10 mg/kg),,50597.0,
1.0,5247.0,,A,,,Intermediate,CHEMBL875166,1.0,,,7487.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Bioavailability in rat,,50597.0,
1.0,4186.0,1969.0,A,,,Intermediate,CHEMBL624600,1.0,Plasma,,7488.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,50597.0,
1.0,4186.0,1969.0,A,,,Intermediate,CHEMBL624601,1.0,Plasma,,7489.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,50597.0,
1.0,6647.0,,A,,,Intermediate,CHEMBL624602,1.0,,,7490.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Half life after oral administration was determined in rats at 6 mg/kg,,50597.0,
1.0,6484.0,,A,,,Intermediate,CHEMBL624603,1.0,,,7491.0,,N,BAO_0000218,,10116.0,,Rattus norvegicus,Half life was determined,,50597.0,
1.0,3249.0,,A,,,Intermediate,CHEMBL624604,1.0,,,7492.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,50597.0,
1.0,6281.0,1969.0,A,,,Intermediate,CHEMBL624605,1.0,Plasma,,7493.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Plasma half life in rat at oral dose 2.8 mg/mk body weight,,50597.0,
1.0,3307.0,,A,,,Intermediate,CHEMBL624606,1.0,,,7494.0,,N,BAO_0000218,,10116.0,,Rattus norvegicus,Half life in rats,,50597.0,
1.0,12058.0,178.0,A,,,Intermediate,CHEMBL624607,1.0,Blood,,7495.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,,50597.0,
1.0,8833.0,,A,,,Intermediate,CHEMBL624608,1.0,,,7496.0,,N,BAO_0000218,,10116.0,,Rattus norvegicus,Hill coefficient of the compound,,50597.0,
1.0,3193.0,178.0,A,,,Intermediate,CHEMBL624609,1.0,Blood,,7497.0,,N,BAO_0000218,,10116.0,,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,50597.0,
1.0,3193.0,178.0,A,,,Intermediate,CHEMBL624610,1.0,Blood,,7498.0,,N,BAO_0000218,,10116.0,,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,50597.0,
1.0,3193.0,178.0,A,,,Intermediate,CHEMBL624611,1.0,Blood,,7499.0,,N,BAO_0000218,,10116.0,,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,50597.0,
1.0,3193.0,178.0,A,,,Intermediate,CHEMBL624612,1.0,Blood,,7500.0,,N,BAO_0000218,,10116.0,,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,50597.0,
1.0,3193.0,178.0,A,,,Intermediate,CHEMBL875167,1.0,Blood,,7501.0,,N,BAO_0000218,,10116.0,,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,50597.0,
1.0,3193.0,178.0,A,,,Intermediate,CHEMBL624613,1.0,Blood,,7502.0,,N,BAO_0000218,,10116.0,,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,50597.0,
1.0,3193.0,178.0,A,,,Intermediate,CHEMBL624614,1.0,Blood,,7503.0,,N,BAO_0000218,,10116.0,,Rattus norvegicus,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,50597.0,
1.0,5960.0,,A,,,Intermediate,CHEMBL624392,1.0,,,7504.0,,N,BAO_0000218,,10116.0,,Rattus norvegicus,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,50597.0,
1.0,13950.0,955.0,A,,,Intermediate,CHEMBL624393,1.0,Brain,,7505.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,,50597.0,
1.0,13950.0,955.0,A,,,Intermediate,CHEMBL624394,1.0,Brain,,7506.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,,50597.0,
1.0,13950.0,955.0,A,,,Intermediate,CHEMBL624395,1.0,Brain,,7507.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,,50597.0,
1.0,13950.0,955.0,A,,,Intermediate,CHEMBL624396,1.0,Brain,,7508.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,,50597.0,
1.0,13950.0,955.0,A,,,Intermediate,CHEMBL624397,1.0,Brain,,7509.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,,50597.0,
1.0,13950.0,2046.0,A,,,Intermediate,CHEMBL624398,1.0,Thyroid gland,,7510.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,,50597.0,
1.0,13950.0,2046.0,A,,,Intermediate,CHEMBL624399,1.0,Thyroid gland,,7511.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,,50597.0,
1.0,13950.0,2046.0,A,,,Intermediate,CHEMBL624400,1.0,Thyroid gland,,7512.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,,50597.0,
1.0,13950.0,2046.0,A,,,Intermediate,CHEMBL624401,1.0,Thyroid gland,,7513.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,,50597.0,
1.0,13950.0,2046.0,A,,,Intermediate,CHEMBL624402,1.0,Thyroid gland,,7514.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,,50597.0,
1.0,9866.0,178.0,A,,,Intermediate,CHEMBL624403,1.0,Blood,,7515.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,50597.0,
1.0,9866.0,178.0,A,,,Intermediate,CHEMBL624404,1.0,Blood,,7516.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,,50597.0,
1.0,9866.0,178.0,A,,,Intermediate,CHEMBL624405,1.0,Blood,,7517.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,,50597.0,
1.0,9866.0,10000001.0,A,,,Intermediate,CHEMBL624406,1.0,Bone,,7518.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,50597.0,
1.0,9866.0,10000001.0,A,,,Intermediate,CHEMBL624407,1.0,Bone,,7519.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,,50597.0,
1.0,9866.0,10000001.0,A,,,Intermediate,CHEMBL624408,1.0,Bone,,7520.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,,50597.0,
1.0,9866.0,948.0,A,,,Intermediate,CHEMBL618644,1.0,Heart,,7521.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,50597.0,
1.0,9866.0,948.0,A,,,Intermediate,CHEMBL618645,1.0,Heart,,7522.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,,50597.0,
1.0,9866.0,948.0,A,,,Intermediate,CHEMBL618646,1.0,Heart,,7523.0,In vivo,N,BAO_0000218,,10116.0,,Rattus norvegicus,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,,50597.0,
